<SEC-DOCUMENT>0001144204-13-061598.txt : 20131114
<SEC-HEADER>0001144204-13-061598.hdr.sgml : 20131114
<ACCEPTANCE-DATETIME>20131114131049
ACCESSION NUMBER:		0001144204-13-061598
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131114
DATE AS OF CHANGE:		20131114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		131218462

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v358947_10q.htm
<DESCRIPTION>10-Q
<TEXT>
 <html> <head> <title></title> </head> <body> <br> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Washington, DC 20549</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">FORM 10-Q</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">(Mark One)</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> x</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">For the quarterly period ended September 30, 2013 &#160;</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">OR</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">For the transition period from &#160;____________ to&#160;____________ &#160;</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Commission File Number: 1-12584</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">SYNTHETIC BIOLOGICS, INC.</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><i><font style="COLOR: black; FONT-SIZE: 10pt">(Name of small business issuer in its charter)</font></i></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Nevada</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> 13-3808303</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt"> (State&#160;or&#160;other&#160;jurisdiction&#160;of&#160;incorporation&#160;or&#160;organization)</font></i></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt"> (IRS&#160;Employer&#160;Identification&#160;Number)</font></i></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">155 Gibbs Street, Suite 412</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">Rockville, MD</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> 20850</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="62%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt"> (Address&#160;of&#160;principal&#160;executive&#160;offices)</font></i></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="36%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt"> (Zip&#160;Code)</font></i></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code:</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">(734) 332-7800</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(b) of the Act:</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Common Stock, $0.001 par value per share</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(g) of the Act:</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">None.</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><i><font style="COLOR: black; FONT-SIZE: 10pt">(Title of Class)</font></i></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;Yes&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt">x</font> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt">x</font> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#160;&#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one):</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 53%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="53%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> Large&#160;accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 47%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="47%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> Accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 53%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="53%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> Non-Accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 47%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="47%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> Smaller&#160;reporting&#160;company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> x</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 100%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="100%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> (Do&#160;not&#160;check&#160;if&#160;a&#160;smaller&#160;reporting&#160;company)</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> &#168;</font> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;</font> <font style="FONT-FAMILY: Wingdings; COLOR: black; FONT-SIZE: 10pt"> x</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">As of November 12, 2013 the registrant had 44,654,414 shares of common stock outstanding.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> <b><font style="COLOR: black; FONT-SIZE: 10pt">SYNTHETIC BIOLOGICS, INC.</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">FORM 10-Q</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">TABLE OF CONTENTS</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Page</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">PART I. FINANCIAL INFORMATION</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 1.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Financial Statements (Unaudited)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">3</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">3</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">4</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2013 and 2012</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">5</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Notes to Consolidated Financial Statements</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">6</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 2.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Management&#8217;s Discussion and Analysis of Financial&#160;Information and Results of Operations</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">13</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 3.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Quantitative and Qualitative Disclosures About Market Risks</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">23</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 4.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Controls and Procedures</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">23</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">PART II. OTHER INFORMATION</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 1.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Legal Proceedings</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">24</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 1A.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Risk Factors</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">24</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 2.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">34</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 3.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Defaults Upon Senior Securities</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">34</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 4.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Mine Safety Disclosures</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">34</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 5.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Other Information</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">34</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Item 6.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 80%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="80%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Exhibits</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">35</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">SIGNATURES</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">36</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="90%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">GLOSSARY</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="8%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="right"><font style="COLOR: black; FONT-SIZE: 10pt">37</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both" align="left"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">PART I.-FINANCIAL INFORMATION</font></b><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 1. FINANCIAL STATEMENTS</font></b> <div style="clear:both;CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. and Subsidiaries</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><u><font style="COLOR: black; FONT-SIZE: 10pt"> Consolidated Balance Sheets</font></u></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">(In thousands, except per share amounts)</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> (Unaudited)</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"></font></b> <div style="clear:both;CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> September&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; TEXT-DECORATION: underline" width="71%"> <div style="clear:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Current Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">5,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">9,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">2,509</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 30px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Total Current Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">6,792</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">12,463</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">223</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Long-term note receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Deposits and other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Total Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">6,953</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">13,423</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; TEXT-DECORATION: underline" width="71%"> <div style="clear:both;CLEAR: both">Liabilities and Stockholders' Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Current Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">584</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Total Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">584</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Stockholders' Equity:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Preferred stock, $0.001 par value; 10,000,000 shares authorized,<br> &#160;&#160;&#160;&#160;&#160;none issued and outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Common stock, $0.001 par value; 100,000,000 shares authorized,<br> &#160;&#160;&#160;&#160;&#160;44,735,896 issued and 44,654,414 outstanding, respectively,<br> &#160;&#160;&#160;&#160;&#160;and 44,444,230 issued and 44,362,748 outstanding,<br> &#160;&#160;&#160;&#160;&#160;respectively</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Additional paid-in capital</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">83,358</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">81,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Accumulated deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(77,034)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(68,941)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Total Stockholders' Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">6,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">13,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%"> <div style="clear:both;CLEAR: both">Total Liabilities and Stockholders' Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">6,953</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">13,423</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> </div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">See accompanying notes to unaudited consolidated financial statements.&#160;</font> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</div> </div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both; FONT-SIZE: 10pt"> &#160;</div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">3</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt 4.4pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. and Subsidiaries</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 4.4pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><u> <font style="COLOR: black; FONT-SIZE: 10pt">Consolidated Statements of Operations</font></u></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 4.4pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">(In thousands, except share and per share amounts)</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 4.4pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt"> (Unaudited)</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 4.4pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"><font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="clear:both;CLEAR: both"> For&#160;the&#160;three&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="clear:both;CLEAR: both"> For&#160;the&#160;nine&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Operating Costs and Expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,890</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,073</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">4,270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">3,717</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,475</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">763</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">3,796</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 18px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Total Operating Costs and Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">3,365</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">8,066</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">5,413</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Loss from Operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(3,365)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(1,836)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(8,066)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(5,413)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Other Income (Expense):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Interest income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Other income (expense)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(14)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(59)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 18px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Total Other Income (Expense), net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(27)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Loss from Continuing Operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(3,368)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(1,826)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(8,093)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(5,391)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Income (Loss) from Discontinued Operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Net Loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(3,368)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(1,930)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(8,093)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(5,002)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Net Income (Loss) Per Share - Basic and Dilutive:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Continuing operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(0.08)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(0.18)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(0.16)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 9px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Net Loss Per Share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(0.08)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(0.18)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="clear:both;CLEAR: both">(0.15)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 11px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="clear:both;CLEAR: both">Weighted average number of shares outstanding<br> &#160;&#160;&#160;&#160;during the period - Basic and Dilutive</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">44,654,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">33,383,226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">44,636,935</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">32,801,415</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> </div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">See accompanying notes to unaudited consolidated financial statements.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both" align="left"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">4</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. and Subsidiaries</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><u><font style="COLOR: black; FONT-SIZE: 10pt"> Consolidated Statements of Cash Flows</font></u></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">(In thousands)</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> (Unaudited)</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="clear:both;CLEAR: both"> For&#160;nine&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Cash Flows From Operating Activities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(8,093)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(5,002)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Adjustments to reconcile net loss to net cash used in operating activites:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1,303</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Provision for uncollectible accounts receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">269</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Provision for uncollectible note and interest receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">763</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Loss on sale of equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Impairment on loss of equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Gain on sale of discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(677)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Changes in operating assets and liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Accounts receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(135)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Deposits and other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">189</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 14px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Accrued liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Net Cash Used In Operating Activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(5,015)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(4,143)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Cash Flows From Investing Activities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Purchase of property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(25)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Net Cash Used In Investing Activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(25)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Cash Flows From Financing Activities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Proceeds from issuance of common stock for stock option exercises</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">231</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Proceeds from issuance of common stock for warrant exercises</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1,955</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Net Cash Provided By Financing Activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">231</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2,049</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Net decrease in cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(4,809)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(2,101)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Cash at beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">9,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">6,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div style="clear:both;CLEAR: both">Cash at end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="clear:both;CLEAR: both">5,145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="clear:both;CLEAR: both">4,577</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700; TEXT-DECORATION: underline" width="74%"> <div style="clear:both;CLEAR: both">Supplemental disclosures of cash flow information:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Cash paid for interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="clear:both;CLEAR: both">Cash paid for taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> </div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">See accompanying notes to unaudited consolidated financial statements.</font> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> &#160;</div> </div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both; FONT-SIZE: 10pt"> &#160;</div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">5</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. and Subsidiaries</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">Notes to Consolidated Financial Statements</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><u><font style="COLOR: black; FONT-SIZE: 10pt"> (Unaudited)</font></u></b></div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Organization and Nature of Operations and Basis of Presentation</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Description of Business</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of <i>C. difficile</i> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <i>Acinetobacter</i> infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Therapeutic&#160;Area</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Product&#160;Candidate</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Status</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Relapsing-remitting MS</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Trimesta</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> (oral estriol)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Completed enrollment&#160;in Phase II clinical trial; dosing and monitoring underway</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Cognitive dysfunction in MS</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Trimesta</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> (oral estriol)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Patient enrollment underway in Phase II clinical trial</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt">C. difficile</font></i> <font style="COLOR: black; FONT-SIZE: 10pt"> infection prevention</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> SYN-004</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> &#160;(oral enzyme)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">SYN-004, second generation candidate in preclinical;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">first generation predecessor candidate</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">(formerly known as P1A) is in Phase II</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Pertussis</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> SYN-005</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> &#160;(monoclonal antibody)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Preclinical; Collaborations with Intrexon and The University of Texas at Austin</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Acinetobacter</font></i> <font style="COLOR: black; FONT-SIZE: 10pt">infection</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> SYN-001</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> &#160;(monoclonal antibody)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Discovery; Collaboration with Intrexon</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Fibromyalgia</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 27%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> Effirma</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font> &#160;(oral flupirtine)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 44%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt">Partnered with Meda AB</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In order to further prioritize the Company&#8217;s focus, it previously elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, the Company is seeking development partners for its zinc-based intellectual property and assets including, AEN-100.<font style="FONT-SIZE: 10pt"></font></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="FONT-SIZE: 8pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"> </font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 10pt"> </font></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt"><i>Basis of Presentation</i></font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2012 (&#8220;2012 Form 10-K&#8221;) as filed with the SEC. The interim results for the three and nine months ended September 30, 2013, are not necessarily indicative of results for the full year.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</font></font></div> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="FONT-SIZE: 8pt">&#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">6</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></b> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;<font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>2.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Management&#8217;s Plan</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company has incurred an accumulated deficit of $<font style="FONT-SIZE: 10pt">77</font> million through September 30, 2013. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of research activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the number and scope of research programs;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of preclinical and clinical development activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">costs associated with additional clinical trials of product candidates;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the ability to achieve milestones under licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#183;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">the costs and timing of regulatory approvals.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company&#8217;s shares or debt and other sources, including sales of securities pursuant to the terms of the Controlled Equity Offering</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">SM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">Agreement that it entered into with Cantor Fitzgerald &amp; Co., as sales agent, that provides the ability to conduct an at-the-market (ATM) public offering for up to $<font style="FONT-SIZE: 10pt">15</font> million of shares of common stock at prices to be determined at the time of sale. As of the date of this filing, the Company has not sold any shares under the ATM.</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.</font></div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;CLEAR: both">&#160;</div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">7</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="FONT-SIZE: 8pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 10pt"> </font></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>&#160;<font style="FONT-SIZE: 10pt"> </font><font style="FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>3.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $<font style="FONT-SIZE: 10pt">700,000</font> payable pursuant to the terms of a two-year promissory note bearing interest at <font style="FONT-SIZE: 10pt">5.7</font>% per annum secured by all of the assets of the Lab. The note and all unpaid interest were due on March 1, 2014. <font style="BACKGROUND-COLOR: #ffffff">During the three months ended September 30, 2013, the note receivable and associated interest receivable were deemed uncollectible. Accordingly, the Company recorded bad debt expense of $<font style="FONT-SIZE: 10pt">763</font>,000.</font></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">In accordance with <font style="BACKGROUND-COLOR: #ffffff">Accounting Standards Codification (&#8220;ASC&#8221;)</font> Topic 205-20 &#8220;<i>Presentation of Financial Statements-Discontinued Operations</i>&#8221; (ASC 205-20), the Company determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been classified as a discontinued operation and its results of operations, financial position and cash flows are separately reported for all periods presented.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font>The summarized statement of operations data for Adeona Clinical Laboratory for the three and nine months ended September 30, 2013 and 2012 are as follows <i>(in thousands):</i></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"> </font>&#160;</font> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"><font style="FONT-SIZE: 8pt"></font> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div style="clear:both;CLEAR: both"> Three&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div style="clear:both;CLEAR: both"> Nine&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Laboratory fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Operating Costs and Expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">287</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Cost of laboratory services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Total operating costs and expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">403</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Loss from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(288)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Other Income:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Gain on sale of Adeona Clinical Laboratory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="clear:both;CLEAR: both">Income (loss) from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> </font>&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 8pt"> </font></div> </div> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;<font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>4.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Fair Value of Financial Instruments</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</font></div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#8901;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 93%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#8901;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 93%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#8901;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 93%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.</font></div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">Cash and cash equivalents include money market accounts&#160;of $<font style="FONT-SIZE: 10pt;">5.1</font> million and $<font style="FONT-SIZE: 10pt;">10.0</font> million as of September 30, 2013 and December 31, 2012, respectively, that are measured using Level 1 inputs.<font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;<font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>5.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Selected Balance Sheet Information</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>Prepaid expenses and other current assets (in thousands)</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> September&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Intrexon prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,543</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">2,412</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Other receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">2,509</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"></div> </div> </div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"  align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">8</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font>The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>Property and equipment (in thousands)</font></i><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> &#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 8pt"></font>&#160;<div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> September&#160;30,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Computer and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Laboratory equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(173)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(242)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="clear:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">223</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;<font style="FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="left"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">6.</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Stock-Based Compensation</font></b></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">Stock Incentive Plan</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">During 2001, the Company&#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed <font style="FONT-SIZE: 10pt"> 250,000</font>. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of September 30, 2013, there were <font style="FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt">953,507</font></font> options issued and outstanding under the 2001 Stock Plan.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to <font style="FONT-SIZE: 10pt">2,500,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed <font style="FONT-SIZE: 10pt"> 250,000</font>. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> 443,573</font></font> options issued and outstanding under the 2007 Stock Plan.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to <font style="FONT-SIZE: 10pt">3,000,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">2,407,500</font></font> options issued and outstanding under the 2010 Stock Plan.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">9</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"></font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font>The Black-Scholes assumptions used in the three and nine months ended September 30, 2013 and 2012 are as follows:</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div align="center"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="3"> <div style="clear:both;CLEAR: both"> Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%" colspan="5"> <div style="clear:both;CLEAR: both"> Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">$1.96-&#160;$2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">$1.70-&#160;$2.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">153%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">108%&#160;-&#160;174%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0.63%&#160;-&#160;0.65%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0.37%&#160;-&#160;1.98%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both"> 5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both"> 5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="clear:both;CLEAR: both">Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div style="clear:both;CLEAR: both">0% <font style="FONT-SIZE: 10pt"></font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="clear:both;CLEAR: both"></div> </div> </div> <font style="FONT-SIZE: 10pt"></font> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">immediate vesting,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">half vesting immediately and the remainder over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">quarterly over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">annually over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">one-third immediate vesting and remaining annually over two years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">one half immediate vesting with remaining vesting over nine months,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">one quarter immediate vesting with the remaining over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">one quarter immediate vesting with the remaining over 33 months; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">monthly over three years.</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 67.1pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">During the nine months ended September 30, 2013, the Company granted <font style="FONT-SIZE: 10pt">117,500</font> options to employees and directors having an approximate fair value of $<font style="FONT-SIZE: 10pt">185,000</font> based upon the Black-Scholes option pricing model.&#160;During the same period in 2012, the Company granted <font style="FONT-SIZE: 10pt">1,840,000</font> options to employees and consultants having an approximate fair value of $<font style="FONT-SIZE: 10pt">4.0</font> million based upon the Black-Scholes option pricing model.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font>A summary of stock option activities as of September 30, 2013, and for the year ended December 31, 2012, is as follows:</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div style="clear:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div style="clear:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div style="clear:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Average&#160;Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div style="clear:both;CLEAR: both">Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div style="clear:both;CLEAR: both">Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="clear:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Balance - December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2,979,010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">6.01&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2,075,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(374,851)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">0.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(225,413)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Balance - December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">4,453,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">6.43&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1,308,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">117,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(291,666)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">0.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">(475,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Balance &#150; September 30, 2013 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">3,804,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">5.76&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">932,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Balance &#150; September 30, 2013 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2,902,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">5.27&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Grant date fair value of options granted - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">185,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Weighted average grant date fair value - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Grant date fair value of options granted - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">4,468,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="clear:both;CLEAR: both">Weighted average grant date fair value - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;<font style="FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="clear:both;CLEAR: both"></div> </div> </div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"  align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"  align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">10</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"  align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font>Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended September 30, 2013 and 2012 were $<font style="FONT-SIZE: 10pt">338,000</font> and $<font style="FONT-SIZE: 10pt">395,000</font>, respectively, and $<font style="FONT-SIZE: 10pt">1.2</font> million and $<font style="FONT-SIZE: 10pt">1.3</font> million for the nine month periods ended September 30, 2013 and 2012, respectively.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;As of September 30, 2013, total unrecognized stock-based compensation expense related to stock options was $<font style="FONT-SIZE: 10pt">1.9</font> million, which is expected to be expensed through February 2016.<font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font>7.&#160;&#160;&#160;&#160;&#160;Stock Purchase Warrants</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase <font style="FONT-SIZE: 10pt;">635,855</font> shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $<font style="FONT-SIZE: 10pt;">1.60</font> and a life of <font style="FONT-SIZE: 10pt;">five</font> years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of September 30, 2013, all the warrants were outstanding.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for <font style="FONT-SIZE: 10pt;"> 250,000</font> shares of the Company&#8217;s common stock based on achievement of certain stock price milestones. Upon initiation of the program, <font style="FONT-SIZE: 10pt;">50,000</font> of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date of issuance for an exercise price equal to the price ($<font style="FONT-SIZE: 10pt;">2.20</font> per share) of the Company&#8217;s common stock on the date of execution (March 15, 2012). In March 2013, the performance warrants&#8217; vesting period was extended to March 14, 2014. All other provisions of the performance warrants remain unchanged. The incremental expense related to the modification of the warrants of approximately $<font style="FONT-SIZE: 10pt;">76,000</font> will be recognized over the one year extension period.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant was paid a monthly fee and on February 2, 2012, was issued warrants exercisable for <font style="FONT-SIZE: 10pt;">100,000</font> shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price ($<font style="FONT-SIZE: 10pt;">1.14</font>) of the Company&#8217;s common stock on the date of issue. As of September 30, 2013, all the warrants were outstanding.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>A summary of warrant activity for the Company for the nine months ended September 30, 2013 and for the year ended December 31, 2012 is as follows:</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 95%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both"> Number&#160;of&#160;Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="clear:both;CLEAR: both">Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Balance at December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">3,259,186</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">985,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(1,768,167)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">(844,373)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">3.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Balance at December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="66%"> <div style="clear:both;CLEAR: both">Balance at September 30, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="clear:both;CLEAR: both">1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-SIZE: 10pt"></font></div> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Stock-based compensation expense included in general and administrative expenses relating to warrants issued to consultants was $<font style="FONT-SIZE: 10pt;">0</font> and $<font style="FONT-SIZE: 10pt;">1,000</font> for the three months ended September 30, 2013 and 2012, respectively, and $<font style="FONT-SIZE: 10pt;">22,000</font> and $<font style="FONT-SIZE: 10pt;">271,000</font> for the nine months ended September 30, 2013 and 2012, respectively.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">11</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>A summary of all outstanding and exercisable warrants as of September 30, 2013 is as follows:</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div align="center"> <div style="clear:both;POSITION: relative; TEXT-INDENT: 0in; WIDTH: 100%; CLEAR: both" contenteditable="false"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px auto; WIDTH: 88%; BORDER-COLLAPSE: collapse; CLEAR: both; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div style="clear:both;CLEAR: both">Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div style="clear:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div style="clear:both;CLEAR: both">Contractual&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%" colspan="2"> <div style="clear:both;CLEAR: both">Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">3.34&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">54,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">18,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">18,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">2.25&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">635,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">635,855</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">4.08&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">51,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">2.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">0.45&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">3.16&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">1.66&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">2.38&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">1,432,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="clear:both;CLEAR: both">3.03&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div style="clear:both;CLEAR: both">111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="clear:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"></font>8.</font></b> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;<b>Stockholders&#8217; Equity</b></font></div> <div style="clear:both;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">During the nine months ended September 30, 2013, the Company issued <font style="FONT-SIZE: 10pt">291,666</font> shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $<font style="FONT-SIZE: 10pt">231,000</font>.</font></div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"></font></font> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><b><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font>9. Net Loss per Share</font></b></font></font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><b><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></b></font></font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at September 30, 2012 and 2013, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the nine months ended September 30, 2013 were <font style="FONT-SIZE: 10pt">3,804,580</font> and <font style="FONT-SIZE: 10pt">1,632,501</font>, respectively, and for the nine months ended September 30, 2012 were <font style="FONT-SIZE: 10pt"> 4,258,746</font> and <font style="FONT-SIZE: 10pt"> 1,324,102</font>, respectively.</font></font></font></div> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 10pt"></font></font></font> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</font></font></div> <div style="clear:both;TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">12</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL INFORMATION AND RESULTS OF OPERATIONS</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">The following discussion should be read in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2012, found in our Annual Report on Form 10-K. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intends,&#8221; or similar expressions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under &#8220;Risk Factors&#8221; in this 10-Q and as applicable in Part I, Item 1A of our Annual Report on Form 10-K.</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Overview</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We are a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing an oral enzyme for the prevention of <i>C. difficile</i> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <i>Acinetobacter</i> infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"><i> <font style="COLOR: black; FONT-SIZE: 10pt">Product Pipeline:</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><img name="browseimg" src="ft0002img-1.jpg" count="1"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt 31.9pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;<i>Summary of Infectious Disease Programs:</i></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt 34.1pt; CLEAR: both"> <i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Clostridium difficile (C. difficile, C. diff)</font></i></b><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;infections:</font></b> <font style="COLOR: black; FONT-SIZE: 10pt">We are in preclinical development with</font> <font style="FONT-SIZE: 10pt">SYN-004, a novel second-generation oral enzyme drug candidate, for co-administration with commonly used IV antibiotics intended to prevent the development of severe effects of <i>C. diff</i> infections <font style="COLOR: black">(CDI), the leading cause of hospital acquired infections (HAI), that generally occurs secondary to treatment with intravenous antibiotics.</font> Designed to be given orally to protect the gut while certain IV beta-lactam antibiotics (penicillins and cephalosporins) fight the primary infection, SYN-004 is believed to have a similar profile to its first-generation predecessor, which demonstrated favorable protection of the gut flora (microbiome) during <font style="COLOR: black">treatment with certain penicillins, with the potentially added ability to act against</font> a broader spectrum of IV beta-lactam antibiotics. <font style="COLOR: black"> Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.</font> Roughly 14.4 million patients are administered "SYN-004 target" IV beta-lactam antibiotics annually, representing an estimated target market for SYN-004 of 117.6 million beta-lactam doses purchased by U.S. hospitals. While the final dosing regimen for SYN-004 is yet to be determined, the addressable market is extremely significant. Currently there are no approved treatments designed to protect the microbiome from the damaging effects of IV antibiotics. This worldwide opportunity could represent a potential multi-billion dollar market.<font style="COLOR: black">* In October 2013, we initiated</font> manufacturing of SYN-004 material to support our planned preclinical and clinical studies.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">*This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">13</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL"><font style="FONT-FAMILY: SYMBOL"> &#183;</font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt"> Pertussis:</font></b> <font style="COLOR: black; FONT-SIZE: 10pt"> In December 2012, in collaboration with Intrexon Corporation (NYSE: XON) (&#8220;Intrexon&#8221;), we initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough. We are developing a mAb therapy, SYN-005, designed to target and neutralize the pertussis toxin, in order to reduce the mortality rate in infants and potentially shorten the duration of chronic cough in afflicted adults. To further the development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin to license the rights to certain research and pending patents related to pertussis antibodies. According to the World Health Organization, each year, <i>B. pertussis</i> infection causes an estimated 300,000 deaths worldwide, primarily among young, unvaccinated infants.</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-FAMILY: SYMBOL"><font style="FONT-FAMILY: SYMBOL; FONT-SIZE: 10pt"> &#183;</font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Acinetobacter</font></i></b><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;infections:</font></b> <font style="COLOR: black; FONT-SIZE: 10pt">In September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for the treatment of <i>Acinetobacter</i> infections. Many strains of <i>Acinetobacter</i> are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. A treatment for <i>Acinetobacter</i> infections represents a billion dollar market opportunity.</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Summary of Multiple Sclerosis Program:</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-FAMILY: SYMBOL; FONT-SIZE: 10pt">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Trimesta</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">(oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting multiple sclerosis (MS) in women. Patient enrollment is complete in this two-year, randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. The primary endpoint is relapse rate at two years, with top-line results expected in 1H 2014. This trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial through completion. Annual worldwide sales of current MS therapies are estimated at $14.1 billion.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL"> &#183;</font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Trimesta</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at the University of California, Los Angeles (UCLA). The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test (PASAT). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations and charitable organizations and we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment.</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 100.1pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 34.1pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Summary of Fibromyalgia Program:</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 10%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="10%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL"> &#183;</font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 83%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="83%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"> Effirma</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">(flupirtine) is being developed for the treatment of fibromyalgia by Meda AB (Meda), a multi-billion dollar international pharmaceutical company. On May 6, 2010, we entered into a sublicense agreement with Meda covering all of our patents&#8217; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. The sublicense agreement provides that all ongoing and future development costs are to be borne by Meda and we are entitled to receive certain payments if milestones are achieved and royalties on sales. According to Meda&#8217;s 2012 Year-End Report filed in February 2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia. Meda also announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted at 25 clinics in the U.S. Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In order to further prioritize our focus, we elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, we are seeking development partners for our zinc-based intellectual property and assets including, AEN-100.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Recent Developments</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On December 19, 2012, we entered into a Patent License Agreement (the &#8220;License Agreement&#8221;) with The University of Texas at Austin (the &#8220;University&#8221;) for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to Pertussis (more commonly known as whooping cough) antibodies developed in the lab of Dr. Jennifer A. Maynard, Assistant Professor of Chemical Engineering. In connection with the License Agreement, we and the University also entered into a Sponsored Research Agreement pursuant to which the University&#160;is performing certain research work related to pertussis under the direction of Dr. Jennifer Maynard and we will obtain certain rights to patents and technology developed during the course of such research.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">14</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On November 28, 2012, a closing was held for the transaction contemplated by the Asset Purchase Agreement (the &#8220;Prev Agreement&#8221;) we entered into with Prev ABR LLC (&#8220;Prev&#8221;), pursuant to which we acquired the <i>C. diff</i> program assets of Prev, including pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents. Pursuant to the Prev Agreement, we paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev. In addition, upon the achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable 50% in cash and 50% in our stock, subject to Prev&#8217;s option to receive the entire payment in shares of our stock, with the exception of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial; (v) upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi) upon BLA approval in the U.S. and upon approval in territories outside the U.S.&#160;The future stock issuances are subject to prior approval of the NYSE MKT, LLC. No royalties are payable to Prev under the Prev Agreement. The Prev Agreement also provides that Prev has a right to the return to it of all assets acquired by us under the Prev Agreement if on or prior to the date that is (i) thirty (30) months after the execution of the Prev Agreement, we have not initiated toxicology studies in non-rodent models or (ii) thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty (30) and thirty six (36) month periods can be extended by us for an additional twelve (12) months upon payment of a cash milestone payment.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On October 30, 2012, we completed a private placement (the &#8220;October 2012 Private Placement&#8221;) with certain accredited investors, pursuant to which we sold an aggregate of 6,750,000 shares of our common stock at a price per share of $1.60 (the &#8220;Common Shares&#8221;) for aggregate gross proceeds of $10.8 million and net proceeds of $10.1 million. In connection with the October 2012 Private Placement, we filed a registration statement with the SEC which was declared effective on December 20, 2012 for the resale of our common stock owned by certain of the purchasers in the October 2012 Private Placement. In connection with the October 2012 Private Placement, we also entered into an agreement with a certain purchaser that is an affiliate of Intrexon (the &#8220;Joinder Agreement&#8221;) pursuant to which such purchaser agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement with us entered into in connection with the Second Channel Agreement (the &#8220;First Amendment to Registration Rights Agreement&#8221;) and we registered the shares issued to such purchaser in accordance with the First Amendment to Registration Rights Agreement.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Griffin Securities, Inc. (&#8220;Griffin&#8221;) served as the placement agent for the October 2012 Private Placement. In consideration for services rendered by Griffin in the October 2012 Private Placement, we (i) paid to Griffin cash commissions equal to 6.0% of the gross proceeds received in the October 2012 Private Placement, (ii) issued to Griffin, or its designee, warrants, which are five-year warrants to purchase 635,855 shares of our common stock with an exercise price of $1.60 per share (the &#8220;Agent Warrants&#8221;); and (iii) reimbursed Griffin for its reasonable actual out-of-pocket expenses incurred in connection with the October 2012 Private Placement, including reasonable legal fees and disbursements. The common stock underlying the Agent Warrants was registered under the registration statement declared effective on December 20, 2012.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On August 6, 2012, we expanded our relationship with Intrexon and entered into a Second Channel Agreement with Intrexon (the &#8220;Second Channel Agreement&#8221;) that governs an &#8220;exclusive channel collaboration&#8221; arrangement in which we will use Intrexon&#8217;s technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases (the &#8220;Program&#8221;). The Second Channel Agreement establishes committees comprised of our and Intrexon representatives that will govern activities related to the Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. On October 16, 2012, a closing was held for the transaction contemplated by the Second Channel Agreement. Pursuant to the terms of a Stock Issuance Agreement with Intrexon (the &#8220;Second Stock Purchase Agreement&#8221;), we issued 3,552,210 shares of our common stock, $0.001 par value, which issuance is also deemed paid in consideration for the execution and delivery of the Second Channel Agreement, dated August 6, 2012, between ourselves and Intrexon. We registered the shares issued to Intrexon in accordance with the First Amendment to Registration Rights Agreement.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On February 15, 2012, upon stockholder approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues trade on the NYSE MKT (formerly the NYSE Amex and American Stock Exchange), under the symbol &#8220;SYN&#8221;. Prior to this time and since October 16, 2008, our name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE MKT stock exchange under the symbol &#8220;AEN&#8221;. We are incorporated in the State of Nevada.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On December 21, 2011, we announced that the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic biology. In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the Adeona Clinical Laboratory (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner, in consideration for (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000) payable pursuant to the terms of a two-year non-recourse promissory note secured by all of the assets of the Lab.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">15</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On November 18, 2011, we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon 3,123,558 shares of our common stock at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed paid in consideration for the execution and delivery of the channel agreement which was entered into on November 18, 2011 and terminated on April 16, 2013. We also agreed to an equity participation right in future securities offerings.</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Since our inception in January 2001, our efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising capital and recruiting personnel. As of June 30, 2010, we emerged from the development stage after entering into a sublicense agreement with Meda AB and receiving an up-front payment of $2.5 million.&#160;We consider this sublicense agreement to be an indication that we commenced our principal operations.</font></div> <div style="clear:both;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt 29.7pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">To date, we have financed our operations primarily through public and private sales of our common stock, and we expect to continue to seek&#160;and obtain the required capital in a similar manner. We have incurred an accumulated deficit of $77 million through September 30, 2013. We cannot provide any assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete additional corporate partnering or acquisition transactions.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Pipeline Programs and Therapeutic Areas</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><u><font style="COLOR: black; FONT-SIZE: 10pt"> Infectious Disease Programs</font></u></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We are focused on the development of biologics for the prevention and treatment of serious infectious diseases. Infectious disease outbreaks are increasing while intervention options are declining due to widespread multidrug-resistant bacteria, increasing numbers of immuno-compromised patients (e.g. the elderly and cancer patients), and the isolation of new pathogens. We are developing an oral enzyme for the prevention of <i>C. difficile</i> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <i>Acinetobacter</i> infections.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">C. difficile Infections</font></i></b><b><font style="COLOR: black; FONT-SIZE: 10pt">:</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">According to the Agency for Healthcare Research and Quality, aggregate costs associated with CDI-related stays in the hospital were $8.2 billion in the U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by <i>C. difficile</i> bacteria result in diarrhea (<i>C. difficile</i>-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death. The</font> <font style="FONT-SIZE: 10pt">Centers for Disease Control and Prevention (CDC) recently identified <i>C. diff</i> as an &#8220;urgent public health threat,&#8221; particularly given its resistance to many drugs used to treat other infections. <font style="COLOR: black"> CDI is a major, unintended risk associated with the prophylactic or therapeutic use of intravenous antibiotics, which may alter the natural balance of microflora that normally protect the GI tract, leading to <i>C. difficile</i> overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">CDI is a widespread and often drug resistant infectious disease, and it is estimated that 1.1 million patients are infected with <i>C. diff</i> annually in the U.S.*, and it has been reported that</font> <font style="FONT-SIZE: 10pt">30,000 patients die with a <i>C. diff</i> infection annually. <font style="COLOR: black">CDI has surpassed methicillin-resistant staphylococcus aureus (MRSA) as the most frequent infection acquired in the hospital. Controlling the spread of CDI has proven challenging, as the <i>C. difficile</i> spores are easily transferred to patients via normal contact with healthcare personnel and other inanimate objects. There is currently no vaccine or approved product for the prevention of <i>C. diff</i> infection.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">C. difficile: Acquisition of Clinical-Stage Program</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In November 2012, we acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of CDI, the leading cause of HAIs that generally occurs secondary to treatment with intravenous antibiotics. The acquired assets include a pre-IND package for P3A (SYN-004), Phase I and Phase II clinical data for P1A, manufacturing processes and data, and a portfolio of issued and pending U.S. and international patents intended to support an IND and BLA with the FDA. Utilizing this portfolio of assets, we intend to develop a proprietary oral beta-lactamase enzyme product candidate, SYN-004, previously known as IPSAT P3A. When co-administered with certain intravenous beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the GI tract, thus preserving the natural balance of the patient's microflora, and preventing opportunistic infections including CDI. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.</font> <font style="FONT-SIZE: 10pt">Roughly 14.4 million patients are administered "SYN-004 target" IV beta-lactam antibiotics annually, representing an estimated target market for SYN-004 of 117.6 million beta-lactam doses purchased by U.S. hospitals. While the final dosing regimen for SYN-004 is yet to be determined, the addressable market is extremely significant. Currently there are no approved treatments designed to protect the microbiome from the damaging effects of IV antibiotics. This worldwide opportunity could represent a potential multi-billion dollar market.<font style="COLOR: black">*</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">C. difficile: Oral Enzyme Background</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A). Beta-lactamase enzymes have the ability to degrade beta-lactam antibiotics that may be excreted into the GI tract. P1A (the first generation candidate) showed acceptable safety and tolerability in a Phase I study. In addition, two Phase II clinical studies demonstrated that P1A had the ability to preserve GI microflora in hospitalized patients treated with intravenous ampicillin or the combination of piperacillin and tazobactam.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> </font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><i> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></i></div> <div style="clear:both;CLEAR: both"><i><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">16</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></i><i><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">C. difficile: Clinical Development</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Compared to the first generation oral enzyme candidate, P1A, we believe that SYN-004 (formerly P3A) will have activity against a broader spectrum of beta-lactam antibiotics, including both penicillins and cephalosporins. Due to the structural similarities between P1A and SYN-004 for the prevention of CDI, along with previous discussions with the FDA, it is anticipated that certain preclinical data collected on P1A may be used in support of an IND for our new product candidate, SYN-004.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In October 2013, we initiated</font> <font style="FONT-SIZE: 10pt"> manufacturing of SYN-004 material to support our planned preclinical and clinical studies.<font style="COLOR: black">&#160;We anticipate initiating a Phase I clinical trial in the 2<sup>nd</sup> half of 2014.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">*This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Monoclonal Antibodies:</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Monoclonal Antibodies for Infectious Diseases</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Acting as the body's army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and bacteria and their associated toxins. MAbs can also be designed and produced as therapeutic agents, utilizing protein engineering and recombinant production technologies. The mAbs being developed under our collaboration with Intrexon are intended to supplement a patient's own immune system by providing the means to specifically and rapidly neutralize and/or clear specific pathogens and toxins of interest in a process known as &#8220;passive immunity&#8221;. Many pathogens that cause infectious diseases are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Intrexon Collaboration: Monoclonal Antibodies for Infectious Diseases</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In August 2012, we entered into a worldwide exclusive channel collaboration with Intrexon through which we intend to develop a series of mAb therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon&#8217;s comprehensive suite of proprietary technologies, including the mAbLogix platform for rapid discovery of fully human mAbs and the LEAP cell processing station, our initial efforts will target three infectious disease indications. **&#160;We also have the option to target an additional five infectious disease indications under this collaboration. To date, we have initiated development of a mAb therapy for the treatment of Pertussis and <i> Acinetobacter</i> infections.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> **mAbLogix</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">and LEAP</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">are registered trademarks of Intrexon Corporation</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Bordetella pertussis (B. pertussis)</font></i> <font style="COLOR: black; FONT-SIZE: 10pt">is a gram-negative bacterium that infects the upper respiratory tract, causing uncontrollable, violent coughing. Antibiotic treatment does not have a major effect on the course of Pertussis, because while it can eliminate the <i> B. pertussis</i> bacteria from the respiratory tract, it does not neutralize the pertussis toxin. Infants with Pertussis often require hospitalization in pediatric intensive care units, frequently requiring mechanical ventilation. Pertussis in adults generally leads to a chronic cough referred to as the "cough of 100 days." The incidence of Pertussis is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated, exposure of individuals whose immunity has diminished over time, as well as asymptomatic carriers.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">According to the World Health Organization, each year, <i>B. pertussis</i> infection causes an estimated 300,000 deaths worldwide, primarily among young, unvaccinated infants. Recent news reports throughout the U.S. indicate that the pertussis vaccine introduced in the 1990s does not provide long-term protection and, as a result, whooping cough cases are increasing to a 60-year high. There is no approved treatment for Pertussis, and antibiotic treatment does not have a major effect on the course of Pertussis, because while it can eliminate the <i>B. pertussis</i> bacteria from the respiratory tract, it does not neutralize the pertussis toxin.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Pertussis: Intrexon Collaboration and The University of Texas at Austin Agreement</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In December 2012, we initiated mAb development for the treatment of Pertussis focusing on toxin neutralization pursuant to our August 2012 collaboration with Intrexon. Unlike antibiotics, we are developing a mAb therapy, SYN-005, to target and neutralize the pertussis toxin, in order to reduce the mortality rate in infants and potentially shorten the duration of chronic cough in afflicted adults. SYN-005 is currently in preclinical studies.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">To further the development of this potential therapy for pertussis, we have entered into an agreement with The University of Texas at Austin to license the rights to certain research and pending patents related to pertussis antibodies. These research efforts are being conducted at the Cockrell School of Engineering in the laboratory of Assistant Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial Faculty Fellow in the McKetta Department of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the key neutralizing epitopes of pertussis toxin to optimize the potential efficacy of antibody therapeutics.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">17</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Pertussis: Clinical Development</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We intend to initiate a large animal, IND-enabling study in the 1<sup>st</sup> quarter of 2014, with topline results expected in the 2<sup>nd</sup> quarter of 2014. If successful, we intend to initiate a Phase I clinical trial in the 2<sup>nd</sup> quarter of 2015.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Acinetobacter Infections:</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Acinetobacter baumanii</font></i> <font style="COLOR: black; FONT-SIZE: 10pt">is a difficult to treat pathogen due to its rapid and well-established development of resistance to most antibiotics, making it a multidrug-resistant pathogen. In addition, as a biofilm-forming pathogen, <i>Acinetobacter baumanii</i> has the ability to survive up to twice as long as non-biofilm-forming pathogens. In the U.S., <i>&#160;Acinetobacter baumanii</i> &#160;has been reported to be the cause of up to 2.6% of hospital acquired infections, 1.3% of bloodstream infections and 7% of ICU respiratory tract infections, and more than half of the <i>&#160;Acinetobacter baumanii</i> &#160;isolates are multidrug-resistant. According to published articles, mortality rates as high as 43% are reported in hospital and ICU settings. While <i>Acinetobacter baumanii</i> is a well-documented pathogen in the hospital setting, this pathogen also poses an increasing danger to wounded servicemen and women in military treatment centers and to those treated in trauma centers following natural disasters.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A treatment for <i>Acinetobacter</i> infections represents a billion dollar market opportunity.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Acinetobacter: Intrexon Collaboration</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In August 2012, we initiated a mAb discovery and development program for <i> Acinetobacter</i> infections pursuant to our August 2012 collaboration with Intrexon. Discovery efforts for the development of a mAb are currently underway.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><u><font style="COLOR: black; FONT-SIZE: 10pt"> Multiple Sclerosis Program</font></u></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Relapsing-Remitting MS in Women:</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">MS is a progressive neurological disease in which the body loses the ability to transmit messages along central nervous system nerve cells, leading to pain, loss of muscle control, paralysis, cognitive impairment and in some cases death. According to the National Multiple Sclerosis Society (NMSS), more than 2.1 million people worldwide (approximately 400,000 patients in the U.S. of which approximately 65% are women) have been diagnosed with MS. The diagnosis is typically made in young adults, ages 20 to 50. According to the NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting form, and 10-15% with other progressive forms.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Rebif</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Avonex</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Copaxone</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Tysabri</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Gilenya</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Extavia</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Aubagio</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">and Tecfidera</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">. Many of these therapies provide only a modest benefit for patients with relapsing-remitting MS. All of these drugs except Gilenya</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Aubagio</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">and Tecfidera</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">TM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">require frequent (daily, weekly &amp; monthly) injections (or infusions) on an ongoing basis and can be associated with unpleasant side effects (such as flu-like symptoms) and high rates of non-compliance among users. Despite the availability of therapies for the treatment of relapsing-remitting MS, the disease is highly underserved and exacts a heavy personal and economic toll. Annual worldwide sales of current MS therapies are estimated at $14.1 billion.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="COLOR: black; FONT-SIZE: 10pt">Relapsing-Remitting MS: Background</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Research has shown that pregnant women with MS tend to experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester. The PRIMS (Pregnancy In MS) study, a landmark observational clinical study published in the <i>New England Journal of Medicine</i> followed 254 women with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated that relapse rates were significantly reduced by 71% (p &lt; 0.001) through the third trimester of pregnancy compared to pre-pregnancy-rates, and that relapse rates increased by 120% (p &lt; 0.001) during the first three months after birth (post-partum) and then return to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol, produced by the placenta during pregnancy, plays a role in&#160;&#8220;fetal immune privilege&#8221;, a process that prevents&#160;a mother&#8217;s immune system from attacking and rejecting the fetus. The maternal levels of estriol increase linearly through the third trimester of pregnancy until birth, whereupon it abruptly returns to low circulating levels. The anti-autoimmune effects of estriol are thought to be responsible for the therapeutic effects of pregnancy on MS.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Rhonda Voskuhl, M.D., Director, UCLA MS program, UCLA Department of Neurology, has found that plasma levels of estriol achieved during pregnancy have potent immunomodulatory effects. She further postulated and tested in a pilot clinical study that oral doses of estriol may have a therapeutic benefit when administered to non-pregnant female MS patients by, in essence, mimicking the spontaneous reduction&#160;in relapse rates seen in MS patients during pregnancy.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Estriol has been approved and marketed for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by the U.S. FDA for any indication.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">18</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Relapsing-Remitting MS: Clinical Development</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Trimesta (oral estriol) is being developed for the treatment of relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured by brain magnetic resonance imaging (an established neuroimaging measure of disease activity in MS). Over the next three months of treatment with Trimesta, the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82% (p = 0.09). They remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and numbers decreased by 82% (p =0.02). Following a six-month drug holiday during which the patients were not on any drug therapies, median lesion volumes and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88% (p = 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A Phase II randomized, double-blind, placebo-controlled clinical trial is currently underway at 15 centers in the U.S. under the direction of Lead Principal Investigator, Dr. Rhonda Voskuhl. The purpose of this clinical trial is to evaluate whether 8 mg of oral Trimesta taken daily over a two year period will reduce the rate of relapses in a large population of female patients with relapsing-remitting MS. Investigators are administering either Trimesta or matching placebo, in addition to a standard of care, glatiramer acetate injections (Copaxone</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">), an FDA-approved therapy for MS, to women between the ages of 18 to 50 who have been recently diagnosed with relapsing-remitting MS. Relapse rates at two years is the primary endpoint in this clinical trial being run under an investigator-initiated IND. As of January 23, 2012, 164 patients have been enrolled and enrollment has been closed. The patients will be dosed and monitored for two years with the last patient scheduled to complete two years of therapy in January 2014.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">With over $8 million in grant funding to date from organizations such as the National Institutes for Health and the National Multiple Sclerosis Society, the ongoing Trimesta clinical trial should be funded to its completion.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="COLOR: black; FONT-SIZE: 10pt">Relapsing-Remitting MS: Patents</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt">In April 2013, we announced that the U.S. Patent &amp; Trademark Office issued U.S. Patent No. 8,372,826 entitled, <i>Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases</i>, to the Regents of the University of California which includes claims to the use of our drug candidate, Trimesta&#153; (oral estriol), in combination with glatiramer acetate injection (Copaxone&#174;). According to Teva Pharmaceutical Industries Ltd.&#8217;s Form 20-F for the year ended December 31, 2012, filed with the SEC on February 12, 2013. Copaxone&#174; is the number one selling drug for multiple sclerosis with approximately $4 billion in annual sales. Currently marketed exclusively by Teva Pharmaceutical Industries Ltd., Copaxone&#174; is expected to face generic competition as certain patent terms begin to expire in 2014. Through our wholly owned subsidiary, we hold the exclusive worldwide license to U.S. Patent 8,372,826 and 6,936,599 and pending patents for multiple sclerosis and other autoimmune diseases covering the uses of our drug candidate, Trimesta&#153;.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">Cognitive Dysfunction in MS:</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">According to the NMSS and the Multiple Sclerosis Society of Canada publication, <i>Hold that Thought! Cognition and MS</i>, it is fairly common for people with MS to complain of cognitive difficulties, such as remembering things, finding the right words and the ability to concentrate. Among MS patients, 50-65% have some degree of cognitive dysfunction.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The major areas of cognition that may be affected include complex attention and executive functions<i>.</i> Complex attention involves multitasking, the speed with which information can be processed, learning and memory, and perceptual skills; executive functions include problem solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related physical problems can widely vary, not all people with MS will have cognitive dysfunction, and no two people will experience exactly the same type or severity.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="COLOR: black; FONT-SIZE: 10pt">Cognitive Dysfunction in MS: Background</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In the investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement from baseline in the PASAT cognitive testing scores (p = 0.04) was observed in relapsing-remitting MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores are expressed as a mean percent change from baseline.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><i><font style="COLOR: black; FONT-SIZE: 10pt">Cognitive Dysfunction in MS: Clinical Development</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our Trimesta (oral estriol) drug candidate is also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate Trimesta&#8217;s potential neuroprotective and therapeutic effect on cognitive dysfunction in female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at UCLA. Up to 64 patients between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Dr. Voskuhl will administer either oral Trimesta or a matching placebo, in addition to any FDA-approved MS treatment. Each patient will be dosed and monitored for one year after being enrolled. The primary endpoint in this clinical trial being run under an investigator-initiated IND application is expected to be improvement in PASAT cognitive testing scores versus matching placebo. We and a private foundation have pledged to equally support this new clinical trial, and we will also provide Trimesta drug supply. The trial also received contributions from several other supporters. Patient recruitment and enrollment into this trial is ongoing.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">19</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i><u> <font style="COLOR: black; FONT-SIZE: 10pt">Fibromyalgia Program</font></u></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <b><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, often accompanied by severe fatigue, insomnia and alterations in mood. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million people in the U.S. There are presently three FDA products approved for the treatment of fibromyalgia - Lyrica&#160;</font> <sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">, Cymbalta&#160;</font> <sup><font style="COLOR: black; FONT-SIZE: 9pt">&#174;</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">and Savella&#160;</font> <sup><font style="COLOR: black; FONT-SIZE: 9pt"> &#174;</font></sup><font style="COLOR: black; FONT-SIZE: 10pt">.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Based on an estimated annual price of $1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Fibromyalgia</font></i><font style="COLOR: black; FONT-SIZE: 10pt">: <i>Meda Corporate Partnership</i></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On May 6, 2010, we entered into a sublicense agreement with Meda, a multi-billion dollar international pharmaceutical company, pursuant to which Meda assumed all future development costs and may commercialize flupirtine, a molecular entity with a unique mode of action for the treatment of fibromyalgia in the U.S. As consideration for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon the FDA&#8217;s acceptance of the New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million upon FDA approval of such NDA. Pursuant to the sublicense agreement, we will also receive a 7% royalty on net sales of flupirtine for fibromyalgia in the U.S., Canada and Japan, with such royalties being shared equally with our licensor, McLean Hospital, a Harvard teaching hospital.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Flupirtine is approved and marketed by Meda and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to millions of patients worldwide. We believe that such substantial human experience with flupirtine should greatly assist the FDA in its evaluation of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> Fibromyalgia</font></i><font style="COLOR: black; FONT-SIZE: 10pt">: <i>Clinical Development</i></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our Effirma (flupirtine) drug candidate for the treatment of fibromyalgia, has been partnered to Meda (see &#8220;Fibromyalgia: Meda Corporate Partnership&#8221; section above). Effirma is a selective neuronal potassium channel opener that also has N-methyl-D-aspartic (NMDA) receptor antagonist properties. Effirma is a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that Effirma should also be effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable from most marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits no known abuse potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed. One common link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major receptor subtype for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic acid-mediated neurotransmission. Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda) and has been approved and is marketed by Meda in Europe since 1984, as well as other countries, for the treatment of pain. It has never been approved by the FDA for any indication.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt 27.5pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">According to Meda&#8217;s 2012 Year-End Report filed in February 2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia. Meda also announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted at 25 clinics in the U.S.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Critical Accounting Policies</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described in the MD&amp;A section in our 2012 Form 10-K.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Results of Operations</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">Three Months Ended September 30, 2013 and 2012</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">General and Administrative Expenses</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">General and administrative expenses increased by 76% to $1.9 million for the three months ended September 30, 2013, from $1.1 million&#160;for the three months ended September 30, 2012. &#160;This increase is primarily the result of bad debt expense of $763,000 associated with the determination that the note receivable and interest receivable from the sale of Adeona Clinical Laboratory is&#160;uncollectible. <i>See Note 3 - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.</i> The charge relating to stock-based compensation expense was $264,000 for the three months ended September 30, 2013, compared to $279,000 for the three months ended September 30, 2012.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">20</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Research and Development Expenses</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Research and development expenses increased by 93% to $1.5 million for the three months ended September 30, 2013, from $763,000 for the three months ended&#160;September 30, 2012. This increase is primarily the result of additional employee costs and increased program costs associated with our infectious disease programs. Research and development expenses also include a charge relating to non-cash stock-based compensation expense of $74,000 for the three months ended September 30, 2013, compared to $116,000 for the three months ended September 30, 2012.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Other Income (Expense), Net</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Other expense was $3,000 for the three months ended September 30, 2013, compared to other income of $10,000 for the three months ended September 30, 2012.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Loss from Continuing Operations</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our loss from continuing operations was $3.4 million, or $0.06 per common share for the three months ended September 30, 2013, compared to a net loss from continuing operations of $1.8 million, or $0.05 per common share for the three months ended September 30, 2012.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Loss from Discontinued Operations</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our loss from discontinued operations was $104,000, or $0.00 per common share for the three months ended September 30, 2012. On March 8, 2012, we entered into a Membership Interest Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC. This resulted in the classification of the Lab as discontinued operations. <i>&#160;See Note 3 - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</i><font style="FONT-SIZE: 10pt">&#160;</font> for summarized statement of operations data for the three months ended September 30, 2013 and 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">Nine Months Ended September 30, 2013 and 2012</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">General and Administrative Expenses</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">General and administrative expenses increased to $4.3 million for the nine months ended September 30, 2013, from $3.7 million for the nine months ended September 30, 2012. This increase of 15% is primarily the result of&#160;bad debt expense of $736,000 associated with the determination that the note receivable and interest receivable from the sale of Adeona Clinical Laboratory is uncollectible. <i> See Note 3 - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.</i> The charge relating to share-based compensation expense was $916,000 for the nine months ended September 30, 2013, compared to $1.1 million for the nine months ended September 30, 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;<i>Research and Development Expenses</i></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Research and development expenses increased to $3.8 million for the nine months ended September 30, 2013, from $1.7 million for the nine months ended September 30, 2012. This increase of 124% is primarily the result of additional employee costs and increased program costs associated with our infections disease programs. Research and development expenses also include a charge relating to share-based compensation expense of $286,000 for the nine months ended September 30, 2013, compared to $238,000 for the nine months ended September 30, 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Other Income (Expense), Net</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Other expense was $27,000 for the nine months ended September 30, 2013, compared to other income of $22,000 for the nine months ended September 30, 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Loss from Continuing Operations</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our loss from continuing operations was $8.1 million, or $0.16 per common share for the nine months ended September 30, 2013, compared to a net loss from continuing operations of $5.4 million, or $0.16 per common share for the nine months ended September 30, 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Income from Discontinued Operations</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our income from discontinued operations was $389,000, or $0.01 per common share for the nine months ended September 30, 2012. On March 8, 2012, we entered into a Membership Interest Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC. This resulted in the classification of the Lab as discontinued operations. <i>&#160;See Note 3 - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</i><font style="FONT-SIZE: 10pt">&#160;</font> for summarized statement of operations data for the nine months ended September 30, 2013 and 2012.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Liquidity and Capital Resources</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We have financed our operations since inception primarily through proceeds from equity financings, corporate partnering license fees, laboratory revenues and miscellaneous equipment sales.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt"> </font></div> <div style="clear:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt"><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt"> &#160;</font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">21</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our cash totaled $5.1 million as of September 30, 2013, a decrease of $4.8 million from December 31, 2012.&#160;During the nine months ended September 30, 2013, the primary sources of cash were proceeds from stock option exercises of $231,000. The primary use of cash during the nine months ended September 30, 2013 was for working capital requirements and operating activities which resulted in a net loss of $8.1 million for the nine months ended September 30, 2013.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our continued operations will primarily depend on our ability to raise additional capital from various sources including equity and debt financings, as well as, license fees from potential corporate partners, joint ventures and grant funding. Such additional funds may not become available on acceptable terms and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give no assurances that any additional capital that we are able to obtain will be sufficient to meet our needs.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><i><font style="COLOR: black; FONT-SIZE: 10pt">Current and Future Financing Needs</font></i></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We have incurred an accumulated deficit of $77 million through September 30, 2013. With the exception of the quarter ended June 30, 2010, we have incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical trials, and our research and discovery efforts.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the progress of our research activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the number and scope of our research programs;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the progress of our preclinical and clinical development activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the progress of the development efforts of parties with whom we have entered into research and development agreements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">costs associated with additional clinical trials of our product candidates;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">our ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">our ability to achieve our milestones under licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="95%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">the costs and timing of regulatory approvals.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources, including sales of securities pursuant to the terms of the Controlled Equity Offering <sup>SM</sup> Agreement that we entered into with Cantor Fitzgerald &amp; Co., as sales agent, that provides us with the ability to conduct an at-the-market (ATM)&#160;public offering for up to $15 million of shares of common stock at prices to be determined at the time of sale. As of the date of this filing, we have not sold any shares under the ATM.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations and our business, financial condition and results of operations would be materially harmed.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"><b> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></b></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">22</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biologics, Inc. is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 4. CONTROLS AND PROCEDURES</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt"> (a)&#160;&#160;Evaluation of disclosure controls and procedures</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;), the Company carried out an evaluation, with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), of the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&#8217;s CEO and CFO concluded that the Company&#8217;s disclosure controls and procedures are effective as of September 30, 2013 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;TEXT-INDENT: 14.3pt; MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both"> <b><font style="COLOR: black; FONT-SIZE: 10pt">(b) &#160;&#160;Changes in Internal Control over Financial Reporting</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended September 30, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt 14.3pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">23</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<font style="FONT-SIZE: 10pt">&#160;</font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><b><font style="COLOR: black; FONT-SIZE: 10pt">PART II-OTHER INFORMATION</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">None.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 1A. RISK FACTORS</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The following information updates, and should be read in conjunction with, the information disclosed in Part&#160;1,&#160;Item&#160;1A, &#8220;Risk Factors,&#8221; of our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2012, which was filed with the Securities and Exchange Commission on April 16, 2013.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt">RISKS RELATING TO OUR BUSINESS</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">We will need to raise additional capital to operate our business.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <b><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">With the exception of the three months ended June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect to incur additional operating losses in the future and therefore our cumulative losses to increase. To date, other than the licensing fee we received from Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the U.S., Canada and Japan and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March 2012, we have generated very minimal revenues. Inasmuch as our sole source of revenue (with the exception of the Meda licensing fee) has been our laboratory revenue and our laboratory was sold in March 2012, we do not expect to derive revenue from any source in the near future until we or our partners successfully commercialize our products. As of September 30, 2013, our accumulated deficit totaled approximately $77 million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient to sustain our operations, we will need to seek additional sources of financing and such additional financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive effect on our stockholders.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We have not been able to sustain profitability.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Other than with respect to the three months ended June 30, 2010, we have a history of losses and we have incurred,&#160;and&#160;will continue to incur, substantial losses and negative operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still incur substantial losses for the foreseeable future and may not sustain profitability. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we do the following:</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">continue to undertake preclinical development and clinical trials for our product candidates;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">expand our research activities with Intrexon relating to monoclonal antibodies for infectious diseases;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">seek regulatory approvals for our product candidates;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">develop our product candidates for commercialization;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">implement additional internal systems and infrastructure;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">lease additional or alternative office facilities; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 86%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="86%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">hire additional personnel, including members of our management team.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We may experience negative cash flow for the foreseeable future as we fund our technology development with capital expenditures. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. Our failure to achieve or maintain profitability could negatively impact the value of our common stock and underlying securities.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">Our research and development efforts may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We must continue to explore opportunities that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at any point in the process, including after significant funds have been invested.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">24</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Regardless of whether our clinical trials are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully develop new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations. Innovations may not be quickly accepted in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">The technology on which our channel partnering arrangement with Intrexon is based on early stage technology.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On August 8, 2012, we announced an exclusive channel collaboration with Intrexon relating to the design, production, testing and commercialization of monoclonal antibodies for the treatment of certain infectious diseases. Although monoclonal antibody therapeutics are well established in the biotechnology and pharmaceutical sectors, their use for the treatment of infectious disease is extremely limited. In order for monoclonal antibodies to be effective for infectious diseases, they must not only properly target the organism of interest (or its toxins), but may also need to overcome defenses and forms of resistance of such organisms. To accomplish this may require the use of more than one specific monoclonal antibody, and mixtures of different monoclonal antibodies, which may create additional unforeseen complications, including increased manufacturing complexity and expense. In order to be competitive, monoclonal antibodies will be required to be produced at a low enough cost of goods in order to be profitably marketed. We have very limited development and manufacturing experience in the field of monoclonal antibodies and infectious disease. We cannot assure that any monoclonal antibody candidates will provide satisfactory in vitro and in vivo nonclinical results sufficient to warrant the expense of cGMP manufacture and clinical testing in human clinical trials.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We may not generate additional revenue from our relationships with our corporate&#160;collaborators.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On May 6, 2010, we entered into a sublicense agreement with Meda AB whereby we may receive milestone payments totaling $17.5 million (including an upfront payment of $2.5 million that has already been received), plus royalties on our flupirtine program. There can be no assurance that Meda AB will successfully develop flupirtine for fibromyalgia in the U.S., Canada or Japan that would allow us to receive such additional $15 million in milestone payments and royalties on sales in connection with such agreement. The successful achievement of the various milestones set forth in the sublicense agreement is not within our control and we will be dependent upon Meda AB for achievement of such milestones. According to Meda&#8217;s 2012 Year-End Report filed in February 2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia. There can be no assurance that Meda will initiate or successfully complete such planned study.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We have experienced several management changes.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We have had significant changes in management in the past few years. Jeffrey Riley was appointed Chief Executive Officer and President on February 3, 2012. Effective February 6, 2012, C. Evan Ballantyne was appointed Chief Financial Officer. James S. Kuo, M.D., served as Chief Executive Officer and President from February 6, 2010 until February 3, 2012. Changes in our key positions, as well as additions of new personnel and departures of existing personnel, can be disruptive, might lead to additional departures of existing personnel and could have a material adverse effect on our business, operating results, financial results and internal controls over financial reporting.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We may not be able to retain rights licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to develop, manufacture, and market our products.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In addition to our own patent applications, we also currently rely on licensing agreements with third party patent holders/licensors for our products. We have an exclusive license agreement with the McLean Hospital relating to the use of flupirtine to treat fibromyalgia which was sublicensed to Meda AB and an exclusive license agreement with the Regents of the University of California relating to our Trimesta technology. Each of these agreements requires us or our sublicensee to use our best efforts to commercialize each of the technologies as well as meet certain diligence requirements and timelines in order to keep the license agreement in effect. In the event we or our sublicensee are not able to meet our diligence requirements, we may not be able to retain the rights granted under our agreements or renegotiate our arrangement with these institutions on reasonable terms, or at all. Furthermore, we currently have very limited product development capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed the technologies. Our exclusive channel collaboration agreement with Intrexon provides that Intrexon may terminate&#160;the agreement if we do not perform certain specified requirements, including developing therapies considered superior. Our agreement with The University of Texas allows the University to terminate its agreement if we fail to comply with the terms of the agreement. Our agreement with Prev provides Prev with the right to the return of the assets if we do not perform certain requirements.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">25</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We can give no assurances that any of our issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection or be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability, nor does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We will incur additional expenses in connection with our exclusive channel collaboration arrangement with Intrexon and our agreement with Prev.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Pursuant to our exclusive channel collaboration with Intrexon, we are responsible for future research and development expenses of product candidates developed under our collaboration, the effect of which has and will continue to increase the level of our overall research and development expenses going forward. Our agreement with Prev requires that we initiate certain studies and file an NDA within a certain amount of time, each of which are costly and will require additional expenditures. Although all manufacturing, preclinical studies and human clinical trials are expensive and difficult to design and implement, costs associated with the manufacturing, research and development of biologic product candidates are generally greater in comparison to small molecule product candidates. We have added additional personnel and expect to add additional personnel to support our exclusive channel collaboration with Intrexon, and research and development of our biologic candidate, SYN-004. In addition, we have commenced manufacturing of SYN-004 material to support our planned preclinical and clinical studies which will require us to incur additional expenses.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Because our biologic programs are relatively new, we have only recently assumed development responsibility and costs associated with such programs. In addition, because development activities in collaboration with Intrexon are determined pursuant to a joint steering committees comprised of Intrexon and ourselves and we have limited experience, future development costs associated with this program may be difficult to anticipate and exceed our expectations. Our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, unanticipated technical challenges, changes in the focus and direction of our development activities or adjustments necessitated by changes in the competitive landscape in which we operate. If we are unable to continue to financially support such collaborations due to our own working capital constraints, we may be forced to delay our activities. If we are unable to obtain additional financing on terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue development.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Developments by competitors may render our products or technologies obsolete or non-competitive.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Companies that currently sell or are developing both generic and proprietary products to treat multiple sclerosis include: Abbott Biotherapeutics Corporation, Bayer Health Care, Biogen Idec, Genzyme, GlaxoSmithKline Pharmaceuticals, Merck &amp; Co., Pfizer, Novartis, Sanofi and Teva Pharmaceuticals. Companies that currently sell or are developing both generic and proprietary products to treat infectious diseases include: MedImmune, Pfizer, Cubist, Optimer Pharmaceuticals, Symphogen, Merus, GlaxoSmithKline Pharmaceuticals and Merck &amp; Co. Many of our competitors have significant financial and human resources. The infectious disease market is highly competitive with many generic and proprietary intravenous and oral formulations available to physicians and their patients. For our monoclonal antibodies, we currently do not expect to be able to deliver our infectious disease candidates via the oral route and may thus be limited to the in-patient and/or acute treatment setting. In addition, academic research centers may develop technologies that compete with our Trimesta and flupirtine technologies. Should clinicians or regulatory authorities view these therapeutic regiments as more effective than our products, this might delay or prevent us from obtaining regulatory approval for our products, or it might prevent us from obtaining favorable reimbursement rates from payers, such as Medicare, Medicaid, hospitals and private insurers.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We operate in a highly competitive environment</font></i></b><b><font style="COLOR: black; FONT-SIZE: 10pt">.</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The pharmaceutical and biotechnology industries, including the monoclonal antibody industry, are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships and other types of joint ventures with larger, well established industry competitors that afford these companies potential research and development and commercialization advantages in the therapeutic areas we are currently pursuing.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Academic research centers, governmental agencies and other public and private research organizations are also conducting and financing research activities which may produce products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Competitors could develop and/or gain FDA approval of our product candidates for a different indication.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Since we do not have composition of matter patent claims for flupirtine and estriol, others may obtain approvals for other uses of these products that are not covered by our issued or pending patents. For example, the active ingredients in both Effirma (flurpirtine) and Trimesta (oral estriol) have been approved for marketing in overseas countries for different uses. Other companies, including the original developers or licensees or affiliates may seek to develop Effirma or Trimesta or their respective active ingredient(s) for other uses in the U.S. or any country we are seeking approval for. We cannot provide any assurances that any other company may obtain FDA approval for products that contain flupirtine and estriol in various formulations or delivery systems that might adversely affect our ability or the ability of Meda to develop and market these products in the U.S. We are aware that other companies have intellectual property protection using the active ingredients and have conducted clinical trials of flupirtine and estriol for different applications than what we are developing. Many of these companies may have more resources than us. We cannot provide any assurances that our products will be FDA-approved prior to our competitors.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">26</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">If a product containing our active ingredients is already marketed or if the FDA approves other products containing our active ingredients in the future to treat indications, physicians may elect to prescribe and substitute a competitor&#8217;s products to treat the diseases for which we are intending to commercialize; this is commonly referred to as &#8220;off-label&#8221; use. While under FDA regulations a competitor is not allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot direct physicians to select certain products for their patients. Consequently, we might be limited in our ability to prevent off-label use of a competitor&#8217;s product to treat the diseases we are intending to commercialize, even if we have issued method of use patents for that indication. If we are not able to obtain and enforce our patents, if any, or otherwise receive orphan drug protection, a competitor could develop and commercialize similar products for the same indications that we are pursuing. We cannot provide any assurances that a competitor will not obtain FDA approval for a product that contains the same active ingredients as our products.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We rely on method patents and patent applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited or eliminated if we are not able to protect our products.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our competitiveness may be adversely affected if we are unable to protect our proprietary technologies. We do not have composition of matter patents for Trimesta or Effirma, or their respective active ingredients estriol and flupirtine. We rely on issued patent and pending patent applications for use of Trimesta to treat MS (issued U.S. Patent Nos. 6,936,599 and 8,372,826) and various other therapeutic indications, which have been exclusively licensed to us. We have exclusively licensed an issued patent for the treatment of fibromyalgia with flupirtine, which we have sublicensed to Meda AB.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our AEN-100 drug candidate (gastroretentive zinc acetate) is the subject of U.S. and international pending patent applications, such as published U.S. patent application Ser. No. 11/621,962 and corresponding international applications that claim priority to January 10, 2006 as well as additional patent applications. On October 26, 2011, we received a final rejection letter with regard to U.S. patent application Ser. No. 11/621,962. On February 15, 2012, we filed a Request for Continued Examination. Our inability to obtain patent protection could hinder our partnering efforts.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The patent positions of pharmaceutical companies are uncertain and may involve complex legal and factual questions. We may incur significant expenses in protecting our intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other infringement litigation by or against us could cause us to incur significant expenses and divert the attention of our management.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Others may file patent applications or obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in any such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how they will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another party claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large sum if we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign our product, which may not be possible.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We also rely on trade secrets and proprietary know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors, current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">As of November 12, 2013, we employed approximately fourteen individuals, eight of whom are full-time employees. We have also engaged clinical consultants to advise us on our clinical programs and regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities. We have been and will be required to retain additional consultants and employees in order to fulfill our obligations under our exclusive channel collaborations with Intrexon and our development obligations under our agreement with Prev. Our future performance will depend in part on our ability to successfully integrate newly hired officers into our management team and our ability to develop an effective working relationship among senior management.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Certain of our directors,&#160;scientific advisors, and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly, we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">27</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;CLEAR: both">&#160;</div> <div align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt">Losing key personnel or failing to recruit necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for qualified personnel in the drug and biologic development areas, and we may not be able to attract and retain the qualified personnel we would need to develop our business.</font></font></div> <div style="clear:both;CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font><font style="COLOR: black; FONT-SIZE: 10pt"></font></font>&#160;</div> <div align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> <font style="COLOR: black; FONT-SIZE: 10pt">We rely on independent organizations, advisors, and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval, clinical management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may not always be available to us on a timely basis when we need them.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> <b><i><font style="COLOR: black; FONT-SIZE: 10pt"> </font></i></b>&#160;</font></div> <div align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> <b><i><font style="COLOR: black; FONT-SIZE: 10pt">If the parties we depend on for supplying substance raw materials for our product candidates and certain manufacturing-related services do not timely supply these products and services in sufficient quality or quantity, it may delay or impair our ability to develop, manufacture and market our product candidates.</font></i></b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font>&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">We rely on suppliers for the substance raw materials of our product candidates and third parties for certain manufacturing-related services to produce material that meets appropriate content, quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution. With the exception of FUJIFILM Diosynth Biotechnologies UK Limited as our manufacturer for SYN-004, we have not yet established cGMP manufacturers for our biologic and drug candidates. To succeed, clinical trials require adequate supplies of study material, which may be difficult or uneconomical to procure or manufacture and there can be no assurance that we will successfully procure such study material. We and our suppliers and vendors may not be able to (i) produce our study material to appropriate standards for use in clinical studies, (ii) perform under any definitive manufacturing, supply or service agreements with us, or (iii) remain in business for a sufficient time to successfully produce and market our product candidates. If we do not maintain important manufacturing and service relationships, we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements with them on terms and conditions favorable to us and, there could be a substantial delay before a new facility could be qualified and registered with the FDA and foreign regulatory authorities.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;CLEAR: both"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">Clinical trials are very expensive, time-consuming, and difficult to design and implement.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that clinical trials of our product candidates would take at least several years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">obtaining an IND application with the FDA to commence clinical trials;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> identification of, and acceptable arrangements with, one or more clinical sites;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">obtaining IRB approval to commence clinical trials;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">unforeseen safety issues;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">determination of dosing;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">lack of effectiveness during clinical trials;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">slower than expected rates of patient recruitment;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">inability to monitor patients adequately during or after treatment;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">inability or unwillingness of medical investigators to follow our clinical protocols; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">In addition, we, IRBs or the FDA may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the FDA finds deficiencies in our submissions or conduct of our trials.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">The results of our clinical trials may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily predictive of future results.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">To date, long-term safety and efficacy have not yet been demonstrated in clinical trials for any of our product candidates. Favorable results in our early studies or trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned, we cannot be certain that the results will support our product candidate claims. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful. Furthermore, success of our predecessor with P1A, does not ensure success of SYN-004. We cannot be sure that the results of later clinical trials would replicate the results of prior clinical trials and preclinical testing nor that they would satisfy the requirements of the FDA or other regulatory agencies. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Any such failure could cause us or our sublicensee to abandon a product candidate and might delay development of other product candidates. Preclinical and clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Any delay in, or termination of, our clinical trials would delay our obtaining FDA approval for the affected product candidate and, ultimately, our ability to commercialize that product candidate.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">28</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We depend on third parties, including researchers and sublicensees, who are not under our control.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Since we have in-licensed some of our product candidates, have sublicensed a product candidate and have collaboration agreements for the development of other product candidates, we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and medical institutions or private physician scientists, to advise us and to conduct our preclinical and clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs or the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any of these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they fail to comply with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development of that program. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking those programs ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance and failure to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the drug candidate involved.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">These collaborators may also have relationships with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors could harm our competitive position. For example, we are highly dependent on scientific collaborators for our Trimesta development program. Specifically, all of the clinical trials have been conducted under investigator-sponsored IND applications, not corporate-sponsored INDs. We have sometimes experienced difficulty in collecting data generated from these investigator-sponsored clinical trials for our programs. We cannot provide any assurances that we will not experience any additional delays in the future.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We are also highly dependent on government and private grants to fund certain of our clinical trials for our product candidates. For example, Trimesta (oral estriol) has received grants totaling over $8 million,&#160;predominantly from the Southern California Chapter of the NMSS and the National Institutes of Health which funds a majority of the ongoing clinical trial in relapsing-remitting MS for women. Although we believe that the grant funding received to date is sufficient to complete the current clinical trial based upon current cost estimates, if we experience any additional unanticipated costs or require further clinical trials, and our scientific collaborator is unable to maintain or receive additional grants, we might be forced to scale back or terminate the development of this product candidate. We will also need to cross reference our IND with the inventor/IND holder for this program should we elect to file our own corporate IND for our Trimesta (oral estriol) program. The on-going and future development and commercialization of Effirma (flupirtine) for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&#8217;s acceptance of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">With respect to our product candidates in collaboration with Intrexon, we are dependent upon Intrexon&#8217;s synthetic biology facilities and capabilities as we have no such facilities and capabilities of our own. We are also reliant on their vectors, monoclonal antibody discovery, production cell line development and know-how. If any of the foregoing were to become inaccessible or terminated, it would be difficult for us to develop and commercialize our synthetic biologic product candidates.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated with lawsuits.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">If any other person files patent applications, or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to participate in interference proceedings involving our issued patents and pending applications of another entity.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The intellectual property environment in the monoclonal antibody field is particularly complex, constantly evolving and highly fragmented. We have not conducted freedom-to-use patent searches on all aspects of our product candidates or potential product candidates, and we may be unaware of relevant patents and patent applications of third parties. In addition, the freedom-to-use patent searches that have been conducted may not have identified all relevant issued patents or pending patents. We cannot provide assurance that our proposed products in this area will not ultimately be held to infringe one or more valid claims owned by third parties which may exist or come to exist in the future or that in such case we will be able to obtain a license from such parties on acceptable terms.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We cannot guarantee that the practice of our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition proceedings, either by opposing the validity of another&#8217;s foreign patent or by persons opposing the validity of our foreign patents.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We may also face frivolous litigation or lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect on our ability to continue our operations.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">If we infringe the rights of others we could be prevented from selling products or forced to pay damages.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">If our products, methods, processes, and other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling to offer us a license on commercially acceptable terms.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">29</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;CLEAR: both">&#160;</div> <div style="clear:both;CLEAR: both">&#160;</div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt">RISKS RELATING TO OUR STOCK</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We will seek to raise additional funds in the future, which may be dilutive to stockholders or impose operational restrictions.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We expect to seek to raise additional capital in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions, issue equity as part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity that may be dilutive. Our stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We are substantially controlled by our current officers, directors, and principal stockholders.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Currently, our directors, executive officers, and principal stockholders beneficially own a substantial number of shares of our common stock. As a result, they will be able to exert substantial influence over the election of our Board of Directors and the vote on issues submitted to our stockholders. Our executive officers and directors beneficially owned approximately 9.3 million shares of our common stock, including stock options and warrants exercisable within 60 days of November 12, 2013. Randal J. Kirk indirectly beneficially owns approximately 9.8 million shares of our common stock. Our executive officers, directors and principal stockholders together beneficially owned approximately 19.1 million shares of our common stock, including the stock options and warrants exercisable within 60 days of November 12, 2013. Because our common stock has from time to time been &#8220;thinly traded&#8221;, the sale of a substantial number of shares by our executive officers, directors and principal stockholders would have an adverse effect on the market for our stock and our share price.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">Our shares of common stock are from time to time thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to raise money or otherwise desire to liquidate their shares.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our common stock has from time to time been &#8220;thinly-traded,&#8221; meaning that the number of persons interested in purchasing our common stock at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">We cannot assure you that the common stock will be liquid or that it will remain listed on the NYSE MKT.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We cannot assure you that we will be able to maintain the continued listing standards of the NYSE MKT (formerly the NYSE Amex and the American Stock Exchange). The NYSE MKT requires companies to meet certain continued listing criteria including certain minimum stockholders' equity&#160;and equity prices per share&#160;as outlined in the NYSE MKT Exchange Company Guide. We may not be able to maintain such minimum stockholders' equity or prices per share or may be required to effect a reverse stock split to maintain such minimum prices and/or issue additional equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders' equity required by the NYSE MKT.&#160;If we are delisted from the NYSE MKT then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE MKT could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities. In order to remain listed on NYSE MKT, we are required to maintain a minimum stockholders&#8217; equity of $6 million.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">There may be issuances of shares of preferred stock in the future.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Although we currently do not have preferred shares outstanding, the Board of Directors could authorize the issuance of a series of preferred stock that would grant holders preferred rights to our assets upon liquidation, the right to receive dividends before dividends would be declared to common stockholders, and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock. To the extent that we do issue preferred stock, the rights of holders of common stock could be impaired thereby, including without limitation, with respect to liquidation.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">30</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><i> <font style="COLOR: black; FONT-SIZE: 10pt">Our failure to fulfill all of our registration requirements may cause us to suffer liquidated damages, which may be very costly.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Pursuant to the terms of the registration rights agreement that we entered into with Intrexon and an affiliated entity, we are required to file a registration statement with respect to securities issued to them within a certain time period and maintain the effectiveness of such registration statement. The failure to do so could result in the payment of damages by us. There can be no assurance that we will be able to maintain the effectiveness of any registration statement, and therefore there can be no assurance that we will not incur damages with respect to such agreements.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt"> Stockholders may experience future dilution as a result of future equity offerings.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by existing stockholders, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by existing stockholders.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We do not intend to pay dividends in the foreseeable future.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We have never paid cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the operation and growth of our business and currently do not plan to pay any cash dividends in the foreseeable future. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the market price of our common stock price appreciates.</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">Resales of our common stock in the public market by our stockholders may cause the market price of our common stock to fall.</font></i></b></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">We may issue common stock from time to time in connection with future offerings.&#160;Any issuance from time to time of new shares of our common stock, or our ability to issue shares of common stock in future offerings, could result in resales of our common stock by our current stockholders concerned about the potential dilution of their holdings.&#160;In turn, these resales could have the effect of depressing the market price for our common stock.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><font style="COLOR: black; FONT-SIZE: 10pt">RISKS RELATED TO OUR INDUSTRY</font></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We are subject to government regulation, compliance with which can be costly and difficult.</font></i></b></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In the U.S., the formulation, manufacturing, packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various governmental agencies, including (1) the FDA, (2) the Federal Trade Commission, or FTC, (3) the Consumer Product Safety Commission, or CPSC, (4) the U.S. Department of Agriculture, or USDA. Our proposed activities may also be regulated by various agencies of the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA, in particular, regulates the formulation, manufacture and labeling of over-the-counter, or OTC drugs, prescription drugs, conventional foods, dietary supplements, and cosmetics such as those that we intend to distribute. FDA regulations require us and our suppliers to meet relevant cGMP regulations for the preparation, packing, labeling, and storage of all drugs and foods.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements, reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors will be able to comply with these regulations.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The FDA regulates prescription drug labeling and promotion activities. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products. Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to comply with these laws and regulations now or in the future.</font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The FDA, comparable foreign regulators and state and local pharmacy regulators impose substantial requirements upon clinical development, manufacture and marketing of pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval process required by the FDA under the Food, Drug, and Cosmetic Act generally involves:</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">preclinical laboratory and animal tests;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">submission of an IND, prior to commencing human clinical trials;</font></div> </td> </tr> </table> </div> <div style="clear:both;CLEAR: both">&#160;</div> <div style="clear:both;CLEAR: both">&#160;</div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">31</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <font style="FONT-SIZE: 10pt"></font> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">adequate and well-controlled human clinical trials to establish safety and efficacy for intended use;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">submission to the FDA of an NDA or Biologics License Application (BLA); and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">FDA review and approval of an NDA or BLA.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis, if at all.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Preclinical tests include laboratory evaluation of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical studies are conducted concurrently with clinical studies.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">We will submit the preclinical test results, together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before we begin human clinical trials. The IND automatically becomes effective 30 days after filing, unless the FDA raises questions about conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve the matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence clinical trials.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Clinical trials must be supervised by qualified investigators in accordance with good clinical practice (GCP) regulations, which include informed consent requirements. Each study must be approved and monitored by the appropriate IRBs which are periodically informed of the study&#8217;s progress, adverse events and changes in research. Annual updates are submitted to the FDA and more frequently if certain serious adverse events occur.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Human clinical trials of drug candidates typically have three sequential phases that may overlap:</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Phase I:&#160;The drug is initially tested in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Phase II:&#160;The drug is studied in a limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and establish dosage tolerance and optimal dosage.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Phase III:&#160;When Phase II evaluations demonstrate that a dosage range is effective with an acceptable safety profile, Phase III&#160;trials to further evaluate dosage, clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">We cannot be certain that we will successfully complete Phase I, Phase II, or Phase III testing of our product candidates within any specific time period, if at all. Furthermore, the FDA, an IRB or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health risk. Concurrent with these trials and studies, we also develop chemistry and physical characteristics data and finalize a manufacturing process in accordance with good manufacturing practice (GMP) requirements. The manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality, purity, and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are submitted to the FDA as part of a NDA (or BLA in case of biologic products) for marketing and commercial shipment approval. The FDA reviews each NDA or BLA submitted and may request additional information.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Once the FDA accepts the NDA or BLA for filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation of the data submitted or identify new concerns. The process may be significantly extended by requests for new information or clarification of information already submitted. As part of this review, the FDA may refer the application to an advisory committee, typically a panel of clinicians. Manufacturing establishments often are inspected prior to NDA or BLA approval to assure compliance with GMPs and with manufacturing commitments made in the application.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Submission of an NDA or BLA with clinical data requires payment of a fee. In return, the FDA assigns a goal of ten months for issuing its &#8220;complete response,&#8221; in which the FDA may approve or deny the NDA or BLA, or require additional clinical data. Even if these data are submitted, the FDA may ultimately decide the NDA or BLA does not satisfy approval criteria. If the FDA approves the NDA or BLA, the product becomes available for marketing. Product approval may be withdrawn if regulatory compliance is not maintained or safety problems occur. The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval, and requires surveillance programs to monitor approved products that have been commercialized. The agency has the power to require changes in labeling or prohibit further marketing based on the results of post-marketing surveillance.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Satisfaction of these and other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or uses.</font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">32</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse effect on our business.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">The FDA&#8217;s policies may change, and additional government regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased attention to the containment of health care costs worldwide could result in new government regulations materially adverse to our business. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></i></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><i><font style="COLOR: black; FONT-SIZE: 10pt">We do not have a guarantee of patent term restoration and marketing exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</font></i></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">The U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA, or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month stay of approval of the competitor&#8217;s application. The discovery, trial and appeals process in such suits can take several years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period, the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator products by submitting significantly less clinical data outside the ANDA context. Such applications, known as &#8220;505(b)(2) NDAs&#8221; or &#8220;paper NDAs,&#8221; may rely on clinical investigations not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use and are subject to the ANDA notification procedures described above.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">The law also permits restoration of a portion of a product&#8217;s patent term that is lost during clinical development and NDA review, and provides statutory protection, known as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five years of patent term for a patent covering a new product or its use to compensate for time lost during product development and regulatory review. The restoration period is generally one-half the time between the effective date of an IND and submission of an NDA, plus the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total patent life beyond 14 years after the drug approval date. Applications for patent term extension are subject to U.S. Patent and Trademark Office (USPTO) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there can be no guarantee that it will be given at all.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Hatch-Waxman also provides for differing periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &#8220;new molecular entity&#8221; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change. These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative change.</font><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">33</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">None.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">None.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 4.&#160;&#160;MINE SAFETY DISCLOSURES</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Not applicable.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 5.&#160;&#160;OTHER INFORMATION</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">None.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">34</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">ITEM 6. EXHIBITS</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">31.1</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) *</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -29.7pt; MARGIN: 0in 0in 0pt 29.7pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">31.2</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) *</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -29.7pt; MARGIN: 0in 0in 0pt 29.7pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">32.1</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Certification of Principal Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: -29.7pt; MARGIN: 0in 0in 0pt 29.7pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">32.2</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="92%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Certification of Principal Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *</font></div> </td> </tr> </table> </div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.INS</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Instance Document *</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.SCH</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema *</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.CAL</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase *</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.DEF</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Linkbase *</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.LAB</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase *</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 13%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="13%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">EX-101.PRE</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 85%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="85%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase *</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">*Filed herewith.</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">35</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">SIGNATURES</font></b></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</font></font></div> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 42.98%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="42%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">SYNTHETIC BIOLOGICS, INC.</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">By:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">/s/&#160;Jeffrey Riley</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Jeffrey Riley</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">(Principal Executive Officer)</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Date: November 14, 2013</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.9%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="56%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 5.58%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="5%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">By:</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">/s/ C. Evan Ballantyne &#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="62%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.4%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">C. Evan Ballantyne</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"> &#160;</div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="62%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Chief Financial Officer</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="62%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">(Principal Financial Officer)</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 62.48%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="62%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 37.52%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="37%" colspan="2"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Date: November 14, 2013</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">36</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="center"><font style="FONT-SIZE: 10pt"><b><font style="COLOR: black; FONT-SIZE: 10pt">GLOSSARY</font></b></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Term</font></b></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="bottom" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><b><font style="COLOR: black; FONT-SIZE: 10pt">Definition</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Adverse Event</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Any adverse change in health or &#8220;side-effect&#8221; that occurs in a person participating in a clinical trial, from the time they consent to joining the trial until a pre-specified period of time after their treatment has been completed.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Bioavailability</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">The quantity or fraction of the ingested dose that is absorbed by the body.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">BLA - Biologics License Application</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">An application in the U.S. through which biologic sponsors formally propose that the FDA approve a new biologic for sale and marketing.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Clinical Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A research study that is conducted to find out if a treatment or procedure is safe and/or effective in humans.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Controlled Clinical Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A clinical study that compares patients receiving a specific treatment to patients receiving an alternate treatment for the condition of interest. The alternate treatment may be another active treatment, standard of care for the condition and/or a placebo (inactive)&#160;treatment.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Double-blinded Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Both the participant and the researcher are unaware of who is receiving the active treatment or the placebo.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Effirma (flupirtine)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Proposed tradename of Synthetic Biologics&#8217; centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">FDA - Food &amp; Drug Administration</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The U.S. government agency that ensures that medicines, medical devices, prescription medical foods and radiation-emitting consumer products are safe and effective. Authorized by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture, import, transport, storage, and sale of $1 trillion worth of goods annually.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">GMP - Good Manufacturing Practice</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Regulations that require that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive steps to ensure that their products are consistently produced, pure, and stable. GMP regulations require a quality approach to manufacturing, enabling companies to minimize or eliminate instances of contamination, mix-ups, and errors.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Monoclonal Antibodies (mAbs)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Acting as the body's army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and bacteria and their associated toxins.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both">IND <font style="COLOR: black; FONT-SIZE: 10pt">- Investigational New Drug</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">An application in the U.S. submitted to the FDA for a new drug or biologic that, if allowed, will be used in a clinical trial.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">IRB - Institutional Review Board</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A committee designated to formally approve, monitor, and review biomedical research at an institution involving human studies. Institutional Review Boards aim to protect the rights and welfare of the research subjects.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">NDA - New Drug Application</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">An application in the U.S. through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Open-label Clinical Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A trial in which both the treating physician and the patient know they are receiving the experimental treatment.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Phase I Clinical Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A Phase I trial represents an initial study in a small group of patients to primarily test for safety.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt"></font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">37</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; PAGE-BREAK-AFTER: always; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; CLEAR: both; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Phase II Clinical Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A Phase II trial represents a study in a larger number of patients to assess the safety and efficacy of a product.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Phase III Clinical Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Phase III trials are initiated to establish safety and efficacy in an expanded patient population and at multiple clinical trial sites and are generally larger than trials in earlier phases of development.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Placebo</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">An inactive pill or liquid. Many studies compare an active drug to a placebo to determine whether any changes seen during the study can be attributed to the active drug.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Principal Investigator</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">This is the study director who is ultimately responsible for the conduct of the study.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Prospective Clinical Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A clinical study/trial in which participants are identified and then followed throughout the study going forward in time.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Protocol</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A clinical study/trial&#8217;s plan - includes the schedule of tests, requirements for participation, procedures, and medications.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Randomized Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Participants in a study are assigned by chance to either one or more of the active treatment group(s) or the placebo group.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Single-blinded Study/Trial</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">One party, either the participant or the researcher, does not know if the participant is taking the active treatment or the placebo.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Study/Trial Coordinator</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Staff member who is often the primary contact for research participants and coordinates their care and evaluations throughout the study.&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic Biology</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Synthetic biology is an emerging field that combines molecular biology and automation to design, optimize and construct new biological systems and functions.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">These technologies utilize a combination of automated processes including, DNA sequencing, computer-aided design, DNA synthesis, fabrication of modular transgenes and high throughput testing to create and optimize biologic products.</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="28%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">Trimesta (oral estriol)</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="70%"> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Proposed tradename of Synthetic Biologics&#8217; investigational oral drug for the treatment of relapsing- remitting MS and cognitive dysfunction in MS.</font></div> </td> </tr> </table> </div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; CLEAR: both; FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> </font></font></div> <div style="clear:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> &#160;</font></font></div> <div style="clear:both;TEXT-INDENT: 0in; MARGIN: 0in; CLEAR: both"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></font></div> <table style="WIDTH: 100%"> <tr> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="left"></td> <td style="FONT-STYLE: normal; WIDTH: 34%; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: normal" align="center">38</td> <td style="WIDTH: 33%; VERTICAL-ALIGN: bottom" align="right"></td> </tr> <tr> <td><br> </td> </tr> </table> <div style="clear:both;BACKGROUND-COLOR: rgb(0,0,0); FONT-STYLE: normal; TEXT-INDENT: 0in; MARGIN: 0in; HEIGHT: 1px; CLEAR: both; FONT-SIZE: 1px" contenteditable="false"></div> &#160;<div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> <div style="clear:both;CLEAR: both"></div> <div style="clear:both;CLEAR: both">&#160;</div> <br> <div  name="Section"  style="clear:both;CLEAR: both;clear:both;"></div> <div style="clear:both"></div> </body> </html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v358947_ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="color: black"><B>EXHIBIT 31.1</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;<B> &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;I, Jeffrey Riley,
certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="color: black">1.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="color: black">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="color: black">2.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="color: black">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="color: black">3.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="color: black">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="color: black">4.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="color: black">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="color: black">a)</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="color: black">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp;material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="color: black">b)</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="color: black">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">c)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">&nbsp;Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">d)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">5.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">The registrant's other certifying officer(s) and I&nbsp;have&nbsp;disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">a)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%"><FONT STYLE="color: black">Date: November 14, 2013</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="color: black">By:</FONT></TD>
    <TD STYLE="width: 38%; border-bottom: black 1pt solid"><FONT STYLE="color: black">/s/&nbsp;Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">&nbsp;(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v358947_ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">
</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 100%; border-top: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: black"><B>EXHIBIT 31.2</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, C. Evan Ballantyne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">1.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">2.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">3.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">4.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">a)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp;material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">c)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">d)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="color: black">5.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: black">The registrant's other certifying officer(s) and I have disclosed, based on&nbsp;our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">a)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="color: black">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="color: black">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%"><FONT STYLE="color: black">Date: November 14, 2013</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="color: black">By:</FONT></TD>
    <TD STYLE="width: 38%; border-bottom: black 1pt solid"><FONT STYLE="color: black">/s/&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v358947_ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: black 1pt solid; text-align: right"><FONT STYLE="color: black"><B>EXHIBIT 32.1</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">Pursuant to 18 U.S.C. &sect; 1350, as created
by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="color: black">(1)</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">the accompanying Quarterly Report on Form 10-Q of the&nbsp;Registrant for the quarter ended September 30, 2013 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="color: black">(2)</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">Date: November 14, 2013</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">/s/&nbsp;Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v358947_ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: black 1pt solid; text-align: right"><FONT STYLE="color: black"><B>EXHIBIT 32.2</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">Pursuant to 18 U.S.C. &sect; 1350, as created
by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="color: black">(1)</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">the accompanying Quarterly Report on Form 10-Q of the&nbsp;Registrant for the quarter ended September 30, 2013 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="color: black">(2)</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">Date: November 14, 2013</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">/s/&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ft0002img-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ft0002img-1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!!@*3`P$1``(1`0,1`?_$`1@````&`P$!`0``````
M```````#!`8'"`$"!0D*"P$``@,!`0$!``````````````$"`P0%!@<($```
M!@$"`P0$`PP/#!$,#`\!`@,$!08'`!$A$@@Q$Q0)05$B%6$6&7&!D:'1,M(C
MEA=7&+'!0E+3)%24U"65U296UG*2,U.3-56U-I=9&O!BLS1D175&=K8G1SA8
M>#D*@J+"0T2DM&4WR"F)X?%C<X/#I<5FAJ9WATFRXJ-TQ(7F9RB(MTBH$0`!
M`@(%!0H*!P0(!0(%!0`!``(1`R$Q$@0%05&1$P9A<8'1(E+2%!46\*&QP>$R
MDE,'"$)B<J(SD]."(R07LN)C<X-4A!CQPD.C-$24L^-D=$7#I+0U5?_:``P#
M`0`"$0,1`#\`EJF4CJ%SU?NJ.;==:_4ICQ.C]3-WHL?3X.P(*LB1C-HS>-S(
MF48J&!)N#GAQVU\0^*OQ';LW*LM-F$*@_-]5P7Q7'L9=KC`P,<D>-2'^*UGL
MNQ@\P;JN3VWV.,ZT`I1]?&-V';7RO"?F'DNPU[)I!JI+9L?_`(BX$G')@$2X
MP_:XUO\`BO=0(<1\Q+JK#YLXT#T[;<8WMWU/_<+<&?3^Y,_46CMTYSX^-;?B
MN=0/;\HCU6\>("$VT$!^9^UFHGYDK@WZ='V)OZB7;SLA\O&EI.F+/`$*`^8E
MU6;@4H#^W;3M``W_`-+/7K&?F3E1H(A]F;^HEVZ[.?'QK?\`%BSQ_A$>JS]V
MFG[V:/\`<E+SCV9WZB.W3G/CXUC\6'.X_P#XQ'JMW]7OMIV?N9KK7+YA;C>)
M.LG.@Z,*&3/.],8\<_EXUC\6'._'_P!(CU6\.W]NVG#YO[6<-:_Y_87SS[$S
MIH[>=G_I<:T4Z8L\`0=O,0ZK1XA_IVT';Z$9KEXO\Q%TN=W:^[.B\NA2R;YI
M@1V\3E\O&B"=,>>CF`I?,0ZK!$>&X3;38!^']K>&N;=?F1UI`)$?LSOU$NW3
MG\O&CQZ6NH#M^41ZK>/JFVGTOVL[1UW6_,`S4F9$4#FS?U%+MYV<^/C2'\5S
M/W^$)ZP>W8?V\9\!](#^U7`0UQO]R4O./8G?J*/;KL_EXUT2=,6>.4H?*(]5
MP"!"[@:;:"<.`?7_`+6=OKT_]R4O./9G?J([=.<^/C6?Q8L[_P"$1ZK./9^W
M;3][-(?,E+SCV9WZB.W3G/CXTF/TN9[%P*J?F$=5[@4TB%5#WZT*!$C*&]H`
M]V\1XCKMW'Y@9=[(`(!/U9OZB?;QS^7C3+BL+=0DEE&Z4!7KWZJTH:KU>MS<
M>^"=:"JY=3;R0:NDE!]V;\J1&11#X1UFVF^.UXPT2S=X.#FDF(F^:8$^WW9"
M?'QIY'Z8,]"<WA_,'ZKR*#N(":=:"7E#ZX`WC->.NOS)W]]Y$N#*\T_]1!QX
MY_Z7&B3],>?RF(1QYBW5"T*N(E3.XLD:W`PAQ-W9EF!`.)=PWVWVWU]0N?S`
M3[I<CB%YERW26BGD375[ENE';[LY\?&EI>F'/K0@<_F(]5:I1#@9.<9G*.^^
MPE,6-$#?.UYO$/FIN;7T2@!_<3_U$NWG9SX^-)QZ8\]`4##YAW5<!!V$#C,-
MN40'L$##&;"&M>&?-3<RVF4(?W$_]1+MTY_+QKCO.G;,$?--*\_\QGJEB[/)
MH%<QT4O=FA3R;)0@*$701-&[E%1$0,)2_6[[:]$_YK-GPRF4(_\`V\[IJ7;[
MZK1AP\:ZQ>EW.C4!13\PGJN;$*(_:E+&V=B!Q'G4,#@\;NH4QS";_*@.VN/>
M/FMP#W8C_P#;SNFH]NNS^7C1Y>F#/H@7E\Q/JL3`YN0A1G&A!4/L`[$*:-`3
MFV'L#<=8G?'29CC.T\,`;=3R869K*17R;?C7/O.U-_E3+$@_NX9W^9RW_%<S
M_P`?_2*=5G#_`,>L_6(?V-]8:X%Y^/5_D&P;-H;D[]19N]V+9_',Z2U-TPY]
M0(HN/F&]5SHZ"3A=!`)UF/>.$FRRB0"`1OUNY==O97XZ7F]7V9UB%D2XBB::
M>%ZUW3:B_3WEMX/)AG?YRH[QA@KJ!O%'K5LE?,!ZKF$I,MU"J($G6G=$3B9!
MVV*H/[6;<2D^?I8O\P[)$\RRX`Q(H;-_46_MXY_+QJ1U.F;.29>97S%NJ=$A
MA`G>+6%@@F!CCRE`5E(XI"[B/KUNPOXS3<0`?+=%T<TWIJ+\?F,87-/*`H];
MC7!E<%95@$VCN:\R;J.BP6D`@(DI,@LED'\J8X)@`G(S,18P'$-P`1VU'&/B
MYBK(@!HHR:WIKD=[\6S^-_21SGI9ZAF97;9QYAG52@9!59R_D?CP@*``4QE%
MSHB:.Y"(\!$`_,E$-<.Z?%_%R_E9_P"UZ:.]^*YSI?TD;"X`S'.QZ,A!>8SU
M524>H"I$W3>QLWJ:AFJIVSDP+IQA@.5-PD<HCV`(:,5^,&,8?*ZT#01&'[[R
M!ZZTK:*=,EM?,<;9%/K<:Z8=+^?'BB"!?,&ZLS>\%19(O"VADV0;+$(58PK%
M]U&$-TU`'F$0#8=<'"?F&QF^WGJ[VLA'-/S[LQ6=OOAZQ^]QKD1?3UF*:>RT
M7`^8_P!3,Q(5U7P,TT8VUH\=,UB#P5=)>[S"B54=P`=@`=M?1KW\7,4NF&NF
MD-)<(_\`5H^^@8\^/K'Q\:ZH],&?"J&1<]?_`%8)&`-S;SK4IB[`!@YBC&`)
M=RCOV=FO*;/?'/%IU[+'V7-B:]=G.>8D<>=&,:>'C6I.F7-YR\[;S#.JLY@'
M8JB-B8K%*8.W<4XX0W#?LUV+_P#&R]8;BLN_WYHZBV-H!LUPIJY-NE53]HI\
MJ47R''6"KUO,5N'3+U!#L`>8AU8;B`"`>^FNYBCV&*'NS<2CZ!#6P_-#@3*#
M+'_MYO37,[WXKG.E_20_%FZ@M]OE$>K`!#?<!FVH;;#L.X>[.&PAL/J'4#\U
MF``61+$:O_'G=-`VOQ7/XW])#\5_.G,4I_,%ZKQ5.([`,ZU*=0_:;D(,:!C#
MQWV`-9A\6,6GNUTLG5NY0_%%!I%%NBA=CM]Q$2XQ._QINO,*94B;5`U1YYC?
M55[\FV3AU%1'OUF*I^[652`QBA&\YB&4(/'L]'HU3-^-F(W`Q?`PSZT_\Z.W
M79SX^-=Y#I;SJNJ4'?F"=6+8I7"7O02S[3=OWBBB9#)A[MX"<$@`0UW]F_CJ
M+Y-,R>6QS69L*#NO3[>=G,>'C3&H&$^H>]ENYGW7_P!5,8YJ%^EJ<T(2;9\K
MJ'CFK5PQ=G'W9[2JIG!MQUQ=N_CVVZ.`E$-WFS1EW)B7;[\Y\?&G[^*UG\HB
M4?,3ZJP'8!Y1G&8&X]FX#&;ZPX7\QDD79O6"-^S-/EF)]O.SGQ\:S^*WGX@[
MG\Q+JM`"\3`,XS#AMV\8P.&NTSYA,/FP!?1]B9^HEV\[/Y>-&!TQ9V_PB/59
M\'[=L^/_`,F:LF?';#&2G3F/Y8!(Y#Z_;2[>=G\O&A^+%GCM^41ZK=@X"/OI
MKP']S-><_P!R4O./9G?J([>.?R\:'XL6>/\`"(]5O[M-?WLT?[DI><>S._41
MVZ<Y\?&L?BQYX'L\Q'JL_=MK^]FMX^8^498/)C#F3?U$=O'/Y>-)ENF/._,7
M_P!(EU;]G'P\TS$O:/UV\480-^5KGWCYD&1,"!^S-_43&/'.?'QK"?2UGUR*
MI4_,)ZMG)`;+"IW\XR+R"'(=/DVBPW$PD$!UVMGOCMVO+G3;0A+(R3<HW7E'
M;QKB?'QJ/<58:Z@\A51Y.S/7SU6,G;>YW6MLP2G&A?$,Z]8'J!5%!]V=I2F`
M`U.^?']MT=8):?V9OZB?;[L_EXU)!NEW.FP\OF#]6"9@V]LTZTY2"/8)MXP-
MOGZX%Z^8[5RS,!%'U9WZB.WG<X_>XT!Z6L_E#<?,2ZJP[1XSC,/R8S5%V^9/
M6$!UF/V9WZB.WCG/CXTF'IESQ_A$.JWX/V[:[#Q_U,UZ*[_,"V:RU:'LS?U%
M'MPY_+QI6'3%GD"@(^8AU=@&P=DRR`G_`%(C$]GJUSG?,,`XB(KYLW]1/MY^
M<_>XTE4Z7\_F.(D\Q'JP$O#;O)MGWG```>8`C`].H_[AMT>S-_41VZXY?+QH
MY#IASV4HE/YB/58)^81``FV@CR[!Z/=N_;I_[BK-$1[,W]1';IS^7C1ANE_/
M9^!/,1ZK`$!X@,VS`>/8&PQN_HT?[BX\WV9OZB!CISGQ\:(<=,6?FJ"S@WF(
M]5OZ7*!M@G&>_/SD*`"'NS??8^K9/S"-O#PPD#]F;YYBRWK:2\R&!UV)M$_6
M'D*8^7<)]0&/*)9;<S\PKJG=N:]-5V/1;.)YKX9<)E5H!R*B6-`>Z'OQW$!]
M&O;7+XT,FR+9@8_5F=-8!M?BN<Z7])2*YZ5.H)-P^=_*"]6I#MW;YD1K&3S,
M[=,KLB+D3%`\8IL0@JCQ#7G<9^.\NXASRX0:(^K,R?MJ<K:W$W3`UYY!--+Z
MO:7+'I>Z@@VW\Q+JL#<=@WFVH;CZ@WC.(Z\C*^977CDD>S._476[=(R^7C2G
M\5K/X%`1\P?J]'T;A.,@((@`;\N\5V<>ST`.G,^934B+B/9G?J([??G/CXT<
M7IASR4.4WF']6*9@WW(M-M!4+Q_-;1@!Q]'P:UR_F5EO8'1%(YD[]1+MYV<^
M/C6WXL>=_P#"(]5G[MM/WLU/_<E+SCV9WZB.W3G/CXT6?I?STH`<OF&=5ZNP
MCORSK4H!OV?Z6\1'5DOYAY=YB8BCZLW]18[UM/?)!`NQH-=+AY"BC],.?VP=
MX'F#=60#N!?Z_MO3_P#NW5G\_I7.^[-Z:R=[L5S^-_22&1Z;^H9C%2DNTZ_^
MJYRZC8R0?H(*3[42*J,VBRX%,!HWLV3UINGQZ9.GB6'")^K-Z:OD;58A-F!D
MXG5G=?YW)L8WP3U!W.@U2TK=??5<5]8XF"E5D0GFG*49=)<RG*'NWAR=SV>C
M4K[\P0N9(M"(^K-_471..F%?EXTZ@Z6\_CP#S".L(PCZ`G&@B'T(K?7GG_,@
MYYY!R\V=^HCMUV?R\:.#IDSR7E*/F']5X&^M`IYMISB8.`A_6SVC`/;MZ==,
M?,*YC0+0JYLW]1(XX<_EXUG\67/`A_SA_59ZOZ]-.T!V$/ZV=H"&HGYCPRLB
MCZL[]1+MTY_+QH]'IDSORCOYB/58&QMOZ]M`]`#_`&-UV[C\Q5PG2+<YT'QY
MDWSS$^W3G\O&COQ8\[_X1'JM_=MI^]FMG^X3"N?]R9TT=NNS^7C12O3'G?E`
M0\Q'JM'CP_;MH.XAV@'[6<1#T^K49GS!W$RGB0X%T.9,Z:.W79_+QHMOTQ9T
M471*KYA_5:*1U4P-RS;3<WMAL4!]V;?7!L.O+8'\P37XJ6.=$$Y6S85?WB?;
MI!K\O&F-C_"W4=<$[@I(=>?50@>O7>R5%B4DXS`%FR*Y#D5-M&]H%].O5;1?
M,%*NC6319:T0)@V;3`983$^WG'*?'QI]_BK9YV$?E!.J[AM_I^TV_M;Z=<&1
M\R=POT+#H1S,FC_]1+O`_G'[W&@'2UG\?K?,0ZNP#B`%)-,1*&W`0*/NH=P+
MK8[XZW0")F&'V9G33[P3!](_>XT:7I@SP4H`?S$NK'F#@/>3;/GW'L`W+%@&
M^VK!\P.'M%DOI'U9GZB1QYYI)\O&B%>F3.X&#;S$>JT0V`-_?;3MW'A_6SMT
M_P#<'AW/^[,_42[==G\O&MD>F3._M;^8CU6!V<1FV@!Z?7&:P7OYB[K)<UDE
MT8_5F^:8CMUV?R\:._%CSOOM\HCU6[\.'OIIOQ[.'NSTZJ'S"%PM`B!^K-_4
M3[==G\O&L&Z7<[KAW`^8?U5CWNQ>4TVU*4?:#?F$(T!`NX<==C9SX]R\7QN5
MA;B(O^K-R0SO(4Y>T!8ZU&K?XTP?O/\`4/XOW?\`CW]3&WWP/O<\WOYMS>%]
MR?&;QO\`G#^B;^Q_,Z_1'?65]7\&-3N-:>\YA_QS[ZDKH[*HI:.LE),AU!6Z
MLKXD<J8\I@2.1OSG$?SI=N.OP7\QMZG3II8RJ(R;BPX]<CKC&/CW59RX7:G5
M&)(YMMIK$#&)OP:$5LB_NZ.2$I@$QGTJ(IE8MR@7VE.<O+Z]?GG9/9/$<=N;
MKK('[R9#Z+S5N-$5YIUU<V4794SF^=,.3$A%M*_D2IVQY<K`5C6X^!>A8F*B
MZ*HRBA45Q,X*8`]X=H".VNM?_@[M"T>J8#^SG=%9=6Y3`F1RW=(-G)W+(Y"^
M[V*(.`"..H;V0`5.?N]A'X=>,O?PLVB:^D&C^SF]%&K<D8M'"#I9JHDX.X;K
M*H+\RX=QWR9S)J=R<3<ID@.4>40'B&MK=D[VQH812!"IW$EJW;J6`@J7;F:J
M.#?TA!<IRI>H?8..PF#C\_4NZM[S>)W$C5NS+<K-=3E,@FN54AP,HKX@H`@A
MZ4C#S^R(#QV'4V[#8S>1K+N/W?V)A\@3$MV9)UB'=N7""*2RD?RI'<+@X*)'
M!TC"(IE-S\IA*/$?FZE_+_:#,?RYG11JW9D6HLFR?-"K.B,G$ZLDQBV;E^B@
M90X@8H'(4ZI.\,0"\"AN)O4.NAAWPXQB?.+;P#8#8^I,'_*C5NS)ITVY5^WO
M[=&UMXXEW--DU(VR$!`\<T:O2&V.5PJJ5$BY2CZA'?6R;L+?KB;0$(?5?YPC
M5N3V27$YC>%(Y,=$#*JE=."IQR":>ZBA^^,<"%(D0HB(@/``USWX9>Y<9)RT
M5'B1JW+EU6P52ZL4Y6K343:()U*RA'<A57J-G2"3-OREYBJ.BF-S>C7.&RU[
MS>)W$EJW9$H3:*IN?#F(Y2\0V(T,^6.5MRG;$!,S95(!*5!8@E$#)[!RB&VV
MEW6O?@'<2-6Y'HHK=VF!VATS[G19AXDGB#]R<R1C\G/S#SG((A\`ZWW[9&^2
M;@R="MN9_$C5NX$G7'98Q3%<@L4$@<`Y$3&!3O1'V-Q^LY!#Y^N5@<F]R;X&
M9CF.?>093U"-='_^H7,O#_>]Q\/_`,K3VOIN*2P+DQ]XKL[R-4]38FL#<4E1
M.5,I$3B<QBB8!((>T0``!]HWHU\^N#[L[%`V(];.,Z-4]><_7=7SSF1.E"L)
M46UY10L$EE(6-&BY-6+1E':M<CS-6ZKPKAOX),K@"J\XF+MR=NOVE\/<$P"_
M7>6S&W-;AI;RR9IEBKGQ$-*>K<F]B)[U-42UXYP-+9*;Q2E3P]-9CR"T<,S6
MRP'5+/V%>*IZ$@=%Z9<R+5(J!@*81`!U[/$=B_@[:M:Z1"K_`,W_`.8EJWQ2
M*E]4V9%%,39"D,GP>3XG+$+>9*5P!6V*A'V#35U)52+B;*W*@FH51,2``E,)
MA'6O#=B_@Z6PUTB)_P#K?_F)ZIW"HRKN5<FV'(F#LN/\ITK)5E=86R/<X6&9
MMJOX^BS\BT6?I5@Z2W(Y0<015_#&(I]L**6QN(#K).^%7PS<U]F=)U;R#_Y;
MLY(^ENI:IP,<JER4ZOKC'5ZES5<LT=<'<+TDV/*%SBW255=D^^")FL.>(11(
M<PF78`S!0Q`]H`UP;S\)/AE[V3_[MW31JW)H9%L65W]5Z7[B7JKB;'(2.3:G
M(3SZ!&/+$U,EMA8B44KKY2*(+5)W%^-%`P*#SEY=A[`US\1V5V<P#"G7?!RU
MUT$3$32\1-?*)*Z%WO-SD2M7>/Q(YP/*5ZQI(HI$(BFZ;O1CC.8UP_2+RFE'
M)7CATI)\VP=XFZ%QN4>P=?E3:;$;I(OKFC/G"T=?PWP<.-+&FP*FV_4LA_:Y
MYKTFP4EN-S[Q*D4N;(+L_P#1BLUZO%UO#`V[>M'.#Y%"O3GQP3CK@(_M2\^M
M3[XW&P2W8EL;O!^#8=?)-M,.O<C&C*;0+9R'<W%@U;\R@OS#@*ETX)%9C&J+
MK9!HJ1D9.WGJK98%+*X(*3SD>LP3:J@?E5$=@`@B.OT_\'MD)U\E2IKQ^[!I
MH?5P!3ELL/:]_J`TJEM!FGU->!C08NCRBD%UI1IV$,A)!>\<UROSE5CK%*Q^
M-KH960027)(KF*3NEPX@&OT)C6QUR$:(\+EU.T,-\'#C4MP'4CF&PKT^Z.LH
MURPQ>9+]DW'DMT\>&.M)X\@(QW-PPV6;(*0JD<+131NJ=<YA`YAYMQWUP;IL
M?<@^K[SD=H8;5_S#C4?8BRG=8''6(,6T/,,#@EBAAG*-H=7VRLC`SMDE#W*Q
M@>J-UE$%""L[4;]TD7@)BB&VN=-V3N6,WY^%`4-=#UG>:E<V<!-F%\O\,U9?
M&E=EZN^H.<6Q)#URQ&Q_<KMC6'5BH&+J7C(^_P`H>4/`33^QOE62I(YHVAHY
M!PV34,0#'5$P!QUVY/P0NN%,%^<P@5USM_*(*O5N3OE\SY`I%SO]0@+)2Z5-
MVCJ)JN'GV:YJE$A'<=!O*36'T[9;C(!')`Y1>NEQ;M14$Q2^'$0VWWUSL9P6
MXS<-FRQ_TQ`\H^&E`EN5P<J9)>8MZ9[CDZ;NK>_VOW+.,4KFX=B"5BLY)(]9
MK[JN%3,0SJ/\`UW,V*`]Z`@'*.OE&R6"7,XP69+7..<HU3EYVX3S0\PCCSJ6
MK,6M?8BTQ-4K^7:0[S!#.8-0II*/:1]FEJ4T=(HC/5MJY04`K4I5`,.WLB.O
MO4O8#`,4GLD8K`7)X-HF8]@]H$0TJZ0629@F3OPQ7D\:<\;U4Y_A,(63)Z=U
M>6J%M&3*EC;&=JML`%&5JT>9LV%V=[(`VCG"+!)=<PHJ*FY!V`=]M57[X-?#
M)D2)DH?ZM_271[0PW<]H<:E6K9>ZGK"CAV@OK;`5BPWW,5SH+B]HOJ?<4I:@
MEC??QK0LL#F0(:0"27,(!V\P:\;>?A/\,V.B)LFT*1_%NX/IHZ_AI$,OVAQJ
M)G&5,NWV<Z6W=@SDZI]B^^]E+%LE;R-18,YV5I<NB5A;)4$4BM&9[/!.40$O
MLD`XB4H!MKL7?`L.;*U;/PVB`Y1-`JWUR7,+G%P]6-"N7C-F&0>J?-.5W#9-
M6,Q7#HX?QU(M2CX05(Q,LI8U$Q`.3G-/R3D3[#]<([Z^&?$HW3#I3R"!"/TN
M-1U;U;HHAXAONF)53]^Y74$!V75>MV[P52CZ0$%]OG:^)[,7^;?;X723%A,,
MAJ.X@RGY%`V"G`HIY=*84O#JYBM)%$A?"P=*JA7J_P"&*S5!5+F4YQ'?CPX:
MZ.UV!7R_N'$[S!&J?&I2/8\DXVK4R6-L>1*/5K":/BDWD)9)9*1M"YU=RM$6
MAE%5C-A5$=N\$2@3AQ#5DOX8XIB>%L9=@2X.CZLTT<#2GJW98KKKW*NNKJEC
M4T@NG<7=;)9&$8Z,+I*3AS\HI'-,E%1L+50H[@'>;!PUY^_?#':"Y`D--']G
M-\[4:MR[Y6*JRX+(HBHJU`2'2<NB%9%Y>T4CF4Y!$`#AL/;KS#MF,=E3@R8#
M9C3R'\2-6Z%1BCO#*G*9'E70!13QQ&QG!0/(@'$"I`)]S\WP:ZO=6]9O$[B2
MU;D:1-51WOX==J51(%/$F<`4$!.4!%F8PGV`Z._*(=O#1W6O7@'<2-6[,DYR
M`5(HJMU6XB90"&;KD%RJ('$`,NF4_,4I]MRB(<2B&NB-E[YJ@`,F9W$GJG9E
ME%H^3Y@%J(*&#OMD')#&.R'@"BW*<>57G*;<!V'8-<N\;+WXF@?==Q(U;N%;
MH%`'#$Z1#E;B]*4IC*`H`K%16[P.!AV$->XV*PB]W+#[W'*X9#F&<(,IY%2@
M+IL0!UC2:1Y5C";(66A*"*/?'$Q+M*G`!)L;8H\O$?1KS&*W"^7F^ZL93F/F
M"6J?&E29:<AT*H&1/>+A0*]\9449!!C:+D6)4>!&`#4"#''>I`XV,&_)RCV:
M]%=-@+[?;D3"D@9)GF">K=!=>.`\DT0D(>8]_1YB@LPGHY1*T5J914X^#8GW
M=$W2*/+N&W)MOK'.^']]N1M`'V9GG"-4Y=99%5)5F*C9<_.8.9%DY*J:/X]I
M^0XB00USWX7?+NZQYCQ(U;DW+I?Z;1W51B+3/B$U>IN0@:9'KCW\;<%X]HE(
MNHZ*$.8K*78>(Y%C#R"90!XCKT3-C+X]@?9,"`:GY>!&K>E-)LL'?ZLE9*-)
MDL,>+UVR.*(>Z'S)\@\7;2K!Z"_AS+&C)-)5#FX@<$^8!$!WU/N5>^:?9?Q(
MU3UR#7J"#(!<9&>D<7KW8G+(L8QJ=-ZE$*++MR=])@0J0&!TW5W#G^'TZYEZ
MV/OK)MD#)S7\2-4Y/)%FZ,X53!%3O2JI$!RN\3%=FY("IT^_7%3945C)B```
MCML.LW=&^^#7\2-4Y-)M>:W)7ASC[WLB%X:5YI<Y>([O999M*JNF1'G.(<2)
M@S#T\=]<G%L%ON$LE3S]*99]5V_E$%INLR3=GEUY]0[L/*HWZBC\F"[4F(A_
MG^G%^;N_3_+U]3V<DWF9<+1S9BMW:&&^#AQJ<DQ`J:9MREY6+DPF..Q`Y2MQ
MW./8!`VX_!KYKM9*O<V^"Z@T/<&U'+XU"9?</>TL8>611RAQIJ6O(6/J6HR)
M;[?6:N^FE`5C6=MLA%4'',/LS-;15<G,U(7;<#@!0#;7;V;^&]]O`$0=$SS!
M<NPY;(7:GSUJDZ)#6)I/W5C58^Z3B)G::\/'5JT*>`BK-%/.<R3EY--H<%SB
M41$QC[ZOVB^&U]N\N@&K-,XDM6Y.10JBBBI@04`$UE4TDBK`49%-)4Z::Z9!
M,`F%4A`$?A'7BV[)7MC0PBD#,_B1JW+4J"XB;N4%P5Y1.JAX@-VR'9W9B\VY
M>("/'UZEW5O>;Q.XD:MR4,4"K[IE(H""I3`UYE`4YY),!,D4NQAV,4=QU8W`
MKW=:&Y=QW$MMUGW>[-(O%9JI`\L%SHZ=B;,U+)PDTWFF+5VZB'IFZQ508SC$
MW=R317D,/*J0^VX#Q`=/LR^^#3Q+5VCAW@X<:Q9`*%5LNW\7YGT_^+5_AUU\
M#PJ^/Q%@=53D/$JI][N<^49<G\0_6!\0*C/`X;X9Q0`"4!&ELP`QPYB`(NG6
MQC!QW*4>T/3J>-8'?)LXM`,=YW$N=JWQJ3IL^1,=X_;Q@W.]5^@.;%XEVQ?7
M"P%K:]C>,Y$\.#>$0\0W49PQS);=YL4@!Z=>JV8^&-]Q"7;<*(1]69FW`EJG
MKH,[C2)Z\V#&,-+A)7VIPK*Q2$!&R!7WN&(D&Y'+:<KLZ551*29R3=0%2F(J
M?O"&`>.^J;_L/?)9(&0D5/R'>3$IR<(D.X315;KE.9<@"Q2;*E2[P2@!5E#I
M"8IO$JK`8RH[<5!,/IUXB_[*WUA_JNXD:MV4),5NX()P5:.%%^<2KH@N`F2-
MMOX@P<^Y2[#MO\&N1W+QN\_O9`_=U>H\^0(U;LR4I-3`*2GB$/M3E`43.3@L
M#M<Y53%21Y1,',V*0PF^`VCN'M%N_ES.BBP_,4VD+M2%!@56]SA%B2ECF8Z$
M;MUT>]&>8&!.8C0#?BJ*IB@)>WAKI8?LGC&'ZV;>8V2R`Y#Q3PA!EO3A0V!>
M+!(.[9E*_P"];B&PI2(JB(B(#L(".^L6`X5?.UOVLQXD:M^901@@1!E?!`O,
M(95N`@7;F$X@X)L0`'M$W9KU^T^`WZ_,;<F>O-@T<EU9&X(Z$M4]2?*7S'4#
M8?BM;KI2*[;"LD)-_6'UO29V,K1Z'-#;5PSPB8F4#;E#N^.I;,?`O:*@N::/
M[.?T4]4Y;0M]KEGL%OJ4'.MEIVAHQ`72/9<B#JNM)]LD\;/8_E$O,Z?E6`RG
M+O[1AUNVB^%>T&'RZ0:O=S?.U&K<G>X;K)E!DX8K1Y#&37;E1=%4>KH(`":+
MEZ4JACD4>)D!4=]OK]?,YFP6/N>26G\N9T4:MU<%DC5P"@F(S!PL\`'";8KI
M,6P(_P!!!ZY-WG*FXYDA`=]A`"AJ'<''^:Z/]W,Z*-4Y%*=VV73!Z+<[0.\1
M?&='(NR*5<NZ:C10!,3=B9,3*"`\`$-:;IL=BEUO#67@$%U7(>/*$:MV9<9C
M<*E()Q[U*Z5]PX?%GFL89FX0[U^-94236<I"4WMIQQ%1*<0^MY@WU]3NNQ-\
M=<[<,F9_$C5.7=C)>*GF+&8@9!)^RD3+"QD$CE42>LVAC(RI4E"B('Y'0;#M
MV:XFS^#WK!]KKO>G4!CCD=N9Q!5S9;PPD*ON_P##K_\`NAW_`/\`G/7Z][3F
M0K_])')G62Q,L\&;ZRCKH\$2V3K(,41*;\<+(R?,`[#R$3:\A-_SI=^`?#KY
M+\PEXE-OQ@`&VAYUZC:6^WL7J`F/A'/NJ><ZUNOV+#V36,]7&]E:,JA89!C&
M':E<K%DBL51;N&28AS"\(J(&+V[B&N;\'<5PRZ.ESY[640IIS;@6:[3)DRZQ
M>23#*O-=CC9O(8M\N*%BG*^/WEJ=*-;-D&FP#B,MA9YM6(J/>JIG,3FA9)5\
MW,*JS@`(H?<0VWU^E6;1[.7@_O94EPW0_HJ$5'-\RIGUMC3'U8)>["PIE:R-
ME*NVW,ER7MT5'*R%/F'D+$0MCL54JUODT)1X9N!TT4V2J0F'^BZTB^[$3>5,
MN5T='ZK^BA2M5)C+\_:,<L;CE>_2\%5>ERYWFW!CA270@;98*U+2J<0FZF9F
M+C)%[958YND"ZAVB2QQXF3*(B4*.POAW.-IN'7*)I_#=E6<N=&M5^K.=,V?$
M[/4[&Y.M$;'?>SJETK3]@ZD;6^HR=CFE5EHL)1XRADD;*C'K%2[LI3"ER@3C
MR[ZM&QNPTZF7<+I^65&T[.GU,93S%$5;J&=X8R'D[*M*KM'QA.3EGMR5@"QU
M2PV!-%*P0T.X:0SGW2Z!MRN3G(5?8BH#L.NA(V;V/N4C4LN=V;3&AA3#G9RG
M-3LF9)IE`KUHL.6W=JQ_']2--CI5]4'-JN,C$TNPQK$TA"6J=DZU7AD$2N`/
MWC1)(10/ON;8=>?Q##=GV1U4F4W>:46GYRFK;9%WDX],R59+[E5.H5;K3"NP
M5K;JR,$SA*4[*R]PR*S0S95S[IAESF,3V13*)QW'CKFX==L&%X<',EEI;59*
ML82:U(=JOUS6M]UIUIR;E&N86L/53/QUKR)38)RM9HJL5>E0'NA:/E44T!+5
M[')=ZZ5,*9N950PAV[:S8IA^`/:8R97LE6*T>=,B-J3TC-W>,)JP7V8N\-'8
M\QO8)F/=J3ESF[(J4%IELR(4KNOS$2U7[L72Y>0!X[<->)DX%LT_$96LN\DR
M]8(Q8:HU(5$&$GD?!^.^J["[.JV?"3QG1J-<<.(MY9S.O22!7S.!L,K&2<6T
M413E))PP776$!'F.<P[:^N7G`-@G&V[#[F7'+8<@0`AD3SZE)#+]!M--QE#9
MMG("E*XLB[DTO$]8;>P4L]\GURO5F:D]&TV534<-SK]V1L)"\I0Y>8=M]<:;
M@6P@-%QN@'V'(3/S7E_,58S!0$8NY6V,GZJ?%L-.Q0+SB4#>`GX:*?/YYE5S
M1)7/A6P.^Z<N#G+XE5,RNQ>;8.5M:-B).!"3=[C=!.:RL-='+N(7M^Z[I190
M1%%RL0C87,FU;BWCY-90"JF7CBF.8QFR'/W([[""B9@U^2)G53BI%T8UK;50
MJK.="@JK$*;J(S3S%`0#'F/1`!^&8G]>BQG5B5)ES@"'--!3R*77KYK%-%9!
MW(,H=LS:+++2DEW/NI@F42\SJ6,LJB4D<F41[PP")@X;`.O--V;;>IFMN,L,
MFYV@1\9"(IO1SO&64)EC=ZF^J&37N/7[J*I%IK!AE9NGO_"(H6XEC,Y&/"/7
MDR"`-N3O!,B!=M>JN^&;?7638;?;WU#++M,LG-]+(HNH:2,R[*M.AG<L2U-J
MIM:F3$:ZC<%H5!.91@3JJN3D;O3/0$S,7*YQX@8.8PZ\_B5VVJ)#1.GV8Q]9
MM>4UJBT^-:8)Z%B_&R=GR7][ZJ455N@NYF+/'Q"9["FX2()YBPRQTC"4RTL!
M1,L8"@4_JUJPN[;4P!ULZ/VF\:+3LZ9./&73)/V&34Q%2JZA:$ZQ&W)R,#4S
M13^+@+\89-W8HJ=7$S*03M+-YWR[5+VR@IRB`#KVP.V%FSUF\PA5:;QI6WYR
MG'1Z?T]QEVO%5QQ1J.%FQLX-\;X6(@TXUTE`WAHDNWAY-^[.HV<H2[42N5$0
M^M,H(=H:@Z7M6[UI\\_M-XT6WYRNH&%\)Q,,RH,ACJB14!)33V8:4U]$-1B9
MB?;N3J)23,AGJ)G,XS6^UD.0=@Y`#T:Y^(WK;`70W"7>;P&PJ#FY>%4ODRIA
MM3&@NW5*3B-4;MF)2I3D<V:QK4.XE6R*:K8R;A4#)]VDLJ;P?=[`7?T>G7QV
M_P"!8S*O)O6*6YDN/TRT^1Q*CU6[UV&HDIE=WKE59`.]9/!CRL43IH=V1@Y!
M8YS#P!7C\_CKZG\.,>PV5.O-UPV7+DWYMV-IS(AQ&8T0\:LERI4HVI;0';BB
M+IX[M/"..`,!P2\//IB1)/O#B1*<D.Y(1/F+S\AC<`W#MUXC$[M?\6V@=;>]
M_+RP.;.0K2YQRK;)-AP+*&''F6IK&"WAG#5])52]3I(]NFL14RD<Z78BU<B+
MI-97F3`3!N<W;QU]5NDKX@X)=FOP7$+[=I+0"1+<P"&;UDB2YMDT@IPML2XW
MCXY@6,QS!HQ$'+Q=QJ4-#5IL2#6M8-TVH7<B8/A/[T*@D4O?<PEY2]FG-VR^
M(\X?OL4OSANS`L_5;OS&KHQF),;1=LLES98VJC&[SB3E@^FXV-;H2D@WDD>Y
MEG)C`<R8%,3<B@D#L#M].N9.VF^)9=&[XI?VG<F-1U6[\QNA<R3PWA=]!0%;
ME<>TZ8@(.1<$KL3+Q"2S:(<*II$=,6)R'#NFQ3I^/`-Q#OW)Q'MUT[CMUM-A
MDR7-FWR\#$/IOM\HNSD@&E:&\AMAE#0JE9]Z9\/9#RNU2L.>VM)F+/$5BI&Q
MNHK6%UT(^JG!Q%NZ8Z<V2(?UYY*M%$Q.<K=1(Y_S0F`2A]O9\1=K<2P)P=B%
MZ>;!K?51N@)VG5Q*M[+XAQJ\BIJN25#AI6#M*T4M/$L3('4G;IZ"CV\?"RD\
MV'<KJ6;(-``':*HE.00#T;Z_.S\:^(%[O-Z9+Q"^Z@OI;;;`T(M.&5=0,8TQ
M_#Q-73H4)\6*][CL,95DV9!@8*3*Z<E8NV;=90Y$^=XD<YQ$1#GXZY^'WO:Z
MXWO6LO5X;-C6'-CY46G9TS<WX.I^<*C+1<_$/F=C=1KBMI9"@6S=:?@HM9X5
M\:*;JB8I30_BRB8Z8!R[&'7V?`=I=J[V]DF]WN\3&0I#G@Y%&8-8VP^EISJ*
ML(](,!C5OD!U:54,H2>4Y=F\L(.H$J5`AH*,;IM&!HR&>O`*M+E03V551*'M
M;CKQNV&+[7RWV;K>KS+:,SQNK/U:[UV&Z%-[+&.,:X%9:QF/ZQ!H5R6=NZA'
M,8LQ$*](KE[HUA9[JF.U<228;&4$1`P>C7E,'O6U=X=&]WB\/WW-/G3ZK=^8
MW0C)/"^-+'7U:M*XTK"T8FM/6QHZ49H%BD[NX<\SR10^V$42FUUT2GYBB',8
MH<-M=+$L?VWN\YLJ[WZ]LET4!X@M(<X44P36AF>/.F#%;AS(V*7;T]6S+SMD
MLMF0&1EIRX9&D%GKXKE%#E5`J4NY4;IF,`!W29=+:*[XEC&%&??FNFS#+:.4
M08D"!->4B)W2D'.A23%3*EWI@8]^50>15FDW6./!9BJ@44#)$X&22,W`@<H\
M>&ODFR]WO-ROAERHL%LF`AG.Z@N=5%09@DZ"+'*"BPMCD4SK/IJ,UD!54>@,
M<P2)W2O8@9L!2CN.P"&WJU]+FXIJ;TP7MUID:08PR9@G;=G5.<IR.#8/JLSD
MEG:*3FX1]@.$A8Z&DJA)6*0E[2[3E>\+7GS,"H?&!T)FY4P$Y`'NPW,&VOU!
MLGB6!7C"6,NTJ4R?E(#HD0W0K);B8@J(Z`XS+6*PRI4QD:>QY(?BE.)FL%M<
M;(/BPD,IDBQK,W%E(V;N%(:6+6A9M1,5PL<B*9`Y.`CKMSKM@UX$)\N6\'.T
MJQ9B\GR]BJN&X6\9'S%1,/K7:^1.3,AB]D33,_8RR!#5]U6,@-X]0\5C)%#8
MC5!1F.PB)1/QWUS7;/;'O<'S;E=COL*"4IR7?[`C;K\*^:\UQ-OH">.#=-]'
MAHF4,RR57I0Z(OI>WOR-S-S+K[CWP@/9K1V'\/\`_P#S[G[#N)9PYV=/V0M&
M?%,[.NF"1EKHXFI*\QF>CV5@HX)$L,8KU-@_D*2-@%/P98Y2VKN4%&?U^Z>V
M^GV!L#9M]GW.R3#U'5HMNSJ&\29%SO-VV\6A[DX`E?"9G8V+',RYN"$W`O(#
MNOBDG6X]&K.H\IF+%4B;0R;E0#%(`]NX!P<5PW8V40V1=+LUNXQR+3ZXE2!,
MV[)G3GA;IXZA5[KDR^H6FJNZ]D^J7"1>F.XN.182-1KKYZT?,F+A5:N/EC*-
M3\H`13?M'<-*_;,;+3\(=.N]TN[9MDP<&&-6ZBV[.8+TDP35;+3L58SA[A,R
MEEM"D<VE)VPS3P'TH^D)1)R]%%TJ`%W,S16(0.`;%``U^;"V_7+$KQ(E37MN
MSGF#10T;@"N82132FMTTID-CQ^=4RA&Z&3,K.'*B2G=G203NLP!U0,(@`\HG
M#AZ=]>2Q:_"Y7YKW&B(CX04U5_K0J]KL^9NF.)JT!5;O+2$5>8)2O7.$7D:T
MU2>'6]VSTJ=(H%(JQ2.)B'$?9,`:_6?P[Q+9J][.?Q,F2^]66\HAQ/D47&#2
M<J9>/,2Y#HV8L=X39Y/N+R/Q]@&4RB2G59PZ9P=AO#V=L`!'^]5""R4(U(BF
MD"'-WADR`4`WUZN9(V3G43;O=W`YVNXEGMO.50/@K*G4TX7R5:8O('O>S+XE
MR7*K8A4<7BS6M"YQ%IDHQ=VA!*TY@RJ+:":(E,U;"Z65*0`X#KGOP+8"88S+
MA<R?L.3MNSJ1"2$%(L>E-Q6LM7?,#_[Y;6:OSJ\-)=-]`3;NHIC8XV.\3&I'
M:-B2_L`&Q1V3+OQ#70;=]DV@-;=[N`/JNXEIBA1@ROE5K1:O9LC93IT0RPMF
M:V.C03E5G+25VJMVL$14UWL@1H@D*:<=&I`FB8H*J$'<`'?<7J=E/\O(]EW$
ME%<XN6.H>0ISVPU]]<)FTR_2!!KJ(,XA<\JE,15TGH2UW&#062;KQ]M9Q4<5
M513O#J")^;N]A`1@["ME;Q^\ZK=S^R4(O-N1HJNXYQ]6,$9IS/?("2]^VO[Y
MMAEI2/>%EF\:D^1K_O$T499_)1[\ZB"J!DTRI)<FQC<W"/8>RO\`E+O[)0K`
M=,T_:[=GFF7*R>.<RUFZ.\>2%D<OF#@5F4T2=L;4K,\JJFB!EED6X*G()>8W
M/OKXS\:[A@5RP&Z3+E(E,F&]UM:1D5,^7+F,A,`(!5GNH7E'!UM.H`#R2-0'
M<0WV_;`FVOG>!XD^5<[,MQ#89"LANUVYC8[RG,I3*$2[DI3;M%MB"/*101*V
MV3,/'E(<>`^H!UY:^WN[G')$V\-:YHG-)C'B4F7:0'AP8V,<R\V>JJAVO('4
MYB.NT6KX]N=CL6*LB0DJZR.[7DZ2P8*/7C94C51!L5-*PU-(=F6W$O*';K]:
M;#[0;)"&NN]W(W0_HK?`J%G>$;#1I^[5**R;D>'FL*]).+FR%NJ0N2?'F692
M4^[CV+UX*!CO09,U"ID+P$I-@VU[O',8V!FR8.N=S=1S7]%"X&6L\Y@/D_'"
MT7:;C5UF2&#`EX1V:TI)6,EJ8I&G757CHZMR#*0%0@E4?"=PG^F#*;[:+E@O
MPUO=QEWDX;<2]S8QU;N)4O<0^`-">0Y0R]"9&ZIH^L7"QY'LWNBX/J,5NZMH
MU:F,TY+W3'U^9@%JLB,9;V'N]1X5RBLN4&SE,-A$!US[U@'P]:2&8?<AO2W<
M2C;=G*F?H*L^5G<Q.+7')25XK9H^F/%V4NM89=]4+*];+-Y].-EYB"@B*\KE
M,=TDR'%(QAYA]H-?--K+OL7AU[D2I=SNH:]IC!KAYD]3*G",UH=#.I/Z,&ON
MVGYR9E;.6*7XS&6!;H/FZZ"Z[9.9$&[U#ONU%8FVPAP$`#7P7XBXA<I#+>%A
MLE]`BR(J$!D4>IW052VZ%:N=.8:M9^8PCM`38!OZO=SG;7$V"O-]G7ID^]3'
MO:!E.<*;+M=V.ML8T.&51_T]@"F$<7"J/-M36@;CV@7QCL!XAN(>SKKXYBXN
M]^!M0;'.<YW%>:U3OJPH\[>^J?%496*G0;>\GL`Y!B9HU\7<.:W7*N>5?QK<
M8?F;=RA90<`+I+\UWP@.OT%\,ML<&EW<-O;9;J(4VLVXU%2@^P8AMN-9;*L!
M7<F9.@)[!'33C$E>LU9,Y,O:[@HF@9V6T2!4#*V0I&12(D22]I-$H%$`VU]`
M?.V.O3C&[7<DF/JNR\"SESHD`E<;+>:,M'S7CEY$3-XKJT&KA`;)#JR%C0BK
M+$35782%GDH2KQU;?HS@+.70@X)XA(2*D$AMC%'6;L/8R]D?P=V/[!2M..4K
MLLLM9DCI[J884Z^73)=P0@+?/T:668W%:H0$*O9Y1)E6IF+<5MJI7[-!LR")
M#)F<`1F=#MXZ[(V>V.NV#PDW.[,FVC2&&*+;LZGWR^[#E2P.IGX]9$A;K$DB
M*F^;,RR%DGI"IVU\VDQL1%7\W7*^1,BA")E(DF57D'FW'B`C\BOTBX2[\628
M:FT<A`@BTX&LJ&Z+$J>^^GGQ%:>*'1Z]<VOY5!9DZ39HU)8D<$8Y5,8>4&AG
M::BB>X\HF,(AJ.T<G![O@FM,J67F-):<RLEN)C%>OA@[QP1T`;<BKTC@/2NL
MZD7'AGI@])R(%`H#Z@U^:;K?FMQH]7Y++63_`(*Q5_P>0IF>2TQ`O*&4;64`
M$>0H`HL4IMS?F`$!XCZ.W7M,0Q42)LJ\./[QC@8TQ$.!!HJ5'^H;%M^RMU:Y
M`QA3:O2Y%*R]/M;9KV*]NW#UK774;(.!;354?(-BJ)RC*.$I4S<PB!2@&VOU
M+\-=N\*G8:)M^L3'P%+K9-/[*SVG9U'5LIUJH=IZG+=4;]DF!F\5L^G:KQIJ
M^1T"%Z<-X^/:SDA-G[@Q[-'+M"@5,B?MIH\H&X@.NAB>U^RU^ONIO$J1,EQJ
M(>?^5%MV=+7F9,GNNL:O(0=HM4%`3V0HNMV&ERCVUN#NX21HK*6/:8VO-JPX
MC%*LR=N!!1N#T%`43$!V'<-=AN#[%7FZMO,NYW46Q&ACD![LYBN<SREF&)H_
M4;`4NUVO(%LCBMY/X^QCFXS%';UE2Q3#)U\6XEQ5(]U2+4D@VY'*!3.P(W(D
MH`CS[:\Q?\(V;8?W<B2T;C"BV[.K;]%<Q>)RB7R*N-[@<BUQ1B:0JBS*4L,W
M*5I24AWP2D9*2<[7:\`N%%6Q`%!(JIDC`.XAN`C\ZQ@;.7/%KLR?(DN:X&L'
MB*=M^<JI^'88_<=-B[QK)LSDCNJE!^R&+?D29E-)IILE%%3#R_MKW9!+O]?R
M!MV:^PRKYL0S`R67*Z:VS79=&K[*5IV=>A'1RBNETVX2\:+E%X$9:DS,'+=9
M,\:NA9Y4'X_;/:3/*)F3,IS?7<H:_*N*XAA]XVP9=[JQC6%Y@!'<SA!)=0:E
MU?\`7U__`'0_^;IK[C89"H?^+YU&`L\'G4<]'PC\9.LL/0'5SD%P'\VJFVY@
M_F0VX>G7S+YC,,FMF%XKCG]"V[3'^+X5=(3"<%R&*F8KDADE"*$YR"0W:`D-
MN40';B`[@.OSEL[BMXPW"WN82'-AG\Q"5SHN?`DI(Y(J2:`HQYBH/%7K8?`,
M@%FHJ?G$C`A$"I1Y"\``4"IG$`XF'7?D[98A&(>8;[NFDM%63%R81=,(UR4#
M*&19KQ<:>'1.N(F=KFKWA`KSU^]5$3JNW+5=V)Q$05`==F7MG?VB-MU6=W31
MNY%AJT:M'+-TBU9E7C>])'<C!BBDR;+E`KIB5NW;(MW3-V;<RI%R+<YA$1'C
MKSLGXH8_+O!;:=9#C[S(?[Q9G>L3NI@7S%U1R)692G6"&8)5^7=,7<DS@8N&
MK/C3QKH7K--R:`C8X5D$5=@Y#;E$H<=QW'7M\/\`BWB[6BV3HF?J*,4](Z#C
M&$6YCVK!FU(X;MFCA1HT;,O%I,2@5H:2:LT6\=,*MTR@0IGB+@W(4"CN`:6)
M_&#%G3X,)LV1DF?J(6Z$9')M'<=[KAAC'+LDH^BDZ_`,XI_+)%%-*4=1K",:
M,3/R%*&RA4RB(AQUY^=\4L9FBLZ)GZB%D(V*]W%8+0T,YCDSE`\6XAHP\:XW
M;(-5#KL`:%;&66(W*(J`4%`,&Y3%UC'Q,QF22\$P.Y,Z:MEY<RU!C#K(JM'D
M+%.&;D4/$)*,&X)'\./L',@0A6JB@I`"8B<AMR%`!UGG?$W&9H@28;TSIJY'
MJQD>=9LJSBXW]*`Y*V(:/:&;M0<G`P*,F?="R8+M2>RDH@FF8H!Q$1XZPM^(
M&,&>UP)H=FF=-"/=M$$NY%*+;+F0$"%,]CHN54.Q!TX>%BE5Y)D[<'CBKNC"
M!.?<-@]KAKN3_B7C]5IT-Z9TT)&JT3D4S(R,+'/4Q;MFZ1)*'AY9%J#8XJ%6
M9-Y=@^;,EU#CN8R)";?F0+KB7CXE[0"HNKS3.FA;+Q;-:50FE8V$4E&B9D6C
MV2A(>2D6B!W2SM1LF^?L7+OPXK.#`0HG'ND^4B?*4H`'HIFTV)XEA4I\QQM.
M;32[SN*24J&.DFJ!>Z!/E?.$T4N;N&XBMXLR:)#&-W:0KKF'EWVX\-M<K!Y<
MTWO63*X^=`4*5@Q4^HC-`F`>4V.\<I@(>A99U*N$@^8*JIOG:]/M*\E]V#:K
M)34)]>+>5+@Q@[=0DY/4^#O=)D<M1]:!][Q^)Z$L=20,<&#A%<T&1$2F>IB)
MA4(`!PU[W8Y]U:6B?"G<'G2*@'J4S'B,]*K[CIFD9:IU^TW^R1%@NU.AG5"J
MB-@9P;(\-)S!TBRCV2;)H$*@@`D*!U`$3<VOT=@W8%ZEMD30VR1S6>=)]#3O
M*/J?-9(S7&4&,G,K9#J[%ITJW^SNYBG6!XV![8:W,.TZZR>A(P*_>S+Q)`IE
M@#E%0H^R!=]0Q'"-EK8H;#>E<2S)K9+RI8+76FJ>7LH9%QW'R'2!"25*4J$8
MLZ9Y7RFT5=MIEC;&#Z*>J)Q[I),NZ:9TU@$1W/K7AF$;+6:FZ)7$A=B4N64H
M"JY194UW;*W6X/$'2ZV0GHF);$4HM7L<6Q)8['7RIL22+V18,R_;"N5ET$E@
M,'=%#8H=7J&RV4C_`+7$BE-;X_1E;C^K(N,KOE/)5;L63,15Z#RS)*HU&U1W
M<U&/=/+#:P2K3PL_$.G+@QDP;F;%`@``;:9P_9;+"'^%Q*1!`!(KJ1-8E)"[
ML>BN\YIR3>G,#!=0N5:"]L#.0DXI`Q&TLI*5DCM4D4J8JCIQ(;AWR9RG;F)L
M8-4'9[9F?.%YHU?^'D_923^Q3<>H&R]3?>63+BD&6,R?9JW8:+)K2<X,M4$C
M@-;=$8JMV"48U51/S)J@JKWAQ,`E*`!KY[\0,*V5=<'RKO9$R&:5Y@D/$O9Y
M8%3`]0*8$V22LLU2#E(F4Y"Q[DP'(3E$Y1$P?GMN.OS%L9LV+EM)?;S*)+#=
MG#UHBLY`$*">GXYCX)QP<.=8XQ\BX[IKN"QE'-BD@4*D(&W#E!,!#T[;\=;<
M&$F3M#^^`HF;F89T950/)\_A&OYZZS$,N11[/8IFG5EOCUG\3W,N\L,K*19"
MH)TM\=T*<<Y8/3D$YC$7$.41X#K]476^8&^Y,D30WE`#U69MU"78?J&7Y"QK
M56V7K*<)*T+I&HTE%P<?**(1KRV2[>:"6;/?%M72SA^D1DAW/*<ABF,(FYMP
MVY]YPS9UDRR+,/\`#XD!1_!]1-DG:_B]&MWJQI6VI].&2R9""?!W#-8ZZP4>
MT!LT?R3ABY([EBOU5TSCL45#E`2[>GWVRVQ^S>)0M!IC_==$HC1NJ;O+NG9:
MW?';(%GO5UGH\D55F*&-KW+,)*18G]UI-9*WQ;=I$13ENS>3951`RG/WC,$]
MA`?:'X_\3-D<*PW$9HE-8UC9A-H%L2**#0!`9(`(I!IBN#AF:Q74[?FZM=13
M%D_SA)Y:FC8Y=S-5<NW%MK[DBCFJL:'/.P>*P,7'KB#<4]U#B=,P\W'8.OL5
M+P:=<C(+HMLY;"$P:9D:[RMRQ<[B\E9,LW4#(3^1%<]XXEVX_%'&M.@O>#6&
M0JVT:S*R+%1R*2J8+BY566.<1/RB4`]?A>!;,2M>9@:'.(]W3NF(1E7*H4)E
M"=2Z;63WJ$S2VC,QTC-)KA-E,P:E+&U%U(R=;>QS(\.HM"O8Q\H9,P+J.`=)
M\$P3'CKDWG`]F7SHLA&/]GQ(2`N7)UVRQ,SRKG;*&,ZY*=/M^5?S%,8IH2=G
MOL%,/XZOO%85ZW?NF[9ZFV1[\W>"8XJ&$HE`0`/08=@V`W0=:="PT?4R\`0E
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MU99[$KMEG:-C3DI%9(ZJ;@B1`(!1()BB8>S>\+V;&!DB$;']GQ(7NDW%(Q8@
M'?>E45:PSSVS%!SLX8IK$!RER@5%0I3[`0```*`:_)>*72Y,VJ=)N4-79&;/
MN4(K5=<#J]]&Y9*`B!/OUVPH@`%'?9C&\IN8Q1,4Y-N`E$-><VRNTV[N$QE%
M!\NXC(IN69,'SU%\YB8)P[3$AE'#Z$BWR[DB:8)D36=/6CAV3D#ZPZ1TU"".
MY3!JFY;7XG@^'L=*<Z),/IGR."ME0,48I').4_"N48MTRY2(D:O(N.?<K0FX
M^[SO'K9Q(NHTXB/,V7640X_6]FK/YH8SG=HF?J*Z`1QXMD=)5H>.@#QAC(IM
MH1:OP;F!CHU$G+[F80;F/5BDV"A]SF,9(SGG$1!4.&T7?%#&B"`3'>F?J((H
M6O@60J(JG+%*K-6Y63!PM7HE9U'QR0;(1S-THU,Y2:-P^L#G$Q?SVL7\R<?S
MG1-Z:RQ288Y,5"*@9KSE(JB=;PZ`.W+990RQVKA_R>\?"BY.97NP5`H',/#;
M8-/^96T$(1,/\3IH29.*8MGAWI6469X9($P=DA85)R4#B)G!_&(1R;M95V!M
ME3**'$P``!MMKCXQ\0,?:UDTEUDC^TS_`&TDR<BXEJ&6*XQK%L1?'B(ZQPEF
M109NN0#OX%X=ZP14*Y(Z2*R*93D,F0I/M92@`@.XC[;`_B5C$["7,FFBR<C_
M`#O0I40(3W@R`A>[36?`8$2B?NT2E;K%(F@4XFY$RE+L`<>&LNR>*3<7OMY?
M>*VS!"@Y1NDJZ55PJO\`TT%*XQM-HJD`Z9\E970.7<P`=,UVE3&`P@8!XB77
M&^(-SF,<'R\X\FXKE.KMNB==-V9)$7S<KI%J_,W;G>M&KOD*LT;.#I'.D@)2
M;!M[0;CQU+!=H\3PG9R9-DN-IH;S_,X*MU+3O)+W#("(E28LT#(%`B3AN@"+
MXB17CE\5$LDGM(E0*Y=&,!`5`O`.';O@_F7M!G.B9^HLZU9-VT<NHM'M8^/.
MX74=OE(Z)BHU_)/70?MF[D9N/8MIYX>85W4<IG="B<XB($`.&C^9>T&<Z)G3
M3IJ2])I&($2(UA:^S(B\)((%:5V#1%%V5!-`5R*!'"J910J>YS&,8QC"(B/'
M1_,K:#.=$S]1:D0JDS`Y0+'1J8%7%PH"+!JAWZAS&4,"HH))F*B(GXIIB1,^
MVYBB(B(G\RMH,YT3/U$).JBB8Z!TF;)`[1N]38JLV39DHQ5D5!%\X0.S3;F.
M#E`I$C(*]XT$B8#W7.)SFZUT^)V-MD@.+HQS3/U$;ZR6/B5V2\<:N5=)F=($
MRMT:M7TVR!S)))*.&C/W<9DS=+]SS**))D.H8P\PB&P!I_FAC6=VB9^HBA=(
MJ+)%5-=",CFKDK9&/!RU8H-%1CVJ)BM6&S8B216K8W,8A0*&QCB/IURL6VKQ
M+:>5+N=Y)+&/#OI"FKZ3G#Q*N9ZJ@;J**`8'MNXB7G?4[<>'#FD4P';U;;Z]
M?@UQFFZ<"H4ZIINDNZ*W,@8@++M1[PIC""((-3"/`P!WG;\'P:\7C]TGLO%I
ML;0-%)4F>L$F*QC&TJ=9"/8$V1629+^!:&<1*SQR9R_?1K@Z)ED7;Y4X][S&
M.F8.PH:GA>+XG<A&TX<+N,+1Y4>Z[A5VLOX1D!EC))/1!BT_;-FU,N#9D_W1
M'O6B0+CRD+R@'#;76O.T^*7AMDO=I?TD]]$%CHXY2"K&1;CE;D:I&<Q4:X6:
MIH()MFG@7:S4[V.,R(D`I^'42`#"(COOKD#XHX_<W=3:YVKET#\3]0+._P!8
MQ6&\'$MR@=&.9(*;`*Z[9HV:.G[DH#WCZ5>-$D7DL[<`8`4%R=4I@*`<NKV_
M$W:"9$EQ_P"Y^HHH@8YBDW6;-V;)F98BY3NHZ.CXY;G66(MWW(Q:MVIG"9DP
M`IQ3$VPCN(ZYUYVIQ?%;[*?.<8M%'KCRN*MECD\*.0:MD1<`W;-VH.7#EZX*
MU020*N]=*&5<.E>0@"=98QO:'TZS[1S;Q/EMUAKAG5B1SJ1?BK:.)O[GYD>T
M/3'N0'T?!KWVQ5V#,,,T#E`#R)A1S@,HI84Q8F01`#TMH/,/$Q1%T[]H/1N`
MCZ0$->5VKNL^9.+F1COE!-*E)=./=NB/7K6.>/4F:3)L\7AVOB6B2>XF%NLD
M5,Y165$3G`=R&.(CRAV:X>%8EBEQ$&.<``<K\VX0BE+`11.<ZRB+99551%<R
MJK)H8YSD1(F(J\R`^((J)><2*]X0IA'E`H;!KG2/B#M++G$%SH!Q'_5SGZZR
MFLKCJP46M)>\C1,:,BFDBDVE#1[19^S(FH=;9BNNBKX(.]6-P2`A0[``->YP
MSXG8Y+`+R=$SII)>+>/;F=BFS9-E'Y5SNE&L>BT4<+.@3(LX=JQX-#2"J@(A
MN#GOBCZ0$.&NK?/BSC.JU()T3,O^(A:-R-VZBIF"$<P4<E3!92*@HB$$PH(%
M;IJG+&,6J2RPD+Q,<IC"(B._'7C9FWN,/G%X)T/Z:$:C'Q15DR#%QW=MTRJM
MB@T2+X5^45!/*(&*4IBR#@5A[P^^QM@X<-=>7MEB.*7=]UGDV`TGZ?G<?(K9
M65&$.J#ML@0"BF*;9F.X")S$;F.<JIAWV%<PF'F'L'U:YNSETFWK%8BN.=71
MI@H)P8F8\?E$YB[\N5;23E`!V$HKE#B';V:]'MG=9\BZ$,C:LYSF2.=3DA'M
MV[A1\BD@26-W::4SX)@:4;,4B`F6+0<F:CNP``^L.!AW].N;LIBV*7+"H6G#
MDC*[C"RH#$ME5'2JJ3!4[H4U0[UBR,"#E)(B2;P"^'`KAP0I`$H+@JF0?K2@
M&P:Y4G:C%IV*V2]U>=^<_600<B)<M&RBB/B6<6X6:*-54'WN>)2DTED$5$SJ
M(S+=BC+H@[[XPJD(N5,1X`4H<->V?\4<8N3>I!SOW=%4S]1%2-29L>X.U;QL
M<PCQ(FF6-BH]I$LN=,A2F<NB1J+525<+CQ4,],Y`X]H;<-<^=\3\8FY3HF=-
M-:@S9-&7@6<?&1[85A7%*+B8N((+@Q1*JN=.*9LDU55R#L<3@;?X!WUR)^U.
M)XK>&3YA(,NKUQ7ON*/(@BV8$!%%")A4$&K1!JT0".;%29E3555<*MQ`@*D7
MD3+#X@>804V#@&VO2MVRO[;J;N7NJSNZ2241S+P0E;LC-F+`7"ZR4<T1219M
MO$^TLDV3*7F324.',(<PCN/;KA[-OO5YVMD7F9$MM&LG<SQ3RJ`>[/\`'K^B
MH_\`"CV]/9^+EO\`GO7K]@1Y/^E\Z/H\'G5,<(]6/3QA&^=6]>RED(U5FI3J
M6NLXBU6K\J\03(NL5N9HH^;$%OXA($N;M]H#``:^F?&CX2WS:6[F9(O,J5&'
MK,>[)N%=?&+C.OUZM,!:(Y02K#)^8AT7*D.<<V,^0H")BE@)<RI@#M!-,I.8
MQO@#7YKN?RQXY/PZ8QF*74`P_P"C-Z2Z$G`KS*P\OM`PR62MR^85T5G_`*%F
M8R@AQY?BM.EV^:(I[;:JE?*QCTO_`/+70_X,WI+#V;>>:=!2;Y1GHGYC%^_E
M'B*8?;0+`2Y^['MY1$I-C#\S6^7\LF.,'_\`9W6/]S-Z2.S;SS3H*+#S&NBL
M>)<UM3%$-RF^+LP&X#Q`=N3AN&M7^W>^-;9UC2X9;$VG=];*JCA-Y)C3[)2Y
M#S$^BM3E#[];`"]THJHH:"E0[OD,8.0Q!)S"8P!N&J7?+OB<>1.8/\.;QI=D
M7K,=!0-YBG1<"*)QS4Q(5P054P"!EC[E`QD^8>4G#<2]GJTO]NN)UNGL)_NY
MO&KV8'>7-B3#@*2?*+=%B?./W[&9N<-N%>F.';Q'V/AU<WY>;^!`S6G_``YO
M&GV#>.<-!1?RB_1<9,4RYJ:"83`;C7I<`V#;UEVT3_EYOTU@8V:T0/NYO&GV
M->90)C'@**^41Z,`XJ9K9$3`!$YA@978`V_F1UG9\N5_'K3F'_#F])0[,O&8
MZ"EZ'F+]%2#1LNIG&/;^+4,FFD:`ES'#8>4##RDVV-K2SY>[Y+(>9C3"GU)O
M&CLV\FH'0447S%.B]0C@2YO155;K@@HB$+*`?;?;O!$Q!`"_!VZU.^",]V0^
MS-XTQAMY'T7:"E3CS%>BDB90-FY`J@>R)`AI,X@4H;=YN4FP`(<=NW6!_P`!
M;T\Q)I^Q-Z2.S;SS7:"N2?S%NB$YS&^_HV/O^:&OS.X[>CZST=FH'X&8O9U,
MJ:&M%49<P^=1.'7@5@QWBC/E$.BOPQU4LU)J-^5VDJJE5YQ?NC&22'<Q2)\P
MAL'9K?<OE_Q\.#VWA@_P9G&GV?/S'05&<!U^]($=FG(MFDLL))0EKHE"3A7*
MD#*D.HYAW<FFX`R)B=X4``2G`1VX&VUIQ/X!;037,_BI=`/_`$9G&EV?/J@=
M!4K(^93T6^-515S.Q40>%`[Y-6MRBR*YD"B5#G;*I';.42<P[I+%.D?\T40T
MKO\`!'::[>I>I</[F9QH[/GYCH*Y`=?G0N()E<98JZX\K<'3LF/^Z46-&',:
M%71A2,"UIF[1YN5=5)L510H!L.NB?A-MFV462+[*;,R$W=Q@H3+A/#"8$\"6
MN?,0Z(US$4',;14Y%B.R)A79B+:H.#D`CI!!O"$9$".6#V@1VVYNW7`O?P3^
M(MY,1BEW'^E<L?4[QS7:"EB'F#=$2)FQCYC6=>[060C/&U*?>`DR<!]N;'(Y
M2433*901$.Z`@!OJ^Z?!GXB78`'%+N?]*Y/J=XYKM"3M.O[HA;F8E-E=%5NP
M9GC@$]*EE%Y:*D'3Q_)QLYWS<R,@U;NGQ@8E,`]PD4H#N(:W'X(_$1QM=JW>
MG_Z5RN[-O.8Z"D1^OWH73CQ@%<U,EH=PBS92#)_3G3)<C*.:I(QH-$8YHU;^
M*;<FQ3K%/NGRAH_DA\1/_P#4N_\`[5R.S+SF.@I2'F#=$ZZ:)4\QLU"E!+Q)
MFM/F'+'OVI03;+-8A9%6&9O^Y(7O'1$2NC#^;Y0*`>FN?P@VV9A)N4S%KLV>
M7$Q-V=Y$'#+QF.@K17S`>B@[A)ZIE1B#DKM-X90F/Y%9T5R0.55V28=-%9E5
M9RF4I1(JL9$G+N0H;CKPMZ^6[X@WN\F<_:'#[!-75'^4%+LV\9CH*6'\Q7HQ
M*@Y3)E9U(+*'DW#9!2KS:;MX\=M5D6K))P*0((`85!$3'#E``U[+9OX'8]LZ
M9LR]7Z1>WS9=B$N4]L(Y3$U*V7A%YF$BD<!4=87ZZ^CVC8UHM5G<M*1ECB8Z
M6*=-*ORJZ146TH^=>-(\32,W*0Q77+RB.X"4=]>7O/R][3S<2-^DWV4UI=&!
MD3"?*KNPKSG\13Y<=?W0VN!5!RG6UI(1CS>_7=*5=S;$6*?(/NITJT.9$5A_
M/;ZZKO@=ME.+)<O$)+($4F[O@-U(X)>0(DQAN%*0\P_HN%RHZ4R\L+MS[L*\
MDDZ;+EDED(QJ""34KCPW!MWHF,!1X`!MM5WGY<MO9[[8V@N`_P!*_C6;LR]9
MCH*85PZV^@:\U^8J5FR1$N("P(*1DTS:PM@BE@CU0!-=PP59&06;3"X%`RAC
MB*8J;\-N&OH>R?PGVNV=(ZQBUUG0YMW<WRH[,O.8Z$P</]0OEV84?V*6HN:K
M)*S%CBXV%>6"X1$Y/2R<1$+'+&QB#MND5`6K*.*DV(&V_*GQXZS;<?!O:C:Q
MCQ=\5NLA[LKI#G>0A+LV\YC'>*F]SYAO1,\?"]ELHMI1P+@SA!=6ESJ2\&X1
M']).J\NW135:.4@XG,81YA[->'P+Y<=M\'M6\>N+P<UU>/*4^S;SF.@K=?S"
M^AYS[P5^^P=!])D`7TF>GS*D@^7,*??.'+P[<7)SJ@4>8`-RGWV,`AKL7KX"
M[<SS^YQVY-&[=G%'9EYS'05H3S">B=-VNZ0RPP.J#=PTC#'H$F!XUN+I9=H#
M9,C4J"!D4EA*J"92E5'B8!UDN_R^[=29@>_';BX;EU?QH[,O.8Z"F,XZON@)
M[DB,RD^R<5_9HJJOJ@T([H;U:+0BWARJF%O'*,C,T7`*@(B<"`([^O7H;W\%
M]L9^&.N+,8NC9KH<HW=Q%&XF,+O)H@=!3]4\P;HE63(FYR4P>`DB)$22&/W<
M@BBHF;=H*!7;)4[9%`O#D2$H>K7GY7P"VZ8(.QVXG_2O4^R;SF.@I4;S`NB)
M0[99;*3==1NDJ0Q76.)-ZFL#H!!PCS/&:RR#5+<>X*F)>[U<?@)MP?\`\Y<O
M_;/2[)O.8Z"DIO,`Z%"H-V".7H5JQ3!5%=(:F]!V1$@%(T$IE6YA5=IE3+WH
M..<O,`\H!KB7[Y?MN[U-#QCMR`!'_I7Y.%9S<KR#"R[0BG'7UT/R1E7<AF&-
M>23UDRCWTL7'SIXN9JQ=+.""Q<*L5`06.*@"(A[)3[@``&P:VS_@3MS-N!N3
M<;N8="$>K.@EU*\<QVA*E/,5Z,F[KQZF8%7XIG,X>.1J<\FL=%$XD:"Y$R7=
MBJ*!BI!R`!0Y.S7GL`^6S:S"K[K[]BEVO+R8VF7>8T0C&%:OEX7>7MM`$<!4
M48HZ\>D"L,,B(3.74(U25RI/3C45:]+CWC62BXM=(FQ2;E43(<.;YNO3;1_`
M7&L1D\F\RVP&65,/D*F<(O1-1T%2?\HIT4&X??P:'W]!*[,@/#T[]WZ->.NO
MP"Q6<3<YD]G)ICJYL/*I,PJ\MC$'05L7S$>B@I@'[]:/`?[`3'V&MW^W/$/\
MQ+_+F\:GV;>>:[04?\HOT3A_OU(A\/N"7X?#_0_1ICY=+^TVC>)9`_LYO&CL
MV\GZ+M!6/E&^B7\/`?<]*?H.KO\`;_>/>-]B;QJKLB]9CH*0'\QCHCYC;YO0
M,/,.YAK\SN/$>([);<=/_;]>/>-]B;TD^R;SF.@HTOF+]$_*'+G%F`<>!JY,
MB/SQ[OUZ>)_+_.O]S9=F/:U[!")9-(\3E'L>]9CH*/3\QGHK`H@3-C0X;]I:
MY,\!#;AQ)JNX_+_?;G=S(,UI)!IL3>DGV1><L=!2A#S%NC,7311',2;@S=4R
MI$DJU,F%94452HM^?NQ*D9<X[%,;APT\*^`&+X=>9D^5>98:]T8:J;YRD</O
M$J@M)CN%0W@?KRZ3Z=1'S&R94+&/G5_R#(BW/7I94J"<K87<HBFHNFF*0JID
M=\@AZ3$$>S5^/?`/&<88&2[U*81"N5,/D*.J3^:[0I=5\QGHM4WVS4U#YM=F
M/7OZ$]<^Z_+UBMRN#KO>+S*F-@*I4T5<*B;G/(A8=H*(^43Z+OPUL_N=F?T/
M63^0<[G#V)O2579]XS.T%9^43Z+OPUL_N=F/T/3_`)!3C1:'L3>DGU"\<UV@
MI0'F-=%H``??I;<`_B[,?8:Z`^7.\$1UTOV)W25O59_,=H*)/YBO1<8PF#-3
M4-]O];LQZ``/SFG_`+<KQ[Z7[$[I(ZK>.:[05L3S%^BTH;#FEJ/'T5Z8#_XO
M4#\N=]CR+Q+#?[N;TD=5GY6.T%'$\Q?HL'?;-30O9VUZ8X]O^4TC\N=__P`Q
M+_+F])!NL_FNT+<?,4Z+S;`3-3,Q]Q$I/B_+@)Q`AO9`1)L`CI#Y=<38X.E7
MJ4"#[N:?.HNN<]PA9=H*BC,?7;TBVW%%BK$-F!F^E'+FG*$:!"R:1E#%>E6[
M@JAR`0#B5,>/9PUZ^X_!W$[I)U3IS7;TN8/.H=0O$/5.@J5%/,0Z,07*T1RX
MNB[$S]PFB>L38@99!)!)PS!8$N[!1(2"/-V"'9KAXA\!\7OLX36WF6T`QIE3
M.--EPO`<.2=!2+Y1'HP$O'-[03?GOB[,\?HDUCG_`"^8M-]2\RQ_A3>-;.S;
MSS3H*W#S$^B[;CFUH([<1^+LSV^OZS6=OR[8R#$WN5^5-XT=FWG,[V2CR>8W
MT3D*!3YP9%,':`UV9W]8?F/2&LKOEIO[YQFNO,J),?PYW253L)O3C&!AO%&!
MYC_1*!>7[^#+M$?[G9GT@`?G-=&[_+K>9/K3F']B;TDNR+UF.@I,;S&.BHYM
MT\W,S^L`KLSPW$?\IJ%[^77$IL^7-NUYERVL%(,N:8_>2.'WF506N).X5LEY
MBG1<!A_W:4#;@/!.LS2IN(=O(5/?;6+%?EOQS$0`R^R60SR9I\A2ZI>.:[04
MGE?,,Z-G<%.QS3,0KNW\/)M6Y/BG.I@959BX(4!.=/E*&XZ]#@/P'QW#+MU1
MU[E/.<2I@JWRI,N5X<;-EVA,?$77ITCUO%^/H6<RWX![#UE@T=@%7FG!0166
M<JHO"BFG_0C\P!MV@.I8A\`<9GQ/69<3_93>-7=FWG,=!4A_*']'0\?OU.ON
M.FOT'7`_V]8O+,#>99']U-XT=FWD?1.@K/RC/1<`\ILU-^8.!A/7)<IA$.`\
MQ>[#E-OVAZ-;7_+M-$#;;&',G=)8C<+S$\A]>8I<3S&^B842@.:V)3[#OS0,
MJ`[\PB&Y>3?;;6<?+O?'"#)C6_L3>DH]0O7,?H*0*^8OT5E-_P"7=HF`A]:G
M7I4P#VAN(BF;CKG7GY=,29/CKFD0%4N;QI=2O(K8[045\HOT4[E$V=VJG+OP
M/7)8-MPVX<J8=NIM^7Z_``%P_+F\:74KQS7:"LG\Q?HI.?F3S@R$=MN4*[,[
M[>O?D]&FWY=L7O$6W:>R6^%9E331I5TBXW@D@M(X"CFOF,=%**Z*BN:VI@(H
M4?9KDR8PB(@!2E*!-Q$QM@^?KL[/_+UCN#7C7SKS+F",8"5-'E*T]GS\QT%1
M=BWKVZ1ZHROB,]E4&19R\V:>8*DKDPY!1)1V4"MCII)B<BP!Q$1X`&NMM%\#
M\9Q>6;$YK&@994P^0IC#KP3"!IW"I1^4:Z+-_P#RU-?N>F.W^IZ\Y=_@9C$B
MY]6U@+H0CJYG&GV%>L_W2@'F+=$W:.;&NX]O[1RX?-X=WPUYZ[?+ICLB^F]N
MO,MPC5J9L:SNIG`KT<OB*1J^8QT5@H8"9J:B7AM^T$N/YD-^/+QXZZTWX`8E
M.FF:9C8N,?PYO&J'81>&D@U[Q1R/F.]%)2"!\VLR#S"(`-=F!X;!QX$'TZDW
MY?[\V@O!']W-XU'LF\>`*!_,:Z)S[?[N+(NV_;7)G]#U7>/@!B[P!=YK6"&6
M5-/G5K,&O#Q0?$5H'F*=$Q^'W\61O3L%>F2?/W$FN9_MVVCMVNM2X?W,WC4^
MPKSG\11J/F)=$::I#JYO;@F7F,<4Z]-+'``*8?82(3G4'AV!KU^R_P``<:[5
ME,=>I;(&-HRIL!"&ZH3,&O,IA>35N%0W^/%TH?&WWA]\Y3PGW\/OA=Y[@EM_
MB=]Y'XL^]>7N^;F]]?:NY_HFWM=FOT1_)K$H0Z_=_P`*Q^&^N,8UK/V?/LY:
MLVZO8'R@L*XWR2UZ[I2]4&A6F1CNMK),5&RD_5HZ<?-X=)C%K)(">0;F*FF9
M14_YKAZ?1K]";6W.[NE,E/8"'-C2!"B`TK[K+V:N]HN>QIB<H&[N^&3*O0O.
M$?T2X!2J9;]A&ENWEVD)&,K+:KX*<WB0D'<.@DXDC*1=+KT[*LF;1!4#G<*H
MD1Y=QYM@'7EL,P:0;HYK6-#0`30%U&8/=B!(L-`.2`3RJF.>B&X4FK9"@\<X
M'+7;JJFWJTL[JM9BVM@>JO%X]..B%)!LU%[)JO&YTR-D^9<QB\"CP'4C@UWC
M"`!WO2AVS=T)_#:/V1QK@5"!Z,+$ZR/'%QKA6`5QE<_BE8#S$'#1O=S8-V[P
MK8YWK)!1<56KM)0O=\Z9BG`0$0'4NQ;O1R?$.-/NU<R!"6W0.-3#(X8Z4HEV
MR9S%`P/$O91XDPC6LBPK$>K)2+E$CI&/C4G*2(OGBK=4JA$40.<4S%,`;"`Z
MV=7PP4:MM'U&H.SEQ@'6&P.XH\R!CWH^I"-A<.\0X8E;-7F;&3DJM&U"JRUL
M/"._#E2ERPB1#S:D3LX*'B>X[H./M;`(Z3;MACGP=+8)>>R/($#9JY6A!C23
MDLA.V)P[TGNW)(E'&N"HZPJ,G$H[J"\33VUAC6S)-,S]5U#M`7=%09E.4RBH
MD`I"G`1$`$-#9.%B+3+9`$P(8#$9Z51/V?NLM\`QM6:'D*.88GZ19.0/$QM,
MZ?Y.4(W4=#'1;6K2#WN$BE.JH#5HDLL8$TU"F-L41*0P&'@(#IF3A626WV&J
MKL*[<QOAPKL*X'Z7DI12!<XSPLC-)H+.C0ZL+`(ROA6S<CIPZ*P.V([,T0;*
M`<Z@%$A2CN(Z1DX6:!+;'[#5;*P"Z/)#V-AO+CI8>Z/7T$>Q(4C`KFM<JG>3
MR;:L'A2E1`!<`I*%(+%,6W,'>@*@"D([&VT"1AONV^PU:.[-Q%-AN7(,B:]A
MQ7TIP$?,22.*,,SDE#Q+.=2@(V(AI25""?@/@IM2':-%WK>)=\@]VY%,$#B`
M@!M6=7PAP`L,`A2;`T)=VKF'6;#8FH0'&F`93R_(V.FY2P5WIUK"];@H*=NZ
M4W6Z)%.:VVLC=NXAPF4WRB!V[QTFZ)^EQ#OR";8Y"CN&LKKGA@)LR99`^JI=
MW+I'U&4T>J$ZH#'?2#8K%8ZRAAS#[5K$0+"Q!;EJ+4/BP\BW2BJ/CV<V`#$/
MD#+(']I)8P$`/:V#;0;GA<`6RI9=3$64CLW=&L@6-W[(3]>X@Z0(>'CYQY3.
MGMA7Y`A?=LTYCZ8QB'Y2E`%%6CP2^`41*??F,10Q"^D0U)MSPD`.?)8''ZH7
M.G;.7<S#"6V&CSKJMNFWIAFD&DFTPUA^41?H*>[))O3H"08/FX*'*86SDC02
M+(&,41*<HBF<H@)1$!U;9PUA%F6T-^R`?$J^[D@?]-N@<:J=0>G7!RG6[G:!
M+AW&9(J-P=AYRUB1J,.DT9NW5EN97*[=-)HHF!W!42<P@`?6@'KU>]N$OEMY
M#'/!,>1HK41LY)+G%TML(4544[_E5QE>F+`"0BH;"N+.<"CV5&-.<?6!"$CC
M&.8?0``(CJK583[MOL-3[MR8_AM\.%%!TX=/12&6/A[$Q$4R%.L=2K1:96X'
M`#%*Y$\>4&RFPAN53E,'I#096$FJ6V/V&JR7LS=GOLOEML:?.M_Q<>G;<2CA
MW%`?:$W&YJG%@4R"VX$.01CP*H!MNP-Q]>HZC"_=M]AJV=TL.]VRO,.-$#TT
M=-)17`V#<3!X8P$5WQ_#`)1$`'V0%AN<H`/$2[@&J^K8=S&>R.)6=U</]U+]
MD<:-_%EZ8^`_>(Q(8#'[L%`HU=%,Q_@/X3EVW].^C5W$&$&QWO0M8V7PZQ:U
M4N$(^J.-&)]-'3L8J@-<'XJ311/W9B?$R*1`I]@,/*4D=R"41'?F*(@/KU:W
MJ`;`M%'U&GRB*@[9?#;0C+8"1$<D<:*4Z:^F_GY7.%<2@<#)I$%2BQ*Y5#K;
MBFFBLHP*50X[#[)!$0^?J$RYW6<ZVQ@AO`(;LOAWT9;*?JMR<*W3Z8^FM0PD
M+A/$1E"E3,9,*!!]X0JI`.F91,6?.0IBF#81`./#MU7V==^8-`3[LX>/^DSV
M6\:YMEZ7.G0E<L"B>$L3)]W"2YS*)42"(JF!8QT8#I'*U`2J%,`"'IU-EUND
M@VWL:1O!43=GKB&?NY;`X_5'&JI=`_3A@BP=*>')F2P[C.4>.X>PJ*2<C3H5
M63.O\:)A$`,Z%LHH!>Z3*&X"/``#T:OFG"RZTQK0`14VL932%E;@$@`M<QIC
MN#C5R?Q6\`>G"N+=O3O58P0V^$/`\0U`NP]P(:UMK[#0FW9Z[6A:8V'`DGXJ
MW3M^`S$'W!0?[%USM1]0+=W:POW;/9"1K=-?34W.1);#F*43&4!$"C5HY(A#
MCV`8H,.1NGZA$0('H'4=0TGU1%!V5P\-MF6+,(^JVK2M@Z:.FLAU.]PMA\FP
M%,)W%(ACG,01Y04[Y9D4RB6X;`?ZT`].GJ8460I#9?#@T$2V$'ZK>-;EZ8.F
MS<@'P?B`175,1(2X]AC`;;AS'$K,0(0=N!C;%$.(#MIB3G:*T=VL.I(EL,!'
MU6T>-:ATR=,R@$%+".'%BGY^0Y:%`]V;D4.D8"J"UY#&!1,0V`=^&GJQS`GW
M7P\BT93(#ZK<O"L'Z8NFM(ISJ8-P\@!/KA4H4$F;M_,E%H!S[_``Z1E@CU`$
M^Z^'1#1+EQ-7);QH)],O3.H<A/O+X94YS`3E1I%?4/N;L`2E;&$GS1V`-(R?
MJ!5'9K#@#9ELB*^2$$^FGI946.W2PMB$[E'F%=N2BP!G+4";CS.D`:"JU*;;
M<HJ`4#>C?2U(YC56=G;E3^[91]4<:6!TV=-`B0/O.8G`3D*<N]$@`X&+S`0V
M[8.57E#?D'8_P:-33Z@3[N7,@D2VP'U0MR]+_3RH4JB>%<7"F<`.0?BA$DW(
M8.8H\G@?8W*/9Z-;.SKME:(K.=EL/C^&W0.-;?BL=.AN*F#L3&,/:8]&@U3#
MZMSF:`8W#3%PNHHL-T*0V8N`$-4SV1QI,[Z6NG,J*Q/O`XE<D.F3=,*-74RN
M"E5$5$C'4:@0G=EV,`F$`'T<=0`N$F<)+VM#X9O0IC9VX@0$M@A]4<:I[TB8
M#P1.3G5)XO$6,'K6-ZB)R+B'+FG1#=)&-;UJ`%*-;=XS$YDV2IS;"`<@\VX"
M.NC/;<I@;98VS8@8-%?#Y4=V[DP67L;:)C4*N`JYOXL_3R';AS$@#MV?%B'*
M/_@(#KBR[KADN\.<)4L&'-\`EW>N`^@W0A^+1T\_@<Q+]S<1^PM:]7A_NV>R
M$=WKCS&Z$/Q:.GG\#F)?N:B!_P#V+09>'^[9[(1W>N/,;H]*._%AZ?\`\"N*
MON1B_P![M46<+]VSV4=W+E[MN@<:3&Z9.G?F'?#6(0'<=P-6(@!`=^("'@>`
M[Z+.&>[9[*7=ZX>[;H"W+TS].X``?><Q$&WJK$-Z_A8Z+.%^[9[*.[MP]VW0
MMOQ:>GCT8>Q('S*U#A^0RT6<+]VSV?0CN]<>8W0DCOICZ=%2@*^$\3O4B%4,
M*)*A!.#`8"[@J"B[5--'NB[CV[F]'$-6-;AI$!+97S?0H.V<N),;#:C19&FO
M(J9]"V`L%6'&-_6D<58ODG41U`9NBBO7=/B`'W<C>90D0BDZ%J<HE3C@3#E`
M>`;`.PAMJPMPV-$N7#[*H&R]R`@6M-/-"NL/3-T^?@>Q-]S,/^PM53)>&.80
MZ7+A]D*7=BX<P:/2L?BS=/?X'\3?<S#_`+"UDZMA'NI>@\2?=BX^[&CTH?BS
M=/?X'\3?<S#_`+"T"[81'\*7H]".[%Q]V-'I6?Q9NGS\#V)ON9A_V%K<&8;#
M\-GLA+NQ<.8-'I0_%FZ?/P/8F^YF'_86BQAONV>R$=V+AS!H]*'XLW3Y^![$
MWW,P_P"PM%C#?=L]D([L7#F#1Z5@>F;I]]&'L2_/K4/^4QT[&&^[9[(1W8N'
M,&CTH%Z9NGT3I@;#F*!YC<I>YJ\2H?G,4P`(`##@'K'T:+.&^[9[(XD'9BX<
MP:/2J,^8QT\X=K72K9WM;Q;CB$DC62BLUG[*K,`<`W-/,B*)%.BQ`RPG1$Q?
M;$`V'MU(,PR-,MD/LJ)V7N)$`UL?LCC5RT.EWIJ%R1J&",4J$$Z:[(2T2!`S
M=L=FV45=F<BTY3',H/M`41/ML/'4;&&P_#9'[/H5C=F;B*+#*8?1'&NW^+3T
M\_@=Q+]S<1^PM&KP_P!VSV0K^[UQYC="'XM'3S^!S$OW-Q'["T:O#_=L]D([
MO7'F-T(?BT=/'X&\1C\VLPPC]$6.C5X?[MGLA'=ZX<QNA#\6CIX_`WB/[F(;
M]@Z-7A_NV>R$=WKAS&Z$`Z9^GH?K<.XD+\RLPW[!T6,.RRV>R%5,V:N#B#8;
MH1:W3%T[JDY5<-8B5)N`\BM4@UB;AV#R*M"%W#U[Z`S#309;!^R%6-FK@TQL
M-X0F5>^FGIOBZ/<I$N$,0"9E5;"Y)X>DUT5P42B79DS)\C<Q^8IP`>''AJZ5
M+PT3`0U@IYN30K6;.7&U`2V1/U0H7Z.NG#!$OTQ8=EK)A/%TW+25+9*NI12D
MP"YWQEWCM1LB<QFIU`!!N(<3;%`/3OOJ5XEW`OM!K;$1]'<WLZT-V=N3>09;
M"X9P.-6@#I?Z:OP+X<X?_0>O?L;7/>,,!Y3&>SZ%'L"XQ_#9[(7#L>#NEBG1
M2DY:L:X/JT"BJB@I,V&(KD#$(J.#BDV2._D4&S)$RQPV(43\?1OK;=Y.'SQ%
MK&F`YH\ZN&R^&./X;8U^J.-=1OTU=.KU%%VWPKBERW<I$7;ND:O$*-W""A0.
MDN@L#(4UD54Q`Q#E$2F*("`B`ZN?=+@QMHL8`/JM\R#LOA0$2UOLA'#TS]/"
M8#OAC%"0%`#&`]5B.`#PYM_`C[(CK"6X4XDN8PG[/H6>9LKAKG1;+:0?JA&!
MTQ]/PB`!A;%0[E`X&"HQ8D,4V^PE.$>)#=GH'3U6$^Z9[(58V5PXU2V:`C/Q
M7L!B'LX5Q7\ZI1(?DL-62VX5+-H2VC]D*F;LS<6C]W+;'>@BE>EO`"B9B.,'
MXL<(FV!1$:A"G`Y=P'B15D5,W*(;\1]&K7/PV!@UL?L!4#9V[@Q,MI\-]4DZ
M0.FW!,PAG=9YA[%\H\CL_P!SC(]T^I,(J1A$E51,@U;E5;&,0B8@(;`&K)QP
ME]#6LLP,>36<U2C)V=E-/*8TF(K`H\:O!^*_@/\``KBS[E(O]@:Q:O"/=L]@
M+;W?N_,'APK7\5GI]'B.$\6[CQ'^"<5V_K'3U>$>[9[(1W?D<P:!QHHW2S@/
M<>3"F+.7T;U6+`?H`P]>EJ\']TSV5DF;-R"\FPU;EZ7,"E#;[RF*^W?^Y.)-
M],T?OHU>#^[9[*CW;N^66U;_`(KV`_S6%,5_<E$A^1'Z-7A&26SV0M$G9V[M
M!_=MKW.-8'I<P`;@;">*]O@J<5O_`.`!HU>$>[9[(5O=^[\QOBXT0XZ5^G\R
M"I4\*8J`YB[!WM/B%DQ`1#F`Z1V0%.42[AL.KI#,.$P&0QHF;C0%GO6`7=LD
MDL:=\#C5!/Q=\'??/\-]Y[&WA?Q[_BKX7XFP7=_%K\4'WM[BV[CE]W>^?TYW
M?UG>\=M]=NP/^W:7#[(D>[9ZT:A[-=2C/R4"">!Z]#`114R?7+D<Y4DC@3O#
MIQ\3]K4$P"'=B(^T';K+M!>S-E,<`2X`Y,\-U?0Y,P/E`BNE6FZU<+9,S;D;
MIV;8RNMJQ=+U]QE)R[R536[47<,92!CD6L,NVDD5FITGBH"F*A@V,43;!OJ&
M%SBW#7AT+9:*(+BWJ]395Y:6M)KR'C7F7=^E3*DNQP#`6VBW2MU&FU9>M^X<
M40Q;A,,,\+WV8=*Y%B?>MQIL9&-+"@HFZ8+'YT629QYP$0V&OK)C53O*(Q2>
M3`-,3]4\:<V=<"9D&J98J4MC:PY&H&0^II\_7G$XM*3NTC&0N+JC7Z8LDHRL
M57YDI&XQSMJN?<"%3;%.(@!M&O=7P)]J7CFG0>-,V>Q+;92Q-,<7W%M\R7FR
MI=,>&8N"E8^>"(BL29.;`<D:L,<G(OA4M!(\J`N78K.&Y6Q2)"H<Q1-J@8&V
M:-8'B#J?7]"?:DX1:YKK0^J:#I3ZL/3[D9I;^J"-A\:6ZR2%^Q(X86?(]O:&
M83CB^H.8)-Q1L56V/MCA1>COG3)5Z05(ENHV(N*.YN3F$&`\F(>($<_T*/:D
MX&%DQ^R>-.-WTOY&@[=D#.S6OS<;D9EU?5NP1%E1LKQ=U%X70QY&1]M91BRK
M(46U28.FO=ON9F_.Z.3<A`#VAB,"Y=@/IA&-JC-FK6F7?7/9;>.5',HDZ":Z
MK+Y&R0]B)"0QGU!Y9H4V3&UZ5KD5-51Y2X:YS4G8;#-O8W(EB.:XS!)#[09U
M&00^"*BF#<3D,4JFX()++;G1%5#HFG@5C;S:,`*8'(K&99Z4LHS"'6#;(*%F
M[%FNV0]0@\?7!U8'8S,Y3(V'ATK'\2XQ-PQBX=_,()G*<%EM]@$.W2&"M(:0
M_P!:KE>6A53+Z^6TEH,=Y1MB_I&?2T7BRKS]-RK*XS5S5(VF]5.V,"5RNMV<
M?1XMB"+'W;:W<@O7"RY#E>IJ`47"_M$X:D[`@T$E\2!'U_0J1B<XPY)@3#U3
MQI/%=$=RJ%8J4I1\>V6$ODGC;.U-M<I(3TD^G7+4;0_7Q_C1YWTR9L,.Q8J%
M%HN3VP3-VZE+P$.?`/%'UZ/(EVI.S&/V3QKFW'HW=V5]U&0\WTTO9FW90Z=\
M.-X6SQR'CH>9O=,@8%6]0\DB_M;(B<^HHW5*@H`<AC"'JUO?@+&4NF-#8P]?
M+H3&*3C]$Q&X>-/B3Z;K)>)B2:5G#UBK&'YB<P$Z7HTQ)/FLHC"0[)5&<:%=
M-IQ1!E'MEMPEFH*&%5QS"GN40$9'9]HC^\;[?H2[5G9C[)XU53JFQ?.4M>&P
M.]J:S_$K^]=0$RM1VI&LLTC,<2DBVF33T$SLN0J"<7<4DJ<&`)2RJJ10!/PJ
MABB`S[!EZELS6-@X"'+IIJ$(4%=:3>"^6'.K@OHDZ>258^&L/NJ4M)N:J_IE
M>=5]Q,%4)+J0!X5F2OA)IG32!%\C"@@14A2^P<HE$QS`)AXEXP8VGAKO5^MP
MT4*W6@4J*<>B`=?745Q[,%85]/H^,UW#U_#K-*PJPTN>XV7?6ISYD:T$T*V=
MY/8@K4V-1BXJ:LXQRP043/2#F)A9"2$H>&:RDJS:OG4:R5.&QUTT%CIAQ`AN
MS5S<+ED1MD`"-+CQ)ZS>7D/0NOC*C69LLMU'XLQOC7'-<RY/X)0G,89%M67+
M[:<@1:S<B%,@JBYQM3FH1JAE]_'J.%%`(40$GIUH;@C74!XB1'U\FA0=>-6+
M>;<4Y)=?N*JBTE[%E":%11Q=+I6*I"T.K6"9NIX>JN@(H$I$>$!NDX8(B!G(
M$,()%[=M,8'R[-L1A'U^#,LW:#X0(,-[TJ0J;U]=..1U[<K7;L\(UH-'8Y0>
MR$Q"NHF/F:5-$,8JD>[?E;MI$[84S)G!$YQ(<.4>/`!V!AL(O%)AZ_HJ0,0?
M"$*-[TKDNO,)Z7BX^;WI&Q3@P3Z^Q>+F->3KDF%L/89XJ+ABJG7>Z-,"DHW=
M$5(()"!D3`<-RB`ZQ.P2;$B)]H\2V#$R*?-Z5BM==F+I?+&8,5!!7QNMAVM,
MIR4M*E8FDHN1AS0K>1.9`JK,.=T0IQ)R@/,8Q1VTNQ9G.K^L>)':9(A"HQJ]
M*X8]44EG;&M$RITM3L3)1[FQO(!U&W&D3:CM%9(AB*(.4`>,7,8^3#8Q#+)`
M7E,`[\=6@3+BT2#$PX?&CM$D&BLYO2I!Z=LO97O=V/$6&JMH6JQ-<BXN5<K0
M;Z*EG-X9M^^G%P7<NG23B%.@JEX?EV]OGXCV`Q>G$U'0DZ_&8>5'0K>V8Y/B
MK902`PE/`V(3B?@("G'.N7;U\VE,:Z^-U9H\5="L;>=<X1%6YNJI7ETB/XFV
M$N`_UIGO7_&N:^'X=9CA%DP+JOK>A7DM,8*[X;B.VP_3TV8=JWA]HT'/Z%62
M&@NS+'=E]1M=.G<6?KFX="J!U+9C#!-<=W$:U(6>?F+-!4;'U=KT@G'O+9:+
M"(`TC["[=LY!K$0K954HF<`4R@$$3`0W`-(`QR*1Q!Q;9(-G>S<*K?!]94U0
MY3(-?ZT*%5<(V6AT)E>PGJ%:I7)M*EL?SEGDJP1NPDW%<JTFZL3"=C%TG:9F
M"14G`&*F*B8$4,68YD^TG--66-7I4FM>NS!1KO7L;H25HA+==(=X[IPSM7F8
M^.FQKY7*;=!5S(-&Z;%>62;AR(J;*&XB`"&G9<#&A0.(Q$(44Y,_"I'QIU`L
MISIT3ZA<D-V-+KB4;/2LDP;`*Y&+&$G)5FF\;"``99Q(>$$0(7MX;;[Z++C5
M!-N(D"-.C@SJ,&WF-=*DC4*YD9O;[%+Q]EFV\!'0<56'KRQI2*B_ATD'4")2
MOT4%!$#G,8H<I!`W8.^@L>3&"0Q*RRP!R3N>E-<?,9P,RL^:H.TH9#JK#"8Q
M(STNO1Y`K!^A96:4BQ00<D2,59\"+E/9),14V.`[;"&BP[+4J;QB1$DP!C1D
MC5PK,9UTXY0/E.WV>8&,HE*:X^/!QC2L2Y,DJ.K5%$D"-K'%*(`[E#N^8HI(
M-DS*@40X:5A<SM2;3R7;G)/&GM0.KBO95RI@>K8]9IOJ1ERGY7N4P_DFJ["=
MB9JE+1A4XUQ%.2INV2Z*C\2G(H4IB[;"`"&BP-Q29B4Y[@T-=3]4[^=7W*8!
M`!V$=P`=P*)0'</0'H#X-4F>X&"Z`O<R%7B6>8/4;Z`Z76'>`1UN9F\2YD@]
M(W`W,0RR::/>.6Y2&$YD%#B0#DV#8Q@.`[@`[[:4K#Y5^O(F/<!,<("+H"C<
M@L\W$)LL^K%N6CTKY[X+S;NC'HBS1U08;SY=+#`W-7-LC:&L?$UM>8:E@92#
MB"L3BX(HFF4X"F8#=H\->\D[%7Z]26.N3Y1;8!I>8Q.\T_\`%8CC;&1UI`.[
M`>4J1U/^D6^6(!BF#)=X,4X#RB6A.>4VVVXE-X@0';X!UFF?#[%V$N<UN_%\
M/Z"K[PW8F`>S2WI+3_&+?+%_"3>ON#<_H^JNXF*9AI=T$^W[OSV:6])9_P`8
MN\L7\)-Y^?0W0!\\07$0#0=@\4S#2[H([?N_/9I;TEG_`!C'RR_PF6C[CI;[
M'6?N%B.;QNZ".\%WY[=(Z2U_QBSRQ?3DJ[B/IY:(Z$N_^5$RP&$OJW`!T^X>
M)<WQNZ".\%WY[-+>DA_C%GEB?A)O/W!N?T?1W#Q+-_2Z".\%WY[-(Z2'^,6>
M6)^$F\_<&Y_1]'</$LW]+H([P7?GLTCI)*\_Z19Y8HH*E)DJY&5*@NL@@XI#
M]%-RHF0"@B*B1E`#F[WT[?!OJQFP>)')1'.[H*J;M%=Q]-ND=)5@Z2//.\O;
M#=`M5<N^0;3&RLME?)=WCV3"HOWQ5H:WVF0?L5%51$B?>(HB'`1W`!`>.^KY
MFP=]M?N0;.Z7=!4-VCDBMS?%TE:@?^D6^6-^$J\_<&Z_1]1&P>)NH@-+N@K.
M\DCG-TCI+'^,6^6-^$F\_<&Z_1]/^7^)YFZ7=!'>21SFZ1TD/\8M\L;\)-Y^
MX-U^CZ/Y?XGF;I=T$=Y)'.;I'26?\8L\L;\)5Y^X1U^CZB=A,3%$!I=T$N\E
MWYS?%TD/\8L\L?\`"5>?N$=?H^CN)B>8:7=!'>6[\YOBZ2'^,6>6/^$J\_<(
MZ_1]'<3$\PTNZ".\MWYS?%TD/\8L\L?\)5Y^X1U^CZ.XF)YAI=T$=Y;OSF^+
MI+8O_2+?+(`P`7)=S`3<Q=UJ*^*4/9,.Y124.?GX<.&EW$Q/,-+N@CO+=\KV
MZ1TE53K&\]/R]LR]/DU1Z!DNQNIUW/TMZV([J,HW*J"4LBY7$RBA1`R9$4C[
MFVV`0XZLE;!WVU^]!L;A='^@JSM)=[,&O9'?'25HT/\`I$/EB,R'1'*EI0*W
M4&-CSDI$LJ9==JV;IN?K0$")"8HE(H(B0^VX:B=@[^"(#DTY7<'T%)NTEWCZ
M[([XZ2/_`,8M\L7\)-Z^X-S^CZCW$Q3,-+N@M?;]WY[-+>DA_C%OEB_A)O7W
M!N?T?1W$Q3,-+N@CM^[\]FEO20_QBWRQ?PDWK[@W/Z/H[B8IF&EW01V_=^>S
M2WI(?XQ;Y8OX2;U]P;G]'T=Q,4S#2[H([?N_/9I;TD!_Z1;Y8P]F2;S]P;K]
M'T=Q,4S#2[H*J9M%=VD<MND=)9+_`-(J\L<X\OWRKQQ]=#=#_P#'Z?<3%,PT
MNZ"K[R7?G-\727%M?_2$O+5F:K:(>,R+<%Y&5KDY&LT7-'=H('<OHMTV2*LL
M"IA2)S*;[[#JV[[!XHZ<T0$(TTNJ]A39M'=W.A:;I'24.=,/GW>6YB+`F,,>
MV7*=L1FZI`0%6>$3ILNY[QVN5R\,JD<$]C%1!3E.;L*.P#MK5>OA_BUHZIO[
MO)&W&K[&>*M&/R,KV:6])3Y_C%GEBC_ODWK?U?$-S^CZY4S8#%(\ICN"WT$^
M\%W`C;9I;TEYK>:]YR70QU;]#>:,%X<R#99B_7<((*>B_KTQ#`^DH]TJ99%N
M[)RFCG,>H7;F-[!A#??;CKO;,[!WF9>^7`2:8Q<08Y*V+S\W;,B(;^):A51#
MVMY>(G0?YW'6ST<-F54>V8,^8?8<D-(8US$^43L;%FQ6,U>)4RS1)'ICIHJI
MG!$7!2^P!0#<..O5;0?#UDN[VV$$@&I_$Q4=])VY[/\`67V9="'G)]&W6PFE
M4JM=#8]RD9DG[PQID8[*-\`L")3J,X.;<.TF\LUYQ,4G8J8P#[/9O\3Q#9MU
MSG/EET(9"XQKW@O683C4R_743@*;1R4>4KV#:&(9!`Z0\R)D2`3NS%5;B`<>
M=%0HB!R'`>`@(@(;;:YYP>%3OO'B73Z],S>+TKIE[.P?R/7J)PP0@"?:]"LE
MWASZQ3O("'`?KNP?R-+LOZQ]H\2MUAS*A_1&40:]0H[#_P`(6Y>O^FIZF<((
MH+OO9N!-LV)J5[MQ]7Y/U=1[*'..GT*^`0W'U?D_5T=E#G'3Z$0"VW^`WSO_
M`&]+LH<X^UZ%2YY!@*D-_@/_`)/GZ.ROK?>]"5L[BP(CZ`'Y^_U=`PH<XZ?0
MK&&U6L;CZOR?JZ?90YQT^A3@%J8P@4W#T?#]76FZ7`2)PF1-6>/F6._$-NSB
M%YS;_P"ZM^:_YPW_`,S#LUZVR(_Z1>7UIS?254O)%_K#U\?\O'*_]KX;7+O/
MX@WCYEZ"[5>&ZO;647(W(9950R:1"B)SE`3B4HAR@/)QYMA-KG?2"UO_``G+
MR[R_UZ2>)\D98II,$V.>IN%[)C3'^2<@HS;@J3M?(52@;+"-J\P2*!P4#XQ)
MD4`AAY0$1U-8B2*$Z,7]:3&Y3\%1;)0YBE7^:R->,6SM1<2"C\M8=X_KK*P/
MY2/>`0H]W*(/BBF?<=P,'$=&XB.15!RAUH9-2G[QG3`-`KMA&7P#`.HFB2@E
M:6R2DH[,5YQX_<2\US$7-'(K5TP)@(`&P=NMC1%L#20JR:8J>?QK+90LBY`)
M*5NVY`N1;;C6O.,1Q2*22,!;+G763X8NHRZS9=3P`&<[N#")]U1/N.@L%F&6
M"8)BF;;.NXD=;8*RY,0L6/,;T:CY$AL[8^6*P>?%JY1;HK>N0WBDHXL\5F_8
MJ(BZ?$<=P4AN44]RF,+`HHAG]*(YU)'0+D'!63BY3D<48:IF++A'6QVE?GU'
M=,)N'D7,DS;S<(:#LRT4BSDA=HO>_<M^[.5JLL8P"'-I.C"G,D*T?#^8"S]W
MY-L),;.HR-I=U6QC5ZX_G4'%QMF2%WRC$P2T8HS2=0D'*/"_I!=$"('X[;EV
M`"PZ%=*<1F3`R+UMW?"61;=;<XUA[0H:#Z4*C<G&+SSZ*X(VZRYMR!6%W9+"
M^:/FK9R,'&-!^V(J%(7AR[;:`UI;12B)!IK7<IGF*1>2&='@:9B^QWFQVFUV
M"D2K"OSYI2'@$*J<BCFZRUC0CV+UL3PHB)@24(3<FQ=@';2+.21$0B@&E.6#
M\P)@I,H3$QAFSQF+K+]\%3%-U;O'4B_R%,8[=NV,DW:P!2"=BLMX3?ZT1+OH
M#:3$B*"=":C'K*?WYCB/)!H.?@6%L0R0=3&U,E&5M<7@\&QCI"%AYDJ3!->E
M6&.:KE(\(J50Z*H&*.XEU(-`I,(I1T*:\7AB3KTQ]&7[*>$JJ_2@K0Y2A&LO
M),+*[CWQVC.0?"DX;-&'@5H9\N=NY1[LO>+HF,;F,(F&-#"0$ZZ2KS1+&/CF
ML.UBD&[>/02;MVB;/=-F"#1BW:IE:L_K&"294@+W90`-PYNT=)M(<36@Y%4'
M'O\`P_NHW_[B<*?[9[KJN;ZK=Y-N7>\X5WWHB1N94I3J"@4BW=$'8RP)F`>Z
MWX\#^G5*`O..$Z+)^%M4%-J6ML9)AU>V;J=".,W(*QV,@V`@0)'.^Z!Q$P")
MNW8-AT*0H(2&J='5TB<H-<B*7.*=BC;,YVMK"-VB;5PT+E]DR/W:T@0W.L)!
M_H@?FB_-T02IX5'%G\O67NM!J..Y.Y1!*[`81L6))<D-%(-')YM[8']@B%6!
M"B)4XHJS\-R\2[<=]"(&$5QAZ)<LKXG>56,C\31>1GEUAIJTVH[BUO+@P<P<
M5'14#:JU?#VD)")LJ3%B1T=-N<C=)!0K0B94TRE#KB]-LC>]"4,F5/VQ](V>
MY8V820>95ES9<Q)CBKOK7),;!'3C>_XN8A%2,BBT:3C=!O$WXB0."[$`QB*>
MT81W$:A/#@V(@&F@>('@3A"HT%3CT.]-ULZ=ZED"(MTVUEYO(-M-?9`&!9!-
MG%KR$)%QHPZ(2+^16$&G@!`W*<"\V_#??62]/$R9;&9:9-#%=X6Y$!(8HF$Q
MD$R&W'<-BB)@``]`;CK,K5Q+/_<Q9_\`8Y.?VL=:$*I?ET_\#7"/^I4__MKF
M="%=_0A#0A5"ZJL".\^TA:JQ5H=4><K]QKU^K=A;@54CRS0A458YD[(;M;&,
M@4A@X#RCH0JB77HRS!F]+(UMSW<:W%Y!LM-J&)Z>C76B:E:C8".N*EODG\BP
M[Q4BLG-R+E<QEQ$.Z.?8.S;3"R/!+B=U)LN]$V6<J]2ZF7'F06+JH?'R"MD-
M4)^0DB/:02MPR]:*QBR(/T&S]G*&0]XIG,F)@,Z$@#L4`TU`TDE3#+](4Q8^
MBYITL3UO$DBLT7;-)I)!\#5N\3GY"4CT15BWC%91LH98"J<YS`)=7239-I(U
M0RJO,ET.9<5Q4XKT&TP_5LAS-K0!S?8A.QP-G@7$>C%L(VQUJ8^,BA73TK5@
M;O&RA5$G`FV,40#6C7`94@'%2E<.DW+T_*9`K:>1X^7I^10QM8WS^X-10M_Q
MGQLR:5ITL6):+-8L[2;BX1!0JWA^8W#B.JIDRTP@5P5LH$3*:D5ESH[R+.9C
MN^=\>W2(B+O,W?$=LQPTL+4).$5<T:JQ\0Z//,>=-5N*XMA[LQ3D,0-A`=9%
MKBNY@CH_M^.\JTC+EIM32?LR3G-\WD5&.3(DE'3^4)-D]%K!&`3'",YVP@&X
MG$0+OOQT(7I[Q](;#Z0WWV'TAOZ=M"$-"$C<@'.B<3<O((AOOV@H(%$O)^:$
M=M8G22;V)N2A9KP_DV/"E?'!U+>43)=7G4KU7=34!?"R`1N776/UZ>,>D46)
MXJ!B'93E-P,J94[X0$-N&WPZ^H;-;12\,<UKC`@1K`\R\3B>SS[_`!@(C>)\
MZK@GY$64D$T4SN1!,H&421\"4!;D5'<";>C<-?3)_P`1I3[JV4)@H/.;T5Y>
M7L#,9.+@R@CFNZ2,^0JR;^J3?K(NN=W^9SQ[3>BM/<6;S?N'I(?(59-_5)OU
MD71W^9SQ[3>BCN+-YOW#TD/D*LF_JDWZR+H[_,YX]IO11W%F\W[AZ2'R%.3/
MU2/ZQ+I]_F>\^\WHH[C3>;]T])#Y"G)GZI']8ET=_F>\^\WHH[C3N;]T])#Y
M"G)GZI']8ET=_F>\^\WHH[C3N;]T])8^0@R>Y.3BLZ00_3+A%-J"?.5(2\O-
MM]=MS#I=_F97_>;T4=QIO-^Z[I*/,5>3E?,L5B=LD>FJS3A+]=*6H0R`'+WE
M5G7<((<H^D!9?.T=_I?/^\WHI=QIO-^Z[I*1/D*<F?JD?UB73[_,]Y]YO13[
MC3N;]T])#Y"G)GZI']8ET=_F>\^\WHH[C3N;]T])#Y"G)GZI']8ET=_F>\^\
MWHH[C3N;]T])#Y"G)GZI']8ET=_F>\^\WHH[C3N;]T])#Y"G)GZI']8ET=_F
M>\^\WHH[C3N;]T])#Y"G)GZI']8ET=_F>\^\WHH[C3N;]T])#Y"G)GZI']8E
MT=_F>\^\WHH[C3N;]T])8^0IR@42KD64.#8174*1J"8]V4AR&-S!Z`[S1W^E
M\_[S>BJ)^PTVR.3EYKNDHSS#Y-&0<,8SL.19ILX=1U:+48QLV,GN#E2>>`@"
M(`&XB(^,`=@]6CO_`"^>/:;T5E[C3>:?9=QJ4E?(CR0S6<-4/$F\4U713,"8
M?I(D85`W<B'8`$!;;;1W^E\\>TWHJ3-AII<!9,/LGC17R%63?U2;]9%TN_S.
M>/:;T5O[BS>;]P])#Y"K)OZI-^LBZ._S.>/:;T4=Q9O-^X>DA\A5DW]4F_61
M='?YG/'M-Z*.XLWF_</20^0JR;^J3?K(NCO\SGCVF]%'<6;S?N'I(?(4Y-_5
M(_K$NGW^9S_O-Z*.XTWF_=/262^1/DXQR`5510>8!Y2-2IFV](\P>@-'?YGO
M/O-Z*#L--YOW7=)<F6\C3)D3'6267*Y[F*AY"35`2<!3CVJCLQ1W]!NYVU7-
M^(W5&&?*?RQ]9OG:EW%F\W[KN-<''7DM9#R=CJDY#CF[EBC?:Y'O6:7=[>YA
MD#KBHN;FVY`="W]/;OK'_.&]\]WM,Z".X\SF_==QIY_(49.'_NH./^@"Z/YP
MWLT6W4_69T$^X\P?1/LNZ2KCU:>4_?NE7I[R;U!68$W431(1K)I&4*4I2B_>
M.8PH#L.Y>+7;;YVM>';6RYCBXN$74^L,O`H]VGBBR:-P\:\"\=8:SEU`32<#
MC*I2;U0CHOB5T&BC-DU1<J=Z0Y'X%*5T`)GW'CP'AZ-=*_;52M4>4*LXXD^[
M;N:=!XU]&_0MY&,E*6*IVO+;R3N]@AGS:P1M<:.750:PBJ::)RNWMEC%&S]P
M"2Y#;H]Z!1`N^W'7Q/::^C$,3-X!B+(&>I?0=G+H;EAHDF@VB5]S^#J]8:I0
M(2O3SQJZ]TQ[1@P*R=+/FS9HU3[DB`/72J[QRJF!`*8QSFWVUY]=Y3%H0MB?
M7!\_\@="%17HE_SOU"?\H2Y?YL30A7HT(0T(0T(0T(0T(0T(6I_K3?,_+#4V
M>LL]Z_!*\Y?]];_UAW_F8:[67_3K@<:J1Y(RADX3KU1%,2'_`!Y,F'3*L*BB
MJP&CHCO%N[3$RHCZQV^;K!>HVAPKN7:H\'G7M^NHH"9S'3*'*4?;!)RF8FX"
M',55<H)$$/680#6#*%J?^&52VZ='V-[Q(Y;>2SRQ$<Y7OV-\F64[5^U;'CG^
M+H&$ID:G%G*H7P_O5*J)G7$!#<QQW'4UCA&E,FQ=#%.G9&9ML'>\ET.T2F7'
M^749VN.61)6'D9"&;U>S4=J1MN=U".6C(O.H`&((`7E-L`:$B,RXT9Y=>)86
MEGI!IS(4M'CC./Q"G<G4K'FDTX-A>+/D9.;>J]X5:1D%;%;G!5EC@8ZO=@8=
M]]]:@7"@`6DH`TTP3+R?T,6*=-5%*[E"YO;;*Y*QG(77)2\JG!6&";46,)!*
M.ZNQ;"V0DG2I&13&,H13O%!$VXCOM(/&6CB2+<R?A?+VPX$!&Q]GF;?=ECL+
M:QG[!9II$LQ8K;/..\4NTV852>.G3D*FGW!N8ABI%'EW$=T'&U9R4(@(15@\
M#X.F\,UR?K<ODRZ97";?(E3G+K&0<,ZBXMI#1T<SCDRQS=F"K9F5M]K$0$QQ
MX&$=M1+XP+H0'"G`1@.)5QN7E_4*[/\`)LY>LAY-M%YO16K"'OJH1=:G\?-H
M%0KF$4JZ$8BP]_-ZXH("B=4JQTBF'D'B.FUQ,*JZD$`51*[%AZ$:A=X&59Y"
MN&1,F6R<Q76L>2%ZDG,,61:M(6W3=L0L<4P<BF@C:&,K*JIE7.0%BH)D(`\-
MM%LBB`"(`YRGO0^E.-KLCCJV6#(-SR!.8_1LK)O/W!O&PB<Y'6!4P)0LW!L4
M6B9SM4=B@X,B!E.`[Z9=&+744?\`%`$*132F72^ABK4&\'N+').3I1.(D[W*
M8GKS]PR<5_%$SD<[EQ;`KI&0"_<-B.'9U>ZDP%$5!W'?MT!T8@P2(RKCX[\O
MC'F/',),??%R!/7>$>6.PIY%D%HF$L!G]@;D:R#Y)I!$:-7?CU4><_L"0_#M
M#;0'DUPI06CZ*GOIUZ=66`&=@0:VJRY`L5]L32QV.U7"/%JL9PRBF,4Q*@S8
MH(QK)5K&,4FY3E*4ZA4@$XB<1'0X@TG)XTQN959\#")B'[I,'!UUCF`.[35Y
M"#W(*F(]$J@ARI[`)>&VJB8<D')X5(`BJ58_25'KSZBG'<K"BI@G"Q2+@(*)
MJ*%LUW,<B8LS&/S$V`1`>/T]1>8M:F!`D*[8*F$H%[E01_\`=&[X2[!_-$'C
MOJ"%N9982B!DQ$H@(&`$'PB(#P$-N3CPT(I2<`3`I4RM3`0I03*0&KT"@0"@
M0"`')L!`*&VW9MI01!*2AR"42-T2B1(J!!*V7`2HE^M2+L3@F7T!V:=*<2M0
M9H?7>#:@(I=R/Z74#[3SBKW6W)_0^\,)N7LW'3B4D9L)!$"H)!NIWHB""X[J
M]O>"($XG^'MT1*:W2$J)?9;\G,)S#W#9R4!$ZAE#B/(0-S&4.8P^L1WU`UK3
M*,6H',*FW*B;<`VW.B[+P]``(%[`]6DK%P;,4Y:U8C&(`)E@)L5/Z,3<GNMV
M`@)EP*F`;B'IT(5/_+L1<-^CO!Z0=_W2,39P4\2L@=4QG%LFU&H*`D<5.8I1
M]D"\=MM"%=W[?^='Z#W['0A'=ZO_`$LG]0<_8:$),)0YS&%%7G,H"IA*D]V%
M0H`4IPV#M*4-@'U!H0DWAFQ53K`U,"RB7<**]P[[PZ(J'6%(QN7F,GWJIC;#
MPYC"/IU(1@LDR-LI2D8R1"D23$I"%`A2F1=>R4H`!2E`2\"``<`#AITJ()6W
M>&#ZY+MW#V$%_2(B;?V.P1'Z>J)SW-@!YT>&5)C(MC@F'@DA[HJI4@4:*\J9
M5]N_`FZ?L][L'-MV^G5(G/C_`,4QFR<*5)**D'V4DR[@`>RBX#ZTH%*'`O$`
M*&WS-6-FN<8&KA5DOU_^*P*93&6.9HW$[DA4W!A:+B98A0V*1413W.4H=@#V
M:N6A&`)R[`5!$`!,J0`#9P&R9-^5,/M?UA=^`=@:$+?O5_Z63];N?L-"$.]7
M_I9/Z@Y^PT(17*)G"2ZB*8\H&*)@07[PH$]HO+S%Y2["<>(_.U(`$;J@Z6"X
M/*HST;H+>].JL[Z,42.YZE[*X3[QB_+XI(M?KY$70E52`QSB0H!S]FP!Q[-0
M<V=39,#OP5DLL8:11O*[0)D,H8QF@&.<`YC*M'.Q@+V<PG3#<2^C58ZU4'&&
M_P"E6/G2(0,=`XD9W*?ZB;?K57[#4OXOG'VO2J];(^MH]"'<I_J)M^M5?L-'
M\7SC[7I1K9'UM'H0[E/]1-OUJK]AH_B^<?:]*-;(^MH]"'<I_J)M^M5?L-'\
M7SC[7I1K9'UM'H0[E/\`43;]:J_8:/XOG'VO2C6R/K:/0BS-T!$!,T3`?_<V
MS@`V^'E+VZ7\7SC[7I4A/D#/H]"T.V2*45$T.[!(>\4V1<@=1(I#B9(`Y=S@
M<=MR]@[!\&B%[YQ]KTHZQ(\`J-]`[18^,LD*.&/A^[ZBLYJE26;/4171?W:0
M=HJ\BY"G4V,L([\0X^O?2A?*BYT?M*3KQ=R8MJHR*\X-B`(#X-O^MUQ^ERZ<
M+WSC[2CKY&[[*,[E/]1-OUJK]AI_Q?./M>E1ULCZVCT(=RG^HFWZU5^PT?Q?
M./M>E&MD?6T>A#N4_P!1-OUJK]AH_B^<?:]*-;(^MH]"'<I_J)M^M5?L-'\7
MSC[7I1K9'UM'H0[E/]1-OUJK]AH_B^<?:]*-;(^MH]"'<I_J)M^M5?L-'\7S
MC[7I1K9'UM'H6#-T3E,D=DVY%BBD</"K<IB'`=RF]@2\HB`=O#2/6S](Z?2H
M/FR,D>$*AWF.LW9>DZT)LFG?J(6.A+"F@W?JKF[F>8)@9,J)#*\R1`#;\Z`:
MB&WO(XQWU69T@"H0WBKQ(1[8JN_@DC)@R17%4S9<5UG3A10KL51$G.H98J9.
M<#>T(`'-V!IPO?./M)MG2(T`:%T.Y3_43;]:J_8:E_%\X^UZ5=K9'UM'H0[E
M/]1-OUJK]AH_B^<?:]*-;(^MH]"'<I_J)M^M5?L-'\7SC[7I1K9'UM'H0[E/
M]1-OUJK]AH_B^<?:]*-;(^MH]"T.B3ALR;_.:+_]B0='\7SC[7I3$Z0,^CT(
MH6Q#\!9H=NX#X5T780](#R!QTH7OG'VO2F)\C=T>A,G(\>C][R_CX`AQ/2K0
M4Q46[LZJN\*]`"E*0HG.;?;;;CN&K;NR:Z:&WAQ,HUQ,?$4Q>)&;[JA/HM9\
MG2M@Q!XQ6,Y+CNNE6,\9O3*J`FR341!0[A/O#`F*HB4!X!N.WIUMFW>[-F$,
M`+8#(T>5,WB[QB*M[T*U`(EW#])M_P!:J_8:JU%WS#[JAK;ONZ%7GJ2Z<,8=
M46);AAG+T`>9QE9$FY)^`C$G[1](F;+G=H-U`1(07;/Q*QCB3B7F,(ZJN-\G
MMFDM-()A2<_$%69,@_1&A5)Q+Y8^$,5GCT(:F0=;IT8FW1@JQ7XM1%=HV1*`
M`I)*-&X`L[>*`*ZPF$3"HH;?COKH7W$YSY9LO)@,Y1J)'-&@+T>K-4A:NQ;L
MH.(:L4&Q`2;BFS<H+E2*4"[',5(#"([<=]<:3,?-9:>271*8:UE#!`)TE%4I
MS*=T3G,4I3'%)V8PE*(B4NYB?6@(B/S]6IHT%%C<!3+\Y%R7Z?*&A"!N\Y1W
M*8`V'<4P<@?_`*GEX[Z$*C_12"J;7J!3\"Y;K_C!74P&>-9)--4@JH\IRBNF
M`B``._#AQX^C0A7?[U?^ED_J#G[#0A#O5_Z63^H.?L-"$.]7_I9/Z@Y^PT(0
M[U?^ED_J#G[#0A#O5_Z63^H.?L-"$.]7_I9/Z@Y^PT(6BBJW(?<A0#E$1$$E
M2;;<?KE2E3+V>D=M39ZRHO/X)7G!WCC[ZG>=PMR_*#>+_P`\1^W<_B:>%[W^
MB;=QWOI[.;7<H_\`VZX63]I>77E?=,U,SB7KJGK5;,K1:D=UNY'30BJ/=U*\
MR?F]UQ@%;E9`@*1G1Q^M.*@;;:Y]Y,*%V+LO3Z-Z!\'.B]XUR;FN45;D;H/&
M[/,JJRS)^HH<%R/46;=VJ@Y9;<IT`*;<P=N^X:PM$7"-2UO_``BNO\GIB0J#
M@`R?U""9T9'D`V4WH)N`1,8WAU2)1RKA5$YU#"<#$+N81$=M:"Q@K!@L*V#R
M_<-,B-UF^2NH=NI')I-&Z[#*T@1V0J900/&-%/=IA!,2EW<AL;O3"(B(:1EC
M)7X>5`(RI$UZ`\#/45?=^5,R3'NX3LSJ-<NO5FC!ZQ,=VZ;.$6<>Y2;';$<%
M,*1S`8GIU,3*1$0X$68+,?T&87E"`I%9ESK/-%3MTS.$,O.7[=R$8HH+]J1V
MUCSI'D2FV`Q@,!B&W`0`=].V<T$60=U*4.@#%`IIF'+?4*DS44!R=K]]!^@@
M9%\LHX!GXGW6J4#HKJF*)`]L0#8=M2+X40II2AE21?R^\*PJ<N]6R9G"%8QS
M9QXQ9SEMZFU024/W@23UNJQY!03YQ`3B<`-V<-M(O%!&5`:4:CT"883;HK,\
MCYY(P:&/))IMLJOUCO8\Q2HHN2&]WG#NW#TICD,`["38`W``T!Q_:\/,G`9(
M^'I7,LO0E@NLMFTK<<P9@8-3.CM%9:S9C=-63I[,*&1;0I':K!)-$!?E.<H;
M"(&'1K(TPH2AI70#H!Q(`-E1RCU#JBN[C&*ZI,M/Q(\0B$N1/QLB,5R.V0$,
M&P\I0'UZ=K,,D40\J!?+\Q*5%=DGDKJ#,[65(](5'+$A'*)$WW4;L'@QBH/7
MR6P]Z8`#O0[0+OI6R*'0BB"P[Z`</QC)98V4<],FQ8R2.:45RB]CXIL@9^N]
M=*S#]:/$"J'<+&V`0+W9?9[``=`?N5:401K#R_,-RK%-=EDG-LJW>JHRQ%F^
M97[M@<[A(IA48N21@`JU!/9;E`-MC[;[<=`>(1=12BSF2HOEZX:3WWR9GY,I
MRKMB\F59`Q4C'^V%,D)8TW*18IP.`;CL!NT0XZ+>6%-"(054Z+T+XY<=7F:*
M@\R)F064+AW%CYH[9Y#?%EE_>%DM:1RR#T&7,X3(5`.0HE#E$1'54[(4-RJU
MY_+FPT)N8V2NH(0$/PG2FV_HX>[]O3JE-:AY<V%OPD]0/S0R?*%$/AW]W<-0
MF.+6Q%:!25H;RYL-[AR9.Z@0XAP')\H;YW];PUFUTW(1H4H;J5?)T8<_")GW
M^^;)?L#1K9F<:$H),;RZ,.<QO]TG/X<1X??-D^''L_SAK0&`TF,4EN7RYL1"
M`"7).>^7T<V2I,1[>.X^"#TZ+`W4H(&\NO$"(<ZN3L^$3_.ER7)DW'U[^!'4
M@V`4VOF,$&P@M!\N;$#D`.3)^?C)[^R`9-D]PW#TF\!QTX)ZZ=7%NA<J<\NG
M$S"`L#U')&>UE6\!-*$27R?)`@<2QCHP%6`T>('2$Q0YB_F@T%6RGS'F#H05
M:^A[H-QO<^D_#<U+7O-;%P]B),CAO"9-?L(\I65EF443HLB1R@`<2%]KVO:'
MCI*]6N#RW\-!Q#)/4'N''CE&3_8&A"W^3AQ+^$G/7]\J2_86A"*'RY<-[CS9
M.ZA0-N/,!<HR@%`WI`/VN'@`Z$(L?+AP\8=RY/ZA-AVVWRA*;]G'_2[UZD(P
M61X-LHY+RXL0E*(!DG/:G'M6RG)%,'`.``:/#AIP*A`K"OETXC2`NV1L[!S"
M._+E:1#?;;U1P[]NJ9DIKZ79%5,$X0,N&B*-+Y=.'S%W-D;/AA](%RI)J`(^
MGV0C0[-0%VEUQ.E0#;U68:"@/ETX=*4QAR'GT-@'C]\V3_+C]2;)EM,03%3E
MZYKHFK>2?Y/##?X1L^_/R9)`'SQ\!PU;!:-<_<02\NK$IE!*;(V<A`/5E22`
M?[7;:()ZY^XEGR<^'0X#D/.^X=O^ZK(_O=IP2UDW.%CY.C#GX1,]A_,Y/DCA
M\XW@`WTH):V;G&A(W'ET8:-WK<^1L_@DY2!-7ER?)@8`3/WA!3$(_<AN8=A'
MTAPU2)P;>!+)H@H/O<]G(!;9WE4_I@Z'\7W!_P!0B;Z_YH:^Y,]SD0W&)OLE
M'G6:MJ]!$2.],5HIXER(?7'';?U:[,936BR(Q;&,549NM;RS3N*V@^71ADH@
M/WRNH(P;=ALG29@^;M[OUC-_;=W$S0+)JR>-&HED\BU'?BL_)V88_"/G_P#O
MERG[WZ.VKMS6Z1QI]6.ZA\G9AC\(^?\`^^7*?O?H[:NW-;I'&CJQW4/D[,,?
MA'S_`/WRY3][]';5VYK=(XT=6.ZA\G9AC\(^?_[Y<I^]^CMJ[<UND<:.K'=6
MX>75AC;_`,H^??[YDI^]^EVW=N:W2.-7MN;"T$QBBU/+DPRI[09+Z@B;!ML3
M)\H4!VX]GNX=QXZ!C=VRM$-\<:EU*7];2DA?+MP^V,LL7)&?%12;+"!'64I,
M$M]B[B8ON_[8`>G6B5BMSFTP$`::15N4JF9=6MJM*I?19T)8JN>,;Y)2M]S0
MT7;9ZS1$D+!Y&D6+<S6)O4NQ:"HW(R4YW(H(AWBFX<QN.P=FG>,6N+71D@%F
MZ1&/`56+O$95;HOES86*8!#)/4&(@._')TJ(?/#W?K(,<NMJR`V.^$^K'=1W
MR=F&/PCY_P#[Y<I^]^I]M7;FMTCC1U8[J'R=F&/PCY__`+Y<I^]^CMJ[<UND
M<:.K'=0^3LPQ^$?/_P#?+E/WOT=M7;FMTCC1U8[J'R=F&/PCY_\`[Y<I^]^C
MMJ[<UND<:.K'=0^3LPQ^$?/_`/?+E/WOT=M7;FMTCC1U8[J'R=F&/PCY_P#[
MY<I^]^CMJ[<UND<:.K'=6Q?+LPR!@.7(N?!,GNH7GR?*)D`P%,`"8?=X[@'-
MV>G3[9NI-(:!OCC4770.$#%4VZ]>AO%U"Z8[+8(:]9D=/6UIH(D3G,D2$I'G
M!299HG*NT,S1!4IBJB(!N&P[:;,7N<8OAJ]PB--7TLU:B;BRS'E1B,IXE;4G
MEWX>64[X<B9W()'::I2ERM)`D(KH)O3D[L(\>9,%G9^4N_`O*'HT^V;B#'SC
MCS0X4-N30X>M7G70^3JP[^$?/G]\R4_>_4.W+GF&D<:V=39]9*0\NC"^P;Y%
MS[OL&_\`NGR@<?F>[^&EVU(YK=/I3ZBS.[2BC>77A@#"'WQL_!_^$R4'T>OW
M?QT^VKOE:V.^.-4/NMEQ`C!:_)V88_"/G_\`OERG[WZ.VKMS6Z1QJ/5CNHM3
MRZ<-'`.7(^?@V_\`YF2@?_-^GVU=/I-;I'&EU<[JT+Y<^&@'VLD9^V^#)LIO
M_:_0<:N?T6B.^.-'5SNIN7;R^</1%)N<FVR+GA1=C4;,X2(\R5)J-3&)"/N"
MY!8`!R<>S?2&)7*]$29PA*)I@X`PW*:T&[495$W27T#8JL73'A&2<Y#S<DLO
MCFOD4!AD^1;(;%C6H>PD5@?E'8/7QU3.[(:\F7;U>Z\1W<J0NPA3&*L+\G=A
M@.W(V?A__"9*?L#6!]XPQHJ,?MA2%UI%:X;SR^L'1Q2K/,JYO:@@N*KEQ-9F
M>19D&KA0Z*`*J+QP)NVXJD$$B&$FQ=B[\-6X>)MJTT$MWBNC>-7*;R#3`94L
M1\NG#0D(5/)G4`V54,ILJ3)\BFHOQY@4;@1BJFNB?M)L;@3;70OIFN90!0,@
MC#?S%9[O-$UT'\2,+Y=6'#G$BN3,^G.F()B*>4Y,RG``,/B"A'?:EAYM^7U;
M#Z=<.3,G,)91".97SW:N999ZL,M*4_)SX93#<F2.H#VNWO,GRAPX=FP>[PV[
M==:2`X1?3O4*@S7C,L!Y=6'C^R&1\^@/;PR9)@/_`(!JV:V6&\@$'?BK);RX
MTHQ/RY<0`H00R/G_`'*8#AS9/DREYB#SEYC"P$`#<..J%<JF])_0OC.UQ.9%
M7U_S,W<,\_W-J0\3DF09=XDFJF7],%!BIWJ@AVCPWT).,!$*V_R=&'/PB9]_
MOFR7[`TX+)K9F<:$2/ETX>W';(N?>T?]\N2_8.B!1K9VXL?)U8?#_?$SZ/\`
M^$N3_8&BRLS[S>0X@0AO+'R=>'_PB9]_OF2?[`T[*CUJ];FA;!Y=.(!_WQ,^
MA_\`A+D_V!I$06VZS9DQI,RN.:"P;RZ<0`&X9%S[V_A*D_V#I+4BC^75B$2&
M`<C=0!0$``PI9,DRJ`&X;\AO`&V-\[5UW($P$JN;+;-86.C`JE7XE^,/OE>#
M^.^:>[_'9^(_-\>7W>^[/Q3??WC.?P7]>/%^SXG;?N?8Y?3KT5NFH?@VN&%6
M\N-J)>[Z\*\B@WH!E+A`]*7FJ2N/R/1N+/JQRPI"+QQ=Y!FY]VPQ#OF1@*H*
M+EFW,<Y#\IN40[!UQ;UZPCNKI7;U3P>=6#/;\-X"PG4KMT\Y05?Y&R$GB*E7
M>X.)UW=#8\B\@)[V/*EBKSUVV9M9MC*BL911=0J291XAPUC8`9C0=U:GDB42
M%&F0NN+/-?82&*8[(47./XRVV6K5?/F/Z.=VRN$A7H.*FW;XZCZRK1:+!N[F
M/".U415(D9N<=A[`VPC&/JD5+G[U:>]YZANJNKEO4DIE2H@KTS8,Q1D2]1D7
M55)1A>K3=B1*DR>&FTY1-)$LH:2/RD%);N=O3OHY)R5T:$Z=%*XB5JNDQG2N
M)M,MI89IB'5=U+4^T1]?(=&`MSZ&K59<5.%L1907BAGUI<*JD.=%5$J*H&Y2
M#V`SG`B4AFR+>O=6>1J14*35XH:]"-,_3<Q3\(MZ[$OCC!Y?C<I6AI9T^5V\
M<N;"@Y8L>Z.8%6Q3'W4*!2B!`"T$Q*45)G3GU4=2V4NJI.K2;"/^]BRN^6ZC
M<J\H#%)Q2&]9?F]QNGJ#ATW>N)6>7,9P@J5/ND4%2$V4,43#![6AI.53:3%<
MOS#,NW51UF[%`Y?@\+TBF].D3:V[B:B',E;LB2MHG'+66BXQTA(QB;@(Q"/3
M1*1(JAT3J=X.X&V`:`,E9T)$QT+LL^H_.0VD>FB)=14?D6`1;9!)*.$"J$:=
M.BU(AYBFRAB**-PD4_C6Y>Q:ZIE$RE.S%4=^;D*X`NCD\Z43""KFK;;SU,1.
M":AD*]*2DC1NK"LPV6ZPRBA>0)[1*5[XRU"-82[.=02M<`^,\*9P=(J7AE!$
MHD-MN,JHP&1%>^IP<];MT/5:!#Q]VI9+:%0SVG;ZX4%%G$%*T"==QS5:8BPV
M78$8E;$*3F5^V[#MMVB@T1)-:(F`&1<N1ZI>HW'$&Z@K_EJGKS%YJV";<RR8
M%-60JF%HO*ZJY+!97;;WHHK)-FID-P1,N@"??AN?V>)9!IR5'=@B)J2.V7#(
M<?GBV'D>IN!O<`/379YF-IQ4%&E-OS>%77:23F-B"NUE'DK'K("59RFX^WF]
ML$R\VP``/*(I1N9%RF?5]E>*KK":976H4YA0J?@A&F8)95QP[OV3QO=:AY][
M*Q/-*)*-8U^TEB1P[I.?#KLE##N`\H!:":16B)@IVPOG[J#D<L8^L-\NE6D*
M+E7->2L70^/(ZO+LW=,0I\@Y0:`]GC/5DII5FW(5H<X-FW,J@(^G8$1!I&6"
M<22%:G'R9`Z^>H@Z8*%`<#X6YQV`I04+:+R`D+OS<WLE`=]@^NVU1,C9;&N"
MD*W0\*0KCV><95B!E+%)K+IQL.T4?/SHD%54C5`.94R2)2B994`["AMOJK(G
M6(JL^+>L3!V:IR5K-!M+V1D8CQ9)`SYH2+8H+,>7Q+,[Y=0R9)$G,'VD0YM]
M(L#^1G42`I4IN6:E;R6)>.4>1S"JV-W6I9_9%6<0B=\R;-G*JD9WBRQ7[?\`
M3(%Y@,7B'PZ@;J&D`UH:(B.0*14YZ/6<K-D'C-RH@**BI6TBR7,@R5`0%\Y(
M0XBW1(J4Q>.X#R[[Z>H;".161-43'?2`]MA"M%I$TK'%CDEA(+T\JR(W,F5=
M1HH8JQA!N*P.T3D*ES\Q@`!W`1VU.$*%"$5QT<FTAW8;!56%MBGT]4TX]:T1
M;-^P5<UQ&41!S'+S!%541:(O&H@H0P[@)1T)B-4:E'^5,UQ..6]:E7,/)VN`
MG'KEFK+5UXS<-F96_/[210*8L@Z,8@[I%,3EX>T/9I&M:94C6-M5KGXNZC*%
MDVRLZQ6??;=V_JD;9P&100320,_%8#1(BFHKN^:@GNH'#8!#AHCNJ9NMD14S
MV-P+BJV8R9S*IE@+"DX`1*445$XQT`%V`FYN;CZ0VT)ZHRZU5+R[!(?HWPB8
M`,7:*GN7V]Q#:U30#VAMQW^=I(5W=Q_/'_G@^QT(1VP^L?I?4T(4:WZ_U_&T
M#-6VY2S>$KD&W3=R$BY=)$*F19=9(J""9R%%PZ$A"F*F`[F$^WHXB%%^)NIO
M$6;5)Q"BW(`?UE5(E@AY],L%+1;=8`,@^5:N1.4S-VF8ITE`.!3E,'9J0J61
M_KD`J4GMT@V:;PPS;)PM'LGDHX8E7:KR:D8Q4<)+NV35)<WBB"=J?D*!@$VW
MHT*$,Z;>-\NU3*5+ALAUM=0]-GG3IK'R,HV"/<\[9RLS%91F*BH$;*.6RA><
M5```)OZ=@2U7>R`8TTJ0"6F&*T9O_><.6,?+"@VE0DFR<>L<RQT$$DG1_85<
M+*)&#D#L$.W10M')K*Y#+(]+FY*R0$59XAY,U91)O8(U&48>/AS.$A706?MQ
M5`6[-9'8Q51$0$#=FB`5<TC5F$(IFP66*S/V>X55!9XU<TEG"OIB6?*,D*Z1
M"<C6\DSY985^3F$BXD$!+Q$H\=-88'(B7.6:LPR)3L:)23=];+[7+%::DD@"
M9HJ8BZN=H$X9O*)JJE,JR2?I&$`3-OS;"(:2`"3`*=`*&P;@01V#<0+P$?2(
M<>S36S4M61``#U?`&P!^0.A`D-*YJQC&6+RE.;8-C`42B8H&X`;82AN&X>O7
M#O(FOQ$!D2+(\:RWB6&F%="\3L<>8%T@]*.4NI[&F;\Y5RH71?/,Q,$@I!4A
M'H,G=?@S(JG2`1.4IP[!'MVU[*[8?>ILENJ87T:*EPIL]LB)<:O`J:3^<]Y<
M?.9+\9.K&.'$034+N7;T#SF(7Z>H3=F<0Q#]VR[O>]N0#TA1NV+R&S"#,HAN
M4(LWG.^7&0HG/U)UHA"AN8PG0V*'K'E6$?H!JCN%BW^3F>S_`%EN[9NOO`B?
MEIO+9_XS=7_R?/T^X6+?Y.9[/]9/MFZ^\"'RTWEL_P#&;J_^3Y^CN%BW^3F>
MS_61VS=?>!#Y:;RV?^,W5_\`)\_1W"Q;_)S/9_K([9NOO`C2^=)Y;0@`AU.U
M7Z(:CW"Q;_)S-']9:&XS=;(Y8TH\GG3^6D0H@MU0TTAA'<.]4,4VVVVX`0A@
MVWTQL%BW^4F:/ZRF,8NG/&GT(A;SFO+:>E429]3E-=&.F=(W()U"(][L!3J&
M'N@(4>4?7OMK3=]@L7#K(N<P@FDPJ^\J)V,76NV([_H53NCGS7^@/'&.[Q!6
MGJ'JD<^?YSS/86O*!@(K#S=YEI*'=\YC[`60CW":I>`\#=H]NIWWX?8C*<UL
MJ[O>"(DAM1IH];(J&8U=B*7@&.?T*V9_.=\MP@"8>INJ`!0W'8VX[?,WURF;
M`8GK(]6F$YK/]93[9NWO0B/EIO+9'_\`V;J_^3Y^M7<+%O\`)S/9_K([9NOO
M`E/RSGEO?\9RJ?SX?5T=PL6_R<WV?ZR.V;K[P(?+.>6]_P`9RJ?SX?5T=PL6
M_P`G-]G^LCMFZ^\"'RSGEO?\9RJ?SX?5T=PL6_R<WV?ZR.V;K[P+0WG/^6V4
M=C=3E4`=M_K@^KH[A8M_DYOL_P!9+MFZ^\"+-YTGELEVWZG*J._J'?\`+T=P
ML6_R<S1_61VS=?>!`GG2^6T<Y$R]3-2-WAN015'9,@&`=U#;&`=B[:8V!Q1T
M8W28*.;XO60<9NWO`543KE\UOH$RKTZ6"D4SJ(I<E89*R5-1FSYSEYR14VQ5
M6.H(''D242((E-V!MMK3(^'E_FN,N;(?+9`&):33F]91=C=WLP#@3'/FX%;(
MGG)>7$@\78'ZE*>#AN^\.J.P"@5=DQ:IKD*OX@"F`O)N`[=O#;5#OA_B=JR+
MI,(IILYOVLJD,:NQ(B\:?0NA\M7Y:?\`QFJC_5B?9ZJ[A8M_DYFC^LMO;-U]
MX%N'G3^6L(`/XS-4X_Y?_P!G3[AXQ_E)NC^LEVS=.>%J/G/>6XH/.7J;J@%'
ML#G#T</2/K#3[A8N:[G-]G^LLS\9NMH_O`L?+.>6]_QG*I_/A]71W"Q;_)S?
M9_K*/;-U]X%D/.A\M=+^C]4--2`?K164$H#MV\O(4_9OQT=PL6RW.;[/]9+M
MF[9)@\.!:J>=/Y9X%W_&HHP<0X@LK^A:8V!Q4_\`I)GL_P!9(XS=\DP:?0F?
M>O.4\MV=I%RA8OJBI3N2E:K88]@U344.=P[=1+M)!$A#%3`QE%#`&W,&KY&P
M&*&:T&ZS`"::*MWUE'MJ1SQI]"C#I7\W7R^\?].^&JE:>H>GQLU%42#9/VZZ
M@)J-GS=OX9XU.GSB8%&QT-Q'T\P<`UJOGP^Q&6XMEW=[V@D`AM=`,?6RDD<"
M;<:N^5PT^A6`^6<\MWAOU-53YO/V_0'7#F;`XI:B;M,$#S?ZRGVS=LDT+RZ\
MWOS3.D3,_0?G+'^#^H+QN3YB.BR5%6HN@B;0L]82"C\JD?+MUSJ(H$`X$`O<
MCV;COOL'KL%P&]];:V9*<V38,<P(H`--9A%<O$\9EB20'`F(\^XO$?H2_P"D
M(=6?31&UZN9S4D>H[$@-63-=$QTTLHU5J*92+%83QDG"$JJR`>0QCMR"/)ML
M&N_?MEY36%S60<:373O\I<JXXZXS(%WC'$OLPZ*?,WZ/>MROI+X6RS"_&QN1
M%*5QU:'[&%O,8Z*R;N'*;]JJLI[P.05MN^(!>82\O(&W'YQ?\-?=;P6O$(98
M>DKV,F?UM@FM-="]'2&W`FRASE,7G`Y3$,F/HV*<H;&V]>LL1+"M,0$I2+[0
MCSF[.P=OJ?!HUH?1E5\D4Q2C;X1'Z'Y0:2T*B'1(;9CGY,2DV1ZA;L(;%VWY
MUR#P#<=A#0B$:%>??^:^B'V.G2EU=N=;@`;!V_1_]C3I2U+5GDW[!'1%5.E4
MT$H<GPCHBEJCG*V*40#M'Z7Y8#I$Q5LMMD061*(_FC!\S;ZFDIHM4AA3-RJG
M*;;@;V1V'</1MQU-A`<"1$)&I></=N/OJ_YY-_SAOYPO_$RW]6N_%F;_`-+X
MLRY7ZJI_Y+:)UZQU]D*HD4GX\&217272(LW=M_=D655FNFH4Q3(N2CRF^#7/
MQ66ZXV7WBAI!JIS+7=JCP>=6V>P/2]BB]Y%QY.XKQ#0*)<\3*W;*]EG'-96C
MGJ3Q=P1U#/X&5*NU"!9%3W*HHD+41,(%XAKFW<ZYHGRJ6`[U:U/_``G!1?)=
M-G3#U/XUQA,=+>3Z77:'AAW>*S!H8W]P6_'+!I>6Y#WZO6*#<-92%+)IE.<Z
M;GNBF2*8#%-P`=;0X@D.K@L!&45)ST;(OE_8BQLXQBMEO%4^TJ5/KL5;G-BL
MT4L_G8)F"#>+=/W[HXC+QL:HW)W:FYB@)?7IQ<111%*A3],ATBVJ.=#.O\2R
M4!"2,?E^6.1S'I@2<MP@ZC;\\>IG*1%.<`_>)+''[800XB&P:4'@<FM2%F--
M2K&TZJ.D^'LU#JU]KN/*3(1N;K54<$F?,FW>.;/#H@NSGZFKL8L:K84G0+&6
MX`LNH<1W'?4R(B!-"B#`Q"?<#D/H\KD@&:\AHX1H68K>:ULCR:SFLS=D?QE'
MMTI5%)ALX*1=VY,H]BCD?F2-LW=@HFIL<AMHGE19DAX:$X94GR;E/I2O%TR9
M8<X16-%(OIYF*/78"WW,C%Y!R\-D2D5Z\,&U>6="I'KEE&]@(!E"E$@<H%[2
MZBRH0C2F:S'(I0C\>8!>VV>ZCWD[4I&$NN$XC'<?+2*K%:";XKKXOY.5B$9!
M<ID9"&67DUN^%,PF3*(;"&FXDT#.H.<U@+G>K!1O5;MT`T#%>.K;4+;@2KX7
MBKR#2B65B[KI*["WYLJ=H<(F133&0<7;V>1)9910S?FY.'`-(A\3"D04!>9-
M%)!CF*;T!D'HPBQS%EC(-&Q/AU&3R!,4.<M%R91D:^R!'.2M7QW")W(`+-S8
MB2!%5DPY3'Y_;W'?3<'!L03%#9\DNA3H*F&X7#HW5F)7%5YGL.)OK)1V@6*C
M3[R)$TMB1LB9Y`21XU4PF:1#9L!?!GV*FKM[&JS-%0\"K@,ZC^$NWE[S./&>
M5HR?P(>@8?<*4JO64BC!0:0>:;I.G]0=N.;O2OYGF[Q)B(B8_-V#IZUH-9(2
MR)"\NO1U!9%<96OD'ARDUG#F,*1?Z;F^URT(A,MZM;W,B2((0YSE<P\)'G0%
M)!)</K@$I`#;2,T%NZ4Q!73I]6QO+P%9L=.B:=+PSK>YT^P1K!LLT>REL*$U
M(VR(>`0Q>[F1?=]SD$!.8PCOQTQ-$8DE(B"@+'AA/U^=1(#S@=/`>$D3;CLD
MH<++>1,L4@<"&,8VP_``:J>X$`#(ICZ6]YPKOO4P51*D)1,!UDP$.Z(L3EYO
M:[TBA3%%+E[1$.&HH%"\)V>!+Y+V!C77&*<E0]4E_,0L%PM[F)CU(9I-XOD$
MS`QE7SV/1;.4JBHZ1`5`*<H%V#?@(:;"&FTDUMHP"X+?I^RCD#(53JF0*CDU
MQC.'O?4E*,4(X;%!(OXR.*WCZL:2=E62*Z647:_I8#"(K``"7??6DS9,(B-K
M>4]0_@WUP&O37U&4#&G@\.0>1D,A7GI5DT+;*6YQ8'^UG4GY1VWCP.[<')'V
M$T&H02(\%04'D^N#2ULFD&K>1J9BBIIBVZQG3*:P+N.HBZ"QSO7K+3,7RV"<
MMLDI>31B8J.3J<W4A12M#.%D)-!1ZO+*'+'"HL93ZW64F))%2K4TV_'-RJ-Z
MZJ;,?IXNXY1R7TV8<D8Y9",LU@HYG$7#BSO#)64@'!$#SE>>`9!HQ44,Z6(B
M4I-^.A.K?5E/+EQ+;93#%ACLT1MR?0T)EQU8\2I7B(G*;,,J[*046[`_Q7F!
M0EHZ.3=.%"D0=E,IS`(]@Z4(UK;=Y\J7+LN)M4Y-"]"*-@W'E"DG$M5*ZE$2
M2BZ:RKHKE9QXE4S5))==,JRBAFY#G*(<G`-PW`-AT05XO4@T.)AO*2+.B4E6
MM'=D!+>OSIC`7;94YXQSN<WP[Z("%"J=/EOH!).]D52_+I((=&N$M]N$3/B/
MS[7-?4T056L9"*NYN'K_`"=)+7,1O>%]?TATX)ZUF=>>WF#XYM5ZQ/$RM2I\
MWD)2F9$HUIF:3'F4(XF:Y79AW(SOAV@<IY83MEP`K8NYEN[`"AH@4:UFZO.G
MJ`K]UZF5LTY:Q-BG,M%J:>!JKAI%D[H<IBZTVB>+D5Q*25B;U%\T9V8R4'!/
MRLB.S[E52;<Q![OET+.\VG1%2Y64\>9KA.M"`K.,,:9?KU$QY8X-PT/&05GL
M\)>:%\34??DZZO',ZBF#P9)T!#Q!SE6!8#F$FXCH484P"M@;'?4$EY9R]`I<
M?8:YF4E6ER>)6C'"\S%QB]HEI1R5A$)%[^6E4XQ;[2DD0RIQ/L7CIPH4'F8&
MPE^M'/!4%:8\R5!X.K5O>R74Q?4RY`;2&.,9R^&,C0:+A4[>,CI2`G8%5HW?
M0;-S*M5UT95QRMFG>"<Q@`P:C2J+5[W-/I4P7G!,ZO:>HV-;X*RQ4\CYQ2Q#
M:XN?J#>U/(F+H$33:S$W>NN[DQ<'BAF&T^W=$*SYN_4(43A[(Z8\:LEF\$\N
MK?7?R]AS(%1R)E\#XZRO.=,T-,=/Z5LKU::6B0LEGQ]5Z\DWN4E6O=ZWO&RS
M#9R!`,P:F%PKQY0TU=EIJ3_Z3,891B<S=/MJ?TO(K/&M=8]4TCCU&[L9)"<J
ME)R+.1;W'\?8TI/>1A9%XT(JB=BZ$%VJ:!!4#V@T(;ZR]NR@)2@7<!Y0`N_K
MV#;?@&W'1$+HQ:@;<0X;=OPZ(A,.:%R7K4[A-5%03BDIW(%(V5,W<=X53FW!
MR`EY2"``&V_HTF2@)FN`!,/(LUZ<QQLC*OB#ZR_*)R7U7=7O5CU-U>8K+N%+
ME8],:Q#X'J$HSDH&OQ"[PS@[0Z2KI)5-T0"',)BB(#MQWU].PC&<!NUW:R].
M<)MD1A+C3ER+R.(8??)Y.I`/[0"J,;R5,U(HF%2(K"P+J`=0PMI5WL<@CR@5
M)VHLB8!]>VX>C76&U6SUU=K)#GVC_9D>1>7G;/X^ZF2UD?[P#SI*/DM9CV':
M"K`CMP#W.LCO_P#"H$363^:4P#J7?K!^<[V'*CN]M/S6?FCC1?R+F:/XO5C^
MI3_[(TN_.$<YWL.1W>VGYK/S1QH?(N9H_B]6/ZE/_LC1WYPCG.]AR.[VT_-9
M^:.-&!Y*^:A`!^+]5XAO];._LG1WYP?G.]AR.[^T_-9^:.-;AY+N9R!RC`UH
M!#\ZG/B''CP$'6WIT^_6#\YWL/6AN!;2AH%AGYHXT>EY+^:!]DL-!D$1X%23
ME0*/`.(^(5.;?Y@[:??O!\CG>P]/L/:3*QGYGI1Y_)3S>L*#<T3#"@Z6%(Z0
M*2J(K'[A84B"H@LGW8=HB)AV#6N[;>8-9(+G1^PY9YV"[1@@66?F>E1YCKRE
MLG9+K3NTU^%A&D<QGI&DJ-5@L)Q4D*,)*W(+B070FXNX\X@?L4WY@[=53MM<
M)>8L<[V'(;L]M0\\EC/S1QI[&\EO,_*.T/6S[!]:*-A`#?`.[G;;CK$-L<,E
MOUCB8?9<K#LSM4!:+)</[T<:3_(N9H_B]6/ZE/\`[)U;WYPCG.]ARJ[O;3\U
MGYHXTH^1=S-_8FN?U"P_LG3[]8/SG>PY'=_:?F,_-'&C/D6,U#_I/7/ZC8?V
M5I=^L'YSO8>CN]M/S&?FCC6?D5\U?V'K?]1L/[*T=^L'YSO8>GW>VGYC/S1Q
MK4?)=S.F.QH.M'$>.XI6'L[-O\]?!H[]8/SG>PY+N]M/S6?FCC1*GDO9F-MM
M7ZR.V_\`VJP?ENAT=^L'YSO8<CN]M/S6?FCC18>2QFE8>Z"!K*8*>R8X)SX"
M4H]HALYWWT=^L'YSO8<CN]M/S6?FCC3/R)Y1F5L3TZ9OME@Z\I#1CB'AWY&J
M,NY=`6:<(I1YVR+A95`RIU#AN)RB4GI#1WZP?G.]AR.[VT_,9^:.-2`KY*F:
M0*[;#%L#-"H/GY2BQC!5"4?O!`B9UO![G3`$3`)NSA\.GWZP?G.]AR;=G]IP
MZ-EGYHXUS_D7,R_V#A/F^Y8[]A:??S".<[V'+1V)M)S&?F#C1WR+^9?[`USY
MZ$V0?GD07(@0?@(`$#T``:._>#<YWL/1V'M+S)?YGI1A?)9S2<`,6%K90'\S
MW5@X;</U5Z1#2[]8/SG>P]4.V?VF+B0QD/[T<:V^17S5_8>M_P!1L/[*TN_6
M#\YWL/2[O;3\QGYHXUD/)=S0CQ-#P6QN'VE*8WX?GO$+*!]#;1WZPC(YWL/2
M[O[3\QGYHXU@WDQ9H.`E)#Q&_;Q3>AP^:)M'?K".<[V'H[O[3\QGYHXTDDO)
M<S4SAI:8=0\9X"(CGLJ\%J=8KOP\:W4?*@W!?F2%42H<`,`@(<-7W?;O!A,!
M+G0_NW(.S^T_,9^:.--ZD^4?E3(=,K.1Z_$QX0MN:1%AC`E89BJL#289$7E@
M.W\&"S84%C$Y"\##ON7LU=.VXP=XH<Z/V')=@;3<QGYHXT[0\E7-7]AZW\SN
MK#^3XG7.F[78:\T$^RY,8!M-$<AD/[T<:AO/_E>Y(Z;,27C.MI@(61BJ#&)N
MDP:1QD@0%Z)R&,]!4@*D(58@@4Z@[F#VM^.NMA6-X),,0YT2>8>)7WS",5G,
ML,:VT/KA>*5&JN5LISQ8'$=<L3U\=SXAR6L)*+N`/)J>,5`TB0IT(IND=<0`
M5!`#$#<.`ZZN(8O@K9<2Y\(<ST+)=<"QB2\.>UL/MBA>^G07Y.^3'N0:UDW(
M\_.Q4[&/&DG&(XQE58:SI.4@(N6.ML[&@DA(E*H(BHF81$2F]6OD&/7[#[S?
M"^0260%;85+Z'A,J=)N89.A;B<L5^@+A1G9&=`KK.T`M[SC(9A%<RJO,91!D
MB":1UR[[F>&+Q44'Z\?F:\C>1;_"XET\BF),>41YO5^7K/*ES&O)?5#.M$M[
M6BE'<Y?7](=:8*S6L5$>B8?TMU"?\H2Y[?.63TJJ34FV=+C34KR<P_!JO7RL
MY5VOE9RMP4X!V=GJ'3U\K.5`S96<HT#\`[/IZF"UPB*DXM=2*EGG^9]/3H10
ML@</3^0.E0@PR+/.7U_2'ZFA)8,8!*/'T?#]33%:BXAK234O./O2??6[1_YP
M_D[/S7XF&NUK69__`$UGA7&US/\`N*H?DHF[F`Z]E%#G1*7KCR1N()'4$^T=
M%`*?*4HCL(B&_JTML/PI?V3YET;K5H\ZFKK)Z4<D9PR%9[)7&%;E:_9>GZKX
MS=QTR(%;N'T9>9JR2!W*(E$P@XCI%)+EY=]B`'8&N/@I_@71W/(M,S\-RGK#
M>%+/CV_=65H>-HR-@,QV.`F:,PCVD:SDZ\QC<85NG+Q;YC"J+1+B//,1"JR7
M=*'5,"FZA2COK88P$?/D6"BE52QYT*R]9;8A]]42B*3%;I'4%#VEV,/%2'CI
MK(DY*25;?H'5`R1YMDB\(5T=<2-QV$$%#\-,98Q24=271YU+PE)>TBEU^@S+
M'(>'L8T>TR;PA6?Q,E<>RBZ;IZU;.4DUY.-?-DP%JV(43I)<H<H=FGEI24Q0
M72[GBM6BMVV-C:7*R,3U$6:WR4=-.'<4B7%=HJ\5"+2E6?Q3)ZLQGH*1CE7#
M5LJ"*GV[8H;:1.A-57E<"9GC,K5JA1.-:G9;-/X/Z@!\#<W4HJU@F.0<XW>R
MLY-I8!8.&B\],0TPD\52.H5R#M50HE`2Z*!3DBBNC*GG?>@'.K1PK)5M^VG5
M*Y?L%3[&IDM\@W<V:GT7#E*QQ-P1)=<I30*Y).KK+<YN45B*E#?8-.()H1!7
MDK_3LNRZ.'6$7&,&,P]E*[;6[G',]<G"44^>6&R/I@$9FQM#N'!EV::Q#(.B
M<RJ:B9>4-M]HD0-I!;;;9R*J^/>G+K%QN&'+W,MZADVPT![E*NQ&/[LY%9W1
ML>W5=LE%R86F,:R+>SV-RBV`LD*Y^^!!)/NN<VX!*+79%6)!%6:&E,O)'0+F
M>9FE\@!#H3DBG<<H^*Q]5[6I!1DLTOS..5:9'K4^_.Q=,K`R(91LJD](V.!4
M_8WX:1<"T[R!(@:BG^/0=9W#//[.)8P-!4OF%L&4.AN8F:EII*"0QE%1Z9*"
M+V0;)2J4(_,U[ETJ4G*(''FWXZQ*Y<2?Z7\Z7U2ZY'LF'Z#4[E(PF.J-1Z17
M9U9BTQV2K,'))C+R$W#MCDFI)G..#-(^/$#+>ZVZ/L@'`!"36CH[ZC7Y;=*W
M6#@<IV2;PWTYUA$U:L!J1.GR)CAY8#3UWCYA$$(Q66:.'J8D1>+(MW#5-,#F
M`1$H$$X+U%Z=*UD&I8GHM?RK((R=\AD%6UBG4>X21G5P$3-W?=)B`E<-&1DV
MS@1*4JBZ)SIB9,Q3F$E$>/G*/X_/40(G*0OWBL+`"AC%*0XA9;N`\IQ$"F$!
M'C\W1E4@:_#*%=A\9!9N!1,BJ4ZA`*0PB=%0_P"9(J*8'Y4S>D1X!IE%"YO=
M%7((.S([B($,""RA4DR%`!(U`.4IS)";;<P!M\.D:E.7ZXSHTJI5RF3=^&.*
MH&*Z3`5^Y2*G_1SMMTB[F7.'-MPYQU%:D>DJ/*H0J;$G.L"O.*BA162$"B+@
MXD3]EP(!]8/'?0A)MVQQ*ESG.!CE?E$QU4U@43$`3$J@E!(FX!_0Q,`@'#;4
MQ4L9K.^M2IH)\W(4I@`5U/#BJ(I.$GBHN%A7*8.03I.%#<I1]''0E1#=71:=
MVF50%5$!5%4QCJ%$A04`VPI[!P_H:8@3_J=%"*#76E7>(AV*I?SY/JZ12("X
M-I62^*]F^VI_W/38_7E[`C7(B/;Z`T)MKX#Y%4GR[5$R=&N$Q,H0H&B9T"B8
MQ0`PC:YS8`$1XCHXD?1T^974[Y+^FI_SY?JZ2BAWR7]-3_GR_5T(2(52]X41
M\-]M.9,RA#G*H"93"!>;<@!V>O@.I4*5"YSDS8K@#B5(Y4RE2,N*:IU5$U%%
M0%F($3,!T^8NXF'@7??0A&MC`=)-9?NTU$TS&(1)94"$\44!%!0!*4Z@)DV]
M&Q1X>C0D#!;%303,AQ;@J@F9N3D.L.Y0#G1*"HDV*`F,/./9QVT(J1`+'[QL
M0RJ:1S&,=PV/WSA'O3!]H31<`D9)%$=A$_$-M"<4I0*V(0P`8"<JIE%$A54$
M@.#;FY$S"7VFAA-Q`-R_/T4($.!92%-(A"D!JD5(#=^WYE!13Y]S@9L`$$JQ
MC"/'U:$;R3F,`@"#DK?PIQ303$#JJJN55B`L8JI2)F!!H"PB`B80`-N.W#0@
M0-:[2*A"HI%.9NF<J9`.FDH`I$,!0`Q$Q'813*/`-P#AJ"V"I'`<@\0.00]8
M&`?R]":UYDA,0HG)S"8!*',7F'EV$=@WW';?5C8AL1F6>9#6".XJ']'3)@[G
M.KA)XDBNB?J?LYP*J!3$$WQ9K8"(;[AZ!U<XN!%GFJ@!I!CG5S`@J]RF_:^.
M[LAN4A!;H[;<.(;EWVW].E-)L@&M*"Q[CK?]C(S];H_8ZSIH>XZW_8R,_6Z/
MV.A"'N.M_P!C(S];H_8Z$(?%RO#Q!A&``\0#N$.&_';ZW0A#W#7"^R,;&"(>
MGN$>._'\[H0C$X"MB'-[NC`$!X?:$`]7K#31!)GL/"II)@FQC^85P!(2H([]
MZ*"Y2%+L7ZXV_``XCJZ5$1@L\X"T(JCWE_1,6IAZ[DD6D<91MGW-S<$E4$0.
M0Q+U+<Q#$,',4Q"B&X<!#5SW$.@*ULNXIBKSA"5H0']K8O\`J"/P?!JN8YQ;
M34M<S\(K'N.M_P!C(S];H_8ZS+`A[CK?]C(S];H_8Z$)6$+7-@_:V,[`_P"Y
MT?5_,ZE0I0"S[EKG]C8S];H_8Z*$4).K!UL3!^UD9];^IT?6/^5TBHG<6@0-
M<'LBXT?F-DA_['20C4X*OE$QBQ4=N!#"'Z52'L#T;E[=-`5$O,791[#I4M[M
MNT8I>*M./?;!!$"\A)IB0#;\H`(%`!^9H4J+,<M"NRRC84Z;-NI'QYC*LV:A
MC>'1$#_;5U!#?E$!V*8#?,,`^D-"5"Z'N"O?V*COULE]CI)+7W%6_P"QD9^M
MT?L="$K2@:_R%VBHX0X[;-4A#M'_`"NI""8@MA@ZZ7@:,C0'X6R(?DET4)P"
M(5A*V(!^UL9VC_W.C]CI&"1AD118*MCN'NZ++P[100`.T.&XEVXZ$DS<AQ,,
MEC;(B;=E'&4&E6H$P311$XC[C>B/*4I1$=@#T:G*]<(H@8J%NBR+@UNE+!!U
MF,:H4^/8$"F[E$P&-[O;E-RCRB`B`AL/JUH<76N3'(D(0I5J`@Z\(@'NR-_6
MR/V.JK4W=T*0#8JIO5UTK8_ZO,'WC`.0#N(_'E^;MF]D=PB`MY=Q[ND%Q08$
M(CW3CP_)L7F[!+Q[!U*Z8DZ[3+1K$<V7?WELZDPC?WU0_`7E-8BQ!()Q50H\
M72J3!F2BX]1B+8+%),HT`;)NY)X!@4<F>@GWO$QM@/MVAMK=>L>=.99%4-SC
M3ZA+\(KUKH^,J10D&Z4+&134S=N5%%8C9!!=4I>'?NC"4#*.S=@F'<=@#7(:
M\S!;=6LTR6)3K(J4CD5;")CE53YA``,`*%Y0VWV``WV#\O351SHWODOZ:G_/
ME^KI(0!5+</MJ?'@'MEXB/``[?2.F*T"M47Z*%$R->H,3J$('XQ-U0W,8I0[
M\%4A%'<1`.]`!XE[=1(B"$#/D5Y>\2_IJ?\`/E^KK+J7[J<5MS%_/%^B&C4O
M1%;]ZD&P"HF`@`=IR^KYNM#06M`-:UL]0(=\E_34_P"?+]74E-#ODOZ:G_/E
M^KH0AWR7]-3_`)\OU="%@5D0`1%5(``.(BH4`_)U-@)=`4E5SOPRO./G3^^K
MOSDV^40[[?F#;NOQ,^3O=]]N[Y^'-V;\-=34NS'\*-67,O-Q_IKRX\J\G5,P
M_'H)@"#PD]APZVLD^.<7"9L;*2%4T;%B/>"WBI%/FX=@%^?JS:\0E-?'Z,(;
MU9\:[MVB*EZOE?\`F5\.:M=,G+QW_A5:>SA_]$-<'"=6;I&9ZV2O-N+7,CJW
M'*C/'^9)_%KIE^ZJT_R0UOA+\(KGVG>$$7X_S+/XM=,OW56K^2&C]UX11$^$
M$8>0\RDA0$*YTN"/+N;>XVTH[@''<!IP!N`]NPZ49-7&I0?"-$.!:$E/,E.4
M#&@>F(IAWW*2VVE0H;>HWQ1X\-2L2\Q\:C:=X0251UYBB;L)):G=+SAV#<6J
M4DG9[09^@D)S*`@F?XH\W<\YA-MOVB.BPV,!ZN:E$37E1S=[YD@E'GA>F`3]
MO-\:;3XL2"(\O?A\4>4"AV!Z=](M8#EAPIQ=#_@E`OO,D(`B$'TRCZ-AM%H_
MDCIV99S^-72(N<=Y8"3\R7T0?3)QX\+5:./_`-D=&KE9CXUJL;BQ[S\R3^P?
M3)]U5HX__9'UZ3F2[)@#XTBT@1`6OO#S)?XM=,GW56G^2&LM*P6MY:"_\RW?
MV:UTR[;^S_"JT]GH_P!:'JT)Q*/(^\ROE#>M],8#QW#XUVOU_!4@#LT4HI12
MK[S*C"*:5;Z8RN!25,FHK:;69`H[`!=P"I<_/N'S-%*8M1W>!5(H+WKW3ZO\
MV^'@^F]>Y?><Q7\8`4M%I\&1K\8[<#`6NU1VW[T50,'J`/3MH2$:PK<"^\RK
MEW3K73)MPV_A5:>P?@^*.BE$2M2O_,MW_N9Z9.P?]=5I]7^Q#2*G*)MA;>\/
M,N_BUTR_=5:?1_\`5#T:2UK'C_,N_BSTR?=3:?Y(:$+47_F7;C_!KID[1_UU
M6G^2&FL1)B=]8\?YEO\`%GID^ZJT_P`D--*)0\?YEO\`%GID^ZJT_P`D-"(H
M>/\`,M_BSTR?=5:?Y(:$17%L3[S(!A)3WE7.FHD=[MD_>`H6FTBKX/W6^[\"
M@-1#M+I)1BJW=$3WKX/TL88-08#IR]PA`3@F)*VBU<YG(6>9$0;<M1$0'?LW
MX::8CD5J_'^9;_%GID^ZJT_R0T(BAX_S+?XL],GW56G^2&A$4/'^9;_%GID^
MZJT_R0T(BAX_S+OXM=,OW56G^2&A$2AX_P`RW^+/3)]U5I_DAH1$H>/\RW^+
M/3)]U5I_DAH1$H>/\R[^+73+]U5I_DAH1$H>/\RW^+/3)]U5I_DAH1$H>/\`
M,M_BSTR?=5:?Y(:$1*SX_P`R[^+73)]U5I_DAH0"5MX_S+?XL],GW4VG^2&H
MK:*DH3>^98)`$:UTQ[\?]==J#TCZJD&A-$N'OF7\I@3K?3$4XE+W9PM=JYRC
MS>WMS5/EVY-:)6KL\JOA6:<76H!51Z8'G7R64ZC1JT'TW+O1SU-!/%7M-I`A
M'P5V#[P4]JB/M"IOOOJ]]BBTLX)A14K5B_\`,M_BSTR?=5:?Y(:HF6+/)K3!
M*U\?YEO\6>F3[JK3_)#5*E%#Q_F6_P`6>F3[JK3_`"0T(BAX_P`RW^+/3)]U
M5I_DAH1%#Q_F6_Q9Z9/NJM/\D-"(H>/\RW^+/3)]U5I_DAH1%#Q_F6_Q9Z9/
MNJM/\D-"(HE9]YCH@`R=>Z:4VVQ^7P]IM(N#.>0?#@C_``1``,`\VM$B%,5E
MGET1"I53Z,GW7C][2Z&IE?Z<1;??QS`643D;1:0=#,_&MZ,B/]R`AR]]JQX:
M7<J,8+9=HJW'C_,FY3<M9Z9.;;A_"FT?!_\`1#5<P,LT5\*US/PR43X_S+?X
MM=,@?"-JM.P?"/\`!#LUG6**W\?YD_\`83I:^ZNV?R1T01$[GB6OC_,M]%:Z
M8Q#T"6U6G80]`A_!#L'0B)W%CQ_F6_Q9Z9/NJM/\D-"(H>/\RW^+/3)]U5I_
MDAH1%;!(^927?O:]TR)`/9_"JT\?7_K1#LT(BMR2/F2G51`(/IBY.\W6WM5I
M'[2!#B;ZVI;[[[:$1.XJ7=>\KUVCTP6H+K!=.YX8]@I'^<K/:-]AF6NP)_P1
M[>\VT4I1SJX+)YYD`"`IPG3+[F\&B,84+1:/'>'!DT[KO/X([=N^^WU-%*=*
M7>]/,C_L)TQ_=7:/Y):$16HO_,L$1$M:Z9#`(\#?&JT\0]`_W(>D-"(K'O#S
M+0X>X.F0G^5^-5IX?_9'TZ(E$2@$KYDQ."E=Z9#F[0'XU6KL]7]R/KT)6H9E
MGWQYD7\6NF7[JK5_)'0G:WM`60E?,B/[(5KID]?]U5J_+J(Z$K6]XDWKD^\Q
M8U-N(2=>Z:4HX:E9O&JHVFTBJFW]R/N\,F`5$/:VU.7ZXBBU1`04+=)3SS"P
MZ:\+#48'IH<P/WN:_P"[_$6FT@(*A'-^\'<M1[.\Y@#X=:'V(\JOA2!="BI6
M(]Z>95_%GID^ZNU?R2T6)?A%%IRV"8\R(>(UKIDYNPW\*K7OOZ>/Q2]&LU]N
MS&MM2J1O<:D<0#3`^5*$Y;S'Q*'-6>F41X[C\:[7MP'AP^*FL-SDF8Z+_4SP
M".T!7YUJI)>9$<0$E9Z9=MMN-JM7K'UU$PZZ,YC);K,LQ$,T$&=K>5Z429_Y
ME/#NZUTR?#_"JT_._P!:&JD1*U\?YEO\6>F3[JK3_)#0B*W3?>96)R@>N=,A
M"B8-S?&FT\/5M_!#MWT(!.15*Z67O7X9MFSXHP?3458,VW`LW[TM%I\,:S`N
MGXD4>2H\XF,ER]GP:8K$:D".16T\?YE?\6NF3[J[3_)#6F$KPBHQ=X!*`>^9
M1L&];Z8]]@W_`(56SU?[$M+]SX13Y?A!%'?>98!A`*UTR;<-MK5:?4'KJ`CK
M,^%HV:EM9&R(UP6OC_,N_BSTR?=3:?Y(:BI(>/\`,N_BSTR?=3:?Y(:$(>/\
MR[^+/3)]U-I_DAH0L&D/,M`HB-8Z9C`'$Q26JS@<2[AS`43U$"@;;LWX:ON^
MKUHUOX>6OS*J='5F%<%3?WQUH??)_N6P[XG\=7DV^-DOR?&S\4_;E_N5_K7[
MJX^OO->HL7>/^'N^IX<*\Y%W_<\:,\D/A$]?>WIZX\D[_N=%:Y>V'X4O[)_Y
M5W[KEX/.O<S?ZSY_Y6O-X=_XRU/_``W+?6U88!%G$0`=A$.S\G2*154>J?,*
M.!L26K*AH\DZ>-*U8P$,55<C>9ODB[-%P#!X"1RNTVA%RD[[NCD(<=Q$.(Z$
M\FXFQTUP/4\V.ZG>H?)]`LYK-$(.&F.Z+4Y"%;4Z8(U2>R46G+.I:0=/#-7"
MPE.8QA`P@/+L78`(N&4I03!ZJ^KY3#DA9JE3*3;[_:(''3^[WY*L.&;9EC:+
M>-T&E<DYA^X9.BD.^DN8I&Y1(H<I>8!XZO92T1-,5'/O*C63.J[JF85Q"#PT
M,S:<J7N7PYB9TNG'1Q*]C_*<O0*W>)N08D>,EW\N$E'V0C%RFHN9NW<-3&`A
M3F-JUS16:H)"-0K6,<=8F?5)EA<<WR5IQ=BN:R%9*#4&;-E%R4@O7,4,&M?O
MMPG%G<>N=N>6NL:\(UWV*/-L7?4O*@$BHD*RTUU<W:?;T]2>H=^P4A8[5)V&
MOJS`-WJ^4<?U"HL)MW+R""C(AZQ!N6TBT%<[<41*IOQW$=0:T`Q!)R*9F/JB
M0F9C[S%EH:4Q'C2]5V=R!DZ=<TI#+,W36*JD+4Y[*#)"2H[(4D$U4`29UY9N
MJY`.4H"?<P;B(BBV#2I,>XO;2:U[+(E]@-Q$1]>^L@J72F-9:H:W0C`#@'$>
MP/3IQ4"&QJ&A&E`-@U$UJ!`C4%HH`<H\`^M'\DNDE`9@J(T<`)U^=18%`"A]
MX#")MBARAS#:+UN;8-@YAV[=-530`*,WG"O`8Y2(B=03"!=A`"F,`B.P;%#8
M0'COIA9P4A6DV7B3,`>-"N"-_%G0%Z0CMND&YC*JH]YS]V''MX:DT@.&9/<"
M3!))+MQ<D<)J%%)"09MU7A&W(AOW;5913G*)D'A0$Q><1*;X=6%H!AP(#G0K
M*5J.D5"G3,X*0.45U%D70;MV_:T74)S")2+%]?`=O3I4"D0*(NJB4G%ZW25%
MN*Y5UVRB9"($=`"[IP]*5;G[D5!5!+[9N4.(``<.&F*HB@D>(>=;N2:8!+"R
MC)7O")2#91=J<Q7;=HLBX7(<@B4Q#I@8QR&`0X@(!L.HV;1@W@1!N8)&]G(]
MB0'3J29(QY``')E7*28M@-V*KJ<X=T`#P$!V$-1=0::UFG0M[B4MW8.4062=
MMW**QA6:JM%2JI':G_H2@*)F,!P,`=N^VD:E2:ER;.8PU>S@)A$/BY.=HB/^
MECK44-KX#Y%4GRZA$W1MA'FX[14]MOQVVM<T`;;]FP::617@W'0B)0YP]8?1
MTXA2B%R32C%%86CEXC'N53F%!%=VB"SDHG'91%-81,)3"'``#0@)01XB)0[U
M<R)^("10"E-L`B`&$.7L.`;A\`Z244@>2;$KALU!ZB=\H1=VP9@X!-R\\"!#
M/`*B4Q3+(HI*E$W`0#?0@)0D_1,HN<71>X`4P1#AN(*HIN><3<=P$JP``>@`
MU1/<0120I`@5U+=639)$YC.B@&X!OP';<?YG68O.0E!<,BV1?-EMA3=@??L*
M.P;CZN`!JZ[DNF@$DJ),0E7?E_/%#X>/#X==&PHQ*2*2;-'B=X4-O@`?^QTM
M633!.U!*$7Q5P`4S@8!`#`(>D-@$!X#Z0'5!K6\5)8`B'YHP_-$=)"+,8H"4
M3&-OS%#@/K'6.;<'3YVN$R8T9@Z`HW%!\]DNAP&A44Z,E2?&#JZY0-PZGK.7
MV.4!V^+5;'B)@$-MQ'Y^M#9/5!RWN<*Z3%5B^7<T@4"BI7@%8=AY>^'LWXIC
MMZMMB^G2<Z3>_P!T'V2*:"`KI;Y-YY#:"-R"+[XW^B/^M^PU#J+/?.]L*WJK
M><-(0[XW^B/^M^PT=19[YWMA'56\X:0AWQO]$?\`6_8:.HL]\[VPCJK><-(0
M[XW^B/\`K?L-'46>^=[81U5O.&D(=\;_`$1_UOV&CJ+/?.]L(ZJWG#2$.^-_
MHC_K?L-'46>^=[81U5O.&D(M01/RG,90"HB938Y2&$QN0X%$OL[E,3MW#CJV
M7=94N@S7$GZP2-RE.(M.IWPJ0>7^0"8AOK@AW"HN.H3/:NZX%[\1'*%E(8XF
M,`F-N0A0W'T``>C5TR1(80&S28YW!+J4J68->:=T*\P*J[#[*NVW'82<`W#C
M];JN,F5RS,!`^L"F9<N2+9=$#)&/B0\0!"CS"L`B`AOND.VX;;["781#U:S3
ML3NLN,3X:5GF7J2/H^)>9>6?,0Q7@SJ0?8(RK$3,$G(PT1)Q5[CRJ/F:B)R"
M)_>K7D.UC2APW.0I-PW$=>6O./W-LR&L<!X;JY,W%I#200-'I5^*/DNF9$AD
M+#1K3$6V*<$1.BM6GB+\I$W!"J)^)3*HJ9(Y2&#F#8.4>&O;"\7>?*:9)C%H
MRC-N*R7,M0/#0I"2#E3#Q"X"MN(FY=RAL)A$@;<P\0((`/K'7/G7'6.);-F"
M/UEU)3FN%0B@90A>!5.8!#M$1$=^SU_!K3(#+I)$N8XN(C23$J]Q`-(:BC"F
MH(<YPX;[;CZ^WM^9J,S$[M*%%>\HES3D;H6ZB;<2$,4Y2=VJ"@"`A[9@*?[6
M;;;F*;TA\&HW6^,GN?"JSO5FNE!#3D%6XO/KS+!$_2):4Q6$5366BN!%ND(@
MU;EL#(YCF33`1*F4G;\W6K"KM*F7TL?,<6QRD%*C,%>9LHV6(V<E[LB?AVCY
M@Z!<Y4EFYV;8AAY"F``3V#;E^M[.&^O/;32'"\RC+FO81,@0UT!02(4;BL%F
MF@1A10NV91,#!L5/L_.Z]%=90%W:"2:*XI-LEM01O?E`-P$.S8`X[?2[-<R[
M23U]T9CBT"JU17F4:#1!L%H54IRCS<N^_;L._P!$=3QF5^XBU[FD9C!-UD.H
M`T+8IDA4+N)=]@``[-PW'?<.P>&K[@P,N@)<7$QB28H:&$$D!;<J'?;"<-QV
MV`#!MOMV;=FN3U<NO$S]Z^%KG)&S&H+904DS@(&#F$NVVX#\_8/3KIR;FVLS
M'D_:4>2<C="8^2W&V.,@<2_W$VGU]GN-]\.NA=[NQLUL7$B(RA)]@-)(`4"=
M#JI`Z4>G\A1`I!Q]#EY2\"\&+<WUH<.`C]/4[Y=6%[BUQ@`#6,L5G#Y<!#.K
M8=^7\\'T_JZPND2Y=<QVD)A[(JK_`%,=2-,Z6J"?)]_:RKNL(R[:"<-8<3+N
MV[J4/WB3Y40*<>[Y#;\NW`-<R^8C=)-;W6117Z5?>[]<I,N+FMM'ZHR>`7:P
MOU$8ESM7&TEC?(L;9A.V,Z4C4#M4;.V*8YP%M(QX["@=`?9+LF`F*`&WW'?5
MF&8E=9@Y#@317_Q6*YXC<YKK4&D@U65/[14I4`*=3<Q?S"@AWQ.`#R*_^Z`(
MZZEYGLMT0I&3T+3>GRIDRW+``(J`A3O(U)4YS'X"!0VY1[-]]_R-8B]Q-!,%
MF!2M+<3#OQX>G4Y-JW$DU*Z52:4HV#U!]#6E7P&8*A_104IVW4&!RE.`=1%S
M5`#`!@!454P%4-]]E!``]KMT(@,RO3N.A$!F1X`&P</0&A$!F6=":&A"&A"&
MA"U.`"0P"&X"'$![!TQ6D:EYR\H??5VV#;Y0KN]M@VY/Q,N;D_F.;CMV;Z[\
M3G/_`(BY-EN8?BJH7DD'$D-U[<H@!C]<F1BAS;[")HZ*[=N(;[:JVP_"E[Q_
MY5MNO%YU[*L+M$2$]+UAD_*[G()N60F&G(5)*.9NA$K7]-&`J!C*<@B7F,/P
M\->=PT`W*WEB`M;S^[=F3?O.8Z'C8]6:W>V1E?=7:30KM22=.X\7U@F7!RD9
M^[&A5!%T:0[P!*4A1`N_';6J*PQ4A%=.3J*%4422)WIQ2(=)0%2HM?86\2;8
M$TB+&#F(;AN`\-%:*ZU67JDQ_C'-.)KMCW*=C>0E=0BF%MF9&`E08V*DMH1R
MHK$6>'7CU`?`87Z1CE..^X<!X:2(`CPH31QUBJ\Q;6H3LOU(9,O44Q!G;9"3
M?=\A'6^MRL>W80\4(,T4SH*)MVR;IP9'E.998YCCQ'0C+$E1EGCH6IF;<@7"
MW3^1;I0X?(L%5(_)U=K,J@SKET/1)/Q=)=/7;LW?I-ED"$3<]V8".N4"*;\N
MVM$NAL<L5`BF"C:Z8'RG4,NM+=0L82MVJE#7R+EANZ>VVLHS]QR+>RBRK->J
MQ47Z8I(T4J!5BF=\I4VIR))#L3E"TF+8&N"0%-"[49T(5ZVX<JM9RS:I(\XC
MBFS4FUN*G*^+C5;5<;;(V6RR+(Z9U%CVR"LKE4-VOVHY@,0VY``-1#R3N1\2
M=FC@4C2'2'[[C(")R)E:]W&P5.FWNH,[F\AFB;YM7<DN4HY]%(1C!D6-4C2Q
M\4DF(G3'PI``"<NVE$"H98HI.A9Q[T6T_$V8I3+5)M5@:PHMXIR\HKQ@U>5]
MX^@*C!U)":4L:S<\PY="C"E%!/OQ3;CN*8%$1TWN@T@UIMH<'#(KYGE2(,".
M57I&3=-`@.W2Z14DD3=V"P.TA7*`"FX*;8.?V`[.W?61:3//"N.UR14W-IC*
M4G+HGL\S736V.C$DEC][7A.*:3TRW**9!X<0$P"(]@;:*4]<3OIWB\%),#&,
MN<0**HI@U-X@X<YB=TF0"`!MA+Z`$VW'L'458#:`*"3U-51TW4=-Q5;G!,Q"
M>RJGSH(KE(X*;@542J`/#ARB&A-4GHI"CU_=0X\_/SX!PB`E#;@'QHO/I#U[
MZ`J9M7!YPKGOS<A2%!1%$`52$IUQ-R`8!W``$.TX[;`!O9]>I+,%XCVJ`?P_
M5G;:IDBQS4Z?J5DIJE8ER/C/)4BG(8_6<L5C&I%NH,7*E8QC>"4;\ZDJ+0%_
MMG*=7T:G+-E\<B(1H5<YUGFC+W3;;Y&[7RZT><>YYQ9TE4Y]6K*O#D5;8BD)
M>O.[XY<1SE-(Q+],1(K&`P\IBJ![/*;CKC!UD9HJ,*(JT?3AU(6Z4R%U&S5E
MK]YR)D/'-?Q5CK(>%ZCW3N9A[(FU29R,J:'0,*3!-X0@2>R!2E!)T4H>P!0"
M+A0($`QBF#`JO5JR!8WC.^]047?[1&]5%;ZFK52X/'3^TR*<6O0*Y)RJ<+&.
M<;I.P;E>/JJ1I^F"M=P6W$#``Z<(BR?5@EUC=ICN)11;\CA0N#,\46RY(R7D
MS-..\B9$SAC1K;I"\&:3[ABPE".EX%1Z^)2TH6PR[E@DV:$0(J5GL<HG`V@@
MF+<D$:_+$);TZU.Q=4U%ZSL$QF8+RQR!.S5.L3JVRH3#%6MV6PXRITA8ZPP1
MD$BIQ+>'FEUD^Y;%(B0X"(!S".L\[UTPZWRHKV*Z6L36/!6'*CBBU6=Y<YBI
M131HXLL@LHZ=/Q[HI1!1TJ'.J(&`1XCN&^JDZJ%.%G_N8L_^QR<_M8ZTDVU\
M!\BJ5Y=/_`VPC_J3/_[;)K32R*\&DA)%"E*<H!P`3%`?3P$2[]N_KT(7A+=U
MZ7D9EU89=O6;[+`9FPOD>^TZC5OXZ.ZJGCR2AWC0,=1S2E"]9L;VTMT0X;/4
MU':#HIQ>&3(/*F4"B,D4<IU<=5;&LWJUW*_T7'$%3PIV-(.N-:$%IO4MD>>@
M(=PXE9!5_&/HUJQ93#I=!,%3%0.DD!S;\P"+0C.F_.N2,]=2G2S8;]*&3E8&
MM=55,G4(MM[J&X*4^?95]M8G,#&E2@R@@NU4#F;I@D(!L/9H1E3LMW6#U)EZ
MN9K%V.H.+4QOB>[U;&%LK$I!Q:SRRQDS76\O(92<RQD1L#?W,U5329-&!RHN
MEDU"G(;;5C939@IR)',FICGK`ZG)U[2GF2;OBV,JN<Z_U*OZI(5RF.&S#$D)
M@>T34=`7"7D9]@4LS9K5'LBE>QC@ZK=NH38B1#".GU9A.]NI)36.L[J$Q=BC
M$F7LS7.HW*BYABLB(U*9@JM7XY5:=D'B2N'DY1"'9H>"</X)VV<*(E`HJJ*G
M*8H\NP29):Q\6UA.H1R%(I#JKZY4GLB=K:<,E?X\M6'L=W:KKQ3<(N4F,O0$
M5**SSB:%(',6\IRKXY3M4E4TE%2\AR#V:OH44BR/UL=2-1BF&'$I:O6'+Y\K
M96J;O*\37:HVA%8VA^$D:[`DAI-LE7TIZ<CY%(CP!2`Z!@$2<H\=("C+"">5
M>LN`;==;WBW'5MO\$VI=JF8-LO8H1BNE(-?>P-4?&-VC@IUTA:I.N<"'3,)3
ME`!`1#;6%U9WUT!4K#$$YB%%0H$.)0YB@.X!PX<?F:2:1.C<IMP-Q3*50Y-M
M_8$PE`_P;"4=<O$,1O%S;^Y#B!F`*QWB[.F.UN00H7S*!U49LQAU0=6&.JJP
MLI*&.9WEB3GJ_`MWI$I*6K\.DN1Z]4;G,)"E;%Y2".P#OPU\,VLVGQJ4YXEM
M?9!/T!Q+R]^U\EQ:V-@$Y%(QNL[/R"6X2E][T#F**J]8;"DNES#R'`B+3F*8
M`]7#UZ^1';G:B[7ASI+)A.Y*:?,O/7G$\0NU,@%QW&@^9$_CL]0(<33%Q*'I
M$*J81#YW@^.I_P`QML?=S?R&]%9.W\9YDSV!Q+`=;>>MP_;VZ=O\4A_86C^8
MVV/NYOY#>BEV_C/,F?ECB2K\=?.W]G;I]R8_L/1_,7;'W<W\AO13[?QGF3/R
MQQ),;K;ST!C`$[=-@$0#^"0]F_\`^I:/YC;8^[F_D-Z*7;^,\R9^6.)8_';S
MW_9VZ?<D/["T?S&VQ]W-_(;T4=OXSS)GY8XDH1ZUL\J%$1F;X?8=MT:LW(4.
M`#L(+LP,(\?1PT?S&VQ]W-_(;T4=OXSS)GY8XD:GUH]0!G3<$7V1%R%!554I
M:I'*ARIE```Q3LQ#CSCK%>MOMMIQ!9+G4?V#>BF,?QGF/]@<29]%ZA,JXNBI
M"O4X^16L8\GIVX/.:!:.$CS%TEWD]+_;E&YCD,,D\5."8#RI@;E````#67OO
MMS[J=_[<=%';V,#Z#_8'$G>IUHY^*F<PO[ZF`%$1.:MM3%+\)BIM1.8/@#CK
M5<]L=M9]X;*G2YHEFN,AH\=E:;IC.*3YPE36N$LYV`>9<\.M'.ZIBD&:NPBH
M8I0VJAR[B8P`''P0`&XCJ^^[1;3@'DOC_=#B6R=>[VVH^(+S^ZEK@K;,KPN4
M[9.3K2VNFKNNV%G8HULE'/X.%#D(DY;'1!L/?)@(=Z(<P]N^O$WO:#:8S"YS
M7DDQ_"'$N%.FWA\TO=6330H0QQUE1>,;;[QP!:KY3IM%9%=2)8>)1ID@8QP.
M=H:**/NMP@8VY0,)!$2[<=?3ME-KMH)DU@<'Y!^&WB7LKM>"T-,:8!>[F/\`
MS,<F3O3]E"_7+'S.IV3&]/0L*$[(K-R1=I%5R9H4\;%I+\YE.8GM%`@>V`[<
M-M?8W;4XK=[M;<UUH_4;Q+N2+S:$3ZV>A3=T+]9.0^I.S.XRU)H-F+:CQ=J$
M$(0(T@J28J'(!%544UU`!("AP'EX>O?7J\$Q&\XO@)Q";&UK'"H"K>H6HW@D
M\JO@175]UA9&PEDLE.K+N+;LOBX$R"DC`JR?>G7$"IE;K-FZHE,D)1YN\'E$
M!#;TZ\O/OT\7FQDCF"1GD&!*MK3,O3\_TXH926!`)_XIK2ZKDS$09F>$2.8#
MDCP)N0.'`.4"AZ=;\5Q"]X7A76[N#;)(J!\JLESP6N,1%HW%0W"/5U;^H/)<
M%BN\L8&8JDRU,>7AG%7;$))KL71P:"51=J"9.Z%(!`!$"\/7KR.S>U>,SL0/
M)?2>8W)P*'621`G-F4Z]9_4A;L`#CUK5%X-!:<+.).6SZ!<2)#-&BR8H(H)L
MVZB+?NP]D-MN(<=:ML\=QG7RG!KXQ$>0.)-T\-`@1$@QJSJ>L`9DG<G8&@<E
M31VI9F2C[`Z<;1[EJF4\?+RK)J`-TTRI@!$6A`'8.(AN/;KT6#[28P<)+@'6
MK-/('$K-:TR[8<VU"J-,50K&G7OE"VY?KM#>NH9['3UP=US](UIPT7029.3M
ME@4<.&Q$^<3)CN8H[>KAKR-PVEQDXQZKZ^8,YW%0+Q$@1$%:;K*ZE;;@*&JT
MA52MUU)>=>1[Q)>+/(J"@W2`2A[*2B1-C[\2\=NWCOKH[6[2XRT`@.C]AN?>
M4W3@UT`0="</2'GFUYQP])9`L_A#2C&:F6(`C&KL`!LQ;@X0+X9%-,AC`)MA
M-MN/IULV=VBQB9AKS,#HP/T!FWE=*>Q[(N<`8Y]Q4XQ?U[Y)NV:8:B/4H].*
MD+/,PYU?B^JCS(,)5RU2`JY4`.4013*'-ON(AOKSUWVBQE]YFT/]>'J#<W%G
M%XIKHX%8SK4ZH+MT^LZ<M5`C".9EP\!\L^A9"32%!%+<B9$R(JF3/S!N!@#;
MUZ]&W'<88X!@<:,C!Q*V?-;+<`P@B&^I=QQDF4RSTQ(7BQ')XNU4"7-('8L5
M6R8G=1K]%4Z;,Z95B@)1#8I"[_3U=>MH\8D71TVR^B'T!EWPJ'SVNEF)\B\S
M^C_J[O<=.8?Z?V+8RE:9QJ%4CUE*XL4Y5V:BB8+F>BV[Y0I6B1"CN(AN&_;K
M7AVT6,7B7&R_V!Y@L(O!H&2.XKI=9_5)><!&HZ=0C0?*659XFN4T*Y?"()%#
MN@#O43]WM\';KS&TVTF,7.;!H=2.8/.%?/FMEN`81`C?7CCU5]5&3NH[$D_C
M"T,QB&LJ[86HTF2`7CB1/Q;#PQR++H-R"H5TH01Y3B("`^K7P[:O;/:"4PV@
M^$8_AMS;R\)B]_GOB'&B.8;RH5$YFH^,G-<GV64EL39+09D<IO:^>3AC2JI!
MYF2DN@Q!).02<-03$`6`P<AMNS7'V3VYV@O%YL$/I/NV[FXN/A]\FZVOR+UK
MZ3O-VL$[)PM,RI`FOS1ZY(R3R%0XY0TLV$")HIFF8E+9NHV+R=X9P9(3#SB`
MCP#;]>[(XI>;SA39E\B)Q<8Q`:="^FX7,,RZASZXKZ$:I8&-EB6DK&NB2$>\
M;(N6SU,"E$P+`)NX73(``FY1+L!R[!L.OH5TA,$3F73$()UD,7<>/Y.MKA!7
M20(E&@8!X`/Y.HJ]40Z)?\[]0G_*$N7^;$T(5Z-"%MS&]?T@T(0YS>OZ0?4T
M(0YS>OZ0?4T(0YS>OZ0?4T(0YS>OZ0?4T(6IC&Y1X_2#UZDRER1J7G)WAOOK
M=O\`^,0Y>ST?B8:[\*?](N5^JJ>>2B";VN]?[<ISE*IUQ9(1.HGP43*:,BMU
M"?Y8``=8L<G'$0V618@#53FXEKNU4=[SKI=2Q\I6#/ULQI3YZ\U.I6/.O2+6
MG$S4XQ1&2;U*4ADW=N!.<*X3,F54SG90W*)2[<=]<F[-;=I&HA:CE.1:)[BV
M0YP$57.QT3*\Y,8ZLSF8R];<C8<F.LJ/Q$K8'SES%I.<53LI'XYFI!,6ZG*M
MX)`@MA*!A.!0$FIQS+C]:?&AM&^H]PGD?J`?X=O=JR'GE_-XTGLGXKK669''
M+S(5DN.,82,JD6UO9)9:XU&F&;.Y2635[\(WQY$S#P,;1$H%Y?'U:-]358Z[
MC6KY0OENQ[:LH+EO71OX7!B]O4LTQ'VY*%G)@)<\Q'+19`(\C6!D#(@KRJ."
MG`Q@)OK0V3$1BM=K-4N8I?<I.<F5P1R3E:,ZB6-@P@;$^(VL)8T*,\PNYQ_`
M-L@R"4<=BG`O4GDPB\.J"SI$S=8!*`&$-&HW:$1TJ9^GX,K5[*?3Y;)"[Y9G
MVF;\F]1M6R94;.\<+U*/K%>O\^C2CLF.RQ8\\05`2)\_+S$'AL&PC,-L@@4D
M5(!IIJ*<7F`9&3@>H/']5MN7LE8RK5APK9YJ":8Z(_30D\I1TS(K8]<3A8H'
M:PE:J&(@"9R%(Y`!W,4`TVM`$*Q%!,3&I0G-2G5I(XXZFLUJW7(HYRQSC_$S
M&HT"4/*-J'1E9.B5R4O5N]TD:>(4=OY%^[46.S3=.DQ]H$C&W*$@&MH$!%(D
MFDID8LS+GW%.!V'4(;(1LS42JY(0J+.JX]6R/='C*(RO7(]G<WL@[MM+J%E>
MO*O:RJ.VR1HXJ!!7,3O0`@&,66PA!$2D"S[JWK74YAW&5ES9'4R7@&&*EJJ6
MY/,@\N08=_%DL-O-7Z[7JA/5>=F$IJ1<1BR$C)Q_)X4%.81,)03@TM)2)("<
M\%4,R2#.G/Y&_9HGG?4-8NN6"R3"O74TW8P451IR6=4!C"%!LH>)09-5DVS5
MP)=E"I@)0`=P##25EU[[`="F)HWH)!#VFXTS#V/F>!+9D2R1\+TZLH/(L[)-
MYI];H):-F7;7("RDO,,XV2))U20(NW23;)KD<@ES`8-]M%*76)F0>-/6+L5O
MR:]C,=8@S-FM[TW7'+6-JW$9*5:61O;W,O,5:+4N#`JLBQ9NH^)8RI3K&6$H
MD!54R8;E(!S."Z;)_)$!%>G_`$5NK<IB)>'ODA.RLE3\@WVEQKZ>3=*S;V#@
MK'(-(I_*/7J:"SY=ZS3(J"@EV*4X%`1`H")!2UYS)#CQR@IU^=1/(F=,J>!<
M))]X8.!^6T7@-B_S(C]/1"E1<^W')1YPKHS+5.18N6G>G*#I'NCF2V!0J9A`
M3"F??<BGL\!#LTU74J_0?35AR"R/)99@J'!Q^0GYWRBEF69@^>I+RR8(3;E#
MO3D!)Q*(@!3G+L(=O'0#!(&"<B>!<6HP*E62IL.%<6M#*WJQ2C4%433D><Z[
M5\0Q@#NW23M918%`#F`YQU9K71M98(%`@N[`XMI=6LEMN%9K4)`6N]+1SRWV
M:(C$F<_99"*9H1;)Y.R:8][)&2B6:#<`.`;`D`[\=@-88TB+<R`84BM-,_3M
MAP^15\N'QY7%,FK=TJ:Y*0B*LJ9ZBW!DF]44$X%65!@0B0B(`(E+OOQUF-^O
M%6JHWUEU%,;1BA3.F_"V/)Z>M%$QS6ZI/6H.6QR,5&)MG$D0[US).DP`>\*T
M2>2#M150I/9,8VEU^\>[\:.KC.5)D+3*W7WMAE(:%CHR5M#Q-[./VK-%%=^X
M(@BAWBQDR)F.)BI!VB.VK&3'36VGMLG-&*OEML-A6G7PW.(```<X'V#T"!"D
M[?3ORZE%3C%<.SB`5BS;@8=Z[.!L4-Q_K6Z'@'SM),5\!\BJ7Y=HE)T<82+R
MJ_UJG]A,0"@'\*IHVY_:'E+\.GD1D5W.?X4_ZI_^;I(`B8),H/>?!_D#ZFB*
MOU`SJN-UZ6^G^Z9!3R9:<356PWHRT2X"Q2<,DY6.YA0`(MXX3YTTWKQCORIJ
MGW,4A2E_,AHBC4#.G+8,!8PL<';:W,4F"EHJ[O&<E9"2,>DJ>7?,`1)'N)$!
MV%PK'M$$T$AW*)4R%#?AHBC4#.M:?@'%&/0ABT2@URFA66]I;5CW#'D:J0B-
MU?>\[05JL',IRRT@)E3AP]HPCQT13U(C$%$6#IYQ#9;W%9+E:)!.[M"MW"4?
M/.&G>NTW"Q"))/U3%[H7#UH@3D2.<1Y`[-6,F6!0*8I:@9T5*=.6&IB+C(-_
M08,T/#I6!",9IMB)>#3M;Y:1L::"H$^UDFW;@YG0`79;?CJ8GD1@!$HU#<ZA
M/(O15C2TTZB8VAV9ZO0JEE&N9.5B&J*4D5X[J[UR^BHEB=8S<L(P05="3=,J
MGVHI2\NQ='6"3ZH47R@UL8JQ<CBJ@/U)Y9Q48@R5JE(R=GT`:(@$G-Q:XJ-)
M5RIR<RCM(.0"&$-R`F&VD)S@(9E11&*9UMZ<L/W9&9CK+0*]*-K)/FL\^+N-
M157>3@LF;`9-JX`2*1[Y9!BGWZA>85A`=]M]&N<-Y.`4Q5J#95YA!04,T1CH
MBNM%&+5BB0`0!$2D(4B)1']+II`3V"AS<I1VW';?5!K6\)ZAW90Y15XA^>'<
M0WX[=O8'H^#0A)EB)&5(/>%V,4Q5`V`>\3+Q[L1WX``FW^?H+),QA;,8UT<Z
M#>!+:6%H*\KL-X2K^7T^IR.6(=HX+U(64KA^T5*V>G;!7H$&Z"BW=G,LDB8!
M$H"(<HF$?3KRV);(X?B0(<&M)^J#YPN7>;NR]"JRG2IY><2LHJ)KO9$$AY`1
M(F_*AX<I?S`+`!S'`WI]D-]<"[_#'!9$YTV99F!V0RQ1]Y8[I@TADTOFP>"*
MB!QHL/+LA0'<M_M8CZ`+-\PCZ.!11`!UN_E]L_[J5^6.-='LRX^Z9H1@>7?%
M@(#\>KAPX_US3^PT?R^P#W,K\L<:.S+A[IFA&_)[Q7\?[-^[`?H&C^7VS_N9
M7Y8Z279=Q]TS0B!\O"*$1'[X-FXB(_UW#TC_`.\Z?\OMG_<RORQQI]F7#W3-
M"Q\G?%?A!LW[KA^@Z/Y?;/\`N97Y8XT=F7#W3-",)Y>D(0-E+W/JCON`JR(*
M&`/4!N0NP;^C2_E]L_[J5^6.-'9EQ%4IFA&%\O\`K+0_B%[E95011<*%3:/B
ME$_VH2"101["F$X"';Q+K7=_A_L\&F,J5&/NQQJN9A]Q9_T99X%4?HSZ*F-\
MQ-:'LS?KBYDH3.V9X$CI])\Q7$3#6MU"1C8^_.9,&B<?SD`-PW4$.&VXRF["
M8!*I$B23]@<:J%RN1JD2]"M@/EZ0.P\MWG4S>@Y)00.0?SQ1[H=A#6)^QV"V
M?W=WE!V<-'&HS,.NSFPERV,=G`I19O+UB0*8"Y#LXFY1Y=Y<>)MO9#^@=@CK
MBWS8FX/C"6P?LCC6.9@HF#UB.`<:\5NOGH1RFXS1/,JV$PZQC'T"J>\9F37.
M7EF54A"7)"B4AB2"K@P"!MQ(;?7DKUL+AX<09;(_9&YNK%,V<E%U,P@_9'&G
MGTT^6PYE6[=*+JCIM#F%J)GDLU)WZ*9"DY3D!0@=I/1OPUZO!OA]AF%N;-!#
MS","P#=YQ73EX"Q@'[TD?9'&O<S%_1;CRG0<BQEX*(L9IJ%0AY5"4CD%VZK9
M#VB))D%0Y`$I^/UH[#KTU\P"Y7N5J@QK!"%#0?.MTO#6L$+1-&9.W%/3Q%8S
MO\S<H=15".?P[>O&BA11%)FV9F.=!-F<G=F2;)IJ``)<NP"`COQUT\'PB3AV
M#]F,,66W.C"%>2$3Y5/J`)!+R1O)C9[Z3I',MM2L[.R/(),8T\6L5F5%,R[3
M8HI=\*@B*P)&YA`OL@`F'CKCOV,E/O&O-X=7&%@0\J3K@'&-LZ/2ISKN+PA<
M3DQ@1^J=5O77$*$J9---=0ITC%,Y'8QDRG#\YV#Z]=>]8!=KW<NI3#R<]D'Q
M13;<0&%MLT[BHPMA*"Z/2%S_`'&U.I.#JZ48S,V,T03*Y">?E0.<X)*&4,=J
MJY+L0.!]^T-<["=CL.PJ?KQ9F',6`>0E1&'P,;9T>E6;Z@<!*9M"H!'3TA"N
M8,9-PD[9"DF"[&33;N2=ZBKOR;@?EVYNSAKHXOL]<,6A;:UA'U8^<(-PC6\Z
M%)6*L:*T#%\9CE1Z\<.8UI*-B.A$K?O@E7SU^)SI$!0A10,]$@<?:`H#Z=M7
MW/!;E<[J;JUC2"(1A#Q*74>39MN59J?T2OJM>6-Q-;Y%R$9.J3+1@[(V70!0
MZIE3E(<IBF1*H(CZQ#X=<N1LCATB]=:%DNC58&>-<5$8?]<Z%-F?<%KYBB8%
M@W?C$J1$DYDA2;=VY144<EY3DY%03!/<?;$P".XCV:OQ;9?#\5$'AK/V0?.$
MS<+1C;.A=+!N&W.%L?NJ8=^O*KN9)_(E5-W;<!3?H@F8ADTN\*'=G`=N/'8-
M78?L]<;A=S=VAK@<MF'BB5)MR+1`3'5J`Z1T;K5/(K&[!89!T@QEGTMX8S-J
MB!#/WR[U0H*E4.<0**W+OMQ`N^L4C9'#I,Q\P!IMF/J"CQJOL_+;,=Y31U#]
M/[G.#"OI1]D?P/N1RJJ*K<40.X3=$%-9$YUMN0NVW``'FV]&NH,$N`,;#3P*
M;[C;,2]VB*ZR5'/CGI^F:8E)KKOJOCZPMXZ6$I#N?$-HB063>`!1*1)7<>P-
M]M%ZP2XWF[.NQ8QMJ%-F,(;D51/NFJDN<'DG)0J(="_3)+J4;`N9YRZR\NHO
M5&\RLF+=NW.#V1*=V*PKE554-R>(%/?;B!-_3MJ^X85<;@R#9;'$9806.3<G
M.@[6.!WO2KJ]073NOE\E9583[Z/7@E'"B0J+D,!A<``")P.7V1)MZ-]]<7&M
MD[AC!M.A+@,C0[RD+8<*$RG6NA#-'SKR/Z[^D7(5)Z?9]Y2[#8[Q95[3"PZ<
M'6VQ5)25CI!`#2"3D$=SLFS1QS`)R\_,`;B`;Z^7X[\-L.Q=NK+A+A1$2P:J
M(TN"X5[V:EWB-J:13S1DX5Y'XPZ"KI8K@A*7B.FIRQ)F*T-'KE"1+'I)&[AD
MU7(8FR1FC-,B9O3N3CMV:Y>"?"?#L&GB<V;K3F,MH_YBL<C9&3(=:$YQ_9'&
MO>WIR\MAM7D8J8M";*%2*8BZ:<0"#)\HB*9!*#E<A!-R\VX"ER[<-]^.OL>&
MX))U`<PZMHH@!11PY5ZRY7$7>0)=HG@7KG5ZQ&4^*;P<0)P;-$R)@(%!-,W*
M78#;%$P"H(?7#Z=>FNTH7=MGUELU%%:<A`.81`IQW^$1UI<\/H@`G#54BF*.
M*"I#`<PB8"[B(`81$0V'L`=@U&"6N.94=Z*#%*RZ@5.1;VNH.Z"("0`$-E4A
MX>UQ`-^.E!+7&%2N_P"+1_/?2'1!&O.9;\RX\2IIB4>)1%00W`>P?K?5H@GK
MCF1Q>;8.8``WI`!W`/F#PWTE<TQ$5G0FAH0AH0M%!$"&$H`([<`$=@'CZ]3E
MPMTU*$QUEA*\Y.[7^^K]:G_SA?>_7^G\3+;E[/5QUZ&RV-9_\3Q+AZ\YO^JO
M+/RK>I2FX03ZZH29JN3K`\E>MW)3M!W1Z>%CCTDTXN*$".7!I5B*2A@$>'*/
M'7+O#27`Y!%=2[FB"]/U.M[$!E%79L4YX\:[48OWS_[T:*KM.2B8QHPC'+<Q
MK`!CG:B@82CN'+OPUSLH6J8VU*(21+KDQ*F8A28OZ@B"82"+H,0,^^;'2`"N
M%4P]][G/.CN=UL)1$QAYA/IQ&18A=QP;R3I]8^#&Z3UNRPKF5LWD%=Y)F."8
M8(26(LIWKMR_A&<NR2<R!A'E*JL94>&X[[[:<0GJFQR:`EZ_6G@MR5B0<.9Q
M7!#O8Z)0'"\4LYAXQ?E2D(^./[W2!DT?$2*)B%`2E$=MAVUK#'5Y=_0HN@##
M(D[KK<PN_?"Y=8JS\WF&@(I,ED,2Q:\ZP8(B551E!3'CR.V<:5;F*=(!,'UV
MVW,.G!\8F$?$E$0@$K#KOPF3P2R.-,V-C,7,@^9)M,*ANU<R+M99VL10L^?P
MZ[@QQ%42["8^YO3H@8[XA7Z$40W=Y,B8ZI^F2<R,SRC(8;SU+6IC!$KK)>2P
M\G-Q18Q)0ZZ7<M'DMR-7R2ZAC%4*.Y1'TZ"'0@8:8)BR*<N]%/8G7=AU=9L1
MQBWJ%,HN8II!53$2;HTJ=R4Q'2$L;WJB1XV;%V(B*A3%(0`#D$``-1+3"B$=
M_0@$1IJWENSZU,%1\>O%1N',^LFR#TZJ[-CA:#8(.U3J;IJJ,VSII'N"D';8
MPD*<`_-;Z8$P"%&E!LDQI1"_6EAKQA3S&*,W.YJ`<G5:SGWF8M\[8O)%ZY?K
MH0KF0DG;ICW/B0*!TERAPX$#47,<*1ZN^FV!HRG<1Y.N+$'*F`XIZBD3)DE&
MR!T,7,`&/3?N5%7+YH)9(NSR8(!1<\=A$P@.^VXYHA&I$!F1:?6SA=LJH>/P
M[FM@BZ*LB[:!@^..F9FX4,NZ9%\-.LTE$7[E0RBO>%/S&,(CN/'1$(U+?`(H
MO7+AMB9JA$8DS]$MV::QT(V/PU#LX]I(.0*(2;8B$FFF1VV(/=D.!0-RE#<1
M'B+BF>28"M.9KU]8D3Y>3%O4,T.Y7<&%,F+$![U0I"I@Y4%*;2+WSA$A3GX"
M/.80W';?21R<YT>E57H_7!BIAU@YLL:]"STN24Q!BUAX5/&(C(-S,;%;%C'<
MMB3INZ24%8H$-N/,(#P#;B)"&6I6X-Y@N(0*!PQGU$#PY0`,5*B;C\V;#LT)
M\C.='I1"/F"XC(8W^YEU%#S"/UV*3E#YXFGM@#YNA+DYSH]*4_*$8D_!EU#?
MWK2_O_H3@S.='I6GRA>(_P`&'45_>G/^_>F$H,SG1Z44/F'XJ`1`,:=1H``B
M``&*";`'H#C8`'AK8+LXB,&T[OH3M,SG1Z487S#<3"4!-C+J+$?2(XG-OV\/
MK9T2]FCJK_J:?0ER#3$Z/2MOE!\2GXAC3J&)Z-CXK$@C\(`:?*.VL\UA8ZR8
M<"(,R$Z/2A\H'B?\&_4'_>N#^4&JD<G.='I7'L'7]BQQ7YYNCC?J#*HO!S"7
M..+0Y$@/&NBBLJ;XP#R(I;[F'T:$4"HF.]Z56CHCZW<;TWI0PY!R-&SI(JH0
MTD*KN%QL#U@H#ZRS*J2:3D9Q$1,F4P<_L\!W#33$(0).CTJU!>O[$6X;8VZB
M>W\&!?W_`-(IM#;0I.CTH[Y0;$_X-.H;^]:3^46DMBW^4+Q24@B&..H914A1
M$6Q,5@+A$A?K#'3&>V`J@;"0=_:#8="$`\Q;$A"@97'74(1/E,(KJ8I."?>`
M4#B@(DG#;+AS;<NW:';H0LK>8CB`"=XMCCJ$``[L2?[E*VZA%$RJ`=,/?([E
M#FV'LV,`AH0L)>89AY;N^[QQU!CWHF``^]4L`DY0W]O]N/9`?1H0DRGF&X<5
MYTQQMU$;(J%[PY<4J@4H`/$XF]]!LF'I'Z6A",/Y@N(5"`'WM>HA,O+N4Y\5
MJB4Z0=JI!]^;]UQ[="A,]0HH/,)PVJ((!COJ#`P"4.<V*EP(/M!QYO?6VP#I
MK)R<YT>E91\P/$3I=06^->H58".569C$Q<`$[](1`Q0,:PE'8PAP';CH1R8U
MG1Z4I'S",3IF$#8LZBR'*(@<HXK+SE,`CS%,/O\`VW`>`\=);14LCYAF(Q'<
M^+NHOF]/^Y4I\[ZV=,'9\.A-%'\PO$6Y1^]=U%[!S`(_>K,`%`^Q1$W-/%$"
MAZ]M,+/-LVJ8Q52^E7K;Q?5GG4>LZQ]G5Z27Z@["[0+'8X\0=%,U>@3D!R7W
MX0$CB4P[AN/$--5"S#E*VQ?,+Q*&_)B_J(`WK-BL#AM_,_&#2*ME68T1\.%;
M?*&8J_-8QZAA+Z0#$X%$0^`WQ@X:2T(?*%8C]&+.HL!]?WKO_P"(-"$/E#<5
M_@RZA?[TH?RAT(0^4-Q7^#+J%_O2A_*'0A;!YA6+!#?[V?4&'S<3E`?H?&'0
MA:'\PC%`B'/C#J$,.W`0Q.&VWJX6#MT(2-UY@V)A3*0,7]1)?$J%8@<F*``J
M9W6X$45$;$'*B3NQYC<=@UID!Q:80@"J)\(4YE4SHHZV\:5'&60(YY0\X2"I
M^H/-[L%HK'`/VW(^O<J]1(*@S:(]Z1%P4#AM[)MPX]NH7HP`*SM(`IBK?_*#
MXJ#C][/J#';T!B@HB/S/X0ZP2BTS0#$^+SE3M#.='I6ORA.*1X#C#J&#U_[D
MQ0V#T_ZX=PX:WF0U[:AI'$E:;SCH]*9EBZW<"6Q!)A9<8Y\F&!%A7!)QB=4@
MHG3$HMPW+,B*Q""'$!X>G6=^$RI@I`\7$CDNA$GPX4X8[KVPQ$LR,XW%W4&V
M0`"ARM\1&2*<H``!P+.$X<H>O5?5(4#(MHJ2\WF'8F)[*6,NHLA0VV`,4B(=
MG'ZZP%'B/P=NGU2*%H7S#L2$-S?>QZC3`/$Q!Q4'*8WY[;XP=NVK!+U8LH0^
M40Q&!A$V+>HU0H[<J?WK``J8\=Q+_"$/KM-"P3S"L2K+IHEQ?U$E!P)D=CXJ
M`I0YR&]H3A8A$-@#U:$*G/77UH8KNW3/8JZTQ]G!NJE8:2#=S8L=^`B]PF&B
MI"KN0FE]DQ*EV\H^UL&WIT(5O6WF`8E31V<8OZB.^<@BT4*GBT"B06H`SYF_
M\(!'PJBK0QBFV#<HAP#0A=0?,+Q,8H@?%_44)Q#;O0Q6!3_!L(3W#;0A(OE"
ML1E,//C'J/4V$0V-BW?\FP@'TM"$87S#L/EW$N*NHLHF[1#%GT!_N@'U:$(D
M?,*Q'S&$,8]1P\P[[FQ6!A#T;`(V$-B_!H0CTO,+Q1^8QIU&[!L!B&Q6'*8.
M/H^,'#0A;&\P;$IC\QL6]19BCVHABT"$W';VQ_A"'$-O7H0FI=.O+%$G3[@Q
M1QKU!-#.JE9T"JN\7@DV3[R#?ASK+_&`_=IAZ]AT+->X=7=%0QTC=<N*JCTV
MX+@1H'4#(@ACJ"7758XR*Z9#WL<V/W9%_?R8@!!'\[Z=/)!9;L19`RQ5D1\P
M3$0BH*F+NHQ0#=@#BX?9]8%VL`>GYFD%U&1R9ESW/7KA]P=)3[U74$11,%.8
MQL1I*=YS%Y2@8I["(=X0H;<W$=]/J$LTD#Q<2PO<+7H3+K?5STU5%P]>0V#\
M_MI%^Y7>/'BF*2N5E'3M8[E8_.>P=G>JCL`;;!PU'L^7&H0X.)1Y$*S'>]*D
M%+S!</\`=\@8HZBN7TF^]=R^UP["A8N`;;=G#3U0D\@5+7*A8H1_R@^)N4"E
MQCU$$*7L`V+`X;AZQL`;]FA6+)?,'Q.&X_>TZA@^9BX@#_MA'1E54V%FE;?*
M%XH#;;&O43N(E*&V+B#L)Q`H"(>_NPHCN/P::SBR,IT>E5#Z3^N7&M:;YN;N
M*1G.3-)9ZN:Y%8C&H/$FI53HB"3LPSB0(JF`!`0X["&FD(95;'Y0/$?X+NHO
M^]9__$.DG!F<Z/2M_E`\3^C''42`>K[UQ>'P?W0>C0CDYSX<*5$\PK$Y"%+]
M[3J&-L':.+@W'T\?V_TEK9Z@AF6_RAN)_P`&74+_`'K@_?\`T*2R'F&8G'_>
MSZA`^;B\`_\`G_0A9^4+Q/\`@TZ@_P"]@'[_`.A")7\PO$_<J[8SZAS#RC[*
M6+0.H/P$+\8`YAU9*CK!"M5S8:LQJ@J-_CDXX^^3XSXF9M[O\=CX[<GWOOMW
M@/Q3O<?NWD]\_P!>O%>WW&^W<>WS>C7?B[<_"L\.;>W5YR+<Y]?PRU^$4K\D
MHIU8CKX$Y45Q2ZX\E>'5\,@DL5,\;$<Q1.JF("78OY.N7?VONY!G@L!C70NY
M=A$>&ZO<+N#[@/<`/$.&S#CM\Q$/7KG![7"VT@LSY%N%2W[D_P"I2_09?H>E
MK&9PE9&=:"4X!N+0`#TC^DMO\ST:R7S@G9.=<"4>)QS9W(*,E3'BF[M\/A$V
M1U7!$43.3()_:1`5>Y#?8..W'6YM401"&6*YKZ'&-<51G$O7WC'(MC:5^9K]
MCQFM,UVYW:K6RY1C2*@I.D4R2=,9^=CY-RB5)Q%)+M3G.J4>4"G`=2<T1W,R
M0-&ZK&AU'X/;P$!<!RO2&=7LCYTSA')9=F"<](MVI'2K"*.U.1-Z].T,5?DV
M,<4U"CV"&H.;D@2<ZDTD98!-S$G5W@/-K-ZZQ[D6'D"L[2ZJO='>.4U'$TFJ
M9$D>T+WQ15=**$-LF7<?@TGL=&J-"`ZB@P"?SW.V(HZ2KT4_R=46[ZV3"M<K
M[-2>,DYEY=%ZXC73&/*9R'?.VL@T51.4O$BA#%'80U$,=F4BZ)K4;7WJ6Q]%
M1EN5I=@K>0++2I`(:Q5!E83++L##)FBE"S)1=^'8IIOT5$C*+!R@H02CV:M:
MP@0RUJ!(KX%)]9RKCNVVR:I$-=(25MM=*@\GJ8R=1+E2(7%!-1=JY521$>];
M*&$#B)N8NWJU!\6BG-"-*G+I<!NJ5^4_ZD#_`+R_0]8]9*YP6^R<ZSR*?J,/
M^\OT/1K)?."('.@*`B&_A2`8>T.5KO\`,$03V[-6MI$14L4P$/*(516,013;
M@DLEN=,W*S'F$0`.7F,F8I-]NT-ATU6J54%553KIS^V*46ZI,$X87435."9>
M=6S74O.4&/<F$1Y>(F$?@].Z3&7>\ZNL)'"1`,==,-Q`/Z,]XB(\-N9<1XZ=
M"(P%!2;QB8$(H=VW415<"S*'B%C%6<]X=`6Q>]5.F97ODS%V$!#F*(:2(DBF
M,$<0Q%0,*31,P$.9,QB^%$"'(.Q@$0)P$H]NA)%&=<@K@9X@`MN47`"N[W0`
MX`8HJ?;O9`Q1W#1P)VCNZ4:19!7;E!!4P\@[E.U-S"H4#D$!.43CWA1W#<1$
M0'CK$;T^T0`:]Q*!\()(>3:E356(^:)-T'`M%3>(4*FBZ`PE,@84%"(E5Y_0
M`;[_``Z.MORM*D"0$H,=/<?$&;G.4Q"")SI&$HJANDF(N^\4`3\1``'8=:94
MS6-B1`H@YU(!(01\.X,L1!-NL9N<B:Y4_`F%$ZJ*;A,B@`E[)CH+%.`#VE,`
MZLB$6'9BN39T%"5JPB5`J11@9HJQP(SW!$8IX)N`)`)O:`O#TZ(A,,?D!50?
M+O46<]'6#E%&ZIR*Q-G,J#A-H)BF;6R:(VYQ[H.)R\2B'HT4)6'0J*NX4@B(
M"#`!#U\K7]#TBFUKK0H.A;<O^@`'_J&?V&DM>^JEW_JKQ[CCJ+Q9TZV%E.-[
MAF:$F9R&M+-BU/7(M&!?.(YK%24B9`R*+QVJV$I"F'?F#8-"@9DMOK.`7,@^
MLK%,WG7,6"F[Q=*2PG2(/(-WLCTJK>MMEWD@\;.XY.13.FP!Q%HM"BY3*`"1
M8#`<!,`ZE8?7`P4=?)YS=*E:.ZG>GU_2VN16&:\>NZ2_FGL&TLX69%2(6F45
ME3GB4W`.>0'J*0?T+ZX`#@&VVGJWU0*-?)YS=*73?4=@RO0E9LD[EZAQ4#=A
M0"I2[NP%086#Q*@(H&B5Q<@5R594>4HEX";AOOHU;\Q1KY/.;I3>RCU(8EQF
M25B92[0#NV-J[(6!K1DIAPI9IM%BU2>"WC(\CKOG"SALL4Y2@&YB\=&K?F*-
M?)YS=*Y=-ZGL2V"+QPM.7BM5&SY'A8R9K=0G)U>/FACYDYTHE`T>N[!4[B1.
MB8J.X?;!(.V^V@2YD:BH3)\FP>6W2I(;9MQ3*6-[2([)=.=6Y@:40>5YO,E4
MF&BT,3FE2+,P<"J52-*("L!@]@.W4]6_("LVOE$0M@\*K=D+K0PS3J5*WNG3
MD;F!"*O-0QO/0]-<13US"6"QO3,R2TFDU2!1JCWH&`QC;!N4=M+5S.:5($&D
M*\@IF`1_2@#Q'B/@Q'YXBGN/S]5+>*`AR./S!03+Z"=XL7;U\$#D2#<?4&A"
M(,5;O2D42!8JJ1R#Q*<"`'$!,+D%%-MQ[-^7X-],9EFFGEPW%1[HR=&7ENJ1
MJX#VF743/)D%0&`@)#0,*!2DV1`.'+J88\U`D*#6/(H!*O`'<I[[@B(\.`^!
M#_XH-/5334TK1*E303%I6>]1'L21$?4!F/Z'HU,WFE7ZN9S2MN<G](3^BQ^P
MTM5,S%&KF<TZ$.8O](3^BQ^PTM7,S%&K?F*',7^D)_18_8:-7,S%&K?F*&Q1
MX\B9?@W8</HHCHU<SFE&KF<TK8"^I`A_A`6'T."1=*P\5@I6'Y04A?G%%,5#
MII)H%1<"N4PL@Y@[KE(IN">Y01,._#UZT2);G`M$;4:*_"E43F/H,"J/]`)"
M$Q-D(AE0743Z@LTG,90S(P\JMSD2%'?NN4"@=,Q.''<H@/9HO4B=$"RZG<5#
M9;X5%7D`4_SJ0_!NRX_02UR9LB]L9:9+>7#<4Q*F$P#23P(P#!V@@3?T"`M=
M_F\"`;AHDOOH$7RYC0-P<23I,QOK-(36#(=.^,SRF?&R""W1[5L_?5H9!0)I
MHR>!NU=+QXK@NF@X`-R&$-C>C1.Q;#KN87F?)ENS.("B39,":4ZP,X4,8"*%
M$0XB4%GG,4/A+WW#6V6^5-%J6YK@<RW4595LF`K;[)IKF*(E.8#(G'<!VV$7
M!3J[AV<1'Z&M$`QO*,-*$:"1M@_2Q/\`O+U_^]ZH<YKC%IB%$K;N3CV-2#\Y
ME^A:BA#N1#83M2@'M;&Y6@\@\H@!@Y4P-N&_HT)$@5J@?F2',ATDVKD1.B*5
MCH?>F0\&"R_[?L1!),.Z$HJ'X;;!O\[0E;;G"O$V*HJLDX\/S]_&L"HIB1D)
MF@]\X,81#NMB[@;B/8`\`T(M--1"[/<J?J,/H,?L-"DL]PI^I"_09_H>A"'<
M*?J0OT&?Z%H0AW"GZD+]!G^A:$+`I'+VM"\?@9?H>A"UY#?J0/H,OT/0A,?)
MR1S8VR"'A^Z_@3:?M@>"`2?M(^]H!%/;??UZ%GO37.D.:T1,%`_1`BJ/29@8
MJA!6<.,?09C+&!D8Q2D8H;;B5$$S!L`;!MOIY%GN\M[6B((*MB9%7]1AV^IE
M]AOH"Z+2M125W'])>GU-?T/5&MG9`Z"QN8ZT8`UK'=']+0H?`/A=_P#,]&MF
MYG>)+5OS>1;=V8/^Y"_.!G^6GOJQKG.$71BM,L$-@:U@2"':R`W_`%+,?^P#
M4E-8$FX#^D`[0_,M`]?J)HRJJ:"6T"*T[LWH8@4?SW*TX>OM3V[-2BJ`U\:C
MH5(>B=1NNQZ@0;-%DN3J#NH*@Y!F43G[U/<2?:@+R<.'TO3H0&/S%7?[I3]2
M%_[S^PT1"+#LQ6>Z/_8\!^'E:\?A_H>E%%A^8Z%GD$.`QX>C\PS_`"R;Z2U,
MH:(UH<O_`(O#^<9_8:%)#NN?_N(I=O61EQ^BD;0A#P_^A"?SC']`T(6!0,4!
M$C8A3`'`>5D&WH[01`0X#J3?654_\(KSV\&/WTN3O%-OQ_\`E^M8;?\``X\1
MW?\`0=N[W_,^OX==/E[OX<>#/X4KSUD_?53_`"1?ZR]>W_+@R3_:Z*U;MA^%
M+^R?,N[=:M'G7N0(E*!3&$`*`")A'L`.';KS-SIN1&XMH,&F*P*[8-MU"!N`
M"''T#V#J%@YE7:;G2=5PR%$P"L3EY=]]QW[0XCP]>BP<@07#(:4T["*,E"3L
M4D5!9=W6WW@RNC%1(=5R@\8);',(<H#R`&X>CCKL-B``:H^E836<Z\5G_ENS
M@])Z4%#GF8WJ$(QBD6LO'69-N=C2HZU2MD>UBHSJ[Y)M54;>PEBH.P,J@594
MAA/N''5EL6J?5!\:5FCZWF1F"^B.X4^V=.-DL%(L<>TIF3LAWC*,5E&Y-+4X
MKJ,K68BM5V:@)9O)2L>ZW&,$@()JB)0]K;8=]2)Y,6UJ(%--2<?XO_47CYM'
M+T3!-8<N\4]7-MR_66HVF'!QDZA76PR14WL<\3=B6OR\;#D;J.$G)D0%,Q`#
M?;;4;37"$:PG`A1NUZ2NI=DRP/*1N*V\+F6%M^79&<O1[;#3E`A8.^Y0M5@=
M5N\U-_);6M1_77R2"2[=NZ,B8.8H@.IVA7%*!14STG]0TW$]256JN*T:/CVS
MR-:E*W$2D[4+.PL-M0N:T_*2M2193+Y]3:\G`KI(&9.2-3%<(G-W?'<47#.B
M!5N.F_">4Z5U+9SL/Q*<TO!MPE)NT1SV\355O]BN.0+!/2+QK9J<[BIB:=5R
MD(0:C8B31P+8I>40$@"&JIC@^7`&F"L8++Z5Z@^*8_T\/Y[7%U96VUNI2#AK
MR@(*$VX<?J_#IV-Q%IN=%^*:B<2=Z7?<`#<>&X@`[!\X=;Y=$L1S+),(MDQ1
MPB42CRB`AL/8._JU,J!J5%Z+_P`X#U#?\G["/^VJ\:2!EWO.%<BQJJI0[LR#
M8[Y7N=DV!2_UP/RF$K(ZOUK1-P8``5A$`)ZPT($,J\:*5U;9[E4.H*R%;41:
MTXBFI0QL+-:^[898:4F)L\@1=TW.XC4$[=")L.=0%&RK@3"`B''0BF$%R;[Y
MBF5@A*#E#&>/V-KPE>\IS<%'U=Y"ND+-*XXHD/`GR#;4A,R$YD(Z:D5^<^_#
MNQ`="(D#<BK=8LZMJ1<BY<?7:[T.FUNK9'/0\86-Y;X>H.[=$OZ%6;[#Q-:3
MDWD>:8G%(JP$[LB?.H;<-M&5,4JJ,QUZ9.QC3Z!GO)=+K$MT\YH^.\?C6OQI
M#OK_`%ZRI33^/H+2;5;-U`D$K:P1;N958%#E;+JJ`([!OK6VXL>ZP/7$(T#*
ME&B)%"[MKZK>J7'%7LM?M,#7+!E&8PC#YBQQ\1F:<FWK45)RJJ+QM*4M!`9&
MS(U-0XM.]0;+]Z"',/;IC#V.JA7#)7F0744J<,/Y\F;R3';JU9%J5JBW*>98
MW*DQ`1"]82KU@J*;)I#^\H9ZT8/(RRM%0,'AU$R*`7E-M[6LTZ3J'V%JE&+8
MY58/I$^-$A29^R6VUVFTOY>VV9",=6=BM'JFK,;/R#2NN6J*P`*J"D2DD4J@
M!L8I0V'52L5E+;_<I9_]CLW_`&L=:$*GWEU_\#/"?^I%A_VU36A"O$E]8/S/
MJZ$"M8+]7\O04YF5>3W67TPY;S#E^4OF/H=DD[J.(W#G&LD:>1:+NLVQ4B]>
MU@LV4JQ5(^LIHJ)"IO["@[B8-2(BN3>07;ZK5;^A;-TE!.9!9&$?VZRX*HE@
MOY5Y-$[.Z=0X7N=R#D.KN4T5#N9J-<.)WP\<ZY#H),2I$$Q0+RAL8>0`:_"E
M9`"G/5^CG)MGR?3LCW7#M%QI6Y_J$B<FVC",7.L9!E#P<51(:LMI22%BH:(<
M3@2D:N[;-T3&`WB3$X"00"0<(0!I4B#&)$&DU)I/NDO-5%58.4,*U[*S>2K^
M<*!'UYW8H4D?BBO7+(5JL%2L#>)G'[8LHS=0=B;KN#-2*JLW"9R;!L&G:;&&
M51LNA%.2H])6<L6R-BI"6,Z_EUSD+$U/J;GJ#<35<B7N-S4C'T75D8QA"KOP
MFE$)-XR.HV<HI?;14,90P!VJT"1`J0!`,16-"::72)U!HM'M!DL3TVS1.2H3
M#+-/+4S<68N.GQ[C>N1E5?0U<0%R=XZCX)S!C(L01+^FEI178!$HZ=L#*J9K
M'.ED!2Y$]%N3X"0@[#6JW2V63HW*&5;'.V>3[[N9ZM6=N*<<FLJ=$PF2<."@
M&P^@PZ6L`RJ,B0ZU`QBJFTOH2ZKEE<PJ6&I2S66R"YZ?C/T;'DB*L,'(OL73
MSZ6MC.KA&R\@C0ZPP9R*(,6RX-%W!2[=WOJ)FMCZR[4F40VE?2UN`\0WV'B&
MX"`[#QX@(`(#\W6%;$-"$A=+E24*<R@$*V3,LOO_`$I0>0OT3%'Z&LMZG&2R
MV*A2JYC!^(3`!>+N$.KS%>%<I=5N.YSWM)69'/DK8P:Q")W*H,):"B$V@N"$
M'<$Q,@8";\-P'7S3'-O>RFNBXQ'UGCR`KB7G%6W1I!C')2>)65#S#L<]]LO4
M[HF?8W(F,6O[9>'M;;!OL&O`CXVMESBUT*,EJ;T5RAM7R[(S9W<2/^4,QL/`
MM2N>_H_:M;5A^.,J%3?:F]!6':DP]+N)9^4*QW_%*Z?N4KJ!^-\N%0]J;T5#
MO0_P+N)8^4+QY_%.Z?N4KK/_`#OWO;F]%/O0<WC=Q(?*%X\_BG=/W*5T?SOW
MO;F]%'>@YO&[B0^4+QY_%.Z?N4KH_G?O>W-Z*.]!S>-W$M3>83CP>VH6\WPJ
M1ZA!^<''<-2'QOS0]N;T4QM2101XW<2(6\P+&RA#G5J=H0%-!<I5E62@(IE4
M(`'%41V`"B)2ZOE?'*R#5'[<WHY%5-VJ!W##.[B5<^F#JNK6%J7:*W:*[9WD
MM,Y,O]Z!9@P.=,L/=K&^G8@IMMAXHNQV]'IU<?CFU[1K2'$$UOF]%4LVH:UM
M+B71SNJT*R@>8=C8W`:I<A`>&QXQ4"_/$>`!JMWQQDM$0&Q^U-Z"OD[5@O%>
MEW$L'\PC&G(;:I6PH`4PB)&)N?8`'<"@`[B;;L^'5G\ZQ/E&$!^U-Z*MG;4C
MZ0HWW<2\*^M/(<G<>L"OYQI:=PJL!9Z7&5IA9F[UTT>P\O$)\I%95@FJ7G!(
MYM]C`.OE>TGQ.=/O)<UY+8T<I_!6%P[WM-^])EGD1HI=5H5K,+>8]F7%"D7#
M9QC#Y-HIQ2;FR-&J_P`/6I1`I/&##%`'2S#E`#%4VVY..OIVR7Q0??+$@F(H
MIM/\X6NY[5.G&P<]<71\B]M<*]06*,_0[>:QY=:_94RH%5<1*3]`MG8'3^UF
M2E8T#@NW6*8O88`W`0'TZ_0N'7]F(206D%L-WSKV]RO`O(BTQ'#YU8-`3B43
M&,(E,.Z93%Y3)DY2@"8^L0$!'?X=;2P2^2%MF"R8;B5)^GYWY>DH(*_6#\P?
MR-,*J;ZJ\]O,I_X)UJ_V78]_M['Z>7@6?Z)X/.KWQOUZ'^IK/_-5]"&>LN]J
M*VH:$(:$(:$(M3T?/_*T(1>A"8N4?_)GD3_8/:O[2/="%!70Y_P4>G__`.[J
M$_M>AH0K;Z$(:$(D_P!</SOR`T(6NA"&A"&A"P/8/S!_(T(5#NB+_.G4+_RA
MKE_FI="%?+0A'AV!\P/R-"$4?ZX?G?D!H0M="$-"$-"%@WUIOF?EAJ;/66>\
M_@E>>/\`OJ_^L'_\S/79R_Z9<3IJH7DC?UEZ]O\`EP9(_M?$ZCMA^#+^R?,N
MQ=_5/!YU[5V%X:/BY%\0ISF8QDB](0@`8QCM&*SA/E*)B@80.F`["(;ZX6%B
M-S(WO,M,YUF2XY%XE8RZM+GB;"E5M3J'97-[GVLYQO\`5'LR^<IFM>5*S.R#
MH:,ES=[[O-*LED6K4A=BB=,>4.&NCJF590N3UB%--*5V[K"S%F1;$:>):S5V
M$@3*.-ZNI%+V.82B#Y"<TV/DKUB:X+%K0JMT*;-+*I*N``P'Y!X:-4P"E,3[
M1`%?ANIW*]9/4->&\92<:XVQRZS)$1EBL&965PMQHW&KF.IDS(5@P4.<+'*/
M7OO1]7W`(E,@F8J0$,<I1,.BP&UQA5I5\;56^N$CYC>6[G%2&8<8XPJDU@[&
M<36T<Q!:+.C#Y%0E[$SBGS]''M:(T7:6:.:.98$6XNG4=S%1'EYNT2P`+)SH
MB:UWIGK9S))FFW;F@52.PG9;C>\-UU^A>/`Y<<6]F=P\C[&XCTH27A(6)3*)
MB<A73KD$O-OL8``LP(A6$1H.9,>K=8><(2JL$JIC6N7?&..:C0[5D&2M62W[
M>W/H.Z/5(R<EX99"FGC[!)0<JS6<)-C.&@"DJ3VA`=@"T6HTQ0"8*3,4];&9
M,O=5)L6TRFT-]B>/L-N"VHJ2$HWRE78"N)I1:,[-QB<>ZKY_C5/-7!F@$D2*
ME1*4>0PB(`BV`HK1&G<4^9ES=EAEF=OBO",)CN36J<$G?,N2V1IES`.#U%]+
M23%%I32,V;[WC-(-XM0`W3`HF`"FV^NT-``$:BBNK(JFI=?>7&XQ>4)W&E$)
M@C)HWA7I^+&R;@V2!8U!V=!XWRK`H@HPJ;&W-"HJ,U6+B542VV522WX.S$V:
M8H)@(T03[S)U]36)X*9=C7JR@\2QYC6VQDPXETG%883N55UTSH7&&KY;%+-T
M6;A(^_=<P;![.X;#I:EN2I4=8"@0O4EUC7.\]+=IK['&1+E9JQG1S(P*=AL"
M6+K%1ZPY!G!6E@<]6"02,Z1C%G"2:R0*IIK%`VP[Z>J8`CK$3NJT.$\X.KIU
M,X0N,<V[J)ZE>E92VRT6V=NW<5#OL>N%%FQF(.T6W*#IU(*E!3N2"H4H;[@`
M:RO%EY"T2S:%H5$+U1+P4```0#NCFV'UG$3C_.B;;YVHY4\JHYCX=^OSJ(W_
M``"83_VU7?20*CO><*Z\L*I6#@Z/B.\(B)BBV*514H\IB@<$3&(#@I#&`13Y
MB\P!]<&FD%06F=)60$<P/\NY<RTADR?84NT4JE(0.,66."0U:MZ3U-PC-NVU
MNLA[2Z8`\$"G530$3!S`&A/B75J_1M`PT'TQ1:EBD)!#IK8W-FS3\,BBE=_C
MI#QS.18.T1$J94"':F*<3@(J#Q$!'1!$$V^GKH%QOA>NV>O2[%IDR/G<BV>\
MU=M<$DU&V-6EC(1`U;KIU`75<NX]JF"*2Q@`Q"%*4H@4H!H"047)>7(=RM&5
M>\91L=VPA2G5C7PWB1W"Q\?/4.6M+]>1]XMKZ286\;'0QE^[1:'B>9--,I>]
M-VZVB^AA)E@1,(QW*((`C04_J5T?99J*=TM:W4>ZELTFHC3&&,LHV'%;)VQH
M5,@960E6$7(5)K;S_&TR(R0I'5%W'>(`@&$FCKK;)9`623'A,4X14W=/O3;'
MXNI]@:V:9#(]RO%M?W^VW,T*UK\=8+%8&C0\N\C*HFYE`K#([A,2F9F=NS`<
MHB*@[\H99LP32",@`T+3*]16QB&/N]HFU(V(V22*!4R)[`4"AOL0"E``(4OJ
M#AQU4K4DMO\`<I9_]CLW_:QUH0J@>73_`,#7"/\`J5/_`.VN9T(5W]QXZ$Q6
MCP[/HZ9K2<N>N`!S"```F'VAV#<WH]H?3PT<2Y-[-!WUY?=;W61:NFV\4Z"I
M;"BVHYX4MKM5(F74S%W-Q$.99.`9352DF\+(UQ`&JB*@&(_=,N84Q`!$-A';
M+'(!-<%D:>2`F*MUE9K/E64<QM#QS]YF.R:3#+B>=7:2D,E+6J6K+.?I[^0C
M&=34AF\0W<OU"G.V=N2\-N?<!`)61"!4K15?6>9.I&6H6-;!FI[7/C58%.K1
MC4'F([RY2D4FM`9)-&L9.14O6F;&2>'>-U#BF=VV%`AP,43\VP.BT1E2(-D'
M)5Y_.G=BKK8S11,1TB.RY1*/,6RP85PO8L**0MS>3'BW-M@F$>NCE.4=P4(U
MK(^*;B8X-AE3`(CR\VBS`Q"=HP@I%>=874`#A]A1:A8O1ZHG%^=4]YWEL.ZQ
M+`I&ID)=E92+L!&",I./`K$^Q(FW7C60`N0^ZG`=9KQR9)<RJ"L;%SRUT+2C
MK"_6?D+&V)6B61XP;'>[!&V"8QMX5^23D,@Y#<Y)LU?D*^R<%,1M88Z,8-FR
MA2-N0Z*`!N7TZY.M<NA=Y-`C6O9V#)+K1+!&S,X]C/+P\<^L:D0N91#WD4A2
MK))`=-/F*"I!V$?1ZPT]8X&E=.7+!;NQ@I!(8#D*<`$`,4I@`P;&`#``@`AZ
M!XZVBD15!$#!%G^N'YWY`:$ERWY5#!L@4._[LQRB8`$IBE$/M8]N_'UZQ7R6
MZ;+L-K@JIDP#D95\\R/1I%Y8R%U39DAH-2;MY\[2T4^;>-7:=RC'U^%,WY`1
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M=?Q[<7+_`+N2'Z+H_DO?O!S_`-)'=V=F\9XEL3HCO+\Q6CG%P%;`<KQ4R\](
MD*)V8&.BF`@H.X*&..X=@[:OE?!:^D4U_;?^DL\[9R9$6@=)XE%>&^GZ\9?I
M4K:@Q8BFYBLD7ZD+E;STCW@%ITTM!D*(`</8*+,=@'LU9_)6^"O^F_\`25/=
MUV8Z3T5*7XEM^#_>M6'X/?<A^6IJ)^"E[<(?\[OTE=(V<F:RB.D]%9+T6WT1
M#?%JI"[AS&-,O]B@(\3#LI]:4.(ZF?@[>[O*.7]MWZ:NG[.30/2>)>7/6BTN
M^(<MAB2*K:D;-)5M"4;0,6L\DFZ@31-TK,L[<"8J`A]=R<.S7S3'_AQ>94VR
M8QCG=T%QIVSDVUZ3T5$6$.CW*=JDV:MKFYN?<+."&$47#\A3"H8#"4Q"J<I2
M#S?6]@=FOIVQWPWO5U>Q\*"`?6=T%KN6S<Z2\'SGHKZ0NACH_N.(WGQBCREB
MF*Y4PE&JO,1=P(;=@[`)Q,0H#QU^E\'N#L.D`.KAO^8+W^%R'784KV8;E`J"
M0!O]87@;M`?2''X==-SQ,-H5+IS'6WVDJ3]/SOR]15:"OU@_,'\C3"JF^JO/
M;S*?^"=:O]EV/?[>Q^GEX%G^B>#SJ]\;]>A_J:S_`,U7T(9ZR[VHK:AH0AH0
MAH0BU/1\_P#*T(1>A"8F4O\`R99$_P!A%I_M*\T(4)=$@?\`]*6"?_N]@?IL
M&V_T="%;#0A#0A#0A#0A#0A#0A#0A4/Z)0V;=0FW_&$N?^;$T(5Z-"$>'8'S
M`_(T(6="$-"$-"$-"$6K]8;4F>LJ+Q^"5YU?[ZO_`*PC_P`S'7:R_P"F7#Z:
MHIY,%XJ=6B^O!M9;96H%=[UOY*58MY>=8(NE$"1L28QCI#X?EX#PX>O63$IC
M[X0V\Q>T`^%$,R[%WJ*]GI'+&)G#)TD]R/1S-E6ZJ"_=V&/%04'!#(+%(`.>
M(G34$/GZYLH"2W5RZ&9EL+6O86O$6E4?HF!,"H8ZI>.LF6_'4_#8JSA9\E8M
M2-9D&SBJ,VMJDY^HIL56,B@L<8]!\0#D7%4C@NW?`H&VKM=,KC2L_5;J:"P0
M&Z5+M.Q+TE48YE(2?ID><^0I7*ZHHW`QA5R).;^]K0H*LHIWK][S#SE-NCQX
M$#09LPY4Q=;J*F>,IFW'IUZ,+E%1T,[L]7CDHJ6MTFDZB[F>(>"E>'GC+`P.
M_CI=F[59O5?:*F=0Q$!,8403$QMUK9E<59JI/-1-DZ=>BR?LM:N+GXEQI8(:
MK"+,(VSEBX&TM*R!T:PK/0,5),XR5",/ML==%0RH$`%!,`!HUK\Z-7)YJBW$
M/2MTZ4ZU6V\W^WTB;M,E?KO/P[5"Y*KPS&/GUE6*ARUQ285KS20.R3!/O$VI
M#E*&Y1`PB87K9F=9IK6A\&B`5@(O"_2#'P$W48N5J)*W8H.!@Y&NDN0`B6`J
M)#>[D$`4DSKE*P(8!-R&*9;8!4$X]IK'UQ5=EL*50_"W3&&*>I&/RV;-V%(J
MH0%QMUKDK%3YZ9;7W)]5F?:AZWDEN]MS^I+-(%54Q4#(QC=7?<2&*81$0S'D
M0)H0*#%7HR3B?I=RA>ZU?;C8*O\`&FG&*G'O&%]=1GOJ.>RSVP147+J1LRU\
M6P2>R:RG(??F!3D$>0`*`)CQ440!3<@>GWHOJ%PMEKC9"ENG4Q&V-BE!O+>9
M>!B$KDNX>64(..<2JL;"F?NG9S@9HFB*`;%2$A0``-;,SI%H5;LL=%W3JMC2
M=@,(V3&<3;Y.9QZ6PFOEV<2<!:Z1C4QY*/KDB^CIR*F&[)HRDDTN\;N4EQ`O
MM',/'4M=,SJKJ\G,%)_2_@3%.+J_7'&3LF4*5O$`2\1511KMU=.(:D5+("ZJ
ML]3JXC*3LF=>$[E3N$%'AG+Q-(@""W.)C#'6S#0304Q(D@Q@%(-"QQBC'N9H
MNX161Z+&8YQ_AR&PMARKEGX]:6K)5'[U:5(=11T=98CAJHBDF*_>G,D0HB83
M;F&#G%QB:UNERY88+(H@KH$RGC4O.JO>ZDD8AWB!D3V&+YR"@Z6(938%^;VB
M@'S`V[=14]6S,J44#(V.$NN;/<R-[J@1;[!F'&C61<S\81-RY:V6ZJ.4$N59
M,!%N"Q=_3[0:854QK6U41'G"NFKEC%9N[$<BTH.[.50O\)(\FQR#[(CR/2\Q
M>/$H[@/IU)5P`I!"+/E?%2PAWF1J0/+N(<ME8ICQ'?B)'Q1$-_0/#5<UQ#"1
M05)@:74P.E;_`'V<5<PF^^)1MS&`W]T4=L!@[#%#QFQ#?"&V^LNNF<X>'`M%
MB7F6@Y4Q.(IB.0J*84CJ*)\UCCS<BBH\RAP`7HAS"([@/YGT;:6M?'UO#0BQ
M+S+(95Q+[`CD"A&,F`@0Y[!&G4(!NWE5.[%0-]_7K3JV9DM6S,@.5L3"`!]\
M.C!L<BFY+*Q(8QTPV()S$>@938.WF$=_3HU;,R+#<R.;Y4Q0D000R!2B%YU3
MB"%AC.7G5.990P[N#CS'4.(_/U(-#1!M2D`&B`J1OWVL5IB)CY%IX";^F62-
M$!V]0"Y*`#QTTUP[/EG%;BM6)NED.GJJKP,RDDDA8HLRZIS1CKV$2BZ-SJB4
M!Y0V'<="%4SR^\EXXBND#"K%[<ZY'.$X>?/X:5G8U!^0GQJFS`JLB"J8E3'?
MMV`-MM"%<O[[^+?PC4;[HH[]EZ$54K'WX<8?A(HWW0QO[+U*A9M8XY1X<"R.
M5\7'#<V0J>;?CN%AC.4?3N'V_LT4*A[&O]:E50S;A+I`Z@+4G:\BV&OOI-&#
MCZS(>'NIV#>=KT=).9QE%N46,JV2<(MY1XH<1Y><PCRF$2@`!,3'@0!H4!)E
M9O*NP3'O2>S*0C2=IS-N%NCKTXCR6)DS+(3D1%MH6,*7PSI$R*;-HQ+L1(2D
M$QA,8!$1'3ULS.GJ91R)K1.#ND6-,ZVGZL[:K6.\VQLV^-:;M*+D\E-4F5M1
M:IN9%P5J#]N@'.!`+L(B)0*/'1K9F=(R968'2F+`='_0Y6J;;*,QFHA[`VN"
M@X)<TCD21E5*_`5$PJU]C`N)*==KPRD693[49N9)01^N$VC6S,Z-3*S!9==+
M/1<^H#&E$L48F92U(6PE]+=U1N[ZR(QS2'\3(V`),)GN1A6*;4Q>^!(R1`W+
MOQU"8YSVV7F+5;)E2A,%";]BZ<<!IV?I`BZ78L:5_%72[:[_`)'AF"EM4=/8
MPLZ^*=F#&1<32DH0AEP,)C"J/,8?:W#5&IE56:%T`6BH+T7/D_%!Q.)K_3MU
M.0#B6PQI1,"?U@"8BQ1$"^KLT:F4/HJ;9KFPAD2K[[>,/PB5#[H(O]$U8JD2
M?+V+@,(#D6D`/#@>Q1H&[`[=G)0^EH0BS9<Q<)DSCD:E@4#&`.[L47LH(@'V
MOVG!A$>/H$-,+--A;IS*D_1[D;'L;,=49Y"Z52.([ZB9YPV2=ST85(Z9J_!B
M!TQ[\ACB8!W'<1`.'9J8>X94F3'M%!@KI??9Q5L(??#H8`([CM/Q@<?7P=AI
MZU^<JT7J<*G^&A8^^OBKT9$HGW0QW[+TG/GN]1Q4NN3^?X:%J&5\5\W'(M%^
MZ"._9>LKF8F:0\V=[T*;;W-)I=1X;BW^^QBK\(E%^Z"._9FJ+>(>\.CT*_7O
MSH??8Q5^$2B_=!'?LS1;Q#WAT>A&O?G1Y<IXI,4#??!I@[^DEAC>4=AVX;KF
M_)[=;F39P8`]T7*.OFYUM]]+%/\`'^G_`'0QGZ-J>MF9T:^;G2!]E;%12"E]
M\&EE[U)?E$]@C!V43)S)B7=;;<##O\.I,G3`8VB"L-[O,UKVBU`$'-P9%2OH
M)R#0H_%^04YF[TMLJKG[-#TAB3T6078O[E(.UW(@*WL]ZNJ8VQ0`O'8``-@T
MYEZGS"'/<2:DY$Q[ARBKPCE'%.X?P_I_W0QGZ-J.MF9UM:YP%H&E9^^ABG80
M#(%.`1`0W&PQ@AQ`0X@*H@.V_IX:1FS"($T*+ICW^L8JG>;L.=.>59YQ8C3F
M.BVF>9,HN;MRD]&&DG$?'`!630BHN139H-P[`0!,!].^N+>L#PJ^NMWJ2'NW
MW#R$*ATJ6XQ(I3YQ?0>FC%Z"2;"Z4EV_*FESK+3<4(&<E(`**%$RQ@`#*`(A
MKIR9;+N`V2+(`@/`JQ6#0RGBQJ!"CD&BHJ$+MREL4:0`+^8`2$=$(/L;>C5K
MGN>(.,0B*4??>Q;Q_P!T:C<1W'^$4=V_KO4&M#1!M2%D,P8N#LR-1ONBCOV7
MIH0'+^,%-B%R)2SB<1*`)6&-$P;E,/-Q<FX%V]6F*U5-]541\Q.^T27Z4+.W
MB;M7)AP-FHJ@I-YZ),Y'DG&9@$I$SB`G(F7?;E]&FLV2@JZK/+.-2)IK!?Z@
M#5!NV;(N"V.)%P^.1%)10ATA5$"'2,J(F`H!Q$=!4F^L$XOOO8M_"'3ONAC/
MV1J*V(@<PXO`1#[XU'#81#8;%&[AQ[!_37;H0L??AQ?^$>C?=%&_LO0A#[\.
M+_PCT;[HHW]EZ$+`Y@Q</;D:C?=%'?LO0A9+EW%IAV^^+21^!.Q1O-]-R;A\
M[0A,[)64,9N\=7YLCD*HBJO3+.F0"V"+$PF&%>[`4.]XB(AH5%Y>627.:8.`
M4$=&65<>,>EO![=_?*6P7;8[KYY)NK8HTAHXHQ[<$MP4<"/VT``VYMPX\-.`
MANK/(FO<T6G1)5IQS#C#\(]&#_ZPQO[+TET&B*S]^+%_X1Z-]T4;^R]"1K0^
M_#B_\(]&^Z*-_9>A"'WX<7_A'HWW11O[+T(0^_#B_P#"/1ONBC?V7H0MR9@Q
M<)MAR+23!MV$L,;S?^%#PT(1OWW<6]GWPZ=N/`/X0QG:/`/^Z/2.A"H_T<9$
MQ_$,LWE=7BLH.I/J"NRJ9'\_%))*H]\02'1.51/?8N_KWT(5UOOOXM_"-1ON
MBCOV7H0MOOPXO_"/1ONBC?V7H0A]^'%_X1Z-]T4;^R]"$/OPXO\`PCT;[HHW
M]EZ$(??AQ?\`A'HWW11O[+T(6Y,P8N$VPY%I)@V["6&-YO\`PH>&A"PXR]B[
MN5!+D6E$,!>!E9^.,F4=PXG`KHAA#Y@AJ<MKGO#6`ERBX-<(/]5>=WWS*)]]
M+O?C]5N[_'\]Y<WBV_)X/\3CP?BN;QO^</$^QWO9WG#?7I^K.A'5NCU6'[48
M0WX4KDV)6Y^(J(>4CTPX%S&'79/9)QI7;5)L^MS)B*"LDU!9%-)2,B"\I6H_
MI<!*&^P\NX;ZXEY<0X`98K;=@"(^&5>P`]`W1^D!E$\!X_$Y"B)0-"-#!OL(
M`(E%(0';??7/-86I[K,HE)2]`_2&BFFL."J$=Z5L5N9R:%9]XJ/A$68JG**7
M(!CIH`([!MS"(ZE!9->F#<>F#H/Q\P;R5VQ1B:L1TC*,H&(DYQ%FT8OIUZN=
MH6((HH)!,]!VB<H%+OPV'1`!/70%/G3H<=$/2&=-V8V`:%X;PJ+M4JT,DB+)
MDF0YE':G,F'?;`D(@5+<W#CH@C7"F%2;E-Z4>B/(<&6VU7#='E(MZ8\3'.2P
M@-2JGBG:I"\C9\B0H.C&+[)@+RJ%V$-]]$`EKTZ"=$/1ZFBNO]Y3'#=ZL+MR
MJJ:&33*!DU53+N'0&2`R:*!0Y53\"E4*(;[!IP2+@^DUKD_B;=&$LP;/H7">
M-;,U>J&,5W$EAE0,T;'Y73UM()'%,B"!MP43(<%%`#;8=MM$$@!E7.+TI="K
MBUR&/U<1X_/97E98V-_`>Z%4TW,,9Z[9LG0H&3*@JD==D<$>`J'Y1$-P'?0B
MA=Y/HMZ/"I))IX"HID)E(RQU3QC9(A4V!"),1'Q)06;H2"@"5L8-N?EW#0B`
M@B)#HVZ,8AL3XPX3QI&M@?Q\6!I.,08-E922*4K5BB^>D2:O#*N"G*4`,;F`
M`#MWT(AE1CCH4Z13*&;C@3':2J978>*90[!@!6$HJ4Y%TVB"::2K9),I43CR
MCL).'#0A=Q;H;Z/5GIBK8&H)'*@G4%P2*9E!,XB/,3O$2[)G*81X#H11PI6C
MT&=(FPK(8,HR:PF,<CE2$9K+D7*4$4W)3JI&$3D*F'+Q[-16QGJA`_03TB<_
M?JX,I"S@_,9=<\6@!G!Q3*FH=0.02AWG+N(!L&_'0I*FM$Z,.E13K6SO4'&"
MZ"XB(/"V(YA@12&;<Z3B6LEQ2<E#9/;D`K0FP]HZ`J9PHCN>=7,'H.Z03%Y_
MO!8_';M_:9MP#;<1^L]&I+-1D"2)="W1XLH8J>!\;@`")0`\0W`XF#M#;N]5
M3OPRK)7KK<G0MT>**BD7`V.><O;^U+?T=NWVO7/6I*/Q$.CO\`^.OW';?H>F
M*TZ$67H3Z.CK`F7`^.S%Y!$QRQ#40(8/S(_:]@V^;KHBI"*-T+='I%"D-@+'
MIRF,8!53AVQDR``[!SF[L0`1TT(D_0[T9@<Y3X&H103[3EAD.42CV'+RE`#$
MYMPW^#0A+B]!'1VJ4#DP/C\Q#%`Q.6)0,80-Z1`Y!Y="$W;'T']([2%F7S;`
MM"1=1D3+2+!R$.VYVSUK&.S-UP+W?*82"8=@'A\&A"K/T&]%W2_=.E3#5JM6
M&*-,V%S7YYHYDU8-DB=9N6U38`F9!!(B`!R@`<`WX:$*X'XA/1_^`/'_`.XK
M;[#0D:EI^(3T?_@#Q_\`N*V^PU)8J%'DCTK=`D5>8/&\CBS$S.\6>-DIBN59
M9%BE-3$5$'%*2D&3`P@LHT9+E,0YBE$`VT4(Y*2)]+'0:]N$GCYGB[$LQ>:]
M$,[!)4^+,R5GH>&D/::2+^+*<731J]`>9(QR%`^P[#H1"F"=(=$O1NH:/'[Q
M-`<+KJNSL5"PQW!55&>Q'"J'(D<ZC<4Q+RF#@([Z$(?B3]'3<"F;X#HJ2B[Q
M/Q"3B)+'G3!QS`=TH5R1(2)*<H%()M@.;<`[!T(`"1271GT80T#+SLAA3&K2
M-AV:TM*J%;HNTV'N\JBKDSX&O/S%2*D?;EWW$-AT(HRI-2^D3HJO4-7;O4<,
M4&7A+C!MK!!2[6*$C1["OT0<LES(+)AR&69K$W`@<P*<P>C1"*;3`Q3E2Z(.
MD!`JBC/`-",9X0L:N@K74E7)XUN)A6*9LLB)DQ%4!V'8`'@.E!2UV:-:8UNZ
M7>@['\4RL-WQ!BZO04A+L:^W=O(P$S)3LJ8$XV)=G4*5!N\<J\Q0*80W$`VT
M00)PC3&'"I-)T#]'XE*)\`T-,XE`3$&+0,)#"`"8@F*`E,)1X;AP'26M&!T$
M='P!L&`Z!\^&;B/T1((Z$)*[Z`>CU<I-\#4,A@,7NSIQ#<HIFY@$#E#DY1,&
MWI#3"S386MU4^Z3.CCI9L4MU0-Y7!E!=$@NHRP1303PS43&20K5>$%CCW0;*
M'`VP@'#AIJJ`LQW5<'\1#I`_`#C[]QFWZ'HL6Z$J%J?H1Z00(<0P'CH@@`#S
MJP[<$B\0XG$$]P#;Z>I":)%9\44"!*3CT,]'P'5(;`./2=SLH!1B&2JSAN(;
M=\@@B0ZH%YAVW,`!PT-Q1E,LD1-'JA6"`Y0C0E2?0CTA*<^_3]CY,4C;*`:'
M:''8`W'D[L@[CJ5H4T#0$:X9%DO0ET?&`#!@#'^Q@`P<T(V*.PAN&Y13W`=O
M1HM-W-"CKPC@Z".CXX`8<!T$!'T!$(@'#AV`4`]&JG$$Q%2UM,6@K/X@W1[^
M`2A?N2E]324D0XZ#ND)NF/=X$H'VS<!$T,W/R\I#&`2\Y#;#IBI<V_UMSJF/
M0IT:=+%LQA?G,O@F@&!/.V9FZ"1(9J4B*49?YV+3`ABI%./>IM`,;?\`-".W
M#;25UW5U!Z!NCW?_`,@E"_<E'ZFFMXC9*S^(-T>_@$H7[DI?4TE!8'H%Z/A(
M*0X'HO=B&W($6D`!_,[!N&A"R7H'Z0`*!38(HAP*`%)S1#?<I0#8``2D`1V`
M.T>.A"V#H)Z/P_W@Z`/PC#-S#\\1((CH0L_B$]'_`.`/'_[BMOL-"$/Q">C_
M`/`'C_\`<5M]AH0LAT&=(28E43P-02'3'F`2PK7C[)@$H_:_K3`/'3%:IG>J
MJ*^87T<],5*Z6K=-UK"U(CI!*ST)-NH2';&*@=><8HBJ4ADC`)@26,&P\!WT
M+/"B.]YU<AKT%=(8.FBAL#445$C)"4WNMN!!6=IB@NOW0$[OG,"`#V=HCHK"
M;/6&^NS^(!T>?@&HO[EH_8Z2VH\.@CH_```,!X_X``<89L(\/6(DW$="%G\0
MGH__``!X_P#W%;?8:$(?B$]'_P"`/'_[BMOL-"$/Q">C_P#`'C_]Q6WV&A"R
M'0/T?'X#@2@!Z>$,W`?H@4!T(3-OO0MTCQ5+N3QG@6A$<M*C9ET%AB$#`11.
M#?"4>0Q#%-L/KT+->_\`QW*#NCKHAZ4+1TQ8:E)G!E"=N9S'E>3D!-",RE6(
MA'M@2`0(D7ZP"!\W3R++=@("*M$/05T?_@#Q_P!O]A6WV&D%U9>YF0_$)Z/_
M`,`>/_W%;?8:$C6A^(3T?_@#Q_\`N*V^PT)(?B$]'_X`\?\`[BMOL-"$/Q">
MC_\``'C_`/<5M]AH0M#]`W1\<O*.!*"`;[[EAVY1^B!`'0A%AT!='A!`P8%H
M@B4>8-XI$0W#B`_6]H"&A"IETB=%W2O;(O-[6P8/HL@2%Z@KDDP,>(;IG2("
MI.[+S)IE$0(&_P`W?0A74_$)Z/\`\`>/_P!Q6WV&A"'XA/1_^`/'_P"XK;[#
M0A#\0GH__`'C_P#<5M]AH0A^(3T?_@#Q_P#N*V^PT(0_$)Z/_P``>/\`]Q6W
MV&A"T/T#='QR\HX$H(!OON6';E'Z($`="$G4\O\`Z.S$,4<#4;8P;>S&I$,'
M$-A*8I0$H@.K9+W2Y@>PP<$G0A34J+_BA].?WR_!_>HJG<_CQ_$?;W<WW^+W
MXI7O[PGUG;X_VN;Z[;TZ]-UZ9')^!:X5QX-_[BX?DAF#W/U\!Q]GKAR2`_N=
M$]FN/C,EV'AKYT"#$T<&>&=;[M4>#SKW)'B&WYX-O_;UR)$QL]HFM]49UIF2
MW3)1:V$5S9),X(\A3`!C^P`@(AL)@V`1$`W`-QU<X@U+F/N4X^J6^/B7@]UN
MP&9>I:TVZ)I=!;R^*>F]J162:6=V\B1<9+9RAGLE:X-)HU?&EVK:)0(9`2!W
MYEQ.'(`<11--%2B;E>#1:;#AXD'64ULFY@N%@R#-9LJLS1L>U&]8"Q1%UN\Q
M]8GP>U5O*RTVO8QA"U"1E9EW(`88YR]0.@(<AMA`0TZZLRJ-WFU1;0%&:-1S
MA/13&PS=MS:P?8^)@G#=?JT3%3L'%NL@W:0-?[;D!RW;H'(JSA(VRHQ:SK82
M$!KMN(!OI0*75YT*PC\>FZFLBYWZB+ID?*5FK#NA#G%DI@JOU_(;N7:T^!6<
MUZHP:DC)5F,HTFSNL&Q2GTACI-XY,>1'[5ON&ILEN=4K6G4M#7F+E%C&$H=&
MQ!A['BLQU&0.*9C!3S)%9C*I6LBHS&0.I";G9520I+YV]@F4C"-*`GX)T4LB
MDU9._$G*FL;D'4Q)><RD9[!G78L:.7K7E*=B+#8<MQ/6$%+Z<L?T6)AH6RI5
MEY-QD"SN%GNY[D5@%2;Q(EE3(N4%WJ3D5N<I$CB`Z9DN%,1!29,#S``Q76KM
MNRK<,HPUVB%LZRO4LW?9@O&4ZH]@[7%8NC4\)-#0](QXS<3C",@YA-\H51TS
M28JN/$F,(CRCL`HR7"DD04XQ69&JXXR=@OIAD).T=1%Y@LCYPQ^MGFU3<3DY
MFXQ]?(ZOP]H=1L92Y*JM9TD`$W,*-4G)$3-C&2,('Y0YAB9;A&.0*0$2!G2N
M@W#J8LV;\XY,O.3IN(=XGC<@^Y\&1\->0E(2JU=Z_IN+'=J.XKZ%7<Q^1(YB
MC)G]W/GJOB5S>QM[6JXJS4OW%['](>)++BC"=41M=IMEPN=PK]?LUJ/=#'*\
MA9^8BFTA-1:9#*N%4BLI!PHF!!V$.3CL.B*>I=#(K@IALF0-C!L0H>UMOP``
MWX;AQTE>T66@+!PYQY0[>41X]G'?YOJT*2HO0T3!U]]1BFY=CX!PD4`X[@);
M1>AX\-O3H"IFU<'G"NE(.TFS%0RBQF^_*0%0(<Y2F-L``<4RG%,@[;"8VQ2^
MD0U)9@(JHV1^JF(QYDVCX2CJ/9[;D6SPSFU.HBNM(]XK"5=FY407F9!=Q(M6
MJG."8G(DV477.3B!/1I.ENFC5M@#NIZP2N4X4!-Q+KFQ@JHSC4X.T-+BXN%]
MJ3ZH/(4$K-"ACY,SR0LTU%E<'6C:Q,PYT'L<NKRG7;N4^8A#\Q"U=GSHPBWQ
M\277Y5=E^@<:QB+KWQ)FJ`Q+8*@RFT29?>R4?$1,TR:1U@KKN-21='1M$*+Y
M1^U%S'N47*7AR.>9!8@CL([`=0G"-+:-_B3%_DD@0=3N>E=7.O5[$X9LI*-`
M8\O.1;$WICC(=T84B*CWDA3ZOXI1HUD9B+EY6'E>XFWK=PDS.W07(8S=0#B3
M;CNE7.9,;$%M!A_PH6C7MS%14?S"\5!/IL8B*N4MCY9]1XF[92;1+(M!Q_,7
M>&82[*,L<T\DFRK=VQ:2*(O"H(K=R=4I>([@$FW*8[Z38TT1IHX$:]N8J1E>
MM&CELV?,=1=>MZ<]@2GP]EEY.9K;QA!V"&FG3ENT4JT@IN28#Q3=1,RFR:'.
M40!01`=J)LITEUAQ!,,BL:X/$0KA4F;/8Z[7YU5`K5>7KD3)*-><AE4"/4"N
M4B+$(<W=J<B@;AQ#?TZJ4ET;>(&J=G``V_@[.?,_K6[T(50/+G,`=&N$]]^,
M38`^C:IH/R]"%=W0D:1!8VTXK-J7[B\.^OFL7!+J9B,YTFM6F8M/3]BLV1JM
M,0<;(KR+]""EWZECQC`$20!J]"T)D$RA%%4BB<X\=N.B*>I?&@A5E?5S+41+
MY5S;7XK($/=>I+IMHN7;_,0U7E#W.A56UY7MT@2@1TDH"*)K#2J,HU27:@H`
MEW."7>$`IC6ME%PC$053A9,#D3OK\5/Y+LL#0,:W;.4ATO7+JB@(JLW`Y;77
M[$O`J4N/&UIP<S(1S=_%5=E-IJ-@\0BBF9RDH(;@.^F9+@(F$`D""8"J*9]M
M?9!;5NGUK,]TZBJCCNJQ.:ZMC*<J3>XS$E<,E5C)5K942,O+V`BI)_(M31"4
M=W2KE)%D!E#B58P<VSU+CE"4:$_ECWFS3]EBNIF7Z@HW-:G3_1G.,:#`15L<
M42955H<8G?VTH>M1<Q4UICXRH.Q4*\?MW6YA$B9SB)0CJG9Q!/?4?,YZ\H-Z
M_!3+G.5?R_#PV'PZ2J)7("WLZ)/UU6M0SJ64E'"<83W8-7L"S]*4\>DU333[
MD2&4YN!J75`B*A,!<PAM#E.-;99II]I:9PE)W-5FG+1ES+%)LM%;*O?=C>`9
MMA&)3B4'1T#IG<#N"2AB$*)M^7?;B]2\TQ$5DU,ZN(CPJE=4ELO7*!S3#RT1
M<GM&&Y=-5LAZ^NVR!:_<%GE+G8D)YM+'L-6@W1I^)0;)F=G8I.V29#%'Q`@/
M!:E]40@29U41"*^L0A3%*4IS]X<I0*=38"\Y@``,?E`1`O,/';T:I7<%`@MM
M":*5.0O*!S`0.<H[F[.`[[<-QW'4J&MM$@"*K?)<X:R(@O+GIKSEBC&MQZKX
M.XW2,B9IWU)6*23BC$=KOB-%JW7R)J*H(-E#$*84QV'L'UZ\]B.TV&X8"9Y)
MLGZ);YW!<R;?)4EA#HQ!&;C5H@ZP.G@3'*&0V?L"`";W=+B41WX@&S'<1#;7
M`E_$[9P372CK01EC+A_\191BEU+RR-(W6\:V/U==/*I13#(3$XG`0`@QLS[0
M[#L'];Q[1UCQ/;K!KPPOD/(HRNEYMQZ8Q.YUD^-O&O"[K7ZJ;C4^L6DW7!F3
M92(AY?'!84X-$I5>I+SZ#Q<?"3#9PDT\,=RF!2B8A%#`!M]O1KY->_B-<KKB
M4LQ>6!X-%@QS_36&9M%<V.@QLV,,PS?:5P^GOS4X>171J74G5%,:3J0@4EMK
MB+F3I(;;\QG#YP5I)\@#ZFHZ^E7'XD85?Y@9*ESP8Y6L\SRJ+OB\F>\-#7@Y
MX#QTKUQIEZJ>08)G9J=8HJQ0#YHD[0EXYTBJV.FL4#I\Z0'\2@H<H[\AR%$-
M]AU[JYWA]^IDFC=]$5WY=V?-]4M*?Z._=EW#;MVX@("&X[&`0$0V,'$-=UC7
M,:&N]8+IRV&6P,-81NI*:3.MN3CZ"*&^<4FP_/\`:U)I`6.],+W-(A0J+^7S
MRIXER(&W%+J'STW-L`<3ER;8U=R]GL<JP!Z]PTH4(E$,$2KX![7$/5OQ^CHA
M0M3)S2+(C%9TE)#0A#0A#0A#0A#0A`0W*;^9$?I:8H5<QI<(!>>_F7)BITE6
MT@"`"-LQX._P!/QQO4/H#1%5ZET"*,GG5]&X$7%LNF'*4Z318`,``;EYU^`@
M&X`;CZ]$4-E.:Z)A!=326A#0A#0A#0A#0A#<0[.WYNVA"9.2Q`,<9`./$2TF
MTB/I'^LCWL$=M,*B\MM27`5P4!=#I1)TGX),.P@CCZ"YMNT=V"/UO9Z_@T\B
MSW>4X0%%!5L3"'T](!=-C"-"VTE`UH:$D-"$-"$-"$-N;@':(#^1H0J(]$:9
MBM>H4!$./4+<A]/]-)\&A"O=H0AH0AH0AH0AH0AH0L#V#_D[-2;6HO,&DKSH
M[L?OK=H?\X?WGI[/Q,.SL[==F'_\9<36MW?Q%4CR0C%-$=?@@.X!US9+3'X#
MDCHGF+\TN^C;`_NI8^J?^5=.ZU:/.O<W\Y\_\K7FL/\`_%6X>JY))%,ZI`!,
MHG'F`=B]OH[-:E6FNM6D#@NV+&M%47[DS]=R(`U52<&X_IM%$@EE!#;L5'8W
MIT(5;NJ>\.<+X>F+K&+U^,ETY2#A0D)Z"5FX5F65?H,TR)Q2+Y@LT7=H<H)E
M37[HAOS.W#4EB=6JZ./,-P\XNE[H56HN1YJ;A4;^T833FI[5NR9#I2T@TL%#
M@G);`15U,'3CP41'E`$$S`7G]D-"4<B@[!?F74\M.Q2OU!0<W6KYEJ5;3Q(9
MA4DTD<:4-TIX2@N;M(+SXO'J,VR`A$W9SJ"(ARBGL4!'3*#K$0LDX@O@[<4S
MYKZ[:)C=EEQY3,.9&RB\PW7;#+,[3%UAK+T28=Q<DH%@J\5).9..)[YA7BIF
MYDDTR>V38%#@&K8$Y:U3$#=@D9>M.KL%K_9[K7)AFSK6,,/VZ$Q9'U#?+[:X
M7T5W,9#>[U)U0\A8'[%5/P*)7A"<@!S[=FD6T!M85\EW*)JH75E?,,PE7Z=0
M)H:ADV<LF2I*]Q\9C>/I#5SD:`D,:,6,K:XFWPJ$ZV^+LR2.D4W*J@/'("0W
M$#;[`G-)H%52T`YZU)T'UG87N.1L;8YQY6[/:Y;*%;B;TUGHR`CCU>NIG;@:
M)1O;@TFV/`.%R"**8M&KPX&2$!$-M0+#`FJA281:`W5<U*MM53JKK1B9EY`$
M2/-F<<59="-`"(1LK)>$%Q(QB)]SM`4`1VVWUD6Y/5,W(DB4055$J:8&.L!!
M6$0)L(J\A2D[T1^NV``WWT(1AAW'?YGY`:$+0I1YQ-MPY-M_A]KA]/0A4:H:
MA#=>W424#`(EP)A3F#U?PFO0:`J9OF\X5SG3,SQLJW$3%35+LH`;;*I_FD3;
M@/LJ!V[;#\.I+,O-#K2PQEO+MDI,#BO%"+:P*1Y'E9ZC65M<TVQX2L,4^*=F
M9ZP:LY(+G$*-DC?I!8Z:2H+>T(;<9,<&NBZI!87B$"4J9=*V0F?41FS,3RO0
MDR_OW3I"T!G95I51N_L%ZBHERP?R$G')LA9PHR1U"("LWYCJ-4$N;B&KNL2P
M`!""@;N7$EP,2H`I_0+F2NY<Z:)V.0@:]0F>&8^)SXR8R+@\]`Y+84F#J+V:
MQY+@W31%U(-X9$2'6;["H03"'HT&\-@85H%V$:J%W[!TI=0>";1(3>#$Y[/:
M>2<)L\&66Q9CM*;'(L&N6\6VY1UG>V")B@9N8.&^."J(H`U`_*B4@&V#<;1.
M;9;#D@&,-/&K(.B1"*CF)Z'.HRE05FZ58NM56Q87R[:<=7RS9@>S;@KNJNJQ
M!0D5;HMQ50C0+*O)"0@RG8J`Z3`Z'(8X`(\H/7M+A,^D`>&*(.LPA0K"5^@9
MVLW6+DMQ=^GA%/`-SQ1!8>"ZN+P9.4ED*G89VP!9GE=0BBH1*,J[FSE2;E77
M$$R%,)PWV#+/?K'VMQ:I0@Q>H,!&)1+0K-LT!BS01;-6C02[J-V[)!-FBD9<
M3"*A.[0`Q0V#;?5*L6MM_N4L_P#L=F_[6.M"%4#RZ?\`@:X1_P!2I_\`VUS.
MA"N_H0AH0F^O'N!5.H1N@H!E#$2%PJD.S58PG=I*%.U4W17.(CRB80XZ$*GW
M4MU2T'IMG\?,+S7+BI&Y`FBU5*:K[>'<TRN<P(HD>W)PN*+YC'L$5TN[(1%5
M$0.'`1$=MC!R15%8YGKE1^EUYX,994;X:95Z_E29VQ7'K:UQM5BF]!;WU.*)
M,(PSM=`4_=*\RFX!9!1),14[[<>41$`++K,:(J$1'<4(1/7O+Y+J=0LD9C5Y
MC-63?9[K*]+RW")M2S<OB;O`0EJPI'N'"18@SY(RRSD1[TY5`X`(:G9;&.51
MB80R)XX8\PC$E\Q4-LR'&WC']QJN.*-:IZ'D*N5BG87%YC&T@><Q*HZE)!_;
M8:8G5G"3=551KR%'84QVW&)!%`%'A0G$&G*G)^/QB9Q3&=^;8[R0SO"=FDJ%
M]YM:GM'&:XN:,Q3E8\ON]:8\/$59U756DBY.DL8WAW">Q!-N``:0:Z/*B.E)
M,']>M$NN'G&0LH-E*[/5Z$E,D/F24<BV;/X%#(EKJ=>78)+F%T63E48LA5.<
M`-SCL;ET.9`P;E0",JO'5E4))"!E31;Q!"=;#+(HA%1K%5(LCN*4%-H)HG!9
M2&Y-Q6Y@,43<-QU%XH)S>$4VFD!2\@0R:"*9@V,1),A@YQ4V,4@`(=X(%%38
M0^NV#?MUE-=%2WHW20DK@A%#%()1YAVY3;;E`0-N4!XAQ,.N9?Y%\G`B[N<&
MPR`()H@:E\QECZ8KA9.H7JUSRTM4D@D^S0]IT?6:\Q]X+*.8:O0ZSMPX15`$
MDA!%V00$!W'CKY'M)LOC-YM.#9D#'Z(XUYJ_2-:284%<4,56R/!...ZOJRB(
MJ*F<?%MN(',K[1B"('`1$F^VOD=_V'QV4[6-9,I=S!TEYR9AI!B!X:4#XSMO
M*(^.R`AL)1[U.LH&4)L8!`2`*FPF';;Y^JG;'[0:CU9L8<UO&J>H.YI\.%4I
MZN[;(XME8BMOVT](/SH_'%LQF(=JTD^^6(*2;9,J:@B!0,F!MM]?.L2V4Q^5
M?&S'-F%K7CZ(R<*8P]\86?%Z55W'INIW*Z[527ER1-;>B4$FR\1XA=8I^`@G
MW@\PB/P[:^F[,76]B<T.#H<"Z5TN&K,2/#2O?GRZ\+Y@QA82S,<O;'D>\33*
M]A9]9<*R<B@E$[QLT!001$_$Q2@&Q0';7ZDV6D%LIMNBA>JN?[ML*BOH)CDC
M),D"GX*"45%"\PF`BJIC**$*)@`>0AS"!?4`:]1.AK#"I=&,:4NV$0W]`:K0
MDCKB00#B/=+%^>)0V#YH\HZ8K6>=6%17R_#%-B7)`E$!`_4?GM0H_GB#DB>(
M!@^`3IF#YVGD5.3A5\T_K?\`J?RM&162O66=16I#0A#0A#0A#0A#0A9#L/\`
MS!OR-"%Y^>94(!TG6S?A_"K'OTYR/#0A7NC`$$628AL<K!F8Q?2!1.MQ'X-"
M%U-"$-"$-"$-"$-"$-"$R,F@(XVR$`<1&D6K^TCW3%:KG?AE0+T0"!NDS!X%
MXB?'T#R`'YK9@AOM]#3)H54CUE:TW9\_0%TA6CN4WJ^F&HK.:U@0VX#H26-"
M$-"$-"%L3ZX/G_D#H0J*]$O^=^H3_E"7+_-B:$*]&A"&A"&A"&A"&A"R`"/9
MH0@)1`!$0]'P:DVM5S?PRO.S_?6_]85_YF&NUE_TJ\]^HJ>>1Y_67K_'T?CY
M95X^@?VNA^S4-KJ6,AS#Y0NW=JN'C7NG^<^?^5KSN'@]56X$67+?8?4/T-:5
M5$(``[AP'0B(55NJK#RV=\6O\;!)O(E23F&LV5P0"@&]<>(O$BE'D-L!B["4
M.T=2`,%B=7PJ"(_HE+&?$DB=U>`_I&7<M9/CY5%NB3V,H@\2FF<@86_Z:,U!
M85DP-Q`3Z(%+<H43R'EX*L)BB6.)L<'9UHBBU3'-VA+Q#)24-:ZU4'JIH5_`
M+%03&/FS1Q4QW`P<?1K3)(#8&N*R3V\J.8)]+=&V3EJOF/%[G,KE3"62WEPD
MZS4T*@T&?J%CN<E[YC5UY$(_Q1HFMOS]X8IC&*<H[&WVU87-M`Y56`;!;DH]
M"XDWT/9`F)9W?7686;?*XL,/KL+P-5:A',+-A]!1L6>?1YF0HKQ]@3$I>[,7
ME`2\`#07M:%;(!+EU,>=$,Y2KC4[].Y#=6F^INLX3V2IE*#8QT?;;!F2"80B
M2U9W8D3B_#(,2\$^40Y=M1#VPW%I@>%-6N^7W<H&7Z>F;3*S:/A,("*X2-=K
M"$/<K1X1XHJ2(F+,DS(H];-RFY.4QMA#<?3H)%EWAX139ZPWUZW(=G^3X-8E
MO61[1^:/Y.B!0AL/J'0B(62FV$2B'H$W'A\'Y6B!0J)T1("=>W44</S>!,*;
M[?!:+P.W#YNF(Q5,WS><*\:7U@?Y/0&G`K+$(XO;JJ=$2R5;)$7P6W^3L'ZF
ML%HYRMEC>0_R=@_4T6CG*5@;BT$>(_-UT0^@5U+"X<H[ZQOIV]]);AQ`.'^3
M<=$8TK5*]1#8="M3?MO]REG_`-CLW_:QUH@41"J!Y=(;=&V$0'@/NJ?X#P'^
MZR9]&A$1N*\&PZ$HC.%C3@4UL?ZP/YD?R`TD+S"ZP^AJ=ZH,E,K.WR2ZJ\&:
MF1-&EZN>,2=M5V\+9G=N"R1YSME#)R;A1^#,Z@#N*:)2^C6QC@&P.989OKG?
M3I6Z/7C9E(M?CL9PWE<XQ>;C-V40U92)C0$4W28U?O2-04[U<ZZ@G-VB3E*(
M\-2MC+O*$-T)D#T2VB39UR*G<DNGU;JEBSF[J<:UAFRLBRJN?T$U)1J[.#05
M!=U67.XY##^9'T\-%H`EW!H3@2()B,?+YR0[J\>UON;4;)/8YH-%QGA"6AZF
MQ:L:Y7<8*"I#K6I-*/`DDZ<F5$#=YOS<NDUPC`9:=*"#7X4)PO\`H<S$>96R
MFCG*.4ZBE\@$OJUM4J[-*H+L$*M$U(D>,85B5%,[=A%E,!@`-S!MZ-M%H6:/
M4@B!C'*HZG^AVUH2'190T7]AM\54[]?I3.E^)`MF[:\5!_:Y"XN8&Y%09)()
M0MBFY0ZD>7D(":9?9V#1;`:3E3#8D`U+V0;I`BJX4*B!$0,"!4DP*4$`V#<R
M8```4I@-OPU%U+0WZ4([Z`:8_1BNN0G(0I`YC`0I2@(\1$"@``(CZ1$`UE6X
M$06VP^H?H:2(A)E>4%$]Q$!YR#MZ]A'T;<=0=?9,@ZI\;4,Q-:IF$EP`J5%.
MCUNV7G>K4KA$JY!ZG[.(<Z1%@`!K-;#F`#E,`=FVX:B_$[G.@YS>2T0]0U\:
M@V2'--J%>XKGGKE?4W.$6T%7L$3,6XCMZ>`I;<=9W.N%Z<&F4R@\P><*$^Z,
ML1;7'<185J'`?ZULB[<>;W>UX;!N`\4=O1J]]TN`EG]TR$.8WB6/JH7F[U:=
M`=`SK?2Y;>LWTE9(NMMHUE$MBD3:&$JARIJ"B5+E$"B.XAZ@U\^Q+"\.O-];
M(;*;RW`>HW+P*;+H"\0$0GEA3H-IE)2B9&TIL7\LP$%/=R**0-Q,0=P+L"8!
MQ$-=J[[&7"YOY`%&8,\S5N=<V-I@/$K]QD1'12*:,/'LXY),A4A*B@F02%3`
M"@3F(4-^4H:]3(NK;JVRVI5$!KH`+NAN8`'?FW#M`.`_,U8M;3R1%&%^M-\_
M\C0I1"YZ_I^:;_\`(4TP#%9Y^141\O<!#$-^_P"4%G?_`/RE:A_('3@5G5^4
M_K?^I_*T9%=*]99TH%:D-$"A9V'U#]#22B$-A]0_0T(B$-A]0_0T(B$-A]0_
M0T(B$-AV/P_,&_(T(B%Y\^99_P`$RV_[*\>?2GH[?Z&B!1$*^S'^C(["`_M0
MQ[!W_-K>K0FNAL/J'Z&A*(6-AT)H:(%"&G`H0V'20L[#ZAT(B$R<E?\`DYR!
M_L)M7]HWVF!2JYOX94`="_\`P4,"_P#W?P?_`(`E^0.@JF56K8&[/GZD`ND$
MK#L#YFH+.2(HHP>T/SOR-"41G"UT0*:&G`H0TH%"V*`\P</7^1H1$*BO1+_G
M?J$_Y0=R'YW?$X_,T0**%>C3@4(:(%"SL/J'21$(;#ZA^AH2B$-A]0_0T(B%
M@3"0.8=P]'9H1$+3O@-[.X\?6&WT]2:*57-(U9I"\\/]]7_UA._SOQ,=M_HZ
M[>7_`$J\_1N?BKSU@O)NSG3;-DV3Q!YD_4!A&#R;DBR9)E:GC>',V@23,^KW
MCKO47#IFW,JF(;`(\0'LU6+VU[Q$&(JJ6GJQ`C'RIW%\J3K-$0`/.-ZOMQ'A
MLP8(B`^C94LSS$^:&K.M,:"7CD0W%$2#&@TH*>51UK)#_P`\EU>%`/SSEF41
M`/YN<#T:JZW<#6T^)2U#\X2,WE7=9SC?;SE>K@0[.#^/$=N'JG]3;?;BRH>1
M+4/SI27RH>M#E+_Z9+J['V0V_24>KPV#_MOOH>\W_/>GMU/M.[Y!1P+ENPN<
M7$YSN\2R/E5]9:7L&\Y+JY`0[=U6#8>/'^@A.EY-]_5Q[=5F^W-QM.%/`EV5
M/\(K8OE8]98`)0\Y/JWX]GZ=CP$.'^KV^HF]W`F):8[ZUR<+G!E.?=1)_*CZ
MSE!W^65ZNM@'?@[9<?FB$[J;;_<VB`'D5G94WPBCB^51UGG#N2><AU<*FV`>
M03L'0"`<1$4!G#;@&_;MPTV7^YM?;:.5P*;</F2J35PK/R4/6L7B/G$]6Y-O
MS16<>B8NW8)50F0%,0]>K7XG=G-+7"@[RGJ'9T`\J3K4$0#Y9+J]_J[,>(_!
M[[XZS=<N.8^)3;=W%P$49\D]UM_X9/J]_<UA^_.K.OW3FGQ<:U=GG/Y5M\E'
MUIAP-YQG5\)@X"/NQAQ$.T?Z[^D=3&(7:'J^3C2[/.?QE%&\J3K4W';SD>KX
M@?G>9DVVX?TD)LH$W^9Q[=5/OMR+HN%/`I##GD4>=8^2FZS0*(.O.(ZO5$S"
M7N77<L'O<N`'<"GWFC&*00V'LVU9+Q*ZRVG5CR)'#75&OA3<B_)_ZL$;/.75
MAYM74VE9IUA'PTW/QT3&$?2K*(6<+L&SXWO4IC$:*NE#%`1'8QQU8,4NY`!%
M`JJH66]88^(]*=!_*CZU@+_SPW5PWXA]L(WCVQOYGO2S("`#ZO3J$S$;JYL'
MBC@6487,R>=%!Y4O6IO[7G)]7I@])?$L^/P?U\U0+Y<139\B?9<WPBMP\J;K
M/W#;SB^KS]<LA^E[\XZEUZY<T^)'9<WPBM_DG>MO_#)]7O[G1_[[ZEVA=.;_
M`$>-+LR9G\J'R3O6W_AD^K[]SF'[[Z7:%TYODXT=F3,_E11O*CZURCRF\Y3J
M]W#_`"S)MV\?Z"$V`%_+[=1-]N),2VG@3[+F^$5N3RH^LT0^W><AU=G-OP$7
M3,!Y>'#^O@>G?5+[_(:Z$L0;P+;)PR9JQ&/C1A?*HZST]_#^<1U<K";@8!*P
M><H!V"`&FS=WOZ_3J':+,D/$K>SG"OSI,OY3?68Y(8CWS?NK-PU7*HBY9JQL
M:9)ZBJF<AV2X#,C]I7`VQA^#3&)#<\2Q7[#'OE0:<NZFQ2O)\ZMJC6("M0GF
MT=4U5CX`DP<E?BF$6DR;#*/5G15D7",R`)J`903;AV".CK[3$F$2(9%S>R)]
MF!-5,*4ZODI^L[T><7U>;CP#],,QX^CA[\X_,T-OS+0M0L_LIRL*G":TF,([
MJU/Y476F3BX\Y3J\+\V-C_RYC8=;1B-U;4W^CQKT`PYQJ,=*3_)0=9H\0\Y/
MJ[$!X@/B&2>X#Q#[6$Z`)_S/H[-+M&Z&F'D1V;,\(K</*<ZS!`!'SCNKLP^O
MPC!SO_\`#C,B)_H\.ST:L;BUW:+(%'[*YT["YAF$T^/B6X>5!UH)\$_.0ZO"
M!OOL!633CZ^0)H.;YOSM53,1NDTQ>*8;GF4!A<T#_BM@\J3K5]'G)]7GZY9!
M_P#/>LLZ^76C5CR+7=\,F!ICGW5N7RI.M7?CYR/5X</27](.OG]R,T8!^;MP
MU6V_2VF(`CP+0<-=E\ZW'RH^M0W`OG&]7@&'L'W9'\/_`)7U=+Q&7:Y8BW@4
M>S_"E:_)/=;8?_CD^KW;_4Y@7A\WWQ[/Y6M'7[IS3XE+L\Y_*M?DI>L__#%=
M7?ZZ9?OYJ/7[EF/B3[-F>$5M\E/UH?X8KJ\_73+]_=9#?I<:(0X%SW8;,M'?
MW>):#Y4W6IO[/G(=7I`]!?%,^'_RX/:.HF^2B8T>)+LV9X11/R4G6P#A-8GG
M&=6"[ALFH9B#MLP>]TNJ'=K&%4TP?D(=(`#;T#Q].M<F_79LHM(]:@U([.F`
MT>=-NI^3QU5U!"42K'FP=5D(C,RSJ;F3-6["/4DI]V(>/?*&+,D%8BO*'*([
MZTOQ2[NA:'D2&&S,GG3K^2FZTA^L\X7JZ;C_`$P'3+?^9_KYZ=99^(7=S(-%
M,=Q7R,-F%QCYUNGY4G6N*A=O.4ZO-]^&ZK%8/GI#.""GS-9!?)4:AXEJ[-</
M`K"_E0=;8FW^63ZO!#T[1L>.X".XAPE_1JUF(RPX"`A'<2%P+3:C5OK;Y*/K
M2_PQG5Y^YD?^^^M_:-WYODXU*E$CY4G6J`CMYR75Z'$>'>LD]O@[OWV')MZO
M1J@WVXDQ(,>!$2A\E'UJ_P"&3ZO?URR_?S2ZY<,Q\29N+YO[S/OHPGE1]:>W
M'SCNKT_'M\.Q>>KAW@S)N7YGS_3JUE_NC1!C:.!1.'.%?E*PIY5'6@FF?;S@
M>K1ZJ4AUD&;J+CNZ742(("0PFE]@*)%!W]>^I#$[NUP@VD[W&LMXPQSH0/E3
M3K'D\=4U.8^YZMYM'595HH[E[97;-BRC&*;J=LJHKRJZC@DR3<>^3WVWX[\=
M#L3NSC:<*31DR1(\JS#"YL("KA3G^2EZR3<"><?U<E./`H@NQ7V'U]S[]-WG
MS-M1[2NG-\BMD7"9(F"::AOK/R4/6G_AD^KH?@\`P#?X-_?'#?1VG=N:?$M\
M=U#Y*3K:_P`,/U<_U=G^_>H]?N.;R(,2(+/R4O6K_AD^KTO^5\2SX?!_7OT:
MAURX\WR+F'#)I).??0^2EZU?\,IU??KEG^_>CKEQYOD2[+F^!*`^5%UH"',I
MYRG5[OV!NZ9AP[=M_?@!VZ8OUR%`:?$MTC#9@ET^=)P\JGK..(E'SE>KCV=M
M@!\Q$>(>G:>W]&I=>N(R'Q*[LY_A%'(^5)UJ=\AW'G(]7"H@J45"&.Q=_:@W
MYQ!$TX8-PW#CZ-`O]S$8-R;BSWC#9A8-_=3=N/DU=5M^KSBIW#S9^JFQP1Y$
MCU6)E(N-5CI$A#E6*U>$&7,!D>](`]@\0U>,4D!VL`Y1`!JJ"Q'"WU<:[R/E
M0=:"(;$\W[JQ8*JMF\<2/AXR.28L&;1,$VZ0'+,$`H$3*'$=M0=B5VF$!P]4
MQR*QF%S&.!C7OH[Y*3K5_P`,GU??KEE^_FJ.N7#-Y%T>S7^$42?RG>L\FYA\
MY3J\`3;F'F=-"AN/'AO.`';JSM&YPA9JWD=G/\(K9/RH>M(2%$/.4ZN1`=^Q
MM'NO2/\`V_WT;O/H\.ST:?:5U%`:8<""#+Y!K"P?RH^M`H@!O.5ZN0'MXBR9
M\/\`WL)LH&^;\[2.(7-U+FGQ(B2LD\J7K1X\GG*]78]F_*Z9F]>V_P"WG#47
M7VXGZ)\2(D(T/*FZU"CN/G)]7FW9Q\"Z_P#T1IH0^?Z-#;[<08AICP(B4G?>
M5%UFN&3MLOYQ/5>^0=-EVKAG(QL:9BY;N4S(.$711ES`9(Z*AMP$-M]6#$+J
MTVFMI&]QH##._=YUQJWY1'5C6*_'56K^;GU5PM=C8L:W64(2*C4TXUJ"PNG3
M@P%EBE`%%C&*'P:#B5V,7$&,0[)6!`9<V1+LYXT;J<GR576B(_\`/)=7G'_Q
M='_OSI=>NG-\8XT'#ID/^/$DAO*FZS=Q_P#3*=7?:/\`W2S3]/\`2PG-B?,]
M'9I=>N6;R+S[L*GVCO[J.)Y4_6;RA_Z8SJ]/V^T#IF(#Q'T^_/1I=>N>;R*/
M9,_PBM_DINL_T><5U>;?"Z9?ESFEU^Y91Y%V+EALT2`#7$YT4KY4?68?EY_.
M+ZNPVWVW=L0]7_CT-3;B-S9ZH\BUG#7Y?.L)^5#UED$1+YQG5UOMZ';$1V_=
MX=#L2NCA`BC@6>?ADPLHS[J--Y4W69RF`_G(=7R)!`2F4(HQ<F*!O9'9`TX(
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M*?ZUE$CD2\X_J_24$`$B@1C#<IBF*8/]-^P>7;Y^K>TKMS?Z/&L]XPB;,E%H
MH]I<;Y'WJJ[_`,9\J;U,>-]__'7Q'NR,[SXZ^[_</QEW]Z_UQ]P?I7F[>ZX;
M^C4NTKONU0K%6E<OL&\9CG^DO6/JRSTPZ9<+VS+KNN2=E1K*K(`AX=HJ]>.G
M,DOW!3E;)#SBF'+N<WHUP]8>%>[U3>!/S&U_8W^E5ZZ)LUH1&R0->F6R<FHF
MR6:KS;!-X+7NES%V,W%382CMOL(:C,>]["T5I"4RL*!>HGJ7D,.2F**C7JZA
M>+ME^4-'0+65LB%3K#PL:=()TC.>7C9!M&NUT5.=@"NY5^P!].LIE3*S%2,J
M6<BBI[UEMHRU36.E,93S3)-8M%F)/5`\]'JNVN-(BOH6I?(AGA6X()13HC]-
MC&"/`ZR1BB81#2U,PYX):J6D&`.OJ%Z@8_IS=5^B2-8D.H&,R.HX@;%+MEY3
M&5CQ=&1,I(UNW(D(B"1K#&2J*[-0OLK`;F#@(:-1-CE4-;+M0HKW4Y,Y=9A\
M7Y&E:Q#8LF[EC_&T=`3.=<CL9ME'&QU%6Y^HQB%6<09%Z:T+,$01<N2%60Y$
M5P'MW#09,W=2ULK(N12.M8U[R+6X9YBY]5L5W:8R76,?YG<V&/\`=M@G,5/7
M$58%)6J'035AXV6F63I"/$SLYEP1`=@WT:B;N^):94V78B(*4.F'J:1Z@I'+
M,:PJEHK9,6VQC78]:SH,DG%C@IJ#C9Z%LC]B@NH=!)TQDBJ$/S>VF(#MHU,U
M6ZUAC0*4GSCU"73"=SJB3[$B\]B.RSD77IC*<3:F3N28S$V021["J4E)H1Y+
M*"[3,17],$*F'I';1JID84JMY8]L,BB.T=;\NWIEBD(''7Q<M:2\NC3UK?8@
M;1#J+C'/A"2TRAX`WA;(J0><L5S&YA_[=PT]3,KIBJ=5+S*P-UZNL-8%HN.Y
MC.>0$ZP^M%3@9$[DT19;(0[)1LBF\L+U.LUZ349@N^4$ICF*!0X=@!OIB3-X
M5(,EM,85)<EUC]-Q+2I0BY8AC6QA7%[;*1SAO,.TVT0BT3D7AU95".!)$K-L
MN4=N0Q@+MN7?0)4W=0;U)SCQKGP'7#TOS%$N>36.:(V0I-.G6<+.2QJ[;6JL
M<H\8MG#0K"#6A"V&79NDW!3IOD&AFJP#SD.)-AT:J:I&\R2(T0"6*=;/3(W5
MK317+4<NYM4!\:*\1C!V*96?5M-96.6E7H142[(T`LBR63$JAB*)G()3%`P"
M`&IF[OB1UN5D(\:CNR>81TSQ3W%Q(JWS%@<9/OCS&<6[@*79YI&&GV2(JC\8
MDDH]NI7X]<#%,+M0B@%YNP=AT:F;NH-[E$U@:5TFG6?A^GL:TGE.XURCR-HF
MIQ"(B8Y[9K<XDT(2>=1)Y>1EXZI(1L6UE#E*!2/#-4RB'*50Y@,`(29N[!3Z
MQ+FQ-!4E(]5^!)#*Z.`F.4X9/+;QR^;MZ\#25>J+E;LV<L0K>908J5<KDT<_
M2,5-1\1<V^Q$SCN`&HF0IBGK&`T`+I9)ZH\*8AMT#1,AWAE7K?:56AH6#48V
M!T8Q72@MFHOY5G`.(&#8K*I&YEGSMNB!OS?$-S4S-U&L:FG9.MSIJK9[2A)9
M/(Y/2I1O$V8*[5[;-A&NGCE=)LFH_AJ](L5>9(A3")%.4"CS"8`T:B;NHUDL
M1,!2NW1NH:$ON5;72H!1NZJT'CJN7^.MYU-XY\SGE'2!>9;F*`E1.S/S>H=]
M&IFC.BW+(J`*;9^M_I=/'WR<1S37BP&*G*$=?WQH^9,9G)R3]S%M6K-!1FC(
M.RE?-%"IJ-4'"1P#<IC%V$7J9D<J5MD(PI7*>==/3-&5^@6)[EENI6\E33NN
M4>;CZ[>9)&3LL.N9NZ@I(S2GKR3)9;EYS>):-RCO[(B78PK43:J4]9+%0">E
MJZL<%URMP]QDLH0<)6;%%V22A;`\BY9['"TK"Q&\J^=MFS'Q+='QW>-D2N@:
MJ*+)F*F50P"4)MNLQ](\RBZ\L:+),#PIGTKK9Z;<HSL5!4C,31Q.V"-EI2%:
M.JO8V4:DA6T.^LL<\"9CH50TU'*I+`**WAW!2`79(P<ICRZE,W?$H];E&LCQ
MJ0\2=46#L\QDVKA^_-;K[FD@AI8093\(:)E5FR3Q%I)(3D+'OFZ"J9AY%T$G
M+8I0XJAN`C%US>*U%UXEN$`0N*'61T]+M<G.6V0P>(XG40)>'<;6+B>.A3K)
M@'=)R"%==!.D043,`JLTUB^C;@.GU&;73X<*K,^7N>/B3=G.O#I?@HNCS\GE
MV*91.1(96>ID@C!6%_'2+9"35@WC=ZC%1,A+M56DJU42.9=JB5,P;F'AH%SF
MQHC$;R>OET$F"8V5>N#%U;ROCW$-7>,;Y=[Q9V%7?0;)>=9L:RA(L'<BO9WD
M\-?6C'#2,;M@YFY#]Z8!]'9JLR9E=*O;?)0$!"/"N7;.OG$]/HN-7BLY#R%_
MR6C6OBI58AG8WS"3;V5PDR8N_>_N!-G#I"5,RA#2IF"!A,($5.4`,)J)FZF;
M[+R'R\2>5_Z]NFW'K+,+J5N,@YD,*1BDE<J]'56S+2K44%P3=(PS4\6BXN!6
MYU.4QXLCI$!*(%.;;<34S-U,3F.Y1@4XH#K7Z;YI[C:/3RDQA9S+%0A+=4H.
M?A+5'/1CK,F56)"69/*^DSA)-0P&*#1\[:N@(!3]V)#E,()$U!F-(@!!2[,Y
MFQO79&R1D]<FS-]3C12MD9I@Z<NX]M/N5C0#A1NQ8.R@UDP$2%'G$>4@`.VV
MXR;=ICQ&E1-X8S*%&45UE]-UML5GJ5;R]&&EJLUF)&?.,--MD6[*NB8L\,6[
M>1[5N[5AA0$%TT#+*F.(@0AAU(W.8%'K4L@4U;ZBNM>8A@"R)96N2MV&-Q5C
MMQ6&,;:7<#-ME[#(66*3D/"QU>19.[F_4;D4`Q0]V)AL(#OMN.@W2:T1I2ZS
M*SA3%!]5>#96T4*DQV2HZPVO(\)'VNC0,8PEW#Z7I;YDD7W](+QC&2CV!Q=H
M*B!7ZS%0AMRF*7;<8ZJ9EBCK,J-!"8^6NL[&M`R'4L0P5H93.5YZ<BXU]57:
M,@FQB&4RC[S*$A.H1KBK(3#=BJ7E2/($V*`"([:0E3<B;KU*I$0"G9!=9G3C
M<)N0J\%EF&-,PEO8TI_&E0F4'WQED.]3CXQ606A0B%4G3QDX3\0U6<L3`0!,
MX)OMJ9N4PYUD-^DQH(K\,B+L76?TV5VRQM/G<P0</-S4DI$QK<Z,PHV5F$G/
MAU(QQ8VD*[K[0R<@8S8>1PNGNF(<_`='47FG)X;J1OLG*1X^),"%ZZL/Q-06
MG\T62)QZX7RQ?\:Q39(TU:B325/MDG`IR3<]/@YQRG%K`T*8'+I%H@0VY3']
MD1U`W:8R@$HZ]*SCQ\2DYQU@]-37)4/B<<O1)[Y8&3-S'1B*,T^CRLG[,CN+
M56L3>&4J;07C)/ORI+/TUP[S<2<=@-1-SE'7I6>CAXDPUO,0Z0U95_#HYKB?
M&QTRQC'?@*S=I-ND,A(.8A$RIAK#5$C`7S!0BC](ZS!J(<RJQ2B`Z;;M->84
MJV5?91=6/'Q*3'W5GTZ,,ARF+GF7:XA=XJOFMCJ#23DE`)6FL:VEUG[2:2CE
M(64<JQ[U)3P[5PJORFX$X#J0N<PTBK@6CKDJ$":>%07</,DZ4Z_CP^2X[(+^
MSP#>SQ-5?&B*W;"2#!U:%`-#.O=HP1W3EIL8"]Z0!#EW$`'1U*;73X<*@Z\R
MRTAL(E21G3JIK>&JOCBZRJZX5&^RK>"7EFD7-NS1BR@%6,[39^[$[$<01-P`
M(\3B`;\H;ZAJIU5*R%Q`SK,KUI=.L&SQY,265F;2&RXO((T"<-`6Z2A'JK-P
MC$"U?.&=;,G`NB/D#]Z28/&=RL8Q=Q$-`DS$A".^NRXZP,`,D,I.WN168,L+
MK%:Y`DVT;(N(IF^67<HA!Q;H&936*P`1`%A2CB.@2*H4NYA`=`DS-U;&7F6U
MH832%'>1.OSIVI&)H/)L;D)K:8VX1,H]QRA#QEC=REM=Q1O"/&,LT;0*B]84
M9OC@DJH^(AL<HB)0T:F;NJ1O<DQ-%._1XE)\[U.XOQWB6FY0RU:1IT798:K&
M431A[//RWO\`FX5K(NXQA&PD"_F)!!L"H"LN@U4(GON?D#8=!DS3G4FSY;JH
M>--V8ZR^FF&G*?6IG+\*A+W6,KUAJS!G$3JZ/N"YK.&<&9Z[3CUF;1PX>1BX
M!XM1LLEQ`4A'?1J)JD)C`:EUNH_-,GA2/KKR*J;NX(6VUPD$Y>L'J$>PI$?(
M*H(>_9=XHDL*L<H93<2IE$_M<.''4=3-KR*N:]IE$#UE"=PZOY*`S`QQ1&4E
MN2>"^,JU96<S/F.DVB7T<V=M92$<H1PMF_>%<`)2*GW,;@.VGJ9I,1%<\PC5
M2I@MG5Q@VB9*K^$K9DE"(RG8'2;&+BE:]9%F:$DLV2D&,=/R;2(<5UHY<QBY
M5#@=\0!-OQ``W%ZB8I"R'9URD.N/I=6AKY/J9Q@6L9CN7-7K*[?,Y2.,C+.S
M=TB,?%*QIY"7C2B3D;.6A%T5EP.)#&+MNM1-W5TM8VJ`6[[KDZ8("HT>ZR>9
MX%K6[X_?1]7<R$?:74E.+Q#\T`Y;FC6]9"7AW*<DV.5QXQL@'?\`,)1$@E,)
MJ9B-8W+F2ZR=:_33#2UGAE\E(.'U"\*XO1(NNV.78UUNJCXI)O*.6,.KW;IP
MDN4PHHE7=%(`&,B!1*8SU,S+%0-Z8PV8P43RGF!=/49>W>/8>=<6:QNL2L\O
MUM^C6K0E5[!`2<U)-&R`SI(-6+A3M"MN0YGZK94PEV%(O+Q6HF)]=EYU)3#J
MWP*G:X7'\[D2,C+S)12%@6A46LM+1"#>5@6%B;M7-U91Y:R@+%H_+LU%QXE<
M/Z&0_*.@29BEUJ6_DU^%:=^+.J3#.9G$["8SO3"WRU0:M5IF-0CK7$G33?K*
MHI2::L_7HE1W$$6;F*59H1T`"''A[6C4S84Q1K&5@!('?5O@).:R=7U,E-SR
M.+(XUAR$P4@+8Y9PD4V*DS523EXZ`<L9E5-RB<QT8H\BN0VX'(3B&F),W@2,
MV6!2/#.N%-==?2Q!U.I7:2R]&E@[NX>#45VD)9U_?*33N`=>(:LH!X\C46HN
M2"(R*;$`W]H0T:F8H=;E9Z.%-+-'7-AW']AJM#@;;&6C(]HF:>P9UEHUF58\
M8NQLEY5O(.9T(CXJM#N&"B9S)C(BJ!1*')N&EJ9N[%,7R4"::.%-;)'7?B?&
M6-T++/S+%>X3"@C7ZA5VUFF3K-W%H&K%47D`KC:/;=W),U]A>G9$X#R"H3E4
M,:B;#+%8IC@][G#*5(]\ZU.G/'ZE\BYZVR'QNQ?3%<BW*EL*Y..)PE?CF#5[
M(-8U1TP:PTLZ33?I&.BQ=NE`*("`:8D3-U0Y*XE0Z_\`I=F8/%<VXR>QB5,T
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MN[0>)&V!-T7V>4AC@`&$U$W=60SI2LG"==_3>IB%IF!_D=HRJA'L1#3HMZ_>
M)MQ"6F48HNUH)6/C*>O94"-%#FV65CB-%4Q!0%@(8!T]3-A")3$^3G'CXE(#
M7JJP>]MT/1VV38A>P3M/)D-B1!L^5C1I!F9)/WE*3O@2P%7=@DXY0(Z=`)BD
M*'`XB4'JIHSJQMYE"@$>-*L:=36)LSP%]L6*K@ROC>@B_;2Z#9D_@W+19HBJ
MY*(1,\RCY-VS5*0Q4I))(T>[Y![A53D-LC*F;JFV]2P"0:,M::&%NJ)GF*>=
M0D97G$2HWI\59R/WA@,Q%%V]DVHBIX=)90>\\"80#8"CR]H:!)F)]99,%D&*
M+F.O?I0A*S:[1)9BC&T)29P*O8)OXN6@S,L\0Z9'+".1)"'5DW#94_(8J'.!
M1`P[B4-],R9NZF)C(Q@()Q)]5F!W5MA*G%Y%BW,U/4H<LE0;14[+L%<;BB<X
M32EF8L%:_#*@*0CX=RX(OV@)`$-+4S=U#GL+:**$V,G=5M8JT75W].D6EN<3
M;RE2SB.;,%4'2]#O3)5W%SD257@HH+=N90FX^T/HU+4S8T>9<Z(!H3`H'F*]
M-EZK\18F5W?QT=/Y'M6'X1.<K]F)(N[92GJ;:4(K'MJ\O*>(54<E*#A)NK&F
M`OM.2:0D3=U`(5_6+QJZ;I*H*]^14O."ITN[,83;B;[68`$A2FW``V'8`[1[
M=&IFK>Q[+(WET0(&V_L\>/UA>'P:CJIBLML6>0/\K_.%T:J8BVQ#D#T;!\PH
M`/T0VT:J8BVQ#E]8[_1^KHU4S=2+I9S+'=)[\W*&_>]_OQ_HO)W?/V]O)P]6
MC53=U1C+3;LL<RF8]2-?Q[>1;.5$4739XU;.V+@!XBBJBY26(8IQ].VX>@=6
MV-THM*+\A8<@LHU0E.F3V.KQS!XT>MY&MR;:-=[LC%[ADW,DT,D5H!2\G*!`
M,!>`#OJ<OD.M"D[J@]Y:V(`BJT=9>`\GYGH-5QQC-#%C&OFD6458&V2(N8D)
MRMP31-LT@)^@S<//0;^#GXU5JH*9S'6(;E+S$,.^]^M(,8#+XU5KWYFI*7I/
M>)VBQVPL^P>3\_T\QO3X]L4HP!Q:+3%P22ON>4?2":B)`9HO%S+J&(0JBAC"
M`GY0``-:80@VN*76'G(U1#6/+L>Q6:L,9,=7Q$*]3\!J8URE4H9$(D;3D=*D
MP='0R9%*QZB+EM,J1]>0,D?F,4VVZ@*;Z->[,VM4FY2W&T7/B=U="[=$V2W5
MCD(#%]\KL3@W+=5J]7SK%7)O*3=^?_%I)!!T_JTTK+()-968%H1-X+A!RD!2
M?:B)]NC7GFMT)=0E\]^D<2XC'H$R&\>CBN]Y%A9?I=I\M=+5CBMU]JI%9#<V
M2W3CV>2C;98RNE5UHB$=RRXM2,TV:HE`O>G4'<1->Z,8-5C+JU@LASH;Z[>%
M>BZ^=)-[R5.8?R'=<D,,R77&T?(NLIS+2<4JV-*13X6)D!9+1C*&)[V66;*1
M[4RA3D(V;)@8IC\QC!GN-;6Z%/4#G.TIRYGP3U1WCJ2Q_D.GV'$[G$5,@&9F
M>([G$SH/ZW9%W9R34R@[@K)"I*O210)+,53)"9)=0^XF+L`2E31$V@-^"<#)
MY3(G?5Z9>BT^=,HV?U6LS4?WR+XA9*NQ;TJ+XCE5)VL*:S4Q%E#)I%."J@'7
M$3"/..^IRXUT4J/67"H!>-OF;8TS]/YZP)8L,8=G[_5*U7YB/LT9%/UH^$LC
M%:4*9G5I]@R*FW-`-D.*9$`05]:@AJ3.0R%!(2U[G\@@!IH4HUSR^;!#9<R/
M>4HG%;>!RA5K=(+R$HC;7&1\?3EVK$9&*UDRB=M1J+^J1JS8001")(L&P[JF
MU1KW9FZ%5U"5SGZ5ME?RXYJ]U.%9UJPU9Y/TJG8KA8=!^6<K\#;Y;'50AZJL
ME:"5><@9IQ6G817.1ND\1,!3[<XZ->[,U'4)?.?I]"?%=Z'[3`UZTI0D]1,9
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M)W0?EUYB!UC_`!AE&*KEB4R42RNA*S3CFMGJ"L%'P(H6I2&4C';M5N2/[TO=
MJI%[U4XB&P@`76VVJA2%&!A6=*F+!72#9\+LRQTW:6<]&O,)0^+%8>*:*D6!
M^R7EG3J8!PHY5-[N:K2QN[*/M%3(4!,([B)K&FD`;L0I671A$Z57[#OENRU.
MKMCKC]MBDDN>[4.2B<@P4=892>NE*ITFZE6J5W:W2S6JOJNUC/CE6\"R9%$`
M`"%+MK.9[HQ`;#>6G4-A6[2GQ8^DCJ&BLA8X<XHNV+3X\@,S63+%HJUHJ[D4
M5TY604(HVBE(J6BC(&39`!$2>T4A0#?<`T:]U<&U(U`JM.TIE5;H?NUO<]2+
M6;=$A*[<,G0K;%<'/(ED(EEC2$E?CW-BFQ.!$@2E;C8)`A`.`CW:90[0$PS%
M]G-%EC60WO2H.N4IYBYSX[_H4J6CH;F[29=NYM%>C&;S*F5,@N'L=$%96%:(
MR/`,(]BDG(,E6YF[UM,-%]U`#<6O=E^N`3"-OT\`"S+H&[QJ)N$DGUIFGT+M
M=&?1[-].]0N]>L<5C^,=6%M%Q2LW0GEW>3-EA65<:0I5+LZNUPMSI*5<)$$Q
MS11HU`5`W!/;8`D+S,GN&L#!9IH'&H/NDN4TECGDFBM1:^Z-NJ5GAO(.#Z;E
MNEPU6A[,P?81FV$,9"SS=.*NH]DZ]E.6.^5+.D15<*(IG2(U6[HI>8XFW$;V
MWD!QF0'*R0H"SF[Q%F+H#=7.QSY?U_KM0K$6_M=)"<A<4YBH_=)PR9F36?R=
MDJP9#@G1!=+N'Q5XF.GRI*<JH>R4`#8>.D^\&!(`C&.BC0FV[-M`6G:4?&]!
MV6(;(U8!'(]0=8>@+HKE`SUU%&^/:M@D:PC$V*'">;NFYQK+&=[TT<W[LQDV
MQP*J=40YM9->Z-35HZA*A"T_2N0KY>V9XV,K].JF0:`:EOJ/0*]EHDY#OWTV
M[EJ),O9*/"GR*4LW/&PRL`\0)W2@+`54H\@E*'*!KW1J:CJ$J!%I^E<*(\O?
M.2F5,NWV[Y<B).K3=;O-3Q69TW.K9HN`L[L\M41=._$\K9U'NG@M3F030`4$
M@#;GYCC>V:UP`@([RB99E<D$V1NKNP/E]Y(2S!0\GW!;%5Z7D:]04<I)RZE]
M6-!6W'$,TKS)_0V3>]-XP`>1L<D9R:10D53N`-RG*GRD+(/:Z,`-"1#A63I4
MNYZZ5,RY#S#+6K&M^J<#CW(RF-`R4HO%KDNK-/'[QVJVBZXZ;O6L6G&/^^_3
MA731TH)3;)G3[=0%X,@!K`"-T*P7=D^+ICG`[A7*L_03.SS&G132S52LO:U(
M9\DGRL#$=VZ</<L2(3%8?NU7#IPLZ80[[G*HF8>")N7<!XZ?7YG-9H]*?4)'
M.F:1Q*#+5Y<F7LBU8UFR!<<-S>665EJ\O$Q%=B;94<;V!2M5YE56L/8CU>XQ
M-M!LM%1*:BAF\JW6%PHH)3E(8"`A>WN%AP;"G)2HS+C)#26N?'?"N;TW]+;C
M!TXVL#^)I4<UDZ!5J<TK5+8.F[&MOVRKV1>,8R6F'\S:U(EPX>&#9W(.#F+L
M!C#VBR]I$!"C<6878`Q)<>%1/DKHMRW;<B6M6KWJCQF(;;D",RO+1S^LMG%^
M;VQ*N-JVM7&TP15)HUJJ+-`%$T/#"OWXB(JB7V0`]H-5-6A!NX(]9VE0K1?+
M!L58QSF3'`2='B+),UQU%X>RM7U;2O>FLFRG'<C%3MM&;LTQ6"3,<FN*8%81
MS%H(*'W1'AMHZV0V-EL-Y4=GRR:7.COA*)3RX9;X[83M3)SC&\)U.*A4\MQ^
M06MN.Q&RDL<O99J?QQ!5>VUNO,W:LM,*$/XYG()""0!RAL.[%Z=E:W1F0;A+
MKM/CO^A.Z?Z$LX5IX$UAR]8UC)Z=ELGQ-\C+=5"R43][O(%D?3IC5UNU?1Z<
M;9FZDJL*"QN\1*`EYTCCN(Y9MX+G1`$%(7"6!&T^)&?T)N4GH>RY"Y'MM*8R
MU=K?3O#W+'3LSF9AH]_>IPU1Q#6*<5]&2PI)LT$)1\P,Z>@9L<IEU3BF"8#L
M%>O=F;H2[.E\Y^D<2DHO0E98['PU9K9:O[Z2P3:,/.)EI7F:4B\&Q7&4FDSL
MW!1`"N5(IV0J@G!1,=@]G;AJ3;P]M(#<]2FRY,9$ASJLZCV$\N-_6,N6.::Q
MN+)NLSU+4CF5FFS7EQDRFVT](@ZE#>[$TKLA26$0LG#=ZN!(<%!64.(*%*(%
M"?7IF1K-"GU9O.=I3VM?1!D`F/S1=-MM+A[Z%`P54Z^^=0)%8A*ZXP;*)V65
ME&"*R"#M@_*8"B?V5^;CWF^V@WV81"RS1Z5)MV`,074'.K#]26'LO96KV.GM
M#M%*KV3<;6N-MK%I9(AY(TVQ60D!%@]:`@>33DO<(.1/R$*Z!8```%4=4B<X
M&,`:%?"*HIDSRW\]7VJTJH1>9(9K',7+ZQ9&K:**T?6D+E8\C2N1YYW7VD>\
M:N'4<NUF2I$3D57Y0$!#LV`'UAW-;H1#(GM=?+_R%D&3Z@&[FU4.(@L@RL;<
M,94"LL9J,HY9Z*%11E:KNF$ZK8FEC>H'*BX]SOXEJHBF4>Y!03'-:)@+;1`T
M+.^[ASXDD$[JT6Z!<O,Z)28*A.L.8TEI&G62D9BKM?BK7)5-9C9)E>7>3M)<
MVNWV&P1\FZ>N%#]^X?.E.<P@(B0"%+*+<U5-2CU<<YVE62S5T]9@G*M@Y]B6
M[5=CE?"$2O6HTUR9.9.FNHB;KT=5[05PS1?L7QET(J,1426!R"P+''VA`>76
M.\3GR:&!L'9U<R66B`<XPHI*B-IT&2$3#6Z(;62MNW]EQ10<?0JDE$).58J\
MU&[W"RSDZ@N93Q"*4C%SZ'<*'.<R(@/(8`';5'7Y]')9'PW5*P[.=*FGJHQ)
MGW*&.J/1L*3F.HD[*8K\E/N+PVDY<[XE.(R19`T-&3$0D#-\HV4[\C@K@IMB
M[;#VRE7R:7`%K(%.!C65:-K2HE^SC).SUZH&N,J1@M89AK7XTS=_-L&Z*!G*
M"[E%Q)E3(+<.[V<;@4.WTZT":1"@94Z^%>)%OPAU%S7F37:16PG.SN%+L+.+
M4LTM9G9Z.F67JS>/?9%:-4@1<L;'"[BFV3!;NBE(`&(8>.F9[H0``1E4VX?\
MM2P4%.-BI8F'095JU4TR5O:PMDLEMNN+Z2/,SB;6-ZM%JA49=TX*=P<\>S9%
M(HJ($(4H%*"ZP[,W0KQ(;7%RYU\\LZVV:P0-O:+8WMAR7W)%@?5&Z!<6<0>J
M7[(DM=VKZ$4J-MJ\FWM$4S?I(I]ZX6:$$@E!#EV``3W`0@W0C4#G.TJ3,C="
M.4)+'.9*MCJ]U^F67)^<(3*<09I%IH1RU985&$@)JGV]V=0\V^;E78F4*LB[
M;NQ(H4AE3`4``ZP[,U5/N4M[K1<^.^N56>A#,U<AX6L0%UIIH62P7(88R81=
ME(+G*HVN=BN<*X@`-*\G.L%I,DHJY!T)T$DPW`0$PFO=F;H4.SY7.?I]"!N@
M3*!+`PI`6VD*X">/J3;YE)I"*-;P.1*91TJ7'LDWZ#\K`M4219@LLGX;Q!EE
M!,"Q2[%`ZP[,W0ILN;&&(<_2K$X5Z5)C&>0\?7R3L#(Z%8P(SQ#*Q[--9)29
MD"3,L\:NE3E<"<RI6CL`!0!`P@'`0TC/<1"`T*T2`/I.TJ"I;HSZH&E7RYBJ
MFY-H4'CZ<L-AM6)YA.!44R'$/+/-.[%+1$_-N7J[1S!BZ>G2(1-NFKW`@`J"
M;VM/7NC&#="3KNUP@7.TKE8@\O6\5&BN8NW6ZI24R]JF1*_)MS1*BD<$[D8&
M8R"S0!>&4(TB561/``)C&(41YS*>@U[LS="IZA*YS]/H00Z!\[0KR#ID1D#'
M(XC!KCB9L'OVL$D+<6ZT>F1M46+`R/C$464._,Q%4Y3)'5[PPB4X!PT:]V9N
MA'4)?.?I]"XUP\OG,9V!82CY"JL3&W&":TK*K>R,'4BZ5CX:WKVFMRF/5?>*
M*,=,.4GBB3DSPCU(P)`!"$V'3ZP[,W0KVW=C0!$T+9?R\,RSV?+CD3(66(J9
MH[R%R-$54IFRAIV(0NM9J]<B"HE(Y+&&%@:L$7'O&QP`ZZ@@&PE`#K#N:W0G
MJ6;JXB/EWY;?Y%Q%>;TTP[D-S4Z?5J/>C31L@L"Q[3'**1*I-TY*!OD0F2<E
MF"P>-\45VV%9/=))(!$!.L.S-T(U#-U6?S=A&[V?J)J-RA$CFKUSZ>;]A!W,
M+LFKP*BYFO&R$?(OE%D3/A;":3614^VE`R94^PX&,:&N=F%<4]2W=7(@.D68
MPGTQOL4=-D'0*=D:7H-=ID]:[$A89V.LTB$,E"NYY1V_L:DDA&D;M>\2;(N$
MVY553;$VX:#.<7!T!1DR*+I#'-+8D141?)[Y0RS3<8U?J"S!(P"F+**\Q]7!
MPDJ%;;R$E()A'IR\X67^,)UWC6+BVPD,D9$H"HIN40$`++K#LS5G[/E<Y^GT
M*8^F'`V3Z'DMRYR.Z6?M<185A,)U>WN%3&2NC4\W8+$DX=<YME5HR,G6S<#)
MB0A3E$-O1J)G.(A`5J;;G+:8VGU$5YUSH;H`JT'B?+U4BH^O,,KY>/<%'%TD
MSV.>*6!LME4G584J<O/O$HAPT*)4C>!\,D(%#<FP``/7NC&#5$7"4*+3]/H4
M;YB\O_,-FCU#8OR+!U1TJ[H\@[@$VZ\7&60]?QM7:&]-9EXE['2CQJB,.=1N
MD1PF4W`5`4$3"+$]PR-0;A*/TGZ?0N2AY=V4C#2*<]O]0@,91.%7F-,AS]9B
MSM[KD)=Z*R`1MB%Z[?UYS&-$D4!3.DP17*<YQ[S<0V.L.S-T(ZA+YS]/H4M]
M'?1W9>FZK9-KTU7L:1\_:8)"EU>R4Q6_R;N0IL0V?,*TVNC^[7>UNCN&Z;U5
M4B+$[)DBJHH*:)"FV`,]QR-T)BXRQ])]6=2IT]]+$_@^>D99W;"2T<OC*,H2
M)$DAY$5HMY,OB/G12J<YU"N)E0#B`@42$)L`"`B*=/<X0(;H4I=S9+-H.?'?
M5:LF>7K:++A"FT*+=T.RVZ@Y/G,C-86V,)EM0;FRL#QXLJE/_%>=KEB<22!'
M(E3.203*`%#F*8!U+K#LS59U=N=VE=1'H:R2:^4H\1)T#%^-H+"S^GV2+Q^U
MG6YYVT2C=RV-6)-E.6&:C7M18F<=XF4R`NRF'<5QT=8=S6Z$"0T97:5P*1T*
M=1X,XE3)&3Z.K-58V)ZU6%ZM#KLDF./,/LW<;#-%"O7SX3RDLT?G,^'?NE%`
M#NR)@`@*%X<!"#=">I9NI).]"W42\A$*E%VW&<8Q:YFG+37\BPT`[9Y1KM2L
MTZA,.DHV3&4/!(//"-4T%""P,BJ43"<AA'F`ZP[,W0C4MW5ZZ1+54")$6=*.
MSH%!HJ[,D1$[M5F/AE7*B29"I)J.#HB<P$*4G,(\H`&P`A/<&V8!!D@F-IR=
M/=%V`-S<.'H^IJ%LHU(SNTK/=%]9OI?4T6RC4C.[2AW1?6;Z7U-%LHU(SNTH
M=T7UF^B'U-%LIB2!E=I6.Z+^>-]$/J:+9W$]6,Y5;LY9<L&,G^(X^OL&3P^0
MLCPU(72>I*J=PC(*KE</A,B!CE(5-(!`WH$>/#4%8I=F+'7JRP>NIN6C8-JD
M^3,1[8'Z$?%IN5C[$21>NE$VYS`<!`$RFY@$=MM]`4)GJ%4YS[U0-L+90QQ&
M3K4SW%<[C?+]\O,NC'.9*QLT*3%L+!#FAVK=-1=ZR1]Y[;I;_7!MJ166A0_)
M^8O$OXRE2%+P9G:1<6?*,#CIY`2-%?PEK@6%DCF\O#V1.+E&"#EW47T8Y(J4
MR)1/R#OOH48Z%TK?YF>!:%1\C7^=@[Q%5:HV9U2HZ8?1A89Q<+Y$NS,G=2IW
MO%-$CI>,03(H&^^Z9P#;?45N%2>#+S#\"SIZ>+%Q;U#7BOP%LK?>5UPT7E:F
M_;+&L-I@$UVY#/V%1<-5"R14@,8IQ#;;<-":;?RC6)D("0L$I2,NUQ<J,9(U
M&&L-%E&EMR!"SBZK>#L]=C%&)5S1CT2;<QR")##R&]HHAH0IYI/5!C*Q=/TY
MG=RSL%;J%44L#.X1%RCEXVR5IS6)=Y%6:)=MU$T_&2S";:J)D(F!MS"``&A"
M@^4Z_P"E0<)!/WF'LS(6^WJNY)O1'%8<(9(6J40IW#C(,C%"V!=*EHH-S['$
M@>PD(CPVU=)!+J%3/]3A3$2ZTK9/9Q<P50>,G6+[/G+IUK=8EB,7A7+RC92Q
MI$V1T_3[Q$`9=ZY6,005Y=C@/HU=8Y,74N"S$BU`>J2E5X\PR+/3[FXI=*R=
M&7C&.6*16[!1YBJ2KVSS=<GG[F*;6&M1<>U57E(>658*BD9,AN<>S0X5QIB"
MFSUA#.$_Y3S`\7*0$;,PE&RQ/V!X]=LK-C>$IT@[R'C1I79%T24G;_!IM57M
M;CVR0<P@\(F)`*/-K&MR6/.O?&3ZQWB$J=0RAD(]!H%7O]JM%;J[DE3&$N$0
MA.5F.C[`HV"(=V-_$.TE%&R*@J)&$2B`:$*(@\RFO6.QTII0L=W:2HETQ%DO
M(B>0D8%2394:5QQ(/(.PQ=@:,FZSU(\7+1BS5<I``RSI)5,FXE$-"%(,/U[X
MR:SF/X:;K]KDAM%>QR[GL@P=3E4L=TJQ7^NM+'48^=!RT*]A'UE:/TSB"_=@
MD<X)GV,40`0I'PWUEXTRQ>7=!9P5^J[]JWMCF.LN0H!W!0-M)6)I]&W%*"E'
MR"#:99UM9L4PKHG.B5)0FPAIA9YU84PQG4=T_6"P!2(3-&-IV[/3^[256N6^
M!G)\3$,`ID3B8QZN[$J"9@,J/)L0#!OMIJE5@S?UJQE2RHVQ73ZQ<)R1CK]5
MZW:LB-*^Z=T2H(/VPN7L*XFT6QVI9ON2F-W`'`_P:G+I?`U)%,QKYJ?2Q)#E
MES'O)R4/CMJQ0(,6W1FG]PA3OW,8K*5B.C>_?'22D&IR&34+S\W``UI`-&_%
M*BF"?5GZY8"BJS[VVQDZR:&K%-EJ/0?<BS3);M]:FHNFD%(LGR!4VSQZD42@
MBH`*)G`2&`#!MHL-(0"8ILMO,PQ/\7J1.+8CSG`DM<%(V7W/\1)!L[JM486^
M5J$K-V;G9]S'LFLC%'4$!$H@F<`X&`0UA-:Z`J5[IR\UJO49WD&<DE&%(AH%
MU:%Y%RS,Q;QL&S;^()(O2JD2<`BN@4#<H\3;[_6B&A"\]Z_YK?3SD'&+J_5J
M,O\`/KCDB/Q8E5:A"N;!:)R8?D\?#'A&D4DY[MA)Q2J3P!.4![E<H=H#JYDH
MN$<BIF30PP3DO?F58NK+&D.(>CY@M\A=R5TLU!U&G/)&?QXM;I!:$K(6V,(S
M4=QC162BW*8FY2D$Z*GIU9J(FKRJ'6`DL]YA%,QVV?KVJJVNX6%D^N,D),>5
MV25,C0JQ.JL'EKF4EVXD[AJHKW)VX!WX'1/PTVRBTPR95!\T/;NKO//,CZ76
M>9([`!K2NWE)JMM+?%VEKW(P1"2L6E8BQ,DN!@-!RBK1T01;N134#F`!#4H&
M-LYJE714HVB/-9Z;+95+7=ZXRO5@^*-IJ56=5^"@EYNSS$YD.05C8[W,QCDG
M"D@BBU;)[&3*;NT^([`&^D6V115X>=288O&=/Z9ZZ*_C="RGM]5M]IG#V]6#
MKU%K-5E%Y>"91T0R?JQ\F<6@HJN$F#HIUA2W`3@(]@ZQK<CIKS&,+P$QCV&A
M*?DZ]!D""ICQG)5*GR<^RIP7]90*A&6DS%LY.T>N%@4(L)>#4$1*KRF*.A"E
M7+'5KC[".3*7CR[P-I=+7M\E$EO+9@+VAP+H[MTZ:MYJ7`IT(T5'!CD1!0Q3
M%#8!V$-:V-BT$506.80'$95%;/S#<,E>W0LQ6;_4HFG,[//Q-FFX)9G&WH*[
M87<7+Q]&=J(D2M1G$L!DTU&@K)\QN01YRB&IP($.!54)X].W5$]R])Y^?66J
M3^-X_&3N,<.:[?X1W6;5#QTM7VLXY4?,9!!J?D/&*D%-7E[M0X"(#JB<*`,P
M5S)@:#D3*:^8GAEQ5K]97]<R=6&U*A(.S02LE5GJTOD>AS<X[@J[9*8FBU,:
M9AIU^S4(B4G.H)0#5"EKQ'<336\QAI*6[']5J>`LSNGUTL=\K-FB']%?L%<6
MS-8CVK]%2_QJK$LA%H.H-RVE07,4B8-G1`$>;?5DL<JN"3IUH02U7S&\94^$
MK*ET@+[:%AJE:MMPN5!I<X>LP,7+R$A$PLRNV=-`?=T]=,^Z(!2\QC"`!K4Y
MI-`A!4@@4FM/R!ZU6EJ<5=>K4C(46FK*VZ,M5$N6/K'$9$=2<"W(]%)D1S'H
M-6Y_!N$E2@IRF`APWT63#=R(!$=Q,1MYDF*T,;QN5Y+&>8H"`L-SF:JNA)UM
M5BY@35!RVBI68=.ET"M7;!R\5$>9`QC&Y1$>W1!T:\_C0;.19ANNB1M%XOD"
MECVQ4.`HN4X>FQ%]M-3DEZQ>8*VQ3.28_%EW&LS#'/BMU3/EA>F*!&ZZ9QV`
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MAHLD[;NDEQ%,P[I&`3:$XC,B,N>837V4MC6MXE@+':75NM&%8U]=%*T]>X_J
M;/)9G;@L'-3K5JHSA;*XKHMGA4EU"'!-R0-N8!T)1TJSN4>I>GXNO5*QHSIM
M_MUGN(KHK&IU:D9=*DU]LH8C:S7)9!NJ,?#/W!3$26';F*&^_IT*1LY%#*GF
M!X@BYG+<),52ZP3_``[$L+)969H,[]_9XB9E9"+(YKK!HBH^?()2,>HD``41
M#@7M`=:Y8-FNNI5F"+E>OO'R&.0LL=1,OK6^9GI^I1&&34]ZVR`E*14,QGTG
M"\8X:%68QIH23;ORG4*!>Y7`!]H!#3@0:81SIT<"CVK==+56F-+!?HM[9`G*
M9`.JG0Z)6YA]D:W62XR[YBPKD.S(V,61F5F\083$1`PI@@83@`"75%XDZR!0
MTY,B0T[S`XB$Q(KE#+%6R#"PLQES(-(5?L:L]7=X]A*Q;%ZU'#<8<C49%B]0
M9(H(.R@0IQ..X<`'6;J9\(HBD\?YF%%JL1G:<R+B+(=)J^',B*8[ITTTK;I^
MPRB=]&M)=&&K+E%L?QCY!LX,LX4()DD`$0,(&*;3;=M6;69$5/=`Z\L,96MV
M'ZQCEA9;0WRM1%<@P=ECV/>4^H0::@M5'5BE@`S0FSP#)@H4XI]X7EWWWU-2
MHJ5Z$V*JB!!4,@J852+%[TAME%R"!2.UM@YBN.4`]DOL`/`.&FGY$O%F`"4I
M>7D!4'*@^T4ZKH@;`8Q2_:^Z.(;F#;M[-06U:>",H1(JZO>'(H=<%]S"NBL<
MXGY6YS<00+S"``/'EX:$(P[%!905%0YN<BI%2;`!515(FD90P]O,*:)0V[.&
MA"U1:F3[TP]TF)ERJID;E,"8`DF1%#O.;VC&!(@`.W#APX:$+8[--1(R?(1(
M3@?F41W*<#+["X,00VXG$H;#ZM"%@S,#BF)CB4$R`0.0`$0%(?TNJ`F`=E4P
M$0$?AT(63-CB98Q5`(+D`*LJ7F*L4"@!2]R)>!1$`X[^D="$>9(-@$I2"H4O
M(!E`WW+MMS&$.//H0DZC7O$R@<J*ZI!]D[@G,!"A];R@`#N8`#TZ$+*C0JAB
MF4`BQRF3.4ZI?:1.D4X)G0V[#D%0P@/PZ$(':``("D("JW1[HAE>8"GW(FF9
M14$^)C@1,.4?0(Z$+<C<H`4#E(H!.4I#'W$XE3W%/O-^`FYS#O\`!MZ="$6H
MW6.5<PJ$4.X*4#H+BHHRW*'+R@F.Y@34*/M<.(Z$($:`0O+RHG(!"E22,F`)
M-NZ(!44D"`&P($$.P>(>C0A%^"5$"G[U,%C;K+B4FR1GOAT$2K%+MOR%,D8=
MAX[&]>A"3OHD))FJS>'`Z*Y4TSI$$Y2))[HJ*@B8!!0P]\B'(!N!2\-"%T#M
M@$X*$$`,5-8")"4!1!9<XG46$0#GYC&'0A8[A0$"$(9/O^4A%5S$XF3`-CE(
M(!S``]@;]@:$+;N`*42)D2[LA`*@D<#"F!MQ$QU`#?<P[]H<="$41NND``DX
M$-DUAV.',45U=N7??<011$/9*'K'X-"%L5)SN03K$``10YR)%$I#NBF4,Y.8
M.&Z*_,'#MX:$+"C7O`,03;)')OW8```BL4`$IT#?7$#F#B'#AH0L^%[P6RBQ
MP%5NH*Q@2*!$E5]N4JA@X#N!="%D&I`*)`X%.KWYA`1Y@5W`>4N_8GPT(6#-
MS")2D4[I,.=0W(&QQ<&-S`?F])2]G'T:$)>F4`(7@'-L',8"@',;\T;AZQXZ
M$(S0A#0A#0A#0A#0A01EC%L-E!?'<K*OI*/3QU>F-X:J1(^T[6AS+>':.1(.
MXQSHZNRP%YCB`!L4="%U+M2Z3DF+4JF1(*-LS)L5A-+0*GZ8CVK@CQ<C4Y4P
M`SA1V*J?8)`W$.W0HO!+2`H*S?TMUS--GJ=@D9N5A34^B9+QFU;PI"*<D+D"
M)CHAXGR@?N@(T;QA-Q.)1'F'8-]-9A+>:"HRM_1Q'2XC:H/(5CH5O0M.+KU'
MVF-9,W,FP#$E9CJL6H1?O!_'LR5N8CF!%E5#JD`W>#PWW`!`E3*UR<@]&%:N
MV/H&EDR+.PUPK.59O,%`R`I"P]BF*S8I]SXMR(U$DB:/D:X=GR)-SIN#F*F`
M;AZ-*"T:Q@HC2B['T&5._P`Q5;?:;/*2=OJM9)5:O(_%N*;.J[!*H*(VB+BF
MC:24+'(7QTH9PX*H*94@$I>(E'1!&L9G7'J?0JA$#$260LT77)UIA!@*Y09Z
M6!A'2]-IM,DW#B*J2S9)\[([3<NS*'6<\P)@H([[%V$13;RA%M2GQ;IPH),8
M97QT[DG\S"93G+W8GLF^7`A6+^USB\[*.68N`39H.233I0S?F.'>"7@(AL(B
MD6.%84`S?0S:;-&5B67ZKLE*Y5KJ=@KJ>6WD<FC<5<8S[U5ZXI$VW.Z`S1DK
MWZI$U%#AN4X"`:LED-,7*F<'!G"N\PZ$*$2R#(Q-@N3")"RXOMC>/;.&WBF+
M+#]"C:)6XI<$W'>I$F/`"]`2E$?MG'8=7B:+-/K+&6TT5*)H#RR:]2:KDB)/
MG6_+2]]&G^(NRT-$13J(7I\H\GJJBBR>3I&<JN9Y+G+S*N43[I\0#<-)TUI:
M<ZFQO+&9/9[Y=XM&D3)U?.=OA<Q+*S3O)>5TH&)<3>8V4^\75GX66B5YEJ2N
M$41.("H55<I0-N`FVVUE6U=&P=`E(F:;EC'5;NUFH#+(TYCB4K#V,;LR+5>0
MQ;!LJ[&OHU/QR"DVK8D(\'*X[%1.93B8-"%P*_T`QM7K]%AHK-5KBWE9)EJ+
MN\HK4XIL^R+!9AL4G89JM23*/F';8JL9-23A1FDB=8YEE#J&*!3%,84@UQJ2
MUMY?<>O,12;;+-C98Z/%UZ-R#BIE!5US%93FZ%"-:M6YF6D_C""[&<A8J,0.
M](5)0._`W*8>W0G8<IMQOTHUK'=DQ9.-[/89,^+JUDRKP<>Y6CV\6I$Y3>(.
M'BKY-!XZ%5JQ?-%!0.8`.!CFX"/#3"S3PYI'"IUK^(\9UZ40E8>A4J.G@<(J
M&F8R':H29W)&R+-T]:O003>&<(E:E,)^7NQYN)@TU1!53R)T5HY&R6:XM,J7
MB&HM@M!KM8<*0JC4*-.VV$0!#WO,2C1VHLWDY!#E$P=T8.<H!OPU)C@QP<[U
M5&!(@$Q:KT)6"A4W(V-Z!F56F1]QCGC3'""%%KCM[CB`/)R#Y_#NY+WN5].%
M=G?'YC`GLF.VVXZF;Y)C`&.E(".^JT=4'EQW!3I]5IO3W:7-KN$:PH+.1@K6
MNU0@;5#03U_*6`'3M\\32B[NZD910S8KA5(J:(D*)PVTQ>9`R@#A19*LABKH
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MG.DT?B5JHBU<`0_$>7M'6)]U(B3`[RRV;QFHWU?..Z+*S'.K(N?(^068W"OW
MVK*D=&;O@CSWV:5G'[B$D':S=V5HU<N#+)H%2$IBK`41`Q1`,LZ\2S0P<GT+
M3=Y,^82(&I-J%Z$J;4,ES%E:W8(RDR]72A+M1I2KQ)CV5ZTJL33V%E4GG[MN
M+>4?(Q(+`"/><AS;"(#N`5&>V$16M(NTV-5!WD@KG06RJ-0KM`E,J6&1B*/D
MBDY-H[HM>AZK/1#FBOGAVL&ZD(Y^^=6%BNU5*&Q2&$"CQ`-!G-(AE@@2)C2'
MD<F.XIE:=*-6:Y3E\H?&.;>/[!:K%;U(PKU-1LT/8:?$5Q1`Z;D4DR"@9H8Y
M2&$#<.S?66!5^L9G7FU+]`_4?1>JK"]WQ>UIEOQ[CB+H]8@+9<T&[EU%PM:.
MNXF!F8]1<DD]F5)1XZ69JI-UBHE6+N8H@.R1K&9U=C.?0E#YESG#9Q'+-LJ0
ML8^N+V2@-(=C:(N:FH(SA)FG&G<2;8*T]19'2*<B*:QSB45![=:63`UH:LSP
M'.)"W4Z'*Q8F\-!IW>V(_$FM9<J[:9BRH)BJME&VKVU14DJW5<DDG=5EUE"B
MBH5("G`2[\P"`2$UMH@GDJNS1NI_XLZ8AQQ"Y697_*EOS9*9I13B+;*VE-E&
M2K\RD<>#8&CHUJ^?(,E&L<EW?>G6`YNZ`!*78-ZIC@Z$*E5-$RME(/A%5+O7
MEZVF*PU8ZI7\MV3(ED:GQ_5\8+7(K,PX[Q327Z;N%@(E$[O=T^B_$&<MQ.*?
MUVP@`\-5$*FQ/(-<0:!N*9VG1)X52NS2N<K0SRW%9,<WG).2_=["/?9:+*P#
M&LR54GF#J30.6O#6HYFU`^YBB5`/@U)D&NBZI62Y=XUG*JSQ7;#H+I)*9;L?
M-K39HN#OD#4:6Y.WA8=0[>NXXLKN:A(MHI[V%3EEU%>?G`O(!3!S"`\-7&<*
MUK$EV5/2R=&"5@M]OOL;>)ZHV.QSMCLT?*,FS:0EX60LM4B*HY21[UZW0W10
MB"JALH`"8X\=2,YD(!(27G(JO3/E:SULQ[CJDW+J%R!,R>,8*1K36Z(UR$+(
MVB)FWY'CMM(P2E@)'G,V22(F9P=?O3[";EXZ9G,R&E`DS,H4[(=`K0\M;R'R
M/8VU%M4IBN8/CX\1'N81K-8QB`JKR=;*C*`HD\OT"R;DD2@38J1"%`3"`@`)
MS84FE&IF9DT8_P`N"*%O<ZS9,AW6Q8Z?0LG2\3T\O@HEOA2I3\][\FD*OW+U
MT1P<KEDBFW$W=CX3NRF`#`(!G>X/=%2$I^6I613Z8(MVAEI*:DIJ3;9N@8"N
M71%RX1!R5"OQ*4-&32!2'%N2;29-DBKB!A*?NB[".W""!+F50H4,5GH(<140
M\);LNWG)%E1FJ9[FL<THA&O(^DX\?NWE:IB`MG#L5(\Q7IRK"<2[B&^VBA&J
MF')2I9ZE.E*M=1#:/;VD\V9BA4+)37,+%>`.V>LK,9JJNL]>/G3=4"MG+1,X
M@4AQ,)-MN.B(1JGYE5*T^5XI;\:5JES^:)=S9ZM+NSH7J+HD&Q>/*VY@X:";
M0#B%3GD&4F6/9Q!0!PNH13<PF`@[<2A&J?F7<6\M5NTE*(G7LO9#@J)4Y+'L
M[8L;,R1XUS(-UQNBBQB+M/.S2!'*3AY#-6K15,J)QV:%]&VA&KF505E<J=,$
MU>,M5[+U.R;,XWLB,*>I78D/!,'D??*JC(.)!E&3?>R;=8A&?BQ21.4IS<I=
MQ`-.(3,MYI@JRU3ROJY5[A=;>YRS=K(:VR+XT?'RT##K+U>#=6B4N2T`UD%)
MLQW4<>Q33E5N!@#NDCE)L'+J]LX-;#,$C)?D\/&I#R-T&OK@_L=KJ>7K9CG(
MUNR0ED*6O,(V;C*'1"B5V@O*\JW\65-%L^@JX@F;NU#%Y@$=2UTN$,BCJIE<
M%PE_+NAVL%#Q5;OMMA9ZLQU(5H%T=,8V=>4*YTX7@!;THMQ)LT7SB0\4J8Q0
M6*).^W#<=]/7,A&-,4]2_,HHN7E0HW*G5^N/<[WT[QC9KQ.W"8?1,<]=VQ;(
M4\A:I>2AD33!$:U(L9(@)("`J\H`?CML(LSF1H-$$:E_"I/O/EXA:4;D<F5+
M-'J3]DJ.2*Z"-6@IM6F9"KT2SAW[]N,E.,$K#'V%)D11^T7!NFJ8.!QWU!\Q
MCFF%<?$F)+MV"<#OHFFY;)6%+S-93E56V&3BHA"5ZCUZN-;/8E2$!:U.GS.=
M%>)A3D`2>XTT%FX']KO!$=9J$&4_(%Z-I%,5),HAL(;;APX>UOZ.'9IQ"-6^
MBA*.41X@'`>/HU%:PAR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH
M0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]
M7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^K
MH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&
M]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0AR&]7TP^KH0C2AL``/^3CH0LZ$(:$(
M:$(:$(:$+SZ\P(<NPO3A<;UA_,$QA&:I<>A+GE(>+CY9R**3]%%PS4;RJ*[0
MS=V"P<YA+SE`H"`[Z$)_5VUH8!PS39O/66E+"<B:;J<R2_01+)3TO)KG?Q[`
M(F%@CB9FFF]*``4Q0*'$!#??0A5UZR&6;B.<57?#O4I.XJ@[I;*'0V\'`5B-
MFPLCFU"V5]X">4<)"BJL1?<-P$2B/$-]"%#%$ZI\KXPO.:*CE!K(7S$M<R&O
M1%<YS-HCD+#7)N.I\/(.ZZA3D:WX!R"^YN005*!A'CH0IBZ+.N)MUB2M\;,\
M;R5&CZ0VC9>KV5G.NI:M7"`F'3HT,N]?25&K2\9-.F1"+.HY@J_0;G/W::ZA
M``YI16(FM-%YU1956P0K<&\K#)VUUUK+8,;.HULLU\=66.5;/"JLRH.'+A47
M'NA@5,#<PB8I.<2E`P`"2R1RQ6TQULVZT1U^=/L1SV-H7W7D!3&=TAYQBXMT
M^6EV92MV-1"`>P[EF;E?,U#%,*H&`1$!)PW%%5OO9DFQ"BOPI2RW=?E9I=;?
ML;75Y%S+UMY-M[Y#GL3+XWQ%>KL1%RL?..()"O'8"VM#&30-SE4`2G$PI@;L
M`B`EVE13Y/2FEC_S'+3EZNX_6@>G^1CKQ?,Q2^*"P<K<75?!H$%'MIA67KK^
M5H_B)E0]:>-50%TV[@%3F*03!QTQ"*DR]:\V(4T>5=QYUE7ZX$N21*,_Q?*4
MS)E0J+8CBXLVU\MT<F9=)VE,UU>K*M82J2;A`P%>H*NQ=%]I,Z/U@.*G:(39
MH77M?F<`6R]3>+H&BP\W-9GEJ5:J-=QM<3-1./9Q6'@8R?BI>M,TF\O)]TF!
M005.;8>8A3=@BDT\H9XJR>4^K*VT<U1BZ=AE"Z9-F<:1F4KA"O\`(1()I6Z6
MX0*I+K0LLI47@W![''(J4R(M8P%!*&YB;[!%;%$/3OE;->=>IW+,\9JM!8)J
M^.::7'$*WG6T@^CK)?8%K-MIJ0JBT0D[07;)O"F$P2YD0$-BI[;:$*L%[SIG
MOH_L.8+YE?J+MO49!8]D4ZU1\-NHZ'KK&]6VT,6CX@3=GA*>]DX""J;AR=LF
MZ0:N'`'2$@E4``4,+G3;\94TR\VYZ59V!Z^B2Z>#(<F%[$QGNHB%38XK:RSX
MT7&N+C#N7"-ZC)N47C&4K"15<%L=PQ>*1YU94A@%0$P'@4*!Q$^`]*YB'F&O
M$G.?ZX7%K>V3.+8)A(4QS7,@A*FRC'MWK^*DK%-"A16R-&0C9..6;[-O?")A
M2,8PD/S`+%2FV\=8$<H4XW+JNFX/I5C\\LZG1YV?>P4%(LJ@7*`.V*2\P03N
MV3.Y-*E'GDI2**F)5&2,>8ZJA1*8Q-MQ>13R*+<%]9&7L[]05+J=8QI6&^#[
MI@6OY5=V1Q=%&LS5)L;;9J[**1D6VK9"3B1G$+R%(JJ@50=]S@(;:DP!Q@:D
M")H7)R-UB/JSUMT_#[6Y4-CC-LU/2[)0I)0Y,E2MPN;8)F'D8]\#P$&C%JGL
M4P&*(D`>.XZW##^1DM^+R)6A'<3UG>M_P-)A[<TQP]EQE*]E6ULZW7K(@]L"
MC[%MIDZ@^BW$=\6E$I>"<O(GF,\`X."ICOW8\-`N`-&4$1T1HH1$<"BQUUI9
M[L-AJT5$T:BP]"F>GVTY1L]YJN1S6"3QQ:(B>E(^2C!:/:L4CE9JLT%(R9]C
MD`.(!KG.$'$"H%;A4G+$=;]S^,N/HAQAF0F<?35[Q?C"RY9D[2@D>7L&2:PR
MGH>10CF#)JFDD5)QN(%*&X"`]H[Z2:L/DSKAZ=<'7Q7&UZG+0PM3(8^5-&0M
M*M5D;NDYA)-5@4LNS8*M"@DBH0IB`;<NVX]NF%FFPMTIL]676BKT[MZ#-,*O
M`W"MVY*,L,NE*6T:Y9(RL2IV31N_@Z^6#E5I=R4[_98BRK`B```]X81$H.*J
MC!1*\ZVKTUOUTI-5P6T)2*A8;CCVG7*V9%]WOY:^U6NL;$6&D:TE79Y1*`F"
MRY2+/R/P6;)IE,5$_-P1473S(%L*$ICJQZA7&*:;;+1!LZ%DBRX=@KK\2*)=
M&-HQJX*I8G[)(\-;+)3PE"2#D&X%-WC94A!$>T=**J[1/@/2IS3ZT<H$3=T*
M#Z=&3GJ697"5;V/'QLD"A6X>M-XEG=S39[Z_K<IW3EW79U);N4(TP<P\H;%V
MT4*3;^7D,S[GI46Y/Z]KU=:,62P/0)SW#&SE#;9*O3B=B5']=L]@63*>IP\`
M,<V)9(-Q];[[\4S,0/:\";LU)6Q5R,8=57WSLG,,8LJ@^C9]G`WY&_RB,DE(
MIX_F*5;YZK=VX6!HV\6I/*0XK-U3MVHN$CE.5,"B`:(A,&FA57RCYC%@QU4;
M7D"2Z=CN*O%91=84H#R2OCYA)Y(N[=VJV671AX&GSCIA$"DV`_BA%9P5<3IB
MF!0`VA1BG94_,%<S,ACJ3<X@DZQ2[9BZUY)MCK(%E5J%CBWT7)/&DC5,?UM&
MLBSN<DC(M%E"(N748Z4;JIK&'F4$A1.(RIC8\\T97)V+LJWB"PL>-<T-U'-J
M0>R6=W7(FYM95MWC$/C5)TLQHJULA04,LP;,)9(`,4"NCB(B!%**?<%U_'M:
MU/G(G";Q]47^%9#-^3+8[NK=@:JL860D*F:#K\0$"X/>'#Z4@#D3.=6&+P$1
MV[-"$T[KU'=23B+P);VF%4JBK>\B2+^M8YKU]:70V5<;.ZK#V!K+W&S257BQ
MJCDI'@\\(U1>"42;>\`V'=%62SRP%Z5X/RB&9,4T?(PQ9(1Q9X59VY;D.19.
M#>M7*C1PR)Z%0(LB8H&*(APTEK4VZ$+.P^H?H:$(;#ZA^@.A"&P^H?H#H0AL
M/J'Z`Z$(;#ZA^@.A"&P^H?H#H0AL/J'Z`Z$(;#ZA^@.A"&P^H?H#H0AL/J'Z
M`Z$(;#ZA^@.A"&P^H?H#H0AL/J'Z`Z$(<HCP$!V'@.X:$+/<E]1?YT-"%C8?
M4/T!T(1P=@?,#0A9T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(
M0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(4&]23;%CS"E[:YK
MD5(C%ZT8F2W22:,@OX2.\6W$%3HQ;5Z]43\0!`$")'[>(:$+MIEIH0,#XT\&
M:J^#*$4$R5#N/`%BV9(@Z)GW*',HP*0_9S@!@`0`0VT(42YL9X6=1N*0R=+I
M1D:VR;1'>.ABD)!5.0R,D"7N&*3]T,GO<D="!.517NT"@/M'+QT(4#3T9T5H
MS%^<S=A2>/OORI/;M'2#>=1AQRL$$@4L,]75AB-2F&"`IA5[P4.4?Z)ON&A"
M4='5=P-#)6]YT]7[)]MIDQ+Q*]=B,F1.4F5!J,?X1,8UEAIS>J]`Q,E!>[Q3
M!H:&5=-@;@3D,)-M2%2Q&L[Z@9G"="!^JDL]&W&Z(WI3(+MHRI,HSRNOT_H9
M<36>!)RT?(.*VCC4^2W!A.)TTI(SPKC?V.;M%&B.XI*D8?HD4I-9:S%KM*$"
M5YF$:K)%9Y,//G76R-/GR6!D4H!24\0UM@N2?;$BF%'E[OG)RF%'=5$UMW+A
MK70=#,<^Y0FQ.1G0`IE+,ZLS88]O?'>#:[&Y<;/T+HJK%XH1B4B5*PQAU846
MRUR>0GAS%1:&6E"#R!W('X:5"KL7'G^)R4XI@>E&&9=.+2-N^7[=8VUWM"^&
M9;.C',K"Z2%K7A6Q7[*<:W>L0LN6.95HJ)HXSY-NW,F8H(G/J67=5TML@$ZM
MT7<-7#0F%4:ST&M,EW\C;(N1Y/([V\UB5G5\J167D[#$"9\\-1:Q5TKC5&"*
MV)TWH.027:^(AA`?Z/L&^A6T9$P;K3^C"0IL;X#+4Y7\2*]:A;39_C77[Y*1
MS?):*<83[V.*C'J`$^(3MXF4QI%@5:$(<Y@!T`@(`E)L+0AG5FNL2#Z3)^QX
MW+G2YW:C6Q&KSJ\`?&;#)LK..Z=[Y<FE6-A"BUV=7+4P6`Y5E'@)(;B8=^7C
MI+:K&8,;=/*-FR`MB*0;.W[N!H/QM9L22I$HN)0@&9:!W2KMD@#A!Y`=P9/N
MS*"4NP'Y1X:$*`<]0W1\_9YR:Y-MEQA)F2LM:5O4E`-,D.;+7[(2`B4X5M1T
M*W7I!\Z65CBH'.:*3=%!4P@<0/N`%"Y,]MU,UUMT'1S.\RC^;A>C%LXH[.YV
M[*\C:PB:F%7EK^VS,CE(R#:7DU(,8!O+5=M9.\D5C+DE>Z1`Q&)2"Y`B7*86
M81IK4"RY1Y3Z=YW$H3KE/\N1Q(YK2QWE?+3!Y,1\RO/.<?0>;EAJ=/3GIE2R
M,L;HQM*72D<=N+2>13=&C/%LRO"+")]Q'0(*V4)(!U1B(YCYT^[G!^70ZZ+L
M1P$A<I>-Z<0MJ:>,+S6F64%KD-Z2=.A%Q`Q456W=L&2<N.^!X06)0*._>;::
MN%4#4GKB&`Z*"WOIQ<8@O%T/8H3$3)'%<?!QV1@2N>(%;%8#L7>2%GE;+`QC
M1K?#RY2EFU&8G6*(\H^R(V2BX/Y`BZ"##(N/?XWRSW7WT&UTL%"C+HXR2B[M
MDA)-IEQU$L,B@=F8(NME<1*^45(@R14P*>(;JQ_=&'93D`PZW,=>K32&F%FB
M!$(>2K.E1`[Z8E7JWE^N[-DHU!R7FJ)LDS5LCI1"<-$Y\>-*A#'FGRF57.*^
MZIQF<BX2G3.4W!8H[PXG+N0NVPC<'WV%+,E-+>-+DQH6U)@_+B)"XD;T2XVM
M:#@ZEDX(J0BFN5R2-TAWC@2Y#-EING5BOHIS$2`*"[]]%:+JKB;E`P[@'&=&
MT8UQ6\5*>XV%Z)0^+ZK&X/C1I,KX==0;8&%Q]QK9)2J+,N.HUJ=S!%0*+FI^
M$,FH<X)`3;F.4>&DFO2)O[Q!:,*F`G0(B*:ZJ/,45BC%L?TPL4O$JQ5/K2G`
M#[;;!IA9YEJW0O+WK=KO0A*9(QVXZG+]-5K(D=1GXL&%?BKF[&?H'O-H+HMF
M5K-<F&[.)\?W7*+Q1`O>;\.W35-&5/9HQZ02+RKA.915E&^8+<X48))6$B\A
MD=2I1(S#"1<H10+-U&]2,V`YU!*D8A2B!QW#2,,M2JFB46_OC!L=WS*N[*`\
MN,F*SL5[MDE7'ZU5,M`3,^TS,$BUIQI5\=%G2FKVI)R9X0DN=<B:C5$X")-R
M\!`=!J5#F7.CEC0[B7$F*GY>ZV*H>%=9/SFU;L,AJ2"%PB8G/Y\ZSEM-"QBK
MN"G(YI25[VSKB=!-&)=ZHR29BP`AN]VW$51PJ36W,$671?',Y.^Z0/EQ.+EB
M20D;O*,4&<%5T*M`T&.R@;%LJ@F9(U*>Y6=5RO/:LG<ES<I2A,.&SX/S28#N
M.I+50I\Z7X3%['J0ZQW=>ND5-9>E[]4Y3*,7%Q,ZT)5(OXLQJ,16'RTA%M(Z
M3>`FF*WBD%W!154$#&!0#%`2WTU\BPG1W(8;D8MS<+M!5=?.,N$'9*&QR@YR
M4QSN2:<FG35=I6*](VE5\L^YRG*U:*)%#<=^70A-RU5WHW2N6#GV2K]DIP_C
MX*<;XVA<JQF6`K,[)>(?EL3^TN[#64(AK?A/SGV?*MWW=]V`);<NYE3RJ%I>
MF^7T&#EF%QRWGP<5O[_47--G+W!Y\$L)*H.90]<CL4LY6C)OW4,]6.N0IXY)
M9`B9"B<X%$HB)4*;\.PW0<QB6R>-[<YF63?I]E6(N+:QR&@Q?X>/>+8O-S=C
M2FH*.(B5&U+2"()..[<"HCS%3$HE,80D&#J_T:1AL>&JMYRY9(HV49AWBHF0
M6.8&;,DN-?034C,?_&NJ1;'[WI(@.\`R0FC=A`.]$=@TBK)7KKT%P8ABMKBN
MH-L4/!DL?(L9`E3D42OD2.X4\FY.\721>-6KE,$'YE"<ITB&$0W`!#CI+6I]
MT(1X=@?,#\C0A9T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T
M(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T
:(0T(0T(0T(0T(0T(0T(0T(0T(0T(0T(7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>syn-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:syn="http://www.syntheticbiologics.com/20130930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="syn-20130930.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2011To12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_12_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-11-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn03_08_2012_AdeonaClinicalLaboratoryLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommercialPaperMemberusgaapCreditFacilityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:AdeonaClinicalLaboratoryLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2001To12_31_2001_MaximumMemberusgaapRangeAxis_StockPlan2001MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2001Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-01-01</xbrli:startDate>

      <xbrli:endDate>2001-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_StockPlan2001MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2001Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_20_2007_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-03-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_MaximumMemberusgaapRangeAxis_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_02_2010_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-11-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_EmployeesAndDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_StockPlan2001MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2001Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-10-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>

      <xbrli:endDate>2012-10-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-03-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_20_2011_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_26_2012To03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-02-26</xbrli:startDate>

      <xbrli:endDate>2012-03-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_20_2011_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To09_30_2013_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2012To09_30_2012_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To09_30_2012_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice220Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice220Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To09_30_2013_CantorFitzgeraldAndCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2013To09_30_2013" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2013To09_30_2013" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2013To09_30_2013" id="Factid_3">2013-09-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2013To09_30_2013" id="Factid_4">2013</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2013To09_30_2013" id="Factid_5">Q3</dei:DocumentFiscalPeriodFocus>

  <dei:TradingSymbol contextRef="P01_01_2013To09_30_2013" id="Factid_6">SYN</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn11_12_2013" id="Factid_7" unitRef="shares" decimals="INF">44654414</dei:EntityCommonStockSharesOutstanding>

  <dei:EntityRegistrantName contextRef="P01_01_2013To09_30_2013" id="Factid_8">Synthetic Biologics, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2013To09_30_2013" id="Factid_9">0000894158</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2013To09_30_2013" id="Factid_10">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2013To09_30_2013" id="Factid_11">Smaller Reporting Company</dei:EntityFilerCategory>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn09_30_2013" id="Factid_12" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_13" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn09_30_2013" id="Factid_14" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_15" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn09_30_2013" id="Factid_16" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_17" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn09_30_2013" id="Factid_18" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_19" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn09_30_2013" id="Factid_20" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_21" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn09_30_2013" id="Factid_22" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_23" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn09_30_2013" id="Factid_24" unitRef="shares" decimals="INF">44735896</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_25" unitRef="shares" decimals="INF">44444230</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_30_2013" id="Factid_26" unitRef="shares" decimals="INF">44654414</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_27" unitRef="shares" decimals="INF">44362748</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:Cash contextRef="PAsOn09_30_2013" id="Factid_28" unitRef="USD" decimals="-3">5145000</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn12_31_2012" id="Factid_29" unitRef="USD" decimals="-3">9954000</us-gaap:Cash>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn09_30_2013" id="Factid_30" unitRef="USD" decimals="-3">1647000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_31" unitRef="USD" decimals="-3">2509000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn09_30_2013" id="Factid_32" unitRef="USD" decimals="-3">6792000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_33" unitRef="USD" decimals="-3">12463000</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn09_30_2013" id="Factid_34" unitRef="USD" decimals="-3">157000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2012" id="Factid_35" unitRef="USD" decimals="-3">223000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="PAsOn09_30_2013" id="Factid_36" unitRef="USD" decimals="-3">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>

  <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="PAsOn12_31_2012" id="Factid_37" unitRef="USD" decimals="-3">700000</us-gaap:NotesAndLoansReceivableNetNoncurrent>

  <syn:DepositsAndOtherAssetsNoncurrent contextRef="PAsOn09_30_2013" id="Factid_38" unitRef="USD" decimals="-3">4000</syn:DepositsAndOtherAssetsNoncurrent>

  <syn:DepositsAndOtherAssetsNoncurrent contextRef="PAsOn12_31_2012" id="Factid_39" unitRef="USD" decimals="-3">37000</syn:DepositsAndOtherAssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn09_30_2013" id="Factid_40" unitRef="USD" decimals="-3">6953000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2012" id="Factid_41" unitRef="USD" decimals="-3">13423000</us-gaap:Assets>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn09_30_2013" id="Factid_42" unitRef="USD" decimals="-3">584000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_43" unitRef="USD" decimals="-3">395000</us-gaap:AccountsPayableCurrent>

  <us-gaap:Liabilities contextRef="PAsOn09_30_2013" id="Factid_44" unitRef="USD" decimals="-3">584000</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2012" id="Factid_45" unitRef="USD" decimals="-3">395000</us-gaap:Liabilities>

  <us-gaap:PreferredStockValue contextRef="PAsOn09_30_2013" id="Factid_46" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2012" id="Factid_47" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn09_30_2013" id="Factid_48" unitRef="USD" decimals="-3">45000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2012" id="Factid_49" unitRef="USD" decimals="-3">44000</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn09_30_2013" id="Factid_50" unitRef="USD" decimals="-3">83358000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2012" id="Factid_51" unitRef="USD" decimals="-3">81925000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn09_30_2013" id="Factid_52" unitRef="USD" decimals="-3">-77034000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2012" id="Factid_53" unitRef="USD" decimals="-3">-68941000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2013" id="Factid_54" unitRef="USD" decimals="-3">6369000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_55" unitRef="USD" decimals="-3">13028000</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn09_30_2013" id="Factid_56" unitRef="USD" decimals="-3">6953000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_57" unitRef="USD" decimals="-3">13423000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2013To09_30_2013" id="Factid_58" unitRef="USD" decimals="-3">1890000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2012To09_30_2012" id="Factid_59" unitRef="USD" decimals="-3">1073000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To09_30_2013" id="Factid_60" unitRef="USD" decimals="-3">4270000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To09_30_2012" id="Factid_61" unitRef="USD" decimals="-3">3717000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2013To09_30_2013" id="Factid_62" unitRef="USD" decimals="-3">1475000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2012To09_30_2012" id="Factid_63" unitRef="USD" decimals="-3">763000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To09_30_2013" id="Factid_64" unitRef="USD" decimals="-3">3796000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To09_30_2012" id="Factid_65" unitRef="USD" decimals="-3">1696000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:OperatingExpenses contextRef="P07_01_2013To09_30_2013" id="Factid_66" unitRef="USD" decimals="-3">3365000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P07_01_2012To09_30_2012" id="Factid_67" unitRef="USD" decimals="-3">1836000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2013To09_30_2013" id="Factid_68" unitRef="USD" decimals="-3">8066000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2012To09_30_2012" id="Factid_69" unitRef="USD" decimals="-3">5413000</us-gaap:OperatingExpenses>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="P07_01_2013To09_30_2013" id="Factid_70" unitRef="USD" decimals="-3">-3365000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="P07_01_2012To09_30_2012" id="Factid_71" unitRef="USD" decimals="-3">-1836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="P01_01_2013To09_30_2013" id="Factid_72" unitRef="USD" decimals="-3">-8066000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="P01_01_2012To09_30_2012" id="Factid_73" unitRef="USD" decimals="-3">-5413000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P07_01_2013To09_30_2013" id="Factid_74" unitRef="USD" decimals="-3">11000</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P07_01_2012To09_30_2012" id="Factid_75" unitRef="USD" decimals="-3">0</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2013To09_30_2013" id="Factid_76" unitRef="USD" decimals="-3">32000</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2012To09_30_2012" id="Factid_77" unitRef="USD" decimals="-3">0</us-gaap:InvestmentIncomeInterest>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P07_01_2013To09_30_2013" id="Factid_78" unitRef="USD" decimals="-3">-14000</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P07_01_2012To09_30_2012" id="Factid_79" unitRef="USD" decimals="-3">10000</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P01_01_2013To09_30_2013" id="Factid_80" unitRef="USD" decimals="-3">-59000</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P01_01_2012To09_30_2012" id="Factid_81" unitRef="USD" decimals="-3">22000</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2013To09_30_2013" id="Factid_82" unitRef="USD" decimals="-3">-3000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2012To09_30_2012" id="Factid_83" unitRef="USD" decimals="-3">10000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2013To09_30_2013" id="Factid_84" unitRef="USD" decimals="-3">-27000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2012To09_30_2012" id="Factid_85" unitRef="USD" decimals="-3">22000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P07_01_2013To09_30_2013" id="Factid_86" unitRef="USD" decimals="-3">-3368000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P07_01_2012To09_30_2012" id="Factid_87" unitRef="USD" decimals="-3">-1826000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2013To09_30_2013" id="Factid_88" unitRef="USD" decimals="-3">-8093000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2012To09_30_2012" id="Factid_89" unitRef="USD" decimals="-3">-5391000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2013To09_30_2013" id="Factid_90" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2012To09_30_2012" id="Factid_91" unitRef="USD" decimals="-3">-104000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2013To09_30_2013" id="Factid_92" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2012To09_30_2012" id="Factid_93" unitRef="USD" decimals="-3">389000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2013To09_30_2013" id="Factid_94" unitRef="USD" decimals="-3">-3368000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2012To09_30_2012" id="Factid_95" unitRef="USD" decimals="-3">-1930000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To09_30_2013" id="Factid_96" unitRef="USD" decimals="-3">-8093000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To09_30_2012" id="Factid_97" unitRef="USD" decimals="-3">-5002000</us-gaap:NetIncomeLoss>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P07_01_2013To09_30_2013" id="Factid_98" unitRef="USD_per_Share" decimals="2">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P07_01_2012To09_30_2012" id="Factid_99" unitRef="USD_per_Share" decimals="2">-0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2013To09_30_2013" id="Factid_100" unitRef="USD_per_Share" decimals="2">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2012To09_30_2012" id="Factid_101" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P07_01_2013To09_30_2013" id="Factid_102" unitRef="USD_per_Share" decimals="0">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P07_01_2012To09_30_2012" id="Factid_103" unitRef="USD_per_Share" decimals="0">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P01_01_2013To09_30_2013" id="Factid_104" unitRef="USD_per_Share" decimals="0">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P01_01_2012To09_30_2012" id="Factid_105" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2013To09_30_2013" id="Factid_106" unitRef="USD_per_Share" decimals="2">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2012To09_30_2012" id="Factid_107" unitRef="USD_per_Share" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2013To09_30_2013" id="Factid_108" unitRef="USD_per_Share" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2012To09_30_2012" id="Factid_109" unitRef="USD_per_Share" decimals="2">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2013To09_30_2013" id="Factid_110" unitRef="shares" decimals="INF">44654414</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2012To09_30_2012" id="Factid_111" unitRef="shares" decimals="INF">33383226</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2013To09_30_2013" id="Factid_112" unitRef="shares" decimals="INF">44636935</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2012To09_30_2012" id="Factid_113" unitRef="shares" decimals="INF">32801415</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To09_30_2013" id="Factid_114" unitRef="USD" decimals="-3">1202000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To09_30_2012" id="Factid_115" unitRef="USD" decimals="-3">1303000</us-gaap:ShareBasedCompensation>

  <us-gaap:Depreciation contextRef="P01_01_2013To09_30_2013" id="Factid_116" unitRef="USD" decimals="-3">33000</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2012To09_30_2012" id="Factid_117" unitRef="USD" decimals="-3">51000</us-gaap:Depreciation>

  <us-gaap:GainLossOnDispositionOfAssets contextRef="P01_01_2013To09_30_2013" id="Factid_118" unitRef="USD" decimals="-3">-58000</us-gaap:GainLossOnDispositionOfAssets>

  <us-gaap:GainLossOnDispositionOfAssets contextRef="P01_01_2012To09_30_2012" id="Factid_119" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfAssets>

  <syn:EquipmentImpairmentLoss contextRef="P01_01_2013To09_30_2013" id="Factid_120" unitRef="USD" decimals="-3">0</syn:EquipmentImpairmentLoss>

  <syn:EquipmentImpairmentLoss contextRef="P01_01_2012To09_30_2012" id="Factid_121" unitRef="USD" decimals="-3">30000</syn:EquipmentImpairmentLoss>

  <syn:GainLossOnSaleOfDiscontinuedOperation contextRef="P01_01_2013To09_30_2013" id="Factid_122" unitRef="USD" decimals="-3">0</syn:GainLossOnSaleOfDiscontinuedOperation>

  <syn:GainLossOnSaleOfDiscontinuedOperation contextRef="P01_01_2012To09_30_2012" id="Factid_123" unitRef="USD" decimals="-3">-677000</syn:GainLossOnSaleOfDiscontinuedOperation>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2013To09_30_2013" id="Factid_124" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2012To09_30_2012" id="Factid_125" unitRef="USD" decimals="-3">-14000</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2013To09_30_2013" id="Factid_126" unitRef="USD" decimals="-3">-800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2012To09_30_2012" id="Factid_127" unitRef="USD" decimals="-3">135000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="P01_01_2013To09_30_2013" id="Factid_128" unitRef="USD" decimals="-3">-33000</syn:IncreaseDecreaseInDepositsAndOtherAssets>

  <syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="P01_01_2012To09_30_2012" id="Factid_129" unitRef="USD" decimals="-3">-4000</syn:IncreaseDecreaseInDepositsAndOtherAssets>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2013To09_30_2013" id="Factid_130" unitRef="USD" decimals="-3">189000</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2012To09_30_2012" id="Factid_131" unitRef="USD" decimals="-3">2000</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P01_01_2013To09_30_2013" id="Factid_132" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P01_01_2012To09_30_2012" id="Factid_133" unitRef="USD" decimals="-3">-2000</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_134" unitRef="USD" decimals="-3">-5015000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_135" unitRef="USD" decimals="-3">-4143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2013To09_30_2013" id="Factid_136" unitRef="USD" decimals="-3">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2012To09_30_2012" id="Factid_137" unitRef="USD" decimals="-3">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_138" unitRef="USD" decimals="-3">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_139" unitRef="USD" decimals="-3">-7000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="P01_01_2013To09_30_2013" id="Factid_140" unitRef="USD" decimals="-3">231000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>

  <syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="P01_01_2012To09_30_2012" id="Factid_141" unitRef="USD" decimals="-3">94000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2013To09_30_2013" id="Factid_142" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2012To09_30_2012" id="Factid_143" unitRef="USD" decimals="-3">1955000</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2013To09_30_2013" id="Factid_144" unitRef="USD" decimals="-3">231000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2012To09_30_2012" id="Factid_145" unitRef="USD" decimals="-3">2049000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2013To09_30_2013" id="Factid_146" unitRef="USD" decimals="-3">-4809000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2012To09_30_2012" id="Factid_147" unitRef="USD" decimals="-3">-2101000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:Cash contextRef="PAsOn12_31_2011" id="Factid_148" unitRef="USD" decimals="-3">6678000</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn09_30_2012" id="Factid_149" unitRef="USD" decimals="-3">4577000</us-gaap:Cash>

  <us-gaap:InterestPaid contextRef="P01_01_2013To09_30_2013" id="Factid_150" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>

  <us-gaap:InterestPaid contextRef="P01_01_2012To09_30_2012" id="Factid_151" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2013To09_30_2013" id="Factid_152" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2012To09_30_2012" id="Factid_153" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>

  <syn:ProvisionForUncollectibleAccountsReceivable contextRef="P01_01_2013To09_30_2013" id="Factid_154" unitRef="USD" decimals="-3">0</syn:ProvisionForUncollectibleAccountsReceivable>

  <syn:ProvisionForUncollectibleAccountsReceivable contextRef="P01_01_2012To09_30_2012" id="Factid_155" unitRef="USD" decimals="-3">269000</syn:ProvisionForUncollectibleAccountsReceivable>

  <syn:ProvisionForUncollectibleNoteAndInterestReceivables contextRef="P01_01_2013To09_30_2013" id="Factid_156" unitRef="USD" decimals="-3">763000</syn:ProvisionForUncollectibleNoteAndInterestReceivables>

  <syn:ProvisionForUncollectibleNoteAndInterestReceivables contextRef="P01_01_2012To09_30_2012" id="Factid_157" unitRef="USD" decimals="-3">0</syn:ProvisionForUncollectibleNoteAndInterestReceivables>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_158"> &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;1.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Organization and Nature of Operations and Basis of Presentation&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Description of Business&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of &lt;i&gt;C. difficile&lt;/i&gt; infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and &lt;i&gt;Acinetobacter&lt;/i&gt; infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="bottom" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Therapeutic&amp;#160;Area&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="bottom" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="bottom" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Product&amp;#160;Candidate&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="bottom" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="bottom" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Status&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Relapsing-remitting MS&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Trimesta&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; (oral estriol)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Completed enrollment&amp;#160;in Phase II clinical trial; dosing and monitoring underway&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Cognitive dysfunction in MS&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Trimesta&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; (oral estriol)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Patient enrollment underway in Phase II clinical trial&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;C. difficile&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;infection prevention&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;SYN-004&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;(oral enzyme)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;SYN-004, second generation candidate in preclinical;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;first generation predecessor candidate&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;(formerly known as P1A) is in Phase II&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Pertussis&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;SYN-005&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;(monoclonal antibody)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Preclinical; Collaborations with Intrexon and The University of Texas at Austin&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Acinetobacter&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;infection&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;SYN-001&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;(monoclonal antibody)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Discovery; Collaboration with Intrexon&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Fibromyalgia&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Effirma&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;(oral flupirtine)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Partnered with Meda AB&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;In order to further prioritize the Company&amp;#8217;s focus, it previously elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, the Company is seeking development partners for its zinc-based intellectual property and assets including, AEN-100.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2012 (&amp;#8220;2012 Form 10-K&amp;#8221;) as filed with the SEC. The interim results for the three and nine months ended September 30, 2013, are not necessarily indicative of results for the full year.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_159"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;3.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;700,000&lt;/font&gt; payable pursuant to the terms of a two-year promissory note bearing interest at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.7&lt;/font&gt;% per annum secured by all of the assets of the Lab. The note and all unpaid interest were due on March 1, 2014. &lt;font style="BACKGROUND-COLOR: transparent"&gt;During the three months ended September 30, 2013, the note receivable and associated interest receivable were deemed uncollectible. Accordingly, the Company recorded bad debt expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;763&lt;/font&gt;,000.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;In accordance with &lt;font style="BACKGROUND-COLOR: transparent"&gt; Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;)&lt;/font&gt; Topic 205-20 &amp;#8220;&lt;i&gt;Presentation of Financial Statements-Discontinued Operations&lt;/i&gt;&amp;#8221; (ASC 205-20), the Company determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been classified as a discontinued operation and its results of operations, financial position and cash flows are separately reported for all periods presented.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the three and nine months ended September 30, 2013 and 2012 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 8pt"&gt;&lt;/font&gt;&amp;#160; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"&gt; &lt;div&gt;Nine&amp;#160;Months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Laboratory fees, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Operating Costs and Expenses:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;287&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Cost of laboratory services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Total operating costs and expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;403&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Loss from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(104)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(288)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Other Income:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Gain on sale of Adeona Clinical Laboratory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;677&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Income (loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(104)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;389&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>

  <syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_160"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the three and nine months ended September 30, 2013 and 2012 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 8pt"&gt;&lt;/font&gt;&amp;#160; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"&gt; &lt;div&gt;Nine&amp;#160;Months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Laboratory fees, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Operating Costs and Expenses:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;287&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Cost of laboratory services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Total operating costs and expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;403&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Loss from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(104)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(288)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Other Income:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Gain on sale of Adeona Clinical Laboratory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;677&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Income (loss) from discontinued operations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(104)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;389&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock>

  <us-gaap:NotesReceivableNet contextRef="PAsOn03_08_2012_AdeonaClinicalLaboratoryLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommercialPaperMemberusgaapCreditFacilityAxis" id="Factid_161" unitRef="USD" decimals="0">700000</us-gaap:NotesReceivableNet>

  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="PAsOn03_08_2012_AdeonaClinicalLaboratoryLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommercialPaperMemberusgaapCreditFacilityAxis" id="Factid_162" unitRef="pure" decimals="3">0.057</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>

  <syn:ProvisionForUncollectibleNoteAndInterestReceivables contextRef="P07_01_2013To09_30_2013" id="Factid_163" unitRef="USD" decimals="-3">763000</syn:ProvisionForUncollectibleNoteAndInterestReceivables>

  <syn:LaboratoryFeesNet contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_164" unitRef="USD" decimals="-3">0</syn:LaboratoryFeesNet>

  <syn:LaboratoryFeesNet contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_165" unitRef="USD" decimals="-3">0</syn:LaboratoryFeesNet>

  <syn:LaboratoryFeesNet contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_166" unitRef="USD" decimals="-3">0</syn:LaboratoryFeesNet>

  <syn:LaboratoryFeesNet contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_167" unitRef="USD" decimals="-3">115000</syn:LaboratoryFeesNet>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_168" unitRef="USD" decimals="-3">0</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_169" unitRef="USD" decimals="-3">104000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_170" unitRef="USD" decimals="-3">0</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_171" unitRef="USD" decimals="-3">287000</us-gaap:GeneralAndAdministrativeExpense>

  <syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_172" unitRef="USD" decimals="-3">0</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>

  <syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_173" unitRef="USD" decimals="-3">0</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>

  <syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_174" unitRef="USD" decimals="-3">0</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>

  <syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_175" unitRef="USD" decimals="-3">116000</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_176" unitRef="USD" decimals="-3">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_177" unitRef="USD" decimals="-3">104000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_178" unitRef="USD" decimals="-3">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_179" unitRef="USD" decimals="-3">403000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_180" unitRef="USD" decimals="-3">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_181" unitRef="USD" decimals="-3">-104000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_182" unitRef="USD" decimals="-3">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_183" unitRef="USD" decimals="-3">-288000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_184" unitRef="USD" decimals="-3">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_185" unitRef="USD" decimals="-3">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_186" unitRef="USD" decimals="-3">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_187" unitRef="USD" decimals="-3">677000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_188" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P07_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_189" unitRef="USD" decimals="-3">-104000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2013To09_30_2013_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_190" unitRef="USD" decimals="-3">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2012To09_30_2012_AdeonaClinicalLaboratoryMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" id="Factid_191" unitRef="USD" decimals="-3">389000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2013" id="Factid_192" unitRef="USD" decimals="-5">5100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_193" unitRef="USD" decimals="-5">10000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_194"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;4.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;Fair Value of Financial Instruments&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"&gt;&lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#183;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Level 1 inputs: Quoted prices (unadjusted)&amp;#160;for identical assets or liabilities in active markets;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -15.4pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"&gt;&lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#183;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -15.4pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"&gt;&lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#183;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;Cash and cash equivalents include money market accounts&amp;#160;of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.1&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.0&lt;/font&gt; million as of September 30, 2013 and December 31, 2012, respectively, that are measured using Level 1 inputs.&lt;/font&gt;&lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>

  <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_195"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Prepaid expenses and other current assets (in thousands)&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Intrexon prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,543&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;2,412&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Other receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;17&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;80&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,647&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;2,509&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_196"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Property and equipment (in thousands)&lt;/font&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 8pt"&gt;&lt;/font&gt;&amp;#160; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Manufacturing equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;152&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;297&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Computer and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;45&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;35&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;133&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;133&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;330&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;465&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(173)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(242)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;157&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;223&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_197"> &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"&gt; &lt;tr&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;5.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;Selected Balance Sheet Information&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Prepaid expenses and other current assets (in thousands)&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Intrexon prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,543&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;2,412&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Other receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;17&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;80&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,647&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;2,509&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Property and equipment (in thousands)&lt;/font&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 8pt"&gt;&lt;/font&gt;&amp;#160; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Manufacturing equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;152&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;297&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Computer and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;45&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;35&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;133&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;133&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;330&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;465&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(173)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(242)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;157&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;223&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>

  <syn:PrepaidExpensesResearchAndDevelopment contextRef="PAsOn09_30_2013" id="Factid_198" unitRef="USD" decimals="-3">1543000</syn:PrepaidExpensesResearchAndDevelopment>

  <syn:PrepaidExpensesResearchAndDevelopment contextRef="PAsOn12_31_2012" id="Factid_199" unitRef="USD" decimals="-3">2412000</syn:PrepaidExpensesResearchAndDevelopment>

  <us-gaap:OtherReceivablesGrossCurrent contextRef="PAsOn09_30_2013" id="Factid_200" unitRef="USD" decimals="-3">0</us-gaap:OtherReceivablesGrossCurrent>

  <us-gaap:OtherReceivablesGrossCurrent contextRef="PAsOn12_31_2012" id="Factid_201" unitRef="USD" decimals="-3">17000</us-gaap:OtherReceivablesGrossCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn09_30_2013" id="Factid_202" unitRef="USD" decimals="-3">104000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2012" id="Factid_203" unitRef="USD" decimals="-3">80000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn09_30_2013" id="Factid_204" unitRef="USD" decimals="-3">1647000</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_205" unitRef="USD" decimals="-3">2509000</us-gaap:OtherAssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn09_30_2013" id="Factid_206" unitRef="USD" decimals="-3">330000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2012" id="Factid_207" unitRef="USD" decimals="-3">465000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn09_30_2013_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_208" unitRef="USD" decimals="-3">152000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn09_30_2013_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_209" unitRef="USD" decimals="-3">45000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn09_30_2013_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_210" unitRef="USD" decimals="-3">133000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2012_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_211" unitRef="USD" decimals="-3">297000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2012_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_212" unitRef="USD" decimals="-3">35000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2012_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_213" unitRef="USD" decimals="-3">133000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn09_30_2013" id="Factid_214" unitRef="USD" decimals="-3">173000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2012" id="Factid_215" unitRef="USD" decimals="-3">242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_216"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Black-Scholes assumptions used in the three and nine months ended September 30, 2013 and 2012 are as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="3"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%" colspan="5"&gt; &lt;div&gt;Nine&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;$1.96-&amp;#160;$2.27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;$1.70-&amp;#160;$2.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;153%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;148&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;108%&amp;#160;-&amp;#160;174%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0.63%&amp;#160;-&amp;#160;0.65%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0.37%&amp;#160;-&amp;#160;1.98%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected life of option&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;5&amp;#160;years&amp;#160;&amp;#150;&amp;#160;10&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;5&amp;#160;years&amp;#160;&amp;#150;&amp;#160;10&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_217"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;A summary of stock option activities as of September 30, 2013, and for the year ended December 31, 2012, is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&amp;#160;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance - December 31, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,979,010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;6.01&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,075,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(374,851)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(225,413)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance - December 31, 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,453,746&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;6.43&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,308,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;117,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(291,666)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(475,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance &amp;#150; September 30, 2013 - outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,804,580&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;5.76&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;932,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance &amp;#150; September 30, 2013 - exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,902,307&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;5.27&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Grant date fair value of options granted - 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;185,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Weighted average grant date fair value - 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Grant date fair value of options granted - 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,468,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Weighted average grant date fair value - 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_218"> &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="left"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;6.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;Stock-Based Compensation&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Stock Incentive Plan&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;During 2001, the Company&amp;#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt;. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of September 30, 2013, there were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 953,507&lt;/font&gt;&lt;/font&gt; options issued and outstanding under the 2001 Stock Plan.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On March 20, 2007, the Company&amp;#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,500,000&lt;/font&gt; shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt;. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 443,573&lt;/font&gt;&lt;/font&gt; options issued and outstanding under the 2007 Stock Plan.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,000,000&lt;/font&gt; shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,407,500&lt;/font&gt;&lt;/font&gt; options issued and outstanding under the 2010 Stock Plan.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The Black-Scholes assumptions used in the three and nine months ended September 30, 2013 and 2012 are as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="3"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%" colspan="5"&gt; &lt;div&gt;Nine&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;$1.96-&amp;#160;$2.27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;$1.70-&amp;#160;$2.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;153%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;148&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;108%&amp;#160;-&amp;#160;174%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0.63%&amp;#160;-&amp;#160;0.65%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0.37%&amp;#160;-&amp;#160;1.98%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected life of option&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;5&amp;#160;years&amp;#160;&amp;#150;&amp;#160;10&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;5&amp;#160;years&amp;#160;&amp;#150;&amp;#160;10&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Expected forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;0% &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;immediate vesting,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;half vesting immediately and the remainder over three years,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;quarterly over three years,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;annually over three years,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;one-third immediate vesting and remaining annually over two years,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;one half immediate vesting with remaining vesting over nine months,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;one quarter immediate vesting with the remaining over three years,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;one quarter immediate vesting with the remaining over 33 months; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;monthly over three years.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 67.1pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;During the nine months ended September 30, 2013, the Company granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 117,500&lt;/font&gt; options to employees and directors having an approximate fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;185,000&lt;/font&gt; based upon the Black-Scholes option pricing model.&amp;#160;During the same period in 2012, the Company granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,840,000&lt;/font&gt; options to employees and consultants having an approximate fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.0&lt;/font&gt; million based upon the Black-Scholes option pricing model.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of stock option activities as of September 30, 2013, and for the year ended December 31, 2012, is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&amp;#160;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance - December 31, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,979,010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;6.01&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,075,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(374,851)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(225,413)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance - December 31, 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,453,746&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;6.43&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,308,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;117,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(291,666)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(475,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance &amp;#150; September 30, 2013 - outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,804,580&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;5.76&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;932,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Balance &amp;#150; September 30, 2013 - exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,902,307&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;5.27&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Grant date fair value of options granted - 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;185,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Weighted average grant date fair value - 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Grant date fair value of options granted - 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,468,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Weighted average grant date fair value - 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended September 30, 2013 and 2012 were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;338,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;395,000&lt;/font&gt;, respectively, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.2&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.3&lt;/font&gt; million for the nine month periods ended September 30, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;As of September 30, 2013, total unrecognized stock-based compensation expense related to stock options was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.9&lt;/font&gt; million, which is expected to be expensed through February 2016.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="PAsOn09_30_2013" id="Factid_219" unitRef="USD" decimals="-5">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2001To12_31_2001_MaximumMemberusgaapRangeAxis_StockPlan2001MemberusgaapPlanNameAxis" id="Factid_220" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2013_StockPlan2001MemberusgaapPlanNameAxis" id="Factid_221" unitRef="shares" decimals="INF">953507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_20_2007_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_222" unitRef="shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2007To12_31_2007_MaximumMemberusgaapRangeAxis_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_223" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_224" unitRef="shares" decimals="INF">443573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn11_02_2010_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_225" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_226" unitRef="shares" decimals="INF">2407500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_EmployeesAndDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_227" unitRef="shares" decimals="INF">117500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="P01_01_2013To09_30_2013_EmployeesAndDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_228" unitRef="USD" decimals="0">185000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_229" unitRef="shares" decimals="INF">1840000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="P01_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_230" unitRef="USD" decimals="-5">4000000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2013To09_30_2013_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_231" unitRef="USD" decimals="0">338000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_232" unitRef="USD" decimals="0">395000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2013To09_30_2013_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_233" unitRef="USD" decimals="-5">1200000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2012To09_30_2012_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_234" unitRef="USD" decimals="-5">1300000</us-gaap:AllocatedShareBasedCompensationExpense>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P07_01_2013To09_30_2013" id="Factid_235" unitRef="USD_per_Share" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2012To09_30_2012" id="Factid_236" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2013To09_30_2013" id="Factid_237" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2013To09_30_2013" id="Factid_238" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2013To09_30_2013" id="Factid_239">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P07_01_2013To09_30_2013" id="Factid_240" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P07_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_241" unitRef="USD_per_Share" decimals="2">1.96</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P07_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_242" unitRef="USD_per_Share" decimals="2">2.27</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2012To09_30_2012" id="Factid_243" unitRef="pure" decimals="2">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_244" unitRef="pure" decimals="4">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_245" unitRef="pure" decimals="4">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_246">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_247">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P07_01_2012To09_30_2012" id="Factid_248" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P01_01_2013To09_30_2013" id="Factid_249" unitRef="USD_per_Share" decimals="2">1.74</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2013To09_30_2013" id="Factid_250" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2013To09_30_2013" id="Factid_251" unitRef="pure" decimals="2">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2013To09_30_2013" id="Factid_252" unitRef="pure" decimals="4">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2013To09_30_2013" id="Factid_253">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_254" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P01_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_255" unitRef="USD_per_Share" decimals="2">1.70</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="P01_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_256" unitRef="USD_per_Share" decimals="2">2.47</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2012To09_30_2012" id="Factid_257" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_258" unitRef="pure" decimals="2">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_259" unitRef="pure" decimals="4">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_260" unitRef="pure" decimals="4">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_261" unitRef="pure" decimals="2">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2012To09_30_2012_MinimumMemberusgaapRangeAxis" id="Factid_262">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2012To09_30_2012_MaximumMemberusgaapRangeAxis" id="Factid_263">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P01_01_2012To09_30_2012" id="Factid_264" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2011To12_31_2011" id="Factid_265">P6Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2012To12_31_2012" id="Factid_266">P6Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2013To09_30_2013" id="Factid_267">P5Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2013To09_30_2013" id="Factid_268" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2013To09_30_2013" id="Factid_269">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2013_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_270" unitRef="shares" decimals="INF">2407500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To09_30_2013_StockPlan2001MemberusgaapPlanNameAxis" id="Factid_271" unitRef="shares" decimals="INF">953507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2013_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_272" unitRef="shares" decimals="INF">443573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2011" id="Factid_273" unitRef="shares" decimals="INF">2979010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_274" unitRef="shares" decimals="INF">2075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2012To12_31_2012" id="Factid_275" unitRef="shares" decimals="INF">374851</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_276" unitRef="shares" decimals="INF">225413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_277" unitRef="shares" decimals="INF">117500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2013To09_30_2013" id="Factid_278" unitRef="shares" decimals="INF">291666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_279" unitRef="shares" decimals="INF">475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2012" id="Factid_280" unitRef="shares" decimals="INF">4453746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2013" id="Factid_281" unitRef="shares" decimals="INF">3804580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2013" id="Factid_282" unitRef="shares" decimals="INF">2902307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="P01_01_2013To09_30_2013" id="Factid_283" unitRef="USD" decimals="0">185000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="P01_01_2012To12_31_2012" id="Factid_284" unitRef="USD" decimals="0">4468000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To09_30_2013" id="Factid_285" unitRef="USD_per_Share" decimals="2">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012" id="Factid_286" unitRef="USD_per_Share" decimals="2">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2011" id="Factid_287" unitRef="USD_per_Share" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_288" unitRef="USD_per_Share" decimals="2">2.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_289" unitRef="USD_per_Share" decimals="2">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_290" unitRef="USD_per_Share" decimals="2">0.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_291" unitRef="USD_per_Share" decimals="2">0.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_292" unitRef="USD_per_Share" decimals="2">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_293" unitRef="USD_per_Share" decimals="2">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_294" unitRef="USD_per_Share" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn09_30_2013" id="Factid_295" unitRef="USD_per_Share" decimals="2">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn09_30_2013" id="Factid_296" unitRef="USD_per_Share" decimals="2">1.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2011" id="Factid_297" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2012" id="Factid_298" unitRef="USD" decimals="0">1308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn09_30_2013" id="Factid_299" unitRef="USD" decimals="0">932000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn09_30_2013" id="Factid_300" unitRef="USD" decimals="0">903000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <syn:StockPurchaseWarrantsTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_301"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;7.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Purchase Warrants&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 635,855&lt;/font&gt; shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.60&lt;/font&gt; and a life of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; five&lt;/font&gt; years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of September 30, 2013, all the warrants were outstanding.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock based on achievement of certain stock price milestones. Upon initiation of the program, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date of issuance for an exercise price equal to the price ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.20&lt;/font&gt; per share) of the Company&amp;#8217;s common stock on the date of execution (March 15, 2012). In March 2013, the performance warrants&amp;#8217; vesting period was extended to March 14, 2014. All other provisions of the performance warrants remain unchanged. The incremental expense related to the modification of the warrants of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;76,000&lt;/font&gt; will be recognized over the one year extension period.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant was paid a monthly fee and on February 2, 2012, was issued warrants exercisable for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.14&lt;/font&gt;) of the Company&amp;#8217;s common stock on the date of issue. As of September 30, 2013, all the warrants were outstanding.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;A summary of warrant activity for the Company for the nine months ended September 30, 2013 and for the year ended December 31, 2012 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at December 31, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;3,259,186&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;985,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.71&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(1,768,167)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.11&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(844,373)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;3.32&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at December 31, 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at September 30, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt; Stock-based compensation expense included in general and administrative expenses relating to warrants issued to consultants was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000&lt;/font&gt; for the three months ended September 30, 2013 and 2012, respectively, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;271,000&lt;/font&gt; for the nine months ended September 30, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of all outstanding and exercisable warrants as of September 30, 2013 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 88%" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Intrinsic&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.14&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.34&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;54,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.32&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;18,182&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;18,182&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;2.25&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;6,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.60&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;635,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;635,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;4.08&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;51,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;2.20&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;0.45&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;2.22&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.16&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;3.30&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;1.66&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;2.38&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1,432,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.03&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;111,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:StockPurchaseWarrantsTextBlock>

  <syn:ScheduleOfWarrantActivityTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_302"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;A summary of warrant activity for the Company for the nine months ended September 30, 2013 and for the year ended December 31, 2012 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at December 31, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;3,259,186&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;985,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.71&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(1,768,167)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.11&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"&gt; &lt;div&gt;(844,373)&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;3.32&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at December 31, 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"&gt; &lt;div&gt;Balance at September 30, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantActivityTableTextBlock>

  <syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_303"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;A summary of all outstanding and exercisable warrants as of September 30, 2013 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"&gt; &lt;table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 88%" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"&gt; &lt;div&gt;Intrinsic&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.14&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.34&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;54,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.32&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;18,182&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;18,182&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;2.25&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;6,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.60&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;635,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;635,855&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;4.08&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;51,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;2.20&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;0.45&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;2.22&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.16&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;3.30&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;1.66&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;2.38&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;1,432,501&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"&gt; &lt;div&gt;3.03&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"&gt; &lt;div&gt;111,000&lt;/div&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>

  <syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="PAsOn10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_304" unitRef="shares" decimals="INF">635855</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>

  <syn:WarrantsExercisePricePerShare contextRef="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_305" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisePricePerShare>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber contextRef="PAsOn03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_306" unitRef="shares" decimals="INF">250000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber contextRef="PAsOn12_20_2011_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_307" unitRef="shares" decimals="INF">100000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_308" unitRef="shares" decimals="INF">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber>

  <syn:WarrantsExercisablePricePerShare contextRef="P02_26_2012To03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_309" unitRef="USD_per_Share" decimals="2">2.20</syn:WarrantsExercisablePricePerShare>

  <syn:WarrantsExercisablePricePerShare contextRef="P12_01_2011To12_20_2011_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_310" unitRef="USD_per_Share" decimals="2">1.14</syn:WarrantsExercisablePricePerShare>

  <syn:IncrementalExpense contextRef="P02_26_2012To03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_311" unitRef="USD" decimals="0">76000</syn:IncrementalExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2013To09_30_2013_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_312" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2012To09_30_2012_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_313" unitRef="USD" decimals="0">1000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2013To09_30_2013_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_314" unitRef="USD" decimals="0">22000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2012To09_30_2012_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_315" unitRef="USD" decimals="0">271000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_316">P2Y3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_317">P4Y29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_318">P5M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_319">P3Y1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_320">P1Y7M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_321">P2Y4M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013" id="Factid_322">P3Y11D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2013To09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_323">P3Y4M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod contextRef="P02_26_2012To03_15_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_324">P2Y</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod contextRef="P12_01_2011To12_20_2011_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_325">P5Y</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod>

  <invest:InvestmentWarrantsExpirationDate contextRef="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_326">2017-10-25</invest:InvestmentWarrantsExpirationDate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_327">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2011" id="Factid_328" unitRef="shares" decimals="INF">3259186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_329" unitRef="shares" decimals="INF">985855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_330" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_331" unitRef="shares" decimals="INF">1768167</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_332" unitRef="shares" decimals="INF">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_333" unitRef="shares" decimals="INF">844373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2013To09_30_2013" id="Factid_334" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2012" id="Factid_335" unitRef="shares" decimals="INF">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn09_30_2013" id="Factid_336" unitRef="shares" decimals="INF">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2011" id="Factid_337" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012" id="Factid_338" unitRef="USD_per_Share" decimals="2">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To09_30_2013" id="Factid_339" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012" id="Factid_340" unitRef="USD_per_Share" decimals="2">1.11</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To09_30_2013" id="Factid_341" unitRef="USD_per_Share" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012" id="Factid_342" unitRef="USD_per_Share" decimals="2">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2013To09_30_2013" id="Factid_343" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2012" id="Factid_344" unitRef="USD_per_Share" decimals="2">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn09_30_2013" id="Factid_345" unitRef="USD_per_Share" decimals="2">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013" id="Factid_346" unitRef="USD_per_Share" decimals="2">1.99</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_347" unitRef="USD_per_Share" decimals="2">1.14</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_348" unitRef="USD_per_Share" decimals="2">1.32</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_349" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_350" unitRef="USD_per_Share" decimals="2">2.20</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_351" unitRef="USD_per_Share" decimals="2">2.22</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_352" unitRef="USD_per_Share" decimals="2">3.30</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2013To09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_353" unitRef="USD_per_Share" decimals="2">3.75</syn:WarrantsExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013" id="Factid_354" unitRef="shares" decimals="INF">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_355" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_356" unitRef="shares" decimals="INF">18182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_357" unitRef="shares" decimals="INF">635855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_358" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_359" unitRef="shares" decimals="INF">517257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_360" unitRef="shares" decimals="INF">61207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_361" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013" id="Factid_362" unitRef="shares" decimals="INF">1432501</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_363" unitRef="shares" decimals="INF">100000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_364" unitRef="shares" decimals="INF">18182</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_365" unitRef="shares" decimals="INF">635855</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_366" unitRef="shares" decimals="INF">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_367" unitRef="shares" decimals="INF">517257</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_368" unitRef="shares" decimals="INF">61207</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_369" unitRef="shares" decimals="INF">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013" id="Factid_370" unitRef="USD" decimals="0">111000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice1MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_371" unitRef="USD" decimals="0">54000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice13MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_372" unitRef="USD" decimals="0">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice14MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_373" unitRef="USD" decimals="0">51000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice220MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_374" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice222MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_375" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice330MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_376" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn09_30_2013_ExercisePrice375MemberusgaapRangeAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_377" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2013To09_30_2013" id="Factid_378" unitRef="USD" decimals="0">231000</us-gaap:ProceedsFromStockOptionsExercised>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_379"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;8.&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160; &lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black"&gt;During the nine months ended September 30, 2013, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 291,666&lt;/font&gt; shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;231,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_380"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-SIZE: 8pt"&gt;&lt;font style="FONT-SIZE: 8pt"&gt; &lt;/font&gt;&lt;/font&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;b&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;9. Net Loss per Share&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;b&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at September 30, 2012 and 2013, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the nine months ended September 30, 2013 were 3,804,580 and 1,632,501, respectively, and for the nine months ended September 30, 2012 were 4,258,746 and 1,324,102, respectively.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn09_30_2012" id="Factid_381" unitRef="shares" decimals="INF">4258746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn09_30_2012" id="Factid_382" unitRef="shares" decimals="INF">1324102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <syn:ManagementPlanDisclosureTextBlock contextRef="P01_01_2013To09_30_2013" id="Factid_383"> &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;2.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Management&amp;#8217;s Plan&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Company has incurred an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;77&lt;/font&gt; million through September 30, 2013. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the progress of research activities;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the number and scope of research programs;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the progress of preclinical and clinical development activities;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the progress of the development efforts of parties with whom the Company has entered into research and development agreements;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;costs associated with additional clinical trials of product candidates;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the ability to achieve milestones under licensing arrangements;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"&gt; &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"&gt; &lt;div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;the costs and timing of regulatory approvals.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company&amp;#8217;s shares or debt and other sources, including sales of securities pursuant to the terms of the Controlled Equity Offering&lt;/font&gt;&lt;sup&gt;&lt;font style="COLOR: black; FONT-SIZE: 9pt"&gt;SM&lt;/font&gt;&lt;/sup&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Agreement that it entered into with Cantor Fitzgerald &amp;amp; Co., as sales agent, that provides the ability to conduct an at-the-market (ATM) public offering for up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; million of shares of common stock at prices to be determined at the time of sale. As of the date of this filing, the Company has not sold any shares under the ATM.&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.&lt;/font&gt;&lt;/div&gt; &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ManagementPlanDisclosureTextBlock>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To09_30_2013_CantorFitzgeraldAndCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_384" unitRef="USD" decimals="-6">15000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>syn-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.syntheticbiologics.com/20130930" elementFormDefault="qualified" xmlns:syn="http://www.syntheticbiologics.com/20130930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>102 - Statement - Consolidated Balance Sheets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - Consolidated Statements of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>105 - Statement - Consolidated Statements of Cash Flows</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" id="OrganizationAndNatureOfOperationsAndBasisOfPresentation">
        <link:definition>106 - Disclosure - Organization and Nature of Operations and Basis of Presentation</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ManagementsPlan" id="ManagementsPlan">
        <link:definition>107 - Disclosure - Management&#39;s Plan</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
        <link:definition>108 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>109 - Disclosure - Fair Value of Financial Instruments</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" id="SelectedBalanceSheetInformation">
        <link:definition>110 - Disclosure - Selected Balance Sheet Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>111 - Disclosure - Stock-Based Compensation</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrants" id="StockPurchaseWarrants">
        <link:definition>112 - Disclosure - Stock Purchase Warrants</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>113 - Disclosure - Stockholders&#39; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>114 - Disclosure - Net Loss per Share</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SubsequentEvent" id="SubsequentEvent">
        <link:definition>115 - Disclosure - Subsequent Event</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables">
        <link:definition>116 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables" id="SelectedBalanceSheetInformationTables">
        <link:definition>117 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <link:definition>118 - Disclosure - Stock-Based Compensation (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables" id="StockPurchaseWarrantsTables">
        <link:definition>119 - Disclosure - Stock Purchase Warrants (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" id="ManagementsPlanDetailsTextual">
        <link:definition>120 - Disclosure - Management&#39;s Plan (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
        <link:definition>121 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
        <link:definition>122 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" id="FairValueOfFinancialInstrumentsDetailsTextual">
        <link:definition>123 - Disclosure - Fair Value of Financial Instruments (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" id="SelectedBalanceSheetInformationDetails">
        <link:definition>124 - Disclosure - Selected Balance Sheet Information (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" id="SelectedBalanceSheetInformationDetails1">
        <link:definition>125 - Disclosure - Selected Balance Sheet Information (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" id="SelectedBalanceSheetInformationDetails2">
        <link:definition>126 - Disclosure - Selected Balance Sheet Information (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" id="StockbasedCompensationDetails">
        <link:definition>127 - Disclosure - Stock-Based Compensation (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" id="StockbasedCompensationDetails1">
        <link:definition>128 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" id="StockbasedCompensationDetailsTextual">
        <link:definition>129 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" id="StockPurchaseWarrantsDetails">
        <link:definition>130 - Disclosure - Stock Purchase Warrants (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" id="StockPurchaseWarrantsDetails1">
        <link:definition>131 - Disclosure - Stock Purchase Warrants (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" id="StockPurchaseWarrantsDetailsTextual">
        <link:definition>132 - Disclosure - Stock Purchase Warrants (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
        <link:definition>133 - Disclosure - Stockholders&#39; Equity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" id="NetLossPerShareDetailsTextual">
        <link:definition>134 - Disclosure - Net Loss per Share (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>135 - Disclosure - Basis of Presentation</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SubsequentEventDetailsTextual" id="SubsequentEventDetailsTextual">
        <link:definition>136 - Disclosure - Subsequent Event (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20130930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20130930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20130930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20130930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />

  <element name="StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseWarrantsAbstract" />

  <element name="StockPurchaseWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseWarrantsTextBlock" />

  <element name="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

  <element name="ScheduleOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfWarrantActivityTableTextBlock" />

  <element name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

  <element name="AdeonaClinicalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_AdeonaClinicalLaboratoryMember" />

  <element name="LaboratoryFeesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_LaboratoryFeesNet" />

  <element name="DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" />

  <element name="DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" />

  <element name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_DepositsAndOtherAssetsNoncurrent" />

  <element name="AdeonaClinicalLaboratoryLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_AdeonaClinicalLaboratoryLlcMember" />

  <element name="PrepaidExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_PrepaidExpensesResearchAndDevelopment" />

  <element name="ComputerAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ComputerAndOfficeEquipmentMember" />

  <element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_LaboratoryEquipmentMember" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

  <element name="StockPlan2001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2001Member" />

  <element name="StockPlan2007Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2007Member" />

  <element name="StockPlan2010Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2010Member" />

  <element name="EmployeesAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EmployeesAndDirectorsMember" />

  <element name="EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EmployeesAndConsultantsMember" />

  <element name="GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

  <element name="ExercisePrice1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice1Member" />

  <element name="ExercisePrice13Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice13Member" />

  <element name="ExercisePrice14Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice14Member" />

  <element name="ExercisePrice220Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice220Member" />

  <element name="ExercisePrice222Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice222Member" />

  <element name="ExercisePrice330Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice330Member" />

  <element name="ExercisePrice375Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice375Member" />

  <element name="ExercisePrice199Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice199Member" />

  <element name="WarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_WarrantsExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

  <element name="BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_BalanceSheetParentheticalAbstract" />

  <element name="IssuanceOfWarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

  <element name="WarrantsExercisePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_WarrantsExercisePricePerShare" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" />

  <element name="IncrementalExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_IncrementalExpense" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" />

  <element name="WarrantsExercisablePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_WarrantsExercisablePricePerShare" />

  <element name="CantorFitzgeraldAndCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CantorFitzgeraldAndCompanyMember" />

  <element name="ProvisionForUncollectibleAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_ProvisionForUncollectibleAccountsReceivable" />

  <element name="ProvisionForUncollectibleNoteAndInterestReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_ProvisionForUncollectibleNoteAndInterestReceivables" />

  <element name="IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_IncreaseDecreaseInDepositsAndOtherAssets" />

  <element name="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DocumentAndEntityInformationAbstract" />

  <element name="EquipmentImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_EquipmentImpairmentLoss" />

  <element name="GainLossOnSaleOfDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_GainLossOnSaleOfDiscontinuedOperation" />

  <element name="DisclosureManagementPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DisclosureManagementPlanAbstract" />

  <element name="ManagementPlanDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ManagementPlanDisclosureTextBlock" />

  <element name="CantorFitzgeraldAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CantorFitzgeraldAndCoMember" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>syn-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" />

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="loc_syn_LaboratoryFeesNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleAccountsReceivable" xlink:label="loc_syn_ProvisionForUncollectibleAccountsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_ProvisionForUncollectibleAccountsReceivable" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="80" weight="-1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" use="optional" order="90" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="100" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="110" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_EquipmentImpairmentLoss" use="optional" order="120" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GainLossOnSaleOfDiscontinuedOperation" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperation" use="optional" order="130" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" use="optional" order="20" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>syn-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#FairValueOfFinancialInstrumentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetails1" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SubsequentEventDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/SubsequentEventDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ManagementsPlanDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#NetLossPerShareDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_us-gaap_StatementTable_50" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember_53" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" xlink:to="loc_syn_AdeonaClinicalLaboratoryMember_53" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet_55" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_syn_LaboratoryFeesNet_55" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_us-gaap_OperatingExpensesAbstract_56" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_57" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_58" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_59" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_62" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_63" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_StatementTable_66" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_StatementScenarioAxis_67" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_67" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_68" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_68_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_67" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_68_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_AssetsAbstract_70" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_Cash_71" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_AssetsCurrent_74" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_75" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_76" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_77" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_Assets_78" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_AccountsPayableCurrent_80" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_Liabilities_83" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_StockholdersEquityAbstract_84" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_PreferredStockValue_85" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_CommonStockValue_86" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_87" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_StockholdersEquity_89" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_90" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_100" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_StatementTable_93" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_93" xlink:to="loc_us-gaap_CreditFacilityAxis_94" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_94" xlink:to="loc_us-gaap_CreditFacilityDomain_95" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_95_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_94" xlink:to="loc_us-gaap_CreditFacilityDomain_95_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_95" xlink:to="loc_us-gaap_CommercialPaperMember_96" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_93" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" xlink:to="loc_us-gaap_RelatedPartyDomain_98" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_98_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" xlink:to="loc_us-gaap_RelatedPartyDomain_98_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember_99" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_98" xlink:to="loc_syn_AdeonaClinicalLaboratoryLlcMember_99" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_NotesReceivableNet_101" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_102" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_390" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_108" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_StatementTable_105" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_105" xlink:to="loc_us-gaap_StatementScenarioAxis_106" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_106" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_107" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_107_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_106" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_107_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_109" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_109" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_115" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_StatementTable_112" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_112" xlink:to="loc_us-gaap_StatementScenarioAxis_113" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_113" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_114" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_114_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_113" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_114_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_116" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_117" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_118" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_OtherAssetsCurrent_119" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_128" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_StatementTable_122" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_us-gaap_EquipmentMember_125" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_126" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_syn_LaboratoryEquipmentMember_127" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_129" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_131" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_137" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_137" xlink:to="loc_us-gaap_StatementTable_134" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_134" xlink:to="loc_us-gaap_StatementClassOfStockAxis_135" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_135" xlink:to="loc_us-gaap_ClassOfStockDomain_136" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_136_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_135" xlink:to="loc_us-gaap_ClassOfStockDomain_136_default" use="optional" order="4" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_145" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_StatementTable_140" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_RangeAxis_141" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_141" xlink:to="loc_us-gaap_RangeMember_142" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_142_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_141" xlink:to="loc_us-gaap_RangeMember_142_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_142" xlink:to="loc_us-gaap_MinimumMember_143" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_142" xlink:to="loc_us-gaap_MaximumMember_144" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_146" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_147" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_148" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_149" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_151" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_157" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_StatementTable_154" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_154" xlink:to="loc_us-gaap_StatementScenarioAxis_155" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_155" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_155" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_158" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_159" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_160" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_161" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_161" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_164" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_165" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_166" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_167" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_169" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_365" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_172" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_174" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_175" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_176" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_384" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_StatementTable_179" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_PlanNameAxis_180" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_180" xlink:to="loc_us-gaap_PlanNameDomain_181" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_181_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_180" xlink:to="loc_us-gaap_PlanNameDomain_181_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2001Member_182" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2007Member_183" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2010Member_184" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" xlink:to="loc_us-gaap_RelatedPartyDomain_186" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_186_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" xlink:to="loc_us-gaap_RelatedPartyDomain_186_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember_187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_186" xlink:to="loc_syn_EmployeesAndDirectorsMember_187" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_186" xlink:to="loc_syn_EmployeesAndConsultantsMember_188" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_189" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_189" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_190" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_190_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_189" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_190_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_191" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_192" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_191" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_192" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_192_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_191" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_192_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_192" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_193" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_194" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_RangeAxis_194" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_194" xlink:to="loc_us-gaap_RangeMember_385" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_385_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_194" xlink:to="loc_us-gaap_RangeMember_385_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_385" xlink:to="loc_us-gaap_MaximumMember_387" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_196" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_196" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_197" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_197" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_198" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_199" use="optional" order="28" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_206" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_StatementTable_202" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_202" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" xlink:to="loc_us-gaap_WarrantMember_205" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_207" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_208" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_209" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_210" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_212" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_213" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_213" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_214" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_215" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_233" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_StatementTable_219" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_219" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" xlink:to="loc_us-gaap_WarrantMember_222" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_219" xlink:to="loc_us-gaap_RangeAxis_223" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_223" xlink:to="loc_us-gaap_RangeMember_224" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_224_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_223" xlink:to="loc_us-gaap_RangeMember_224_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice1Member_225" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member_226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice13Member_226" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice14Member_227" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice220Member_228" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice222Member_229" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice330Member_230" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice375Member_231" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice199Member_232" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_syn_WarrantsExercisePrice_234" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_235" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_236" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_237" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_366" use="optional" order="21" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_StatementTable_241" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_241" xlink:to="loc_us-gaap_StatementScenarioAxis_242" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_242" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_243" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_243_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_242" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_243_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_246" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_246" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesIssued_247" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_248" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_249" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_249" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_250" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_251" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesIssued_251" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_252" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_262" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_us-gaap_StatementTable_255" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_256" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256" xlink:to="loc_us-gaap_EquityComponentDomain_257" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_257_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256" xlink:to="loc_us-gaap_EquityComponentDomain_257_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_258" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_257" xlink:to="loc_us-gaap_WarrantMember_258" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_259" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_260" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_260" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_260_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_260_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_260" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_261" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_263" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare_264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_WarrantsExercisePricePerShare_264" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_265" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_266" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_267" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_267" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_268" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_268" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncrementalExpense" xlink:label="loc_syn_IncrementalExpense_269" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_IncrementalExpense_269" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_270" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_WarrantsExercisablePricePerShare_271" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_272" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_278" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_278" xlink:to="loc_us-gaap_StatementTable_275" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_276" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_275" xlink:to="loc_us-gaap_StatementScenarioAxis_276" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_276" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_277" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_277_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_276" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_277_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_279" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_278" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_279" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_278" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_280" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SubsequentEventDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_290" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_290" xlink:to="loc_us-gaap_StatementTable_283" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_283" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_284" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_284" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_285" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_285_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_284" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_285_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_285" xlink:to="loc_us-gaap_SubsequentEventMember_286" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_283" xlink:to="loc_dei_LegalEntityAxis_287" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_287" xlink:to="loc_dei_EntityDomain_288" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_288_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_287" xlink:to="loc_dei_EntityDomain_288_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCompanyMember" xlink:label="loc_syn_CantorFitzgeraldAndCompanyMember_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_288" xlink:to="loc_syn_CantorFitzgeraldAndCompanyMember_289" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_299" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_StatementTable_296" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_296" xlink:to="loc_us-gaap_StatementScenarioAxis_297" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_297" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_298" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_298_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_297" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_298_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_OperatingExpensesAbstract_300" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_301" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_302" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_302" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_OperatingExpenses_303" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_InvestmentIncomeInterest_306" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_307" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_308" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_309" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_310" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_NetIncomeLoss_311" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_313" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_314" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_315" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_315" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_316" use="optional" order="21" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_322" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_StatementTable_319" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementScenarioAxis_320" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_321" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_320" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_321" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_321_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_320" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_321_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetIncomeLoss_324" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_ShareBasedCompensation_326" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_Depreciation_327" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleAccountsReceivable" xlink:label="loc_syn_ProvisionForUncollectibleAccountsReceivable_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_ProvisionForUncollectibleAccountsReceivable_388" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_389" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_329" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_EquipmentImpairmentLoss_330" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GainLossOnSaleOfDiscontinuedOperation" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperation_331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperation_331" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_333" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_334" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_335" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_335" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_336" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_336" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_337" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_340" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_343" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_343" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_344" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_345" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_346" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_Cash_347" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" xlink:to="loc_us-gaap_InterestPaid_350" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" xlink:to="loc_us-gaap_IncomeTaxesPaid_351" use="optional" order="33" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_370" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentInformationTable_369" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_382" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_369" xlink:to="loc_us-gaap_StatementClassOfStockAxis_382" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_382" xlink:to="loc_us-gaap_ClassOfStockDomain_383" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_383_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_382" xlink:to="loc_us-gaap_ClassOfStockDomain_383_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityRegistrantName_378" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityCentralIndexKey_379" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_380" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_CurrentFiscalYearEndDate_380" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityFilerCategory_381" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_TradingSymbol_376" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_377" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentType_371" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_AmendmentFlag_372" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentPeriodEndDate_373" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentFiscalPeriodFocus_375" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentFiscalYearFocus_374" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_403" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_403" xlink:to="loc_us-gaap_StatementTable_399" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_399" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" xlink:to="loc_us-gaap_RelatedPartyDomain_401" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_401_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" xlink:to="loc_us-gaap_RelatedPartyDomain_401_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_401" xlink:to="loc_syn_CantorFitzgeraldAndCoMember_402" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_403" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_404" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_403" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_405" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_414" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_StatementTable_411" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementClassOfStockAxis_412" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_415" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_416" use="optional" order="6" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>syn-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAbstract" xlink:to="lab_syn_StockPurchaseWarrantsAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">The entire disclosure for stock purchase warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsTextBlock" xlink:to="lab_syn_StockPurchaseWarrantsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:to="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule Of Other Current Assets [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Vested and Expected To Vest Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule of Warrant Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Tabular disclosure of warrant activity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule of Warrant Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to warrant outstanding and exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdeonaClinicalLaboratoryMember" xml:lang="en-US">Adeona Clinical Laboratory [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdeonaClinicalLaboratoryMember" xlink:to="lab_syn_AdeonaClinicalLaboratoryMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">Laboratory Fees Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">Laboratory fees, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">The amount of expense provided in the period for laboratory costs incurred on or before the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LaboratoryFeesNet" xlink:to="lab_syn_LaboratoryFeesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Disposal Group Including Discontinued Operation Laboratory Services Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Cost of laboratory services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Total costs related to laboratory services rendered by an entity during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:to="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating costs and expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Loss from discontinued operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xml:lang="en-US">Discontinued Operation Income Loss Of Discontinued Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xml:lang="en-US">Other Income:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xlink:to="lab_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Net Of Tax</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Gain on sale of Adeona Clinical Laboratory</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (loss) from discontinued operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at end of period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Notes, Loans and Financing Receivable, Net, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Long-term note receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_syn_DepositsAndOtherAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 44,735,896 issued and 44,654,414 outstanding, respectively, and 44,444,230 issued and 44,362,748 outstanding, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Promissory Note [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdeonaClinicalLaboratoryLlcMember" xml:lang="en-US">Adeona Clinical Laboratory, Llc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdeonaClinicalLaboratoryLlcMember" xlink:to="lab_syn_AdeonaClinicalLaboratoryLlcMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesReceivableNet" xml:lang="en-US">Financing Receivable, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesReceivableNet" xml:lang="en-US">Note receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Prepaid Expenses Research and Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Intrexon prepaid research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Sum of the amounts paid in advance for research and development expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PrepaidExpensesResearchAndDevelopment" xlink:to="lab_syn_PrepaidExpensesResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xml:lang="en-US">Other Receivables, Gross, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xml:lang="en-US">Other receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:to="lab_us-gaap_OtherReceivablesGrossCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockSupplementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Manufacturing equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ComputerAndOfficeEquipmentMember" xml:lang="en-US">Computer and Office Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ComputerAndOfficeEquipmentMember" xlink:to="lab_syn_ComputerAndOfficeEquipmentMember" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LaboratoryEquipmentMember" xlink:to="lab_syn_LaboratoryEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Exercise Price One</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Exercise price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of option</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Expected forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Options, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Grant date fair value of options granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">Stock Plan 2001 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">2001 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2001Member" xlink:to="lab_syn_StockPlan2001Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">Stock Plan 2007 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">2007 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2007Member" xlink:to="lab_syn_StockPlan2007Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">Stock Plan 2010 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">2010 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2010Member" xlink:to="lab_syn_StockPlan2010Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeesAndDirectorsMember" xml:lang="en-US">Employees And Directors [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeesAndDirectorsMember" xlink:to="lab_syn_EmployeesAndDirectorsMember" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeesAndConsultantsMember" xml:lang="en-US">Employees And Consultants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeesAndConsultantsMember" xlink:to="lab_syn_EmployeesAndConsultantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">General and Administrative Expenses and Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:to="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-Based Compensation Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Warrants, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of Warrants, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of share warrants exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeited In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Warrants, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1.14 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice1Member" xlink:to="lab_syn_ExercisePrice1Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice13Member" xml:lang="en-US">Exercise Price 13 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice13Member" xml:lang="en-US">Exercise Price 1.32 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice13Member" xlink:to="lab_syn_ExercisePrice13Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 14 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 1.60 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice14Member" xlink:to="lab_syn_ExercisePrice14Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 220 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 2.20 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice220Member" xlink:to="lab_syn_ExercisePrice220Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2 22 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2.22 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice222Member" xlink:to="lab_syn_ExercisePrice222Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3 30 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3.30 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice330Member" xlink:to="lab_syn_ExercisePrice330Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3 75 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3.75 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice375Member" xlink:to="lab_syn_ExercisePrice375Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 199 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 1.99 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice199Member" xlink:to="lab_syn_ExercisePrice199Member" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise price of the warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisePrice" xlink:to="lab_syn_WarrantsExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Warrants Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Warrants Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BalanceSheetParentheticalAbstract" xlink:to="lab_syn_BalanceSheetParentheticalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance Of Warrants To Purchase Of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance of Warrants to Purchase of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants issued to purchase common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:to="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">Warrants Exercise Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">Warrants Exercise Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">per share amount of the warrant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisePricePerShare" xlink:to="lab_syn_WarrantsExercisePricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_invest_InvestmentWarrantsExpirationDate" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">The number of exercisable share warrants that may be converted as of the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Vested and Expected to Vest Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">As of the balance sheet date, the number of Warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncrementalExpense" xlink:label="loc_syn_IncrementalExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncrementalExpense" xml:lang="en-US">Incremental Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncrementalExpense" xml:lang="en-US">This element represents incremental expense related to the modification of the warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncrementalExpense" xlink:to="lab_syn_IncrementalExpense" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Exercisable term of warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants Exercisable Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants Exercisable Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants exercisable price per share.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisablePricePerShare" xlink:to="lab_syn_WarrantsExercisablePricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds From Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCompanyMember" xlink:label="loc_syn_CantorFitzgeraldAndCompanyMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CantorFitzgeraldAndCompanyMember" xml:lang="en-US">Cantor Fitzgerald and Company [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_CantorFitzgeraldAndCompanyMember" xml:lang="en-US">Cantor Fitzgerald &amp; Co [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CantorFitzgeraldAndCompanyMember" xlink:to="lab_syn_CantorFitzgeraldAndCompanyMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) From Continuing Operations Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from Continuing Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Continuing Operations, Per Basic and Diluted Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Continuing operations (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Per Basic and Diluted Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Discontinued operations (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Share (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activites:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleAccountsReceivable" xlink:label="loc_syn_ProvisionForUncollectibleAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProvisionForUncollectibleAccountsReceivable" xml:lang="en-US">Provision for Uncollectible Accounts Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProvisionForUncollectibleAccountsReceivable" xml:lang="en-US">Provision for uncollectible accounts receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProvisionForUncollectibleAccountsReceivable" xml:lang="en-US">Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProvisionForUncollectibleAccountsReceivable" xlink:to="lab_syn_ProvisionForUncollectibleAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProvisionForUncollectibleNoteAndInterestReceivables" xml:lang="en-US">Provision for Uncollectible Note and Interest Receivables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProvisionForUncollectibleNoteAndInterestReceivables" xml:lang="en-US">Provision for uncollectible note and interest receivables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProvisionForUncollectibleNoteAndInterestReceivables" xml:lang="en-US">Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, note and interest receivables.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:to="lab_syn_ProvisionForUncollectibleNoteAndInterestReceivables" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Loss on sale of equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Stock Option Exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for stock option exercised.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds From Warrant Exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash Period Increase Decrease</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Aggregate Intrinsic Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DocumentAndEntityInformationAbstract" xlink:to="lab_syn_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Equipment Impairment Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment on loss of equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EquipmentImpairmentLoss" xlink:to="lab_syn_EquipmentImpairmentLoss" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GainLossOnSaleOfDiscontinuedOperation" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperation" xml:lang="en-US">Gain Loss on Sale of Discontinued Operation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperation" xml:lang="en-US">Gain on sale of discontinued operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperation" xml:lang="en-US">Gain loss on sale of discontinued operations during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_GainLossOnSaleOfDiscontinuedOperation" xlink:to="lab_syn_GainLossOnSaleOfDiscontinuedOperation" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisclosureManagementPlanAbstract" xml:lang="en-US">Disclosure Management Plan [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisclosureManagementPlanAbstract" xlink:to="lab_syn_DisclosureManagementPlanAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ManagementPlanDisclosureTextBlock" xlink:label="loc_syn_ManagementPlanDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ManagementPlanDisclosureTextBlock" xml:lang="en-US">Management Plan Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ManagementPlanDisclosureTextBlock" xml:lang="en-US">The entire disclosure of Management&#39;s Plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ManagementPlanDisclosureTextBlock" xlink:to="lab_syn_ManagementPlanDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CantorFitzgeraldAndCoMember" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CantorFitzgeraldAndCoMember" xlink:to="lab_syn_CantorFitzgeraldAndCoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>syn-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.8 on 13-Nov-2013 [06:57:20] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensation" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrants" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrants" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#NetLossPerShare" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShare" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SubsequentEvent" roleURI="http://www.syntheticbiologics.com/role/SubsequentEvent" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationTables" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationTables" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsTables" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ManagementsPlanDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#FairValueOfFinancialInstrumentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockbasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetails1" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockPurchaseWarrantsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#NetLossPerShareDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#BasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/BasisOfPresentation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#SubsequentEventDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/SubsequentEventDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#ManagementsPlan" roleURI="http://www.syntheticbiologics.com/role/ManagementsPlan" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" />

  <roleRef xlink:type="simple" xlink:href="syn-20130930.xsd#FairValueOfFinancialInstruments" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments" />

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract_368" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DocumentAndEntityInformationAbstract_368" xlink:to="loc_dei_DocumentInformationTable_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_369" xlink:to="loc_us-gaap_StatementClassOfStockAxis_382" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_382" xlink:to="loc_us-gaap_ClassOfStockDomain_383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_369" xlink:to="loc_dei_DocumentInformationLineItems_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityRegistrantName_378" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityCentralIndexKey_379" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_CurrentFiscalYearEndDate_380" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityFilerCategory_381" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_TradingSymbol_376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentType_371" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_AmendmentFlag_372" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentPeriodEndDate_373" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentFiscalPeriodFocus_375" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_370" xlink:to="loc_dei_DocumentFiscalYearFocus_374" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_20" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_23" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrants">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_25" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_25" xlink:to="loc_syn_StockPurchaseWarrantsTextBlock_26" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_28" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_29" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_407" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_407" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_31" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_34" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_34" xlink:to="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock_35" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_38" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_42" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_42" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_43" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_45" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_45" xlink:to="loc_syn_ScheduleOfWarrantActivityTableTextBlock_46" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_45" xlink:to="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_47" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65" xlink:to="loc_us-gaap_StatementTable_66" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_StatementScenarioAxis_67" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_67" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_68" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66" xlink:to="loc_us-gaap_StatementLineItems_69" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_AssetsAbstract_70" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_Cash_71" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_AssetsCurrent_74" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_75" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_76" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_77" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70" xlink:to="loc_us-gaap_Assets_78" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_AccountsPayableCurrent_80" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_Liabilities_83" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_StockholdersEquityAbstract_84" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_PreferredStockValue_85" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_CommonStockValue_86" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_87" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84" xlink:to="loc_us-gaap_StockholdersEquity_89" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_90" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract_398" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureManagementPlanAbstract_398" xlink:to="loc_us-gaap_StatementTable_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_399" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_400" xlink:to="loc_us-gaap_RelatedPartyDomain_401" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_401" xlink:to="loc_syn_CantorFitzgeraldAndCoMember_402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_399" xlink:to="loc_us-gaap_StatementLineItems_403" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_403" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_403" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_405" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_49" xlink:to="loc_us-gaap_StatementTable_50" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_51" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52" xlink:to="loc_syn_AdeonaClinicalLaboratoryMember_53" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_StatementLineItems_54" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_syn_LaboratoryFeesNet_55" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_us-gaap_OperatingExpensesAbstract_56" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_57" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_58" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_56" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_59" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54" xlink:to="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_62" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract_61" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_63" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92" xlink:to="loc_us-gaap_StatementTable_93" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93" xlink:to="loc_us-gaap_CreditFacilityAxis_94" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_94" xlink:to="loc_us-gaap_CreditFacilityDomain_95" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_95" xlink:to="loc_us-gaap_CommercialPaperMember_96" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_97" xlink:to="loc_us-gaap_RelatedPartyDomain_98" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember_99" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_98" xlink:to="loc_syn_AdeonaClinicalLaboratoryLlcMember_99" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93" xlink:to="loc_us-gaap_StatementLineItems_100" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_NotesReceivableNet_101" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_102" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_390" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_104" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_104" xlink:to="loc_us-gaap_StatementTable_105" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_105" xlink:to="loc_us-gaap_StatementScenarioAxis_106" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_106" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_105" xlink:to="loc_us-gaap_StatementLineItems_108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_111" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_111" xlink:to="loc_us-gaap_StatementTable_112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_112" xlink:to="loc_us-gaap_StatementScenarioAxis_113" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_113" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_112" xlink:to="loc_us-gaap_StatementLineItems_115" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_116" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_117" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_118" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_115" xlink:to="loc_us-gaap_OtherAssetsCurrent_119" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_121" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_121" xlink:to="loc_us-gaap_StatementTable_122" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_us-gaap_EquipmentMember_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_126" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_124" xlink:to="loc_syn_LaboratoryEquipmentMember_127" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_StatementLineItems_128" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_133" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_133" xlink:to="loc_us-gaap_StatementTable_134" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_134" xlink:to="loc_us-gaap_StatementClassOfStockAxis_135" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_135" xlink:to="loc_us-gaap_ClassOfStockDomain_136" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_134" xlink:to="loc_us-gaap_StatementLineItems_137" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_139" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_139" xlink:to="loc_us-gaap_StatementTable_140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_RangeAxis_141" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_141" xlink:to="loc_us-gaap_RangeMember_142" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_142" xlink:to="loc_us-gaap_MinimumMember_143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_142" xlink:to="loc_us-gaap_MaximumMember_144" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementLineItems_145" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_147" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_148" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_149" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_150" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_145" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_151" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_153" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_153" xlink:to="loc_us-gaap_StatementTable_154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_154" xlink:to="loc_us-gaap_StatementScenarioAxis_155" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_155" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_154" xlink:to="loc_us-gaap_StatementLineItems_157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_159" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_160" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_161" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_162" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_164" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_165" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_166" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_167" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_168" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_169" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_365" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_172" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_173" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_174" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_175" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_176" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_178" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_178" xlink:to="loc_us-gaap_StatementTable_179" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_PlanNameAxis_180" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_180" xlink:to="loc_us-gaap_PlanNameDomain_181" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2001Member_182" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2007Member_183" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_181" xlink:to="loc_syn_StockPlan2010Member_184" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_185" xlink:to="loc_us-gaap_RelatedPartyDomain_186" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember_187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_186" xlink:to="loc_syn_EmployeesAndDirectorsMember_187" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_186" xlink:to="loc_syn_EmployeesAndConsultantsMember_188" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_189" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_189" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_190" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_191" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_191" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_192" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_192" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_193" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_194" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_RangeAxis_194" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_194" xlink:to="loc_us-gaap_RangeMember_385" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_385" xlink:to="loc_us-gaap_MaximumMember_387" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_179" xlink:to="loc_us-gaap_StatementLineItems_384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_196" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_196" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_197" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_198" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_199" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract_240" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_BalanceSheetParentheticalAbstract_240" xlink:to="loc_us-gaap_StatementTable_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_241" xlink:to="loc_us-gaap_StatementScenarioAxis_242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_242" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_243" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_241" xlink:to="loc_us-gaap_StatementLineItems_244" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_246" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesIssued_247" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesIssued_251" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_252" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_201" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_201" xlink:to="loc_us-gaap_StatementTable_202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_202" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_203" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_204" xlink:to="loc_us-gaap_WarrantMember_205" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_202" xlink:to="loc_us-gaap_StatementLineItems_206" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_207" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_208" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_209" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_210" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_211" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_212" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_213" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_214" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_215" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_216" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_218" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_218" xlink:to="loc_us-gaap_StatementTable_219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_219" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_220" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221" xlink:to="loc_us-gaap_WarrantMember_222" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_219" xlink:to="loc_us-gaap_RangeAxis_223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_223" xlink:to="loc_us-gaap_RangeMember_224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice1Member_225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member_226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice13Member_226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice14Member_227" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice220Member_228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice222Member_229" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice330Member_230" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice375Member_231" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_224" xlink:to="loc_syn_ExercisePrice199Member_232" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_219" xlink:to="loc_us-gaap_StatementLineItems_233" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_syn_WarrantsExercisePrice_234" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_235" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_236" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_237" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_366" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_254" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_254" xlink:to="loc_us-gaap_StatementTable_255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_256" xlink:to="loc_us-gaap_EquityComponentDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_258" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_257" xlink:to="loc_us-gaap_WarrantMember_258" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_259" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_260" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_260" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_261" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255" xlink:to="loc_us-gaap_StatementLineItems_262" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare_264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_WarrantsExercisePricePerShare_264" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_266" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_267" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_268" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_268" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncrementalExpense" xlink:label="loc_syn_IncrementalExpense_269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_IncrementalExpense_269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_270" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_syn_WarrantsExercisablePricePerShare_271" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_272" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_274" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_274" xlink:to="loc_us-gaap_StatementTable_275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_276" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_275" xlink:to="loc_us-gaap_StatementScenarioAxis_276" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_276" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_277" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_275" xlink:to="loc_us-gaap_StatementLineItems_278" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_278" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_279" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_278" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_280" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_410" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_410" xlink:to="loc_us-gaap_StatementTable_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementClassOfStockAxis_412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementLineItems_414" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_415" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_416" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/BasisOfPresentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_356" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SubsequentEventDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_282" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_282" xlink:to="loc_us-gaap_StatementTable_283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_283" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_284" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_284" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_285" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_285" xlink:to="loc_us-gaap_SubsequentEventMember_286" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_283" xlink:to="loc_dei_LegalEntityAxis_287" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_287" xlink:to="loc_dei_EntityDomain_288" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_CantorFitzgeraldAndCompanyMember" xlink:label="loc_syn_CantorFitzgeraldAndCompanyMember_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_288" xlink:to="loc_syn_CantorFitzgeraldAndCompanyMember_289" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_283" xlink:to="loc_us-gaap_StatementLineItems_290" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_295" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_295" xlink:to="loc_us-gaap_StatementTable_296" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_296" xlink:to="loc_us-gaap_StatementScenarioAxis_297" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_297" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_298" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_296" xlink:to="loc_us-gaap_StatementLineItems_299" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_OperatingExpensesAbstract_300" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_301" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_302" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_300" xlink:to="loc_us-gaap_OperatingExpenses_303" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_InvestmentIncomeInterest_306" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_307" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_305" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_308" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_309" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_310" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_NetIncomeLoss_311" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_313" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_314" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_315" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_312" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_315" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_299" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_316" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_318" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_318" xlink:to="loc_us-gaap_StatementTable_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementScenarioAxis_320" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_321" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_320" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_321" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementLineItems_322" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetIncomeLoss_324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_ShareBasedCompensation_326" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_Depreciation_327" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleAccountsReceivable" xlink:label="loc_syn_ProvisionForUncollectibleAccountsReceivable_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_ProvisionForUncollectibleAccountsReceivable_388" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProvisionForUncollectibleNoteAndInterestReceivables" xlink:label="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_ProvisionForUncollectibleNoteAndInterestReceivables_389" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_329" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_EquipmentImpairmentLoss_330" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_GainLossOnSaleOfDiscontinuedOperation" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperation_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_325" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperation_331" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_333" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_334" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_335" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_335" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_336" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_336" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_332" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_337" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_323" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_340" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_339" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_343" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_343" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_344" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_345" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_346" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_Cash_347" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_Cash_348" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_322" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" xlink:to="loc_us-gaap_InterestPaid_350" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_349" xlink:to="loc_us-gaap_IncomeTaxesPaid_351" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_353" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_353" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementsPlan">
    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract_396" />

    <loc xlink:type="locator" xlink:href="syn-20130930.xsd#syn_ManagementPlanDisclosureTextBlock" xlink:label="loc_syn_ManagementPlanDisclosureTextBlock_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureManagementPlanAbstract_396" xlink:to="loc_syn_ManagementPlanDisclosureTextBlock_397" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_359" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_359" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_362" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_362" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Black-Scholes assumptions used in the three and nine months ended September 30, 2013 and 2012 are as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="3"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$1.96-&#160;$2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$1.70-&#160;$2.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>153%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>108%&#160;-&#160;174%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0.63%&#160;-&#160;0.65%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0.37%&#160;-&#160;1.98%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> </tr> </table> </div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">A summary of stock option activities as of September 30, 2013, and for the year ended December 31, 2012, is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average&#160;Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance - December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,979,010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>6.01&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,075,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(374,851)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(225,413)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance - December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,453,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>6.43&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,308,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(291,666)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(475,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance &#150; September 30, 2013 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,804,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>5.76&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>932,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance &#150; September 30, 2013 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,902,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>5.27&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Grant date fair value of options granted - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>185,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Weighted average grant date fair value - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Grant date fair value of options granted - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,468,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Weighted average grant date fair value - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#4VKBTTP$``!\5```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;PWK
MVBFB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"&((9)X;EC8VO,^Z\63[.T/EW45
M+<"Z4JN,L#@A$:A<RU)-,_(^?N[T2.2\4%)46D%&5N#(<'!YT1^O#+@H[%8N
M(X7WYIY2EQ=0"Q=K`RH\F6A;"Q_^VBDU(I^)*5">)%V::^5!^8YO9I!!_Q$F
M8E[YZ&D9;J])+%2.1`_KA4U61H0Q59D+'TCI0LF]E,XF(0X[VS6N*(V["AB$
M'DQHGOP<L-GW&H[&EA*BD;#^1=0!@RXK^JGM[$/K67Q\R`%*/9F4.4B=S^MP
M`K$S%H1T!8"OJ[B]QK4HU9;[2'Z[V-'VPLX,TKQ?._A$#HZ$(T7"<8V$XP8)
M1Q<)QRT2CAX2CCLD'"S!`H+%J`R+4AD6IS(L4F58K,JP:)5A\2K#(E:&Q:P<
MBUDY%K-R+&;E6,S*L9B58S$KQV)6CL6L'(M9.1:SIEC,FF(Q:_I?9O6A?@+:
M_O[]+-HQO_0?SJ\J<&?^9ED/_2VY$!;DF[>AJ#L[P/?9QSA"C36RVKA0Z%DX
M_12VC5VSNV/"(+"^A%UG=ZC[VB6&,O#TP+WR#9JZ48(\D$W;>G/P!0``__\#
M`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($
M`BB@``(`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(
MNR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[
MUVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+
M\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F
M?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B
M2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#
M!!0`!@`(````(0![DWK.SP$``/X3```:``@!>&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;',@H@0!**```0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``"\6,MJPS`0O!?Z#T;W1ME5FSZ(DTLIY-K'!PA;B4T<VTCJ(W]?D18GA79Z
M,7L)2":K830[X_5\^;%KLC?G0]VUN:+)5&6N+;JR;C>Y>GE^N+A168BV+6W3
MM2Y7>Q?4<G%^-G]TC8WI3Z&J^Y"E*FW(515C?Z=U*"JWLV'2]:Y-3]:=W]F8
MEGZC>UML[<9IGDYGVI_64(L?-;-5F2N_*LFH['G?IZ/_+]ZMUW7A[KOB=>?:
M^,L9^KWSVU`Y%U-1ZS<NYFK8"OKPA,PD85;Z#SB)#UDX-P@.SX3A\`S!D;XK
M>%5,TMP0Y.9R3#@A[IO4BH.*O];H_.LQCQ^:YHA@V/KNHVL$AE@8#3&$(TT.
M07;X2I@=OD+LF%';.J9L<$?9');Z\`O;1UHP6"_2MDO0=CFEMF@H\13IA6^E
MX=PB.-(Q`&4L+1RH&Q*G!G+#HR;DD$='KQFVOB.*+Y%NC+3E&.@YTID`(X&D
MT1"$PZ,FU"`3H!S\YBD])#`<$D@Z'@C&`TG'`\%X,-(F:*`)2GL@M$#IFX(7
M1=+4$.2&I>.!83RP]`C#<(0QTIYCH.>84?,J5-:[\BGZ])7L=`8_W49O%M+Q
M,*2#_O'5;O$)``#__P,`4$L#!!0`!@`(````(0!!GY'D/0,``*L*```/````
M>&PO=V]R:V)O;VLN>&ULE)9=;YLP%(;O)^T_(.Y7/ONI)E4_M4I;&RE9>VFY
MX`2KQLYLLZ3[]3O`0@]X0=U58@BOSWG?YSB<7VQ+X?UBVG`E)WYT$/H>DYG*
MN5Q-_!^+NR\GOF<LE3D52K*)_\:,?S']_.E\H_3KBU*O'@A(,_$+:]=G06"R
M@I74'*@UDW!GJ71)+2SU*C!KS6AN"L9L*8(X#(^"DG+IMPIG^B,::KGD&;M1
M654R:5L1S02U4+XI^-KXT_,E%^RI[<BCZ_4#+:'NK?`]08V]S;EE^<0_A*7:
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MM:B)&H9N_^/A_C?<9`HBE16D`MWKEO9Z_\L<>Y$<(9F3H<P=Y9H\45$UE=]Q
M">ER*@`38W6%JSE&,J=#F3D3+'/XV,&&9>#DZ)J*0D?'JNSUBAKHZ5J5<%J8
MIBTL<(H%'%CGM0"953HK0(4\4ZTI((($4IBX]PH<4AN!0HD<S@IR^[."F<$/
M]R;%`?2!6?)-&4,@#Q@1JG$0:8PW=K`<#Q3V;;"IIS7%HQ8Y9(YGT1/":$8.
MFXT5;AAD05\$'/BH($QJY*"Z)Y-_Z&!4(X?5X:R0&V8I%X8LV-9B5E/,:N3`
M.NXTI-0Y79_.'2NP&)R,XT*04B>48NQCA]KQ*>Q%AO&/77I'YQ"W=MAKS2%Y
M'"+<VB$>B=C!>A]$;7;(HAA#!(N!U^,ZV"+XZT6A?9CJMJ">17A@XP]C[7;6
M"]_!>M]XM#J]SGKA.UR/"_4ZPR=(XG#="/7/0#1K*+,$9P^+06;N<8ADME@'
M.YTT5`?-[,`+349%!F]:]4=]^#7%!KOWS.D?````__\#`%!+`P04``8`"```
M`"$`^CX*GA$%``#+$P``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)28
M6V^K.!#'WU?:[X!X3\#<`E&2H\.ENT<Z*ZU6>WFFQ$E0`XZ`WK[]CAD2[*%-
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M\['[2[S^SLO]H8-T^T`DP9;;]Y2W!404W,P=7WHJQ!$F`'^-JI2E`1')W_K_
MK^6V.ZQ--YC["]ME(#<>>=L]E-*E:13/;2>J_U#$!E?HQ!F<P(C!"7/F3N@S
M/[CMQ<(9]8!IWN6;52->#:@:>&=[RF4-LB5X/I/A/"ZLGZ$"HW3R77KI?0%%
M"_EYV?C!RGJ!D!:#)$;)PC1&2:A+DK-$!E"Z3<]?C&.8/B0[*V3V@.B"!<&B
M6"ZD_>.$G2GD($*QT-\73R6.KDBF"C_2)>E40IQD4X7B1`-U==#K@%(,M:?D
M(+#UN<4H\12)KRN2FXKTIB*[IM#P8")J'J_C2?':A-A=2BP@]1*C).Q+E(41
MH4\TL[UP=?14-7O.@HS.5+.[8&/M:$BPRNY'DF*"1&HE1HF/2-Z"I@O-7F]>
M!)1('>PN(K)H,]7,`L6L$05?(9)B0D0F%:,$B5PWH$2JF84NF7.JFD,[(.9,
M-?L>&]^M(<$^=7^2I)@@>7KEQ"A!I-D'3)K]`RC-_@&59O\<2QY(E-W^^G*2
M8K);D%3$*(&ZOZPXHDAN*M*;BNR:0LM:]!4\*299([42HP37#B-;2:(:R4Z0
MJC:7+-A,-8X#-1`&O>K^1/5J@C)N/GTKC0<-LLP8J<]$,[-Q5D,?EM-9F\-@
MI17UYDP;[(RX.I)LU7?7'L/&KNWEY+@0#YIA5N-"[B>5:-8I$?H?QCHD6IDV
M^%,BV:7O)\*>KA&1@T',4#-N$P0YT04L=$C%IKH@M",2EDP7^&XTEK6>+MFB
M%3AY,+Q]@F+8V%5(VB7C08.A)Y66:,89LTF=IIJ=#,XTHQN.T=7)9)M6R*YO
M@@R;ND8TAFQ86VKCE[O[)&V:@$4NF7DZO`7/);./TJ9Y\&W[LU4F.[8"=V?:
ML,]#\B[[^&)\P0")&IC'14/W>OF3J-\F/I6DMR7958F>2=G+OPZ+)P`MHV25
MQ`PU47]JFMES>Y)1*B"Q2*D'1CQD$\&XE'5(V=J_#HD'`@V2K*68H0:+CE1D
M<LV87C-F@Q%C!Z$;5XO.);OZU[GP+*!QD=#'##57DD<%Q$-*/4R31SRPT8,.
M*7L]@?1@E=S8<_"$H$&.U3$L1]1@J_"\P/>\:5-7-:[KAJXS;1BJ!ORX0>2.
M,/V[Y-6*7-?#@=P);>9-@/'N!*\6*M[L><*/Q]8HQ+.\%W%@(5V^Q3N;F"WA
M!S_\;B??I_(NI[^-N1C@*N64[_D?>;,OZ]8X\AVXM.<+"&2#ES'XT(E3__/]
M471PB=)_/,"E&8>K!'L.XIT0W?E!7AA<KN$V_P,``/__`P!02P,$%``&``@`
M```A`%3\KOS!`P``Y0P``!D```!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MG%==CZ)(%'W?9/\#X;V!`D$PZJ25].XD.\EDLS/S7$*II($B5-EV__N]Q06$
MTO9C?!#QGGL\Y]:MXCK_\E[DQANK1<;+A4DLQS18F?`T*W<+\\=_+T^A:0A)
MRY3FO&0+\X,)\\ORSS_F1UZ_BCUCT@"&4BS,O935S+9%LF<%%1:O6`F1+:\+
M*N&VWMFBJAE-FZ0BMUW'">R"9J6)#+/Z'@Z^W68)BWER*%@ID:1F.96@7^RS
M2G1L17(/74'KUT/UE/"B`HI-EF?RHR$UC2*9?=V5O*:;''R_DPE-.N[FYHR^
MR)*:"[Z5%M#9*/3<<V1'-C`MYVD&#E39C9IM%^8SF<7$->WEO"G0SXP=Q>"S
M(?;\^%>=I?]D)8-JPSJI%=AP_JJ@7U/U%23;9]DOS0I\KXV4;>DAE__RX]\L
MV^TE++</CI2Q6?H1,Y%`18'&<GW%E/`<!,"[462J-:`B]+VY'K-4[A>F%UC^
MU/$(P(T-$_(E4Y2FD1R$Y,4O!)&6"DG<E@2N+0GQK8GK3\-'6+R6!:X=2_`X
MRZ1E@6O'XEINZ!,_N.W(QNHTQ8ZII,MYS8\&=##X%Q55^X',@+FK,M:DK_MG
M98=Z*Y)GQ;(PIZ8!%170*V]++W+G]ANL;])B5HB!]QY#QHCU.<+S-4S<853K
M@(7>!ZS0T,?E+NGD*K"2J[I&Z5_A%T-MFOKU!40XEA^?0_RHAXS$0B,,Q:JB
M>[!!KHM620L3?J2OGQ=Y/3_Z0(S?K``)/-=WM/JMAPB(1R0,QASQ$$$\=T*<
M4RU&+J!=ABZNJU=@7?UD_,LKQ$P:]<XXML88.HM"/_3],2#NDD_E.2%&LF'W
MWR];@779)UXL.F(NR\88RGXBTR`DP503WJ7?%!X\(ER!=>':2J\0<UDXQEKA
MX63B3;5>B[OLF[KA6+B_X`JLZ]8JMD+,M2Z_B8A'B&M=KN8)[8"\O5=5DN9B
M<!9@VR`FPKUJ1:>CH@FOM;#6=#&&H>G[T^"$&+5[]#OZ59*F/]!VY`HQX<7=
MBK'.VU0[A&(,WR&>P*GX>/6;+%V^IF'5@B[K;X.=`4*<X4NCBEOT/7[4X^OA
M;B+XT!L=_<'I4,9V:D&?^$$&].-9GI8<M\GW.%!/N<<=X+-Q[$`[4%8P3:JN
MZXI^MB-NQ-4TJO*OF<!I$P>@@M4[MF9Y+HR$']0D2:"7^V_[*?>Y&7+M/@!#
M9D5W[!NM=UDIC)QM(=6QIG".USBFXHWD53->;;B$\;+YN(>_$PSF#<<"\)9S
MV=VH::;_@[+\'P``__\#`%!+`P04``8`"````"$`+T'"U2P%``#B&```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R<F=N2JC@4AN^G:MZ!XGX+""A:
MZJY6/)^M.5S3&)7:(A;0;??;SPH1FR1L%SU]H;+ZRY_#^I.8V/GY$9Z5=Q(G
M073IJD9-5Q5R\:-]<#EVU;__&OUP5"5)O<O>.T<7TE4_2:+^[/WY1^<6Q;^2
M$R&I`@J7I*N>TO3:UK3$/Y'02VK1E5S@/X<H#KT4'N.CEEQCXNVS0N%9J^MZ
M0PN]X*(RA79<12,Z'`*?N)'_%I)+RD1B<O92:']R"JY)KA;Z5>1"+_[U=OWA
M1^$5)%Z#<Y!^9J*J$OKMZ?$2Q=[K&?K]85B>GVMG#Y)\&/AQE$2'M`9R&FNH
MW.>6UM)`J=?9!]`#.NQ*3`Y=]<5H[QQ5ZW6R\?DG(+>D\%E)3M%M'`?[17`A
M,-B0)IJ`URCZ1='IGH:@L":5'F4)V,3*GAR\MW.ZBVX3$AQ/*63;A@[1?K7W
MGRY)?!A0D*G5;:KD1V=H`+PJ84"=`0/B?63OMV"?GKJJV:C93=TT`%=>29*.
M`BJI*OY;DD;AOPPR[E),I'X7@1)W$:->JSNV83>^H=*XJ\![WA2S9M7MIO.=
MMC3O*O">JX!@Q8[`I&"C`?U]E/[V<!CY>!B@=Y>I6Y6[HK$491EWO=3K=>+H
MIL`L@D8E5X_.2:--I<MS#,FE\`NENRH,`Z0O`5^^]\QFHZ.]@YG\.].7F3I/
M#$H(AT=<&;%;/#*4$=,6:AHQ!EX?[16(L4R(%4UD1!"9RH0H,I,1060N$Z+(
M0D8$D:5,F([!#]Q*9@25M4R8CLFK;,H8BV>V,B/4M),)T_DRE`8F?3@5)L`W
MG$IIZE2Z.E'K]L7`0`RX8F`H!D8L`&U^V,EL-OD^C\L8P=V3"LRT`C.KP,PK
M,(L2QM'Y?BTK,*LR1LCXN@*SJ<!LRQB;;_/N.<.YRQ3<1?<\Z[=[7KX>TE*<
MR\3`0`RX8F`H!D8LP'9#:MVQ&)CD@:(/A>5Q6H&956#F%9A%SN23;9D'"@VT
MA$FPRIF\T%H,;/+`$Y5MSN0JNT*`2[#UOQ),2W55\-'7C'>$&=]GC,VV0T>W
M;''N#(J$9=EFT_I:X[+5R>6(NNU(Q+!(U%O-EFX(,W3$"'A]M%68#V.4F*#$
M%"5F*#%'B04CV)BV;-/6A4%?HA*KHH1EF793V,'61:!NZ_2/7S\V:"5;3L/2
MFR##:^R*A)E5\D5P!H7%AMO?JJU`M)1H4&&F]1D##?F=,08HX:+$$"5&C&!)
M-0QYK,8<X%AR1B9H)5.4F*'$'"46C'CBSR+`S,7[8E4$2NV)-F)3E"BK8\L!
MI>Y\5@GG3CCO2.YLP,GR^7F!EA+=*6Q4?<8\<R=*N"@Q1(D1(YQL&3<<NA[P
M&1L7@<R;(C%!*YFBQ`PEYBBQ0(DE2JQ08HT2&Y38HL3N&<$Y%$ZEDD--U*&T
ME.#0EI#X/F.>.10E7)08HL0()<8H,6'$_<N*Z4@NGW)`2YX&LR)@P,6<)#'G
M"+;G\5-IP8@G([I$B15*K%%B@Q);E-@](SB#TMO1XE4+W>#Q)926$@TJG.C[
MC+DO7:V2E`P8\63`7908HL0()<8H,4&)*4K,4&*.$@N46*+$"B76*+%!B2U*
MP%TQ]5!Y]IE%V5TPNQD,27PD`W(^)XH?O=%[7KI</**/*^@7D]ZN"/&^T>Z7
MQ0=&&\[",N\:;3@2R_&AT8:3,<2U1P5PQ7SUCF3IQ<?@DBAG<H"FZ;4F?(>)
MV24U>TBC:W:O^1JE<+F<?3S!;PD$CM)Z#>!#%*7Y`ZW@\>M$[S\```#__P,`
M4$L#!!0`!@`(````(0"L>`;M504``+<6```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;)R86X^S-A"&[ROU/R#N%S"'D$1)/BV';3^IE:JJAVM"G`1M
MP!&PF]U_WS%#6#SPD:0W.<W+BY\9VTR\^O:1G[1W7E:9*-8Z,RQ=XT4J=EEQ
M6.M___7R-->UJDZ*77(2!5_KG[S2OVU^_FEU$>5K=>2\UL"AJ-;ZL:[/2].L
MTB//D\H09UY`9"_*/*GA:WDPJW/)DUUS47XR;<N:F7F2%3HZ+,M[/,1^GZ4\
M$NE;SHL:34I^2FH8?W7,SM75+4_OL<N3\O7M_)2*_`P6V^R4U9^-J:[EZ?+[
MH1!ELCT!]P=SD_3JW7P9V.=96HI*[&L#[$P<Z)!Y82Y,<-JL=AD0R+1K)=^O
M]6>VC&VFFYM5DZ!_,GZI>I^UZB@NOY39[K>LX)!MJ).LP%:(5RG]OI,_P<7F
MX.J7I@)_E-J.[Y.W4_VGN/S*L\.QAG)[0"3!EKO/B%<I9!1L#-N33JDXP0#@
M5<LS.34@(\E'\W[)=O5QK3LSP_,MAX%<V_*J?LFDI:ZE;U4M\G]1U!!U)G9K
MXL#H,6[;AFM[_OP1%[=U@??6A3D/#P4&W?#`^]7$-NRYQ[S9;2`3D]/D.DKJ
M9+,JQ46#"0SXU3F1RX$MP?F:9$Q)E_8?91W2+4V>I<M:]W4-$EK!5'G?.)ZU
M,M^AO&FK"5`#KYV&J8IPS(5HHJM&UEO>.K[:RJD$3!T85*X/-CYKKN.78CG^
MJVN`/_0':Y/!CBCFJB0:2AR/V,1#C;?H;!0@F(+W`TGQ6@?S+MF.YW2^3>8"
MU'A-N5S7<WQWIBK"OL)>^`N+D:)&J(!YW=W'4SWBO@<LG'G_+@H?F-S/)\64
MSU7O'*`&^1CS/8L,/NP+;$L*B")"!;S^$&]*H>#!XKH?3XHI'DEL@!K$>[(7
M;#:CY5,44%[8*]041:B8XIM2*'RS1_BDF/*1T0>H:?G<D>J$BL*V/9>1*1ZA
M8HIO2J'PP>9V?_VDF/+Y:NX#U""?,[=<;TYF7]A7C"[0J*\87:!Q7S&Y_&3;
MU'L03.^74DSYR.X7H`;Y[(5E.Q;)0(B*B>I$-Q7QE$*IWT+EDP\Z!WJ2:4YY
M$>7\VIYQ&T7-HME&F>&3-(1JV"&;5(3AB1S$4PJ%D`%.OX3W(397$<89F8E!
M*^H@"46HQ*$KH?M,&Y_"G)2HG/*1WYNJ=W)BHZ`\$F=DG`%#$7):AD]J'9+X
MH)IM?)(3;S$N43EE;_`X)W84*B?I.@*&(N2T#8?D(:1QLG*C-CX.T?9E>(MQ
MB<HI6X3'.;&Q4#G)_A\P%'7S=E!/$B>+-R+7TWK';?P>2-#\#TAY%5V<9/$%
M#$57R!DI5MC&QP?9%"NZ+8DG)6H]9<_P>#VQTU#K27L>^?\/\M%'<09MSZB(
M)"4:%9'RQR.BKQ&IS+*/>)P9NP^5F<S1@`U;%,<G&W0X(OH::5OCH0^1Q),N
M*J_L*Q[GQ6Y$X?7)WA,P%,WQ@>I8\T%;'BH2DHJH#?;GR(`3;S$N43EE?_$X
M)W8E*N=@#T81-D@+!TZ7"$G(^@HVEHFHE;A-LLCU<1<<^_NB8LHFHX<YW14Q
M;$E4O,'6BZ(6SW)&\*8ZFW;.WI3$[6#NJ*5-^J-IR$9-MEZ?;KVMJ)VK\^$_
MR%!1N.YL.)NC5C).@`_328E229LT1S<@1YHBGZR6H+%<Z]?GBT>VTE")VP8C
MUT=M?)+O=E.$YX1X=I7S\L!#?CI56BK>Y!F@#0N@^[4[GWRVY8D.^3UD2SA%
MDL=%70".#<_)@?^>E(>LJ+03WX,EM'_PM"GQX!&_U.+<G)AM10T'ALW'(QP0
M<SB'L@P0[X6HKU_D#;HCY\U_````__\#`%!+`P04``8`"````"$`-7-,_Z4$
M``"*$P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R4F%UOHS@4AN]7
MVO^`N"_$0#Z59%0"W1UI5EJM=F:O"7$25,`1T*;]]WL.YB.V$T-ST2;X\8M?
M'_MP\/K;1Y8:[[0H$Y9O3&)-3(/F,3LD^6EC_OSWY6EA&F45Y8<H93G=F)^T
M-+]M?_]M?67%:WFFM#)`(2\WYKFJ+BO;+N,SS:+28A>:0\N1%5E4P<_B9)>7
M@D:'NE.6VLYD,K.S*,E-KK`JQFBPXS&):<#BMXSF%1<I:!I5,/[RG%S*5BV+
MQ\AE4?'Z=GF*678!B7V2)M5G+6H:6;SZ?LI9$>U3\/U!O"ANM>L?BGR6Q`4K
MV;&R0,[F`U4]+^VE#4K;]2$!!SCM1D&/&_.9K$*R,.WMNIZ@7PF]EC??C?+,
MKG\4R>%'DE.8;8@31F#/V"NBWP]X"3K;2N^7.@)_%\:!'J.WM/J'7?^DR>E<
M0;BGX`B-K0Z?`2UCF%&0L9PI*L4LA0'`7R-+<&G`C$0?]?]K<JC.&].=6=/Y
MQ"6`&WM:5B\)2II&_%96+/N/0Z21XB).(P(]&A'B6,YB2J:S816;CZ@V&$15
MM%T7[&K`JH%[EI<(UR!9@7+KC(^C\_K(*GA$D6=4V9ASTP`7)<3G?>MZWMI^
MASF-&\97F>E"1'8M@C.(ND%[H=<E8I>P)3!\8*GS!;-UZ^M^I-KA(XS#;^_K
M\PN@W?EQQ/ON5&*Z%)%`12214"5N1`0[[E?L(+PQ0;P?/9F)@_,YLZAC-1';
M=KS-N^D_%8F`$\NZ-['F4JA#G8!@"^XQ/DH(R[:D.?<Y0PBY:TS;&FA;PT>M
M@A_80>/]("SY<:3E[7/FD1^QE5A35XJ3#'C2C@LY`-ZZI=*'6G`V^XHSA&5G
MTM!\SCQRQEOOCXNG!K'_W)I/A(\3/DEW#'6:@E?(8^.CB+#L5=YLG+EUXWK]
M/-=^=BHC$8%*N)YTIU!E>A7!(Y8F-WE?GQ\1ECW*.X\SC^*I;0VTK>&C5L'/
M\BM^$!;]N-Y<W#H^9VYCUL\DC]@@$0P2H8X0_!$H6L8'K*9%AX[R"&@@G<4.
MP4<ZL9;2<@NZ]GOYHYZEL$.X1#_-HCU\CH]>CY#>Y0`Z2NIL(*T]KJ-!@F&5
ML$':I0_O`7V6%4WB\WZ\25X="(]Q1\II/N&0QL&N0=KAS2Q728W!L$PHR;C:
MA"O:QG)@O&U>/(BVI77G$UV%P7?G'41)E\$=2-KEX1WD5D=T"G'X@E.DQ4WJ
MR@]HGW!(&^!!)!A6";6(Z!*+AO'QY"6&$$\U%>GJD":>+8)Y!%Y\^D12MP?X
M/@:SJ9FHL$.XA">6#'UQ+KK%LF&\6UYD"&[5S*2K1!JW@TA`!I&P0=JM+U3J
MHDFL&\:;Y%6&:%+)3+I2I#')D79X,\M;"I_YG40UJ!H2416>6@NY,GP4:JPT
MQL\"KTO$65`2%8<TJW('!Q?RPG4]J;H*[D!*HM+K\'CS(PY^`I#1XD1W-$U+
M(V9O>'SAPEM3=[4[6GEV\,58NNZ3%;RNJ]<#/(K!ZW;7`4Y"+M&)_A45IR0O
MC90>X583:PX;MN!G*?Q'Q2[U><2>57`&4G\]PYD7A8.`B07PD;&J_8$WZ$[1
MMO\#``#__P,`4$L#!!0`!@`(````(0!FT*SV+@,``/X)```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;)16RV[;,!"\%^@_"+Q';S]A.X@5I"W0`D71
MQYF6*(N()`HD'2=_WR5IRR(3*/'%EKBSH]E9BJO5[7-3>T^$"\K:-8K\$'FD
MS5E!V_T:_?G]<#-'GI"X+7#-6K)&+T2@V\WG3ZLCXX^B(D1ZP-"*-:JD[)9!
M(/**-%CXK",M1$K&&RSAEN\#T7&""YW4U$$<AM.@P;1%AF')/\+!RI+FY)[E
MAX:TTI!P4F,)^D5%.W%F:_*/T#68/QZZFYPU'5#L:$WEBR9%7I,OO^U;QO&N
MAKJ?HQ3G9VY]\XJ^H3EG@I72![K`"'U=\R)8!,"T6144*E"V>YR4:W07+;,H
M0L%FI0WZ2\E1#*X]4;'C%TZ+[[0EX#;T275@Q]BC@GXKU!(D!Z^R'W0'?G*O
M("4^U/(7.WXE=%]):/<$*E*%+8N7>R)R<!1H_'BBF')6@P#X]1JJM@8X@I_U
M_Y$6LEJC9.I/9F$2`=S;$2$?J*)$7GX0DC7_#$A7U)/$)Y($U)_BL1_/)]%D
M^CY+8!3I`N^QQ)L59T</=@T\4W18[<%H"<RJL@3\>;LR*$GEW*DDG0IH`>UX
MVB3)8A4\@87Y";,UF!GR>DQL([(W$/,>$H"^7B24?KU(E62+C&<]O:YC:R`S
MW3%56#98L`2`,T,!X^XH\!H!55]YDH;.DPUF?O+.B6;#:#J=]+F6IO0:30IL
M:XK#I.<U;AA,JC7=1#,GG%GA.+UTTU(%^_GC3BFPK2I:N#TR&*,JFCC1;!B-
MXXMD2]/T&DT*;&M*TLAQRF#`D+[#EQYI+[,QA*4-7I"/^Z7`KC9G[VP-YNS7
MI4M&US`:#[RV-*FQ=?69H))<;<[3MP8SYML8PM*XL#6.OY$*[&IS?3,8XUOJ
MMG,83"Y!2U$$Q^;0MG%)&NUJNNQ?\T:>0&.&C4)L?<Y1_XX^<SJ/GV(P<Y6Q
MYAB+$D>^&LEOAXTN,V[--&H(WY.,U+7P<G90HS2&<ZA?-6-^&RWAR(;QZJQG
M,/[U>M`'8/IV>$]^8+ZGK?!J4@)EZ,_@O.!F?IL;R3H](W9,PMS5EQ5\9Q$8
M!J$/X)(Q>;Y17PC]E]OF/P```/__`P!02P,$%``&``@````A`.`5+$*W`@``
M^08``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%5=;YLP%'V?M/]@
M^;U\0Q(44C54W2IMTC3MX]D!`U8!(]MIVG^_:SLA@59=^Y)@WW,/YYYK7];7
M3UV+'JF0C/<9]AT/(]H7O&1]G>'?O^ZNEAA)1?J2M+RG&7ZF$E]O/G]:'[AX
MD`VE"@%#+S/<*#6DKBN+AG9$.GR@/40J+CJB8"EJ5PZ"DM(D=:T;>%[B=H3U
MV#*DXCT<O*I806]YL>]HKRR)H"U1H%\V;)`GMJYX#UU'Q,-^N"IX-P#%CK5,
M/1M2C+HBO:][+LBNA;J?_(@4)VZS>$'?L4)PR2OE`)UKA;ZL>>6N7&#:K$L&
M%6C;D:!5AF_\-$^PNUD;?_XP>I`7ST@V_/!%L/(;ZRF8#6W2#=AQ_J"A]Z7>
M@F3W1?:=:<`/@4I:D7VK?O+#5\KJ1D&W8RA(UY66S[=4%F`HT#A!K)D*WH(`
M^$4=TR<##"%/YO_`2M5D.$R<>.&%/L#1CDIUQS0E1L5>*M[]M2#_2&5)@B-)
M".J/\<`)EK$?)_]G<:TB4^`M462S%OR`X-#`.^5`]!'T4V#6E87@S^N504DZ
MYT8GF51`2^C&XR8,EVOW$2PLCIBMQ2PP&C'!%)&_@CB3N*!O%`FE?URD3IJ*
M#!93!5L+61B;=6'YQ<9$`#CS<0$Z*<-`.3K@KZ*9`HM9&@_].`JGX?PR'$3^
MV<&)NFBJ[NW>:?!<53Q][=9B(J/*F\;RRYA_-G0B"`[UI5UO"]+@N:!D^M*M
MQ5A!OC<S,;^,+L]Z)Y*2CTC2X+FD<ZGF#FPMYMBY))J%81II"AL.8F\U%F15
MV5%C;V)'14USVK82%7ROQT@`SH^[=L)M_12.*XR6V7X.D\_LNV,`)L]`:OJ=
MB)KU$K6T`DK/68!-PLXNNU!\,/=CQQ7,'//8P">&PD7P'`!7G*O30D_'\:.U
M^0<``/__`P!02P,$%``&``@````A`$B4OQ6]!0``GQL``!D```!X;"]W;W)K
M<VAE971S+W-H965T,CDN>&ULG%G;CJLV%'VOU']`O)^`P;DJR=%,1],>J96J
MJI=GAC@)FH`C8"8S?]]M;P=\@00F#[DN[^O:"Q.OOW_D)^^=E57&BXU/)J'O
ML2+ENZPX;/Q__G[^MO"]JDZ*77+B!=OXGZSROV]__FE]X>5K=62L]L!"46W\
M8UV?5T%0I4>6)]6$GUD!O^QYF2<U?"P/074N6;*3B_)3$(7A+,B3K/#1PJH<
M8H/O]UG*GGCZEK.B1B,E.R4UQ%\=LW-UM9:G0\SE2?GZ=OZ6\OP,)EZR4U9_
M2J.^EZ>K'X>"E\G+"?+^(#1)K[;E!\=\GJ4EK_B^GH"Y``-U<UX&RP`L;=>[
M##(09?=*MM_X#V3U2)=^L%W+`OV;L4NEO?>J([_\6F:[W[."0;6A3Z(#+YR_
M"NB/G?@*%@?.ZF?9@3]+;\?VR=NI_HM??F/9X5A#NZ>0D4ALM?M\8E4*%04S
MDV@J+*7\!`'`LY=G@AI0D>1#OEZR77W<^/%L,IV',0&X]\*J^CD3)GTO?:MJ
MGO^'(*),H9%(&8%7922*)S2:SA<#K`08D4SP*:F3[;KD%P]8`SZK<R(X2%9@
M^9H9QM'DVI<JY"B,/`@K&W_N>Y!%!?UYW\;+Q3IXAYJF"O.(&'AN,*1!!!!-
M$Q*$H8?47>2K9P$6GD7112B/^(7N)NIV$X]Q(\`;'VPWP<?+96,7/2-F*=,G
M$^UG(SLZQJT`FVYI&%IN$3-%M[,XFH8]=06J#:^K`-N>6[N8,&*49WK#\\ST
M+$@6PQ#>[JQ89$?0MA(C0`Q4H&D+#>.F/D;=@9S#LQ=@VS=M[*)OQ"RP[H2$
M6F,,Q^(B8$W8_>3%(CN`J14`8O3D6X01P=*,X';9!=CT[#(=,5>F$P#HCR9,
M(P@"#=?K<#L*B3;#<)FO0(J`T("^%A"A/5H/[OA&I=*'G6HSA=V7)C?^`-]"
MD#3?P\A/4,;,&&SV*Y#.`!K.>LH_2NZ(JW<TM`=`@;`$4VA/JTQFYX5"C:^`
M6&4S8-XDI[J`(+T"/3,@+M=Z$'<HX,J?.P72Y,:_CD'<ML=,WU*_.YZ[9*\M
MK$H;08I\"[+H<SU*]$B7ZMF:KT#W77])]DB7[K7)J>Q=X:-AN]LPBS]*^X@K
M?AVT1Q!68-;+^LC2NV%S+U?9K+<W&@HT@/71*.&3:-.YRWH%NK*^1VXB2_5N
MDUZB3<>NVBN0JGL\74Q[1CT:)742;?NV6:]``WP+01JM=1'*V&VU5R"]ZY2T
MRF#07MQ6Z&'<*;^K=B[MI<GK!6_:O]V)++D;R/L.V2-.%Q"D5Z"/`J.$+W*%
MKX/W"$+>1Q.X`]<?K4:9?;!4\$X?NM2O[3"J7X0@I")L]N'17!1-WZ.D+^J2
M/J<!NO3=<"WVMSK]AG%`KK(GL2TLIJ]`.@<H:4%&!>)1ZB?1MGM[SZ-`5.[Z
M>PH?6]HW,'NQRG)/VGL9E3V"].Q[)B`>)8(2;3IW)T"!F@DP1Z"O!Q"K3H7;
M$Q`+M!F'>R%0()R`*9G#7R#=$Q"/4D&)MGW;$Z!``WQ_20;C#AD,V\HJ$K@R
M2$E+5',$1@EA[`JA>R%0H-LC8.G>P!'HT#_2\EMECZ`A(S!*`&-7`#M&`$$X
M`O&D'4^CZ-22O]N<EVB;=ZVT8-8*I#8@)`I[*$]'29Y$VZYMRBO0?==?DCW:
M(7L.XQ5([SDE/3M/.DKX)-JN0#M+JOAX-WR3\=32N6&,EZLL]Z1MK7*/HJAG
MWPZ%2;Q1@D?=;9_+>`6Z,G[>Y]F2NSN4[Y(YA_((4E+;O\^AHR1.HJV*.W_N
M*-!]UU^2.=HA<R[E79FCI.<F%XX^1EQC)=JN@$-Y%#K\=[/M#+(-STGP&"%G
MY8']PDZGRDOYFS@#(;`W:KYMSF<>(GG"TOP`QR/GY,#^2,I#5E3>B>UA:3B9
M`R=+/&#!#S4_RT.*%U[#P8A\>X2#,`9_]8<3`.\YKZ\?Q!%.<[2V_1\``/__
M`P!02P,$%``&``@````A`.:)?)`0!0``U!<``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S`N>&ULE)A;;Z,X&(;O5]K_@+@?SN2D)*,2CM*LM%KMX9H0)T$%
M'`%MVG^_GS&DV&1LIA=MXSQ^,8^-C;W]_E$6RCNJFQQ7.]74#%5!589/>779
MJ?_\'7Y;J4K3IM4I+7"%=NHG:M3O^]]_V]YQ_=I<$6H52*B:G7IMV]M&UYOL
MBLJTT?`-5?#-&==EVL+'^J(WMQJEIZY26>B682ST,LTKE29LZCD9^'S.,^3C
M[*U$54M#:E2D+;2_N>:W9D@KLSEQ95J_OMV^9;B\0<0Q+_+VLPM5E3+;))<*
MU^FQ@/O^,)TT&[*[#Y/X,L]JW.!SJT&<3ALZO>>UOM8A:;\]Y7`'1+M2H_-.
M?3$WB>FH^G[;"?HW1_=F]+_27/$]JO/3C[Q"8!OZB?3`$>-7@B8G4@25]4GM
ML.N!/VOEA,[I6]'^A>\QRB_7%KK;A3LB-[8Y??JHR<`HQ&B62Y(R7$`#X+=2
MYF1H@)'TH_M[ST_M=:?:"\U=&K8)N')$31OF)%)5LK>FQ>5_%#+[*!IB]2'P
MMP\Q7<VQW.7J5U+L/@6N.Z2L--,Q%K_0DD6?L7YDS+\=G:KI3/MIF^ZW-;XK
M,'SAYIM;2AX&<P/!@V(JY"']9\Y!-@EY(2D[=:DJH+.!@?*^=\SU5G^'SLUZ
MQJ,,_'XP)DL<GJ18!LOX`T-ZFUPZX`O"H>#K.NZ*#8D&9`B)AX*O.ES;DH$@
MXQ74/?S!L!C[>SXT!TT$)IJ&ZWI#P==U+;:I!TK`U1_6'(MKF_^,L=F<X!GC
ML$PX9;C61%/"Y;HYGB)<2#(E1B&,7'AJYLLE,".7+SC0`M8EUSA_!A/,8,(9
M3#2#B6<PB9AAC#JL4?*X.S^=48=A2RHQ9OF"`RV@$R=Y*GV^(.`+PJ'@:V#;
M2VXL13.8>`:3B!E&$,@8#SDBR(:%2_Q<DTH[%<;UZ"%UV8?+HPRTY,%PQ($2
M;C=]+FQWY7*`+XT(I$0H)2(I$4N)1$0PNF%-&^L6:R8PKWG!:::,2#,EUIUF
M4^/J^]+Z@90(I40D)6(ID8@(QC$LRV/'9$@OH8/$KDDEWO62<TV9L6O'X-:=
MPY2Q'=[YE.%&?B`E0BD128E82B0B@G%.MB"CURJQ:P+SKKE7%H\R8]><HP,E
M%O3MRS9LKB=\:4(@)4(I$4F)6$HD(H*Q#"^L8\OS5C-2B;?-+3P>942VI81/
M"3J=6ZX!/^SC$XP!DWS/`:'T&I&4B*5$(B(8VR:L@[SNA71M[&IQOFWN3KT>
M$@F7(WZ/4.7/C,LS0CD2R9%8CB1"A/5.]AZS)Q.3[E28EQ&;VS%X/23T37,$
MB-^GK+HI9[F8#.!`?IE0CD1R))8CB1!A?9,-RLCWO&G%I-L:UCNWN_!Z2"#U
M($?\)XC#3_?!$VBR\H9/(&Y9B>1(+$<2(<+:)[N9D7WQTFG2O0]KG=O7>CTD
MM$YS!(C?I]`71TN#L\#Q#]?3`4.;FFFOF1]V*0CE+8SD2"Q'$B'"]@.X&/?#
MO)T0'`?RJZN]GLSV%!+(/O0Y`L27(X$<"7N$SF%<0R/F2[)$L]T6,]];9$2P
M`#D=)3IHNK5D(JAM>OA)C^1*5%_0`15%HV3XC1QLDJ7L4?HX='WISERY\H.Y
M@;,P.%GBRD-S`^==T_*8'-X^*?>LC=?EZX\@.%.]I1?T1UI?\JI1"G2&IAD:
MV434]%26?FCQK3M0/.(63E.[?Z]P>H[@0,#0`#YCW`X?R#G:XSQ^_S\```#_
M_P,`4$L#!!0`!@`(````(0`LBFGVD`(``"<&```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;)2476^;,!2&[R?M/UB^+^8S2:.0JDW4K=(J3=,^KAUC
MP`K&R'::]M_O&`>:CW;J;B#`ZR?O><^Q%S?/LD%/7!NAVAQ'08@1;YDJ1%OE
M^-?/^ZL91L;2MJ"-:GF.7[C!-\O/GQ9[I;>FYMPB(+0FQ[6UW9P0PVHNJ0E4
MQUOX4BHMJ85'71'3:4Z+?I%L2!R&$R*I:+$GS/5'&*HL!>-KQ7:2M]9#-&^H
M!?^F%IT9:))]!">IWNZZ*Z9D!XB-:(1]Z:$8239_J%JEZ::!NI^CE+*!W3]<
MX*5@6AE5V@!PQ!N]K/F:7!,@+1>%@`I<[$CS,L>WT7R58K)<]/G\%GQOCGXC
M4ZO]%RV*;Z+E$#:TR35@H]3621\*]PH6DXO5]WT#OFM4\)+N&OM#[;]R4=46
MNIU!0:ZN>?&RYH9!H(`)XLR1F&K``%R1%&XR(!#ZW-_WHK!UCI-)D$W#)`(Y
MVG!C[X5#8L1VQBKYQXNB`\I#X@,$[@=(E`5IG$UG_T-)#A2X#Y3)ARG$U]7'
MM*:6+A=:[1&,'C@W'76#',V!/.3CJQD3>R\P2,I!;ATEQU.,(`L#37Y:IDFV
M($_0&7;0W'D-7$=-=*I872J2[%5#P/%H&Z(\MOUV.P=W3NS<N?8ZNW?^Q;&5
M^,S*&XK9*#EQ`J$=.W$!IN\.V.#(+<HQ_,F819I,1KXWZ359GV9\'4TF9X+5
ML2"9IK/WLDI/'?X[*R<^=S8]<^8U,^\LB<(P/!7`AG80N([EO0Z##\]O6#^)
MDNN*KWC3&,34SFW&"-#CV_&<N(W[K3Y^@'W:T8H_4EV)UJ"&E[`T#*:0OO8[
MW3]8U?5SOE$6=FC_LX8#F<,DA`&(2Z7L\.#.DO&(7_X%``#__P,`4$L#!!0`
M!@`(````(0"4(WZ1100``&(/```8````>&PO=V]R:W-H965T<R]S:&5E=#(N
M>&ULE%==CYLX%'VOM/\!\3X!\Y40A50-H]FMU$I5M=L^$^(D:`!'F$QF_OU>
M^WH`.QE*7F8"]_AP[KWVL;WZ_%J5U@MM>,'JQ"8SU[9HG;-=41\2^[]_GQX6
MML7;K-YE):MI8K]1;G]>__5I=6'-,S]2VEK`4//$/K;M:>DX/#_2*N,S=J(U
M1/:LJ;(6'IN#PT\-S79R4%4ZGNM&3I45M8T,RV8*!]OOBYP^LOQ<T;I%DH:6
M60OZ^;$X\7>V*I]"5V7-\_GTD+/J!!3;HBS:-TEJ6U6^_'JH69-M2\C[E019
M_LXM'Z[HJR)O&&?[=@9T#@J]SCEV8@>8UJM=`1F(LEL-W2?V%[),/==VUBM9
MH%\%O?#!;XL?V>7OIMA]*VH*U88^B0YL&7L6T*\[\0H&.U>CGV0'?C36CNZS
M<]G^9)=_:'$XMM#N$#(2B2UW;X^4YU!1H)EYH6#*60D"X*]5%6)J0$6R5_G_
M4NS:8V+[T2R<NSX!N+6EO'TJ!*5MY6?>LNHW@HBB0A)/D?B@7L6]F;<(21C]
MF<5!13+!QZS-UJN&72R8-?!-?LK$'"1+8+Z=$:0BL%\$6`X!L1S:\++VHI7S
M`I7+%62#D+EM]1`=D=Y`+#J(`[(Z;9#Q4)NHN@^]&]<H!AD:YQV]3&.#D+FL
MKL@K';S0!$!!A@+&/RS`('"8>6Q\&"'!`!+JB'0,H4D#DNG2!#BQ(<NN*;ZK
M?WB#D(5L:D@"4]<P',=AT(W61,%D'HJ:UC`QR!!'.GIL&$)"*8Y$@='/=!CV
M0K>ONB8NTL6--U.`#5&>(0HA*"J:QT8X'8:)%T1^-UQ3!2ME6+)Q50)LJ.II
ML50(";!4H5FI8=3S^K&:)+%K3;8$`38D]9,#)2$$)1G3+AW&YFX?U03%]P@2
M8$.0,9DW"$%!AMAT&//[\FEZ")C0]`I)M*'HRC4%8V*KR12'?6=D"5/%H5:`
M'WS4.G*?G:,5#RUKD#(V3S(F-JS_SCN,<J:C$+UPPF@G3RV"MJS95K]3*'F(
MP5Z&"[.;B@+#?MPKUV4)UYTN"SU:D]5;CI+U[N-BC[PA:QC^6)8PW>FRT**!
MN6M4T*\G)0LQH\T<@^A5N^'V`;P;MS!Q;#+69V#:O<+<=HP/@KHTP^O%1A3_
M\>1`KDT_,%Q]HS#*._KY).N;ZM%^,NKB[K)\<NWY@>$.&X5!=UCX?FBLDE0'
MD-CKA>O2[K)^<NW]09^SFG&(06D/<SCR&HA4L2A$M(@'TT$7=]<V0*[W`?-0
MLU$8_'3D1\8J3K4X\5VOKZNF#*X>VD*==NZ1H_1](3#W!87!8UETO2]H<7)C
M7\`K#9[X*]H<:$K+DELY.XOKB@?'A.XM7J4V9`GG8[C"&.]3<<42[YTN`#><
M4W:@W[/F4-3<*ND>*-W9'%9X@W<D?&C921[(MZR%NXW\>82[+(63MSL#\)ZQ
M]OU!?*"[':__!P``__\#`%!+`P04``8`"````"$`?W<OG]8"``":"```&```
M`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)2676_:,!2&[R?M/T2^;[X3"")4
M#5VW29LT3?NX-HE#K"9Q9)O2_OL=VWS4@3+*!<3X/:^?<WQD9W[[W+7.$^&"
MLCY'@>LCA_0EJVB_SM'O7P\W4^0(B?L*MZPG.7HA`MTN/GZ8;QE_%`TAT@&'
M7N2HD7*8>9XH&])AX;*!]#!3,]YA"4.^]L3`":YT4-=ZH>^G7H=ICXS#C%_C
MP>J:EN2>E9N.]-*8<-)B"?RBH8/8NW7E-78=YH^;X:9DW0`6*]I2^:)-D=.5
MLZ_KGG&\:B'OYR#&Y=Y;#T[L.UIR)E@M7;#S#.AISIF7>>"TF%<4,E!E=SBI
M<W07S)89\A9S79\_E&S%JV='-&S[F=/J&^T)%!NV26W`BK%')?U:J;\@V#N)
M?M`;\(,[%:GQII4_V?8+H>M&PFXGD)#*:U:]W!-10D'!Q@T3Y52R%@#@V^FH
MZ@PH"'[6OUM:R29'4>HF$S\*0.ZLB)`/5%DBI]P(R;J_1A3LK(Q)N#.)@'XW
M'[KA-`F2]/\NGB'2"=YCB1=SSK8.-`VL*0:L6C"8@;/*+(+ZG,\,4E(Q=RI(
MAX):P&X\+>+)W'N""I8[27$J"6W%\HQB>I!X@'=@A,S?SZB"<@3?1\:CO4ZC
M,)),)Q!\NHD.J^OIY9O3%AP4[37<Y<(I\0@JLU<MC"0Q4+[YV)+E18D%%[\'
M3HEMN,2W5RZ,)-9PH[GE^3D+!YK]^EHI\0@G&.$8R7F<\W,63FKC7-?[*FB$
M->KLPDC>[*LWIRVXB0UWN:^4>`0UZN;"2.R^&F_A98V%IVZV5^?&93PE'N'%
MHZTT$H,7QY,HF6:I+5G:DCB.P^B8@`67O0=.B4=PB;UR821[N#2)XV#$#[>/
M<ME+HC2<Q,?CQL"9Z\6<O@->D^^8KVDOG);4<$;Y[@1:EIO+Q0PD&_0INV(2
M+@7]V,`[`($CV'=!7#,F]P-U?1W>*A;_````__\#`%!+`P04``8`"````"$`
M$F'.SPTL``!\G```%````'AL+W-H87)E9%-T<FEN9W,N>&UL['W+;AQ)EN5^
M@/D'AZ`:24`P%,&G5)G)!D61V9S6JT1F%AJ%63@CG*171KA'N7N(8F(6M9G5
M+'O50`_`OY@]/R6_9,ZYU\S<W-P]@E0J<P:%Z:JL3D;8\]I]GGO-XMM_^CR?
M19^2HDSS[+M'X^'H491DDWR:9I??/?KA['CCQ:.HK.)L&L_R+/GNT4U2/OJG
M_?_\G[XMRRI"WZS\[M%552W^^/QY.;E*YG$YS!=)AF\N\F(>5_BSN'Q>+HHD
MGI9725+-9\\W1Z/=Y_,XS1Y%DWR959AW:[S[*%IFZ=^6R:%^M+T]?K3_;9GN
M?UOMO\XGRWF25=%!-HV.LBJM;J*33"?`NK]]7NU_^YQ-M?G+Z&V>55<EFDZ3
M:?CM:;(81ENC0;0Y&F^%7[[+/PVC\6;WEVX9WMS17]ZD61*=5,F\_&_A:$_"
M#\S:/R:7:5D5,7;T+IXG8:LGIS=8?E*ED^A5FL_RRW12#K#AR3!L:<8[!&V*
M>(8FT^1S]"_)3=CNR0C_]^+E]GCG1?C5X;(HT#TZ3LL)AOC7)"Y(M^AU7+47
MMK$QWMS8&H=CF&4<I[.DB`[1\3(OVFLXG<<S-OB8+/*B`H-%A_E\$6>MEF=%
M3/Z+3F_FY_DLG.S)Z;^^"S^S=,CG\SR+3JM\\M,@.KV*BZ2,WB\K86",&'9S
M!WIVLVAO=CS:^%/8XP!L.!56/)[%K?&>7,2SLC60F^5#4J0Y&;B;NJZ=.0K3
M_!C,7X;K>/*G%NN&W>4DNSMW<?YAGI7Y+)WB]*;1JW@69Y,$)(3$EM'3'TY?
M1X^?A8LXR:*SJWQ90CN`/Y?9+"G+*`?G%M=IF43E(IFD%VE;`E\G$TC@6(1L
M,QSTH"PQ9?CI85Q>A9]]*))%G$ZCY#,43HF3QCIT^FABF#KN'.PLK\#IEO&[
M)_Q00(T5T#,<-/G;,EWPU`=1EE3A.M[DV>5&E13S*,NK)"J229)^BL]G;48`
MXY<IZ%DO=-4"NQ?V)HW/TUE:I6;#PNQ7^6P*'?XD.L)*JY9`'4Q$SY;1(K[I
M6I@2Q!LYW&+7)'\,&^$\+A(HDRD,A@C@X]%P-!ICTB+Z%,^6R3?1>#2`(N(_
M4:G2&2^KJ[Q(?TZFH"TL3)26Y1)#"(GZ)1>:@Y*^8J*5,VUO#_:V=@8O7N[Z
M\^'3W9WMP?9X.\KKJ0<X4;)RE7Y*9C<#61E:;N.?S:U1T']K=W.PM_VBOW](
MM(/I%&>99V!(,O-&FD63>)&"05LM)S""RYG(YS2Y2"=IBQ/U'+L.*QRL=>*R
MK?OT7*DG/D#C&M,5SY[UZ8T6HS@.B9YB_]-\-HL+,"MLA7!)2_&T!F@Q4[C?
MOA[*;?=M[7%%V*7)D`_=4+/WVMUT-1\83ER],#/TRHUX=N"T`KM1\4&O7T3O
M<2(QF?6>%B'Y/$D6E=KA"(8E?HB1V+JW$]<R(6:=XF"41MT>&2/1TEK?)QEV
M-1/^CZ?S-!//C,(>4O)C4L(YFEQ)TVD";9"+40C;J6RM6D38XTT.PWE1Y'./
MQ&&;][2K=`+S>1(]-=MYUMK.209+E,`W3Z5E]RCZ7?346,Z6?)D==,[88P+M
M!J`>X-HMZ;[5[!*NPNZ"^WZF&W\-]U.[0OGW]WR75!%[A2/R\^:H\)X,YVW`
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ML!-@(M)QT1E)A-.TUM8U3]@I7-MQFB%L6[>V(I\DR=08'#I`$NIAI6!XYU0+
M[XI[#;FAS4>8E103Q'4M/@/#WG?`Z[@0U*-W+$<&D0*@-]&K&T`3[6V%I&#'
M:3(!S`2J@\4H^6$;(5=<1>>`7[*,9.+QB#+L:XIHO[_1Z7*QF(E[!/^!4@#1
M61)R("VI>2Z@$;$8!U2U^%I6)$$L5845ZL[%N%95_+E]!N^+RSA+?Q9])-+T
M+JZP%*[D?6W.J#EH"V6%<(E+>':=*LP?;@"8QKJ$Y`,.XO?E'.:$0`;/+OSE
MX)P@UZ1JX6)?97A:725X])>SY',5O9HAZFS-]3HI)T6J+(R5OEJ6P.M"!Z(`
MRD@T\X_E(IX`Y81R+Y/B4_)HOQ>*BY[2E/[R]_^`,[X`B/7+W_]7A#/$!QU=
M\.4S^.=1')VG4.&3JXRPWHV8&/2%L`'C`;.#O!S5<RY)7?11$%"$4BQX`?<3
MCI8YC@IL+^:0K;'P%*`,^8Y6A_\*WJ1<E$/@-8E%W;@>,Q%%(89.IQ^<9#_?
MP,,D/P8S86SE3%"+__V`_TF?`W3]F>$]0-S1(_P%:X>NQ>7Y=X^.CPD[CN3C
MXAC>G;8[2^>0D7?)=?0QG\<9.UW$\W1V8X;A!\]E]&K_<(C%7S#8M7"*-_EO
M.'$W,SB:9J7B`+%06R4>JC,'0S*2![";GN?3&U*P0#2/!I:>C:."QU<M2\HC
MA>IW)^X!3$52Y><0T:1HS?Y_D[I#6N?80",#840C9B'71M-B>0EMFTT%NNRF
M<Y',X@7D_G*C2.9I)=8;4$J50GU'T"))`5Q.#V&27V9P1C]!"&_*"SAO(F0P
M*.WVR@(P\T2X*D21$&"*3""]<52?.;G@(CV'`WP3SR[3V`#ZX&DO?0$9!=,D
MB%,F=[<'$.W0'L`V3I>3ZN[VT&X[;$$MW`:-/W:0X>UIV/>LH'Q6K5GO;J.G
MJB&@U:&1.N*#.>C)@"3)"OB\="CO;D&Z#^(*G9Q$DQG":V89,$`\^P9(#P]%
MF!_2DU8``O'G$EF,XCJ^"1=VV'<T[3U\@%7#[-Y"W*B0X;X%-2?$H7R!_@$#
MS&%`QE1B7Z;S>E2/+N[WT7[[UG9D\%ZMI7$+\%@5J9B-T6B[2;AJ'ZQR=VN8
M1<Q)BU=,QP'T)V*W:70I*(S(6BW+."E,;YGFFW"6B[0`SN'U1&.X@##ND#(W
M2MCK*61PGA2P-C]E^36T3!E]&!^(=?8X(^SE-'7XA6YD)_Q8*=!A$EJ4^.#M
M$*89T.<YI(R4**/KM+J")H3^^&PL/71#]$,&]82$+9(3,,EP?;`%>+4'"(G3
MK+D0X>&'J_E_,"96FC25K)Y;*Y-)IS('=6^^:9Y%\RB:1*[VCSV5'GYW!.\%
MB?#P8T]$+F;+1<J$:-)F#F=8A!7>)M,X.G@5CG5"UPTZDZC'Q;+`Z140G!3:
MM$)BQ;>>O_S]W^F*P-D$7%R)<--!A#`DA"AHP'*)9`P4YX8+;-K!T;N-,9(X
MG5Y-/+_)*P2]5\#<F*Z@5^F,[##ZY_P:*J5H6?4R27ZB^O>G,H95W2=FSGX&
M=&G@&49+`JPL,7XCR-:D&A3]9+:<8LA!9-9KS&U=*7"O8(@R1]Q&W'RN$!JK
M3I5>:'#*/<+H&K#\"I`<PLQ$%!@V`<(NE@4C[8H4Q@E%Q1+I4C%]17+)M(Y(
M/`3Z-$'V4O`P^?;H,Y`$`"=TV^>(UNGS/V64<70H406/0`+'=`[70@)EK,4+
M.H<`*B;@#ZR<Z2O,?0/#RUREH1!V-YM1E7!97D>9'LVPS(+8$7=Q?A/],#P=
M1M\?''R0TR=9:/2]N6LZ:+SQ0-KIL>FBXAKH&TBPE$N4=('50Z9F6!<SO3R3
MH&56IA`(+#@3@Q`7-UPZH@W@I`)T450`>H'S9;E(V"%H24HXA1(<US#6P-N9
MI&]MT.4B?!-6U?"B'<=*AST>A1IPZ`C,27Z[-H8^*1S8"9@`?(.3L"-45U#L
M\QB+3R3-+2+*81DT2J8='2%A.'L=G"&HG?9BB6.]0<I"C@&PR'J^+9'.G^&4
MF<6.!31%G[]:+UAT$)ED_4",9Y1UT+Y`D&%Y39%8$/L@RRBX6@S"P/<81XH$
M\<:_N`UP[7#AB`*A9"`AN'UW:^L&1`A0R+!9=Q1Y@#&\0+`X58W-U4)2E!$M
MJ2QU+:&JJR)16!6@4!+!:K-X2"=&M1"$FK"Z+1F"VW_O\[,SU$?Q;5"K='8_
M<F+&!<L=R-)P4W``&!JAS(UNT\GD(+J&VKW"\8G`EB+3@!;(5(0M49&5E(/H
MK\OII<+G/"CHR^5<$!*V!\?%%X0.I&\\9SF6R(11J^SA@:QT/4AEK,Y4]4PQ
MA^@.?NSU%T]RJ5^YF@ULALVL:&"3!*62Z3#Z,S7H+(6MT$7):`J?4^#=;J($
M&BB_`6%X+O&"I@#AA;<&/6]V.M>Z%A5!8H4(UP'+?Q-=6:,TQ0*-ADXSLBXT
M-O@?@3I0;RFZP(KGL5BJ>@F(H,G,EK&`\4.*"%R`;R2OQ\7#'@-W1#/7CZ4%
M/*=`@9D%X-3<>C'IQ5(0/4.IEBE[ZW3;$WBT*-\).<W#R^JVTC+J1^K"EMX@
M*T"W[A`&+D^XIGIX\4RZEGT&RMG8G[$VS`.+>W#:\-W;)1%D],=[>Q'PI!DU
M-60[7UY>P:J&<@P.HWO-D]%$-9L;*_BW)1POG)WJ@/^ZA%8PXH^Z0?;H7%&6
M7*H&=Z9!#[\V)A'BW0F,;$6K@QG@;V&P<X-)JI;RAT;="8N.*'*4F`D$$<P)
MZ8>WJ(S*%BB=*9?`6@D[@;VLR*F>@)&1L$J4=TIC3<$GQ]&?LE-C/0@ZDDLX
M",YMDK4MP$D9U@FI(N;0\,Z2"RBA"NK$AF@:U^,#+IB27*?+K5\=F4XM_N4Y
M&S'2#?`L`,!,58=9JESC7&$X2;G<9/18,T0"_%5T5DXK#T058^4%EE(R7XZA
M5"]219PG-PPY:?%)24`5UD":3M96"0$N$)+EUZ!7"[S_Y7_^CY"?>9J@U"7V
M+BJSI@$.09.<K3"6?4SFEF1#_+&P/H#23P:,YV5G3W\V*$]W$AS*_>&[U*#+
MJI7XXW%E?E=S=*0F+)$H0^&JZRM4+K"Q/23**;6X6BL<5$T'+,L?,@:IU&=N
M[6Z22^T&HGGF67'@,I<%!<'G;GN")@F]L7KA4A?]=Q--*^@`SY)9H-;QCRL9
M[%WJ+)T@&RRJFDDL]2/5@\<XT.FP)"F2/AF`[=Y!>"S=`[7V3X)Z"XTG5V(+
MH=@P%RKE2H6T'C*<DC3-/N6S3R`H=@V"`8$!U$@7&FM+Z%=,^-<"-(?MF\SB
M=*Z[K/W-=M@%TW95E=]PC"Z9,&>)">""<'2PD`E[4"FL1ALYA#+0"@)?G`6,
MI<EY*B]K1^D]MGP8>LW8';V'G`[M=8$RS::&91.G2LZ%"SSV4MU3YB`U:BH8
M9$5@5E`%WK=QBN`L953F8I&R"FX\5?`D)>T0%7Q`[*0JN82R`3`E*LTE,VV@
M8U0OHF7BU!('7J4+J*[%$APUX=QP:#YA3$GERRB>M(GEU)(--ITFYW#@0&D]
M+C.SK]99#R"#\.1-I!E&I]@E3AVGI!.)EJ13?23UI=%[>C8X1SUK#Y1$8%\=
MS-++3',YY1+NBN;?"(C:E,)+_O%U$T6G;UMKL;/Y>2ELYQ\`GCVP6A/'`_<;
M'-C0MJ(HD1N``41FMOKYDA#,-/HO\7Q!6&L(^PR#*5R`<)@.A@Q#:4'4K/;6
MTSPPDJ)4Z7!5&Z#@QCPN?D*^_>G!V=MGCDL-2TCTMEQ0ZAZ/=YP?!E:R/!H4
M&F`#8&]*APKJ%&@"0ALZ'2:T@,X0B\@E`\UP?"F!AO`H'``$?6#(MG>6(=`&
M6D-_$;&^%AW#JX`4D[6Q`Z-SFO#@F:=TJ"8(3G%]\#AIVMFU+9WTY1&1*76`
MWEX!_R'Q`.80S:7O<1%_`KK+2B`3:"!A:(K'3=DOE("$;A*>-?75-`>1N!^!
ME[B?"3&ABL:Q4\,(_4`;$E"=,K`*_G8!#=>(O4"CU67(U'M4T>)I07'&G^(4
MH#26+!NBPL1\=*U%1PCKN+8@SX*&4+1N"LX""V(5`)B0TK/:1("TJ(A93&)<
M/(`S)=`\SNLMI8=C,*91;K4"`YVI>Z3("A:=3G)=S*)<`;0?R@BJ%:H<:X?U
ML`HN^8RB3\XM!2^FF-X18,J:04:DP09`2!Z&W6VN%L1@<"0@SU_))6BKP7&6
M$G*2F2:HA@&,L]0`VKGB=+F%S6/Z$4"DFDS-880!,$()38LK%G!W:'QFL*W4
M!A`0J%V#*-(4^)Z^CV<YYA2#H9.)='G]KRTB1.B`:3M,!"F:@R"J<6LT5<!S
MQA:LPWI?+P$B>C!-$&I'AS8!^$:S'&+\L<!WK&O[V']Q@M%#Q\#<&R8%+`=W
M\'L$>HMR12P;M)0;50H0<Y"N"0;RQ3V*3.YN>T8@A_VZO;_/HK<21KW0^S)-
M9E#-IO`M3]EQ-KR5_GD'T9LWAZZ`!6<AR!GXZ9_AUD/6Y7LJ#-H5JC02ARE=
MG"LDE=I/.OV[`//(ID4B6Y*U1]-&R,G&5-Q6UM!1MX"&`M(*GX+3>6L&XU_#
M-CU-G\DDZ1QLIE`.@._+3)!;4?CU`KQ2=D'IET2K=#213)HB@P%P*=9FL'1(
M[,5BMN2$F/'QGKF:8F[)M"![57B8'RG]ZWQ#X$D83:+R9&0H`P:7L<`Y[B"@
M_7:&>W\@P@6"(M!CRG/)R`B4](!W@Z[5NU/=+X.2S]ETF4D5F!O[&EI,#`FT
ML3*)7JK:'D:OX=E!!W'+"F^N13795&;SB"<3UQ&8F]AKHFM@$#>E72&3(,*$
M!6CG'5Q\B.Y,6($$`)G%835X()GD\=[N%F\(!>I%8H$3P7S05TH6Q<]A<@-G
MSLV>RCW58EIB(H!O@J>#,LR6')QJMN0L7\"CWASM;&R.6*OUK<"QG@/[6Q<T
M?6!H:*KNN-NNRKF-'F726FR7A_NU*J^@$N#@G1X:8CUKZAW/21,'@-Q)!D*I
MG5@)\0)K2#CVDXIP'JQM@"5AM@%V<IY4'0P#98$F@*G8!*$HM``O%-)_[1W2
M&KQ.<^9;OYYLCOAI);%V&#P8.]T%)D5D+%*(Q:-\'E4_>I3.$/H>)+FU&P4]
M`Y4`M\-)Y*4WS3Y9O>;H@LH\7)>1&?NUN'Q="SCW?9_\A=AZ29P(7DX53H2K
M_/WKSWC-`;?_]`*IO<KB4[':/V-JYN[V+>S/57EW"ZPSF=[=.C`7Z:#10,6B
M=D/>(79X8!?P&8LNJ,4O$B9(4!<7#OLX_&`C_.`0B!5E>E:/QBI2QC9A4[UA
M8\X;JJL&2&QF).SQAF7YDDN8^LY*S3)AA_=@C0+5(W"$V]==PAK^?BX+A]4!
MHZ>PG_;NSCT7=(Q\:_0C+X(V%=])!@1D*?%..)G7A3I1/;%5/EY?AQ4%PG>W
M7J>&1EZQ,$KQ!?<#U`K[88K;&"'"\-.81HB7-)$X\)MIY&CP;8V<K'NM)A4:
M@6X]0B%Z7^(3"/[#>\[X`B!]5C*I%+L4'%/';"L5(%!7TH0@+RS?>5)=BW+5
M>%U`6Z)3<)$DP"B7DRMHQ'H?"&D\S:Y(VW*!D3K@-8$`_"$C#168;<22&-/3
M*/O;L&G#FV$D-%?BS9&'@T,D#"#*EXI7(DSX693_#4#-103XLZ`C#*_)Z:P6
M)G_WOT,6>H,$XBP:8TD+W.G]8_2G)=PTYC,$<GB*:$QJ#)+IL[M;:G@@(/`F
M)@@HK$=6.%JSD)?4)H2./+%0M8TPZXR;;L83F1FAL`@D3CV+_M98A`$"$:=E
MD5VN6E6X=_DY=8BXL@GR52#$%)48$\9[7"UB=?VK$WO5T;;<4G[(O.&4(F)%
M-#G"T269@NOE%3WV`@ZAV::YO]G(+HO%KXT\Z898`6QJ$'X-1:7&SB68`Z^N
MVC=!M5D,F$<8W?"$SYL7]#%`(4VK8K)HQJ-U:)#'QHY5U&EQ?VH/(B`>:V/7
MN/-T33A`!J1RDM5@>W#>T=B+LD4(F[+OL6]K<W*_@X99,H($=L#R6+JD,1%[
M2K$!ZG&4E:P:@:'#&A[O#,<./N,8C\>X3U]_(AMWEM#F)[<@<'6YA'ME(;S$
M[MC+K!Z^NZ0V+/OI<;3V<VK+Q%[Y#T3`R$!R@`]`YX3BU[@CT^S5T.@K%?3#
MIX6;+:&2M:9"%15``]9;\6XZ(:WEV[2Q>!IWMUTO9S1J4Z1)ZT;RB:WAA,\H
MZZ+K6"='R<=ZEUC2O'S,(ER(6G,U$E0&K0;ACL,!Q.-H?0A6KE,64QRDJ35=
MNS[G?&:\>@,S@XR2K9RA7QDZZPVJ-V%-`EH,K9$800!-<91;8J90B^@AD$[!
M@,G:QD["`HI,X<T)X)6467:$%4$NCV;'5$Y`7#+$]QS!)FT@ZJ)B[%X#)J?G
MOO^A\\Z>7(ZM'58E)MKSO[P,\UN&8W>W]YH.1/AM\AO>_%[]-^HWEDR:*]A`
M_=9Y(YYY84"H!$!X5(C,47/1U]CSQ?O;$(1O5G]`LGKNXY[R-9(-E'KBW+F2
MWCN]SL,D._DM`4TB,2?=D9,V+PN9,M0/\8UZ+OU%-+6B^[*!5^O&>^Y.J,!P
M@&8:LMI5:V-`([S/!1R)\D0B0'8DQ?@JAU?+#;P6CP/%%7*<#<@\GN*R*,4+
M?3F*/L44S.J`1Z\%5T,04C5#)0_TM*^S(X?$W6HE`%04*V)HD=4KT>_TMJJW
M-LDN6]Z(-%$-@RLUE9>\C:KJ@"J"[\^8:C*'5QH2T!G";2^4V:1`)!$G3I7G
M33<#!@HR8/+R`0VX0^:?X,1DR!JPY`@3;^[(.S7PQNGQXWHL<86@4C@@DQFD
MUICBH',V^Q%=?Z,0=8.)'*#N3+`&@3*P82V!P^PZLW%$S8U?,#IHC.(*J3K5
M7`SJ:>0$6&87T!3YZJ00/X`E3B9U0X&GGC;"8G9HKT[JM/6YASLE[`Q]7D:F
M_@X,5Z4;DH_A'B5AR8)H\<I)`1A2^(78.XY*UEDNX,O:14]1^`+O'DQL$T@V
MYU97#P/UMI&;^.,<=2$)F;,F3\MYNI2I$)3B(NDXQSPJ,^!0.0=+9A)%O&0]
M,+5Y]DJT1B8#O,FG*2FV&=`M2#6CHP@VAR`KF9A",G%"ZSK=:#A`:>SG_YG#
MQ)4WQ=U-*SL;29?I.B5O9RRO1(OXKNUNBIZ`O1<8^.7.UF!GM&?Y![YSUUM.
M_?(1F.)J_[W%M3?EO;[1WOW4$I@3A1].#>VM54.VA55#SKOQK\=K4GL3.VR\
M8`6R3+Q<(T_V/-$#ER5H_2%$RRC>AIH"TI1GJ#:<*:X9?+="UAPOUT&%T6U-
MJ:44M#_!$3!;1(Y1#I*9FD**?:BI9A6=MK*Z$1]HV&F-`',Y2%026+":Q^I-
MSL&YG.I$$$TMC[B*<B7Y'BG:Y8$A)2(KL2E8"#E>9-3Z:WF4<;2G%J(I+9RS
M0;HFB_FGRWC.ASC@64*N<8#.+9#39%(]D&+,X2P?M`2V98P(3B">\=BA5FR%
MD$3Y'%FB4A/>*=R!<?B%H8]HY@;_8,_\7A)5_!?S_`+6;:S5/YZ-W%-6Z+>.
M[TUU^CD21Z@%,:<OH`AO:P&%TSOO%IIW-=<VW2>DTU/3"X-,8XM2I=G,Y)H$
MY.$"VE:HK_J:O=>K/H8[V]O0?'M;#])\/EMV:;XFY^/I/%G9P]VP\:A'_R'_
MA7C6?GL/W2=Y.?_UOO^O^^#>/%SW.0YFM3"#H97ZJW%"_Q#ZZ_]Y<=X<;,/7
M@*%_B$`WSJDET">JUFL/%<45>G%%O7//>6\X.5J&-$D0OM+&P.OF-7A<ZVS8
M+(-S&;\%F(D=6XP%%!3,![!<I"3TA<Y&9XXIZ7B))("?R#6"6@72>2PK7`C3
MA7E`J[%EOO>`X@D),3"A6RM0&Z0SSPE94UO3JB%-PL#+^IVJN%M$.ZL-I>2!
MX2C@1A!2L77*PDN]B!,.IUAB#P/QVN68R`,@)\2-_R,614VI-QHVE*#2VAI=
M6'3[9)$QOB0D/7-60\%Y\FPUNBK)%$GE)E_-8B`/IQ.X,\@<&$-.B2="-<^G
MB=X\"-KYN1;!PP%Z<S2MXZ#C\6O2O*V429!B/7IXBO5>78X^Z_-1JO%"(/+Q
M>/AR=^/N]O'F<'.OX\N]D7ZYW?KR2.[%X"RL1]Q"1O\0CN>ZH`X>41`BQ-9;
M$^/1BS_<W6+.\=YVJ__'M/P)J5@XB'5!#-@AG&8TW-W20?!O.ZU11L.M/3/'
M\.6+UM=ND0@-Q$`H^X23[-S=L@X)*8-?_OYO6.[(_-UJIRY.^+&;!;)S@?P2
M\G`M^OE"J*H"WCSC"A,O-'1)D%CQQ!Q'U`[8I>(=W]3W0%0DG5ZP;^E)I1G%
M`&JP;@RE`"C+>G]4H7#B^K.#=3V9&;]5.P!\YL(I)=<<BHMB1R%4A'D*+694
M&=E`3J`UEKE$5FN]_J8L#$,X[_1C?TM`5"C!3H'$N=6Y]7*--0(>C'F=]RR3
MH)=LNSV@%%C5(]I#D9U[.JBU<PYIK]#UC%K3DKIP+2V_;,2M+9.2Z$R.2D5<
M!\U;5LC`HERRMVO41D[!N3V0B(WO;-`6C<=-AP*VW-IH#<3KB!I,;3/G1#(^
MB['Q;1Y,S>/QBQWQQ`.!NX?)0;&J8I?<4(G?'[!WQV%G6!?4=#^LW1L/7FPK
M[J&*"*4,X0Y\3_A>>]CV\ID/WT>HRPY,716DJ`D':,+>/*G0DS;5V)`>!*G2
M<?/<2Z7"!5BA9.RSK*WEP?7!=8OPXX\V915^<7`),`$72EL]#G2@NUMK4L.>
MAZS695:F_8@XDUYPYM))V,>XY.'''QB>A!^^@44*/_N1=3#AAS;?NQ'9'*FE
M8NOAE=WA:-QCNKY7D#X<W.Z^=>'L6$U9^W<'^I?32MCN#K>W>I9C1X&][1!^
MO*KK522':T8E\.Z7#NN!'NUA-_=ZAA7B*9C4='.M%%OYWJ#L;X4C6V9V;PQ+
M\]9XW9T?-G?K#!XR=ZOS:9^#DNA#X(P!6(`A(+^!A,3(-]\`)T94_[C$^JRX
MWN"#18-R;"*2!@M?J32M^E%/?TW%MJR6^EJQ]\=;6R_$(-`+>+SU4JQ#6/8A
MWXV'FW45"1N/A["3YKZ\74)MZ-S;#'WVSBVD.5O+C.(QNU[EJQF_9>:%C+TN
MICU!ZSNV2,TK!`PH[*;LHQ@,W6RT@$Y`Z<U0=.T4IC].SHLETWL@[&YK!\)4
MD7O<]\_ZFFW+8>YIMN)J2F^/%:G?O>'=K?U/3_]0FI%.>3_!@X_P7C=WNJZ3
M($6!$C#*!.B#ZSJ:UPA&KV\?BG_H<G-X@!FW-1@6XX8Q8F0D!P0\98V@9@5H
M..W5Q::78:3#!-OB6R`-.D'M=Q+M\I<Z=G9L2A'&'1$'A,,(&%9*DXUD`IZ(
M8?K/W&F$*6?>`<B"N2*'N!IW2"3Y@'R5.3N-()"',.K50^3`0KLCU0FH`-0@
M[(*I<W'W-4YQPW##W+F]L0*_DL(&!D.V/*0ZDABG`D1@X=B@&T22:%8A@XDM
MY;@\E$N@N$XNS35)Q_IX>6$2TV.\.7T3%L=#E$AV`#YT)EE@K$N&$D.J1@\$
MH`(K2DVY*$<"2&1??X%[)Y.N0L"9@R3UFUOP+&!+AL"#;Z7R:7P?#C0NI;C#
MEG,$Y$)QO'OLBNR`A!:?3V(N&"XS:(BD*759;)U;L$VS2DE*X/`4-(@+7O($
M7P5#=MT(;3D<*V;K";CSVNDE-"3%7;%&'6`!%),+&]C[D38ARD5A.+Q4`33*
MT,YRH&0U.)>I#?#XGO-!)A>V)*,A!^I`8ROFI0"1!0J+OEUCI$7QYOH1@6'T
M`^M[%?23HF$2BO)DJ:@5"I9?.A9>2@#*"Y)G[->Q,U&\`O^XS37/Q<2F]5LY
M-F_C\J]REBTI=:DW73&A]*>$D$9<AA+NF5UY+^&P?7:W4T(1\$$$?/JTR:@H
M3@&(JY_15U(Q[-AOB:2>"\KQ/7]L@38)E7)J0Z&RS-#;PFRXK\7Z#TVR>B")
M/8HV20FNLM0-B4XH23Q&8:@/K8(OH`61D>RPD]PG<,?Z;I29P8DO_I9DK,:<
MX&#<QA*OPG*P9Z`=ELO@7",F;E!>J--==PF_BP0TI3]N5AHAJ&Y8H%[YKZ4_
MGN+7%GAS@W72X``DIX59^@1_A6#7(Y!0GF3S]'I$&WQ2ZPYK4]D^-&F>_RX+
MQ/N)02J-D_9Q:</<"`BM>*H(E.+V]B7_</>US>J6+Z@HUEA:_6,M8*=LC8?C
M[0=+E%#BZUJ11JQO%:C4Y=-*D@(>,=W?M5,+8>Q!;T1?VP%6X0`\!!RSN3W5
M@M5M]`*OMSOP?R>_UL)2[[O;/_=XDD<&-+^[[0S$;2B*\W-B9=[':P78*]JV
M@B>O;1O>"IU*\0Z[H&"K?QX::?DQE%-,1IJ@.6NQQ!,+.(#'ZJ,]'HLTV9-[
M6`C5C%P4"WJ\N5G'4YM[S>'OS4D,T)JCMY1B@Y>EJ*O^\3GA1E]S.()@YU#6
M[>-9PY:6H\)3[./`]_5:PBYF*&J@\*O#&H&ZN^V"BQP.=7?;B1QM#;>V>Q`-
MF'>;]`BG!9[XHJ?7:+C=UVMK..X#91`!]'VU.=SJFVMK..H#CT18UOQ:8U<;
M?2&AO\2XOX]7?-S_8I\4O;\PG+FFHAV*];<I,=?37#/[5[K>W'TWU[U0Z"WB
MW'NWR'])Z"LM9-\_.?J-1Q)S.5IXQ?8>:G\?]=.,$HW^W'PY'NSN[GHQA1]#
M,-%/_=IZP,%HH':ABOI:<%GU%X#:[N,F[%'[,G^US]_KD2NM=-1/^2Q/*,Q'
M<8%M7N(Q2]MB!8#2U7@%=O)RB-\?6;<`MN`MUSJ6H&X%O7B706H5)>7,V!37
MA;4I"ACI>%SW_S2;I;>^1.1'RB@OE(=F?L])<>#FD6Q9-U[X4]2`VQ2(A<L4
M'."37ES32,5\2WQ`/[<,)0B&5Z4-M`3.2<M*;8I=TR`*ADRB:M#-U:F4YOJ]
MH;:6*M.TF[=X`A*I<US?%[#8-A$89S"M9^!P)3"KW:56R0HB(#M`=;Z"PZZ0
M$"UQ[`9A0$]WXN1?.XP0R\YS'QE5Z'9K\&*T/=AYH8X,!'2+1<8(C`#5!#\\
M^X#!#2Z,7ZG=>8'?I-T5DH\'6YO;@_%HG4]"JP$;_NN?\HF>GM%!*%M/VZ,J
M)IGB#71Z,9BM\8;/B6/*OG6@!0M!\>*'/KDNFSNH'[&JK1YNB\L*HA7J8/W]
MPGMMXSU9./A=Z7O,_L%<-AO(G1R&8OK.GEREND=_L2`=]YOZUTP^-1[[H5_Y
M?%`_;,E2;%'+IIVYYF2N!IALH2S5>H[1CPJ!RO(]F)T?^S_"KOOSHM?UYW,&
ME=I,;/_.-5(^L_I4\:F':V%4(WCX2F!(_.@`KXDS'%V_0>W92BSTGZ`G/(;^
M#YJNH[OGZ'_!"=4/.9O7IZ.GKQ/<W<'U;,H=,M&]OP;=?JCP``)PF$=_>2N%
M_ZU?=/O(@?D\H#/Z3P^\AZ!?ZV]CMQ6.G,Z)7DDQOA1<"X!S`WV58B"_228-
M6BF=/CT$Y=7_=(;0\5WS:3-'EUYZK!BOCR)??W5K3PWXY3`:F3?)0M<-&LT^
MBB7;[UMW_U;Q`MELTLL!Q^X-U8_NS3B>7NO-EC?N=<77>!85"A8@-,%1_)S&
MJT0?ZOH1_T]`-(2D<$#*9JN/L"\=N_-^W_4'_\TK#=.H`>UH4;W"%E,=KW\0
MQ;'+V@,A-*TY7`"@RPPF%P`!#=(UGEF,Z$?(%:-P,X?\G4HN6/Z%P8=Q]`""
M5/@0+Q32P?VQJ[SC/F;3:(%>;G_`&-&X=Y25)G00X6G`\!<?J_V>N\N]3$==
M[RXQXP%<)AM(+V.F>Y25=YMY?>-^2[Z.C$]&FI4,C_?)3O?G;Y'PF>,MNC[)
M?!LC`[#B^R<H=I<T:#CAVBVL.$64,KR%TXG?WC@B.!L.#8ASV%L_Y*SN*_?C
MK@;%#(=Q+:4\I3V-^]Y"9:V%N!;'?95&K@4V0O%9MY054)K%D2,#(T=V6?@1
M5K#@`(K,_IIMSRQK1^@AQ-I^=B4M`JWMV4NXM3U7$W1]]]KO#/FBU==5YL$9
M<05U$=%,$-V\?^)Y3>%X5O0BU*$H5V\CQWC3L@)/=E62HAW;;F=UN^YA'K3\
M%?SFEFUK9Z.]SN6X\D2:.JTIM&[46HY<T7?U^:[JV'^RPM^:WUU9`Q>>H"-I
MK!D<<[]#$L7U0&&O]1IPG4=\9.X%E?B1)#YPRTH.WK3M4];-]F!6=Q>WK\?W
M\G.+,S'\!U.\D8+WCWDA''#-D5_P]M%_IN:U]TR-:=6[I/`F?]]"/)T^:J6L
M,(A_1[)W,O%%[0WQ\#C\&5J71X!`C4S8QNN/O3/@*B:\7;F!/!Z%,_0%A-%]
MP^E!'3-Z^@0.K60(?\OI1#+D]00;"76Z2E]SA^TI:S<XW"J*(G)4]2#4ZUV!
M8<2PIQ4)0(]2%-`[`*C,E\.E>,L^E:"/,_JQ/2P`0(QW>+?C!D@O7'J]@X?(
M4:3=GE^X"OVR(ZQ?Y\[IR1,:L^C*/>Q\5Z<>T][5M->:=S7N->!=C5?K]'5$
M6N$PVB6K*Q12WY+.!Y]ZVZRPB,X,6`^LWS$(AW^R96S[>/PP(QH.9$$>JT>C
M_Q[X@1$K,WKUEUO'MO4Q-CO7<Y]IMC;[I]DTV[6^PY=L`S67=I=A]R?;9OS-
MEU^X?*D-ZQW>>6"(1+I<M?7DP?@KR..X04\AVGSQA=,@/;Z"2F.A$OPVXW?^
MBFGV=OH/PQZVXZEQMZ>X5L#7^4/CE6$A*IJ'KIPYY)CPQ,+OQ76PE:CAE^(Z
MV#*U\$OBA%*^Z2EI5OT[;8_/84*81!,"A/W-RA#KJN.*%[GD*0`88C5688=>
M$WA_-X,(!/!H[UW;2',6\ER)"UH;3L@]M=\9[UZ&2SX1RRJ%J-YVW4M&KSO`
MM:^P2SO5P))6X#TU3.$*O^IT]TR`]#EVR&FYVLT>M^:K+M<S><S[JP<8$NB)
MD?+P<TOD!HW7<3`1^*#XY?X`YU?8N^-P*W.>ZQMN$)"BUC1("EAUF.EO]]S&
MCE@RT*QJ:.\OG$CW]0HW'9K/$S;"AU<V&Z?M&MFX+PD??M5TO6KDC&\;.R([
MQ[K-\,_+LMK_/P(```#__P,`4$L#!!0`!@`(````(0"?.Z4"O@T``/Z.```-
M````>&PO<W1Y;&5S+GAM;-1=;6_CQA'^7J#_@6#:H@%J4Z^6Y%@.SCJS/>!Z
M#7)7M$!3%#1%V<SQ12&I.SM%_WMG^#HKBN226FKE&#E;E#CSS,PSL[/+%7GS
M_;/K*%^L(+1];ZD.+P>J8GFFO[:]QZ7Z]T_ZQ5Q5PLCPUH;C>]92?;%"]?O;
MW_[F)HQ>'.OCDV5%"HCPPJ7Z%$7;:TT+S2?+-<)+?VMY\,[&#UPC@I?!HQ9N
M`\M8AWB2ZVBCP>!*<PW;4Q,)UZ[)(\0U@L^[[87INULCLA]LQXY>8EFJXIK7
M[QX]/S`>'(#Z/)P89B8[?E$2[]IFX(?^)KH$<9J_V=BF54:YT!8:2+J]\7:N
M[D:A8OH[+UJJH_R0DKSS;KU4KU0E,7GEKP'$'W[9^=%WOTM^??.G;[X9_.?;
M[_[UH[7^]T]_++_WT[>JEJDA,B$&]3(O![5BX>U$LI9:<'NS\3UBR`3<A-ZZ
M_NSY7ST=WP,R@'GXL=N;\%?EB^'`D2'",WW'#Y0(H@SVQ4<\P[623ZP,QWX(
M;/S8QG!MYR4Y/,(#,3'2S[DVA`D/:HF&T^IY0#2937.$P=@TQB/4)A=,,O!@
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MWY]>MM`@>C!M0#!:\KF&3S\&QLMP%+=)?">$OF.O$<7C*FY+4VM75_?ZZC[6
M2Y#QHJ@0JNNK60]"[^\6*_%(5XN8`YI`\T<Z_`A&^F:*/X*%ZO#?2IA/TX%A
M(@ID+D^);)Q&#BYGB\5B/KR:S^>+R7@XF<1.?D@9;7MKZ]G"F:4P-Y413`'!
M8CQ?7(T`R&`RCU6=%,$8`,RFT_ETN!A-X/]X).H?@6B?3E79424()$65()`4
MU7@F(Z+TI9D"BSJ2<Y4@D!15@D!25&>"*_!,>E0)`DE1)0@D135>?Q.8J[!8
M*CE7"0))424()$556/.95N"%]*@2!)*B2A"<.JK9M&J5-=;ESDQ8?YSJPB9>
MCU=^VNB*9XTP3WWP@S5,C+-+-<,9S!&38[<WCK6)8$8:V(]/^#ORM_#O@Q]%
M<`WH]F9M&X^^9SCPIY:=D?VN.1.NDL$%L:4:/=GF9U"63+[S3CN1ABKZTI!7
MO0G.)B:SR6`VF8ZND@E;8MW1JEUK;>_<LG6Y[H.\!#?R&4Y\Z.5*4CH4"X$:
M1B$-'^<9<:CC2'.>`)S(*,%YA@@;BT5Q7AO)&7PVDA,X;21G\-H(9#^47)DG
MU_X.+M#N!UC7YX-!LO[(JZ=>(`%^@#&'09!SROYL/.6`1QO/:6LKU)=2;MR-
M\"?NC@]8VG!&V<Z&$PY8V7`&KXTL;[+H,L*9@GH`R9Z_F8]W@P&@DA,S/'M%
M,*U/N!2>7!GA+G>'S6T4?\#JQG.ZF<YM,8$$1K4;0;LHR<[9B[:H4)1"WI,>
M;C-$^+?1!J*$&U@=K]+N"9HQTW*<C]@>_7.3=V2PR'E[\[PANUQ@ZQ%N`\%-
M-/@G7$E(_TRZK^0%A*;JI%'E28JQW3HO'W;N@Q7H\7ZD6$5\%*]8%*_NXK:Q
M>!U?:7&M>)E63<3\$/B194;Q?JGX.E(5GG$%GF$JB`?/,?IA4\]!)X*?N/UQ
MC'Y8!CRH'_PB53^0BUN_2#[@SK"4U!`"2NHZ/"(1P&)/A@""(`,![F1+?0#T
ME($`)M$9`B!H@0#@U+#BF#P8DFH&'"A4@OZ^5$*-R:QD5/9H957Y!?TU5NI,
M^3W*S:3>`M$+-\.+&@!'J:PJL;)*#`D[9%KA`GA1XP(=1ETQ0]ZPJN9+<P@I
MNH"A\`B4@3J/B&,EJ;F@LP!0[Y$[@7T((066(MD0`(X4""000TGC+ZQ"YF5Y
M*&D$IFR0-`13",P8?,*<H)%@1DA)&`"/E*P@A&1&C!.Z@4"052$)&T:R2B3%
M(*M&%J$8R2J1!(*L"DDC(:M$4@RR:B0)A:P222"`1Z142!H)62628I!5(XM0
MC&652`)!5H4DD1CW7"(UNFR:+**2]=,A-+'5:Z$0H6S^OQ^LYTWC2NJP:M8$
MLK+3D^E3,G6$8,23*3*7QB\/&KA-'1=/E2<_L'^%629^B="$`U:@XI=.(]ND
M1[X&QO:3]0QST>0RX//F*`,;,!7Z8>%;5=HH%^Z?([!P1+K!$8V6X\)*X\+\
M'C'8Q>U&@C1BB%<69(-`7Z<8A%-`4(I@YLIV$XR2TC'04,&(V50,6U6S([(5
M9Q?G@F4HVB^4PK@/@2VJ"GZ1`1<:DXUB=<5=.++&\D+H4ADB7#RK&_WNTC6[
MQF)'_92-AFT0#C'!TJLH@(GIBNL`MAJ>6P'JDTF=/'0*0$>4`>$$/T2I(_#A
M[+]WAAV##W),*+XCL'!7],KT:Y-JQVL[PM1>:7O4B`%?%Q-+B#8Q$>Z65LI%
M#P:ME/=99W_>A9&]>6&["-C_HYVT=:"5-4=TKCF4`VP51-$,HBXK9W5C!/N'
M4X2O4W-1!1!NCW1^#>)X?Q6]KD/4X^O>K1K8XP)\&G3BXLWBQ>O(_.[L-#\0
MZ=X3P(TWD[>LV"2=QON76_B]6]E=E:N10#KTC#=UIT#`/5>#5Q%_.CCFJQ+-
M2\YTVGT:HE*@;8;-OM$=&^6>25BNF5VCS`!M6O]A!T_YU;YAN4H`W&-YP%3/
MINY)`-XR,;IGU0G@=G$OF9"Q5>!,\58._N>?;2Q[SS_;V&(&K_B;*_G%K'^X
M7;*-L!?B7RS$-Y&WDS\[S55)/3A3A)4^/)?9=.4%H8:4YYJ1Y"LV18_??CM"
ME0M%`,Q85^#+CC1VIY"SV75@IG=F"U%I#GUXZX`.5[5Q8TAZI999J.B43EWR
MG603.[HV>)KM7;B(T04>X0$+#S>;GT>UIYRH]&89[IEQ@EK1PNEG9@60]F!^
MLHU-*3^%9Z+0MKQ_N*\M,SO@%7[]MW&LJ.`B'"9=54-L.PT#V6C687R3CKFK
M5T^^BITYN1$P#@G9#KO*P@I^9P>S]G65:P@^&C73Z)P=Z@KZLN0HH:ZK_F*]
M6H6/&9[.!!]M9>JC+MU_X+&>2VHRGK^F@IH.D1T@5W6"]23HJ6!U&.EK)F:0
M9VR9K:-NI['WR,:/\?&P?[B\[JWB1'WA.E-.,*!Q%_YY<^+4<(5RHKQLV)X4
MG1*1UXJJ(9G-Q(8VG5T,Z817]`C#]CRGVR?18<#A"H'XKBAEB$#`;*;"J_,H
M+%S%NSS8O,I$/?MJSM:5_N'RUL$JDK!X2UGX2DC"9N8KK.:G-J![<>0C4JDX
MODHB]9^^PML"EDC]&]"=2%5M`6L!?#OT-8VR);BOA/?L,-`_;83S_M0&],W[
M4@$5OI3!VSE4Y2GK\1+QA>/E7'JAXU/E&B=^%YXM*V><I]56G#U)@#O%RFVI
MN60ITM]2/'&@<$!E5N8[=Y,'RI2^^D4)2B\8L?D$KUX+087O-FJ\YD9*DG#E
MY2]?4#AY<)MO"=`KLGP3%@5W<&LPKM!M)-Q?([X7$-S]A]Q+G;V3>GZO(`6?
M];M41X/?*Q?*&Q.O8>8;Z?"+J@\[VX'G8^$]@/`^3B9\R=)W[Y*#Z8UWZF3E
ML\$19AB1!=6SK:P\*T=X;R\B"Q*YK:R\>(_!6B(+;C/?6E;>L,'S;1E9,,ZU
MQ94/C6/6]U-.WT\.Q1&3@=B()O/@HK**.(+GJ"PPN:VL(HX0."H+3&XKJX@C
M("2R)J"DK:PBCA`%*@OHUE96'L<)Z_LII^^O#L:1Y2K>4(P'%Y55Q)'EZIB3
MJU16$4>6JVAR6UQ%'$$J]3V\T596$4>V3DPXZP2UL8@CZ_LII^_W*RK+^!$G
MXQ,I1>S@+^(CO!K!XZ-$2A$UEN5C3I8G4HIXL?R></([D5)$"N01BR;P!K]%
M>8S&K'<GG-Z],]99O\<2!L<9'A@KPS%WCH'/^,@$X==GB$&X08Y+TI-E?E96
M\/R37!";#SB,\@BZ?]XZAF=$?O"BX#WR<G%LT*><XO[L^[F/6`DC>,D#Z"^6
ML;:]1P7\DK36+(=Q3MA&3)X+K'OPCMEMQ,#9"1J6?[C+H8T8.#L1PQ95[)]X
MQ+SSMKL\0FPMQ:&;1\1[V_MLK5GFL!X>`4@>21^L7108.?_8E!IQ.N8#/C4G
ME\&6B/@A./L]XP=X2$[F1-PU0'('>V@>X'_;1<2->!81@C=\X1'RR8[@47-I
M--D<1EA<(GRX;V4N8J^B<,KXAQ%XF"U,ZNYQM,*BXC:@T/VOGXLG*,5^CPQX
ME%[\;*5\/@".6EL;8^=$G_(WEVKQ]U_CAS@"F=)/_6!_\:-8Q%(M_GZ/3\>$
M+(9I$)2;]R$\<1%^*[O`7JK_O;^;+=[>ZZ.+^>!N?C$96].+Q?3N[<5TLKI[
M^U9?#$:#U?_`9:[CA=?/P\E2?8JB[;6FA>:3Y1KAI6N;@1_ZF^C2A(=N^IN-
M;5I:N`V@J(1/EA6YCC8:#!;:0G.-^'EW(.0Z=.!306IL"OYC<6RIDA<)_/B1
M>``;;AJ3&:&%^""JCZCD]O\```#__P,`4$L#!!0`!@`(````(0#[8J5ME`8`
M`*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V
M&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F
M6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$
M/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;
ME8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A/D%#
M3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*
M)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&P-0R
MKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?1
M2F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R
M&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#00(85
MC9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J
M^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X
M6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=
M\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D
M'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"
M53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D
M(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<
MXH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2
M*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7
M$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3JMN7P
MKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%
M*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,
M'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(K
MA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJB
MPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,
M\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O
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M52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0
ML@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD
M_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[M
MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T
M']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/6
M25LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3
M["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__
M`P!02P,$%``&``@````A`$M":0-Z`@``W`4``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULC)1=;]HP%(;O)^T_6+YOG"]#0(2J+>U6:9.F:1_7)G&(
MU3B.;%/*O]]Q#(4TG>A-B,-['I_WG&,OKE]D@YZY-D*U.8Z"$"/>%JH4[2;'
MOW\]7&48&<O:DC6JY3G><X.OEY\_+79*/YF:<XN`T)H<U]9V<T),47/)3*`Z
MWL(_E=*265CJ#3&=YJSL@V1#XC"<$,E$BSUAKC_"4%4E"KY2Q5;RUGJ(Y@VS
MD+^I16>.-%E\!">9?MIV5X62'2#6HA%VWT,QDL7\<=,JS=8-^'Z)4E8<V?UB
MA)>BT,JHR@:`(S[1L><9F1$@+1>E``>N[$CS*L<WT?P^P62YZ.OS1_"=.7M'
MIE:[+UJ4WT3+H=C0)M>`M5)/3OI8ND\03$;1#WT#?FA4\HIM&_M3[;YRL:DM
M=)N"(>=K7NY7W!104,`$,76D0C60`#R1%&XRH"#LI?_=B=+6.4XF`9V&201R
MM.;&/@B'Q*C8&JOD7R^*#B@/B0\0B#A`HCB(,QK1R64*\1GU!E?,LN5"JQV"
MH8$]3<?<"$;S_SH"*TY[X\1]""1KH`O/RS3)%N092E<<-+=C33Q4W+VC>`-9
MC25T-J3<CR4)/>U$P-ZK1ZC<N4?7O?2B5Q>48WB>>7V3PZW7T+X221:F-`N'
M6=Z=*]*4)M-T,E2L!HJ89B/%_;DBGDUG873:9>`S&?N<P*R_/Z7'GKJ@-S[3
M$[_O^ZW7>)_1)(EI&`U=W%U4K`:*)$ZC\-2M?A<XP"Z30S5C.HNR4ZV\3W]`
M_?QV;,._,[T1K4$-KZ!+83"%KFI_//W"JJZ?U[6R<*SZUQIN40[#'`8@KI2R
MQX6[`%[OY>4_````__\#`%!+`P04``8`"````"$`K8:5R(\#``!2#```&```
M`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)276V_:,!2`WR?M/T1^+\$A0$&$
MJJ3J-FF3IEV?36+`:A)GMBGMO]]Q')+8@2I]`0)?SOE\?,EA=?>29]XS%9+Q
M(D)X-$8>+1*>LF(?H=^_'F]ND2<5*5*2\8)&Z)5*=+?^^&%UXN))'BA5'D0H
M9(0.2I5+WY?)@>9$CGA)"_AEQT5.%%R*O2]+04E:W91G?C`>S_R<L`*9"$LQ
M)`;?[5A"'WARS&FA3!!!,Z+`7QY8*<_1\F1(N)R(IV-YD_"\A!!;EC'U6@5%
M7IXLO^P++L@V@W&_X)`DY]C512]\SA+!)=^I$83SC6A_S`M_X4.D]2IE,`)=
M=D_0783N\3+&(?+7JZI`?Q@]R<YG3Q[XZ9-@Z5=64*@VS),BVY\THXFB*<P<
M\O2,;#E_TK=^@:_&D$16@$XB_YW3W`<ZB]^DZ7X^IWRLINV[\%*Z(\=,_>"G
MSY3M#PHR3:$,NAK+]/6!R@2F`7*-@JF.FO`,0L"KES.]GJ",Y,78L50=(C29
MC:;S\00#[FVI5(],AT1><I2*YW\-A.M0)DA0!X'WD_D]>'^021T$WNL@.!AJ
MXIM1505[((JL5X*?/%BNX"U+HA<_7D+@RU6!<FCV7L,1FL.\14C"U#ROQRO_
M&8J?U,3&$/#:$-@FXC.AYP\<&A$HS7`1#6L1/5W:;&.^Z.8-G+Q]8M(0E@A4
M8;B(AF%%=,8;-E&-F2'"#C&UB?@MPC*#(,/--!PA&'4S$S,[[\807;.Y3<1]
MHG6WS&`G##?3L&UV:^?=&*)KMK")N$]<,9N]QTS#MAEV%[A!NFK87>%]Y(H;
M;*3A5=.PX^8L\8U!++=VC5>K,>XC5]ST,W/PN:!AQ\W=!@:QW-K,QJV/M(2U
MVA:VFS[1)_`P>?OLTC<YCNZ&,$C7L14PBH:85D=?&,ZF88C;@5J.&(2&%["B
M'3MG,VYJIJN'G8T37V#:(=A^^AP>/,'8G-K=TP0[6W)3,UV_P-D]\07FFI\^
MKX?[F=.]ZQ<XVW*##3,SDX>GH5/@N`:Z`[@FIX_LX7+F@+?DW*V+^P^!P-V[
M%YAK?C"&=_AIVEY\0;NJS5,,VCK-=&L3M,G-YKC`M(A9?*9C,PU(3L6>QC3+
MI)?PH^[`,$Q-\VW34M:]7O,#-&<EV=-O1.Q9(;V,[N#6\6@.CP1AVCMSH7A9
MM3=;KJ`MJSX>H'>GT"Z,1P#O.%?G"]V,-/\&UO\!``#__P,`4$L#!!0`!@`(
M````(0`2D8W]9`(``$0%```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;(Q4VX[;(!1\K]1_0+RO\:7.Q8JSVF2U[4JM5%6]/!.,;11C+""7_?L>(&ME
MDU6;/#@&Y@PSP\&+^Z/LT)YK(U1?XB2*,>(]4Y7HFQ+_^OET-\/(6-I7M%,]
M+_$+-_A^^?'#XJ#TUK2<6P0,O2EQ:^U0$&)8RR4UD1IX#RNUTI):&.J&F$%S
M6ODBV9$TCB=$4M'CP%#H6SA470O&'Q7;2=[;0*)Y1RWH-ZT8S"N;9+?02:JW
MN^&.*3D`Q49TPKYX4HPD*YZ;7FFZZ<#W,?E$V2NW'US12\&T,JJV$="1(/3:
M\YS,"3`M%Y4`!RYVI'E=XH>D6&>8+!<^G]^"'\S9.S*M.GS6HOHJ>@YAPS&Y
M`]@HM770Y\I-03&YJG[R!_!=HXK7=-?9'^KPA8NFM7#:.1AROHKJY9$;!H$"
M393FCHFI#@3`$TGA.@,"H4?_?Q"5;4N<3:)\&F<)P-&&&_LD'"5&;&>LDG\"
M*#E1!9+T1)*!^M-Z&J6S/,DG_V<A09$W^$@M72ZT.B!H&MC3#-2U8%(`LW.6
M03[O.P-+KN;!%?E20!LXC?TRR_(%V4.$[(19!<P4HQ&3OD6LWT',1@@!?:-(
ML'XN\M_B'/A2W&3D]096`3/U^3I'Z[.)-SM#).<[WQ:/*RHQ4([6LVQZH2!@
MYCZ\/(KG;WX7<J&U'>',@Y-X9`I*0]>&0Y5<-WS-N\X@IG:N(U,H&F?#95DE
M!00`77HQOX9+Y.?)N`!-/-"&?Z.Z$;U!':^!,HZFT+4Z7(,PL&KPD6^4A?;U
MKRU\K3A$&T<`KI6RKP-WT<;OW_(O````__\#`%!+`P04``8`"````"$`2M:4
MZT8$```-$0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R46%&/HD@0
M?K_D_@/A?81&!37J9A7F;I.]Y'*YW7M&;)4,T(9FQIE_?U6T"-4PP+[,"/75
M9W]=U55=KK^\IXGQQG,9BVQCLHEM&CR+Q#'.SAOSQ[_/3PO3D$68'<-$9'QC
M?G!I?MG^_MOZ)O(7>>&\,(`ADQOS4A37E67)Z,+34$[$E6=@.8D\#0MXS,^6
MO.8\/)9.:6(YMNU::1AGIF)8Y6,XQ.D41]P7T6O*LT*1Y#P)"UB_O,176;&E
MT1BZ-,Q?7J]/D4BO0'&(D[CX*$E-(XU6W\Z9R,-#`KK?V2R,*N[RH46?QE$N
MI#@5$Z"SU$+;FI?6T@*F[?H8@P+<=B/GIXWYE:T"YIK6=EUNT,^8WV3CLR$O
MXO9''A^_QQF'W88X800.0KP@]-L17X&SU?)^+B/P=VX<^2E\38I_Q.U/'I\O
M!81[#HI0V.KXX7,9P8X"S<29(U,D$E@`_#72&%,#=B1\+__?XF-QV9A3=S+W
M["D#N''@LGB.D=(THE=9B/0_!6)W*D7BW$G`XT["G(FSF+.Y.\QBJ165`OVP
M"+?K7-P,R!KX3GD-,0?9"I@K96H=#ZV?206-2/(564HN4"$A/F_;J>.NK3?8
MT^B.V2F,9QH/S'Q!(?L*@CN(O'[UHO9AU"6H$!@^D/30!;NEZYI"W+LC5LE`
M)RK#\>CW[3H@%+%O(^9+"O';$(<B@C:B04*$3JG0?H$(AN1KQ,"UZ3?O%&36
M@,PI8C^(\`<101^"R(.%-./8+P_!&Q/V[I%BKI8O.P59E#G*%DM-_9Z8;6]*
MI?M-\\SQ-.^@:9YZK,X=(@F.V7A)"*818]Z,KFJG,/#E#]EZR`81_B`BZ$,0
M?2[5AR5E^.BA$PT=\_0*HC"S,G;:UN^;MB=F:UOD-\V::]"T31?U626BH&Z-
M#QJ"J9AIJY`H3%_0!A'^("+H0Q!]>%5I]('^<X9@JH^Y6BW?*4QWL'IL?H\M
M:-H8JY.<*%G^BA($T^/5*H@*TA>H080_B`CZ$$0>@RXV/E(EFH:J51+OF.Y0
M$6/[7!&S?K"(T5E\4@X9MO#1J5>BJ2#FZ47^#OI$D;HR=!K]/L^`&!FKRQ,-
M$/;N\7I4IV_V+.9IMX$=4Z#.)>^)L2-"/;X!\9W9=;NCBK!;CU>D>CM55#.7
M%[L=JRX`>%?4\F9/C!W%G-@UYX`8GYQ%79>H)NS5XS4AFM:)=AMF"M17*88A
M_C`DZ(50E=BT&RK']6(<;?3Z[M75]A[!ZC[0&<$>HW^G[\SF@!A=[[.:@3W[
MUW6I3D\SLS[%=UT*I&Z(6G+M8<C$G5'&KLQLVC5GG%!KY_9%0TV?:CA+>7[F
M>YXDTHC$*TZ6#MQZ'F_5U+MC*YB88/#1WOLX#9?S[,,`P^@U//._POP<9])(
M^`DH[8D'8<K5.*L>"G$MYY^#*&`,+3]>X&<'#K.8/0'P28BB>L")Z_%#QO9_
M````__\#`%!+`P04``8`"````"$`4/0ET+$'``"5(```&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6RLFMN.VS80AN\+]!T,W<>VCCY@O<5:9Z`%BB)M
MK[6RO!9B6X:DS29OWZ%(2AR.HG72W-3=3\-?G`/)D92'W[Y<SK//1=V4U75G
MF/.E,2NN>74HKR\[X^^/T8>U,6O:['K(SM6UV!E?B\;X[?'77Q[>JOI3<RJ*
M=@8*UV9GG-KVMETLFOQ47+)F7MV**UPY5O4E:^'/^F71W.HB.W2#+N>%M5QZ
MBTM67@VNL*WOT:B.QS(O@BI_O137EHO4Q3EK8?[-J;PU4NV2WR-WR>I/K[</
M>76Y@<1S>2[;KYVH,;ODV_3E6M79\QG\_F(Z62ZUNS^(_*7,ZZJICNT<Y!9\
MHM3GS6*S`*7'AT,)'K"PS^KBN#.>S&UJ><;B\:$+T#]E\=8H_S]K3M5;7)>'
MW\MK`=&&/+$,/%?5)V::'AB"P0LR.NHR\&<].Q3'[/7<_E6])47Y<FHAW2YX
MQ!S;'KX&19-#1$%F;KE,*:_.,`'X[^Q2LM*`B&1?=H8%-RX/[6EGV-[<72UM
M$\QGST731B63-&;Y:]-6EW^YD2FDN(@M1.!7B#ASQW)7ZTYD8J`C!L+OR-TG
M!L+<NFG#KQAH+N<K<[FQ5X`F!GIB(/R*@=9R;CI+C[D[,6XEQL&O=''2'M97
M-T'X'2:X=EW'6[\SPXT8";]3=UKP1'9U$61M]OA05V\S6&R0JN:6L:5K;D%#
M%@3WK2^1;U4(E`83>6(J.P.\A>0W4-:?'\WU^F'Q&4HQ%S;[$1MLX4L+5G=,
M-M!!J(-(![$.$AVD"EA`$/I(0$W_A$@P%18)Z<->@B$TEN:VM)!#`AV$.HAT
M$.L@T4&J`.0VK$+=;0>*>WQ'D/EF@V#MJ_E>>MBM/;>Q(-Q]4;C8Q.]->M<)
M"0F)"(D)20A)58("`+N)'@"V)7[G"F`JL"]"E'MOS?4&^[L71E,AZ4WZD!`2
M$A(1$A.2$)*J!(4$W%=#,ET+S+CS7,YXSXD)I],0"\?&L?"%D=GM%EIA!/U%
M16&S[!709&%OOG^RS!A/EA.O.W2[7<<G)"`D)"0B)"8D(215"?(*]M+[O6+&
MV"M.P"LU@&8?0.YH;R0S%Q`2$A(1$A.2$)*J!#G*6DOE`)JN-6:,'>5$31\A
M`2$A(1$A,2$)(:E*D%=PE*I>\6-USL[R]E3FG_85K`S8!D:\M6%!\$.5:6!G
M.;&['H^G4!#>8'5G)B<N;'?#XMMH1T[8&\G,1X(,!U?<VZA"VBI.>B,IE')B
M=S-"(6'[@1X3RV-]YE@8`,LX=`-Q(`2RL9>.5M_2RNE/XT`BEHB^5?&T?3H4
M5NZ:MS*NOGE%4F90CB6:5$ZPLN686F92*=,IX_BQQN7NE6(R:RUH'#GP,_B^
MT;9>7PRTATH(!(*!,LNA0"YD>]!:#3MT5YT1U8JI5B*1Q:.]PEE,D0B.".MI
ME(C\T"HS>6,$)[=T;B^05EU:?^-+JZ$&`H&<`842L7*&KGBIU6A$56(Y9%!)
M).(J:RW.*1+!(6)MS_\.D>B=U!!QI-62ECK?Y%:HECCR4'-`%Z"PXMV!Z3F:
M<D258X&FE1-IQ8O-<I?:VD^1,HXEZY<F8OFQNGUK4U=W,]%UJ<$42.E!3(("
MBD**(HIBBA**4H2PW["EZ7Y;[ASH=_;(K*W6]R2!X&?81S;:HZ,O!_)7$OS1
ML!\HEVU(K2**8HH2BE*$<#18RZ94P<@1KF:;-WAH=Q%H<,8W"0HH"BF**(HI
M2BA*$<+^L4[M?O]X7X?\ZUL]-:7:,O/-WDKF+Z`HI"BB**8HH2A%"+O,VKC[
M7>9-'W)9('4!$Q28!(44113%%"44I0AA_UA/IOCW8^<D;^R0VQS!6I$Y]$V.
M7+5[$`BV=&6):WU/*`?:O58DT:`52X2U]*9TL)+S2@4::4LMK2V=7L^=-6ZK
M!$+=`KS6QEV,+ZV&0SV0".U]Y"B45I[H1;7`1?+Z(!Q+-"F<2"LN;&VT(S:5
MUSMA5$_LG8Y:3^^$C':BG<#.0-V#M=0?3X65VCT,`V5F0XGX@>YH[6Q$16(Y
M8FAG$XFXB*V)I$@$A^)GM*"PIO1S42"MJ+3<^])JR'T@D-J"2B1:4%M;+A%5
MB>6003B1Z!LJ*5+!,6+-G++]O%,NO/4#.9GBO<61\OSA"X1J@UMYPPX2"BO/
MZ=:.;6N+,J(JL1PRJ"02<17'(]7!;\SG@CU_IV.\ZS6`11M&@;3JT/+J2ZLA
MB8%`J#JX/+SS90\H'\R5)A-1F9C*)!()&<O1:C5%,CA*K)53ZN.'CB?V&D'K
M+05"NXRI;W.^L$*5Q+6FGR1",=`3"\+5]L^("L=RR.3#3R*MN+!E:0E)!V'E
M0%5>4>#@:NVJ'MS['EK@FR2)+D?*Z<"_.O*O2Y>B?BG\XGQN9GGURKXH0GOR
M^-!C_KES;ZZVK"^#E4ZNK.'*>NR*MX6WIB,C0&I4"81&=4P'[M!-G]S;A2M=
M4T.NP,VA=:9W#S9;>*E&>;S9PCLRR@,3!D!30J]`C[--1J_`Q^&G;E<DLX))
MC2CM+?B8/,;M+7P-H7=^<D!_S+D]1(KGN;\S?!2^92_%'UG]4EZ;V;DX0HKA
MFRJLG)I_5N9_M.*9^+EJX7-P]WA\@L__!7S=6[(GR&-5M?(/F-&B_P<%C_\!
M``#__P,`4$L#!!0`!@`(````(0"A>/^H<P0``!`0```8````>&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULK%==C^HV$'VOU/\0Y?V2F,^`@"L@VO9*K515O;?/
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M'+1FOS0[\$?E[?@^.>?UG^+R*\\.QQJV>P0986*SW4?,90J.`DVO/T*F5.0@
M`/YZ189'`QQ)WIOG)=O5QX4_Z/?ZT8B-QA#O;;FL7S+D]+WT+&M1_*VBF.92
M+'W-`D_-,NZ-)N&`(<>=>0,]#YYVWH2%T\'D_KRAG@=/HYHL>%]TH!QH#(V3
M.EG.*W'QX)1"BO*4X)EG,R`V3BKYUMM_LQ8\19(5LBS\B>^!:1+.P]N232;S
MX`WV,-4QZXX8-V)C(G##D#8F0`!ZK6AP_!-$(PN*-LNM#7#-HG^CT$28*3$!
M'(6PMY^@$%G@;#JV1JZDM8KI@U76^Y$;LK$A5C9%'-UP!#Y!-[(L_#Z88S6Q
MR=15M=9!]X3;$"N<(HYPN#I4>'<E,,<5@QM]AG>M$`:5Z*IX.'`5;W00:P[X
MT!V,U>!H3!FBT`8Y8B'H>;$8[(K5R-2>W$T+B2GBK`V7E*Z-%SZ:8IG4)>OI
M.X]$KBZ-3!T+F+6@N=,;&V2\CRGB2,6?:U*;[N\I!KMR-$)L:B$Q19RU(0FZ
M-MHTB!J;[LO`>:X,A<#1,@EO+$(.6W13:F)-!`*O)S*ZGDA'+)Y;JO:^Q";:
MU6@@XE4;BAW(%8"5FFS5TW8Q5>*A5!AWUAJ"Q0RTN4+4C%O'#)=KV?6>NHJQ
M<A/%#RQ3==Z1J2%J60N*&85<`5B#B0"T;`1N/!"B*S?U2T&.7Q:ZZY?F<OVZ
M_GBX<K'R$KD/9.HZ365JB/K5@F)&(5<`%E@BP/CU7[]45)UV=E)#<./(51O?
MU"W\OL2;?=4?.Y`K%LLO$?O`+5VLJ5NT?JO"R5I0[$"N`"RJ1,#_=4O79JK,
MEFOJULW'WH;9*'.)8P=RQ6(5)F(?N(71-^5+04.L&(I9M0[J2[?@U8%O>)Y+
M+Q5G;`M@XY9S"ZN>9<WZT+0TB;9&AC#2D+=&1C#2=!BMD3&,C%%0:V0"(\U7
MY\T(=$VK[O5A0A<3".Z,'\SB04?\:CA;J:[L9N$UY->9'N30F0)DT)7`.IK!
M#VI7RB%DH%HZNS3T8Z?DP']/JD-62B_G>]B8L(<]4*4Z.O52BU/3I6Q%#8U8
M\^\1.F\._4'8@^"]$+5YP>VWO?SR'P```/__`P!02P,$%``&``@````A`(=L
M6I^M"0``>2T``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6RLFMMRVS@2
MAN^W:M]!I?M8HLY6V9Z*Q/-Q:VMF]EJ6:5L5272)2IR\_30(-!M`*QPY.S=A
M_+'[)]AH``V(=[]]/^Q[W\I3O:N.]WWG9MCOE<=M];0[OMSW__C=_[3H]^KS
MYOBTV5?'\K[_HZS[OSW\^U]W[]7I2_U:EN<>*!SK^_[K^?RV'`SJ[6MYV-0W
MU5MYA#O/U>FP.<.?IY=!_78J-T^-TV$_&`V'L\%ALSOVI<+R=(U&]?R\VY9N
MM?UZ*(]G*7(J]YLSM+]^W;W5J';87B-WV)R^?'W[M*T.;R#QN-OOSC\:T7[O
ML%U&+\?JM'G<PWM_=R:;+6HW?S#YPVY[JNKJ^7P#<@/94/[.MX/;`2@]W#WM
MX`U$V'NG\OF^_]E9%J-9?_!PUP3HSUWY7FO_[]6OU7MPVCVENV,)T89^$CWP
M6%5?A&GT)!`X#YBWW_3`?TZ]I_)Y\W5__F_U'I:[E]<S=/<4WDB\V/+IAUO6
M6X@HR-R,ID)I6^VA`?!O[[`3J0$1V7QOKN^[I_/K?7\\NYG.AV,'S'N/97WV
M=T*RW]M^K<_5X7_2R%%24F2D1.!Z0:3#<:P<X:H<9S=S9W@[GL/#._PFR@^N
M%QYX9:OA$<VKPU6)3&]&BZDSG8E7[WCZ3#G"%9_>'9^Y<H!K^YI7/0E&:=-$
MN"I'!UZYHVFWR@&NUS7-@8R3"2!23W;N[+HP.&WNP'^4ZY41=#!CQ'^N;"CF
MBJ,GRU51%#&3[TCY\C=Q%$-(NE!VC"]V\D`.J&9\NIOSYN'N5+WW8-(#Z_IM
M(Z909RGD<&3*WFO'ZL^&*HQ1H?)9R-SW(7-@%-8POWQ[<*:W=X-O,"=LE<WJ
M@HUIL48+,0$(6=<&G@U\&P0V"&T0V2"V06*#U`:9#7(;%!H80*S;@$,J_1,!
M%S(BX!BJ%0+J@9$57;1`%]<&G@U\&P0V"&T0V2"V06*#U`:9#7(;%!HPH@NC
MCD5W#'/&Y84&LU=XP9*B9^]L:$9O)6U&T*UMBD]-DW5KTD:8$8\1GY&`D9"1
MB)&8D821E)&,D9R10B=&M&&B8M$6D\@')P\A<]\?09^VH75FCAG<E3+JBG]K
MTL:?$8\1GY&`D9"1B)&8D821E)&,D9R10B=&_"'4+/ZCZ0W@[GP7?DW`,5`K
M2<0R2UTP&9M=L%9&3C._6S?=]J:F,*,IR&@WE"1&N[M;*ZS-UBHR;F>_-2,N
M(QXC/B,!(R$C$2,Q(PDC*2,9(SDCA4Z,$,)2:X10K-OCA:B>/SKZA)(97D5`
MBI)A9O7WNC7"''(9\1CQ&0D8"1F)&(D921A)&<D8R1DI=&)$7.Q%]4JI.VF%
MM1E51>3V1E0W:T9<1CQ&?$8"1D)&(D9B1A)&4D8R1G)&"IT8(81ZWPBA2%HY
M7WUPQ1!"9G05,7-V8DU@K5&;LXQXC/B,!(R$C$2,Q(PDC*2,9(SDC!0Z,0(N
M)G0CXMU)VYB;<46DI2U'+D<>1SY'`4<A1Q%',4<)1RE'&4<Y1X6!S)"*PO[Z
M>4!L/ZU4163FJEU,DE6;K!QY'/D<!1R%'$4<Q1PE'*4<91SE'!4&,J,L"OP/
M1%GN!Z"$Q&"MQ)Y=!+XYU6IVDVN.7(X\CGR.`HY"CB*.8HX2CE*.,HYRC@H#
MF2$59;P>4KG5OQ&'6.?7W?;+JH+I&-+UPAPQAI)/;?359D"/M$2PS<+@K\7I
M!P0?SB(0N0I-X8Y65<S,&=HC*W3T.0HX"CF*%-(:$:,55-1:(^9F(Q*RPD:D
M'&4<Y1P5"LE&F/TAROK_OS_4YD#O#XF,_E!([P^)IM.FFA\-':O`\\39$_0A
M&&`4?(6TB`9D)0Y]0(9*_B9A0C)`F8C+Q&2E9*S6)&2`,BF7R<CJ<FMR,D"9
MPI`Q>PA&AM%#%T8&%-SMT!#FUNHIT=A,^H69;VNQ91:C9=)&VD4$=[1$M4[4
M/+2"70)9S:V3"Q^M2#Y`U"D?HE6G?(16)!\CZI1/T*I3/D4KDL\0=<KG:#5K
M$MQQK`6VP/N-L-GO8M>EC\R_Z7=A;O6[1&,ZGUL[#+D<>8@6;2KXB$@KX"A$
M1(X1(G*,.4H0D6.*B!PSCG)$Y%@@:AS-D(IMU0="JG9A^JPFD3&4[$.ZM:.,
M*%E<1'18X"&ZU8+,'`.T(L<0$3E&B.B),2)R3!"18XJ('#-$Y)@C(L<"T86\
M%1NO#P19[=/T($LTT<^![).XM2.-M.1V%9K0^N(A,D[U^-S$M`)T)*T0T4@.
MY:&UKXO4?:U%,;J02H*HLT4IU\K0D;1R1+)%HX550A2&BCD2Q&9-[Z1?*\/4
MED_O.XDFQEHSMXY1UXZT,M8:Y4B9Z"FKB3'#\LYC6@$ZDE:(J%,KXNV*T9&T
M$D2=6BG7RM"1M')$L@!R'*L4+0P5HPM']J[ZE[JP43&7#86,X>?,K8IJK:RT
M;'?1D38['B*8V#IJ`ZX5H"-IA8CF/QE_7"5&%U))$'6V*.5:&3J25HYHT;1H
M,K3*Q<)0,3OO8_MW\8./M;@K9*Q$SMQJP1JM*.-<1%11>XB@..CJ)=D(;=`&
MZ$A:(2)9\'QRV#2)!M2D&!'))(@ZFY2B%6EEB$@K1Z2:-%I8I6^!!HV,V4]B
M_Z[/D]U%F/CUR.XGB;1QLE96&G(Y\A!19>,CHI(HX"A$1(X1(G*,.4H0D6.*
MB!PSCG)$Y%@@XD782.S*/Q!286Y-4!)9J6\MQ^OF.>9^!A&5-AXB*FU\1)14
M`2)R#!&18X2('&-$Y)@@(L<4$3EFB,@Q1T2.!:(+B2OVS7J4?VUUD+MOZ$S<
MJ*Y&$EFK@[6M62LK(\65(S7?4U93O=!SV`+/M0)L!&F%5VE%7"OF6LE56BG7
MRKA63EKB,&`VMVLT0\6<>Z"^^`>Z4*A8XT<B:_Q8E<=:_(@'CMIT[RHTA86`
MUHF9?1Z`5IT5KL_E`W3LE`_12A:]EQ88UO`8?3J5$[3J;'BJK+2X9.C8*9^C
ME6SX>&'%K3"$S4P0N_:NP?Q[]?:S0U-0Q:,A.(5FJ2"1-G_(KR?EUUF'\O12
MKLO]ONYMJZ_BRT@H1Q_N6BP_VUPYPZ7XJ0*F"'8'ONB$X_5+=T9PIYE6+!_X
M"/3S);X24I>40.BB_7@)GXSP)W^>@'Y3PUD/7DV6\(T#=UC-EO`#^`4^7\+/
MM!?X8@F_/5[@MTOXB8QS.)->BH-C?@<.BI?B-)??<9W)4AR-\CMP%`IJE^[`
MZ>92'&!R'SBPA.<T=P9M4.##U[?-2YEM3B^[8]W;E\_0_</FG/XD/YV5?YQ5
MZCU69_CDM<G"5_C$N82?EH?B&Y#GJCKC'_#H0?O1],-?````__\#`%!+`P04
M``8`"````"$`'W*#MQ8%```R%```&````'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;*Q878^K-A!]K]3_@'B_(9"0#Y3D:A.T[95ZI:IJ[WTFQ$G0`HZ`;';_
M?6=L8SS`LDG5EV5S&!\?'P\SX-77MRRU7EE1)CQ?V^YH;%LLC_DAR4]K^Y^_
MG[\L;*NLHOP0I3QG:_N=E?;7S:^_K&Z\>"G/C%46,.3EVCY7U25PG#(^LRPJ
M1_S"<KASY$465?"S.#GEI6#100S*4L<;CV=.%B6Y+1F"XAX.?CPF,0MY?,U8
M7DF2@J51!?K+<W(I:[8LOH<NBXJ7Z^5+S+,+4.R3-*G>!:EM97'P[93S(MJG
ML.XW=QK%-;?XT:'/DKC@)3]6(Z!SI-#NFI?.T@&FS>J0P`K0=JM@Q[7]Y`:A
M-[6=S4H8]"-AM]+XWRK/_/9;D1S^2'(&;L,^X0[L.7_!T&\'A&"PTQG]+';@
MS\(ZL&-T3:N_^.UWEIS.%6RW#RO"A06']Y"5,3@*-"//1Z:8IR``_EI9@JD!
MCD1OXGI+#M5Y;4]F(W\^GK@0;NU963TG2&E;\;6L>/93!KF*2I)XB@2NBF0^
M6OC^=+:8`\G`P(D:"%<U$/)R('ZJXN'ZL%I'KEP8&495M%D5_&9!=L+:RDN$
MN>X&0%P[*&5H3S^R%+Q$DB=D6=MSVP*W2LB#UXT[':^<5]B[6,5L>V)HQ*Z.
MP(U"VM``'-"K18/5_X-H9$'1]73;&FA6X;44UA'UD-``B$+8T[;"":1W?V+6
M+N(@2$'BHDL5;&6,!\YHJWT:LM,A6J6)$)FPXVV9^/P\N/O(LK8]\$)K<J<M
MZ[8J:$BX#M'"380(!Y&F\&%?,5CHJWFW$G%A1PS%DY:/*L@5^=Q:3JAOF@Q3
MS4#$SAX1B\%4K$*6.E%W'20T$3(W/).F4>+Y'L-./;C%2$-5*61)+&RGH@ZJ
MG0]-A`C%GFP4HN$=Q6`J1R&RRF/QV'60T$3(W+`(<VXT:;+`EO&H34A$=2F$
MVC33>2+JW$X':9M,A$C%G#6U#OLDHJF@&C*<ZD(A@:@`+,IW;Y0K2SC4AGII
M6P7!##6T:R#S:9I3E\*:"[;1>&H7.HK*Q,I\OTQ9QXE,"1&9&C(%=&0J+BIS
M^8%,+,V&3$P]SQ]!YGVRL:JDF[Y*B`C6T*!@Q44$^TW[IKYB26X)5L_*)XI5
M+3<52X@HUM"@8L5%%3>MDBK&4MU2?)?%LL23G)`0$:RA0<&*BPIN>@H5C,6\
M)=B'Y^@3?U4+,/V5$)&KH4&YBHO*;?HCE8LEO27W+G]5*S`%2X@(UM"@8,5%
M!7_0CEV(:@N^+X5Q8*N:2H@HUM"@8L4%EZ:8^4W_I!9C.S`L_B035/,PC940
MD:DA0\"T4\P4%Y79]"\BTWNH-XEHZF8-&;VI"X4$H@):O4E^S4Q&S8?8W5\T
M^(;=VNL:`DN,+6LYMFNBZO86$H@*QEYQ]\;B&W9;DX*,E\,ZJH%"`E$!6/L-
M`<*QF?^?'%-MQ$@[3T'4L:9CR[>?)JIQ3`\$B`K&TF\('GX4X/"AXYB$Q*F$
M9);'"_*K.&/%B>U8FI96S*]X=`#?0YN5AN6YQM8=!_B*!.+:=SRX`PG:=P</
M0\3106>,!W>$;9T[$[@SZ6&#DY6GWA$P2?\<0-3#LX4)>OFGP"\\:DN:!F$O
M/@O@(Z1GV?,`WOE[\$4`[^,]^#((1>8Z>F(XL;E$)_8]*DY)7EHI.\*VC$6*
M%O+,1_ZH^$6<9^QY!6<UXM\SG,TQ^!@8XQO5D?.J_@$3._JT;_,O````__\#
M`%!+`P04``8`"````"$`V'%5\B0(``"0)```&````'AL+W=O<FMS:&5E=',O
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M.2^GRRE$>KC;5)`!EGW2E-O[Z#%>J70931_N^@+]4Y6OK??_2;NK7W]IJLUO
MU;&$:L,\X0P\U?5G-/VT00B<I\Q;]3/P1S/9E-OB9=_]6;_^6E;/NPZF^QHR
MPL16FV^B;-=040ASE5QCI'6]!P+P[^1086M`18JO_>=KM>EV]U&ZN+J^F:4Q
MF$^>RK93%8:,)NN7MJL/_VJCV(3201(3!#Y-D&3QKD-J'.#3.KQK/S?V\/GC
M+(%2GRI\7AQDJLO6SX(HNN+AKJE?)]#:4)CV5.!"B5<0V)9?%VN8D+?F`R8"
M@SQBE/OH)II`J5MHHB\/\>SZ;OH%)GYM;+(1&VJ16PN<90PK0D"&@/*`*60T
MI`4S^3^DA5$P+4LHLX#+,PERL!;6182`#`'E`20':*XPA_F;*\/.!#K!&B`S
ML:`<,VV30.V&Z0HF*Q],ACP8(AFB?(2D`GT?IH*+_,(NPRCW40+U&GC'LYL@
M.6/T7G*#R9`<0R1#E(^0Y""1,+GD^NJ[,X5N?3:61::1N-\P^P60&R362XIF
M*H9!OQQN(@E'6-H^Q_'=U?80&E-F!DF'E9`S1#!$,D3Y".$'6\?Y_-"8\C,(
M3)'7&;>T7OE@9`LN&"(9HGR$4,8W$&_G?+^D:$PI&T1K&NYV.4,$0R1#E(\0
M?DO*#W?V17IU`UUSX;+#0)2[02"45^YE4.[!:"@W0R1#E(^0=&!97%#OWIJ2
MMI!7<0X)#DD.*0)1FJA(7EMH0>W+WNVJ]>>LAI*!S4B[I+#*C9QBD("]AF+2
MXO$LJ'ELK!;#0A46HHXQ=936RCDJ"U%'IW<T;10Q+^V1].!];,A/2Q[LY+8W
MLEA#L1/;G$."0Y)#BD"4)BK4^32-GODT-13#JG.M'Z>TFGD\6-G\A(5@._$<
MY]116JO;H3#*0;ZCDW2:'TS6!?FA==!F&H+\+/,<6PZL/$A8B";CI*?O8FFM
M7"Q%(,H<U>S\F=':1QI(0Z2!&"3PK0.3<6TF.:0(1&FB@IU/T^B=WT`:"AHH
M>(G)X\'*3H.P$*TY:R#FJ*PC;5DGCC0_E+OS\T/KH($TY'5+#L5F#60@^/!6
M`VL@YJA(+,H<A?!\YD8V_9G1D-<:.<X2[1;!(<DA12!*$P7.HXGZ<,[;8FR$
MT2>L(1SQBAC*L'$$1JZ5C".I?A)HB>2.RD+4\0U)2"X2[-Z:MI*!X*&6>6XA
M+QD+44ZAOEDKYZ@L1!W=5DZF#;\L^=/VOK[UUD$R1IG]9`SD.`GK.&0L#>)-
MG[(0)>YV`DK\(F'&[U;!@C:0ORPX)#@D.:0(1&E>),P)%V8#X<)SBR$)=I3<
M6=F6$A:BU73ZJK7,6KFY4@[RG_C&OII<),R]==`_3(5S8^6UAK`03290%VFM
M_&3\\'1F4#&]#>L[G:_U%2;:%CC#<SBZB>8<$AR2'%($HC11^,ZGJ662T#3*
M27;3)-Q-\5P0DW&E$Q8B-4_#W=1:.4?E(*^!4K=ST?P@_`7YH7700!HBNZF!
M'">1&`@^O&7$&H@Y*NO8QZ+,443/GQDMN61FF`KG"8,$AR2'%($H313%\VEJ
M"24TC:H"-5>ZU(FC/M%)!BN[0(2%2,U3)T1F!V*.RCK2)[H]C^277B3'O35M
M(`-YK9]S2%B()N/$22=CK5SG*0)1YA=I;ZI5U9\9"WG?_#DD."0YI`A$:09*
MBV]VZ2W>6EQZX))R%;80!/.:*U"IW%D-S<4AR2%%()K51<*<<F&VD#M9R#DD
M."0YI`A$:5ZDKZE6.](C!H)5XA78;7ST:2AI9^\5J19`\C0#^1W)(&$=G97D
MD"(0I1EH8G\6-8/FNO``,.5J:2$@[97+O?SHS<Y9N7XTL?R<&*2((\T)I>?\
MTFNA(J4WD".0IPP2')(<4@2B-%&@/)I8^A\[?4VUU)$4#$2+'[ZJ6$>7J."0
MY)`B$,T*-<C+ZOUW0;@V#E]"##3'MT,=65\,ZRO)0]D\EWFYW[>3=?V"E[YS
MO/D88'TCG:4W<"7='^"PD5L8Z34E'(EG*SRTA<>&(RE></?7P6PD@9'^19:-
MI##27X:PD6L8Z2O.1A8PTF^"P0C<L#^./@6(C?("6J/V2&HDP\?YZE'?X`</
MSN8KN-0:*0DP'2.:0=U'RPY5'RWZ<@7'^3P^?'."#$:?G"Q6&;Q)<I\<1O+1
M$0DC<G0$7K#A.6/1LF2YRN"%8^PYRQ6^UO`1"3YR=`3>PZ#R8SY9#,^!K^L\
M6@XC^>@(G+M`/F,^&=0M&ZT;?*^%:&,5E3""W_<X@RR&:'`>RT?@^'J%I[Y\
M!,ZG5WBLRT?@F!JZ=6PDBV%.]>E!T']PR@G/&9L?"2-R=`1.,^$YO<]T"`>_
M!SD5S^7O1?-<'=O)OMS"UC'K[UP:_8L2_4=7G_J[EZ>Z@U^"]/_=P2]_2KA\
MF^%][;:N._L'I#@=?DOT\!\```#__P,`4$L#!!0`!@`(````(0#8$5]N8`4`
M`+86```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%A=;^HX$'U?:?]#
ME'=([!`@"+BZ2=7=*^V55JO]>`[!0%02HR0M[;_?<<;$'RD!^M*6SO%P?&9\
M)O'RVWMQ=-Y85>>\7+ED[+L.*S.^S<O]ROWG[^?1W'7J)BVWZ9&7;.5^L-K]
MMO[UE^695R_U@;'&@0QEO7(/37-:>%Z='5B1UF-^8B5$=KPJT@8^5GNO/E4L
MW;:+BJ-'?7_J%6E>NIAA4=V3@^]V><:>>/9:L++!)!4[I@WPKP_YJ;YD*[)[
MTA5I]?)Z&F6\.$&*37[,FX\VJ>L4V>+'ON15NCG"OM_)),TNN=L/O?1%GE6\
MYKMF#.D\)-K?<^1%'F1:+[<Y[$#([E1LMW*_DT424-=;+UN!_LW9N=;^=NH#
M/_]6Y=L_\I*!VE`G48$-YR\"^F,K_@6+O=[JY[8"?U;.ENW2UV/S%S__SO+]
MH8%RA[`CL;'%]N.)U1DH"FG&-!29,GX$`O#3*7+1&J!(^M[^/N?;YK!R@^DX
MG/D!`;BS877SG(N4KI.]U@TO_D,0D:DP"95)`F`OXW1,YR$)I[>S>,BHW>!3
MVJ3K9<7/#G0-?&=]2D4/D@5DONP,>71[O;95V*-(\EUD:7/!+FJHS]MZ-EMZ
M;R!I)B$Q0F:NTT&(B4@N"%$)8-=1A(W;%`,HX>?B7QB)128C:C/Z!&(QZB/"
MJ(,8'$$ZG>,P-P&&%M"DF,V[M*V@,4(F&B0T$<D0PJ`&2>ZG)L`K%_;=56FF
M=HS4$#)OJSR:^U%@$3/BH>_3+F[0@L;7:8G&NUU5L<A4;NYWZ9$>0H!$MP-;
MN2&$07%J4APNJ@";RLVM!H\1$K;*$:H)TS)/C'#@*UT-4G""=-V&20FP14J5
M`_5"R*0E%:CO1$IZ,%3;,0B)(6<YR.U"BD46,>N[8X0@,:O(B1ZC4]6A!K'H
M*\3$(HO8Q.HPA""QV=2BG>A11=L@1L"]=,F&:]BB+4I62\<2@YQ"RTP2(WJ-
MDS4(;G!"K]9]8CZU9"*(^;R`1C"XQDGX[\.M1="U#6ZV]4O,%6Z8`(.CJ3;)
MS"H*!WZ<'?HV_.S\:6[5*R9#WHX'<Q!BTA1^K-&\45AT;T,\=;S0,0ABKHBG
M!XDZ.B:G+YF_>.*RSF:@/$ERNYB[>`:9^ZJQI&QZ>$0"=8Y,?@\Y/^E;OY98
M\D(,:M:S69D!H]<T>\CX2=_Y@UZ;Z>Y.YE:9$YD"2:FI80IEF?^-YNJ[?F15
M*":ZM5O!Q`B.KG&R?/\&I[[A1[VF0@P.[E'H$]4VLJT,P(1,U%`PY*(/&7^+
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M%?0]2]5TUP_)1+53&T]D$F0^":\]1XJ7I<>/:KO*'`[$?J.,)6C(4@8AAH+!
M0].A19MO+41[I44%)0B]Q#ZM5X(F)V'5FLT-NS!<$=H&0GRKGV()PON-'B?,
M8`>1$UX?XNU:P:H]2]CQ6#L9?Q57@P3>L+O_XK5E#->6[1V?UP7@UO"4[MG/
MM-KG9>T<V0Z6^N,9V%J%]X[XH>&G]G9KPQNX+VS_/,#],(/+.'\,X!WGS>6#
MN$_K;IS7_P,``/__`P!02P,$%``&``@````A`()G]#U``P``[0D``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C$N>&ULE%9=;YLP%'V?M/^`_%X^0Y*BD*H)
M=*NT2=.TCV<'3+`*&-E.T_[[7>-`^.B:-`\0;@Z'<\Z]V%G=O92%\4RXH*P*
MD6/:R"!5PE):[4/T^]?#S1(90N(JQ06K2(A>B4!WZ\^?5D?&GT1.B#2`H1(A
MRJ6L`\L224Y*+$Q6DPI^R1@OL81+OK=$S0E.FYO*PG)M>VZ5F%9(,P3\&@Z6
M930A$4L.):FD)N&DP!+TBYS6HF4KDVOH2LR?#O5-PLH:*':TH/*U(45&F02/
M^XIQO"O`]XLSPTG+W5Q,Z$N:<"98)DV@L[30J>=;Z]8"IO4JI>!`Q6YPDH7H
MW@GB!;+6JR:?/Y0<1>^[(7)V_,)I^HU6!,*&-JD&[!A[4M#'5)7@9FMR]T/3
M@!_<2$F&#X7\R8Y?"=WG$KKM@R'E*TA?(R(2"!1H3-=73`DK0``<C9*JR8!`
M\$MS/M)4YB'RYJ:_L#T'X,:."/E`%24RDH.0K/RK0<Z)2I.X)Q(XGT@<WYRY
M_F+Y$1;OQ#([L[BFN_0=?_X!+:"Z,03G#QNR=#A-UA&6>+WB[&C`_()]46/U
M-C@!$+<AZTBZV/^7.L2M2.X52X@6R(!`!4S*\]ISEROK&=J;G#`;C8%CA_%'
MD.V4QAF21"U"M5L].6Y9U22!I<X7-*SOZ^VA:>4KL)+?LF[:PEFK.Q2RO8B(
MI@C_=D@2:T@_$L\]8P9^8(2N]Z/``S_CPG9<B,:%6!<&VCR[TS_0!F/=UZ9F
MR(/7_?W,U4T#C>/"=ER(QH58%X8:SQ,ST`BSW=?XOC8%#A%TIQM5SQL-P$9C
M0$&'\;MTFM'<7D1$%Q&Q1BR;5VIAJT_WD(&]^=#>=2U0-XUM>AU_8V*C,>_9
MO(B(+B)BC7`<IS'JF]IJXU<=W/CF'/_`-RPY_;9>YUO=-/8]&_G6F%/P<Z\?
MO.[N)4#4!YR[IE<M_=O;J6I_>EO42W5)^)YL25$((V$'M>7YD%-7[7;C^YE:
MP4;UK1/`JCFM;]Q@\R;>#>#-F^(C-X`7$.I6]P#8;6N\)]\QW]-*&`7)0)IM
M+F!HN=ZO]85D=;/1[)B$?;;YFL/?*@+KMVT".&-,MA?J`=T?M?4_````__\#
M`%!+`P04``8`"````"$`D@:GV9T4```A;@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RLG5MSW+B.Q]^W:K^#R^^Q6^J[*\FIN'6_;FV=/>?9XW02
MU]CNE.VY??L%14(@^%?:[IQY&6=^`B`(!$B"+;??_^//A_NSW_=/SW>'QP_G
MT<7L_&S_>'OX?/?X]</Y__TS>[<Y/WM^N7G\?'-_>-Q_./]K_WS^CX___5_O
M_S@\_?K\;;]_.2,+C\\?SK^]O'R_NKQ\OOVV?[AYOCA\WS_2E2^'IX>;%_K?
MIZ^7S]^?]C>?!Z6'^\MX-EM=/MS</9Y;"U=/;[%Q^/+E[G:?'&Y_>]@_OE@C
M3_O[FQ?R__G;W?=GMO9P^Q9S#S=/O_[V_=WMX>$[F?CE[O[NY:_!Z/G9P^U5
M^?7Q\'3SRST]]Y_1XN:6;0__`^8?[FZ?#L^'+R\79.[2.HK/O+W<7I*EC^\_
MW]$3F+"?/>V_?#C_%%WUZ_GYY<?W0X#^=;?_X]G[]]GSM\,?^=/=Y^;N<4_1
MIG$R(_#+X?"K$2T_&T3*EZ"=#2/P/T]GG_=?;GZ[?_G?PQ_%_N[KMQ<:[B4]
MD7FPJ\]_)?OG6XHHF;F(E\;2[>&>'*#_GCW<F=2@B-S\^>$\IAO??7[Y]N%\
MOKI8KF?SB,3/?MD_OV1WQN3YV>UOSR^'AW];H<B9LD;FS@C]=$86%^MHMIVO
MR<81O873HY\_?W.ZQ?`$]-,9B39ONOO**=)/OOMQ=]=.@7Z.CQEOEM%R96)U
MY#FIV`87Z>=I+FZ=(OUDQ>7%FVX9428-]S3_<+KTH$><C#@5S#^<1CR[6,3+
M]69(AF.ZE#[V;EX>'8])Q$EC_N%NMWCCLW'>1)(X;QQS4QK64?K'F^YZ:0MF
MJ+_DYN7FX_NGPQ]G-*E1E)Z_WY@I,KHR9KGR;)C&6OQ1*5(-&BN?C)D/YY12
M5&7/-'_\_C&>+=Y?_DXU?^MDKE$FTA([EC`%;LPF(4A#D(4@#T$1@C($50CJ
M$#0A:$/0A:#WP"7%>@PXI=;?$7!CQ@2<0W7-P!N!(+HLP2I)"-(09"'(0U"$
MH`Q!%8(Z!$T(VA!T(>@]H*)+50C175!:3R\DG+U&BY8,E;U+';UK*Q/3L(XI
M'HCL1I$QPD!2(!F0'$@!I`12`:F!-$!:(!V0WB<JVC1Q0;3-)'+BY&',T-I-
M8SJ&-IZM@O@[H6/Q'T7&^`-)@61`<B`%D!)(!:0&T@!I@71`>I^H^%.H5?R/
M9[F1'L+,X;FVA-96)CM'HF$*#X8@&2_ZX[0>QTFY1JOT":X9:>V:(\.><U@+
M=D`2("F0#$@.I`!2`JF`U$`:("V0#DCO$Q5"6DU/"*&1UB%TA++'*ZO-.%PV
MJJ,0IT`")`62`<F!%$!*(!60&D@#I`72`>E]HJ)J6D9_PW.\9HRTCJHCM@LQ
MFY0=D`1("B0#D@,I@)1`*B`UD`9("Z0#TOM$A9#V\2J$9L^XI(GYQ&G?F-&Q
M=83F&2]CMT'&CD)CQ@))@61`<B`%D!)(!:0&T@!I@71`>I^H<)O>1\7[>,H.
MXCJNC+RD190@2A%EB')$!:(2486H1M0@:A%UB'J%=$C-[MR?!7XRA4V3&>0P
M(Y7$T2Q(8I$:LQA1BBA#E",J$)6(*D0UH@91BZA#U"NDPV^V[W[X7\EHN]NG
M#2('ZSIRR,]H0`E*I8@R1#FB`E&)J$)4(VH0M8@Z1+U".J1FD^Z'U&3T?&..
MRTZ=E\U11IC4#NFDAO9]E.)Q2MB6C%.**$.4(RH0E8@J1#6B!E&+J$/4*Z1'
MP&S3_1%X):G=KMY/:H<D6#MS-F3&0E""*$64(<H1%8A*1!6B&E&#J$74(>H5
MTB&E?#LEI$8\6/D<THD;A[/Q*"6)"R@UG:T>BPQ1CJA`5"*J$-6(&D0MH@Y1
MKY".LNE`3DA<U[#XB>O0:IR@=Q&@!%&**$.4(RH0E8@J1#6B!E&+J$/4*Z1#
M:MH//Z1F-HZ7%Y1!)VZ2(]?(^-%VB(S)-CF:ASD]2DE.`TK9O,PO&:(<48&H
M1%0AJA$UB%I$':)>(3T`IGGQ!^"5R=CU.GZ4_?;']LH1H`11BBA#E",J$)6(
M*D0UH@91BZA#U"ND0VH:%#^D)J>CY87Y=.SEV]WMK]<'`R;/6N=TGC3$\%/D
MVAP_TA;-O6,H)S6W']#9CP*LU)+V&%[6!Y\QI$Z1I#CK,T0Y(SD^+QAI\\$)
M;RE2;+Y"5"-J$+4.V6=4D8[#AN^G(CU8T:NA0WZD&7F19A2[SW'"J25U`BL)
M7P8ZP1*;.X&EZ!2,EC^X3RD"8[0=6FW&\:T1-0[-QR<(O&E98'AJ'?NP,SP^
M<9C/`X(MAT-SG4G!6>J.I1;C@R2,:.4<,SQ:!YUCRE*BF#FTH@H9%>-(#F:'
MRLM1L6#DKR31*CAP*5EJ-8Q3=+$.BJYB`7&I9B1UV#@4>!F<1[:L.-C2(W-:
MTV@^3@A'QJ(%C9D7I^!Q=TYQ+IF:.+0@_5%Q8F2L>4\Q<XKKV1"Z8"ASO%/!
M=Y)R+!G99`YL5'Q5/5,<2-4BQ974.#3M6NNNVF?1PV":/'\9>*5`C'@P"UFD
M"R0.F\G824E2)8S\/)\8!E#,G.+:?JP172R#S5+.EN5F!2/)X)+1UA;"(LC=
MBJ^3`V.:Q#@6X^/+6%BT]O,KCF'2\A],C\EIK6>,K:=#NC3B($P[)^5E>,**
MONL38V+OZ"EF3I'>*O*#%4PM.=ZQX#OZ)6+-4WV:-P]F%^M@[JM$Q[\95(DS
M(Y:;:2^#;4&KO-0C0U/K*=5BQ(-JL2BH%EA.G)0D<&).?LC6_)5J`<7,*0;9
M&(0T9_-RQX*17S(33L0Q%(Z3$L4:;37L%XV25UZ!7RTK#G[IL3`MZ0DSE^M@
MO9UJ;%%0);"`6"DOV1-6?*5*0#%SBM.S=.ZN>G<J^$Z2PR6C'RP@D\\$I3%*
MR:1ET;1KK7)-#X/I0D\8!M>T^L,`?>PN!I0@2A%EB')$!:(2486H1M0@:A%U
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MLE:*T%$_)Z3BN>R>M9^G+;:FRPD66X>BF?>IU`1+)E@ZP;()ED^P8H*5$ZR:
M8/4$:R98.\&Z"=9KI@*\")=>2=T3/Z(:+.E5F1%5_[B@Q8MP.RE2/)DGB%)$
M&:(<48&H1%0AJA$UB%I$':)>(3T`X9[B^$["-)U!AC/RMI.($D0IH@Q1CJA`
M5"*J$-6(&D0MH@Y1KY`.J=EY^`O(*R&U&Q5_V3!'O";*.G%E5V@_"!0I2=Q1
MD5&*4AFB'%&!J$14(:H1-8A:1!VB7B$=9;-O.B'*=INEHNR0G[B`D@6@%%&&
M*$=4("H158AJ1`VB%E&'J%=(A]1L[$X(J=T'JI!:1%T-Y]]NX9`<!24.T;L@
M+)4BRE`Q1ZD"48F*%4O-=$5)US)45.V)L6<-6FM93/SO$/5*4<?9;$=/B+,1
M#U8VBU2<'?+C;)&*,Z#,_&(2F?<^Y<X=\A0+1"4J5BP5Q%FZ+A=GYP6)29S!
MC9:MB52'J%=NZ#B;3?0)<;9[;I7/%JDX.^3'V2(O7.D"4.:0BK.3"L(5I&7!
MQKQPE6BM\L3\_8ZTDB[X<E,)OF6>;^T/K$F;-UCK/#&VUBO?](B8)N&$$;$]
MA1H1B]2(..2/B$5J1`!E"U#,'8J"$9%6<7CJPA/CIR[16N6)^2,B;9P;$>>:
M-[X-6FM_8$U:+#<B:*U7UO2(A)V8V8"?_#[-`ALTA]1`62DORQ(GI=^G64@W
M-CQ2*E(<[8S-RZ#G(N4%>QEL]PN18ELEVJI$RK<5[,!JD6);#=IJ1<JW%11Y
M)U)LJU>V]*B=UI<NL"]UR!N+':+$(7JYBIU*&4D_FZ%BSE*B6#`2Q1(5*Y82
MQ1I1@XHM2G6,Y(Z]4E0A74YUHB<7PF!%K]4.Z8].P\_^=RPE'V0FC.3SR-2A
M]7KXB#G>KK>S\)<Z,E832SDCVLJ.C3"\85.PE'NQX,([A!S*L&0!L5PYM/;>
MA!(D-XN7P2K4H*UV2A&\[%B*4EJ>)7P_J5?F]3B'#6\XX?WS\/U'+Q!20\9O
M$)K?-`LV90Z9QG#T+%X&"^;.27F?EB:B.%:90QO[RDX\6R]GLV`FR]!2+I;$
M!0AAP5+NQ;2+\*V7$BU7#FUDOJT1-:C8HE3'2([/>Z6HQ^NT;GJ)W;1#00$&
M2_J.I22Y$T9^`5KSK@#?S=<+^LX2_<YSQFIB*6?T2@%:XW1<9E\@P0)T`F*Y
M$LN<.S6BAI$HMHSDX3I&VW&V[QD-BGI<3%_L;^7".GK3B[AFX0_+R**@C((]
MT\XIJC)RBN)^ZJ0VYLW?WS^^BVD>"M\CS=!2[I!9+,9*GB@C>S^::H9O&KGP
MCN?=?&D%/!\KMNR7T?B\/((-NM2B8L?(+R/_CGJX3NOME]C;.S27'-HA2AS:
MB%3*2);T#!5SEA+%@I$HEJA8(:H1-8A:1)U#&V_'H*1T2$W'^I]7@.U[_1YG
M:5%0`<$^?^>DO.Q*1)%3*77(+22+Q9*FK&#JR]!2+I:.5H!SU"XD]$YNX&.)
MEBMV2%YLK07)S>)ET`0T:*N=4H0Z[5AJ,]1I-)]M8"WME7$]RJ8U/C;*;]PO
MV`Y;#;-KNJEFQUEF8K_@I*0NDN6H*,-LD5N7HLCL%\)E"0SE8D@\@/@5+,7[
MPO#-ZY(%Q,7*H8W,Q36B!A5;E.H<VLJA8J\4]7"9[M<?KN.'[_2;`+#^6!14
M7U`S.Z>HJF]4E&&QR%7?NW@;K5:!I0PMY0XI%R;&Q=UO?-\TJ)@2+5=BF7VL
M$36HV*)4Q\A??ZQ+-BIZ7/Z6<X8EGC,X%.SN8+O@CAXD11.G2,>T'(K4H:U]
M0_O=8G+7#99RL72TC*PB'5>Z[4*P;RSY2<2ABI%LTFI$#2-1;!F)8L=(2K)G
M-"CJX3KM@&&)!PP.>06R0Y0XM)4<2AF)ZQDJYBPEB@4C42Q1L4)4(VH0M8@Z
M1M+]]HR&Y4V%=/6W'#`,5O0!@T.Z`E;!]+]C*4F2Q"&O>4\=VBZ&))UO9HOE
M)K"4H:5<+!VK`)8:%Y)PPD++%>M(B&M!<K-X%513@[;:*4685CLGY4*PG=.7
ML`81Z)5M/<A_S^G""D\7'/+K"5'BT%:VS"DCV=-FJ)BSE"@6C$2Q1,6*I42Q
M1M2@8HM2'2.Y8Z\4=:A-,^RO]#_5@*YL2^WORQP*ZBDXK]VQE%]/UI:J)XM<
M,L7;63R?!6M3AI9RA\B2I#AD:L%27$^KP'*)EBO6\>MI=%MN%J^"S^P:M-6*
M+5$$+SLGQ?4TFT_4D_7`MI9ZD$U#"X-,WZI+@3&_[<N;[[?_ZN_*MLAJP"U2
MVZUX%9Q8[IRB5X")0]ZA6,I(UJ4,%7.'MK1=&K?^$+F"I5SCLL$SP!)M5PYY
M3M6(&E1L4:IC)$_3*T4]5N$10UB0/%C'M^0K/'IPR#]Z0)0@2AWR^OD,I7*'
MMK(S*AR*9M)TE*A9(:H1-8A:1)U#GJ^]DM*Q-ITWU,6IOP:_LOV[J@77TJM#
M[%5XB.T452V,BN-VVDG1.SR,,E3,'=J\4@O6?#0;?WL2)CLKX?E4L0/>:1NB
M!GUJ4:IC)`_3*T4]/*;7AN'YCZ8MV[VKH7(-O3H_"-O+W0K:_H21;)131E("
M&2-9X'*'HAG-U\?F+7O+:&:/71>+%9ZXE&B^8B1^U8@:1N)7RT@4.T;R0#VC
M05$/EVE;8;B\:GKCS&6[7S5&%GE)N:,O+!C>MY$#L`11RDC6Z8R1*.8.>=N]
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M9)2B5(8H1U0@*A%5B&I$#:(648>H5TA'.>R37XDR-L'F*S`HRM[FR/Z='/MW
M.A[V3U_WN_W]_?/9[>$W\S=PZ"7/C^]';/]`S_4BOC*O[%.XX<J<K@RK4GAE
MM;TR4^*$SGI&?^]G:,!"G;7Y2T##KAZND`<4I@EKT>K*?%?>U)4U71FV*J&U
M:$-7AGU->"4F'?I5^`EK,>G0KV]/7:$GI=]"GK@2T9/:7V4+[Q/1D])7V$[I
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MZ]WC\]G]_@M-7O3E/+2:/-D_\67_Y\6]]O?+X87^--?P!N`W^E-L>_IN_9DY
M;OQR.+SP_Y@;C'_<[>/_"P```/__`P!02P,$%``&``@````A`,;_7"2)`@``
MFP8``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULE%5=;YLP%'V?M/]@
M^;T80I*V**1*5W6KM$K3M(]GQQBPBC&RG:;]][O77FFR1A-]0?AR?,[]9G7U
MI#OR**U3IB]IEJ24R%Z82O5-27_^N#V[H,1YWE>\,[TLZ;-T]&K]\<-J;^R#
M:Z7T!!AZ5]+6^Z%@S(E6:NX2,\@>OM3&:N[A:!OF!BMY%2[ICLW2=,DT5SV-
M#(6=PF'J6@EY8\1.R]Y'$BL[[L%_UZK!O;!I,85.<_NP&\Z$T0-0;%6G_',@
MI42+XJ[IC>7;#N)^RN9<O'"'PQMZK80USM0^`3H6'7T;\R6[9,"T7E4*(L"T
M$ROKDFZRXOJ"LO4JY.>7DGMW\$Y<:_:?K:J^JEY"LJ%,6("M,0\(O:O0!)?9
MF]NWH0#?+*EDS7>=_V[V7Z1J6@_57D!`&%=1/=]()R"A0)/,%L@D3`<.P)-H
MA9T!">%/)9V!L*I\6])\F2S.TSP#.-E*YV\54E(B=LX;_3N"LN!4Y`JNW7#/
MURMK]@3*#6@W<&R>K`#BT[Z`$XC=(+BDYY2`C(/\/:[S-%VQ1PA:_,5<1PP\
M1TPV(AB(CLJ@-ET9P:B,64%7KJ/A4&9V6B9_CPR"(:T'SN?IJ_M1.6+F!YC%
M:66`3`\0P5!:"&O,6YZ^AA2E(VB"-/3#=&D$!^DQN=&2I9='WN2GPUR^1PO!
MQUK1DLU"EQ[V![3980PX+<MY`J[]OT?QVK%"M&3'59V?#@97[>1Q0/"Q5+3,
M7V.)RR!.G):VD9]DUSDBS`X'?08S-%K'';0)N?C7/B\V83>Q\0/LAH$W\I[;
M1O6.=+(&RC0YAQ39N%WBP9LAS/G6>-@*X;6%GX"$,4HQG[4Q_N6`^VO\K:S_
M````__\#`%!+`P04``8`"````"$`<SYXT[("``##!@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6R455MOFS`8?9^T_V#Y/9A+TB0HI&J#NE5:I6G:
MY=DQ!JQ@C&RG:?_]/N.$YM)U[0M@<WQ\SOD^S.+Z23;HD6LC5)OA*`@QXBU3
MA6BK#/_Z>3>:860L;0O:J)9G^)D;?+W\_&FQ4WIC:LXM`H;69+BVMDL),:SF
MDII`=;R%-Z72DEH8ZHJ83G-:](MD0^(PO"*2BA9[AE2_AT.5I6`\5VPK>6L]
MB>8-M:#?U*(S!S;)WD,GJ=YLNQ%3L@.*M6B$?>Y),9(LO:]:I>FZ`=]/T9BR
M`W<_N*"7@FEE5&D#H"->Z*7G.9D38%HN"@$.7.Q(\S+#-U&:CS%9+OI\?@N^
M,T?/R-1J]T6+XIMH.80-97(%6"NU<=#[PDW!8G*Q^JXOP'>-"E[2;6-_J-U7
M+JK:0K4G8,CY2HOGG!L&@0)-$$\<$U,-"(`KDL)U!@1"G_K[3A2VSG!R%4RF
M81(!'*VYL7?"46+$ML8J^<>#HCV5)XGW)`FHW[^//TPRWI/`_:`$^-Y60+R;
M/IR<6KI<:+5#T'"@UW34M6^4`N$A%>]AR.E?,4$^CN3&L61XBA$D8*"TC\LD
MCA?D$>K!]IC;2\P98O4*8G9*DGL(7(>-7D@(6!I\0=+'OEZO\D&^`SOYKNK.
MS^WYQ.I\(O<3QT*2.!G$GDB!XAQ+<1$GT+YO2W*+,@R[#$:3>#SP>Y4>,^OS
M'DVA%<=A&)YB5B>8J]E\'%U@<H^!Z@][30:6$R<`^;@3M^C<R0N_=^(QKROH
M$:O_(N#L</OX-*()N#PVZFWXP\'WO^2ZXBO>-`8QM74??@)!#K/#F703N[8X
MF[^-4NB1R_E5E$*KP#P9%L`9TM&*/U!=B=:@AI>P51A,X=#0_A3R`ZNZ_FM<
M*PNG1_]8P\^"0SN&`8!+I>QAX#88?C_+OP```/__`P!02P,$%``&``@````A
M`,RJ;TS("P``ZS8``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK)M;
M<^(Z$L??MVJ_`\7[`#9W*LFI@*_<:^OL[C-#G(0:P"E@)C/?_K2L;DOJ]I#A
MG,E#2'YN_6UU2W*K;>[^^'[8U[YEI_,N/][7O4:K7LN.V_QI=WRYK__WS^C3
MH%X[7S;'I\T^/V;W]1_9N?['P[__=?>>G[Z<7[/L4@.%X_F^_GJYO(V:S?/V
M-3MLSHW\+3O"D>?\=-A<X-_32_/\=LHV3T6CP[[IMUJ]YF&S.]:UPNCT*QKY
M\_-NFP7Y]NLA.UZTR"G;;RYP_>?7W=N9U`[;7Y$[;$Y?OKY]VN:'-Y#XO-OO
M+C\*T7KML!VE+\?\M/F\AWY_]SJ;+6D7_PCYPVY[RL_Y\Z4!<DU]H;+/P^:P
M"4H/=T\[Z(%R>^V4/=_7'[W1NMVN-Q_N"@?];Y>]GZV_:^?7_#T^[9[FNV,&
MWH8XJ0A\SO,ORC1]4@@:-T7KJ(C`^E1[RIXW7_>7_^3O2;9[>;U`N+O0(]6Q
MT=./(#MOP:,@T_"[2FF;[^$"X'?ML%-#`SRR^5Y\ON^>+J_W]7:OT>VWVAZ8
MUSYGYTNT4Y+UVO;K^9(?_J^-/)32(CZ*P">*^)V&UVGU;M!HHP9\HD:GT?&[
M_<$M%P*77/0&/E%D<+M(#T7@$T7ZC4&WV^D-^K_NDCZ*P&?9G=*M5UP)\[+H
M`7QB.Z]EG?U*RR&VA,^_?]D>A5+]@3*#F\>#U\%K47^@BF\%XDHOU-C5`]+$
M<-CP!UVO6XPFV;2I1W0Q08+-9?-P=\K?:[#JP)@]OVW4&N:-/`@F30TM44Z6
MG\T5F"1*Y5')W-<ACC`-SC#!OSVTO>%=\QM,RBW:C*6-YUI,R$+-0"4;<!!R
M$'$0<Y!PD'(PY6#&P9R#!0=+#E8<K"W0!.>7$8`Q]#LBH&14!,AW8P(F)#YS
M-UE0DX"#D(.(@YB#A(.4@RD',P[F'"PX6'*PXF!M`<?=L'3^#G<K&;@-6`/>
M[[/A/-8V/@2^G!5=%H+2I(R!(*$@D2"Q((D@J2!306:"S`59"+(49"7(VB9.
M0&#U^QT!43+W=1_"7CJ[[;=<=X_1Z%I$2I,R(H*$@D2"Q((D@J2"3`69"3(7
M9"'(4I"5(&N;.!&!FXH3D>HTB99^95TXGAPV1@(?92C\?M\-Q:0THF:!(*$@
MD2"Q((D@J2!306:"S`59"+(49"7(VB:.G^%V>X.?E;7K9R0Z8U7WRXD@@2"A
M()$@L2")(*D@4T%F@LP%60BR%&0ER-HFCE,A![G!J<K:=:HFD&'1N)QHTC6W
MUD#8A()$HE6,-BT8#]:\&+CS(C%6=`&I1NUB.^'T5>U/9?+64!GXY76W_3+.
MX42PV%5,X#8D:3IU4R*N"S2Q7:")[0(DL*I;?6$97U@:45<B(127-I;0@*W;
M26E$0JDF%3Z!S-[Q247?8<-%G5?6;N<U@=VH?3WLSCY!HTXY2`(D9MB$FG0'
M.AOVNT-OT'-C'0F9N)0Q9_=ZS*T)&O4*9:\Q9$E%:LLZX\6#G?,-SBG,7>\@
MZMAW4+_++F""5FUKRIB&%,(0T:!5]&,XZ,+^D3E("L52*"'DHT-X(I8Z,JY'
MH".W>$29,X]HY`Z8+HOTQ$,K:\00*NH>Q50,$?7[14<^>?W>P.NQ&V=$[8Q4
M3,A()82&Z!//:]D_;$"G9%Z(NAY2B?0_7F343ID[3B,VE%AO)]C0&4K8<%C.
MOA"M!FI5^_;P:=#IM/MM/I9T,TLIQF8=HY0@ZNI!V6ZTV:8I=2[(]91*<6U/
M75]Z/,R(_;(;8T3N6!JP*YB0E1D``2%K^4&$ZX_7:_O=%HMZ1,V,4DS(*"6$
MRO6&K4<I&50,'I5CWN`23$EMEVC$1@E;)R:JA`+#RXIM@`@:F@4'M6`@E#<M
MK\_N-9'4BJ560NBJ5NIHN8-%984W>`:32-LS&KF#12X\:&5"'*CJD7*662U"
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MKI=5+GR#EW7J;"]N:M$!Q\-MG`;N1*(`D54X"*55)%$L&R;2*I5H*AO.R.IZ
MX65NF5&7%E)M26:FXRN)UDY#U_6W[1)\N4M`Y+G]X<6%B65&_0F0.?'0)^!J
M+"V**M1BJ9989O:RQ]12RXRN;2K59I:9I=;IN(OHW#(CM8546UIFMAI;DE>6
M&:FM'34WG&I/8<^DOY6M^GIG`J.&3CE&U'62KR[;K$R,%34,")GB2TC(T1JP
MRF-DK$@K)F2T$D*N%L^WC!5I30D9K1DA1VO(^C@W5J2U(&2TEH1<+98,K8P5
M::T)%5IN;-5^QX[M!_<BO3UR@H@[)CL)$/6\B7H!1&W(:(/MM8?.CSO<`S(W
M67)(R"Q*$2+:_Q?%'U<HIE9&*"%DA-*/A:;4R@C-"!FA.2'8[IB,:,BJ&PNR
M,EI+0E>]N$(K['"W`SUV^[LFG4+:C;3:@MT0:;UC<R*MD;.YK(@T6M$^A5>7
M`E\;6+O/$)%5R(@08>74&WB\1A1+G43JI!_J3*7.3.K,"=G%$'_(-HH+J;6D
MAO;>1'AMA5;8W5Y%8&VON8%5^[X;`JNWB4Y@<>=HKROB$B<^6E&YE=5_`SIN
M1G5(R)1.(D18_^VU944\IE9&*"%DA-*/A:;4R@C-"!FA.2'8'UISEMV`%V1E
MM):$KKIMA5;8X:ZJ4?,YBXXMI-W0\HW[!ZNSW*#[N$&_.OHF9*7GK-^`=S?M
M'[9^!6CNS.#R/'33B=`*AS249N''[7DLA1*Z%%-725VA"IVIU)E)G3DA=PJS
MW&@AM9;4\*H35V1ERXO2Z]J1=X.M"A0WS&.L9]CYE$9.N;1B'J.5GL<0;#?:
M(MAH;@9^Z)?G,<'6J!SE?7ACDP=;""52*$5T16A*K<P5S0C9TQI/!Q_6M&:+
MUH(:&JTEH0^F=85\1;3M/CO1;M]6?2G,W>H+H@]NQV2EIS8\['&C$N!Q>RY3
M$S,%(T1T>_+\%H^NU$FD3OJASE3JS*3.G)`]U_PANZ:%U%I2P^M3F:QL>1E<
M1]X-+L@[4_EO[9C@R3\O_"#JP%ZJ'-1RAI.5>@<`WE*%QPH\Z%JY;49]2&T,
MBA`-O4*F8MV-T<+22:1.^J'.5.K,I,Z<D)TC^T.VQ5M(K24UO.JU%5G9\A5!
MMUWG!AU&RV\(NE)A$UVCGO,@AC\?F+312@<=7IE@^]4`#9R97BJ7"SG)8/I>
M]4PUEDH)-2N^I%`\Z4\)H5*GXNGL5"K-J)E1FA.R(^/S_BVDUI(:7O7<BJSP
M0HO7"-P)LW:TW:C#;:*,.KB3S_1?>[2B;MD\ZAH5\U&?47_W0[_:?LA.+]DD
MV^_/M6W^57VO`W80#W<EIB^=#$>/^B$H.P*/3$;JV0#$G1_Q6R-5O*XZ`M]A
M@8*K/`)?;GDL\A"N!0VJ[,<^"%7HC-OP)9D*_M@9/<+3)WGB<6<$[WA6\.X(
MWDFLX+T1O%8G.13.1JHJ)H]`D6JD2E#R")2<1JJ@)(]``6F45AZ!<M!(%7MD
M&RCNP!54'8G[(WAC3K8(!J.PRB?Q8`0ODTE[*!+#N2O=#KU7M539)H0CJBXJ
MCT`9%/I8=01*FG">XDBS'`_P5:.WS4NVV)Q>=L=S;9\]PY!M%0^\3_K+2OJ?
M"SZ)_)Q?X$M&Q4/)5_A2609O?K8:,/^?\_Q"_\!%-<NOJ3W\!0``__\#`%!+
M`P04``8`"````"$`1RE:1]X-``!?1@``&0```'AL+W=O<FMS:&5E=',O<VAE
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M#YO'U8^7XW]VOY+-]NGY2.D>TAV)&YL]_!EL#FN**,E<^4.AM-Z]T`70WYW7
MK2@-BLCJC_KGK^W#\?FVVQ]<^9.A-QR1?>?;YG",MD*SVUG_.!QWK_^75I[2
MDBJ^4J&?K#*Z&HY[?4^(G'#L*T?ZJ1R]X=7`'XXGYSP'RI-^\BGI["=.11=2
MWRG]5`[^]&.G&BE/^LF>XX]YCI4G_52>HX\YTO"L+Y9^*L>/QF6J/.GGA1?K
M4?')6J!D*]_^Z9AZG'CQ#W8AF1-I\#CEXA_L<N8LG&M/)_N#<11#0=Z3D78Z
M\:D+Y'1[.M_M8;B68ZD>FL'JN+J[V>]^=6B^H_@=WE=B]O1F0H4'I3QK,TS_
M;I32\!0J7X7,;9=JA\;?@::6GW?^N'=S_9.F@[6RN4<;S[:8LX48^T(V<$'H
M@L@%L0L2%Z0NR%R0NZ!P0>F"R@4+%RP-<$W!;S)`!?5/9$#(B`QP[.X9&"EQ
MPLT6[!*X('1!Y(+8!8D+4A=D+LA=4+B@=$'E@H4+E@:PPDTCZI\(MY"A!Y!5
M\$XYWTL;GQ+?C(JADX+&I,D!D!!(!"0&D@!)@61`<B`%D!)(!60!9&D2*R$T
M4?X3"1$RMUV?TMX$VQ_[=KCOE=&IC#0F34:`A$`B(#&0!$@*)`.2`RF`E$`J
M(`L@2Y-8&:'GCY61]@4:3_W"N@X\!^Q>$J]'*P(C%WT[%W-MQ8X!HA!1A"A&
ME"!*$66(<D0%HA)1A6B!:&DA*^ST]+T@[,+:#KLBH^81,`<2``F!1$!B(`F0
M%$@&)`=2`"F!5$`60)8FL8)*2Q(KJ&)]XP^O*`L7KG"$D!UO14C*J/*!4^6-
M45/D0$(@$9`82`(D!9(!R8$40$H@%9`%D*5)K!2(_;NYQ#P]G0AK.\Z*R"VA
M6!;.@01`0B`1D!A(`B0%D@')@11`2B`5D`60I4FLH-*>R0JJJ.O^1&R<+RUL
MH60'7!&[L-V52V/4%#:0$$@$)`:2`$F!9$!R(`60$D@%9`%D:1(K!V(7:B7A
M=&77YG:D&1FUC2A`%"**$,6($D0IH@Q1CJA`5"*J$"T0+2UD1UELG,SYX]-3
MN">W8+1&Y)J]9V37^LB9Q+45.P:(0D01HAA1@BA%E"'*$16(2D05H@6BI87L
MG(C=E9F3,Y4O-V-6X!4R*Q]0('HU8G+25B&B"%&,*$&4(LH0Y8@*1"6B"M$"
MT=)"=I3%GNF"**LMEEG>"MGE/7;+N['2Y0TH%$TP.Q<1HAA1@BA%E"'*$16(
M2D05H@6BI87LP(NMT06!5SLI,_`*Z<*=BXZ@';\`48@H0A0C2A"EB#)$.:("
M48FH0K1`M+20'66JRDNB+,R=QZ=$U#GEPIV++BI9#74C+%#(L`H11>@8LU6/
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MZ.\[SR6%[%J:.%<P9RM=``$C8PY22,U!WHAFH9Z3]8C=M%+,2"LEC)H)QYF1
M4C:H9>R0B'7XQX>7Z,*[(9'(J1)WPE&.5I4TCLV$HZSHLPKZ&>:YKQLCU(K9
M44]>":.36JFE94=&K(HOB(PP=\:/1':QP,3C*RN=XH"1GBU"1C0+-$_WELB`
M5LR.6BMA=%(K9:N6FG$7T9^;<'!M[4ODE!),.-+**B7E:$XX$M$T<3)@H!7S
M16BM1*'36JFRDM=EEY)8NIJE]+F`"16GPB2R*VSBS*MST3HDQ[Y981(-]7@)
ME977D\^VOYF/0"I6?B1E!!K61&S%*X`I3%&FLAT]L;`]%;W?=^]_MZZFT_**
MTI?K8QKP/-W<,])3Z1Q1@"A$%"&*$26(4D09HAQ1@:A$5"%:(%I:R([^9>MV
M']?MC"C!S=3E3]S7*=J*TQ,@"A%%B&)$":(4488H1U0@*A%5B!:(EA:R`W_9
M5L#'K0`CL[R5E48!6H6((D0QH@11BBA#E",J$)6(*D0+1$L+V5$6RVIS<CFS
M))2K<&L24<@N;UC_-%:ZO`&%/J`(48PH090BRA#EB`I$):(*T0+1TD)6X/ON
MKN5TX&MS^^''2-?R'%&`*$04(8H1)8A21!FB'%&!J$14(5H@6EK(CO)E.Q[J
MV[A+#(7,YA.B0"&C.1>B580H1L<$K5)$&3KF;'6ZJU<89CP62U2KV$R7UP+1
MTG*T0R^V-Q^?6<2G.YW5G4*>?3]NGVINF/']!(I9^9`G<-6<U774HA:C6F*8
MF4]U1RTUS/C:,E3+#3-#;>"L$0K#C-5*5*L,,U/-F9(7AAFK+2TU.YUB:V6F
M\U-K>+%2=[,LT9!^Z.71T.FUSI4C6?&U!HQT#R]D9&E-G+9VI*U8*V:DM1)&
MMI:[;-=6K)4QTEHY(TMKZMQCH:U8JV2DM2I&MI;3.%EH*]9:,JJU[-R*7:"9
MVS//(KEI-!<!M+>JMUCF(@`:PW.VXCZ-UY]:?^Q>?<#F>M\6,M*34J00MY'J
M'J(M%+.7%DH8::'TO%#&7EHH9Z2%"D:TX=(5/76:9"5;::V*T<DH+I25NN'A
M@.[8OM\EZ]32=J9)^I),"W-GU2&1U:-HR;2RXNVNVZ0,^M+`:&*$"I$REVRD
MD&K`>Q//;37&J).@3GI6)T.=''4*1F9/S9\Z_882M2IV/-DD6"@K=;NCEL2:
M4;,3ZS8)S@QA;`;T)1*S1%.U+8E55MRU=UXC!*RBJSIDI*?N2"'U&F'4QQ<K
M,7MIH821%DK/"V7LI85R1EJH8$0;D.;N_:GS`"[92FM5C$Z&;:&LU`T/Q:L.
M=\RJP-;2=FHOZT#0D((Q*]&Y,:NLY)CUK^B7",T_SOP5J/-8([@YCQ[!$JF2
MI@X__;'O/$:A1"%C*D@54D(M.AGJY*A3,+*'L+,V*E&K8L<S0[@)HJXCZ%,O
M+7D[V9=U/?K8]5#HW#B6CGTYCBG9=K8AV<I<%WZHSZ.3+:V:*A_3[Q"ZR0:A
M!(52A4X(9>REKRAG9`[KYC9U.ORI,VF5[*BU*D9GAG6+?$NVS7NVLRWZ'1<L
MO%1[Q&CA4@+%:#\WM)65'-KTSM#.2J!4J"PYEZ$69A0IQ(\GS^]!=N5Y#)T$
M==*S.IFR,'1RU"D8V4/9N:82M2IV/#.4FZ#IVFE)KGG+5G(';H?G4SNF6L5>
M@BDTH#5W\ZS")S5;B3<`/^_Z]#$<)^G*@!:+G.&0?32*%)IZM4S+O!NC3H(Z
MZ5F=#'5RU"D8T4JHN7E_ZFSQ2M2JV/%DU!9L9<ICTBUY.^FB@V2.Z,\E7:@X
M29=H9+W/<U\SS<4\0(XCF73ZZ(VS7PV4@3&R0O:I?\>]_A!6Q$@MW]M>S<>H
ME+";5DH9*:5!RTO^#)5R=M-*!2,S,[Y[?R5J5>QX,G(+ME(76G\:Q1XP2TO;
MSKKH+9W*^L=>T8GW_F[:):H'I#RE_!8"^:O.KYO]TV:^>7DY=-:['^(;!F@+
M<7?38/GU!_?^9"9>`=`PAR-3.E*_Z76/]'LST5=M\2&75@^//.C#[BT>'GW_
M`GWDNNV(3T?JQYE[?J]/1^HG.1P9T)$Z(,X1^IJ'K^U:Y-!V=CIYJSV=NNW,
M7P>SK_)K))P3W],5M5W0_7!&OQ77<MNC&?U>5PL?S^B7C5HXY:\M?=3IFXDV
M7HM'OS\3/3,\0CVRF>B`X1'J>,W2UB/4OYJ)[A3Z4#>*KJ#M"'W&="8^0(H^
M@3>:B<]AXA'ZW"7YM!VAWC9=06L2*0:B!8QJ(1T1[5P\0MU;NM.V(]2)I?.T
M':&7Y50M;==V[U/:Z#TFG>>Z*0SZ>H_WU=.F7.V?MF^'SLOFD09GK_XL[%Y^
M08C\SU&]N_^V.]+W>M2O\9_IBUPV],M@/?&[?(^[W9'_(T[0?#7,W5\```#_
M_P,`4$L#!!0`!@`(````(0`@S5*[80\``.U)```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;*R<6W/;.@Z`WW=F_T/&[W4L^>YI<J:QK?ME9^?L[K.;
M.(VG29RQW<OY]PN*@$`":AKW]*5N/@$0!1`D0=%^_\?WI\>+K]O#<;=_ONH%
M_4'O8OM\N[_;/7^ZZOWGS^C=K'=Q/&V>[S:/^^?M5>^O[;'WQ_4___'^V_[P
M^?BPW9XNP,+S\:KW<#J]+"XOC[</VZ?-L;]_V3[#E?O]X6ES@C\/GRZ/+X?M
MYJY1>GJ\#`>#R>739O?<LQ86A[?8V-_?[VZWJ_WMEZ?M\\D:.6P?-R=H__%A
M]W(D:T^W;S'WM#E\_O+R[G;_]`(F/NX>=Z>_&J.]BZ?;1?KI>7_8?'R$Y_X>
MC#:W9+OY0YE_VMT>]L?]_:D/YBYM0_4SSR_GEV#I^OW=#I[`N/WBL+V_ZGT(
M%O5HU+N\?M\XZ+^[[;>C\_^+X\/^6WS8W16[YRUX&^)D(O!QO_]L1-,[@T#Y
M4FE'303^=;BXV]YOOCR>_KW_EFQWGQY.$.XQ/)%YL,7=7ZOM\18\"F;ZX=A8
MNMT_0@/@WXNGG>D:X)'-]ZM>"#?>W9T>KGK#27\\'0P#$+_XN#V>HITQV;NX
M_7(\[9_^9X4"-&6-C-`(?**1$=MX10_NT-P</E%OU@]GXV`\,3=_17&"BO")
MBL'X37><HB)\HF+X)CU(EZ:E\$DW#/JC<#R=-7YZI:ESU(1/U)PXBF]T<`#]
MHKF_^8]N^%NM4+`#^`]:F?'CO]4*=!7;%NXSP:@_#0;SX?3M?288DAGX#_FT
M/QN/1Y/9.6:H[P7<^:9O-G-ILZ%)KM7FM+E^?]A_NX`1"QQT?-F8\2]8F'2B
MM+*!;A/M1WD&"6:L?#!FKGK0V2"%CC`X?+T>!N/WEU\AH6]1YD;+!+[$DB1,
M]AJS*PG6$D02Q!(D$J029!+D$A02E!)4$M0.N`1?MPZ'OO0['&[,&(>3JVX(
M<`1"X5V2()65!&L)(@EB"1()4@DR"7()"@E*"2H):@=XWH444]X=0;?NGB6H
M]QHMF`^<WAL.9.^U,B&$M>WB0F39BK0>5F2M2*1(K$BB2*I(IDBN2*%(J4BE
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M8;/`"P?!4+C57I^PRR*I(=8DL;T^9HT$R?@']TC;ZZU_+9G,VK50KDAAR;!M
MN6A'B=>UMZ&:\;S=T6.AA*,N:Z1]MUHR]+NCF-N6*-14SW;ABP02K.W%P70@
MW*W4(DLF\-&JA8$8T&.EEB`QV4G+]V`R]^^6HM"D"4S0GXJ<RI39',FP#4QA
MB6C?S+]1Z1KR>KZI"<\(1B/N1P/1R%U%A(%XTB5*#;E7KDC17:/H@&C%"-%T
MT+A-1##6"@G=B=,N)61[K["1T57OF4(AE;,4Y4V!J+MI)5ZU3O##`'<Z)PQ&
M7(3!(C\K0E4-HI23%J:>!UM#Z"+<4U5>D!0K1HBF`?;>L1BZ8JV3$.+^FQ*:
M6S,CT74SNNZENXY%^_@<"XNF;O\*0SE*D?GFP?R8F(+(G15>'Z<"(RYB8I&?
M&J%PTQ(5O=1`1?AX+296RE&,T-;4=Y885F)]QP01-)7\EQ+"%.E/Q:"7D0#X
MN6UEJ"/3.H$L%Z@H6BEF_1*ENK(%'N^<R!AQ$1F+1+;(.<1L,YG4X$Z_(O23
M;%&*$2J*WBA<&I-YOF-"R$T9-.\V(@Q5XK3/2([/M:V"V@4%D1-$T:Z2%#NR
MQ%129V0)%EYAV\]NS.8;>%EDB9I`K)33V5>D^),L48H1*G:/TC%>=>Z4T)W<
M[,!6_V`"Z7PF-8&T4A2AXD=-\T<F4V>=X7,LRUR?6]013E-_N*9_=?,2ZQ@W
M-L-`=-&;`*7<$40,`TN6(2>M-%IK%&D4:Y1HE&J4:91K5&A4:E1I5'O(#[6I
M6=QX_&02LB4.[/N0LVX"1.Y*-!RIA4$K18HK5B2TUBC2*-8HT2C5*-,HUZC0
MJ-2HTJCVD.]E4ZN<X65;VGA>1N3L4`0*K31::Q1I%&N4:)1JE&F4:U1H5&I4
M:51[R'>I*3G.<*D1%W.T16[Y'"#B<7B%"+9(N9=:*0=%6C'6BHE&J5;,2&K@
M9Y186.:.&+6LT-9*$N/V5QK5GJ+GY_"\`JX1]_V,R/4S(<?/B!RGKC6*M&*L
MI1*-4JV8D93PLU@^YXY8ZV=MK20QQ\\:U9ZB[V=33;R]/YN7&J(_(_+\;*7L
MCI3=I4`IS\]6RD$1V>(`Q:0HW"6Z9>*(D;M2;2USQ)QUX4A4$KDC1M8*;:UT
MQ%QK8JJO'#&R5GO6_(B8PN*,B-@ZQ!VTS>L1L[YW-C\)L6-7B!SWKS6*M&),
M4B(BHLI('#%ZZE1;RQPQUX=BI9X[8F2MT-9*1\RU)A9HE2-&UFK/FA\14W&X
M$?FE/>K0UBUP&[KE#2(O4%C=N(&RR-^G'HE"8HVV0(K,1V2>;<4LY;AG+!;P
M"4N1K53;REC*M2568#E+D:U"VRI9RK4EDKQB*;)5>[;\J)DJQ(W:ZTO,T!8M
M7G@L<H:Q)4HY:(4(7EA0H]:$)BV*M&),4JR8$&+%5"MF),6*N4:%5BRU5$6(
M[UA[BKY+37GENO37$L$6:9ZG+?+W+>3&V](<@#+C&N\BK`AQKU\CFDZ;C;=P
M/IT/`M'!(U)C2S$A2+9VPT#M;"<DA;MZ_:&8.5(28,L9HJGSUH$1WRP<"UN%
MME5V*:I65B0%"T9^%KGW67OF_3AW5\O\XNC/_<N/7LJ!57K%$;;%,F7&#2)_
M4V0L)LPE2CE;%2M6)%MK1#.[7QX.IN/!0`7:-L&Q%+,EQSGR%49"4O@:J"^W
MG%,4<"QGU"`>;W.-"JU8:JF*$,\6M:?HQ^N\:CK4U30BD8!B2E^2%'?N%2$W
M`:UY3,!WP^D(CB_Z+VXB4F-+,:&?)*`U#MOZYN38H",!48`M9VR9^DZN44&(
M%4M"_'`5H7D[M->$&D4_+K+^_K7Q4I?EH44BC<2::8E23A==D2(W?XUH9MZF
M?[U^%\(X)-_61MI2S)9>32/;T#'F:'\HVIAJRQE9=M.H?5Z*8*$52ZU8$7+3
MR-JR7O'#90IL=WK[R8K!UN/>/&:1,T,M0X56B&;<T]:$>$J/M&),4JR8$&+%
M5"MF&N4:%1J5&E6(9NZ*P7U&SZ6PM/5=^DL9T%CQJWM$(@/$.G^)4FX&L")U
MI34BG$A&HS$,66+HB[2EF"V]E@$D92<2>!DNVIAJRQFB&;]5SAGQS<*Q*`(*
M;:OL4M0K!I*:-8-`,!S,U%Q:>\;]*,M-!!GEMZT78%4M-Q<0B7E)KA=(BO-B
M18B'[C4BG)>"P*P7Q+1$6FPH)O3ZM$12M"Z41QY2$F#+&:(9C\6Y1H56++54
MA6C.)7_M*?KA.F^'`8["J+!8)+)/Y,P2%;WL:Q4Y^RS"['L7SH/)1%B*M*48
MD=<$U:\3DFI?]HJ,2;7EC'2<^4>C0BN66JHBY,P_GJ(?%U/HN_./3*,WG84S
MN2*VZ!")+!)3\9*DN(NN$-DOZS0;>6M$<WL\XMVH:]6M+<5LB<>OCG#9ML,Q
M;+,6"?M#L6Y,M>6,$&=ZKE%!B!^N),2*%2%.R9I0H^B'Z[P-!E@4J+C@!@./
M\TN4\G+&2LVY#ZU1:LY-C[1B3%*LF!!BQ50K9AKE&A4:E1I5A+CZK0DUC^V[
M]+=L,`SU!@,B$\RV(@XG8OA?DA1WDA4BIWA?(YJ/FDXZG`U&XYFP%&E+,5OB
M)G1D@&W[M)U(U("E-D$RMDR#:LZ(;Q9.1#85NI5EEZ)J9852Z(+Y$+[@*#Q0
M>[;](/^>W86AWEU`Y"3/4J,5HCDOF=>$>$T;:<68I%@Q(<2*J5;,2(H5<XT*
MK5AJJ8H0W['V%'U7FV+X[\\HMJ1V"QUPL1G,1#Z)_=HE2;GY9!6]?+((.U,X
M'X3#@9B;(FTI1@26N(NKGIJ0%.731%A.M>6,='C(RAGQS<*)>&=7:%MEEZ)J
M9852E$^#84<^H<<[YB%3T*H@PS=6P3'F!#TMOM]^G'YH2V0OX!9YRZUP(G8L
MEZ@(CT,CT0K1C%=3:T(\+T5:,48TA^=NAVSEN82DL'"9Z3W`5-O.$#F-RC4J
MM&*II2I"_#2UI^@GI*F45:S&Y^ZLFE.M<HWGUN#V&P\H!=,M1T-)K5'*J><C
MK1@CFO/**$$4#+CH2+5FIE&N4:%1J5&%R&EK[4EYOA[]EKV'QHJ_]X!(Y((L
M2E'*S056I("L"7'OB;1BC`@V!%[+!90*!NW193G8:=,9(G@8:E.N4:$52RU5
M$>*'J3U%/SR=FP9_9]@R`1%9@4C,4Z*\7)*4DRB$>*&\)L0I$!%BQ1A1,("R
M]I5QJQ6SVZXC^(:W&O-3;3XCQ.W*-2H(<;M*0JQ8$>('J@DUBGZX3)G^]T>N
MD:WVW:D%D9,H2XU6&JT)\3P=$>()*$;D+/<20KR&2K5BIE&N4:%1J5%%B)M:
M$])5T.BW[`,T5L3`9<MKD0UBD%BBHCMM$.+.LR;$G2<BQ+TN1O2311I*!0-;
M4H5]^8,`J3:=$>(VY1H5A+A-)2%6K`CQP]2$.C)!UOURFX867*^_/H!-%35:
M6>3<TO[&B?T9AJ?MX=-VN7U\/%[<[K^8WR^!-T_7[UM,/ZXR67RP&S;B"AQ+
M7I@CN3#.JRM3N-)T1'5E!E>:7BNNP(^X?&C&><%OX,==FKE$\G`!7\7ON/=P
M`=\:U_S#:/'!GDV2AD;PZS$="C?C!7Q15QNZ@:?N>F@XO;4P1[.T!IQP6ICC
M2_H*G%9:F*-(^@J</`)K75=6X7!A3N=H'3B-`_?IN@)G:^`^75?@I`S<I^O*
M:KJ`KZ;JNR33!7QGM(//%O`-2<WA(.C"G/+LN!(.H%7-:D_$!$[IP9-T^1).
MW(%.<^6R58(?VWG9?-J6F\.GW?/QXG%[#YUYT"R"#_;G>NP?)SQF\'%_@I_9
M:4X</,#/*FWAB](#4][<[_<G^@.:>]G^4-/U_P$``/__`P!02P,$%``&``@`
M```A`/Y"%#1["```9R4``!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
MI)I=<^(Z$H;OMVK_`\7]`#:?H9*<2K#QM[VU=?:<:P).<`U@"CN3F7^_+4LM
M66K&0^;<Q.&A^[7<W9);QO=_?#\>>M_R2U64IX>^-1CU>_EI6^Z*T]M#_W]_
MKK\L^KVJWIQVFT-YRA_Z/_*J_\?CO_]U_U%>OE;[/*][H'"J'OK[NCXOA\-J
MN\^/FVI0GO,3?/-:7HZ;&CY>WH;5^9)O=HW3\3"T1Z/9\+@I3GVNL+S<HE&^
MOA;;W"FW[\?\5'.12W[8U##^:E^<*U0[;F^1.VXN7]_/7[;E\0P2+\6AJ'\T
MHOW><;L,WD[E9?-R@.O^;DTV6]1N/A#Y8[&]E%7Y6@]`;L@'2J_Y;G@W!*7'
M^UT!5\#"WKODKP_])VN9V:/^\/&^"=!?1?Y1M?[O5?ORP[L4N[@XY1!MR!/+
MP$M9?F6FP8XA<!X2[W63@?]<>KO\=?-^J/];?OAY\;:O(=U3N")V8<O=#R>O
MMA!1D!G84Z:T+0\P`/C;.Q:L-"`BF^_-\:/8U?N'_G@VF,Y'8PO,>R]Y5:\+
M)MGO;=^KNCS^S8TL(<5%;"$"QRLB'8YCX0A'X6C9@XD]G2^:TW=X3H0G'(6G
M/9A;H[OQ'(;=X0??-M<+1^EWTPEGPA&..-3)P)J,9BQ.'2><"S\XRA/>,E"8
MH,U`X2C\9@-[,;6FOSKAG7"$(P[TQIA:4'V\&%@9\D3;JA@Z+M*2903_2,^;
MAFMA\;!_<,#CFW)I8?FP?^199?%VC1?+QU+U,[LEFVQJ\1"I`OI%R0[YC&LF
ML+.I-X_WE_*C!ZLBA*HZ;]@::RV9+INZ8X@\'[><S#^;RS")F<H3DWGH0WF!
M>P4+T+?'L36Z'WZ#16,K;)ZIC:5;K-""K1!,UC&!:X*U"3P3^"8(3!":(#)!
M;(+$!*D)LA880JQEP*'`2,!9X#\9<";#`HZA>D:@,F`;T44+='%,X)I@;0+/
M!+X)`A.$)HA,$)L@,4%J@JP%M.C"'"319>5\_4Z$U<N\H.Q;U6O-S.KE-C:D
M59;XU`BP-)$1)L0E9$V(1XA/2$!(2$A$2$Q(0DA*2-8F6K1AW2+1_HU:9C(/
M?1MR*D,[MHRUX5D8=<5?FLCX$^(2LB;$(\0G)"`D)"0B)"8D(20E)&L3+?ZP
M;)#XV]/!YU<3)M1D`"/W+`@<9$ZLF5GPT@C='$)<0M:$>(3XA`2$A(1$A,2$
M)(2DA&1MH@4<^BXMX-W+"K/6HRK(3"[;*T(<0EQ"UH1XA/B$!(2$A$2$Q(0D
MA*2$9&VBA1!Z!"V$?*\P8!USO2^V7Y]+*#B8Y5=".X;&@K<;3$2/+">PU&,I
MK@3AFX2FF^!D"LM9JZ9G^B+N2B,46A/B$>(3$G`R5J</A0W,YM;IY_KI(VF$
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M1,HQ0]0XZB%ENZSV:M8]=]@3`F/R"*3-'K/W7Z%1:_8@&LN(NHCN)%HC4HX>
M(N7H(U*.`2+E&")2CA$BY1@C4HX)(N68(E*.&:+&40\RVVQ](LA\;P;M/"Y]
MS^RI"L1]`A-`+B,SH\%?":-6<3OHI^XA+J+V9L$B*Q+5\M!1:?F([.:&9(TF
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M;*?C(NKNV]!*:7F(E):/:-;$Y,N599(,*40?)1,AZAQ2C%9J2`DBI94B$D.R
M%T:WFZ%!(Z/GB6U,VY/L%WEBYD:>.&I5TLHBR*'(1:0ZFS4BU1)Y%/F(E&.`
M2#F&%$6(E&.,2#DF%*6(E&.&Z$H3QO::GP@IWYIJ_0%'1ND;M^.5):Q4;3B(
M5&OC(E*MS1J1<O00*4<?D7(,$"G'$)%RC!`IQQB1<DP0*<<4D7+,$#6.>N&R
M_6,[RK]W@^>[4"WX'!EW!V-7L[+$]E75C2/01`W?%6C:;O2NW!V(ED>U_)NT
M`F'5FHTAU8INTHJI5D*U4J7%]G^S.>G1VE>GIY!M#?]Y"OD&4TNAV'/J/9K1
M>:RL]LY4_+[&T;3]5)T^!!".T\X.=TWE/73LE/?1BC>]UVXP9.`A^G0J1VC5
M.?!86+5NJ0DZ=LJG:,4'/EX8#T\R35BK!'@9H[L2_BS//WL*VGH6U,CH=R>!
M6NL'?VN#_^A[S"]O^2H_'*K>MGQG;V1`1_-X+[%\7>2I:1\-_@ROD32;%9/;
M\'H)V^V9?+R$WXXH?YHLGV"<](OGR1)^[+C"ITMX)G^%SY;PH)ER9[Z$)[*4
MA_,E/"JEW%DLX>$CY=YB"0\4*0\72WA(2'FR6,*#/^!#&0EXS>6\><N3S>6M
M.%6]0_X*01\UCULO_$49_J$6"7\I:WC!I<G]'EYHRJ&;&[$?=%[+LL8/[`3R
M%:G'_P,``/__`P!02P,$%``&``@````A`*V56DJ?`@``XP8``!D```!X;"]W
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M/\0SQI^X^\TK>B6YT5:7+@"ZT#OZ.N9UN`Z!:;LI)$2`:2=&E#G=Q=G5BH;;
M39^?OU(<[>B=V%H?OQI9?)>M@&3#->$%[+6^0^AM@28X'+XZ?=-?P$]#"E&R
M0^-^Z>,W(:O:P6W/(2",*RL>KX7ED%"@"9(Y,G'=@`.P$B6Q,B`A[*%_'F7A
MZIPFJV`91^MT"2Q[8=V-1$I*^,$ZK?YY4'RB\B3)B02>)Y)T$<R741J#YCLD
MH7>HC^^:.;;=&'TD4#,@:3N&%1AG0/QV0!`)8G<(SNF2$O#5PB7<;]-HO@GO
M(7/\A+GR&%@'3#P@0A`=E$%MNC*"41E3BZY<><-8)GE;)OV(#()S"NO@?!HM
M!EZO[#&S$>8Y!6<!`F1Z@`B&JH"P1M++%](>-$$:ZF&Z-()[Z2&YWA+'T"<C
M;U:#-V=A+CZBA>!S+6]!+6S`<8%`G8V#P)Y+TK[!WBE3/'@N<K*<5^[Z[7AP
M9$_N"`2?2WG+[#D:/U1\TREA*O%%-(TE7!]P8"301H-UF&6[!,^_M,^R73_C
MPN$#S)B.5>(',Y5L+6E$"911@$/%^"GE-TYW?:OOM8/ITK_6\#,1T$E1`.!2
M:_>TP6L8?D_;_P```/__`P!02P,$%``&``@````A`$ZW]$H6!P``'!T``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,38N>&ULK%G;;N,V$'TOT'\P]+ZVJ9MC
M(_8BUAUH@:+8ML^*+,=";,N0E&3W[SL428G#R3K>Q;Y$\=',H>;,D!R)]Y^_
MGHZ3U[)IJ_J\MMAT;DW*<U'OJO/3VOKG2_SISIJT77[>Y<?Z7*ZM;V5K?=[\
M_MO]6]T\MX>R[";`<&[7UJ'K+JO9K"T.Y2EOI_6E/,.=?=V<\@Y^-D^S]M*4
M^:YW.AUG]GSNSTYY=;8$PZJYA:/>[ZNB#.OBY52>.T'2E,>\@^=O#]6E56RG
MXA:Z4]X\OUP^%?7I`A2/U;'JOO6DUN14K+*G<]WDCT>(^RMS\T)Q]S\(_:DJ
MFKJM]]T4Z&;B06G,R]ER!DR;^UT%$7#9)TVY7UL/;)79CC7;W/<"_5N5;ZWV
M_Z0]U&])4^W^J,XEJ`UYXAEXK.MG;IKM.`3.,^(=]QGXJYGLRGW^<NS^KM_2
MLGHZ=)!N#R+B@:UVW\*R+4!1H)G:'F<JZB,\`/R=G"I>&J!(_G5MV3!PM>L.
M:\OQI]YB[C`PGSR6;1=7G-*:%"]M5Y_^$T9,4@D25Y+`59*X4^;.?4YQQ0WN
M]F/#5;HQ=HO?0OK!]4>&@Y+OAX.K&FX^7;#YTEE<?\ZE=(2K<IS>>9[KWW''
MZQK-A-Y]^L*\RS?W3?TV@3D!BK:7G,\PM@)BE3<AUY#)[R42,LA)'CC+V@(A
M($<M5-_K!A)W/WN%BBFDS9;:,&P1*`M>'IPV-('(!&(32$P@-8%,`V8@PJ`$
ME-XO4(*S<"54#%L%C-(8P@3*0KF$)A"90&P"B0FD)I!I``K;H6&[4$[O3UR5
M;^X$4U3+-YO[.)M;86.#W$-1>-@D&$R&T`D2$20F2$*0E""9CB`!8+7X!7GG
M++!\@<I#M`YS<+Q;:71-DL%DD(0@$4%B@B0$20F2Z0B2!/*O2W*]%KAQ'[EZ
MXJU`?%_3@BW-R3X8*;>0(!%!8H(D!$D)DND("A0>\?9`N3$.5"`0J(HA($A(
MD(@@,4$2@J0$R70$107KL!Z56-.G?)/H#E7QO*W%3OI.6AU8N\6*SCEPL`)Q
M^CZ@MPDD(C;A?L$6B`=S;9@%;&FL=]%@I%2+)3*NFLE@HQ,9TRD=C!11)A"G
M?R(D">\SC6W.]GDK\L%"Q_VP#`)Q<(@NGNB!-'*'P@@EPG.@MDCF+[%;)(R\
MNWX'99YK!!P3VN06VA31VJZY,V<Z+5(-&@)=M7<*!A14%<.-L50"<?7ECBW-
M/4`8.6/NP\%-I342B`>74;S%'(L7$Z*$$*42L87`"\R0Z0Q(!P;]L"[$3\VH
MG@0+)"&CF(R--%!66C5)R!VA2$$\(:\;-C=*,J8LB7(965(%"98[0^,,D6")
M>%MES##F_>"BPSB)(9&`C"(R,A=(1[V*).1#ZL:B(3-.63&AFN\:S#%E3I3/
M5>9468E:L[VY,=DSQ(RUY+W:%2V_U)>^<;\^'YGH^*`E4?-H*Z$^WWA$WAV1
M$=5;T^VO`;+)PEV048E;)JWT=<%<%48;]?`AA2(*Q11**)12*$,0%H?W29HX
M'\@NNRI==@$9#9%1#P$;K,:0"111JYA""852"F4(PB'SCNGVD+FU,6TEI+5&
M_',`MQJAD$(1A6(*)11**90A",?'>R<MOI];T$4#AB:8@&!@E<.`"<C3-C@%
MX1[";)-&*\45*VCD2A2$N8S&(1VM%%<FH7=Z)<:[*$V<#^I=]%Q(!=F&Z<\$
MW^/P;AOTP\!+Y+C[A`J"2KFV9DMZ7ZS9GB%<K%A&XD1!5XE3926([:6Q%V3J
M_COK)V^A;I=,-%Q(,@&A;<Z>F^],3'9J8_Y#"8&CRFRD(+'SN,;2&E.21'F,
M)*F"!(ECD&2(!$\MWD5I4OS<U!*M&%)(=F>XJ(S<!TQ:C;D/)81Z)6$%WSGZ
M7LDQIDM,61+*DBKH.RP98D$:V48_>7V&]=9X>960EO5`0GH+)"&__^[;O[)%
M"G+[R!W'F)0Q94F4R\B2*DBPN+Y9'8@%1_XKVD3^3<G8;R2$.FE[;N0U4%9:
M=4A(KPX%B;Q^8@N#)J8TB?(9F5,%21K;-6HU0S18I0\:P)O>X&'R$)4$A%89
M9BYS@71$E20</VBFI:,O)X1GK)\Q)4Z4R_5>6ED)8MLV$I*-Q-J^H;T]8W%A
M!;FV0-W67<-A"E%70-KN((Y+Q/?V4]D\E4%Y/+:3HG[A1R&P`V_N!UB<TVR]
M%7RM@J7<Q/T5?.^A^`-S5@_B8,?T@#N\J:4^6^;"G?XQB0\,+YH7XTZX6,%W
M&\J5+%;P&8;B(?-7$01([T#'LN+]"+T#9U0/?==LC+V%LZM^9S)Q&\ZTWN'9
M0N#OQ?W@KA[@#8@.O`4]1-:&$>!LZI(_E7_FS5-U;B?'<@\)@V,::"`:<;HE
M?G3R5>RQ[N!4JG\K.\`I9`FG%_,I&._KNE,_8.#9<*ZY^1\``/__`P!02P,$
M%``&``@````A`/=G1-\Q`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B
M!`$HH``!````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````)R1T4K#,!2&
M[P7?H>2^3;,-&:'-0&57#@0GBG<Q.=N"31IRHMW>WJQV=:)77H;_SY?OG%2+
MO6VR#PAH6E<35I0D`Z=:;=RV)H_K93XG&4;IM&Q:!S4Y`)*%N+RHE.>J#7`?
M6@\A&L`LD1QRY6NRB]%S2E'MP$HL4L.E<-,&*V,ZABWU4KW)+=!)65Y1"U%J
M&24]`G,_$LF`U&I$^O?0]`"M*#1@P46DK&#TNQLA6/SS0I^<-:V)!Y]F&G3/
MV5I]A6-[CV8L=EU7=-->(_DS^KRZ>^A'S8T[[DH!$<?]-!+C*JUR8T!?'\3^
M-309XJZBO[-*J]Z.JP`R@L[2>_S+[I0\36]NUTLB)B6;YHSE;+9F<\YFG$U>
M*GIJ#??%"+2#P+^))X#HO7_^N?@$``#__P,`4$L#!!0`!@`(````(0#ZZLLR
MT`(``!H)```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````)Q674_C,!!\/^G^0Y1W2*'H=$)I$+0@
M3N*C4@L\6HNS:2U<.V<[5>'7WR9I2T*=W.G>''MG/3L[MA-?;%8R6*.Q0JM1
M>'(\"`-47*="+4;AT_SFZ&<86`<J!:D5CL)WM.%%\OU;/#4Z1^,$VH!2*#L*
ME\[EYU%D^1)78(]I6=%*ILT*''V:1:2S3'"<:%ZL4+GH=##X$>'&H4HQ/<KW
M"<,ZX_G:_6_25/.2GWV>O^=$.(DO\UP*#HZJ3.X%-]KJS`77&XXRCIJ+,;&;
M(2^,<._)((Z:G_&,@\0Q)4XRD!;CZ',BOD4H19N",#:)U^Y\C=QI$UCQ0;*=
MAL$K6"SIC,(U&`'*$:TRK/ZHQC*WSB0OVKS9):*S<40!]60U;,8VQ^(L&9Y6
M$31J1Y89:B:TT.8X%TZB?<RF8)R'\K#%N6)1,ZX)[;K(+E7*KI4CO=@O57=;
MZ";S?0UCK:R6(@6'*;L""8HCFQU4^B_Q;`I_WV+F:*?2:9;IC#WFU+!][E+Z
MNI`6JS9D#*T6["&/9@%*?%1V8G0VV`.XPF#?+O>@8+$E,Z7*O50FPG)-4JJ"
M!"*^IMJA8G^9^MG?D-_8,\BBVOU&*!)5@*16D)4*[RXSE&3-KRW8-<\/<9J_
M79&!4S;6*SK8MF+6'<NFA>%+`K`7,(;,[A=R5N9=:IG2!<2N?Q=D(F_.!W3L
M3EO+2!-R#!B_&/WZG7A3]ZO1@?'+P>;P2B?*OTT).52E#_+5,FR"#H2T;$YW
MIK^U_0+45\3V/MF;N1\S]%;3[[H.T7IMY^?6WQP_M\I3AU[=JN<MIQ_244Z'
M!^HF=93388(:TTW-XYL:TD.M$]-#K7T2&W[S4CL\E`W$I@EI/4)?GIT[H=[L
M4S[7$[JL=^]J>S*N3GPZT7RW_CD1W]*3:F299+P$M<!T%W.X4/X%/->_.LG)
MV?%@.*`'OC$71Y\_-<D?````__\#`%!+`0(M`!0`!@`(````(0#4VKBTTP$`
M`!\5```3``````````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!
M`BT`%``&``@````A`+55,"/U````3`(```L`````````````````#`0``%]R
M96QS+RYR96QS4$L!`BT`%``&``@````A`'N3>L[/`0``_A,``!H`````````
M````````,@<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&
M``@````A`$&?D>0]`P``JPH```\`````````````````00H``'AL+W=O<FMB
M;V]K+GAM;%!+`0(M`!0`!@`(````(0#Z/@J>$04``,L3```8````````````
M`````*L-``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"```
M`"$`5/RN_,$#``#E#```&0````````````````#R$@``>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0`O0<+5+`4``.(8```9````
M`````````````.H6``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`
M%``&``@````A`*QX!NU5!0``MQ8``!D`````````````````31P``'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`-7-,_Z4$``"*
M$P``&0````````````````#9(0``>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+`0(M`!0`!@`(````(0!FT*SV+@,``/X)```9`````````````````+4F
M``!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&``@````A`.`5
M+$*W`@``^08``!D`````````````````&BH``'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"+0`4``8`"````"$`2)2_%;T%``"?&P``&0``````````
M```````(+0``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(
M````(0#FB7R0$`4``-07```9`````````````````/PR``!X;"]W;W)K<VAE
M971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`"R*:?:0`@``)P8``!D`
M````````````````0S@``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M+0`4``8`"````"$`E"-^D44$``!B#P``&``````````````````*.P``>&PO
M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`%``&``@````A`']W+Y_6`@``
MF@@``!@`````````````````A3\``'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+`0(M`!0`!@`(````(0`28<[/#2P``'R<```4`````````````````)%"
M``!X;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(````(0"?.Z4"O@T`
M`/Z.```-`````````````````-!N``!X;"]S='EL97,N>&UL4$L!`BT`%``&
M``@````A`/MBI6V4!@``IQL``!,`````````````````N7P``'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`2T)I`WH"``#<!0``&0``````
M``````````!^@P``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`
M!@`(````(0"MAI7(CP,``%(,```8`````````````````"^&``!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`$I&-_60"``!$!0``
M&0````````````````#TB0``>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M`0(M`!0`!@`(````(0!*UI3K1@0```T1```9`````````````````(^,``!X
M;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`%#T)="Q
M!P``E2```!D`````````````````#)$``'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"+0`4``8`"````"$`H7C_J',$```0$```&```````````````
M``#TF```>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A
M`(=L6I^M"0``>2T``!@`````````````````G9T``'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+`0(M`!0`!@`(````(0`?<H.W%@4``#(4```8````````
M`````````("G``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`
M"````"$`V'%5\B0(``"0)```&`````````````````#,K```>&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A`-@17VY@!0``MA8``!@`
M````````````````)K4``'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M
M`!0`!@`(````(0""9_0]0`,``.T)```9`````````````````+RZ``!X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`)(&I]F=%```
M(6X``!D`````````````````,[X``'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"+0`4``8`"````"$`QO]<)(D"``";!@``&0`````````````````'
MTP``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(````(0!S
M/GC3L@(``,,&```9`````````````````,?5``!X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L!`BT`%``&``@````A`,RJ;TS("P``ZS8``!D`````````
M````````L-@``'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`
M"````"$`1RE:1]X-``!?1@``&0````````````````"OY```>&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0`@S5*[80\``.U)```9
M`````````````````,3R``!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M`BT`%``&``@````A`/Y"%#1["```9R4``!D`````````````````7`(!`'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"````"$`K95:2I\"
M``#C!@``&0`````````````````."P$`>&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+`0(M`!0`!@`(````(0!.M_1*%@<``!P=```9````````````````
M`.0-`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A
M`/=G1-\Q`0``0`(``!$`````````````````,14!`&1O8U!R;W!S+V-O<F4N
M>&UL4$L!`BT`%``&``@````A`/KJRS+0`@``&@D``!``````````````````
JF1<!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"D`*0`1"P``GQL!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMFAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">$ 1,890<span></span></td>
        <td class="nump">$ 1,073<span></span></td>
        <td class="nump">$ 4,270<span></span></td>
        <td class="nump">$ 3,717<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">1,475<span></span></td>
        <td class="nump">763<span></span></td>
        <td class="nump">3,796<span></span></td>
        <td class="nump">1,696<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
        <td class="nump">3,365<span></span></td>
        <td class="nump">1,836<span></span></td>
        <td class="nump">8,066<span></span></td>
        <td class="nump">5,413<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from Operations</a></td>
        <td class="num">(3,365)<span></span></td>
        <td class="num">(1,836)<span></span></td>
        <td class="num">(8,066)<span></span></td>
        <td class="num">(5,413)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">11<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">32<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="num">(14)<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="num">(59)<span></span></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
        <td class="num">(3)<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="num">(27)<span></span></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from Continuing Operations</a></td>
        <td class="num">(3,368)<span></span></td>
        <td class="num">(1,826)<span></span></td>
        <td class="num">(8,093)<span></span></td>
        <td class="num">(5,391)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (Loss) from Discontinued Operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(104)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">389<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (3,368)<span></span></td>
        <td class="num">$ (1,930)<span></span></td>
        <td class="num">$ (8,093)<span></span></td>
        <td class="num">$ (5,002)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Income (Loss) Per Share - Basic and Dilutive:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
        <td class="num">$ (0.08)<span></span></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.16)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Share (in dollars per share)</a></td>
        <td class="num">$ (0.08)<span></span></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.15)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</a></td>
        <td class="nump">44,654,414<span></span></td>
        <td class="nump">33,383,226<span></span></td>
        <td class="nump">44,636,935<span></span></td>
        <td class="nump">32,801,415<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4613673-111683<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
        <td class="text"> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>5.</font></strong></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt; COLOR: black">&#160;Selected Balance Sheet Information</font></strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></i></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Prepaid expenses and other current assets (in thousands)</font></i></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></i></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September&#160;30,&#160;2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December&#160;31,&#160;2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,543</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>2,412</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Other receivables</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>17</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Prepaid expenses</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>104</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>80</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,647</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>2,509</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and equipment (in thousands)</font></i><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 8pt"></font>&#160; <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September&#160;30,&#160;2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December&#160;31,&#160;2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Manufacturing equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>152</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>297</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Computer and office equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>45</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>35</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Laboratory equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>133</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>133</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>330</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>465</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Less accumulated depreciation</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(173)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(242)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>157</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>223</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 330<span></span></td>
        <td class="nump">$ 465<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
        <td class="num">(173)<span></span></td>
        <td class="num">(242)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
        <td class="nump">157<span></span></td>
        <td class="nump">223<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Manufacturing equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">152<span></span></td>
        <td class="nump">297<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer and Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">45<span></span></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 133<span></span></td>
        <td class="nump">$ 133<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">A summary of warrant activity for the Company for the nine months ended September 30, 2013 and for the year ended December 31, 2012 is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at December 31, 2011</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>3,259,186</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.95</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Granted</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>985,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.71</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Exercised</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(1,768,167)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.11</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Forfeited</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(844,373)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>3.32</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at December 31, 2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Granted</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Exercised</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Forfeited</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at September 30, 2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrant Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">A summary of all outstanding and exercisable warrants as of September 30, 2013 is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 88%" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Exercise</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Remaining</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Aggregate</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Price</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Contractual&#160;Life</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.14</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>100,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>100,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.34&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>54,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.32</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>18,182</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>18,182</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>2.25&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>6,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.60</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>635,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>635,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>4.08&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>51,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>2.20</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>250,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>0.45&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>2.22</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>517,257</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>517,257</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.16&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>3.30</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>61,207</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>61,207</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>1.66&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>3.75</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>2.38&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1,432,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.03&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>111,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrant activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfWarrantActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to warrant outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EC4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Employees And Directors [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Employees And Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Employees And Consultants [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Employees And Consultants [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Employees And Consultants [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Employees And Consultants [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2001 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2001

</div>
          <div>2001 Stock Plan [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2007 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 20, 2007

</div>
          <div>2007 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>2007 Stock Plan [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2010 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 02, 2010

</div>
          <div>2010 Stock Plan [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump">3,804,580<span></span></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">4,258,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">953,507<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">443,573<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,407,500<span></span></td>
        <td class="nump">3,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">117,500<span></span></td>
        <td class="nump">1,840,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">953,507<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">443,573<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">2,407,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 185,000<span></span></td>
        <td class="nump">$ 4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">338,000<span></span></td>
        <td class="nump">395,000<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</a></td>
        <td class="nump">$ 1,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Beginning Balance</a></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,258,746<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted</a></td>
        <td class="nump">117,500<span></span></td>
        <td class="nump">2,075,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
        <td class="num">(291,666)<span></span></td>
        <td class="num">(374,851)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Forfeited</a></td>
        <td class="num">(475,000)<span></span></td>
        <td class="num">(225,413)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Ending Balance</a></td>
        <td class="nump">3,804,580<span></span></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="nump">4,258,746<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable</a></td>
        <td class="nump">2,902,307<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="nump">$ 1.74<span></span></td>
        <td class="nump">$ 2.21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump">$ 0.79<span></span></td>
        <td class="nump">$ 0.34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
        <td class="nump">$ 2.31<span></span></td>
        <td class="nump">$ 2.37<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.79<span></span></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 1.67<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Balance Outstanding</a></td>
        <td class="text">5 years 9 months 4 days<span></span></td>
        <td class="text">6 years 5 months 5 days<span></span></td>
        <td class="text">6 years 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
        <td class="text">5 years 3 months 7 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
        <td class="nump">$ 1,308,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">932,000<span></span></td>
        <td class="nump">1,308,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">903,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
        <td class="nump">$ 185,000<span></span></td>
        <td class="nump">$ 4,468,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
        <td class="nump">$ 1.57<span></span></td>
        <td class="nump">$ 2.15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
        <td class="nump">291,666<span></span></td>
        <td class="nump">374,851<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
        <td class="nump">$ 231,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3LAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne', window );">Exercise price</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.74<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">153.00%<span></span></td>
        <td class="nump">148.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.77%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
        <td class="text">0 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod', window );">Expected forfeitures</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.96<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">108.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.63%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.37%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.27<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.47<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">174.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.65%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.98%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt; COLOR: black">1.</font></b></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt; COLOR: black">Organization and Nature of Operations and Basis of Presentation</font></b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt; COLOR: black"> Description of Business</font></i></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of <i>C. difficile</i> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <i>Acinetobacter</i> infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="bottom" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt; COLOR: black"> Therapeutic&#160;Area</font></b></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="bottom" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="bottom" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt; COLOR: black"> Product&#160;Candidate</font></b></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="bottom" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="bottom" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt; COLOR: black">Status</font></b></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Relapsing-remitting MS</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Trimesta</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> (oral estriol)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Completed enrollment&#160;in Phase II clinical trial; dosing and monitoring underway</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Cognitive dysfunction in MS</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Trimesta</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> (oral estriol)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Patient enrollment underway in Phase II clinical trial</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><i><font style="FONT-SIZE: 10pt; COLOR: black">C. difficile</font></i> <font style="FONT-SIZE: 10pt; COLOR: black">infection prevention</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">SYN-004</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> &#160;(oral enzyme)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">SYN-004, second generation candidate in preclinical;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">first generation predecessor candidate</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">(formerly known as P1A) is in Phase II</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Pertussis</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">SYN-005</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> &#160;(monoclonal antibody)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Preclinical; Collaborations with Intrexon and The University of Texas at Austin</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><i><font style="FONT-SIZE: 10pt; COLOR: black">Acinetobacter</font></i> <font style="FONT-SIZE: 10pt; COLOR: black">infection</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">SYN-001</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> &#160;(monoclonal antibody)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Discovery; Collaboration with Intrexon</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> </tr> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Fibromyalgia</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 27%; BACKGROUND-COLOR: transparent" valign="top" width="27%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Effirma</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> &#160;(oral flupirtine)</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 1%; BACKGROUND-COLOR: transparent" valign="top" width="1%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 44%; BACKGROUND-COLOR: transparent" valign="top" width="44%"> <div style="clear:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt; COLOR: black">Partnered with Meda AB</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">In order to further prioritize the Company&#8217;s focus, it previously elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, the Company is seeking development partners for its zinc-based intellectual property and assets including, AEN-100.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong>Basis of Presentation</strong></i></font></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2012 (&#8220;2012 Form 10-K&#8221;) as filed with the SEC. The interim results for the three and nine months ended September 30, 2013, are not necessarily indicative of results for the full year.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>3.</font></strong></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</font></strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font> payable pursuant to the terms of a two-year promissory note bearing interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.7</font>% per annum secured by all of the assets of the Lab. The note and all unpaid interest were due on March 1, 2014. <font style="BACKGROUND-COLOR: transparent">During the three months ended September 30, 2013, the note receivable and associated interest receivable were deemed uncollectible. Accordingly, the Company recorded bad debt expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">763</font>,000.</font></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In accordance with <font style="BACKGROUND-COLOR: transparent"> Accounting Standards Codification (&#8220;ASC&#8221;)</font> Topic 205-20 &#8220;<i>Presentation of Financial Statements-Discontinued Operations</i>&#8221; (ASC 205-20), the Company determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been classified as a discontinued operation and its results of operations, financial position and cash flows are separately reported for all periods presented.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The summarized statement of operations data for Adeona Clinical Laboratory for the three and nine months ended September 30, 2013 and 2012 are as follows <i>(in thousands):</i></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 8pt"></font>&#160; <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>Three&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>Nine&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Laboratory fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Operating Costs and Expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>287</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Cost of laboratory services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Total operating costs and expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>403</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Loss from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(288)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Other Income:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Gain on sale of Adeona Clinical Laboratory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Income (loss) from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="left"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt">6.</font></strong></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt">&#160;Stock-Based Compensation</font></strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -31.9pt; MARGIN: 0in 0in 0pt 31.9pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="COLOR: black; FONT-SIZE: 10pt">Stock Incentive Plan</font></i></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">During 2001, the Company&#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of September 30, 2013, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 953,507</font></font> options issued and outstanding under the 2001 Stock Plan.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 443,573</font></font> options issued and outstanding under the 2007 Stock Plan.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of September 30, 2013, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,407,500</font></font> options issued and outstanding under the 2010 Stock Plan.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Black-Scholes assumptions used in the three and nine months ended September 30, 2013 and 2012 are as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="3"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$1.96-&#160;$2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$1.70-&#160;$2.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>153%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>108%&#160;-&#160;174%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0.63%&#160;-&#160;0.65%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0.37%&#160;-&#160;1.98%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>5&#160;years&#160;&#150;&#160;10&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>0% <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">immediate vesting,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">half vesting immediately and the remainder over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">quarterly over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">annually over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">one-third immediate vesting and remaining annually over two years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">one half immediate vesting with remaining vesting over nine months,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">one quarter immediate vesting with the remaining over three years,</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">one quarter immediate vesting with the remaining over 33 months; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 7%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="7%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#8901;</font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 87%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="87%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">monthly over three years.</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -15.4pt; MARGIN: 0in 0in 0pt 67.1pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">During the nine months ended September 30, 2013, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 117,500</font> options to employees and directors having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,000</font> based upon the Black-Scholes option pricing model.&#160;During the same period in 2012, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,840,000</font> options to employees and consultants having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.0</font> million based upon the Black-Scholes option pricing model.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activities as of September 30, 2013, and for the year ended December 31, 2012, is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average&#160;Exercise</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance - December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,979,010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>6.01&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,075,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(374,851)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(225,413)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance - December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,453,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>6.43&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,308,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(291,666)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(475,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance &#150; September 30, 2013 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,804,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>5.76&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>932,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Balance &#150; September 30, 2013 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,902,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>5.27&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Grant date fair value of options granted - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>185,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Weighted average grant date fair value - 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Grant date fair value of options granted - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,468,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Weighted average grant date fair value - 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended September 30, 2013 and 2012 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">338,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">395,000</font>, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million for the nine month periods ended September 30, 2013 and 2012, respectively.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;As of September 30, 2013, total unrecognized stock-based compensation expense related to stock options was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.9</font> million, which is expected to be expensed through February 2016.</font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 2%; BACKGROUND-COLOR: transparent" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>4.</font></strong></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 96%; BACKGROUND-COLOR: transparent" valign="top" width="96%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt; COLOR: black">&#160;Fair Value of Financial Instruments</font></strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -15.4pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -15.4pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <table style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 4%; BACKGROUND-COLOR: transparent" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 3%; BACKGROUND-COLOR: transparent" valign="top" width="3%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol; COLOR: black"><font style="FONT-FAMILY: SYMBOL">&#183;</font></font></div> </td> <td style="BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; BORDER-BOTTOM: #ece9d8; PADDING-BOTTOM: 0in; PADDING-TOP: 0in; PADDING-LEFT: 0in; BORDER-LEFT: #ece9d8; PADDING-RIGHT: 0in; WIDTH: 93%; BACKGROUND-COLOR: transparent" valign="top" width="93%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">Cash and cash equivalents include money market accounts&#160;of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million as of September 30, 2013 and December 31, 2012, respectively, that are measured using Level 1 inputs.</font></div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">3,259,186<span></span></td>
        <td class="nump">1,324,102<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">985,855<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Number of Warrants, Exercised</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,768,167)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(844,373)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending Balance</a></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">1,324,102<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump">$ 1.99<span></span></td>
        <td class="nump">$ 1.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1.71<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1.11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 3.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.99<span></span></td>
        <td class="nump">$ 1.99<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share warrants exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Net Loss per Share (Details Textual)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump">3,804,580<span></span></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">4,258,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number</a></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">1,324,102<span></span></td>
        <td class="nump">3,259,186<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U
M,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C
M-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T
M:6]N7V%N9%].871U<F5?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^36%N86=E;65N='-?4&QA;CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1I<V-O;G1I;G5E9%]/<&5R871I
M;VYS7V]F7T%D93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN<W1R=3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-E;&5C=&5D7T)A;&%N8V5?
M4VAE971?26YF;W)M83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R<F%N
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C
M:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3F5T7TQO<W-?<&5R7U-H87)E/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^1&ES8V]N=&EN=65D7T]P97)A=&EO;G-?
M;V9?061E,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-E;&5C=&5D7T)A;&%N8V5?4VAE971?26YF;W)M83$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A
M=&EO;E]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=&]C:U]0=7)C:&%S95]787)R86YT<U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-86YA9V5M96YT<U]0;&%N
M7T1E=&%I;'-?5&5X='4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y$:7-C;VYT:6YU961?3W!E<F%T:6]N<U]O9E]!9&4R/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&ES8V]N=&EN=65D
M7T]P97)A=&EO;G-?;V9?061E,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN<W1R=3$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y396QE8W1E
M9%]"86QA;F-E7U-H965T7TEN9F]R;6$R/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4V5L96-T961?0F%L86YC95]3:&5E=%]);F9O
M<FUA,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T
M;V-K0F%S961?0V]M<&5N<V%T:6]N7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N
M7T1E=&%I;#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]$971A:6PR/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R
M<F%N='-?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R<F%N='-?1&5T86EL,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K7U!U<F-H87-E
M7U=A<G)A;G1S7T1E=&%I;#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;'-?5&4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?3&]S<U]P
M97)?4VAA<F5?1&5T86EL<U]497@\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W
M-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F
M,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)#
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@06YD($5N=&ET
M>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DYO=BX@,3(L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@26YF;W)M871I;VX@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)U-Y;G1H971I8R!":6]L;V=I8W,L($EN8RX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<P,#`P.#DT,34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN
M9R!3>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=364X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PV-30L-#$T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M
M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O
M8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E7V4S
M-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B
M8S0O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4%%!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E
M=',@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL.34T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N
M<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@07-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0V
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!N;W1E(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<&]S:71S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPY-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPT,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA8FEL:71I
M97,@86YD(%-T;V-K:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#$P+#`P,"PP,#`@<VAA<F5S(&%U
M=&AO<FEZ960L(&YO;F4@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N
M,#`Q('!A<B!V86QU93L@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L
M(#0T+#<S-2PX.38@:7-S=65D(&%N9"`T-"PV-30L-#$T(&]U='-T86YD:6YG
M+"!R97-P96-T:79E;'DL(&%N9"`T-"PT-#0L,C,P(&ES<W5E9"!A;F0@-#0L
M,S8R+#<T."!O=71S=&%N9&EN9RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@
M8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L,S4X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#$L.3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W-RPP,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C@L.30Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-T;V-K:&]L
M9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#,V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S+#`R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S(&%N9"!3=&]C:VAO;&1E
M<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M+#DU,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3,L-#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T
M,C`V7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970P,RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14--04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L
M:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O
M8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<RP@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PW,S4L.#DV/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-#0T
M+#(S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#8U-"PT,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PS-C(L-S0X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W
M-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F
M,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U&
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E
M;65N=',@;V8@3W!E<F%T:6]N<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!#;W-T<R!A;F0@17AP96YS97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#@Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,C<P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#<Q-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L-SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!/<&5R871I
M;F<@0V]S=',@86YD($5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#,V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.#,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PP-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#0Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!/<&5R
M871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#,V-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#@S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@X+#`V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U+#0Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@26YC;VUE("A%>'!E
M;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M3W1H97(@26YC;VUE("A%>'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@0V]N=&EN=6EN
M9R!/<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#,V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#@R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X+#`Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U+#,Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92`H3&]S<RD@9G)O;2!$
M:7-C;VYT:6YU960@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,RPS-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#DS,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@L,#DS*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PP
M,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DYE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R92`M($)A
M<VEC(&%N9"!$:6QU=&EV93H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1I;G5I;F<@;W!E<F%T:6]N<R`H:6X@
M9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,38I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;VYT:6YU
M960@;W!E<F%T:6]N<R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,
M;W-S(%!E<B!3:&%R92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#`N,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;W5T
M<W1A;F1I;F<@9'5R:6YG('1H92!P97)I;V0@+2!"87-I8R!A;F0@1&EL=71I
M=F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0T+#8U-"PT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,RPS.#,L,C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-C,V+#DS-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#@P,2PT,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E
M7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V
M,6%B8S0O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04A!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@3W!E<F%T
M:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H."PP.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@U+#`P,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N
M=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@
M;W!E<F%T:6YG(&%C=&EV:71E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O=FES:6]N(&9O<B!U;F-O;&QE8W1I8FQE(&%C8V]U;G1S(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W9I<VEO;B!F;W(@=6YC;VQL96-T:6)L92!N;W1E(&%N9"!I;G1E<F5S="!R
M96-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!O;B!S86QE(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]N(&QO<W,@;V8@97%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A
M:6X@;VX@<V%L92!O9B!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8W-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E
M<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O
M<VET<R!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%5S
M960@26X@3W!E<F%T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4L,#$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0L,30S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S
M($9R;VT@26YV97-T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@0V%S:"!5<V5D($EN($EN=F5S=&EN9R!!8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H($9L;W=S($9R;VT@1FEN86YC:6YG($%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R('-T;V-K
M(&]P=&EO;B!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!F;W(@=V%R<F%N="!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#DU-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%!R;W9I9&5D($)Y($9I
M;F%N8VEN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!D96-R96%S92!I;B!C87-H/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#@P.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$P,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@
M8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.2PY-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#8W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A="!E;F0@;V8@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$T-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3<W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF;W)M
M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@=&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83!C-S5D-F5?93,V95\T,C`V
M7V$S8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-"]7;W)K
M<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD($YA='5R92!O9B!/<&5R871I
M;VYS(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VXL
M($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@
M4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VXL($-O;G-O;&ED871I
M;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!$
M:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R`\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[(%=)1%1(.B`Q,#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/B`\='(^(#QT9"!S='EL
M93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y
M9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$
M15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@
M,B4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T
M;W`@=VED=&@],T0R)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z
M("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!7
M24142#H@,B4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI
M9VX],T1T;W`@=VED=&@],T0R)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H
M.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXQ+CPO9F]N=#X\+V(^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$
M15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(
M5#H@,&EN.R!724142#H@.38E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A
M<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.38E/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/D]R9V%N:7IA
M=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO;G,@86YD($)A<VES(&]F(%!R
M97-E;G1A=&EO;CPO9F]N=#X\+V(^/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B
M;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M:6X@,&EN(#!P="`S,2XY<'0[(%1%6%0M24Y$14Y4.B`M,S$N.7!T)SX@/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C
M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\8CX\:3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^($1E
M<V-R:7!T:6]N(&]F($)U<VEN97-S/"]F;VYT/CPO:3X\+V(^/"]D:78^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4E.1$5.5#H@,CDN-W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B`F(S$V,#L\
M+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B!3>6YT:&5T:6,@0FEO
M;&]G:6-S+"!);F,N("AT:&4@)B,X,C(P.T-O;7!A;GDF(S@R,C$[(&]R("8C
M.#(R,#M3>6YT:&5T:6,@0FEO;&]G:6-S)B,X,C(Q.RD@:7,@82!B:6]T96-H
M;F]L;V=Y(&-O;7!A;GD@9F]C=7-E9"!O;B!T:&4@9&5V96QO<&UE;G0@;V8@
M8FEO;&]G:6-S(&9O<B!T:&4@<')E=F5N=&EO;B!A;F0@=')E871M96YT(&]F
M('-E<FEO=7,@:6YF96-T:6]U<R!D:7-E87-E<RX@5&AE($-O;7!A;GD@:7,@
M9&5V96QO<&EN9R!A;B!O<F%L(&5N>GEM92!F;W(@=&AE('!R979E;G1I;VX@
M;V8@/&D^0RX@9&EF9FEC:6QE/"]I/B!I;F9E8W1I;VYS+"!A;F0@82!S97)I
M97,@;V8@;6]N;V-L;VYA;"!A;G1I8F]D>2!T:&5R87!I97,@9F]R('1H92!T
M<F5A=&UE;G0@;V8@4&5R='5S<VES(&%N9"`\:3Y!8VEN971O8F%C=&5R/"]I
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M3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,CDN-W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B`F(S$V,#L\+V9O;G0^/"]D
M:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M&3TY4+5-)6D4Z(#$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!724142#H@
M,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4@8F]R9&5R/3-$,#X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+51/
M4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&
M5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B!4:&5R87!E=71I
M8R8C,38P.T%R96$\+V9O;G0^/"]B/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X
M.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#$E
M.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'
M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED
M.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED
M.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B!0<F]D=6-T)B,Q-C`[0V%N9&ED
M871E/"]F;VYT/CPO8CX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52
M+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C
M96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%
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M=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0T],3U(Z(&)L86-K)SY3=&%T=7,\+V9O;G0^/"]B/CPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y
M9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/
M4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED
M.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%
M4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q
M)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[
M($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED
M.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'
M+5))1TA4.B`P:6X[(%=)1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@<W1Y
M;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2
M.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X
M.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#$E
M.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ
M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@
M0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@5TE$5$@Z(#0T)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A
M;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#0T)3X@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z
M(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(
M5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[
M(%=)1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V
M86QI9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z
M8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^4F5L
M87!S:6YG+7)E;6ET=&EN9R!-4SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C
M93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/
M4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(
M.B`Q)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N
M=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y
M9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C
M93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$
M24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@
M<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/
M3$]2.B!B;&%C:R<^5')I;65S=&$\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N
M=#X@*&]R86P@97-T<FEO;"D\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y
M9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$
M15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@
M,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)
M3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y
M9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU224=(5#H@,&EN.R!724142#H@-#0E.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#0E/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/
M4CH@8FQA8VLG/D-O;7!L971E9"!E;G)O;&QM96YT)B,Q-C`[:6X@4&AA<V4@
M24D@8VQI;FEC86P@=')I86P[(&1O<VEN9R!A;F0@;6]N:71O<FEN9R!U;F1E
M<G=A>3PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X
M.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(W
M)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)
M3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y
M9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU224=(5#H@,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z
M(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[
M($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M
M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E
M.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,C<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[
M($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED
M.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'
M+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A
M;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@
M8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@
M0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`T-"4[
M($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@
M=VED=&@],T0T-"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ
M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0
M.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U14
M3TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED
M.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E
M/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!#3TQ/4CH@8FQA8VLG/D-O9VYI=&EV92!D>7-F=6YC=&EO;B!I;B!-
M4SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z
M("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/
M33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X
M.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@0D%#2T=23U5.1"U#
M3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@
M(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)
M1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI
M9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^5')I;65S
M=&$\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'
M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X@*&]R86P@97-T<FEO;"D\
M+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C
M96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ
M("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@
M4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],
M3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E
M8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!72414
M2#H@-#0E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-#0E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/E!A=&EE;G0@
M96YR;VQL;65N="!U;F1E<G=A>2!I;B!0:&%S92!)22!C;&EN:6-A;"!T<FEA
M;#PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"
M3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%
M1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(W)3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@
M,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"
M3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L
M86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/
M4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&
M5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,C<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))
M1TA4.B`P:6X[(%=)1%1(.B`Q)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P
M87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA
M8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]2
M1$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494
M.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`T-"4[($)!
M0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED
M=&@],T0T-"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C
M96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ
M("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@
M4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$+4-/
M3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!#3TQ/4CH@8FQA8VLG/D,N(&1I9F9I8VEL93PO9F]N=#X\+VD^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SYI
M;F9E8W1I;VX@<')E=F5N=&EO;CPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C
M93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/
M4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(
M.B`Q)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N
M=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y
M9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C
M93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$
M24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@
M<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/
M3$]2.B!B;&%C:R<^4UE.+3`P-#PO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L
M86-K)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F;VYT
M/B`F(S$V,#LH;W)A;"!E;GIY;64I/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C
M96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$
M5$@Z(#$E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-
M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C
M93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C
M96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#0T)3L@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#0T)3X@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0T],3U(Z(&)L86-K)SY364XM,#`T+"!S96-O;F0@9V5N97)A=&EO;B!C86YD
M:61A=&4@:6X@<')E8VQI;FEC86P[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@
M8FQA8VLG/F9I<G-T(&=E;F5R871I;VX@<')E9&5C97-S;W(@8V%N9&ED871E
M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/BAF;W)M97)L>2!K;F]W
M;B!A<R!0,4$I(&ES(&EN(%!H87-E($E)/"]F;VYT/CPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"
M3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N
M<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@
M8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@
M0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))
M1TA4.B`P:6X[(%=)1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"
M3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%
M1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#$E.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]2
M1$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@5TE$5$@Z(#0T)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P
M87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#0T)3X@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L
M86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@
M(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)
M1%1(.B`R-R4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI
M9VX],T1T;W`@=VED=&@],T0R-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^4&5R='5S
M<VES/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/
M4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]4
M5$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y
M9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#$E.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T
M)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4
M.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M5TE$5$@Z(#(W)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY364XM
M,#`U/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^("8C,38P.RAM;VYO8VQO
M;F%L(&%N=&EB;V1Y*3PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@
M0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))
M1TA4.B`P:6X[(%=)1%1(.B`T-"4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0T-"4^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^4')E8VQI;FEC86P[($-O;&QA8F]R871I;VYS('=I=&@@26YT<F5X
M;VX@86YD(%1H92!5;FEV97)S:71Y(&]F(%1E>&%S(&%T($%U<W1I;CPO9F]N
M=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52
M+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M
M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E
M8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(W)3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I
M;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M
M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@
M,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF
M(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"
M3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C
M93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/
M54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,C<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU2
M24=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P
M:6X[(%=)1%1(.B`Q)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R
M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C
M,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/
M5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E
M.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`T-"4[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0T
M-"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y
M9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX]
M,T1C96YT97(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#
M3TQ/4CH@8FQA8VLG/D%C:6YE=&]B86-T97(\+V9O;G0^/"]I/B`\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^:6YF96-T
M:6]N/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/
M4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]4
M5$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y
M9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#$E.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T
M)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4
M.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M5TE$5$@Z(#(W)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY364XM
M,#`Q/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^("8C,38P.RAM;VYO8VQO
M;F%L(&%N=&EB;V1Y*3PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@
M0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`Q)3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))
M1TA4.B`P:6X[(%=)1%1(.B`T-"4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0T-"4^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^1&ES8V]V97)Y.R!#;VQL86)O<F%T:6]N('=I=&@@26YT<F5X;VX\
M+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/
M4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]2
M1$52+4)/5%1/33H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494
M.B`C96-E.60X.R!0041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`R-R4[($)!
M0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED
M=&@],T0R-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]2
M1$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@5TE$5$@Z(#$E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A
M<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C
M:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$
M15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z
M("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(W)3L@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#(W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$
M15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(
M5#H@,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K
M)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%
M4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@
M(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@-#0E.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-#0E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C
M93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C
M96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(W)3L@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#(W)3X@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0T],3U(Z(&)L86-K)SY&:6)R;VUY86QG:6$\+V9O;G0^/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'
M2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN
M.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V
M,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0
M.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U14
M3TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED
M.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,C<E.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C<E
M/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!#3TQ/4CH@8FQA8VLG/D5F9FER;6$\+V9O;G0^/"]D:78^(#QD:78@
M<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/
M3$]2.B!B;&%C:R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^("8C,38P
M.SPO9F]N=#X@)B,Q-C`[*&]R86P@9FQU<&ER=&EN92D\+V9O;G0^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$
M15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(
M5#H@,&EN.R!724142#H@,24[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K
M)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%
M4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@
M(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@-#0E.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-#0E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/E!A<G1N97)E9"!W:71H($UE9&$@
M04(\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@
M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0T],3U(Z(&)L86-K)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],
M3U(Z(&)L86-K)SY);B!O<F1E<B!T;R!F=7)T:&5R('!R:6]R:71I>F4@=&AE
M($-O;7!A;GDF(S@R,3<[<R!F;V-U<RP@:70@<')E=FEO=7-L>2!E;&5C=&5D
M('1O(&1I<V-O;G1I;G5E(&9U<G1H97(@9&5V96QO<&UE;G0@;V8@045.+3$P
M,"!F;W(@=&AE('1R96%T;65N="!O9B!A;7EO=')O<&AI8R!L871E<F%L('-C
M;&5R;W-I<RX@2&]W979E<BP@=&AE($-O;7!A;GD@:7,@<V5E:VEN9R!D979E
M;&]P;65N="!P87)T;F5R<R!F;W(@:71S('II;F,M8F%S960@:6YT96QL96-T
M=6%L('!R;W!E<G1Y(&%N9"!A<W-E=',@:6YC;'5D:6YG+"!!14XM,3`P+CPO
M9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B`G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q
M,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Y-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0Y-B4^
M(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T
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M13H@,3!P=#M415A4+4E.1$5.5#H@,CDN-W!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L
M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A
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M,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,B`H)B,X,C(P.S(P,3(@1F]R;2`Q,"U+)B,X,C(Q.RD@87,@9FEL960@=VET
M:"!T:&4@4T5#+B!4:&4@:6YT97)I;2!R97-U;'1S(&9O<B!T:&4@=&AR964@
M86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,RP@87)E
M(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F(')E<W5L=',@9F]R('1H
M92!F=6QL('EE87(N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#(Y+C=P=#L@34%21TE..B`P:6X@,&EN(#!P
M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C
M:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].
M5"U325I%.B`Q,'!T)SY4:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
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M1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B
M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A
M,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?
M-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA;F%G96UE;G0G<R!0;&%N
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&ES8VQO<W5R92!-86YA9V5M96YT(%!L86X@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%N86=E
M;65N="!0;&%N($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68@)SX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E
M8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%
M4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T-/3$]2
M.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@/"]F;VYT/C(N/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#DV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E
M.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DV)3X@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQS=')O;F<^/&9O;G0@<W1Y
M;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/DUA;F%G96UE
M;G0F(S@R,3<[<R!0;&%N/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\
M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^(#QF
M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SY4
M:&4@0V]M<&%N>2!H87,@:6YC=7)R960@86X@86-C=6UU;&%T960@9&5F:6-I
M="!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^-S<\+V9O;G0^(&UI
M;&QI;VX@=&AR;W5G:"!397!T96UB97(@,S`L(#(P,3,N(%=I=&@@=&AE(&5X
M8V5P=&EO;B!O9B!T:&4@<75A<G1E<B!E;F1E9"!*=6YE(#,P+"`R,#$P+"!T
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M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`R.2XW<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G
M/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^
M(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T
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M05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L
M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^(#QT86)L92!S='EL93TS1"=724142#H@,3`P)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M9C!F,&8P.R!"3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@(V8P9C!F,#L@0D]21$52+5))1TA4.B`C9C!F,&8P.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0V)3X@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T.R<^("8C
M,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P
M9C`[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E
M/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#$P
M<'0[)SX@)B,X.3`Q.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N
M<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Y,"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V8P9C!F,#L@0D]21$52+5))
M1TA4.B`C9C!F,&8P.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Y,"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M415A4+4%,
M24=..B!J=7-T:69Y.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y
M;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/G1H92!P<F]G
M<F5S<R!O9B!R97-E87)C:"!A8W1I=FET:65S.SPO9F]N=#X\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V8P
M9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z("-F,&8P9C`[($)/4D1%4BU224=(5#H@(V8P9C!F,#L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-B4^(#QD:78@<W1Y
M;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=C;VQO<CH@8FQA8VL[(&9O;G0M<VEZ93H@,3!P=#LG/B`F(S$V
M,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C9C!F,&8P.R!"3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@(V8P9C!F,#L@0D]21$52+5))1TA4.B`C9C!F,&8P
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0T)3X@
M/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T
M.R<^("8C.#DP,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C9C!F,&8P.R!"3U)$15(M3$5&5#H@(V8P9C!F,#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P
M87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.3`E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%4BU224=(
M5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.3`E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[5$585"U!3$E'
M3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE
M/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SYT:&4@;G5M8F5R
M(&%N9"!S8V]P92!O9B!R97-E87)C:"!P<F]G<F%M<SL\+V9O;G0^/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#$P<'0[)SX@
M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P9C`[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%4BU224=(5#H@(V8P
M9C!F,#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[(&9O;G0M<VEZ93H@
M,3!P=#LG/B`F(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P
M9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DP)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M
M4DE'2%0Z("-F,&8P9C`[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DP)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S
M='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^=&AE('!R
M;V=R97-S(&]F('!R96-L:6YI8V%L(&%N9"!C;&EN:6-A;"!D979E;&]P;65N
M="!A8W1I=FET:65S.SPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%
M1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M
M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-F,&8P9C`[
M($)/4D1%4BU224=(5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=C;VQO<CH@
M8FQA8VL[(&9O;G0M<VEZ93H@,3!P=#LG/B`F(S$V,#L\+V9O;G0^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9C!F,&8P.R!"
M3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M(V8P9C!F,#L@0D]21$52+5))1TA4.B`C9C!F,&8P.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0T)3X@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T.R<^("8C.#DP,3L\+V9O
M;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M9C!F,&8P.R!"3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@.3`E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%4BU224=(5#H@(V8P9C!F,#L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.3`E/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2
M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C
M:SL@1D].5"U325I%.B`Q,'!T)SYT:&4@<')O9W)E<W,@;V8@=&AE(&1E=F5L
M;W!M96YT(&5F9F]R=',@;V8@<&%R=&EE<R!W:71H('=H;VT@=&AE($-O;7!A
M;GD@:&%S(&5N=&5R960@:6YT;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M86=R965M96YT<SL\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-F,&8P9C`[($)/4D1%4BU,1494
M.B`C9C!F,&8P.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/
M3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9C!F,&8P.R!"
M3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(&)L
M86-K.R!F;VYT+7-I>F4Z(#$P<'0[)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]2
M1$52+4Q%1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'
M4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-F
M,&8P9C`[($)/4D1%4BU224=(5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4^(#QD:78@<W1Y;&4],T0G8VQE
M87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=C
M;VQO<CH@8FQA8VL[(&9O;G0M<VEZ93H@,3!P=#LG/B`F(S@Y,#$[/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V8P
M9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#DP)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#DP)3X@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)
M3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[
M($9/3E0M4TE:13H@,3!P="<^8V]S=',@87-S;V-I871E9"!W:71H(&%D9&ET
M:6]N86P@8VQI;FEC86P@=')I86QS(&]F('!R;V1U8W0@8V%N9&ED871E<SL\
M+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A
M<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z
M("-F,&8P9C`[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F
M,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%
M4BU224=(5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[
M(&9O;G0M<VEZ93H@,3!P=#LG/B`F(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52
M+4Q%1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#DP)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9C!F
M,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DP)3X@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P
M<'0G/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@
M,3!P="<^=&AE(&%B:6QI='D@=&\@;6%I;G1A:6X@8W5R<F5N="!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@;&EC96YS:6YG(&%R<F%N9V5M96YT<R!A;F0@
M=&\@97-T86)L:7-H(&YE=R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86YD
M(&QI8V5N<VEN9R!A<G)A;F=E;65N=',[/"]F;VYT/CPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9C!F,&8P
M.R!"3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@(V8P9C!F,#L@0D]21$52+5))1TA4.B`C9C!F,&8P.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0V)3X@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T.R<^("8C,38P.SPO
M9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#$P<'0[)SX@
M)B,X.3`Q.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ("-F,&8P9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N
M=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Y,"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@(V8P9C!F,#L@0D]21$52+5))1TA4.B`C
M9C!F,&8P.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Y,"4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M415A4+4%,24=..B!J
M=7-T:69Y.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G
M0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/G1H92!A8FEL:71Y('1O
M(&%C:&EE=F4@;6EL97-T;VYE<R!U;F1E<B!L:6-E;G-I;F<@87)R86YG96UE
M;G1S.SPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P
M9C`[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%4BU2
M24=(5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[(&9O
M;G0M<VEZ93H@,3!P=#LG/B`F(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9C!F,&8P.R!"3U)$15(M3$5&
M5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#
M3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V8P9C!F,#L@
M0D]21$52+5))1TA4.B`C9C!F,&8P.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1T;W`@=VED=&@],T0T)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H
M.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B
M;&%C:SL@9F]N="US:7IE.B`Q,'!T.R<^("8C.#DP,3L\+V9O;G0^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9C!F,&8P.R!"
M3U)$15(M3$5&5#H@(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@.3`E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M("-F,&8P9C`[($)/4D1%4BU224=(5#H@(V8P9C!F,#L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.3`E/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@
M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U3
M25I%.B`Q,'!T)SYT:&4@8V]S=',@:6YV;VQV960@:6X@<')O<V5C=71I;F<@
M86YD(&5N9F]R8VEN9R!P871E;G0@8VQA:6US(&%N9"!O=&AE<B!I;G1E;&QE
M8W1U86P@<')O<&5R='D@<FEG:'1S.R!A;F0\+V9O;G0^/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-F,&8P
M9C`[($)/4D1%4BU,1494.B`C9C!F,&8P.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z("-F,&8P9C`[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G8V]L;W(Z(&)L86-K.R!F;VYT+7-I>F4Z(#$P<'0[)SX@)B,Q-C`[
M/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P9C`[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z("-F,&8P9C`[($)/4D1%4BU224=(5#H@(V8P9C!F,#L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[(&9O;G0M<VEZ93H@,3!P=#LG
M/B`F(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(V8P9C!F,#L@0D]21$52+4Q%1E0Z("-F,&8P9C`[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DP)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9C!F,&8P.R!"3U)$15(M4DE'2%0Z
M("-F,&8P9C`[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#DP)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS
M1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^=&AE(&-O<W1S(&%N
M9"!T:6UI;F<@;V8@<F5G=6QA=&]R>2!A<'!R;W9A;',N/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS
M1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@
M:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$
M)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!H
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M25I%.B`Y<'0G/E--/"]F;VYT/CPO<W5P/B`\9F]N="!S='EL93TS1"=#3TQ/
M4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^06=R965M96YT('1H870@:70@
M96YT97)E9"!I;G1O('=I=&@@0V%N=&]R($9I='IG97)A;&0@)F%M<#L@0V\N
M+"!A<R!S86QE<R!A9V5N="P@=&AA="!P<F]V:61E<R!T:&4@86)I;&ET>2!T
M;R!C;VYD=6-T(&%N(&%T+71H92UM87)K970@*$%432D@<'5B;&EC(&]F9F5R
M:6YG(&9O<B!U<"!T;R`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
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M:69Y.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G0T],
M3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I
M=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=#3TQ/
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M<F1E<CTS1#`@('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF
M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V
M,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V
M95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E
M=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI8V%L($QA
M8F]R871O<GD@86YD($YO=&4@4F5C96EV86)L93QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-O;G1I;G5E9"!/
M<&5R871I;VYS(&%N9"!$:7-P;W-A;"!'<F]U<',@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES<&]S
M86P@1W)O=7!S+"!);F-L=61I;F<@1&ES8V]N=&EN=65D($]P97)A=&EO;G,L
M($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68@)SX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[
M($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^)B,Q-C`[/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX\+V9O;G0^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@
M(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@
M/"]F;VYT/C,N/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E
M8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DV)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$
M15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#DV)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQS=')O;F<^/&9O;G0@<W1Y;&4],T0G0T],
M3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.T1I<V-O;G1I;G5E
M9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N
M9"!.;W1E(%)E8V5I=F%B;&4\+V9O;G0^/"]S=')O;F<^/"]D:78^(#PO=&0^
M(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z("TS,2XY<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,S$N.7!T)SX@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
M="<^3VX@36%R8V@@."P@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"!A;&P@;V8@
M:71S(&EN=&5R97-T(&EN($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y+"!,
M3$,@*'1H92`F(S@R,C`[3&%B)B,X,C(Q.RD@=&\@2&%R=&QA8BP@3$Q#+"!A
M;B!E;G1I='D@8V]N=')O;&QE9"!B>2!T:&4@3&%B)B,X,C$W.W,@9F]R;65R
M(&]W;F5R+B!);B!C;VYN96-T:6]N('=I=&@@=&AE('-A;&4@;V8@=&AE($QA
M8BP@=&AE(&-O;G-I9&5R871I;VX@<F5C96EV960@=V%S("AI*2!T:&4@:6UM
M961I871E(&%S<VEG;FUE;G0@;V8@=&AE($QA8B8C.#(Q-SMS(&]U='-T86YD
M:6YG(&%C8V]U;G1S(')E8V5I=F%B;&4@=7`@=&AR;W5G:"!T:&4@9&%T92!O
M9B!C;&]S:6YG+"!P;'5S("AI:2D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/C<P,"PP,#`\+V9O;G0^('!A>6%B;&4@<'5R<W5A;G0@=&\@=&AE('1E
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M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,L('1H92!N;W1E(')E8V5I
M=F%B;&4@86YD(&%S<V]C:6%T960@:6YT97)E<W0@<F5C96EV86)L92!W97)E
M(&1E96UE9"!U;F-O;&QE8W1I8FQE+B!!8V-O<F1I;F=L>2P@=&AE($-O;7!A
M;GD@<F5C;W)D960@8F%D(&1E8G0@97AP96YS92!O9B`D/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^-S8S/"]F;VYT/BPP,#`N/"]F;VYT/CPO9F]N=#X\
M+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I
M;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@
M8FQA8VL[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2
M.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SY);B!A8V-O<F1A;F-E('=I=&@@
M/&9O;G0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G
M/B!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VX@*"8C.#(R,#M!
M4T,F(S@R,C$[*3PO9F]N=#X@5&]P:6,@,C`U+3(P("8C.#(R,#L\:3Y0<F5S
M96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',M1&ES8V]N=&EN=65D
M($]P97)A=&EO;G,\+VD^)B,X,C(Q.R`H05-#(#(P-2TR,"DL('1H92!#;VUP
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`R.2XW<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N
M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M
M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL
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M9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,3(@87)E(&%S(&9O;&QO=W,@
M/&D^*&EN('1H;W5S86YD<RDZ/"]I/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^/"]F;VYT/B8C,38P.R`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.
M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V
M8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$
M15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B
M-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0S)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,C<E(&-O;'-P86X],T0U/B`\9&EV/E1H<F5E
M)B,Q-C`[36]N=&AS)B,Q-C`[96YD960F(S$V,#M397!T96UB97(F(S$V,#LS
M,"P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(W)2!C;VQS<&%N/3-$
M-3X@/&1I=CY.:6YE)B,Q-C`[36]N=&AS)B,Q-C`[96YD960F(S$V,#M397!T
M96UB97(F(S$V,#LS,"P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0T,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/B`\9&EV/C(P,3(\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CXR
M,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0S)3X@/&1I
M=CY,86)O<F%T;W)Y(&9E97,L(&YE=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,34\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0T,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU,1494.B`Q
M,'!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#,E/B`\9&EV/D=E
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3`T/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
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M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
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M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+4Q%
M1E0Z(#$P<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T,R4^(#QD
M:78^5&]T86P@;W!E<F%T:6YG(&-O<W1S(&%N9"!E>'!E;G-E<SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3`T/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-#`S/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#,E/B`\9&EV/DQO<W,@9G)O;2!D
M:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^*#$P-"D\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/B@R.#@I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-#,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#,E/B`\9&EV/D]T
M:&5R($EN8V]M93H\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU,1494.B`Q,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-#,E/B`\9&EV/D=A:6X@;VX@<V%L92!O9B!!9&5O;F$@0VQI;FEC86P@
M3&%B;W)A=&]R>3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/C8W-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#0S)3X@/&1I=CY);F-O;64@*&QO<W,I(&9R;VT@9&ES8V]N=&EN=65D(&]P
M97)A=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$R)3X@/&1I=CXH,3`T*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
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M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX@/"]F;VYT/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^
M(#QT86)L92!B;W)D97(],T0P("!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L
M92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?
M83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS
M:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E
M($1I<V-L;W-U<F5S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF("<^(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[(%=)1%1(.B`Q,#`E)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(]
M,T0P/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"
M3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!724142#H@,B4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0R)3X@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C
M96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$
M5$@Z(#(E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^-"X\+V9O;G0^/"]S=')O;F<^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M
M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@
M,&EN.R!724142#H@.38E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N
M="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.38E/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN
M(#!P="<^(#QS=')O;F<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!#3TQ/4CH@8FQA8VLG/B8C,38P.T9A:7(@5F%L=64@;V8@1FEN86YC:6%L
M($EN<W1R=6UE;G1S/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`R.2XW<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE.
M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`R.2XW<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[1D].5"U325I%.B`Q,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T)SX@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5TE$5$@Z(#$P,"4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E
M<CTS1#`^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[
M($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED
M.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'
M+5))1TA4.B`P:6X[(%=)1%1(.B`T)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A
M;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO
M9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E
M8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@
M(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0
M041$24Y'+5))1TA4.B`P:6X[(%=)1%1(.B`S)3L@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@8FQA8VL[)SX\
M9F]N=#XF(S$X,SL\+V9O;G0^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E
M.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]2
M1$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z
M(#DS)3L@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#DS)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^3&5V
M96P@,2!I;G!U=',Z(%%U;W1E9"!P<FEC97,@*'5N861J=7-T960I)B,Q-C`[
M9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@;&EA8FEL:71I97,@:6X@86-T:79E
M(&UA<FME=',[/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0@,S$N.7!T.R!415A4+4E.1$5.
M5#H@+3$U+C1P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0T],3U(Z(&)L86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0G/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!724142#H@,3`P)2<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$
M,#X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED.#L@0D]2
M1$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E.60X.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@5TE$5$@Z(#0E.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A
M<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+51/4#H@(V5C93ED
M.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$15(M0D]45$]-.B`C96-E
M.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+51/4#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#,E.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4^(#QD:78@<W1Y
M;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B!B;&%C:SLG/CQF;VYT
M/B8C,3@S.SPO9F]N=#X\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[
M($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M
M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@.3,E
M.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.3,E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[5$585"U!
M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY,979E;"`R
M(&EN<'5T<SH@26YP=71S+"!O=&AE<B!T:&%N('%U;W1E9"!P<FEC97,@:6YC
M;'5D960@:6X@3&5V96P@,2!T:&%T(&%R92!O8G-E<G9A8FQE(&5I=&AE<B!D
M:7)E8W1L>2!O<B!I;F1I<F5C=&QY.R!A;F0\+V9O;G0^/"]D:78^(#PO=&0^
M(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="`S
M,2XY<'0[(%1%6%0M24Y$14Y4.B`M,34N-'!T)SX@/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\
M+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.T9/3E0M4TE:13H@,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="<^(#QT86)L92!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[(%=)1%1(
M.B`Q,#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)2!B;W)D97(],T0P/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M
M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"
M3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C
M93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@-"4[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0T
M)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L
M86-K)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/
M4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&
M5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@,&EN.R!724142#H@,R4[($)!
M0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT)R!V86QI9VX],T1T;W`@=VED
M=&@],T0S)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@8V]L
M;W(Z(&)L86-K.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%
M4BU224=(5#H@(V5C93ED.#L@0D]21$52+4)/5%1/33H@(V5C93ED.#L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+5))1TA4
M.B`P:6X[(%=)1%1(.B`Y,R4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT)R!V86QI9VX],T1T;W`@=VED=&@],T0Y,R4^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#M415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!I;B`P
M:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/
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M15A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,CDN-W!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)
M3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`R.2XW<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/
M3$]2.B!B;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@
M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],
M3U(Z(&)L86-K)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&EN8VQU9&4@
M;6]N97D@;6%R:V5T(&%C8V]U;G1S)B,Q-C`[;V8@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C4N,3PO9F]N=#X@;6EL;&EO;B!A;F0@)#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$P+C`\+V9O;G0^(&UI;&QI;VX@87,@;V8@
M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,BP@<F5S
M<&5C=&EV96QY+"!T:&%T(&%R92!M96%S=7)E9"!U<VEN9R!,979E;"`Q(&EN
M<'5T<RX\+V9O;G0^/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S='EL93TS
M1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B
M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A
M,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?
M-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970Q,"YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-E;&5C=&5D($)A;&%N8V4@
M4VAE970@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VXL($-O;G-O;&ED871I
M;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=7!P;&5M96YT86P@0F%L86YC92!3:&5E="!$:7-C;&]S=7)E
M<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<@/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!7
M24142#H@,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X@/'1R/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!"3U)$
M15(M0D]45$]-.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D]21$52+4Q%1E0Z
M("-E8V4Y9#@[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@5TE$5$@Z(#(E.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2
M.B!B;&%C:R<^)B,Q-C`[(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V9O;G0^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M
M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y9#@[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU224=(5#H@
M,&EN.R!724142#H@,B4[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT
M)R!V86QI9VX],T1T;W`@=VED=&@],T0R)3X@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQS=')O;F<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^-2X\+V9O;G0^/"]S=')O;F<^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[($)/4D1%4BU"3U143TTZ("-E8V4Y
M9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU224=(5#H@,&EN.R!724142#H@.38E.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.38E/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/'-T<F]N
M9SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C
M:R<^)B,Q-C`[4V5L96-T960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO;CPO
M9F]N=#X\+W-T<F]N9SX\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D
M:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,CDN-W!T)R!A;&EG;CTS1&IU<W1I9GD^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG
M/B`F(S$V,#L\+V9O;G0^/"]I/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQI
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M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\:3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^("8C
M,38P.SPO9F]N=#X\+VD^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q,#`E.R!415A4+4E.1$5.
M5#H@,&EN)SX@/'1A8FQE('-T>6QE/3-$)T]615)&3$]7.B!V:7-I8FQE.R!"
M3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C
M.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($U!4D=)3CH@,&EN
M.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@<V]L:60[(%=)1%1(.B`Q,#`E
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F
M=#X@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^4V5P=&5M8F5R)B,Q-C`[,S`L
M)B,Q-C`[,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG
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M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!
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M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
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M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0W,24^(#QD:78^4')E<&%I9"!E>'!E;G-E<SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C$P-#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C@P/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV/E1O=&%L/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@1D].5"U714E'2%0Z(#0P,#L@0T],3U(Z(",P,#`P,#`[($9/3E0M
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M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV
M/C(L-3`Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)SX\+V1I=CX@/"]D:78^
M(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M("<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
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M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,CDN-W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B`F(S$V,#L\+V9O
M;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX\+V9O;G0^4')O<&5R='D@86YD(&5Q=6EP;65N="`H
M:6X@=&AO=7-A;F1S*3PO9F]N=#X\+VD^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X@)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P
M:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/CPO9F]N
M=#XF(S$V,#L@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.R!724142#H@,3`P
M)3L@5$585"U)3D1%3E0Z(#!I;B<^(#QT86)L92!S='EL93TS1"=/5D521DQ/
M5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/
M4D1%4BU224=(5#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED
M.R!-05)'24XZ(#!I;CL@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED
M.R!724142#H@,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$-S$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY3
M97!T96UB97(F(S$V,#LS,"PF(S$V,#LR,#$S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/B`\9&EV/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q
M,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
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M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,CDW/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$-S$E/B`\9&EV/D-O;7!U=&5R(&%N9"!O9F9I8V4@97%U
M:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))
M1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C0U/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
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M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E
M/B`\9&EV/C,U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\
M9&EV/DQA8F]R871O<GD@97%U:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,3,S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'
M2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,3,S/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4
M.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C,S,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U
M<'@G('=I9'1H/3-$,3(E/B`\9&EV/C0V-3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M=&EO;CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!W:61T:#TS1#$R)3X@/&1I=CXH,3<S*3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T
M:#TS1#$R)3X@/&1I=CXH,C0R*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#<Q)3X@/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)
M3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,34W/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.R`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M+V1I=CX@/"]D:78^(#PO9&EV/B`\=&%B;&4@8F]R9&5R/3-$,"`@<W1Y;&4]
M,T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A
M8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X
M7S4R9C$V,C8Q86)C-"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP
M96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$:7-C;&]S=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D
M($-O<W1S+"!3:&%R92UB87-E9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;&]S
M=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R92UB87-E
M9"!087EM96YT<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<@/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\=&%B;&4@
M<W1Y;&4],T0G5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E
M8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z
M('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%
M4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M415A4
M+4E.1$5.5#H@,CDN-W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/
M4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C
M96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/'-T<F]N9SX\9F]N="!S
M='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^-BX\+V9O
M;G0^/"]S=')O;F<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.38E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C
M93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.38E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P="<^/'-T<F]N9SX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N
M/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M
M,S$N.7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#,Q+CEP="<^(#QF;VYT('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!I;B`P:6X@,'!T)SX@/'-T<F]N9SX\:3X\9F]N="!S='EL93TS1"=#3TQ/
M4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^4W1O8VL@26YC96YT:79E(%!L
M86X\+V9O;G0^/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(Y+C=P=#L@34%21TE..B`P:6X@,&EN
M(#!P="<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE
M87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^
M/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G
M/D1U<FEN9R`R,#`Q+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I
M<F5C=&]R<R!A;F0@<W1O8VMH;VQD97)S(&%D;W!T960@=&AE(#(P,#$@4W1O
M8VL@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[,C`P,2!3=&]C:R!0;&%N
M)B,X,C(Q.RDN(%1H92!T;W1A;"!N=6UB97(@;V8@<VAA<F5S(&]F('-T;V-K
M('=I=&@@<F5S<&5C="!T;R!W:&EC:"!S=&]C:R!O<'1I;VYS(&%N9"!S=&]C
M:R!A<'!R96-I871I;VX@<FEG:'1S(&UA>2!B92!G<F%N=&5D('1O(&%N>2!O
M;F4@96UP;&]Y964@;V8@=&AE($-O;7!A;GD@;W(@82!S=6)S:61I87)Y(&1U
M<FEN9R!A;GD@;VYE+7EE87(@<&5R:6]D('5N9&5R('1H92`R,#`Q(%-T;V-K
M(%!L86X@<VAA;&P@;F]T(&5X8V5E9"`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX@,C4P+#`P,#PO9F]N=#XN($%L;"!A=V%R9',@<'5R<W5A;G0@=&\@
M=&AE(#(P,#$@4W1O8VL@4&QA;B!S:&%L;"!T97)M:6YA=&4@=7!O;B!T:&4@
M=&5R;6EN871I;VX@;V8@=&AE(&=R86YT964F(S@R,3<[<R!E;7!L;WEM96YT
M(&9O<B!A;GD@<F5A<V]N+B!!=V%R9',@:6YC;'5D92!O<'1I;VYS+"!R97-T
M<FEC=&5D('-H87)E<RP@<W1O8VL@87!P<F5C:6%T:6]N(')I9VAT<RP@<&5R
M9F]R;6%N8V4@<VAA<F5S(&%N9"!C87-H+6)A<V5D(&%W87)D<R`H=&AE("8C
M.#(R,#M!=V%R9',F(S@R,C$[*2X@5&AE(#(P,#$@4W1O8VL@4&QA;B!C;VYT
M86EN<R!C97)T86EN(&%N=&DM9&EL=71I;VX@<')O=FES:6]N<R!I;B!T:&4@
M979E;G0@;V8@82!S=&]C:R!S<&QI="P@<W1O8VL@9&EV:61E;F0@;W(@;W1H
M97(@8V%P:71A;"!A9&IU<W1M96YT+"!A<R!D969I;F5D(&EN('1H92!P;&%N
M+B!4:&4@,C`P,2!3=&]C:R!0;&%N('!R;W9I9&5S(&9O<B!A($-O;6UI='1E
M92!O9B!T:&4@0F]A<F0@=&\@9W)A;G0@07=A<F1S(&%N9"!T;R!D971E<FUI
M;F4@=&AE(&5X97)C:7-E('!R:6-E+"!V97-T:6YG('1E<FTL(&5X<&ER871I
M;VX@9&%T92!A;F0@86QL(&]T:&5R('1E<FUS(&%N9"!C;VYD:71I;VYS(&]F
M('1H92!!=V%R9',L(&EN8VQU9&EN9R!A8V-E;&5R871I;VX@;V8@=&AE('9E
M<W1I;F<@;V8@86X@07=A<F0@870@86YY('1I;64N($%S(&]F(%-E<'1E;6)E
M<B`S,"P@,C`Q,RP@=&AE<F4@=V5R92`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@.34S+#4P-SPO9F]N
M=#X\+V9O;G0^(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!U;F1E
M<B!T:&4@,C`P,2!3=&]C:R!0;&%N+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M:G5S=&EF>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:
M13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
M="<^3VX@36%R8V@@,C`L(#(P,#<L('1H92!#;VUP86YY)B,X,C$W.W,@0F]A
M<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D('1H92`R,#`W(%-T;V-K($EN8V5N
M=&EV92!0;&%N("AT:&4@)B,X,C(P.S(P,#<@4W1O8VL@4&QA;B8C.#(R,3LI
M(&9O<B!T:&4@:7-S=6%N8V4@;V8@=7`@=&\@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(#(L-3`P+#`P,#PO9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S
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M92!E>&5R8VES92!P<FEC92!O9B!S=&]C:R!O<'1I;VYS('5N9&5R('1H92`R
M,#`W(%-T;V-K(%!L86X@:7,@9&5T97)M:6YE9"!B>2!T:&4@8V]M<&5N<V%T
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M<FEO9"!U;F1E<B!T:&4@,C`P-R!P;&%N('-H86QL(&YO="!E>&-E960@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#(U,"PP,#`\+V9O;G0^+B!/<'1I
M;VYS(&)E8V]M92!E>&5R8VES86)L92!O=F5R('9A<FEO=7,@<&5R:6]D<R!F
M<F]M('1H92!D871E(&]F(&=R86YT+"!A;F0@9V5N97)A;&QY(&5X<&ER92!T
M96X@>65A<G,@869T97(@=&AE(&=R86YT(&1A=&4N($%S(&]F(%-E<'1E;6)E
M<B`S,"P@,C`Q,RP@=&AE<F4@87)E(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`T-#,L-3<S/"]F;VYT
M/CPO9F]N=#X@;W!T:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG('5N9&5R
M('1H92`R,#`W(%-T;V-K(%!L86XN/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(Y+C=P=#L@34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/
M3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F;VYT/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN
M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:SL@1D].5"U325I%.B`Q,'!T)SY/;B!.;W9E;6)E<B`R+"`R,#$P+"!T
M:&4@0F]A<F0@;V8@1&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E<G,@861O<'1E
M9"!T:&4@,C`Q,"!3=&]C:R!);F-E;G1I=F4@4&QA;B`H)B,X,C(P.S(P,3`@
M4W1O8VL@4&QA;B8C.#(R,3LI(&9O<B!T:&4@:7-S=6%N8V4@;V8@=7`@=&\@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#,L,#`P+#`P,#PO9F]N=#X@
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M92`R,#$P(%-T;V-K(%!L86X@:7,@9&5T97)M:6YE9"!B>2!T:&4@8V]M<&5N
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M>65A<G,@869T97(@=&AE(&=R86YT(&1A=&4N($%S(&]F(%-E<'1E;6)E<B`S
M,"P@,C`Q,RP@=&AE<F4@87)E(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`R+#0P-RPU,#`\+V9O;G0^
M/"]F;VYT/B!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@
M=&AE(#(P,3`@4W1O8VL@4&QA;BX\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,CDN-W!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G0T],
M3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]D
M:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B`G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\
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M+B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#Y4:&4@0FQA8VLM4V-H;VQE<R!A
M<W-U;7!T:6]N<R!U<V5D(&EN('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R(&%R92!A<R!F;VQL
M;W=S.CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`S,2XY<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N
M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M
M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS
M1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T)R!A;&EG;CTS1&-E;G1E<CX@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@
M5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU,1494.B`C.65B-F-E(#!P>"!S
M;VQI9#L@34%21TE..B`P:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@
M(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C92`P<'@@
M<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-R4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#(Y)2!C;VQS<&%N/3-$,SX@/&1I=CY4:')E928C,38P.TUO
M;G1H<R8C,38P.T5N9&5D)B,Q-C`[4V5P=&5M8F5R)B,Q-C`[,S`L/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,S$E(&-O;'-P86X],T0U/B`\9&EV/DYI;F4F(S$V,#M-;VYT
M:',F(S$V,#M%;F1E9"8C,38P.U-E<'1E;6)E<B8C,38P.S,P+#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,W)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@
M/&1I=CXR,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^
M(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q-B4^(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,W)3X@/&1I=CY%>&5R
M8VES92!P<FEC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,38E/B`\9&EV/B0Q+CDV+28C,38P.R0R+C(W/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$N-S0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q-B4^(#QD:78^)#$N-S`M)B,Q-C`[)#(N-#<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R
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M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,38E/B`\9&EV/C`E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3(E/B`\9&EV/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0S-R4^(#QD:78^17AP96-T960@=F]L871I;&ET>3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXQ-3,E/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/C$T.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V
M)3X@/&1I=CXQ,#@E)B,Q-C`[+28C,38P.S$W-"4\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^,"XV,R4F
M(S$V,#LM)B,Q-C`[,"XV-24\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XW-SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXP+C,W
M)28C,38P.RTF(S$V,#LQ+CDX)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#,W)3X@/&1I=CY%>'!E8W1E9"!L:69E(&]F(&]P=&EO;CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXU)B,Q-C`[>65A<G,F(S$V
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M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/C4@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^-28C,38P.WEE87)S)B,Q
M-C`[)B,Q-3`[)B,Q-C`[,3`F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#,W)3X@/&1I=CY%>'!E8W1E9"!F;W)F96ET=7)E<SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD
M:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXP)3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,38E/B`\9&EV/C`E(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\
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M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)SX\+V1I=CX@/"]D:78^
M(#PO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,CDN-W!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L
M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
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M;W5S('1E<FUS(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,Q+CEP=#L@34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/
M3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F;VYT/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX@/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y
M9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#<E
M/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A
M<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z
M("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C.#DP,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@(V5C
M93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@
M=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.#<E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%
M4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K
M.R!&3TY4+5-)6D4Z(#$P<'0G/FEM;65D:6%T92!V97-T:6YG+#PO9F]N=#X\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED
M.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-R4^
M(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E8V4Y9#@[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R
M96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@
M(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:
M13H@,3!P="<^)B,X.3`Q.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E
M.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X-R4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52
M+5))1TA4.B`C96-E.60X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`@=VED=&@],T0X-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[
M($9/3E0M4TE:13H@,3!P="<^:&%L9B!V97-T:6YG(&EM;65D:6%T96QY(&%N
M9"!T:&4@<F5M86EN9&5R(&]V97(@=&AR964@>65A<G,L/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C96-E.60X.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0W)3X@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E
M.60X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0V
M)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q
M,'!T)SXF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z("-E8V4Y9#@[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@W)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'
M2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#@W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].
M5"U325I%.B`Q,'!T)SYQ=6%R=&5R;'D@;W9E<B!T:')E92!Y96%R<RP\+V9O
M;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N
M=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'2%0Z("-E
M8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E.60X
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N
M<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M4DE'
M2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C.#DP,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@
M(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.#<E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L
M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/F%N;G5A;&QY(&]V97(@=&AR964@>65A
M<G,L/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@(V5C93ED
M.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A
M;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-R4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V5C93ED.#L@0D]21$52+5))
M1TA4.B`C96-E.60X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@
M=VED=&@],T0W)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"3U)$15(M3$5&5#H@
M(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V5C93ED.#L@0D]2
M1$52+5))1TA4.B`C96-E.60X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0V)3X@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C
M:SL@1D].5"U325I%.B`Q,'!T)SXF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#@W)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E
M.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#@W)3X@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T-/
M3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SYO;F4M=&AI<F0@:6UM961I
M871E('9E<W1I;F<@86YD(')E;6%I;FEN9R!A;FYU86QL>2!O=F5R('1W;R!Y
M96%R<RP\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C96-E
M.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T
M<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$15(M
M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494
M.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/
M3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"
M3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L
M86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#DP,3L\+V9O;G0^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"3U)$
M15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=2
M3U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@.#<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E
M8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#<E/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/F]N92!H86QF(&EM;65D
M:6%T92!V97-T:6YG('=I=&@@<F5M86EN:6YG('9E<W1I;F<@;W9E<B!N:6YE
M(&UO;G1H<RP\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,1494.B`C
M96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2
M.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`W)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X.R!"3U)$
M15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z
M(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#DP,3L\+V9O;G0^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C96-E.60X.R!"
M3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@.#<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#<E/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/F]N92!Q=6%R=&5R
M(&EM;65D:6%T92!V97-T:6YG('=I=&@@=&AE(')E;6%I;FEN9R!O=F5R('1H
M<F5E('EE87)S+#PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52+4Q%1E0Z
M("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],
M3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#<E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y9#@[($)/
M4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-R4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#M-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA
M8VL[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V5C93ED.#L@0D]21$52
M+4Q%1E0Z("-E8V4Y9#@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-E8V4Y
M9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-B4^(#QD:78@<W1Y;&4],T0G8VQE87(Z
M8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=#3TQ/
M4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^)B,X.3`Q.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[
M($)/4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`X-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@(V5C93ED.#L@0D]21$52+5))1TA4.B`C96-E.60X.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0X-R4^(#QD:78@<W1Y;&4]
M,T0G8VQE87(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^;VYE('%U87)T
M97(@:6UM961I871E('9E<W1I;F<@=VET:"!T:&4@<F5M86EN:6YG(&]V97(@
M,S,@;6]N=&AS.R!A;F0\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/4D1%4BU,
M1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`W)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C96-E.60X
M.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#<E/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G0T],3U(Z
M(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-E8V4Y9#@[($)/
M4D1%4BU,1494.B`C96-E.60X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C
M96-E.60X.R!"3U)$15(M4DE'2%0Z("-E8V4Y9#@[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8E/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#DP,3L\+V9O;G0^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C96-E
M.60X.R!"3U)$15(M3$5&5#H@(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@.#<E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z("-E8V4Y9#@[($)/4D1%4BU224=(5#H@(V5C93ED.#L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#<E/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P<'0G/FUO;G1H
M;'D@;W9E<B!T:')E92!Y96%R<RX\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^
M(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z("TQ-2XT<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@-C<N,7!T
M)SX@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N
M="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P="<^1'5R
M:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,L
M('1H92!#;VUP86YY(&=R86YT960@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^(#$Q-RPU,#`\+V9O;G0^(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!D
M:7)E8W1O<G,@:&%V:6YG(&%N(&%P<')O>&EM871E(&9A:7(@=F%L=64@;V8@
M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$X-2PP,#`\+V9O;G0^(&)A
M<V5D('5P;VX@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D
M96PN)B,Q-C`[1'5R:6YG('1H92!S86UE('!E<FEO9"!I;B`R,#$R+"!T:&4@
M0V]M<&%N>2!G<F%N=&5D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`Q
M+#@T,"PP,#`\+V9O;G0^(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C;VYS
M=6QT86YT<R!H879I;F<@86X@87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^-"XP/"]F;VYT/B!M:6QL:6]N
M(&)A<V5D('5P;VX@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@
M;6]D96PN/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[
M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#Y!('-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71I
M97,@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S+"!A;F0@9F]R('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!I<R!A<R!F;VQL;W=S.CPO9F]N
M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`S,2XY<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
M="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0[($9/3E0M4TE:13H@,3!P="<^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M
M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@
M(SEE8C9C92`P<'@@<V]L:60[($U!4D=)3CH@,&EN.R!724142#H@,3`P)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4[
M($)/4D1%4BU43U`Z(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(",Y96(V8V4@,'!X('-O;&ED)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0V)2!C;VQS<&%N/3-$,CX@/&1I=CY796EG
M:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^5V5I9VAT960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-C$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X]
M,T0R/B`\9&EV/D%V97)A9V4F(S$V,#M%>&5R8VES93PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#8E(&-O;'-P86X],T0R/B`\9&EV/D-O;G1R86-T=6%L/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DEN
M=')I;G-I8SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/D]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E!R
M:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#8E(&-O;'-P86X],T0R/B`\9&EV/DQI9F4\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E9A;'5E/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/D)A;&%N
M8V4@+2!$96-E;6)E<B`S,2P@,C`Q,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR
M+#DW.2PP,3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N,S0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
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M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C(L,#<U+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BXR,3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH
M,S<T+#@U,2D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C`N,S0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY&;W)F96ET
M960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(N,S<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-C$E/B`\9&EV/D)A;&%N8V4@+2!$96-E;6)E<B`S,2P@,C`Q
M,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+#0U,RPW-#8\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C$N-S@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^-BXT,R8C,38P.WEE
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,2PS,#@L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\
M9&EV/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$W+#4P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^,2XW-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,CDQ+#8V-BD\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C`N-SD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY&;W)F96ET960\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^*#0W-2PP,#`I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C(N,S$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\
M9&EV/D)A;&%N8V4@)B,Q-3`[(%-E<'1E;6)E<B`S,"P@,C`Q,R`M(&]U='-T
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M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXS+#@P-"PU.#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/C4N
M-S8F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/CDS,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0V,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY"86QA;F-E("8C,34P.R!3
M97!T96UB97(@,S`L(#(P,3,@+2!E>&5R8VES86)L93PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPY,#(L,S`W/"]D
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M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XV-SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0U)3X@/&1I=CXU+C(W)B,Q-C`[>65A<G,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY,#,L,#`P/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/D=R86YT(&1A
M=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@+2`R,#$S/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$X-2PP,#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^
M(#QD:78^5V5I9VAT960@879E<F%G92!G<F%N="!D871E(&9A:7(@=F%L=64@
M+2`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0V,24^(#QD:78^1W)A;G0@9&%T92!F86ER('9A;'5E
M(&]F(&]P=&EO;G,@9W)A;G1E9"`M(#(P,3(\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^-"PT-C@L,#`P/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY7
M96EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92`M(#(P,3(\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)V-L
M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@)B,Q-C`[/"]D:78^(#QD:78@
M<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG
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M=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R('=E<F4@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C,S."PP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^,SDU+#`P,#PO9F]N=#XL(')E<W!E8W1I=F5L>2P@
M86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+C(\+V9O;G0^(&UI
M;&QI;VX@86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+C,\+V9O
M;G0^(&UI;&QI;VX@9F]R('1H92!N:6YE(&UO;G1H('!E<FEO9',@96YD960@
M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DN/"]F
M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/
M3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F;VYT/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN
M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[07,@;V8@4V5P=&5M8F5R
M(#,P+"`R,#$S+"!T;W1A;"!U;G)E8V]G;FEZ960@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!S=&]C:R!O<'1I;VYS('=A
M<R`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,2XY/"]F;VYT/B!M:6QL
M:6]N+"!W:&EC:"!I<R!E>'!E8W1E9"!T;R!B92!E>'!E;G-E9"!T:')O=6=H
M($9E8G)U87)Y(#(P,38N/"]F;VYT/CPO9&EV/B`\+V1I=CX@/'1A8FQE(&)O
M<F1E<CTS1#`@('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF
M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V
M,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V
M95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E
M=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:R!0=7)C:&%S92!787)R
M86YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!0=7)C:&%S92!787)R86YT<R!;5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^/"]F;VYT/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^
M(#QS=')O;F<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/
M4CH@8FQA8VLG/C<N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4W1O
M8VL@4'5R8VAA<V4@5V%R<F%N=',\+V9O;G0^/"]S=')O;F<^/"]D:78^(#QD
M:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T)SX@
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/D]N($]C=&]B97(@,C4L
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M<FEC92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,2XV,#PO9F]N
M=#X@86YD(&$@;&EF92!O9B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@
M9FEV93PO9F]N=#X@>65A<G,N(%1H92!W87)R86YT<R!V97-T960@:6UM961I
M871E;'D@86YD(&5X<&ER92!/8W1O8F5R(#(U+"`R,#$W+B!3:6YC92!T:&5S
M92!W87)R86YT<R!W97)E(&=R86YT960@87,@<&%R="!O9B!A;B!E<75I='D@
M<F%I<V4L('1H92!#;VUP86YY(&AA<R!T<F5A=&5D('1H96T@87,@82!D:7)E
M8W0@;V9F97)I;F<@8V]S="X@5&AE(')E<W5L="!O9B!T:&4@=')A;G-A8W1I
M;VX@:&%S(&YO(&%F9F5C="!T;R!E<75I='DN($%S(&]F(%-E<'1E;6)E<B`S
M,"P@,C`Q,RP@86QL('1H92!W87)R86YT<R!W97)E(&]U='-T86YD:6YG+CPO
M9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`R.2XW<'0G(&%L:6=N/3-$:G5S
M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C:R<^
M3VX@36%R8V@@,34L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
M(&-O;G-U;'1I;F<@86=R965M96YT(&9O<B!A(&9I;F%N8VEA;"!C;VUM=6YI
M8V%T:6]N<R!P<F]G<F%M+"!F;W(@82!P97)I;V0@;V8@='=E;'9E(&UO;G1H
M<R!T:&%T(&)E9V%N(&]N($9E8G)U87)Y(#(P+"`R,#$R+B!!<R!C;VUP96YS
M871I;VX@9F]R('-U8V@@<')O9W)A;2P@=&AE(&-O;G-U;'1A;G0@:7,@<&%I
M9"!A(&UO;G1H;'D@9F5E(&%N9"!W:6QL(&)E(&ES<W5E9"!A('!E<F9O<FUA
M;F-E('=A<G)A;G0@97AE<F-I<V%B;&4@9F]R(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`R-3`L,#`P/"]F;VYT/B!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@8F%S960@;VX@86-H:65V96UE;G0@
M;V8@8V5R=&%I;B!S=&]C:R!P<FEC92!M:6QE<W1O;F5S+B!5<&]N(&EN:71I
M871I;VX@;V8@=&AE('!R;V=R86TL(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`U,"PP,#`\+V9O;G0^(&]F('1H92!P97)F;W)M86YC92!W87)R86YT
M<R!V97-T960N(%1H92!P97)F;W)M86YC92!W87)R86YT(&ES(&5X97)C:7-A
M8FQE(&9O<B!A('!E<FEO9"!O9B!T=V\@>65A<G,@9G)O;2!T:&4@9&%T92!O
M9B!I<W-U86YC92!F;W(@86X@97AE<F-I<V4@<')I8V4@97%U86P@=&\@=&AE
M('!R:6-E("@D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,BXR,#PO9F]N
M=#X@<&5R('-H87)E*2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!O;B!T:&4@9&%T92!O9B!E>&5C=71I;VX@*$UA<F-H(#$U+"`R,#$R
M*2X@26X@36%R8V@@,C`Q,RP@=&AE('!E<F9O<FUA;F-E('=A<G)A;G1S)B,X
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M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/C<V+#`P,#PO9F]N=#X@=VEL;"!B92!R96-O9VYI>F5D(&]V97(@
M=&AE(&]N92!Y96%R(&5X=&5N<VEO;B!P97)I;V0N/"]F;VYT/CPO9&EV/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#(Y+C=P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SX@)B,Q-C`[
M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY/;B!$96-E;6)E<B`R
M,"P@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V]N<W5L=&EN
M9R!A9W)E96UE;G0@9F]R(&9I;F%N8VEA;"!A9'9I<V]R>2!S97)V:6-E<RP@
M9F]R(&$@<&5R:6]D(&]F('1W96QV92!M;VYT:',N($%S(&-O;7!E;G-A=&EO
M;B!F;W(@<W5C:"!S97)V:6-E<RP@=&AE(&-O;G-U;'1A;G0@=V%S('!A:60@
M82!M;VYT:&QY(&9E92!A;F0@;VX@1F5B<G5A<GD@,BP@,C`Q,BP@=V%S(&ES
M<W5E9"!W87)R86YT<R!E>&5R8VES86)L92!F;W(@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^(#$P,"PP,#`\+V9O;G0^('-H87)E<R!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@5&AE('=A<G)A;G0@:7,@97AE
M<F-I<V%B;&4@=7!O;B!I<W-U86YC92!F;W(@82!P97)I;V0@;V8@9FEV92!Y
M96%R<R!F<F]M('1H92!D871E(&]F(&ES<W5E(&%T(&%N(&5X97)C:7-E('!R
M:6-E(&5Q=6%L('1O('1H92!P<FEC92`H)#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$N,30\+V9O;G0^*2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O
M;6UO;B!S=&]C:R!O;B!T:&4@9&%T92!O9B!I<W-U92X@07,@;V8@4V5P=&5M
M8F5R(#,P+"`R,#$S+"!A;&P@=&AE('=A<G)A;G1S('=E<F4@;W5T<W1A;F1I
M;F<N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#(Y+C=P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],
M3U(Z(&)L86-K)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L
M86-K)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D$@<W5M
M;6%R>2!O9B!W87)R86YT(&%C=&EV:71Y(&9O<B!T:&4@0V]M<&%N>2!F;W(@
M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@
M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&ES(&%S(&9O
M;&QO=W,Z/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#,Q+CEP="<^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF
M(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M&
M3TY4+5-)6D4Z(#$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q,#`E.R!415A4+4E.1$5.5#H@
M,&EN)SX@/'1A8FQE('-T>6QE/3-$)T]615)&3$]7.B!V:7-I8FQE.R!"3U)$
M15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B
M-F-E(#!P>"!S;VQI9#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@0D]2
M1$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($U!4D=)3CH@,&EN.R!"
M3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@<V]L:60[(%=)1%1(.B`Y-24G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\
M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!W:61T:#TS1#8V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^5V5I9VAT960F(S$V
M,#M!=F5R86=E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0V
M-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L
M.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/B`\9&EV/DYU;6)E<B8C,38P.V]F)B,Q-C`[5V%R<F%N=',\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^17AE<F-I<V4F(S$V,#M0<FEC
M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T
M)R!W:61T:#TS1#8V)3X@/&1I=CY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R
M,#$Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,RPR
M-3DL,3@V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C$N.34\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0V-B4^(#QD:78^1W)A;G1E
M9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
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M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
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M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E
M/B`\9&EV/C$N-S$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0V-B4^
M(#QD:78^17AE<F-I<V5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W
M:61T:#TS1#$R)3X@/&1I=CXH,2PW-C@L,38W*3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[
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M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\
M9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T:#TS1#$R)3X@/&1I=CXH.#0T+#,W
M,RD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
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M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV
M/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3(\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ
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M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)
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M3D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q
M,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
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M4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV/D5X97)C:7-E9#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
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M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@;&5F="<@=VED=&@],T0V-B4^(#QD:78^1F]R9F5I=&5D/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0V-B4^(#QD:78^0F%L86YC
M92!A="!397!T96UB97(@,S`L(#(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,2PV
M,S(L-3`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X
M)R!W:61T:#TS1#$R)3X@/&1I=CXQ+CDY/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^/"]F;VYT/CPO9&EV/B`\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`R.2XW
M<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B
M;&%C:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SX@
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:6YC;'5D960@:6X@
M9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,@<F5L871I;F<@
M=&\@=V%R<F%N=',@:7-S=65D('1O(&-O;G-U;'1A;G1S('=A<R`D/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^,#PO9F]N=#X@86YD("0\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SXQ+#`P,#PO9F]N=#X@9F]R('1H92!T:')E92!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!R97-P
M96-T:79E;'DL(&%N9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C(L
M,#`P/"]F;VYT/B!A;F0@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C(W
M,2PP,#`\+V9O;G0^(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DN/"]F;VYT/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN
M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z
M(&)L86-K)SXF(S$V,#L\+V9O;G0^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#Y!('-U;6UA<GD@;V8@86QL(&]U='-T86YD:6YG(&%N
M9"!E>&5R8VES86)L92!W87)R86YT<R!A<R!O9B!397!T96UB97(@,S`L(#(P
M,3,@:7,@87,@9F]L;&]W<SH\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
M,S$N.7!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/
M4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T)R!A;&EG;CTS1&-E;G1E<CX@/&1I=B!S='EL93TS1"=C;&5A
M<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.R!724142#H@,3`P)3L@5$585"U)3D1%3E0Z(#!I;B<@86QI9VX]
M,T1C96YT97(^(#QT86)L92!S='EL93TS1"=/5D521DQ/5SH@=FES:6)L93L@
M0D]21$52+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@
M(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!P
M>#IA=71O.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@<V]L:60[(%=)1%1(
M.B`X."4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1C96YT97(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L
M.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q-24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!C96YT97(G('=I9'1H/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C
M96YT97(G('=I9'1H/3-$,3DE(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D
M)B,Q-C`[079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
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M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$
M,38E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-E/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^(#QD:78^5V%R<F%N=',\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY7
M87)R86YT<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,3DE(&-O;'-P86X]
M,T0R/B`\9&EV/E)E;6%I;FEN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&
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M,38E(&-O;'-P86X],T0R/B`\9&EV/D%G9W)E9V%T93PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT
M97(G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/E!R:6-E/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G
M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D]U='-T86YD:6YG/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT
M97(G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-A8FQE
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C
M96YT97(G('=I9'1H/3-$,3DE(&-O;'-P86X],T0R/B`\9&EV/D-O;G1R86-T
M=6%L)B,Q-C`[3&EF93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@
M/&1I=CY);G1R:6YS:6,F(S$V,#M686QU93PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^
M(#QD:78^,2XQ-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\
M9&EV/C$P,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@
M/&1I=CXQ,#`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@<FEG:'0G('=I9'1H/3-$,3@E/B`\9&EV/C,N,S0F(S$V,#MY96%R
M<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$
M1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@/&1I=CXU-"PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,2XS,CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[
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M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)
M3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,3@L,3@R/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
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M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I=CXR+C(U
M)B,Q-C`[>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))
M1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C8L,#`P/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I
M9'1H/3-$,34E/B`\9&EV/C$N-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^-C,U
M+#@U-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
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M4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
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M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I=CXT+C`X)B,Q-C`[
M>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U
M<'@G('=I9'1H/3-$,34E/B`\9&EV/C4Q+#`P,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
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M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C(U,"PP,#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P
M>"<@=VED=&@],T0Q-24^(#QD:78^-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
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M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I=CXP+C0U)B,Q-C`[>65A<G,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I
M9'1H/3-$,34E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^
M,BXR,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
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M4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$
M,34E/B`\9&EV/C4Q-RPR-3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G
M('=I9'1H/3-$,3@E/B`\9&EV/C,N,38F(S$V,#MY96%R<SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^
M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
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M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
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M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I
M9'1H/3-$,34E/B`\9&EV/C8Q+#(P-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
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M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G('=I9'1H/3-$,3@E
M/B`\9&EV/C$N-C8F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[
M(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^+3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV
M/C,N-S4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@
M/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L
M969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS
M1#$U)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
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M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E
M/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)
M3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,2XY.3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
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M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[
M(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,2PT,S(L
M-3`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I
M=CXS+C`S)B,Q-C`[>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'
M+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C$Q,2PP,#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\+V1I
M=CX@/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E
M,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A
M8F,T+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O
M8VMH;VQD97)S)R!%<75I='D@3F]T92!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G
M($5Q=6ET>2!.;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG(#QD:78@<W1Y;&4],T0G8VQE87(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,&EN(#!I;B`P<'0@,S$N.7!T.R!415A4+4E.1$5.5#H@+3,Q
M+CEP="<^(#QB/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],
M3U(Z(&)L86-K)SXX+CPO9F]N=#X\+V(^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SXF(S$V,#L@/&(^4W1O8VMH;VQD
M97)S)B,X,C$W.R!%<75I='D\+V(^/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`S,2XY<'0[(%1%
M6%0M24Y$14Y4.B`M,S$N.7!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($-/3$]2.B!B;&%C:R<^1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY(&ES<W5E9"`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@,CDQ+#8V-CPO9F]N=#X@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:RP@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES
M92!O9B!S=&]C:R!O<'1I;VYS+"!F;W(@<')O8V5E9',@;V8@87!P<F]X:6UA
M=&5L>2`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C,Q+#`P,#PO9F]N
M=#XN/"]F;VYT/CPO9&EV/B`\+V1I=CX@/'1A8FQE(&)O<F1E<CTS1#`@('-T
M>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^
M/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?
M83-C.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO<W,@<&5R
M(%-H87)E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYI;F=S
M(%!E<B!3:&%R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B`G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B`\+V9O;G0^/"]F;VYT/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2
M1TE..B`P:6X@,&EN(#!P="<^(#QB/CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:SL@1D].5"U325I%.B`Q,'!T)SXY+B!.970@3&]S<R!P97(@4VAA<F4\
M+V9O;G0^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQF
M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@
M)B,Q-C`[/"]F;VYT/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,&EN(#!I;B`P<'0G
M/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[($9/3E0M4TE:13H@,3!P
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M(&%N=&DM9&EL=71I=F4@870@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"`R,#$S
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M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@=V5R92`S+#@P-"PU.#`@
M86YD(#$L-C,R+#4P,2P@<F5S<&5C=&EV96QY+"!A;F0@9F]R('1H92!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(@=V5R92`T+#(U."PW
M-#8@86YD(#$L,S(T+#$P,BP@<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX@
M/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S='EL93TS1"=W:61T:#HQ,#`E
M.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E
M7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T
M+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D
M96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I=F%B;&4@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!A;F0@1&ES<&]S
M86P@1W)O=7!S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($1I<W!O<V%L($=R;W5P
M<R!);F-L=61I;F<@1&ES8V]N=&EN=65D($]P97)A=&EO;G,@26YC;VUE(%-T
M871E;65N="!A;F0@061D:71I;VYA;"!$:7-C;&]S=7)E<R!;5&%B;&4@5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T
M>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY4:&4@
M<W5M;6%R:7IE9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!D871A(&9O<B!!
M9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!F;W(@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,3(@
M87)E(&%S(&9O;&QO=W,@/&D^*&EN('1H;W5S86YD<RDZ/"]I/CPO9F]N=#X\
M+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^/"]F;VYT
M/B8C,38P.R`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,
M969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]2
M1$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$
M5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7
M.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]2
M1$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#0S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,C<E(&-O;'-P86X]
M,T0U/B`\9&EV/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[96YD960F(S$V,#M3
M97!T96UB97(F(S$V,#LS,"P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#(W)2!C;VQS<&%N/3-$-3X@/&1I=CY.:6YE)B,Q-C`[36]N=&AS)B,Q-C`[
M96YD960F(S$V,#M397!T96UB97(F(S$V,#LS,"P\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0T,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/C(P,3(\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$S)2!C;VQS
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M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#0S)3X@/&1I=CY,86)O<F%T;W)Y(&9E97,L(&YE=#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,34\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T,R4^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU,1494.B`Q,'!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-#,E/B`\9&EV/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3`T/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
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M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
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M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^
M,3$V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
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M>'!E;G-E<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3`T
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^-#`S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#,E/B`\
M9&EV/DQO<W,@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^*#$P-"D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@
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M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B@R.#@I/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-#,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-#,E/B`\9&EV/D]T:&5R($EN8V]M93H\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU,1494.B`Q,7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-#,E/B`\9&EV/D=A:6X@;VX@<V%L92!O9B!!
M9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C8W-SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#0S)3X@/&1I=CY);F-O;64@*&QO<W,I(&9R;VT@
M9&ES8V]N=&EN=65D(&]P97)A=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXH,3`T*3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
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M1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV
M/B`\+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^/"]F;VYT/CPO9&EV/B`\+V1I=CX@/'1A8FQE(&)O<F1E<CTS1#`@('-T
M>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^
M/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?
M83-C.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5L96-T960@0F%L
M86YC92!3:&5E="!);F9O<FUA=&EO;B`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO
M;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA
M;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($]T:&5R($-U<G)E
M;G0@07-S971S(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B!0<F5P86ED(&5X
M<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R`H:6X@=&AO=7-A;F1S
M*3PO9F]N=#X\+VD^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B`F(S$V
M,#L\+V9O;G0^/"]I/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M1D].5"U325I%.B`Q,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.R!724142#H@,3`P)3L@5$585"U)3D1%3E0Z
M(#!I;B<^(#QT86)L92!S='EL93TS1"=/5D521DQ/5SH@=FES:6)L93L@0D]2
M1$52+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE
M8C9C92`P<'@@<V]L:60[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($)/
M4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@
M0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!724142#H@,3`P)2<@
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M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/E-E<'1E;6)E<B8C,38P.S,P+"8C
M,38P.S(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^
M1&5C96UB97(F(S$V,#LS,2PF(S$V,#LR,#$R/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV
M/DEN=')E>&]N('!R97!A:60@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X
M<&5N<V5S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C$L-30S
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$
M24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C(L-#$R/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV/D]T:&5R(')E8V5I
M=F%B;&5S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R
M:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R)3X@/&1I=CXM
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[
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M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U
M<'@G('=I9'1H/3-$,3(E/B`\9&EV/C$W/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$-S$E/B`\9&EV/E!R97!A:60@97AP96YS97,\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
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M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@
M4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R)3X@/&1I=CXX,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#<Q)3X@/&1I=CY4;W1A;#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4
M.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C$L-C0W/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R
M:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R)3X@/&1I=CXR
M+#4P.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B
M;&4^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P="<^/"]D:78^(#PO9&EV/B`\
M+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S
M='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R
M/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;5&%B
M;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\
M9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@
M86QI9VX],T1J=7-T:69Y/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0T],3U(Z(&)L86-K)SX@4')O<&5R='D@86YD(&5Q=6EP;65N="`H
M:6X@=&AO=7-A;F1S*3PO9F]N=#X\+VD^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P.SPO9F]N=#X@)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P
M:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/CPO9F]N
M=#XF(S$V,#L@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.R!724142#H@,3`P
M)3L@5$585"U)3D1%3E0Z(#!I;B<^(#QT86)L92!S='EL93TS1"=/5D521DQ/
M5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/
M4D1%4BU224=(5#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED
M.R!-05)'24XZ(#!I;CL@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED
M.R!724142#H@,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$-S$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY3
M97!T96UB97(F(S$V,#LS,"PF(S$V,#LR,#$S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/B`\9&EV/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q
M,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
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M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,CDW/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$-S$E/B`\9&EV/D-O;7!U=&5R(&%N9"!O9F9I8V4@97%U
M:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))
M1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C0U/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
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M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E
M/B`\9&EV/C,U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-S$E/B`\
M9&EV/DQA8F]R871O<GD@97%U:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,3,S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'
M2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,3,S/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$-S$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4
M.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV/C,S,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U
M<'@G('=I9'1H/3-$,3(E/B`\9&EV/C0V-3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M=&EO;CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!W:61T:#TS1#$R)3X@/&1I=CXH,3<S*3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T
M:#TS1#$R)3X@/&1I=CXH,C0R*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#<Q)3X@/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)
M3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,34W/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.R`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M/"]F;VYT/CPO9&EV/B`\+V1I=CX@/'1A8FQE(&)O<F1E<CTS1#`@('-T>6QE
M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?83-C
M.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I
M;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@3W!T:6]N<R!A;F0@5V%R<F%N=',@
M5F5S=&5D(&%N9"!%>'!E8W1E9"!T;R!697-T($]U='-T86YD:6YG(&%N9"!%
M>&5R8VES86)L92!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SY4:&4@0FQA8VLM4V-H
M;VQE<R!A<W-U;7!T:6]N<R!U<V5D(&EN('1H92!T:')E92!A;F0@;FEN92!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R(&%R92!A
M<R!F;VQL;W=S.CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`S,2XY<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VL[
M($9/3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S
M='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T)R!A;&EG;CTS1&-E;G1E<CX@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z
M(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU,1494.B`C.65B-F-E
M(#!P>"!S;VQI9#L@34%21TE..B`P:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52
M+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C
M92`P<'@@<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-R4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#(Y)2!C;VQS<&%N/3-$,SX@/&1I=CY4:')E928C
M,38P.TUO;G1H<R8C,38P.T5N9&5D)B,Q-C`[4V5P=&5M8F5R)B,Q-C`[,S`L
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,S$E(&-O;'-P86X],T0U/B`\9&EV/DYI;F4F(S$V
M,#M-;VYT:',F(S$V,#M%;F1E9"8C,38P.U-E<'1E;6)E<B8C,38P.S,P+#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,W)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$R)3X@/&1I=CXR,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q-B4^(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,W)3X@/&1I
M=CY%>&5R8VES92!P<FEC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,38E/B`\9&EV/B0Q+CDV+28C,38P.R0R+C(W/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$N-S0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^)#$N-S`M)B,Q-C`[)#(N-#<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,38E/B`\9&EV
M/C`E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0S-R4^(#QD:78^17AP96-T960@=F]L871I;&ET>3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^
M+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXQ-3,E/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/C$T.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$V)3X@/&1I=CXQ,#@E)B,Q-C`[+28C,38P.S$W-"4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^
M,"XV,R4F(S$V,#LM)B,Q-C`[,"XV-24\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^
M,"XW-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I
M=CXP+C,W)28C,38P.RTF(S$V,#LQ+CDX)3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#,W)3X@/&1I=CY%>'!E8W1E9"!L:69E(&]F(&]P=&EO;CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD
M:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXU)B,Q-C`[>65A
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M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/C4@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^-28C,38P.WEE
M87)S)B,Q-C`[)B,Q-3`[)B,Q-C`[,3`F(S$V,#MY96%R<SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#,W)3X@/&1I=CY%>'!E8W1E9"!F;W)F96ET
M=7)E<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$V)3X@/&1I=CXP)3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,38E/B`\9&EV/C`E/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B
M;&4^(#PO9&EV/B`\+V1I=CX@/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S
M='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R
M/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!3:&%R92UB87-E9"!#;VUP96YS871I
M;VXL(%-T;V-K($]P=&EO;G,L($%C=&EV:71Y(%M486)L92!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R`\9&EV('-T>6QE
M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G
M8VQE87(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I
M9GD^/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!&3TY4+5-)6D4Z(#$P
M<'0G/D$@<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I=&EE<R!A<R!O
M9B!397!T96UB97(@,S`L(#(P,3,L(&%N9"!F;W(@=&AE('EE87(@96YD960@
M1&5C96UB97(@,S$L(#(P,3(L(&ES(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV
M/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,Q+CEP
M=#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q
M-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P:6X@,&EN(#!P=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=B!S='EL
M93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z
M(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU,1494.B`C.65B-F-E
M(#!P>"!S;VQI9#L@34%21TE..B`P:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52
M+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C
M92`P<'@@<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#8E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D/"]D
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M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#8E(&-O;'-P86X],T0R/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#8E(&-O;'-P86X],T0R/B`\9&EV/E)E;6%I;FEN9SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY!9V=R
M96=A=&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-B4@8V]L<W!A;CTS1#(^(#QD:78^0V]N=')A8W1U86P\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^26YT<FEN<VEC
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^3W!T:6]N
M<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-B4@8V]L<W!A;CTS1#(^(#QD:78^3&EF93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
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M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^0F%L86YC92`M($1E
M8V5M8F5R(#,Q+"`R,#$Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L.3<Y+#`Q
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^,2XS-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U)3X@/&1I
M=CXV+C`Q)B,Q-C`[>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-C$E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPP-S4L
M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@S-S0L.#4Q
M*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^,"XS-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/D9O<F9E:71E9#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXH,C(U+#0Q,RD\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BXS-SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0V,24^(#QD:78^0F%L86YC92`M($1E8V5M8F5R(#,Q+"`R,#$R/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C0L-#4S+#<T-CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XW
M.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0U)3X@/&1I=CXV+C0S)B,Q-C`[>65A<G,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+#,P."PP
M,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^1W)A
M;G1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,3<L-3`P/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#8Q)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@R.3$L-C8V*3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,"XW.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-C$E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXH-#<U+#`P,"D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,BXS,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-C$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^0F%L
M86YC92`F(S$U,#L@4V5P=&5M8F5R(#,P+"`R,#$S("T@;W5T<W1A;F1I;F<\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C,L.#`T+#4X,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C$N-SD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^-2XW-B8C,38P
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M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^.3,R+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-24^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-C$E/B`\9&EV/D)A;&%N8V4@)B,Q-3`[(%-E<'1E;6)E
M<B`S,"P@,C`Q,R`M(&5X97)C:7-A8FQE/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#DP,BPS,#<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C8W/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#4E/B`\9&EV/C4N,C<F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/CDP,RPP,#`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^1W)A;G0@9&%T92!F86ER
M('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"`M(#(P,3,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3@U+#`P,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CY7
M96EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92`M(#(P,3,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C$N-3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#8Q)3X@/&1I=CY'<F%N="!D871E(&9A:7(@=F%L=64@;V8@;W!T
M:6]N<R!G<F%N=&5D("T@,C`Q,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V9F8V,[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXT+#0V."PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C
M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/E=E:6=H=&5D
M(&%V97)A9V4@9W)A;G0@9&%T92!F86ER('9A;'5E("T@,C`Q,CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C(N,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\+V1I=CX@
M/"]D:78^(#QT86)L92!B;W)D97(],T0P("!S='EL93TS1"=W:61T:#HQ,#`E
M.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E
M7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T
M+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T;V-K(%!U<F-H87-E(%=A<G)A;G1S("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@5V%R<F%N="!!8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<@/&1I=B!S='EL93TS1"=C
M;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)V-L96%R
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY!
M('-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET>2!F;W(@=&AE($-O;7!A;GD@
M9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@
M86YD(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!I<R!A
M<R!F;VQL;W=S.CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`S,2XY<'0G
M/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($-/3$]2.B!B;&%C
M:R<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)V-L96%R.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[1D].5"U325I%.B`Q,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&1I
M=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.R!724142#H@,3`P)3L@5$585"U)3D1%
M3E0Z(#!I;B<^(#QT86)L92!S='EL93TS1"=/5D521DQ/5SH@=FES:6)L93L@
M0D]21$52+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@
M(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I
M;CL@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!724142#H@.34E
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F
M=#X@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0V-B4^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!C96YT97(G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C
M96YT97(G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D
M)B,Q-C`[079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H
M/3-$-C8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9B8C,38P.U=A<G)A;G1S/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-E)B,Q-C`[
M4')I8V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0V-B4^(#QD:78^0F%L86YC92!A="!$96-E;6)E<B`S
M,2P@,C`Q,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV
M/C,L,C4Y+#$X-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
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M.B!M:61D;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV/D=R
M86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'
M2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^.3@U+#@U-3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
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M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M-C8E/B`\9&EV/D5X97)C:7-E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
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M;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F
M8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q
M,B4^(#QD:78^,2XQ,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
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M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
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M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^
M(#QD:78^,RXS,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#8V)3X@
M/&1I=CY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'
M4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'
M2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,2PV,S(L-3`Q/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M
M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,2XY.3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/
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M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
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M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H
M/3-$,3(E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!
M1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
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M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@
M=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
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M;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV/D9O<F9E:71E
M9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$R)3X@/&1I
M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$-C8E/B`\9&EV/D)A
M;&%N8V4@870@4V5P=&5M8F5R(#,P+"`R,#$S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z
M("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA
M;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C
M9F9C8SL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,3(E/B`\9&EV
M/C$L-C,R+#4P,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%
M24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE
M9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q,B4^(#QD:78^,2XY.3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$
M.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\+V1I=CX@/"]D
M:78^(#QT86)L92!B;W)D97(],T0P("!S='EL93TS1"=W:61T:#HQ,#`E.R!T
M86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O
M9B!787)R86YT($]U='-T86YD:6YG(&%N9"!%>&5R8VES86)L92!;5&%B;&4@
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<@
M/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV
M('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0T],3U(Z(&)L86-K)SY!
M('-U;6UA<GD@;V8@86QL(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!W
M87)R86YT<R!A<R!O9B!397!T96UB97(@,S`L(#(P,3,@:7,@87,@9F]L;&]W
M<SH\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G8VQE87(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,S$N.7!T)SX@/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!#3TQ/4CH@8FQA8VLG/B8C,38P
M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)R!A;&EG
M;CTS1&-E;G1E<CX@/&1I=B!S='EL93TS1"=C;&5A<CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.R!724142#H@
M,3`P)3L@5$585"U)3D1%3E0Z(#!I;B<@86QI9VX],T1C96YT97(^(#QT86)L
M92!S='EL93TS1"=/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE
M8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C92`P<'@@<V]L
M:60[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($)/4D1%4BU"3U143TTZ
M(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!P>#IA=71O.R!"3U)$15(M
M3$5&5#H@(SEE8C9C92`P<'@@<V]L:60[(%=)1%1(.B`X."4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(^(#QT<CX@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C
M96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT
M97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M=VED=&@],T0Q-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H
M/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&
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M,3DE(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!C96YT97(G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L
M.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,38E(&-O;'-P86X],T0R
M/B`\9&EV/D5X97)C:7-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
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M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W
M:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY787)R86YT<SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!C96YT97(G('=I9'1H/3-$,3DE(&-O;'-P86X],T0R/B`\9&EV/E)E;6%I
M;FEN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
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M/B`\9&EV/D%G9W)E9V%T93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/B`\9&EV/E!R:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,38E(&-O
M;'-P86X],T0R/B`\9&EV/D]U='-T86YD:6YG/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-A8FQE/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!C96YT97(G('=I9'1H/3-$
M,3DE(&-O;'-P86X],T0R/B`\9&EV/D-O;G1R86-T=6%L)B,Q-C`[3&EF93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY);G1R:6YS:6,F
M(S$V,#M686QU93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!
M1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,2XQ-#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$
M24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C$P,"PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@
M1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$
M1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@/&1I=CXQ,#`L,#`P/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G('=I
M9'1H/3-$,3@E/B`\9&EV/C,N,S0F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/
M54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@
M;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU224=(5#H@-7!X
M)R!W:61T:#TS1#$U)3X@/&1I=CXU-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@
M(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L
M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)
M1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F
M="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$58
M5"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q
M-24^(#QD:78^,2XS,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
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M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@
M=VED=&@],T0Q-24^(#QD:78^,3@L,3@R/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
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M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I=CXR+C(U)B,Q-C`[>65A<G,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H
M/3-$,34E/B`\9&EV/C8L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV
M/C$N-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F
M9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M
M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'
M2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^-C,U+#@U-3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
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M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!W:61T:#TS1#$X)3X@/&1I=CXT+C`X)B,Q-C`[>65A<G,\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E
M/B`\9&EV/C4Q+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
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M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[
M($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,
M24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U
M<'@G('=I9'1H/3-$,34E/B`\9&EV/C(U,"PP,#`\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^
M(#QD:78^-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)R!W:61T
M:#TS1#$X)3X@/&1I=CXP+C0U)B,Q-C`[>65A<G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R
M;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M
M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,BXR,CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+
M1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4
M.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@
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M($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!
M3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C4Q-RPR
M-3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G('=I9'1H/3-$,3@E/B`\
M9&EV/C,N,38F(S$V,#MY96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!
M1$1)3D<M4DE'2%0Z(#5P>"<@=VED=&@],T0Q-24^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4
M+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
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M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
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M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV
M/C8Q+#(P-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
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M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@<FEG:'0G('=I9'1H/3-$,3@E/B`\9&EV/C$N-C8F(S$V
M,#MY96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5=%24=(
M5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q-24^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'
M+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/C,N-S4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#
M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,
M13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H=#L@4$%$
M1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@/&1I=CXU,"PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].
M5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H
M=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@/&1I=CXU,"PP
M,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C8V-F9F-C
M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M8V-F9F-C.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=.
M.B!R:6=H="<@=VED=&@],T0Q."4^(#QD:78^,BXS."8C,38P.WEE87)S/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)!0TM'4D]53D0Z("-C8V9F8V,[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V-C9F9C8SL@0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-C8V9F8V,[($)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+5))1TA4.B`U<'@G('=I9'1H/3-$,34E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/
M3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z(#5P>"<@
M=VED=&@],T0Q-24^(#QD:78^,2XY.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%
M6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'
M2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!R:6=H
M=#L@4$%$1$E.1RU224=(5#H@-7!X)R!W:61T:#TS1#$U)3X@/&1I=CXQ+#8S
M,BPU,#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z
M(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!"3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M4DE'2%0Z
M(#5P>"<@=VED=&@],T0Q-24^(#QD:78^,2PT,S(L-3`Q/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M5T5)1TA4.B`T,#`[($9/3E0M4U193$4Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@;&5F="<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L
M.R!415A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M86P[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!W:61T:#TS1#$X)3X@/&1I=CXS+C`S)B,Q-C`[>65A
M<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U714E'2%0Z(#0P
M,#L@1D].5"U35%E,13H@;F]R;6%L.R!415A4+4%,24=..B!L969T)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%1%6%0M04Q)1TXZ(&QE9G0G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+5))1TA4.B`U<'@G('=I
M9'1H/3-$,34E/B`\9&EV/C$Q,2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U714E'2%0Z(#0P,#L@1D].5"U35%E,13H@;F]R;6%L.R!4
M15A4+4%,24=..B!L969T)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^(#PO9&EV/B`\
M=&%B;&4@8F]R9&5R/3-$,"`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M
M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83!C-S5D-F5?93,V95\T,C`V7V$S
M8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-"]7;W)K<VAE
M971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$0T%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/DUA;F%G96UE;G0G<R!0;&%N("A$971A:6QS(%1E>'1U86PI
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^0V%N=&]R($9I='IG97)A;&0@
M06YD($-O(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2971A:6YE9"!%87)N:6YG<R`H06-C=6UU;&%T960@1&5F:6-I
M="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-S<L,#,T+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#8X+#DT,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0L
M(%9A;'5E+"!.97<@27-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,34L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R
M-C%A8F,T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$P8S<U9#9E
M7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-"]7;W)K<VAE971S+U-H965T
M,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$52-4%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,
M86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I=F%B;&4@*$1E=&%I;',I("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@0V]S=',@86YD($5X<&5N<V5S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PX.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#(W,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPW,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W1H97(@26YC;VUE.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92`H;&]S<RD@9G)O;2!D
M:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R
M>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&%B;W)A=&]R>2!F965S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@0V]S=',@86YD
M($5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T(&]F(&QA
M8F]R871O<GD@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!C;W-T<R!A;F0@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!F<F]M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R
M($EN8V]M93H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=A:6X@;VX@<V%L92!O9B!!9&5O;F$@0VQI;FEC86P@3&%B
M;W)A=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC;VUE("AL;W-S*2!F<F]M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X
M7S4R9C$V,C8Q86)C-"]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5524%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1I<V-O;G1I;G5E9"!/
M<&5R871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N9"!.
M;W1E(%)E8V5I=F%B;&4@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,#@L(#(P,3(\8G(^4')O;6ES<V]R>2!.;W1E(%M-96UB97)=/&)R/D%D
M96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y+"!,;&,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEN9R!296-E
M:79A8FQE+"!.970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&]N9RUT97)M($1E8G0L(%!E<F-E;G1A9V4@0F5A<FEN
M9R!687)I86)L92!);G1E<F5S="P@4&5R8V5N=&%G92!2871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C<P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N(&9O
M<B!5;F-O;&QE8W1I8FQE($YO=&4@86YD($EN=&5R97-T(%)E8V5I=F%B;&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<V,RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<V
M,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V
M7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D9A:7(@5F%L=64@
M;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S("A$971A:6QS(%1E>'1U86PI("A5
M4T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S+"!A="!#87)R>6EN9R!6
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W
M-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F
M,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14-$
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4V5L96-T960@0F%L86YC92!3
M:&5E="!);F9O<FUA=&EO;B`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1R97AO;B!P
M<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4T,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U
M,F8Q-C(V,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C
M-S5D-F5?93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O
M4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14Q'044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^4V5L96-T960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO;B`H1&5T
M86EL<R`Q*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5S<R!A8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%N=69A8W1U<FEN
M9R!E<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@1W)O
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M<'5T97(@86YD($]F9FEC92!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQA8F]R871O<GD@17%U:7!M96YT(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT
M(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V
M,6%B8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?
M93,V95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970R
M-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13-,04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#@N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN
M=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N-S<E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AP96-T960@;&EF92!O9B!O<'1I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<P('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP
M96-T960@9F]R9F5I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q+CDV/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q
M+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XV,R4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS-R4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#(N
M,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#(N-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S
M="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XV-24\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XY."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@;W!T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83!C-S5D-F5?93,V
M95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C
M-"]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$592T%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H
M1&5T86EL<R`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,L($)E9VEN;FEN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0U
M,RPW-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#DW.2PP,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PR-3@L-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS+"!'<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3<L-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-S4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,L($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,CDQ+#8V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S-S0L.#4Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS+"!&;W)F96ET
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W-2PP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(U
M+#0Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L.#`T+#4X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#4S+#<T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3<Y+#`Q
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,C4X+#<T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<RP@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L.3`R+#,P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E
M<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!'<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!%>&5R8VES92!0<FEC92P@17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!%>&5R8VES92!0<FEC92P@1F]R9F5I=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,S<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG($)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($5X97)C:7-A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4L
M($)A;&%N8V4@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<U('EE87)S(#D@;6]N=&AS(#0@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#4@;6]N
M=&AS(#4@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<V('EE87)S(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4L($5X97)C:7-A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`S(&UO;G1H<R`W
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($)E9VEN;FEN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M,S`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%;F1I
M;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,S`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%
M>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`S
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)A;G0@9&%T92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+#0V."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!G<F%N="!D871E(&9A
M:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XU
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BXQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V
M7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14,T04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4W1O8VLM0F%S
M960@0V]M<&5N<V%T:6]N("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/D5M<&QO>65E<R!!;F0@1&ER96-T;W)S(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^16UP;&]Y965S($%N9"!#;VYS=6QT86YT<R!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/D5M<&QO>65E<R!!;F0@0V]N<W5L=&%N=',@6TUE;6)E<ET\8G(^
M1V5N97)A;"!A;F0@061M:6YI<W1R871I=F4@17AP96YS97,@86YD(%)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^16UP
M;&]Y965S($%N9"!#;VYS=6QT86YT<R!;365M8F5R73QB<CY'96YE<F%L(&%N
M9"!!9&UI;FES=')A=&EV92!%>'!E;G-E<R!A;F0@4F5S96%R8V@@86YD($1E
M=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY%;7!L;WEE97,@06YD
M($-O;G-U;'1A;G1S(%M-96UB97)=/&)R/D=E;F5R86P@86YD($%D;6EN:7-T
M<F%T:79E($5X<&5N<V5S(&%N9"!297-E87)C:"!A;F0@1&5V96QO<&UE;G0@
M17AP96YS92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$R/&)R/D5M<&QO>65E<R!!;F0@0V]N<W5L=&%N
M=',@6TUE;6)E<ET\8G(^1V5N97)A;"!A;F0@061M:6YI<W1R871I=F4@17AP
M96YS97,@86YD(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^,C`P,2!3=&]C:R!0;&%N(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#$\8G(^,C`P
M,2!3=&]C:R!0;&%N(%M-96UB97)=/&)R/DUA>&EM=6T@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CXR,#`W(%-T;V-K(%!L86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`R,"P@,C`P-SQB<CXR,#`W(%-T;V-K(%!L
M86X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`P-SQB<CXR,#`W(%-T;V-K(%!L86X@6TUE;6)E<ET\8G(^
M36%X:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/C(P,3`@4W1O8VL@4&QA;B!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#`R+"`R
M,#$P/&)R/C(P,3`@4W1O8VL@4&QA;B!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L
M($]P=&EO;G,L($]U='-T86YD:6YG+"!.=6UB97(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.#`T+#4X,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#4S+#<T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C4X+#<T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.3<Y+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDU,RPU,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0S+#4W,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0P-RPU
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!'
M<F%N=',@:6X@4&5R:6]D+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@T,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34S+#4P-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-#,L-3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#0P-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@1F%I<B!686QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]C871E9"!3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Y-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@3F]N=F5S=&5D($%W87)D<RP@5&]T86P@0V]M<&5N<V%T:6]N($-O
M<W0@3F]T('EE="!296-O9VYI>F5D+"!3=&]C:R!/<'1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?83-C
M.%\U,F8Q-C(V,6%B8S0O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%-D=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!0=7)C:&%S
M92!787)R86YT<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M(%=A<G)A;G1S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV,S(L-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-3DL,3@V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,C0L,3`R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@5V%R<F%N=',L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY.#4L.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S+"!%
M>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<V
M."PQ-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S+"!&;W)F96ET960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-#0L,S<S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!787)R86YT<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-C,R+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,R+#4P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S(T+#$P,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG($)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($=R86YT960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($5X97)C:7-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!%>&5R8VES92!0<FEC92P@1F]R9F5I=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CDY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CDY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83!C-S5D-F5?93,V
M95\T,C`V7V$S8SA?-3)F,38R-C%A8F,T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C
M-"]7;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T5T)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K(%!U<F-H87-E(%=A<G)A;G1S("A$
M971A:6QS(#$I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XY.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,R+#4P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#,R+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A
M8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@
M>65A<G,@,3$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M(%M-96UB97)=('P@17AE<F-I<V4@4')I8V4@,2XQ-"!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XQ-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,R!Y96%R<R`T(&UO;G1H<R`R(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T
M92!);G1R:6YS:6,@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N="!;365M8F5R72!\($5X97)C:7-E(%!R:6-E
M(#$N,S(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$N,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R('EE87)S(#,@;6]N=&AS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M8F5R72!\($5X97)C
M:7-E(%!R:6-E(#$N-C`@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-2PX-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,S4L.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A
M;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R
M<R`R.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E
M<ET@?"!%>&5R8VES92!0<FEC92`R+C(P(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!M;VYT:',@,3(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;
M365M8F5R72!\($5X97)C:7-E(%!R:6-E(#(N,C(@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,3<L,C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3$W+#(U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S,@>65A<G,@,2!M;VYT:"`R."!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@
M26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT(%M-96UB97)=('P@17AE<F-I<V4@4')I8V4@,RXS,"!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RXS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C$L,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L,C`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R(#<@;6]N=&AS(#(X(&1A>7,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET@?"!%>&5R8VES92!0
M<FEC92`S+C<U(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y96%R<R`T(&UO
M;G1H<R`Q-R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A
M,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0O5V]R:W-H
M965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2%!!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:R!0=7)C:&%S92!787)R86YT<R`H1&5T86EL<R!4
M97AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R
M-2P@,C`Q,CQB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,34L(#(P,3(\8G(^5V%R<F%N="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#(P
M+"`R,#$Q/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY787)R86YT(%M-96UB
M97)=/&)R/D=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N<V5S(&%N
M9"!297-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^1V5N97)A;"!A;F0@061M:6YI<W1R
M871I=F4@17AP96YS97,@86YD(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%
M>'!E;G-E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^5V%R<F%N="!;365M8F5R73QB<CY'96YE
M<F%L(&%N9"!!9&UI;FES=')A=&EV92!%>'!E;G-E<R!A;F0@4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY787)R86YT
M(%M-96UB97)=/&)R/D=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N
M<V5S(&%N9"!297-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@5V%R<F%N=',@=&\@4'5R8VAA<V4@;V8@0V]M;6]N(%-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,U+#@U-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N=',@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!%<75I='D@26YS=')U;65N=',@3W1H97(@=&AA;B!/
M<'1I;VYS+"!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@5&5R;7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<S('EE87)S(#$Q(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T
M;65N="!787)R86YT<R!%>'!I<F%T:6]N($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y/8W0@,C4L#0H)"3(P,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E
M9"!087EM96YT($%W87)D+"!787)R86YT<RP@17AE<F-I<V%B;&4@3G5M8F5R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L(%=A<G)A;G1S+"!697-T
M960@86YD($5X<&5C=&5D('1O(%9E<W0@3W5T<W1A;F1I;F<L($YU;6)E<CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC<F5M96YT86P@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#<V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@
M5V%R<F%N=',L($5X97)C:7-A8FQE(&EN(%!E<FEO9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@17AE<F-I<V%B;&4@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A
M=&5D(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-S$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B8S0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83!C-S5D-F5?93,V95\T,C`V
M7V$S8SA?-3)F,38R-C%A8F,T+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P151(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R
M<R<@17%U:71Y("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@17AE<F-I<V5S(&EN(%!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDQ+#8V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W
M-"PX-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@4W1O8VL@3W!T:6]N<R!%>&5R8VES960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E
M7V4S-F5?-#(P-E]A,V,X7S4R9C$V,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V
M,6%B8S0O5V]R:W-H965T<R]3:&5E=#,R+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,41!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY.970@3&]S<R!P97(@4VAA<F4@*$1E
M=&%I;',@5&5X='5A;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M0F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT($)Y(%-H87)E+4)A<V5D(%!A>6UE;G0@07=A<F0L
M($]P=&EO;G,L($]U='-T86YD:6YG+"!.=6UB97(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.#`T+#4X,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#4S+#<T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C4X+#<T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.3<Y+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M($)Y(%-H87)E+4)A<V5D(%!A>6UE;G0@07=A<F0L($5Q=6ET>2!);G-T<G5M
M96YT<R!/=&AE<B!4:&%N($]P=&EO;G,L($YO;G9E<W1E9"P@3G5M8F5R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8S,BPU,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8S,BPU
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#,R-"PQ,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#(U.2PQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V$P8S<U9#9E7V4S-F5?-#(P-E]A,V,X7S4R9C$V
M,C8Q86)C-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,&,W-60V
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M,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM
M/5].97AT4&%R=%]A,&,W-60V95]E,S9E7S0R,#9?83-C.%\U,F8Q-C(V,6%B
&8S0M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>148</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Disclosure - Organization and Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization and Nature of Operations and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Disclosure - Management's Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ManagementsPlan</Role>
      <ShortName>Management's Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Stock Purchase Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrants</Role>
      <ShortName>Stock Purchase Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Stock Purchase Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables</Role>
      <ShortName>Stock Purchase Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Management's Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual</Role>
      <ShortName>Management's Plan (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Fair Value of Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual</Role>
      <ShortName>Fair Value of Financial Instruments (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Selected Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails</Role>
      <ShortName>Selected Balance Sheet Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Selected Balance Sheet Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1</Role>
      <ShortName>Selected Balance Sheet Information (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>127 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>128 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>129 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>130 - Disclosure - Stock Purchase Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails</Role>
      <ShortName>Stock Purchase Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stock Purchase Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1</Role>
      <ShortName>Stock Purchase Warrants (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>132 - Disclosure - Stock Purchase Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual</Role>
      <ShortName>Stock Purchase Warrants (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>133 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>134 - Disclosure - Net Loss per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual</Role>
      <ShortName>Net Loss per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_AllocatedShareBasedCompensationExpense had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '120 - Disclosure - Management's Plan (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 102 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>syn-20130930.xml</File>
    <File>syn-20130930.xsd</File>
    <File>syn-20130930_cal.xml</File>
    <File>syn-20130930_def.xml</File>
    <File>syn-20130930_lab.xml</File>
    <File>syn-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
        <td class="nump">44,735,896<span></span></td>
        <td class="nump">44,444,230<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">44,654,414<span></span></td>
        <td class="nump">44,362,748<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-SIZE: 8pt"><font style="FONT-SIZE: 8pt"> </font></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black; FONT-SIZE: 10pt">9. Net Loss per Share</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at September 30, 2012 and 2013, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the nine months ended September 30, 2013 were 3,804,580 and 1,632,501, respectively, and for the nine months ended September 30, 2012 were 4,258,746 and 1,324,102, respectively.</font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,093)<span></span></td>
        <td class="num">$ (5,002)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activites:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">1,202<span></span></td>
        <td class="nump">1,303<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">51<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProvisionForUncollectibleAccountsReceivable', window );">Provision for uncollectible accounts receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">269<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProvisionForUncollectibleNoteAndInterestReceivables', window );">Provision for uncollectible note and interest receivables</a></td>
        <td class="nump">763<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on sale of equipment</a></td>
        <td class="nump">58<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EquipmentImpairmentLoss', window );">Impairment on loss of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">30<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_GainLossOnSaleOfDiscontinuedOperation', window );">Gain on sale of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(677)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">14<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">800<span></span></td>
        <td class="num">(135)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">4<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">189<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(2)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(5,015)<span></span></td>
        <td class="num">(4,143)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(7)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(7)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
        <td class="nump">231<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,955<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">231<span></span></td>
        <td class="nump">2,049<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
        <td class="num">(4,809)<span></span></td>
        <td class="num">(2,101)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
        <td class="nump">9,954<span></span></td>
        <td class="nump">6,678<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
        <td class="nump">5,145<span></span></td>
        <td class="nump">4,577<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EquipmentImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impairment loss on equipment during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EquipmentImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_GainLossOnSaleOfDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain loss on sale of discontinued operations during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_GainLossOnSaleOfDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInDepositsAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for stock option exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProvisionForUncollectibleAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProvisionForUncollectibleAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProvisionForUncollectibleNoteAndInterestReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, note and interest receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProvisionForUncollectibleNoteAndInterestReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 5,145<span></span></td>
        <td class="nump">$ 9,954<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">1,647<span></span></td>
        <td class="nump">2,509<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">6,792<span></span></td>
        <td class="nump">12,463<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">157<span></span></td>
        <td class="nump">223<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Long-term note receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">700<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">4<span></span></td>
        <td class="nump">37<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">6,953<span></span></td>
        <td class="nump">13,423<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">584<span></span></td>
        <td class="nump">395<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">584<span></span></td>
        <td class="nump">395<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 44,735,896 issued and 44,654,414 outstanding, respectively, and 44,444,230 issued and 44,362,748 outstanding, respectively</a></td>
        <td class="nump">45<span></span></td>
        <td class="nump">44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">83,358<span></span></td>
        <td class="nump">81,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(77,034)<span></span></td>
        <td class="num">(68,941)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">6,369<span></span></td>
        <td class="nump">13,028<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 6,953<span></span></td>
        <td class="nump">$ 13,423<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DepositsAndOtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesAndLoansReceivableNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4WBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.99<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">1,632,501<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">1,432,501<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 11 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 111,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.14 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.14<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 4 months 2 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">54,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.32 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">18,182<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">18,182<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">2 years 3 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">6,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.60 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">635,855<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">635,855<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 29 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">51,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 2.20 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 2.20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 months 12 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 2.22 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 2.22<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">517,257<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">517,257<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 1 month 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 3.30 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 3.30<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">61,207<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">61,207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">1 year 7 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 3.75 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 3.75<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">2 years 4 months 17 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidExpensesResearchAndDevelopment', window );">Intrexon prepaid research and development expenses</a></td>
        <td class="nump">$ 1,543<span></span></td>
        <td class="nump">$ 2,412<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivables</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">17<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">104<span></span></td>
        <td class="nump">80<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
        <td class="nump">$ 1,647<span></span></td>
        <td class="nump">$ 2,509<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidExpensesResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for research and development expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_PrepaidExpensesResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts of other receivables due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesGrossCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"> <b><font style="FONT-SIZE: 10pt; COLOR: black">8.</font></b> <font style="FONT-SIZE: 10pt; COLOR: black">&#160; <b>Stockholders&#8217; Equity</b></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 31.9pt; TEXT-INDENT: -31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">During the nine months ended September 30, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 291,666</font> shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">231,000</font>.</font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 25, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 15, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 20, 2011

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrant [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrant [Member]

</div>
          <div>General and Administrative Expenses and Research and Development Expense [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock', window );">Issuance of Warrants to Purchase of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">635,855<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePricePerShare', window );">Warrants Exercise Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
        <td class="text">3 years 11 days<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Investment Warrants Expiration Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 25,
				 2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Vested and Expected to Vest Outstanding, Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncrementalExpense', window );">Incremental Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 76,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable in Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisablePricePerShare', window );">Warrants Exercisable Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.20<span></span></td>
        <td class="nump">$ 1.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1,000<span></span></td>
        <td class="nump">$ 22,000<span></span></td>
        <td class="nump">$ 271,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of warrants held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncrementalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents incremental expense related to the modification of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncrementalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IssuanceOfWarrantsToPurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercisable term of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of exercisable share warrants that may be converted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of Warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisablePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercisable price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisablePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>per share amount of the warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> Prepaid expenses and other current assets (in thousands)</font></i></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></i></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September&#160;30,&#160;2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December&#160;31,&#160;2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,543</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>2,412</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Other receivables</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>17</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Prepaid expenses</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>104</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>80</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; COLOR: #000000; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,647</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>2,509</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt; COLOR: black"> Property and equipment (in thousands)</font></i><font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 8pt"></font>&#160; <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>September&#160;30,&#160;2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>December&#160;31,&#160;2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Manufacturing equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>152</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>297</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Computer and office equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>45</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>35</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Laboratory equipment</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>133</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>133</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>330</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>465</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Less accumulated depreciation</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(173)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(242)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="71%"> <div>Total</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>157</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>223</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amounts of other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsTextBlock', window );">Stock Purchase Warrants [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-SIZE: 10pt; COLOR: black"></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt; COLOR: black">7.&#160;&#160;&#160;&#160;&#160;Stock Purchase Warrants</font></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 635,855</font> shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.60</font> and a life of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> five</font> years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of September 30, 2013, all the warrants were outstanding.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> shares of the Company&#8217;s common stock based on achievement of certain stock price milestones. Upon initiation of the program, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date of issuance for an exercise price equal to the price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.20</font> per share) of the Company&#8217;s common stock on the date of execution (March 15, 2012). In March 2013, the performance warrants&#8217; vesting period was extended to March 14, 2014. All other provisions of the performance warrants remain unchanged. The incremental expense related to the modification of the warrants of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76,000</font> will be recognized over the one year extension period.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant was paid a monthly fee and on February 2, 2012, was issued warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.14</font>) of the Company&#8217;s common stock on the date of issue. As of September 30, 2013, all the warrants were outstanding.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> &#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>A summary of warrant activity for the Company for the nine months ended September 30, 2013 and for the year ended December 31, 2012 is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0in; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 95%" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="12%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="66%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at December 31, 2011</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>3,259,186</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.95</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Granted</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>985,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.71</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Exercised</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(1,768,167)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.11</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Forfeited</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(844,373)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>3.32</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at December 31, 2012</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Granted</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Exercised</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Forfeited</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="66%"> <div>Balance at September 30, 2013</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 29.7pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt; COLOR: black"> Stock-based compensation expense included in general and administrative expenses relating to warrants issued to consultants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> for the three months ended September 30, 2013 and 2012, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">271,000</font> for the nine months ended September 30, 2013 and 2012, respectively.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of all outstanding and exercisable warrants as of September 30, 2013 is as follows:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 31.9pt"> <font style="FONT-SIZE: 10pt; COLOR: black">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; WIDTH: 100%; TEXT-INDENT: 0in" align="center"> <table style="OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: #9eb6ce 0px solid; MARGIN: 0px:auto; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 88%" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="15%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Exercise</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Remaining</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Aggregate</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Price</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="19%" colspan="2"> <div>Contractual&#160;Life</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="16%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.14</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>100,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>100,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.34&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>54,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.32</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>18,182</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>18,182</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>2.25&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>6,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.60</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>635,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>635,855</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>4.08&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>51,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>2.20</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>250,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>0.45&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>2.22</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>517,257</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>517,257</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.16&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>3.30</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>61,207</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>61,207</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>1.66&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>3.75</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>50,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>2.38&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>-</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1.99</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1,632,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>1,432,501</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="18%"> <div>3.03&#160;years</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="15%"> <div>111,000</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Management's Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureManagementPlanAbstract', window );"><strong>Disclosure Management Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ManagementPlanDisclosureTextBlock', window );">Management Plan Disclosure [Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="COLOR: black; FONT-SIZE: 10pt">&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="2%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>2.</font></strong></div> </td> <td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in" valign="top" width="96%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><strong><font style="COLOR: black; FONT-SIZE: 10pt">Management&#8217;s Plan</font></strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">77</font> million through September 30, 2013. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of research activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the number and scope of research programs;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of preclinical and clinical development activities;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">costs associated with additional clinical trials of product candidates;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the ability to achieve milestones under licensing arrangements;</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 6%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="6%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#160;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="4%"> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="BORDER-BOTTOM: #f0f0f0; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 90%; PADDING-RIGHT: 0in; BORDER-TOP: #f0f0f0; BORDER-RIGHT: #f0f0f0; PADDING-TOP: 0in" valign="top" width="90%"> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">the costs and timing of regulatory approvals.</font></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company&#8217;s shares or debt and other sources, including sales of securities pursuant to the terms of the Controlled Equity Offering</font><sup><font style="COLOR: black; FONT-SIZE: 9pt">SM</font></sup> <font style="COLOR: black; FONT-SIZE: 10pt">Agreement that it entered into with Cantor Fitzgerald &amp; Co., as sales agent, that provides the ability to conduct an at-the-market (ATM) public offering for up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million of shares of common stock at prices to be determined at the time of sale. As of the date of this filing, the Company has not sold any shares under the ATM.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt">The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.</font></div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureManagementPlanAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisclosureManagementPlanAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ManagementPlanDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of Management's Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ManagementPlanDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Management's Plan (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Cantor Fitzgerald And Co [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
        <td class="num">$ (77,034,000)<span></span></td>
        <td class="num">$ (68,941,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock', window );">Schedule of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</a></td>
        <td class="text"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt; COLOR: black">The summarized statement of operations data for Adeona Clinical Laboratory for the three and nine months ended September 30, 2013 and 2012 are as follows <i>(in thousands):</i></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 8pt"></font>&#160; <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>Three&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%" colspan="5"> <div>Nine&#160;Months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Laboratory fees, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Operating Costs and Expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>287</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Cost of laboratory services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Total operating costs and expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>403</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Loss from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(288)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Other Income:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Gain on sale of Adeona Clinical Laboratory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Income (loss) from discontinued operations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(104)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001144204-13-061598-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-061598-xbrl.zip
M4$L#!!0````(`&!I;D/^LJ#CKX(``*OA"@`0`!P`<WEN+3(P,3,P.3,P+GAM
M;%54"0`#,Q*%4C,2A5)U>`L``00E#@``!#D!``#L77ESHTB6_W\C]CLPFNCI
MGHB2S2$)R57E"?FJ<;3+UMBJ[>[=V'!@2,DYC4";()?5&_/=YR6'!`A(0,A&
M=G9,3UN0F>^7[\Z33W][GIG"$R(.MJW/+>E`;`G(TFT#6]//K6_CBW:_)?SM
M^#__X].?VFWA"[(0T5QD"`]+X4QSM3'1]-^=L+X`U0_Z`OU#:5_;3VU9E!3A
M?\3>45<]DL7_%?Y_]/5?POG=6&@+W[]_/S"@!==KX4"W9T*['=(YT1R@`>W\
M>G)[)<@'4O#N^8&8^(C^OP"P+>?(60+H1]>='QT>TA;AM_N(7*P_8-NTIUCW
M6CZD.,2!`GWSJYG8^CU6CS9Y8),IE!250_KZ`2"$Q>E;`Z\J1`OW#OV7JZ(;
M37]7O++28#`X]-ZNBCHXK2`T*AW^^O7J3G]$,ZV-+<?5+#V&!>=@3Y;'CMV1
M)36OAE\BK&"@.4$Z%7)FG<&A1G1BF^APHNEN&SW/3<W27)LL+^!WV)!N+RR7
M+.-L<Y!^,+6?#H.7GF3:HM16I%6U!2&@@5GU@K>THARO:""<7@=>I-!!S_IC
M>GGZ)J4"MIZ0XZ97\=^E5+(TT,'T.MXK6D6*5W&PGEX!7J05=^<DHSR\2:FP
M<-I339NOZDPTY\&3;/`BI1?/9H[^_'H54>J%2W+4!MZVP(X%X1,UA"/'4_%;
M-!$\PSAREW/TN>7@V=RD^NL]>R1H`L^65CLTXH-GQV@)A]".[RU.;<M%SZYP
MAW07G)#G*8""[ROTX"4&;1Z)TCW\CW)D;$ORO>+_[2-:U4"6B]UE\&SU%!OT
M^00C(GBH4=SM!!P_O?RY=2S"/_U!1^KV/QTF*X>D#A.T8@CFB&#;2"(`LR8N
M^%QT'(I4E,)VUN_"IB+=,=:5P&04:4W<"*I$(46(AX\"'@9MYS)6'MOBX%X1
MO;_WD;%R%<9"I4%;$7?,V)7&OB?&[EQCE8C&*OO(6*4*8Y7=::SZAER!VB17
MH+XAC2W/V-UI[-"YL?9.4_TTWTU1N?!-W9S9%U6+<$;9*6<DZ1Y"\KYRQLL&
M=\69?<M48M842SEVQ9E]&75$."/5P!DZ7CO#,V1YTT7L$9OG@91[L>]IT_W0
M0+:EG<+`$.N:>:4]V,2;=K@R]:]H]H#(PJ$CV%MDTOF+$<25Y9AHEJ-Y=)R3
M9?3-\!D[]Z?V;(:(CC5SI`'V:"NG!!G8O=!T;&*_]`O++!E#T108YZ[H!2\,
M`/(\-[&.71^]8(0,_MP*AO1':7U9O4MCP:?#U+8CJ,J0+RZ0UC$,]8^8<LZ&
M%T`[3./9]H$6(DI_!ZXA/;?+5/>HEEY:NCU#=RYPD?;T1#/I[-_=(T+NT#*&
M!H@=.*V99]C13=M9$`1<AQ]SV]',+\1>S!UHPES0"5]:!F!A:X&,FSF=Z:5"
MVF_-?RG^Y*GM2^MLD[/M]/$A5W6NZF]OQ)XZQ\15G:OZVYOU2UT`X*K.5?W-
M+<G$)\7NS_]O@>>TNU&='A$;VG:7(Y`5E=*JT,ERO)RC_5;(0IT+"R?8\RKC
MMMU.`T9T`4;2\X6+"##E9C+!.N+*D=HYZFI8O'K;FK)VK5Q%,E4DDTEO4#?6
M4^8\HC0_HKS0(H',(\J^1Y07TQ0>4?8NHNQ.-\+AN!C9Z`@/OFK/>+:8Q9;*
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M0<0>D5OD((WHC]0QH"=DVMZ$;%`@9XO0E:U[&U>X8A=0["K0<OE-L=0CW-=S
M_WNP(9I;([?&]V"-^[%GFULCM\;W8(WO<&C$K9%;8T.ML:GCQK@U?@6V9JWR
M[;'2IRRF13O*TZ4\E<A9^'U;*O'ZZZN-4XGTF,V]Q#L.'!DJP;W$NU6)[%U_
M?.GU;>SZ*[#/AN_O?,^#^YR-OWP#UIMP`=Y.*A!OUX_WOVB$:/%C*:N1.SV/
MX2[I$1[;@I][?F:?T:VP6(PAKR)[N2V);;F[`]F#W-<W%W,=:)H.)')#T((*
M=S-'5:?NP*#<2UQE&J4RR9OPI%VXC>!4HW=61)*X[)LG>^\DV&Y.D8#<>^$T
M`;?_INE`<CH!M*!7>CHAZC9J#!F@)M$O>W#WT6#5\1Q(I6^7R"^X&_*%5H6Y
MBE94T2H(WO9J\7[L:^1VQ>UJO^RJJ>NK/%YQN]IGNVK8<D3&(C6W*VY7^V57
M#5OIS]I1_TR_.>*@$<$ZDI3432!I1C$$MAC87%!QW"%]0;"+D7/^3&\X1L8%
ML6?^/7">1&\FYQJQL#5U1HC</6H$G2S3&]AOD]HI4U[`("-[9KP-Q&FZP:-4
M86OJ<&OBUI1A31UN3>6L299%;D[<G-+-::4<W)Z*VY/,[8G;4Y8]R=R>RMF3
MHO#XQ.TIPYY6RL'MJ;`]J5UN3]R>,NPI5`YN3X5G([@U<6O*F(S@MI3]73EN
M0]R&FFA#K_&Y-+Y8Q*VAH8M%KV\.?+6'FT-C5GM>W1SX<@VWAR8MUS3`(/AZ
M"S>(YJRWO+I!\`43;A!-6C!Y?8/@*Q[<(!JTXO&:UU.=0O,VN<#N'U.Z`]SP
MKK"-60?_YLK&A;\Y3'NW<_L+"_N:YE`33RK##&G.@J#C`)Y7)&PN?!<E05O+
M:/_;W=D]@+KW7$F"C(&?0$>2G*)5KQ<SY'T).ZD@:_K8L3NRI!X!@31H4:8D
M6TPA>(8L>X:M?)(L=B1I;C8:OHWTO!@/,P3$8$*!MN>+#;'$NTL+%&K[TY_:
M[7/3.[(B0)2@)MEN^T4-A(_.;'U!W]%/G@N!3MZB2::O:WGP+JAM&_=2ZU@2
MV__X=)AL*>P5?3Z$AP9]<6%JT](DY-;Q1#,=Y-.(M14E$A(?>89V[AMA:6)*
M*V;1F0VG4;[`CJZ9OR&-7,`3IS3MCD\[3C71:#9='UXURMW6\3]2Z48:C5(&
MYVY`)G*WG#W89FEJO=;QW6_7/KE82U$2YYX+A_QG9EO>C7>>GW)N%BX-Y;1.
MG&[P]4WO$H\$/;4E4%OPR@5>53"0CF>@59];E]<7K>-.I]?M=*2.#XI->Q/I
M+9IZQ[TLE][65YHG?>#)TG(?D8MUX03;ICW%NO-!N+3T@RBH.)D4AH'H()1>
M6@9Z_ADM2^,8Q/.%S(:CE$\7A,0TM:KQ26+KN!U^P#>OY<U^7V`3D5-X-;5)
M^5Y+X,;N0!V@#>$6S6WB4OVBR;=F+:-<B)$)4:RN:B1H@@"PX=_0J)$;XIT5
M-/Y+,Q<HS-HWU38+E!S1VWBTCJ@O."SQ0*0I2SD8=8$//]M-T4;!*Z\'WK?6
MX<)]M`G^`QG%.=YA>PI)]/_)@IPDOBW4+/YV7P?JI>,LRG"TQX;)P.=3W`9;
M%@L+Q(7:L.7&K2SF];<&F!*R*J/,8N-@ER@C07AKARJ+U7Q2`0RUP,Y@L"R]
M!NS*3E26BWLF,14MRR^50IG%5.7%499TG7*!8-3IJ$JW/^CE`$QW487!9;&O
M0/CIT']D)8][!<%5<9YR@<BSSOJ+D-X.9A8C"PU.E)ZL=OH586K.8W&N]>.^
M)HJE#2ZF*W6Z<8.`UHM1S&+`()_B8-#M,"E"4)EKV`ANT1A:Q@V,I,C0<9#K
M!&.(PBQ0Q'Q`4J^C)I,J%O%:\&8P4)'R\<I=<;`MWHJ<E/.1]=2!'$.V#88L
M[B@,:<J=GE(<Q(C8$'W=);U^WP76T:MHO`M<KE$)OG08F+I)!<LFNAW`+*9U
M&2HE*Y4!7MNN=P_.E:U9SBW2$7[2'DP$):]M2R^K8;U\H!&,1>C6@S6+J6H^
M5C61:I0!3!=3SM#<=K#KQ`VZ"E,9,<!WQT5(;@<OBX^,@*&HI?'%3;\PHSJ,
M2-$;=--<2U&J&?WO,/R]I'3D0F1UW5Y8KC/2EE2ORCKW#L.Y=_OQL)U.KBJH
M+-XPO+TRZ%8`=86U!VQZ2^O%V</P\4GV1&B4(I_%"(8'3S(BAWQ\P.X-'XMS
MH;A_3B%3"4D60QC>MQR22/Y=DB$LW]K-&FY6Q)'%#H83[71*X1@:!J;+BIHY
M@LSRTCK5YMC5S$BUPASJ,IQJ7X$1;]R(F<3K@)O!R"[#&_>E@=S=$NXM<C5L
M(2/<_P->:S%;>!LJSM"$;HXHSEV&UVZKJJC$9<^F7@?>+/8R''J[1U>JML3K
M,?W1-@U$'/]NR>+\9+CYGM*+#[XV:55!D\4MAM>7%%'NEX03B0R01FW#*D8L
MV,B66)2W1YK%1D:LV,RPRD)EW!.:6+],_=!`'#$CK$C]07QPP0!0#][8A;AQ
MO(SP(XFJ\G)X"^Q88`2ECJR^(']3+QR.XV5$)465U&WPYEYB6UI[>XR@)'74
M;L+%YY"O`VL.9QD!24W,)NT,:@&E9<0F11WT7A9K#EM9D:NW#=:;.=UA",E`
M>`]S>15E!"]%Z<55=(-D54PY/&.%J;[2JQ=3`9UC!**^V-L1IAP^,8)-MR,I
MY3#Y]X!?V8[C[]&WH/`"R@<5Z8YG-+$)\LN-M6>ZJ1\\JDT,;&ED>>FBF3<-
M!36);9I0]1+Z1)#CEM9,E1&:VANJN4/TK\^H;#50&3&QO6$O;Y)1;!M666/$
M#2-^TXS*T2C6X'3#L[PHHY[@*0V*?F/5'0QKM4I*=#&=[I;X<J3`2!UVAZV`
M*;'2!GF7O"N@P<5G18MB\Q9:0$7M,(CZQ:N.#51&0M&6XK-5^>1K`9O#3N:P
M]J6P%MAPSLH;NH.7!IO-V#YKCX.\!=;ZE+7/BISQ:+`SA#F,9&V'2*Y!UXRP
M@%XRPDU;5E\&8@X3F=LCJB%D9P?E-9(1@.CHH%\R1:D-=@Z'&7$)<G6Y;`JZ
M->P"NLL*5GUQ4#8AK`UV#K<98:O=50;))&\[V&?8T?U*R%C7N4;NS022WJ'K
M$ORP<.F2_-A>G<?Q3^"4-H$!(]!E=FL+D"_=^VS9#IBC7K&3(]H]X$&!,VV,
ML/P6>I^C`:P],?W!RR@`5%JW7=Z,67G!1B2+T:L")H>GC`R@+7E^O@XP!=2;
M%>,WHL[68'(XPXK<75&4BX-A!YH1(B>:@W6Z$$!O0D%&RNF:(OJ5B-WIIVQD
MZ(%X(/;+A,(,A+ON:HZ,!B6ZVFUP5XN<*"YTYLOOJ]1DL;)-3Q(+'10+^MK;
M>5_S0T===BN)A8Y)BY7#_*OW/4_BA4Y9[V'?BUAVYXWW/4_NW8*6#@Y<VFGW
M-^XDB]>I8,Z]:G&8`:0>W'DB4:L%U9WB+F)&)?(>Z:7X7<0$2B0Q4G5^_X+P
M]!&>#Y_`0*;H>D%O(;N9>%4CARZW5GLIFJ<4/JY:#=U.^Y@C,DEB]U%1E+XB
MR[U&]K'(13(%3K^#')7>0.DVNH]Y<BQP=EZ1^Z+4D6KO8VBSR*"W\R#+\:)6
M!3FQ5K7EQ#`UG?!6\/)8S-[)K52`=X;F!-JIRC/F)K@8I"BQ"D#RN,.89.A*
MA8%\T;!%$Z(;"](A[[2@=]5JVIF\0BQBK0`DSJ[DDJ\#:QX7&=/^96%Z5\"&
M)W\O9W,-$_I7I3DM*7E72PJX''K5(>7P*WD/RX;ZBZN#IP5@K5EZIYGH9I*:
MC5?@&WNNNS#UNN#F\91YOD=='^<M!3HRYB$(_.(9\O][:86'/M=GJBNPF1$^
MXF-.)H`:0><QFSEKO;$45`/RX+J)L^!09>JU$Q4$P)[T%AF=*0)LI]W+$Q7S
M"-+&GMXM>D>-:[.%]-/S%43%BHE!WE`&18W(\Z3`6ACO5`;.MK'@3'IY?C,O
ML-E<\,N'4!?F'$XS+['9`6("82/S;'TA1I=:5V8"J!%T'J=9$;<`JQG`KY%+
M+VD:$9O>I6V<++_!L.326AVK&`*2IZH\9RT#=T6IFUQ?+(BF]G[DB8$5BSM2
M9V/1MF(_P"AH!NJ,[:$.B2E!F??U5)`'(PXG#K\7AU)[)_*$4>!JGCKZD"%"
M?VOUMH;!BK)R(;-(P5)[+_(DP8JXZI:=H+$:BNL(&=XB"+V!4+-T&$U$+F"X
ML(GWWYLY'5&$GS6I(!36#4&R(JTRB*JH=MBS'$&Q;B$:=&KKV,KN(NT$'[79
M1C3%@W<>X1I`YG&9M5U[T$WXUQ)0,XSG`EL@H2V]$>OZHU#QRV.IO1=Y[&=M
M]!8[@YJZX57S/K:0S+@J,)\U-N[T$U="9E/?&F<>>UE[Q61)E+;`F7/AAY1`
MP@B>O9[:WP!2\J+59.=9-S!U595),CR$16\2*J\GK*N68L.`-:$*('*4@'6!
M4F$0JQ.3%9E1=I/PBE8U*'DL87A]-I0@[#YA^GTN"*_?H)AITD__P."XCOE/
MUKU'Z]!?%$.]T/.XRW+JP8U-N\!/[_2$`4*HR.O:%4(LZSZE\":2BH!VTY\\
MN;#/HF[9E=!H;LA4L_`?WG+!J6TYMHD-[P=4'T%=&+D%7UP,`K=F>G?G>Z,^
MNNA@VO1C6V/HWHFY<5E<(=GU6\?"7TSWHX&?!,==FNASZ^OP]LOE]9$@SEWX
M]_FC<'%S/3X2)/I[C&?`TFOT7;BU9YKUP7_P0;B#6#@16G^9NA^3S>DFTLC1
M@^T^^BVU+X9?+Z]^.THT]=%[=W?YW^<^J8]UP/#.`X1`D@2$DYO;L_/;]NG-
MU=5P=`>/J1"UN8,^"K]<GHW_3LN)/[0$'9FF,]=HWD3W\7F_YYIAA+^_8\-]
M_-SR"S_8Q$"$/E^C(.L_C1!-0'Q\,SH2_@PJ,C#Z*T2WEU_^/MY\?'(S'M]\
MC3P?#<_.+J^_K%Z(V%H_]%J./;DZOQ@'CX(6_2<;[07TO9(!)^0?H-+P].<O
MMS??KL\HSVYNCP3Z_2?@#+VKM"4\:2:>6I];KCU?\43^@:43*S%CR_]W[GI5
M:(T)J'.F]`((#Z:F_^[7T&;SCW^6>J)7]Y!6#ALZ!-HK'(>NP>5121X/U00C
M'6P*Y.'MBF;0JR8;J/<*PHG&($&S#.%:<R&F"/9$B)SDI"_HABB'/H^&IBJ2
M/8PXQ$//1:]_1NO4&436#!,4Z6!`63$^_W7<OKP^.Z=AI>T_70M@-[YG-UUJ
M"8$Z_7/AN'BRW-0)7$TYA#/DZ`1[TV%4\B<+!UO(<38[B1GRWTW'$T*4!P=J
M#C=*]KVA,BW9B\R/.0H_P?.@DWU9%C\&7QE</9$^"C:)%DAI*E+XKP)X!TUX
MP)#^ZH\6+4#/B'IM"A/ZX4YD"*!&E*JQOBF/JM5#V!R4(UZ!.8$2ULHGN01I
M;EC:H?,N"T?`UL3[ABS\:6"'SKTX!\(8*@<=H7@"0O1#.!IH,-%,`5E_+&<H
MC1*TO;*5TP-H=$)OZ07OM%+P%4T+F$B!:1X:Y+G%F6W9D)%;0$.#!A]L8TDI
M$&U."X3T8ET9(>(N'.I6:6,KXD-(-9%K/T"2CD@J]0,0H:`%%SA_\!K.Z+5@
MD,54T.F>5H-^"C,5!T$T[X7R;8)FV/4^.CE;F"Z>T_09M)K8(4C=GL+8"#^!
M$)?.9&%Y>`!92GF?18^:(T#8<RT8#1EITM<B6"BZ"7X@]FRIF5.LI60.W*L4
M[=H&FJSTX0V/E3S."Q*$?6]T_;(YNEH\$03INO9LG:>KE7+!4$=U1"<?MDT-
MJ3,%[X46X/+7:CL$8WU7^;Q468I2G4+<D\$P-[@M#&Y$;&.ANVOAG89QFUL<
MM[@&6ERG4UE44/7U+8Y.IR]2AK/E)C'>Q`1O"=\9FU&LU7'NB<DUW"E&Y?,>
M/2*W'RX@;C_[)9XRF414/O6F$;L7$,\;7M_OW:9,=WZ]>P=&QGU@H\6SC[8T
M)G06VDV9$F3/9N].:])J!+/FPH^)>?,?/_Q(%W$F/P:SZ^N6<V?LA9_\Y23'
M)=@V__H.U)-[CT:+9Q\S*+IH:2)Z^0^RZ'=DZ"+@6FA`:?1(=_1?7@JZB2VL
M@\&!N6GF1\&P'7]5UZ`+K]BU"?VYL`Q$OFM+GH_M4PQY5V;*O6BCQ</MI^$"
MXO;3:/'L8Q;"YW'VT^^=9NU%XY,YW!&^MGCVT:#X9`Z?S.'>HPGBV<<T:J2Y
MF&[B7D_EK.9CA.RI')YR[5.$>%=&R'UDH\7#[:?A`N+VTVCQ[&..P:=JFN+W
M*AXIWCA8N7F,N,+YZ]7)R,AYSG=@P=S!-EH\S3#4DB<B?KMNBV+G_<T`K9__
M%#DGSJ>"N!?A:5I5+_)!<)!N6X8P1=;JTRRKJPBP%ZW#V:!*Y^%WUH$))HX;
MA0U(#1"6X]ADW85&0?YI8I,9(N92^-VROUN"Y@@C:>A=RQ&9?>-I\SY%XW?E
MZ'@<:K1XN/TT7$#<?AHMGGW,X_ATVW[ZO=7%8N_`KKC;:[1X]M%\_.%KMU'#
MNY>>!$NYSI!/AG%OPI.H\L$X,LDEG-)[$Q_L\&+E[]A]%"XMEZ#GX*Y3>H/I
M-PL_(>)@=TDOR!RC9\T1-%<8TJLG2ZQK\4SLW^Q=:V_;N-+^7J#_@3!.T19(
M4MG./6T!-Y=N<-*F;Y,]Q?D4,!(=\U26M**4Q/OKWQGJ;CMQXK4=RI[%MK4M
MBAS./#/#&=Y>WI6LE':2\31:/*0_A@N(],=H\=1Q\$$9'%/LWI0+ID8/@Y_M
MBJD5T%LRJT:+QPSUG"9#U*0,$66(R)H8)9XZ#M+P+D?_5H2#H?Q0-3U$`[@Z
M>8B54CJRB4:+A_3'<`&1_A@MGCJ.*2CQ4T^[=U*Z_FX%5(LLG]'BJ:,&'7>[
M,NROX"%&PUO8NFX<R#"2'FUC(TORTN*IXQCJ1WYOK4[$?!,.9YTOTXVG%G_3
M>0VOK)U?+T[Q^F='A"SR63<.\6)F%H32#V4D_Q;E&Y2S.ZV;.P<JN;AZC<E(
M'RR`ETV[`R9<8>.9Y5"5@YD[#TQL+/)JA^XW[AQ_7V]:UOB;EWE_X$>A'_2D
MS5P.2`6SG5^@O,'^\.^@LG#DAF<EQ&\\[[S<5'K)<G+5M(P4^UMZ]OHUQWNW
M)2B!BU3'4'\`[8DP&B0W6"LE(MPA:+LQWM*[EM&[P*N7@PC^W"<O)\_8T+MK
MR0]K[`+](AN+RS)UE<N,2Q<4YW;K<,Q%QL.^MG0_\;/N-7Y2"#5BBA\WJ!4#
M_:@5'6NM4Q;L;;\9;Z.?XTN&W<-XLPU-36.VQREW69?'CX@>GUZ?>I@UK``*
M--6[P6]?.-Z'CC>XAT(!TWD^DUZ4*:;G9^(P9J!P8ZXU'W\I^%-,[F2IU,%Q
M3.X%KL?EMIW87K2Y8._U1:L<74!7>MRS)5IM`(%`0ZQ8C]\*=BV$WC6.6NFP
M(`Y5S*%=\!EHR\/8A?Z@`0[%3>RFJX$!4!?"CM$GI4^/[^T>]VZT\>]+I7!2
MZ%WFH5K6P<7Q8?ZM>?`^L?TXXI']$FW2P[WANI$-UH'.A&BXW('V*P/F^,SS
MH]0'0&]=%RE!,DLO:G*@&!`6BK]BB;VZ'K`_-RXVV-=.YX=NVD[O\QC+EPTV
M!2_+1'$'1:E_7]--^>C;@%0/B72!+N"=O@=DJ*2GI*.'<9[>PL_#`9(...(W
MNAD]*.`2]\[KIID?AU";BMU("P7]92*BM1*5T+S,.6-SU8.`R[]+NYF^`K1D
M]63^/Q,/%)"^`V(.A69_1IMT\;A,1]I<'VT-S6<U1#T>`=5`O&#B/D@&(5@M
MC@I\/?:H5@Y#GKS9;@P<'(!V:?J4>`+O5<^/70=;@R$+#B+PG?]EYVSK(3'6
M/+FB`CI(I`!NIV+5E2*S.YZ'0Y.?(O!#&!AY[`1$"DJX_N^\`T@[$QZ^=`2L
MZE^+L#`P[>8::UG-5D4Y]`]Y114]X2`/Z68#>ZP>-"F17,;"8;E%O5"(I"L0
M4>.M,U%/I01=B"#2%+&VI0EIKSU#KJ,BFKN])%<PI2MX`MA![KG=3W0&C2AN
MYM!@RRWF&KN#87\O,Z=:.5BL-#0$T`EV%X>\_XN=FT*-8+P>]X/$76A[P+NX
MD$^_R_M^["46*QW6XQNNY-?235U*4C#4:J8#"+1V6&KH?7V*6IP\0E/C*:&/
M$<%BF>$*DK&/<#;8+_1WKH27$J*BU-#'GFXE[PT3X!_\`3`&N<0##$5"6:8A
MT0E\Z9J[P%R1,!0,D/(]'!`=L%X6%#E`8.I/I8>&19\X;$-LPT&)94)QG_^N
MDL"3*"A3/EO;.#R3#K2W&_I]71_$A3?22XX$SP21R&G(O:0$@-1R>J'1;AS%
M8<ZI">H\)G(I11X9//6X>C\)8G2A=9</_#C:[\I[X1Q,#%&RII,19A*3Y.24
M/X;%QVP`^O%#K-9O.`_VS\,;[LF_M3,\S%4!OG0\ISP6/N^>9+IQD:L&+G-Q
M?06<N13WT1?7MW]_?OWJ]2O&/F;U0Q%PJ]S]&OIQH$ZSJ/2H"+.=\]P9CZD/
MM2V"+S]%]U/CA]6\@O_1'%_ZUMY5V]*?&TPZ$!H`#J1SU=S::WPV)J*ET/6A
MT+6UL,BUM>#`=4[Q:L7ASB\FGE7-HR9RNG0X@?,1<%:3$Z9`M3W&/PZE4<P6
M?WW2:O\(`+E%*7MC5KACG>QV!`S3V&%VQ<-9LI;5#Y-L\W<(`B'(LX6\U6.+
M:>6^P(F52J2TWFYN[#T0*K'D62&>:=E;XPCIW&/?>`@QS6X2CE<G+F"TZ&39
M):ES.Q!IPP`;1\P/`V>-G9T=LG=842FVA^>5@!Z&X7_P,'+YM2X/X;?'\!QH
MB+H0JW@C29*PPGI*+Z>S/'AR(O/O/!%NL%,=LWEB*,T!HU*1Y<7.L)DL]X&Y
MI21%%FID8U:!*_9.OD]"DWY?.$F,HQ3P.)OZ&4<(C.<ADO0<'60D\9-*:]7#
MPCC`-(0?WR0DZ>@-JL)1L)Z["=P8&X:6_S5+>[UC66N69557&P1\H&D:3FV"
M3/M)#,JB.W]=IVT@SL/L)9H!S`-!L,AU()4C`&+&F3J8K8V="K5O,!8#3'AQ
M'\\DC=/L92G5F4;,A6"2;)`F5P?>4#3V`BZ=@NH[^$='H7Z&^R0-M;DQTIO'
M9[Z1Q*-8LZ1(-4W,,$49?26$I#D"WY8Z0Y&36BJ24"T@)G,P7/;UQ*"$)Z.Y
MX5QUX76,*(!I'()E<1UE60%DV&RQMMVN2`Z!-V:`4$_[^/CX>46<!-A7KG&&
MZ9+$OCY?6S14T_32!9I,'CH*X.K(KLZP#LV3="XJ\R152W;I!](&G=I:;UEE
M'Y-/*Y8S&PCX/+?!BN3&^@.CHM(T8$$`>P<$I2V^KVJ:(]"`2@_7%^C\'M@=
M[6E"B7EIKK/%10*/EY<@.,5,!>MQ)YF#ZHMHC&*#@8,B*BEBN^B:NA+S<NKA
M*M&V2.V0IIL9T9D\A9E18)H[2'N1S6%`/T<SBY0(GZT&3SLXG5OPASY6Q?T^
MC`?^%DZ11Z^""T<Z"?(?"3"FFZC1!?5,D4Y)XV#0U6#-M?^=SGO[L8*2ZOW^
M4^?U%RG!THN[8Q,J.>IFJC>=L].OW_?/1!>-:%F1*NLRJXG%<GIS.&C?$]?;
MX!*LX)[IS/)P^#[ZO,2A2H./9DO/_W/\\^3L_-<^NY5*ZCF%2J3^(!E9S#Y<
M8'*2-34>+K"JG&3-&/''<5)SLQ7<EY[GV8T2MYFKV9W(X_*_9]"S9/J[*K_A
M?/.(+AXPX,+EZ6'G+*L80!#Y_;3@KY2B3:M($6^VJ\F',2.2R8F:A72E+QW'
M%8]TI3F#G@RCU]+_L68!FW)?DX6H+R,X7(V/^`>$`@BW1KI^B1:SZ/\W;3&+
M[]IT%E]S&UJ:?K?62/QS$G_JG=/Z%P&'[^`V"0U/04-UPQQ9\]H)T&!K7AF2
MC%+S,#/:9>UNC7`&![TDW266;HNDN\32)=U=9NFNBNZ^W,"I2"V#\&R[V[7M
M>8VFRKDI@6N]/!$M4+[3]70A*OWR@IQ:AT=[_Z\I.AW*F]X#O1Y:2+*5K2,T
MCA.M45:L&R]_@C?!F^!-\"9X$[R-ZQ[!>Y[P;C:WC$?`\H=<7?W?+%AA3`)[
M3OTSTI:9V[U'K-;+]&^,"2+YK6SW")[UEM^2=X_@66_Y+7GW")YUD9\A8<9\
M9W;.\]-]#GT594<U)<=D[*]RD&E"]R9*U$SC-,/^&6F<")X$3X*G\=TC>!(\
M#>X>P9/@^0*11_7PEZ;US'FO)P=F4T4C7X6G#P[7>_^=OO2DBD)]RN0J!Z(F
M=,\D:_4/IVYGV&>3EAX04@FIST)JT]HT7IB$5<(J654#ND=(?2)26[L[Q@MS
M-4.7^4ZDX/0)'O7B%EMEE`AOI2W4*H>RTVY^6\)<S/,88-#2U7IX:D([H9W0
M3F@GM!/:31(VH;VF:&\VMU<9[P9'<O.=A+KT(^Z6KKVS\X5QV?U1JQS@OZ@9
M?+;@9[C_L+96<G%,,VG(0+I"NE(S7:$).=(6TA;R+*0K2ZPK4Q^"/$O=V;06
M>?BB<=JS$CN[SGREDFN`QU^"0M.2ADCU):VCH7FZI1@G$,YKAW,CNS\&T^\@
M5'QOO.`)UZ;@FNPWX7P5<&YD]\?9[];N[DK;;T,BL-D%HW2$'W6/3OE9&ODM
M>?<(GO66WY)WC^!9;_DM>?<(GG61GR%AQIR/\(MZ(F2GGNWW!1W99[H$S31&
M=*H/P9/@:;[\")X$3X/E1_`D>!HLOYI&&D.[I9I&[9;ZRJ7'?(\I[@H\_Z+C
M"-_C[-"5GK2YRXJK8U<Y$*W7>EV#&&#0XO5G645:G4YH)[03V@GMA'9".Z&]
MOFC?WJ$##><4V!DSA91,'K%WKJ_4>]HT-*WFMT'S'3^^QO9?'@$O</?V,_E"
M*]9)24A)IE<2(QE#VY5(*<ASD.<@)2$EF8N2M'?WEE--X&,70JZ,^@I=;X<(
M>[OV5HE0=M^.$%/4^P%KFS+4_1!QP%.9Q(PLVQ4\W`?!]JJL&^;<.+)&FW_P
MBVX?\!,Z(OS4`,9E[6L&[C<MZ\T!TX7673[PXVB_*^^%<]!@MG!=%7!;>C?Z
M1?P><,=)OV=T))U-`)/35OX8%A\S7GS\$*OU&\Z#_2.I`E]Q]VOHQX&"^-F-
ML8&C4M1\G@?-^"N$UG$H+L5]],7U[=^?7[]Z_8JQCVK@[5_8/>'$KCCO/JO6
M)&B_B'@D^L*+.I[3@4[B(^X6+:I+)#YOEV%%\.6GZ'YJ_+":5_!_RVJV+WUK
M[ZIMZ<\-)AV`'[<CZ5P!:AJ?9X2!@V^=GU]/03W@,\L/_4R>#6O>6O+#&KM`
MF+/&#*%8D"&]Y$]9:T94L*SGZ>D]URZW?^M7+GN"J;C?YZ'\6Z#A2:6!4^%%
MUH0Y/.*LZX>/3(_KQQ%4%_5"(?1YHY[T!.L#/3W%A.=`_1<B@/JO1<C:UAI#
M8>F"\*'%>`AO*:C&=?T[I?LB]>@;>ACU_%A!2?4^62$L<VSG-F)8`5^(S[ME
M4S%JP&9%6LDUG&G/H'\X_7YTC(`$8@_8K].CRS^PN%6RU8E9>L`?[XGK;5L@
MLC/'EI9(5FZ,>5[B4*7!_$T`W%GGQP60;8-<>:#`J9R#MSDY._^USVZEDMKM
M5_SK@V2DWGZDP$2;R;@K;[Q/#72B)5XL-!TZG\SGBZQ>,GJ4_<#TA0U&380O
M([C6SIL&XA\0"B#<&CVQ&2UFT?]OVF(6W[7I++[F-K3X"8PIB7].XI_ZP+NI
MX?`=W":AP>S)+;+F-57G^8?\[;)VMT8OV(-!+TEWB:7;(NDNL71)=Y=9NJNB
MNRNQ*JB<FQ*8BO-$M)R9]_IL87K!V:<5F%JB^5>"-\&;X$WP)G@3O`G>1L&[
MV=PR'@'+'W+1D<&UMF7F=H].%:RW_):\>P3/>LMOR;M'\*RW_):\>P3/NLC/
MD#!CSD<&)RN3O1MVZ*M(Z37$Q_>!\)10=(2PZ1(UTSC1*8,$3X*G^?(C>!(\
M#98?P9/@:;#\:AIY#!TA;)EUA+#P(!QQ=13"G;[TI(HP/+D5JQR(FM`]DZR5
MT8?DT9&0A-1Z(+5I;1HO3,(J896LJ@'=(Z0^$:FM73HDU\S09;X3*3A]@D>]
MN,56&27"6VD+.BGWI0X)-RL78\HAX?/-X-#2:T([H9W03F@GM!/:">WU17NS
MN;W*>#<XDIOO)-2E'W$W.[+3NV%VOC!.I`OC5CG`K]>M3S/<?UA;*[DXIIDT
M9"!=(5VIF:[0A!QI"VD+>1;2E276E:D/09ZE[FQ:BSQ\T3CM68F=76>^4G2!
MI\'=,\$Z&IJG6XIQ`N&\=C@WLOMTC::9W:L1KLE^$\Y7`>=&=G^<_6[M[JZT
M_38D`IM=,$I'^%'WZ)2?I9'?DG>/X%EO^2UY]PB>]9;?DG>/X%D7^1D29LSY
M"+^H)T*6W`%/1_:9+D$SC1&=ZD/P)'B:+S^")\'38/D1/`F>!LNOII'&T&ZI
MIE&[I;YRZ3'?8XJ[`L^_Z#C"]S@[=*4G;>ZRXNK850Y$Z[5>UR`&&+1X_5E6
MD5:G$]H)[81V0CNAG=!.:*\OVK=WZ$##.05VQDPA)9-'[)WK*_6>-@U-J_EM
MT'S'CZ^Q_9='P`O<O?U,OM"*=5(24I+IE<1(QM!V)5(*\ASD.4A)2$GFHB3M
MW;WE5!/XV(60*Z.^0M?;(<+>KKU5(I3=MR/$%/5^P-JF#'4_1!SP5"8Q(\MV
M!0_W0;"]*NN&.3>.K-'FRU]FU?EJWZGB<L4/<U\+'!0V=$3XJ0%(S=K7B-UO
M6M:;`Z8+K;M\X,?1?E?>"^>@P6SANBK@MO1N](OX/>".DW[/FD[0E6AH3D[Y
M8UA\S,#W\8,:>/L7=D\XL2O.NT=2!;[B[M?0CP-UZMENC,T<E9(5YWFN(LEJ
M7$0\$GWA11W/Z0!1^(B[^(;KJS@4ZA(;NQ3WT1?7MW]_?OWJ]2O&/L9J_8;S
M8/^['PGU4]A"WF*Y[R)BV!04_RFZGQH_.NK<L]I7UNY5RVJVKI+I[VSVNYC\
M/G/M;Z)_+<)88;4_A0M4.3]X&`TN0^XI;FN2OPS*3SKW4ET=^OV^"&W)W1\<
MNE:NY3`4T)\3X+PKD](-)AU`#-;F7#6WFPT6>S*A],^+HP9SA"W!Z"F4R^<=
M;8<_?GBXJ\/,./.]FTL1]H_$=?0#B`*N\AOQ!0P"".$_\#>^=PK<`;9&/Z$?
M->)5J\2K`'!19E:[\=G:L+9V"EX]FQ,9*Q'//T+_5BKHPXD?_@D@=5T!1"#+
M00(`T_R]7!:JRDAKY\IJ(A/;E[ZU=]6V].>A#K4?%OXZ=&AGNZVE/R5!Y?X4
MHCL10HVHR'AJ'Q1_66I#*OR%N]RSQ45/B`?5^<O@649B#!(V'V=<RK.13D_#
MD5:)(P\KQ(MS9&O^'&G6"R/;B^-(33"R\SA'FLVMW-P\R);,NJ;WP&IBR[?`
M'B<'<-?;O.Q.A,X3V3`;KM4$7GL3X&5M5L8R<V5=O6S5CF4&X.IESW8>&3LC
MUUJ[.],`#LU?A;+'"2OX<9%>)G>H;R.HLP'<:3W)=_YS+BV$YS5!\X1@H!X\
MKYG=?5H<41.>UP3G$R*59G,['X7.CO&9#WA&C>?9]3++,*3=F1P-S8!%\^=V
M33`^*=(:&@H;R?*:F?*GQVQ&<[LF`)\0ZVU:;9,`GK!('[=>9R.^^_0P\9]Q
M:2$\KP?2=R<$F>NSL.4+XGR]+/KNY""T1CRO"=HG!*'KK=W=^:)]]#W<OHR%
MS[VL,3W)/%KPNXC.NY?\OMXV?G)(.EMN+50&-=&"R9-I-91!S:S_LP+6NLF@
M)GHP(8S=WMD9=@9S$$3A+DY"OS^>]NS=3A2%\CK6BY,N_9\B\$,=2L`+T:#>
M?N'I\>W,&+9H2=1$*R;$OB,10>WD42]/L??TJ+BVDJB'9NQ-B)7;NWN+48Q#
MKGK02_SG^*]8WG(76*`ZT2$/PX%>_>?&XQ8^/K!.;^^Q2'2K\7FK.;1,\TGM
MSXAHP$,[P<@0T8^%<EN8@[9F0?4)EZ%^4`)2OE+W*79EB.K-QN<9+6<_^-;Y
M^?7T^SZ#S_`GW3Z1/!O>1+"6_+#&+G"E-FL,+;DN+_,N[RE(]TP<GI^==7Y<
MP,^X+I,'2ARP7Z='EW]@.>O-Q.77^8X#7;A8WUW:U?[P5I-DPX:PQ9ZSFU.4
M;AH9_CG?EI+]GFTRR1Y8TBM^U#57?DF.-],_I34FOXS4E[:O2Z:<:+TI[]18
M3R]9C7"U<,!#0%J#`>+DC?>I$?E!SI.AW25C,)&+67K)G]+"^I%%^F7II21<
MN]S^W:ANPICI9@>VP+T##V\D>&R[$F'H$0RI*/2]FRD1-2]A;VZ,BKM*Z/))
M?V][.O'#>Y/D7]Z&]K]81;([.&`/@8+]8U3D=@:])TL<N]]E)]*#09KD+COU
MH/X8!VYJ:CD_LE>L\LX,/.U3V9=N?CS]?G2,GKBUM[%3YNFT7'S<\BVP?]-V
MY;(G6!>A<*NAP&W;CW$D?`-5<,_AH:-@]-:57K688A&\R/M8&#[RB-WYL>NP
M:\%"O0U$."SRF8+1!N,>E%<B8G[(`B[U`ZTY71$RSES)K_6V&P8]@;)Z#.(.
MDB+);AZH-KH3PF-]'OZ&BD#E(FG+@`-(-UA',17;O;4R@1*ICD38!\*!*J[@
M[SCP-25Q/]#C^X3N,56F?8F50)*"4.+HJ=*-G.8-=E(TVA<<!Z%:=QA8!1;B
M!B0\_Y1#6Z$0ZY&$+O?@+Q[:O0&RL0O#-O].[1L#I+HJR@@QCRH)#:YGY1HW
MI_.,FR\RN%Z!@6I[.GFTYR>/RLCS8M"_]MWGCE<O_OOMR_E969B[[94+0?:F
M%.W>9-G.>Y1Q)FZ%RYK@3H,X4OOL_V(?/2.Z5C#J[V*/.]BL<-X7NMH%/RL=
MZ)4^*5R[7E7VO1+>Q!&#C1LI4C>NGH$#`P>IK-W<V!MQP>O-K8U-\L'D@\D'
MUT0>Y(.75;*U]\&MW`>?ZG_7F*]O"(18V&-_5=RRU)-P\!W:S1RX#IDQM/6O
ME0CU80],2%V#(R'RCR!P1[_M9=\.(&YVR"F34R:G3$Z9G#(Y97+*HTZYG3OE
M/[V28TU^9!@(W_6DW<.<>ZASVQ#^1GBC5L@\/\M@.SSB:VG!4/P5@P/62?HP
M6[#"1++.)_*9@\WZ`9,84M]5LN)C9O=JY*SKFKV>-\Y.NQH+*:)B]?_M?5ES
MVTBR[OM$]'^HJ]N.[HZ@:"Q<Y;8C9,OVZ![;4DB:=LR3`P*+%*9!@(-%,L^O
MOUD%@`2X@B26`I!SQG-$$DMEYE>Y555FL#P3+EC$%T[&FFDRAV]DC,>431UB
M,JRX;)'02ZX5+=8Q6OR7Y;(&OX/!-+;NPJXP[1?JA@]DS^.C"5Q*N-B%^6F,
M#5UC*TKVZLMB:RM[$(IH*QUM;!\7\_N)SOZ@RQU=44Q!IK9%YY'F"A<=W24'
M`!R_[K1[!VY@Z+;E!%/)U#!-MK#(!IGIFV2I+6UY%9]#]W3F\;V21)5:A.U"
MXV.X`C,7?"OS;Y46Z&UW1GERT^0S+`R\PHG`EB>93D]F5O=,#4&K>*;:T+>Z
M^V]9]I.WN/_@.TQ;7?(T<;)HYQ%;`;MB;07,<ABQV4U"GRA4`0LI&L=%$^06
M7`VVOD^#X],N1W:07M`#\41I_-\-9A%LWX4KW#_606ODI?F*8,,N19X;88=%
M^1F\,![PK]A!>-V6A,+-7Q_O/GVY^7Y!6$517I,\$6L,Z6-/IVR>1,6_5Z*.
MK1=L2DFLAB;K-\>8M!IWK%]\4(8CQ!0K+!Y/:Z1M$;4[5ERK0YZVS]/F&N>K
ME=`7`5(_BWK])Y*RK5CZ@:0(0,E*N?L=G>$.IY65&*;.DEJ50=1F"`40*FND
M+[R0)0_`'5E^8"91=/&NDHP"CI$>^9,Q^<I)^2JBRS>CZ7M<B[ZLD+"U/T2V
M2OG:\ASZTV:;%0,7##QGRH)Q[H*%V1X6.R]\LV*EGP<?<IGP:5J1"(&"$QK%
M5(KHL$W->DN:G5U@Y%:W4[`!0X@CQ(N$N-+J%&W#Q8*X.(8]T8DX6\/.<UOA
MD0K>6:-$B6=$IDB..I(G+3)8H5K,2U^E[5Z(R$7D9D7>D<YCVI;VM82J.&8U
MQWAY=:6BR7Y4,4+,(R?6>`8<J=^D#N*]BN)N/`..P_M`:C+<Q;'G.8;)#[:G
MF4WVVDI-?474I^A`WJB4X$E\*28JEUN]3J/#G>H"!"?.<7PY-MW>E89-GB@[
M-ON?OIML664L\?JM'W*K8E>]!U=I@V_Z/;NKNWUO'7M&'6]^:VH6JR++JH3R
M#0VG[/+MX2[?C=#<M\LW$`7?6D(C.:3?TIO)J8C53;8%;!/>KGR"&P<;9VBR
MKB?NN\5]MZGV]U5[YRUNS<2]M\T5,.Z]%2_WF.-:XE?-\L?@4OH./V,=.41-
MSCE7="->A3,FA6^P[39Z[V%%98T`3Y_O&Y:9%B\=X.)8[AQ7#3_8TYGOL2+D
M[)SR>&Q`W"F"_2X]UUL)B=:/O.,T5:>+4!5/EC4G[SBHJHV&JC@V-<=H>-D2
M4`A36KHC5=W-=HUGP)&1L8H'3RLI[L8S`/%>::.>8Z!<ULJC6/Z;$%OBD/I"
M`A6US#,#*&NDOK#L40]C<B',=YXQ.75=5F37G_HF[T@YHC.'Z@9O<]]DYZVZ
MOGKC&<"UW4[-]KO<5_]`=%=1N(UG0`IT*QVET>@6QW+CN=::^^)X/$_XXWER
M%T^QUA(..$TRW=6FE)FL+V*:\&^S.FP9\"?37EC5.V!:O0=O/S<L^/G8_:=<
MU[K@^+.9R;MB:>9[#6[3Z?T3I=ZF#CI'G)#MKY^0%>VDZPG#P%ZG675@5(YK
MP+ABH39@(H]>ISF;B`KJRWJW!RT%G*[GV-;D2*CFAL_NA@9QR9'63_S#WI'=
M87OE`6"AJ^ZI276V9!,:=\*M.[FVQLQ+7JS?'"/0`KNWIFZ=68M6;(7TF,O+
M'F`/O_*`LS8N[.&'M43JM)]/Q/SHD8F^\LM,8!V1F@L8ZXAL<E5KNTL+>_A5
M9L4+*S!@#S^$.$(<>_C5QK#GN(D+>_A5H*!!Q<G#'GZU%6W#R<,>?E4VJ]C#
MKP:3%X]ZB%=U`7OX55/<C6<`]O"KLCW'LTXUS??A(0[LX8<3!R=.-?B"/?Q.
M]B-*[^$GPB&0PIN(;=NG>-CVQ(<G2C3+,W1CQNNY++8.[-TR0,:V0SRXW:(_
M/>*]4/.9DBF\_,DEFD.);FJN:XP->*@&WR3W?+8)>S&KFJY9<S+5YL2CSM2P
M8`S\F9KC:-:$GT8B&OP7+O*`1WPPP?('98_4W"?X./9YT75^HT.GFF&Q]BF/
MX39G>*KO\B=H4]NW/)?8+S`FSU[0NF$GNVB[EC/<<UK%+;2;;LEFBS(V(,0&
MA+AI&!L0XKY2W#B,`L:-PQ5(G&(#PL9DA'#K)#8@1(`CP$],5F(#0C$L=XY+
MGMB`L&*;$6M.'C8@K(\L:TX>-B"LLDW%!H0UF<"X55*XK9(-;\A677$WG@&(
M]TH;]1P#96Q`6'K^"ZG'!H0H:Z0>&Q#6U'QC`T*A9KK@OGKC&8`-"&LLW,8S
M`!L05LARXZ'<FOOB>+90^+.%V("PIG#`:8(-".O4@+"RS?$.:747M<ESY]9%
M6"?L8W@"]BX\(GMIC:YB!V03O?$NW1MK:T^\P1GQ+2.X\E_W5V=D1'4#`..^
M/3M7S][)W8X*L^O/UZG?G<%@9>6'RIOY*2N#'>X>K-*1E>,&&TF%%S>]6]8V
M_>S8KOLA/#6<EJDPAMWCE)8PV/7"TP:WA8GPQ1Z)]SD+CQE@DN6'LTW9,S*I
MDQC:QM<=.::MW%)WCVD@'3XDSM)+WG;H<!YU]O"HU]D@O\3+CAG.5O9T]\S(
MKC0\<#A;NX9RY!W`J=[NH:GJJNAVO??446YE8'_W*#N];H&C7/+RQ^+2K_SP
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ML@QK48F*6B.X9%&G@JA2BS"1\`L9M'FM*HU5LS)-^\6]V)TFR8!7B3(WJMP>
M;FO/F0T#"ZP%M1AQ6&0B<ZX%&;0O=.RM5PM*UM99R42%+]]?S&=?_9Y$L9]$
M]:(=-80RKUB4>^F@U7SEYJSF[C3J6M8U;8&A17)4[6>PB%`(*=NJDV2Z'+)_
M<7Z]T$LY@E.&\:HRZOI2,%/52_J_<E6]_/R1Z>QXX_*-188.%W^.+$$`)&>N
M'`=`=XWT;V"ABY=_%:?_<5M#4'\+(T"!IV^:9>.-S-BT&IN^TEO!*OEH*E'D
M,6;T-HH\;>$DM,(BRG1/[3_QIO3)%&=LCVI.:GV0GIWVJJ(+4IX/N7V;=>:.
M99B@I63F&#HM4++'T5B(J=JPR6X3?>L;[_*5:Y9^9]H^L@V2]/&*N"2Q;M#.
MO\KM8>]\R89?E;:2=E=T@T1=CE[.T"=)N^6Y`9I,;O?3-N)$A)?E>:"NWJBK
M^U)25Z=N(E=+)`OB;R>.*.3@;P>;)0A\-D;4&J7MFET>G37RN;.3K5!.M;BB
MS$A19RBW#9I8>H6"$UR5HHH)H5I+48H__ZKJX:+BK+V_FG=^./17GVU3\PS3
M\.9-CE&$3ZU4PV$55Y1E918.TKMR5RU-\XHK.L&T*2J9$*R=02V%*?X,K*K3
MFK/RE`:OEE3&$K!ROR.^3.OOS^:;?[TSW+_)F!UY,AA6J>L11_-*V_@@0AQ3
MKPP))F$KFDMH]]3->AE^Z38ZT2`">35R=W/.T+;[I:WB8I*VDOYNWHH5_*#-
M#F][.!!?JO7W>`O*X)K&F!)[3.S9`47_:QGIU"O!@EG<:B8BNDL2YU1S8B=Y
MP[^Z4HP+LK1Z.4I=;&6,^BG$.:D&7@L7:,W)RU@)AS5[PFVWJ)2%4\J">-,%
M[=\=V\Z8&AXK>MWD$*I>R1M,'E<TQ]'H-(8(Y-7(&\8=O)@<1L6YYM+5JJ6)
M4+5P5TL3W^M/=.2;]&:\>8CW'MP4#4+WC&?#FY]<7;>/U753%X>])*X_G6K.
MG*7372:-,*E.M$`<!B^XRWY=+Z';XC5T(7S@Y7=9U!A6V[VB>GBES*]46L1P
ML<9N;F#8-J@,>1FH9JR\VY#*NSU1?'CQHI$RRZK6BA8)(2:B6.I$"T),1+'T
M=I>=_$Y90H2.4#ZH`E`%5'L]"SW1NLZK.M&".D)(L=2)%H28B&+9XXE>/E-'
MFQ1YI`[%4UM:4`.@(UIY`0HXK^I$"^H((<4B8\)*:`'M<>/NZ%0S+,.:H(`$
MG4&7DXE#)\56KT`_"/V@.DVQ.M&"?I"08MFGQ<-TR;*/:]B2"24FIF/TP;8\
M1],]7S-11().JFL0D6&YAMX0":%K5'$!"MP^\NA)&&Y11PE65H*W!3>%1/EE
MZJE\,<8H/7&EMV_V_:69?E/D)[`#LY=J=&#*HT24GN8[CB.732FFA1"=B$Y$
MI[#H%);0;M4(19&AYA17IK4*&W(JPK<IEGBOF9JE4W*^5B)`+E#,PM6;$X&\
M&I4]RI#F#9I):0W[PY8DEU;^"!%[/&)_;1!0Y;;:$5Z(92925?!-1K;/JX)4
M"\8-X\"&Z*77EF2L6%L[29^@L@\DO*I:O=$]$@0)DK*K9+@I2/K,"O$5>IH`
MZ\#6.R#*D.:-`9'4[[9`UPHO4D2LX`%1SD!M*Z6EF1"C2<%MRA7'734D7^R%
M'`1W%<!]])I/6?2+LA(D'+P%B7SR71Z*S@N5%ON($..*0)Y(L8\PF9??U7ZG
M->C*?P@O/D2GX'%.OD"5<.&G=/*:WH)1R#@%P8GF7>`X0P1X"A)GY+O"\BGH
M>(EK+,><,Q-,OL4SH*2DRF&QBJ)T6QU9+2U6082+L&J3&;`%7]=1^XASP>UP
MS<D3,MY!<%8ZWLE7:U9(?O6/=[(+_80YPB]<:"L2>94_%%@2^4+J,00W@AO!
MW1!P-Y4\(0,<E%Y)Y)6D6E%W5C7`R7=!9WM=`:7)P:T(Y(F4>Q$ZB]UI=;IJ
MJ]_I"2]21*S@V\OR!:K<[@^$%V)MSUJ+I7BKS8&-=04ZJB!U!1#K0JAL8>H*
MY*S56ZHT:/HI7D&"I7Q/V91<7T"$H%@$\FH4&.5<QTKNM[KEZ27$:UW"HKS+
MK?7QU(T@&!7F`';%R,=%'H')$P[<)9WJJ5EU`1'@+4C<D^\B4>G5!42(<$4@
M3Z3(1YC\R^_*4&[U>CT\L5-!=(H5Y^0+5*G='PHO1,1HK<D3,DY!<*)Y%SC.
M$`&>@L09^:ZOE%Y=0(2(LM2SUV*MP91172#G2FB=H.`S5D*K)<*K5ET@YWY/
M;16;DXENAVM.GI#Q#H*STO$.5E-K3+R37>@G9G4!$4);D<BKUP'LXL@74H\A
MN!'<".Z&@+NIY`D9X*#T2B*O)-6*NK.J`4Z^"SI1=8&0)UWI#;FG,R^L,R#Q
M.@,J.2>V[[F>9HT,:]+DH+?<,X-BI6V$.3R8;[9';0VD3JL[P$,Z]<1]Y<[*
MYG[4I[0M<(CT2FMXP3BP(>[JMOL]02H@(-91JQ>GU8>J4F;]`Q'`+D@XA^M5
MS4HLU>Q$8X'T8V*J`N0AO!'>"&\D']>\JD>>,.!&W5T7>`L29(FQ9D:#H@P:
M@*G)@7>-LTRX9K;E7$EK*"DM52JM=27B'K.K1:Z9]1#I]41ZPSBP<<U,Z>.:
M6>TDC5I][YJ9I.*:F1#A7';E2[;6#"<CS:-DK!D.>=9,GQ)[3.R99]B62R9!
M47&(Z%A@U^3P7@3R:EHJM$#Z,7LEI&TO=094SO:7.U_D0;?I_41$($\X6U`Q
M\G&93F#RA`,W.CIU@;<@<5UV(:Z8>R%%".$;21ZV\*ZV_,HAKV:&MD#Z$=Y(
MGK#D"1GDH/30-4#=684@)=_%I^^4X9&.B/9,'6U"@\6FM=4H7'H2@;R*5D/-
MD#XAE958\*S$TA$N#9VPV:];VF8_L9!>+1C7B3PA0QH$)WH)Z"54(:3)]WC4
M8?OIE":'N"*05U%UA2T>ZA[4E-H\OG)!3\2M#S=?;NX6`RF$>QOF3Z?5Z0V:
MOGM>!/*J&2EA=RD$)[H>PLNO_I%2=D&CF#O41`B*&TD>MH&HMORP8A-6;$)X
M(WG8(:KQTJN);D7=6=4@)=_EG$-VJ.%BCN@2%E-9848%%W.:M$/MY,6:@_"O
MM.4N(K]ABEDP\H0,<1"<Z#6@UY`ZQ'GM\5+6BX^)>[9^X#>!")P1==Z>P9@B
M?O&Q7<B2].H-X1>=F]K<]KV+L?&3CMZ<$9V:ICO3=,.:\!O9YYDV&H6?.14\
M\EK\-8K^>AW_TUG^&1'PYVO?/9]HVNSB7G^B(]^D-^/[)\VA[S67CC[8TQFU
M7(UM5[OW;/WOFV#GVJ7N&<^&-W]@CWF@/[WW)OSX[I=__/(/0OZ,GGAEN+II
MN[X#SXP_Z8Z:$#/!PUW/7;[K5IM/J>6YB\<1W;8\^'!'QV_/;B7Y!_R7'?YY
ML*7A#U7B?Y\18_3V[),&XQG]4.3!V;M(M!%SOU[>?;X&:`!>X%_HG03X645=
M*_BB1>ZI8XQ)`BG1XW23:LX%S*.G)()7`;P*U2R&$0`H',CWZZN'?[(',-2$
M_AQX45\N;^_AG;IMFMK,I6MSYBP.P#VX6BJ%N%:(A_I;'4JJT^%HL!C8EX^?
M'F+?1DYC=+ED)&;\>>@->A!?P_`<0,7RGN!1_(Z0!<JK-3<T>&`\1[XRH/"Z
MM1'QB^'N,Q;,&Q/K[9EGSQ:,4%[MPP17?=??KCXRX2K#=I]IJ87L#2OXQ\00
M/I[IQ\4$'@/@HX>&/'@T-?WO=2ENNB.A4'];`=5OK=]<!J??-C^+9/DPKF'8
MPU)\.#Q6:2JT-J$H8J/K.;8U.0Y&O?:Z5)+/$UQ(PUYA4H)7E26FI9O"#?$Y
MMYDD;E:/%F-:UR8#,YC0C^>JW!YN49`D^&VS<CJ$6[M53I:6?47@9%WBQG&B
MYP(GUY8.$\%XIN36U#8(VT@C]JQ%N,O$55-TD6'^C^]ZQGA^I&V^\AUPHH@B
M27*+>$^43U3-F@?$#12Y_\8E[VW-&;'S(%>&0W7/=ERB64RE@KB?;!.\-/AB
M9,_8F@-[!GL:V00&\CO[.7JV(KV)7<G!$OTBO_FC31[@6L_V-)-8/N_4`R-P
MF1ON\K_X72^&]T3@FQF,"RXF+T^&_A3^%IU>68R5:+,9$&!P+12$M"Z9:G/R
M2!='7.`90#ZQ+4KH=&;:<\I/PL180VR':,3U'UUC9&C.G(P"'H:WG;."^V0&
M;H<](KX%S%GE"><$$&("8;9'Z$^=PHLS]9*4KK38RQT!LTTNX8W:"\C2)3/?
M<7VV*@3T;A^>1YVI8;%U(W\&'&,71E\Q#H9\"5A'$Y`)>,?B)#)F_`+>.%1S
M;0M&$8S`L'33']%(2BTF1<\Q=":$0,JM[5)K,0:/68#.VCJ%H&!RUC7WZ?R1
MFYR0TE7(!:]?1]HJ!UA0IQD`'YTZ[`]XO&><CPS3Y^.8.?:SX7)\&0%GZ#.C
M%GBBA>-V9Z;A142`%C!&%$8(W(#Y#ZC0M9G!P*V-V!1FK&H1S24C.C8L&'[X
MU!F,9?,`^0A&0#=G,$/GU/"\)5R#60OR#9;_0K8S)L%W(QH(D@9##_I>P=M`
M`+1%GD$4#-+LFA;\.C.<@/M\#9$]@J$C((-=$_+>MD9&,.7"(03O;(6RYI-$
MA]B-.@G\1&]CK+.">XCF<<QX`'M`#'_@>L<NKK$<2E[8_V0=&&0V%X==M=4-
M&RMMC"\6BLIP79\!EZ'$]UP/_F!\V:I$-CC$E3$\I!;F\\8B7S4'+(["(2GU
M#S.B,S:'ET:SG]IH]K<83:X+V.4,2EPWP@O]&9OQV=H70/2ZA8E99QVT$<SP
M0/?!V^,6]LFQ_<D34PHAE0ESW0*C:/W7!_&,#3I:_6V'15AH6/I?WX"@B&GC
MZ+>X;6%/6/\&9IGA!7HLT&O\VZ0I`3KL\1@TI`./#*Z*?`3^_KAS!,K0]4V8
MPIZ[ZC^PG]F[%BZ$05VFX@V7:WORHL6@\3A/^EE`\#?X@>M!)<!<8!Z2.GSI
M(47*):%%XO@!K"S-`7\ANTB/!6Q<FAML2QS,+4Y6Z$Q1)C_.+@?$3L%HL#=K
M@47C6U"FFO,W]98GC;?-F@2.0A>$&R'V1T`:&W^(K?KYC/T`$F5XBV$*'0@%
M(=!X;TP"`&2[B&"XOAL.&]P0QYXNY0/T<_8$N)A0"XR^:<X#9X*YD1;AG:F(
M-O9"<I?;E/:;?$UDB]_I@,7OJQE9_'ZA%O_@Q#"Z`=P-2"IE66IMT9/[(F=9
MVN($)!R`Q55E.0"\T18Z`-DZ`(<9\00&:F7$T?(<[Y=W(`;IKDS+HVU/`F)H
M>X2T/=>KV2=KH9,2DS"6N$L$J>`.@VNI4]!S;+*#)K`GEO&_*\H#)@_\34/S
MHGF+=W"]Y3![`VJ;):^HX]!1\F;V3&<$W_(LH@%ZU@#-LIQT+$'D>E0;M9:Z
M):%4XJIX%FR_8"]<C'5$'(VM!\T#_1#<PK9N+')+@:HH,&%R[/:)[9M\A$;A
M0PQ03T'\:C+K'9.EINNV;W%I\(PEH(Z["R0IU]#4NLP[X"X"5U>!>4PB@VH0
MMH7F`QX(]W%$16X&`(0)?\IQ$+<ZD8$@OLN3G,P4,LK.[W7PR9C[,@M3O`;;
M<4*F]HB:[6S]IS4@YK*GX6&--`V4_C1R)MQEFAE\,AID=BV6%`9S[3T!_RPV
M:]=M(;^0G1[AUE!C*6C3M%_<BV)-Q(YEV>J9B,6(F5-,G4PW=<4V.G[A^QP3
M;(SO45C90A7?R+6Z=6)('WLP14'+$=<VC='J)HKUWV-R2KQPY[ZPF[\^WGWZ
M<O/]@K#UEL>U0\5;AQ'MG%B]8/]VLM4M3R4<%SM]AZS:%V2'K!A[M;><))&7
ML(G3&LS!<@2G#%^=,?P#0@&$ZAKI#TQ5+^G_RE7U\O-'IK-CFW`BY;W\"K3X
M$>+/D24(@.3,E>,`Z*Z1_@TL=/'RK^+T+^^X+^KOND_?395-8J/9S@QEPWF_
MXUJ%%*"2CZ8211YC1F^CR(\Y>X]66!29JG$CK51@2I],<<;VJ.:DU@?IV6FO
M*KH@M2L9L\FQ_)A8=RQ0LL(=GSWX^'-&A25*\3O/4=+96:62Q+I!._\JMX>]
M\R4;?E7:2FD=L,05M3@]#X[T2=)6T6F`)I/;_8[P$&@(PE%7'Z:K^U)25W<:
MK:L%\;>S:ZZVV=]FF\_I:+%GT2U+Y")4Y2S:4F78.$\DIUI<46:DJ#.4VP9-
M++U"P0FN2E'%A%"MI2C%GW]5]7!1<=;>7\T[/QSZJ\^VJ7F&:7CS)L<HPJ=6
MJN&PBBO*LC(+!^E=N:N6IGG%%9U@VA253`C6SJ"6PA1_!E;5:<U9>4J#5TLJ
M8PE8N=\17Z;U]V?SS;_>&>[?9,R./!D,J]3UV`G"TC8^B!#'U"M#@DG8BN82
MVCUULUZ&7[J-3C2(0%Z-W-V<,[3M?FFKN)BDK:2_F[=B!3]HL\/;'@[$EVK]
M/=Z",KBF,>8E$((B!TV.=.J58,$L;C43$=TEB;PL58SBX*^N%.."+*U>CE(7
M6QFC?@IQ3JJ!UZ;W?11<">?0@!65<@V]Z8+V[XYM9TP-SW<H[N"M3?(&D\<5
MS7$T.HTA`GDU\H9Q!R\FAYNC./FG_*J;"HV)<IIQCTZO&+J9NUL_Y%)B-B-:
ML%OCH566@Z+:;J(V=J+J=O#5HG%?K"`VJ[:\UK[."9J=$VWB4,H;G`<UEQ<5
MM)=WA#TF7!J[F#QISW11F3]L"H>%@7/"TPZ]B\W7-S9?[A?6>WDE7;!!^KM:
M+^>CU<1KAEU<+^S36F$?(X_!4)(K)Y!!<3-D4.04,:93.C)8W?_0DK722R:9
MRQ1,8*C1Q)(':C3!!%)7C?:DF>.%6[Y0;V;05RQPY:>:P=LXA>UPV$9WOC"%
MN@]U'^H^U'V5U7W_]37'H\ZRTQ>J-E1MJ-I0M55?M6F6Y?-&I:C94+.A9D/-
M5AO-9EOTW'LRG!%92\;QF#6(5X-/"1WX8J,&1`V(&A`U8/4U(.%INW4%^&)X
M3S$-&'W-%6"L%R^J0%2!J`)1!59:!8;9NVU:<+EVL="`&`:C!D0-B!JPN1I0
M54,/\`V+E5$'H@Y$'8@ZL*HZD*NR#6L<[>,4V\J9BEPWE9_+W79GRZYRTNNW
MY88?3KCR'6:TF`F+Y2T(M49T1.[IS*/31V;/I!9AS9%;_,KH-,,$I@4[?;#Z
MVI..(<ERO]65I`1/P[I'+O%L0J<STYY3>"3+0H\,A^J>[?"C#$$RFFBSF6/_
M-*;,4(\UPV$3R.?EDW[-<J3RH-N25@>Z<G[C/>/\^;W^9)OPY(`*WJZ5#75J
MCZC97L(H)@M7FU(R@Y?;(W;4@W7N+8+UK4%'6J=I*_-U^-8W/2T\25(L^SOM
ME6%.#=/<<(0FC0BJ.W]+/M*2$169HGB-#[D<H;LDKC^=:LZ<`9L?YXJPI>F>
M\6QX!N5GJ>#736J439_P1!:WI:'&O0(O(+A2;H6SWL`C6?GA=P>$LN)E<%[U
M"S\<FV!NW'-<.8<5/PVVZM`.Z6-/IS#X1>O*I&N[_GN,[L0+=QXNN_GKX]VG
M+S??+P@[0/C(CMHFO-BMPXC\V=4+]I])"P'%SA''SZ0568WF])/:/5%J08A7
MU>+X4_5UJA"0`2T20DQ$L=2)%H28B&+IO3IC)AJ,*-A)98VN[Y05UJ$CE`^J
M`%0!U:Z+B)YH7>=5G6A!'2&D6.I$"T),1+'L\40OGZFC38ILS8;BJ2TMJ`'0
M$:V\``6<5W6B!76$D&*1,6$EM(#VN'%WT:Y6%)"@,^AR,G'HI-@NR.@'H1]4
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M56ZK'>&%6&8B507?9&3[O"I(M6#<,`YLB%YZ;4E><H'7\4.L5U_2)ZCL`PFO
MJE8_;S+,!0F2QOP_>05)GX.BB&7).35QU70OLY-==0*B#&G>&!!)_64-49%%
MBH@5/"#*&:AMI;0T$V(T*;A-N>*XJX;DB[V0@^"N`KB/7O,IBWY15H*$@[<@
MD4^^RT/1>:'28A\18EP1R!,I]A$F\_*[VN^T!EWY#^'%A^@4/,[)%Z@2+OR4
M3E[A&E0P\H2,4Q"<:-X%CC-$@*<@<4:^*RR?;&=,#5QC.>J<F6#R+9X!)255
M#HM5%*7;ZLAJ:;$*(ER$59O,@"WXNH[:1YP+;H=K3IZ0\0Z"L]+Q3KY:LT+R
MJW^\DUWH)\P1?N%"6Y'(J_RAP)+(%U*/(;@1W`CNAH"[J>0)&>"@]$HBKR35
MBKJSJ@%.O@LZV^L**$T.;D4@3Z3<B]!9[$ZKTU5;_4Y/>)$B8@7?7I8O4.5V
M?R"\$&M[UEHLQ5MM#FRL*]!1!:DK@%@70F4+4U<@9ZW>4J5!TT_Q"A(LY7O*
MIN3Z`B($Q2*05Z/`*.<Z5G*_U2U/+R%>ZQ(6Y5UNK8^G;@3!J#`'L"M&/B[R
M"$R><.`NZ51/S:H+B`!O0>*>?!>)2J\N($*$*P)Y(D4^PN1??E>&<JO7Z^&)
MG0JB4ZPX)U^@2NW^4'@A(D9K39Z0<0J"$\V[P'&&"/`4),[(=WVE].H"(D24
MI9Z]%FL-IHSJ`CE70NL$!9^Q$EHM$5ZUZ@(Y]WMJJ]B<3'0[7'/RA(QW$)R5
MCG>PFEICXIWL0C\QJPN($-J*1%Z]#F`71[Z0>@S!C>!&<#<$W$TE3\@`!Z57
M$GDEJ5;4G54-</)=T(FJ"X0\Z4IOR#V=>6&=`8G7&5#).;%]S_4T:V18DR8'
MO>6>&10K;2/,X<%\LSUJ:R!U6MT!'M*I)^XK=U8V]Z,^I6V!0Z176L,+QH$-
M<5>WW>\)4@$!L8Y:O3BM/E25,NL?B`!V0<(Y7*]J5F*I9B<:"Z0?$U,5(`_A
MC?!&>"/YN.95/?*$`3?J[KK`6Y`@2XPU,QH49=``3$T.O&N<9<(ULRWG2EI#
M26FI4FFM*Q'WF%TM<LVLATBO)](;QH&-:V9*']?,:B=IU.I[U\PD%=?,A`CG
MLBM?LK5F.!EI'B5CS7#(LV;ZE-AC8L\\P[9<,@F*BD-$QP*[)H?W(I!7TU*A
M!=*/V2LA;7NI,Z!RMK_<^2(/NDWO)R("><+9@HJ1C\MT`I,G'+C1T:D+O`6)
MZ[(+<<7<"RE""-](\K"%=[7E5PYY-3.T!=*/\$;RA"5/R"`'I8>N`>K.*@0I
M^2X^?:<,CW1$M&?J:!,:+#:MK4;ATI,(Y%6T&FJ&]`FIK,2"9R66CG!IZ(3-
M?MW2-ON)A?1JP;A.Y`D9TB`XT4M`+Z$*(4V^QZ,.VT^G-#G$%8&\BJHK;/%0
M]Z"FU.;QE0MZ(FY]N/ER<[<82"'<VS!_.JU.;]#TW?,BD%?-2`F[2R$XT?40
M7G[UCY2R"QK%W*$F0E#<2/*P#42UY8<5F[!B$\(;R<,.48V77DUT*^K.J@8I
M^2[G'+)##1=S1)>PF,H*,RJXF-.D'6HG+]8<A'^E+7<1^0U3S(*1)V2(@^!$
MKP&]!O[MV`:?/B0D,<3?5L;X6^LWESK&^+>U<2U?\9H]C;\D;?3TVN-5LF-C
MC`:CFU1S+D""3TG>K;)NTV#67[_UP^EO?//U\N[S-4@#_H9_H4,0_+8JZ%;P
M18O<,U:2D'/;`9?EZ`PK^`<\(III3*RW9__Q7<\8SQ<\BX,A=%$>34W_>XO(
M[SU;__O\47,A2-3MZ8Q:KL9V^A'ZD_U-B6'IIC^"7^&]$VI!&&D2S8*(<C0U
M+,/U'+C\F4:7N_PWA[I`J/[$/XSH,S7MV93"N!97.=2$^ZP)\6P8+`QAL<'0
M<%T?W@;?T^G,M.<T?*8./_JF!^&K2\:V0[PG"O\<2LD4*'YR";78*#<4<V=W
ML_B6O%"'DE^SG#&JNMPH$\T;_KYLWS+LKKVEQ9@\HSICOCEO9?]2N:TDR9H:
MILF`D<.;U,UOBL1L&58H93*#Y]BC%,).\J>]6[.)/457=$OEJ;ATV8;B==FU
M8-)[H%U\RZ&Z/;&,_Z6C0#GLTD]<DP0*(ZE(7C0W:YP.-^*T15Z>#%!VALL'
MI8>C>5PHQ1%35+8_>2*?Z*/C:\Z<T=O;`\K$!VYBP1=R1M1Y>P;.0400=Q(N
M9$EZ]8;PB\Y-;6[[WL78^$E';\Z(3DW3G6DZ*%M^(_L\TT:C\'/TZL">!T[1
M8CCQ/YWEGY&Y__.U[YY/-&UV<66XNFF[OD-OQA]B4KH+A//!=CWW_DESZ'LF
MR%MMSJR!^T!_>N]-D-F[7_[QRS\(^3-ZW,=0\X.%?39TNKPS_NQOMO5,77CZ
MY8OFC-P'AIWX[^REWVSOW]2[6\")6[N;$"!@43P8P1T=OSV[O71O+&GX0Y5^
M,"B>$6,$8-%`?8Q^*/+P#$!I!%?^Z_[J#&R:;H!'Z+X].^^>O9.'/`6P9$<A
MXU]EVN:W7#J.9DTHX_?[^9H(^*O#Y_&M_^ZU=<M5[&?'=E=8),D_X+^*),D/
MMJS\4(._?WS5?AI3?_J53V;?96.Y8Z^\_&FX/_B`;TW-8I?&+V'??=.F_*HD
MMQ4IQFV7C=B-,_SZVZ>S=THWR?`<:,^:O3>^YX+WPN;=-Y_KO1WX.XIO\GZ^
M#;MJ5^IGQ[<UHLK@F@HL8U#L)[C63\DU)2W:,H1;[FQ+/Y?[L;G<3S^7TW)7
MK>5<3LU>67VPM\SJM!SL[.=@IZ-V^VJE.)AB7LO`0X7Q38KS3992\JV[GV^J
M5-MYO1UXJ1G82S%U.U*_VY"Y&_ET[J4UNC(@0O%LQTTHRL#7O=4<;_X`+W$9
M(^&%[^?Q7S8PNK^?T;)<&)_=N97QXS]IAO,7WV=0+I\'V[UX"5@\Z')=D"/]
MY4%9B;%82;#XPS*ME@F3ARG`/.@49O&+1W-AK%:EW5%I)[)N!2+ZTH1PGHUY
M\_L^ACF;).?Z>_7`R9S[\3G(7,.S+A-YZW!$["5W8=*:Z9UERCJ\(/[::TNW
MI_3>@S>P*[XPBADSUR4D[]0XJCI(3(-TS,N4Y3F"M226*[M9/NR6Q?+]UJZJ
M+%?W9,>4%2^[!*;7#^>=/4Q73V+Z229C81TN7=>?!O;C8]!.F=XZADYOK%0F
M8(7B;I+B'S/J_.`#6)GCIUJ\-,//S)/;_+)@$>'*>#9&%-##=NNFT-\K_(K'
M;S-_$YL*&WTA[/K+9DO*IN'-=S!L%\#ZY3(L.?Y<679GN']_<BB]!A:!A^X=
MR;!!.0S;-/J-['K<_\+'0R3T0)VI?`2?AF?O;J5_KW`CE\%E&?9$#_YD.V-J
M>"!?QN@H!#B<#1UI+USR'W;9!B[IB'P%=V%;NGV%>7(:ZZ>`X6\/>P4:0$'X
MN&/98H6/2DH^*FVE7Q='(I5EW.%*=-0=,Y=CKIO%ZD/UC./1L[FS@Z$=4(5M
M2>KEQ=+4YK-\AJ:?UMT4#.V6S=`B_9&CH=D#9Z5;J+,B"H_2HZT//)(;XM'M
ML@O[`X#Z>G0;\WDK_!FF=MKZG;HX&SNR%BE8UMT?)#0H:Y&&8?(^WZPS:)1O
MEH9GRGYOH9_%+CGAO84TS%(+=P@*MW5IV+#+96^*K3O6J>RFRMT'AK#(]+T@
M?$SM>'9[J;,7G=ID+U(X%#M\U&[)67TQ'8JC)_(NCY_/7ZF9WL;1,WJXUQ61
MAWFQ5,1,T*D([>T*($+?3BW=MQ-ATJ?&:&]OB,&BU[(G?9'N\M'@5.J?7#L9
M;6H#DFLI')>>2`''R:)8/R`1E::[#"K3W=&I!O/(FGP`1CG``U\SF8R4+9R+
MG4&4Y17.=0%!O7]WKC*`T/'C%I=U2HQUJZ#K<=9UOW:1>0>G"'I]KMV'7T5$
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MTP5]VJN093W(05MA2`J751U(G>Z@2JY&+%H[F"%IBAX-)47-THE?&V]^9_3Y
MIRN([0\J/;'"HQW'6G,M%[$^>`$8M<-E&>PXBBHQ3=,;%,ZI?*S^2E(D$Y2E
MWQG3S2V@WDN7F&S=A<GT&V7D+(X%B,'6[;GBQ,:=]#'ZH)\:G6H62\"'T7$P
M^]Q3Q+>#A:D0.4B-2$4^@)79T20>.W?IS<.VUM>!G='3<P+H4$K)4>FPN9XI
M64(R=0=,AVF/[4KM_K`R3#TU5LX8N.F/]&:R\2L+*JO`\EVP5M.S_!!C5B66
MG^YLK>*XD]ZD9;$C-&=G*R_V;<7D`6<,#E&U8K)O^U+]L>Q+&S')[5X^2:&2
MT'=M>8YAN8:^(=3<%1L-^SO3'OED$I.#%8$KJTIL3Y%551KD57%9&-YLG6([
MVD@`;X:J4B)KLMDVE'R1G)HWJK2CF"GCC:2N\R:7(2=RK7R7A^_H3_"8[YK#
M8[]%TY*#W295DL_>"=.P;%-CG'B?NGA+GV5#MD7OFQP;#BV>[WJ.;4TV]1O:
M/]I^.]8V*>5?7-XD$CB))+[>IB<YL"*:,`G<9&Z_+&XL<J-[-ENB4KJML#T7
M:^S%)J]FS0GEYV58BSG/)AK[>FI;9$4<EQ.'\KE-7@SOB>C4\308IJ;K<*OA
M\=M90QW;<=ODTB4SS?%8HRGOR7")%MV<?''8;.XEE#1KVS2+WI=I9\6>VFT-
MNMWD'`I6WM@8]8#BH($5#(*-<0;\"^@%;X@-W':(`6,$QVQJ>+RIN^N"=(#:
M![A\0<.3]DR)QAID!0X4F7%/$-Z2<3>LWH:^=QHQC3%_6:;L&QO/-/FR.8!\
ME?*@G1(QIE,`A.91<\['1%F@2%<AV&^3>\/261-!ZL8>PIL$3MC?G,,+&#&.
M_M<WO#EQ-.!J$D<`&.(Y-&A$]D2G[$:-C'CY>KAY3-G>"Y"RZP5#!K'[9HA.
M&(&S*##+GV3!)(![X%;6!9&_E"-Z2]<TS33Y8Y(DV$OS7TKWN[`=]_6WJX_,
M,"G#=C\SA5*%EGBIU.)7WB533J,4P_Z7#$<+9<8[)&HP.RS-T@W-Y'H$W*B@
M:C!@U[$!R=-6>%W0/)&C[H6:SXO.F=Z3YI%'.@&(`P)C/>J"87'LZ3$_BS_.
M]6'DBQ>P@2\[=+)6>#/-8.J`OP(FXIA2/AE?#$#K(XTT+Q_4F+7795,Q1'"D
MNGC/._:N3'6)TI76>W8N57%,!`'*!HK<?^,F533W*QFS-/W)H,^!,)@>#XU2
M<%6@>*>&R:R214%=_6L&]QC@YQH!(\/W+=B8*:&;Z(Q>N,[T2'T&"FJ35'A_
MPZ1@DIBR`ZU,QHX]Y:\9L<,A\!,3-G\4OV?--(&*`^Q&9H]_]7NFMDII*RM\
M@&$',O\CM<SACSA-0(/N<R'^GIS%?[3)=32S`P6]C>.Q=W'FL[D=\I,UKX38
M(FAS"IP)7]'AK^C`C(19!*H,J`#L/!LNG^Z[A.OP$QP08X%S`S%2*&8P@`X'
M+_!_0T--]K2I/3+&H4:)WK!X*K.+,QC!3PC5N+W-5&S]WCJ`(_T1:Q%J/].@
M3RS,,8[`@'.,)R$[T0"*:@"OJ!ZX,Z&QD8^S@4L+J(U@-MA@O=R@]Z:[Q_CM
M,&[+)ZQ8MQ=MJWE+V,_(JK/K5R.-7$V<+)ULXA*N]:KJ][D92RCU&'^9L[[+
M$@"GO#*L@-R6.PF6'*W[.17HDM=/(V4Z"Q-\N`2=,ITRM0"0B:85B_F>64@9
M=3J/]-YZY_,]+<^C&P+SQZ]<J%95#A01F\6@B<:V:=HO[H4`"%3E]C#.K0.%
M51SBU@:S,V^9P0O)]^NKAW^R#ZRQ=X)I\+KEJX*^X.'+;O[Z>/?IR\WW"\(\
M0OCA#7E_<W?U\>[\X>;V@OS?(7WL@5:59C^):YO&:/'SW?7G?S[LN@!X_^7R
M]AY&IP-ZM)F[?/3[FX>'FZ\;;XXQ:7'YEX^?-K\I)'C8?;6W9WDTUTTZCG'=
M<R(^_/-C0(^LS'[&?A]MA59BFJ^*A@!7'ZX_7'XYO_QR_1G(`6EZ]C2\ZWOX
MKHXD16K@X=]?X,D6<\'-4';AG3KW9\X(;]K^]JS7>Y4`S090)QK"!^W8LR5F
M:HQ&#"@G$R.73TMF@JD5+4KYQ"#(-M&B,DUG,T5GL9T5JX1%^R&6!(8[(T27
M&5?+ITOLM>>@;L=IMR*85:\C:')*Y*4CD?O$#$ZO+1E@CY=_)]:,4<#5%'"T
M]6S)`KX)3729UD'OOK_\\#^?[V[^]>T*1*_KX[&NG\R*3:KXO6;RW)7FK<7)
M<K%RSH/B7*9S(I3<,BN%D'?CJ'>8H_B&W%Y>75U_^QQ%\UV8J+N"`+6E=(<M
M>=!#O%=.XONH_[6.1!\'<[D][#89X>*8\S'_3R[F_'.P7ZM$.6=$G$B..)*7
MFU(:#I;;01&O0@FTYN0=:T3[989%I4M3'".:8TR\J`'79'>I$M*K'WE<+>U4
M0;_+K7YOT))[_3\0G^()L.;D'6LVFYU-%,=LYAA[AE4I,/K,7WIYK`TUG@$I
M3.^@TVFI?;5,PXL(1X2?A/##UT?:JM)DP(MCO,M9!RY3^*5[;A5=(FHV]4<&
M*:V>JK2Z4J,CE8I*O-G4'[T@/&PRU,6QZ[@@7'U_'<G+1"F=(U+%$V7-R4.D
M5MAVXCIPE2<MDE<;G82B;"9YB-0*6T]<#J[RI,7%,N$6RQH=%517V(UG`**]
MPE:\F'7A]8I;3?;AA%@JVJ()5'C9R/8?2ST^7U\&X?(R@J*.)Y%%FBRX-AW[
MF]4V7'S,JBPG?_366I&E56'=3J<H-3#SJ[H:='HY#XKJ)VHQ1S7)#4LW_1$O
M!$TFU*(.J_3,VHV,IH9EN![K`_E,H\O=H(8Y*Q/MV<L:O&$)9OAJ6<O9Y<69
M,RTSO*$K2K9EC-=+.T?57[TGAZ:K%QL4IG:H.Z.L!BTUYZWL1ZHHZT/-_B7]
M'0Q)73]WG1^E5&C.6`V(.-*\5'FBP#*KOQVKMAVV`5H6,%_H!&U+"6^LE7PL
M*0N;$!9=RY)+>ZHB;WMS-8HDSWY>:+YGIZZ4/!BDKY2\QI'*U=,4*#EY.BW=
M\HFI8^E(I`5!5@'!U(D6!)F@@AG6M+AXG656)UI0,:SF,ROH<_=2ULENBCBK
M)R*L1X\B0A&=ZBW=\>:IAC5!&0D[C2XG$X=.-*\YUJC<C5@%M.G8(_%*-.40
M=T8*(,&;Y1(-RK'"<ORX7%I#.8HLQSU^S@?;\AQ-]WS-7'+ABS%&J0HMU3VS
M\QJ$:EBNH2]Y\)=F^LT1:D:.DLBE<&JP#?-PHE/LL=R0AERT@6_H'LN*"KO9
MU!\)=4E:[(U#M%=)WLVF'M'>+'DWF_J5`MR#C:6(.TL>S*GF%+Q:@')&'[U(
M5=[M-%V3BW/*.K\#YT<#OE2JCHTZFUU-7E1IUIR\(\$Z:,D#A*N`\JPY>0C7
M>LFSYN3MC]R4MM(5)W)#0:*GNE>;]DH.O4H'J3BAEX"YA@HF$^1VK]&I!%&E
M67/RCM2^:K<UZ'81K^()M.;D(5YK)M":D[<_^.JTI8$XP1<*$GW5_0M?,BY\
MB1)]83HA"T0K;:71V011I5ES\HX$:[?L+60HT&:2=Z2[@'`55)XU)V]_\"6U
M.[CR);X@T55=THIM782(NS"3D%'<5>:6F-+S"*)*L^;D'9OVZK>4;A_Q*IY`
M:TX>XK5F`JTY>6D.B\D]<0(O%"3ZJD('7J4#5)S`"[,(68!9;:N8D150FC4G
M[\CM6W)+D<KT8U&>S20/X5HO>=:<O/UAE]SN"11VH2#14Q4Z["H=H.*$77OZ
M4)]4*E1DN.=)][&A6Q]/,E12WHUG0$7WCR'D$?((>90X,B"S@B,JGGFK@ZC1
M<Z]**%LZR"O3WR`*^K?@1H67C6S_\;AV$14NKYHK7XXMFC(<-CD]5%\\((/R
MF3"MGJJTNI*,LZ:.H$`&Y31K.CAKZ@L*9-#)`;W:EE1Q`GJ<*QB_5,.PR&57
MTBE]JL33`J\]WIQU\3%^S]BVO`0C(KI_6R'\M]9O+G6,\6\1"0N&\2'R![.'
M+3XD1K;U`Q\:`,L94>?MF71&HL%P#ES(DO3J#>$7G9O:W/:]B['QDX[>G!&=
MFJSKI6Y8$WXC^SS31J/P<S2.@`^!Q!=CB__I+/^,V/3G:W=N7=Q[MO[WK>_H
M3YI+OVN.HUF>^T!_>N]-^.'=+__XY1^$_,FOU)_HR#?IS3B\[%+WC&?#FS^P
M)RYN(3KP!S[<T?';LUM)_@'_5219?;"EX0]5XG^?$6,$DM#@`2/X3CE[%PD_
M8HQN@AFX@*GXE$3J*E!78?WU\N[S-0`,_H9_/X.;@]]60=X*OFB1>R9QDL!@
M9L,PK.`?`(AHIC&QWI[]QW<]8SQ?R&X-G/%9^N'FR\T=Z"13T__F=UP2UY].
M-6=.[#%Y"01!M%`29&P[Q'NBY(,]G6G6\K-E6)1,X45/+J'6B(Z`Z)E'IX_4
M(:K4(DPH1+-&BQN8%0ZOO*)Z>*',+U2(X1+-A4M-TWYQ+W9/BGR8&6J3ZV]7
M'YEX5;D]#*?HYOF^DZ4KRB9/4M8&LPDH6;Z0?+^^>O@G^\!43()I\+JS%0T5
MONP&M/^G+S??+\BSX1K<J"4L[)`^]G3*YE=D8<.?0\NU_0+@_9?+VWL8G0[H
MT68N73>IZS?'F+2X_,O'3YO?%!(\[+[:JSVC&<FM41;YY>,<C</-YTK?X%ZO
M_-4C`9H@BR>86M&BE$\,@FP3+>KNYNC?*0LOZ&A)X.4S=;2)\-W1Q5H[1-U>
MJVF7Q\+^@1/SF\_<ZB4#[/'R[R@20P%76,`??U)'-URZ9,&M8^BH=RM:;FN3
M*GZOF9H%`8CFK<7)92[XE+YAIZ*]?)M-?8H\](8@0&TIW6%+'O00[Y63>(57
M9(J&N=P>-OKDE#CF/*-EITWF_#-SNB%4;O":6B5D5S_RCE-*PT'9O:E0H,TD
M[U@CVF_T/CAQC&B.,7&4]BC3C);N+E5">O4C;V6WX085]+O<ZO<&+;G7_P/Q
M*9X`:T[>L6:SV=E$<<QFCK'G)]L94P.CSP*DU]B3^WDR((7I'70Z+;6OEFEX
M$>&(\!P/[F]:'VFK9;:I*1WPXACO<M:!L4=1]9:(FDW]D4&*`,?#4>)(?8$+
MPF76#RE=V.+8=5P0KKZ_CN1EHI0:7?!:5%'6G#Q$:H5M)ZX#5WG2(GFUT4DH
MRF:2ATBML/7$Y>`J3UI<+!-NL:S144%UA=UX!B#:*VS%BUD77J^XU60?3HBE
M(JP(6P:#<'D905''D\@B319<FX[]O;TP;#5+MJ8KQ+JS=NN-[[F>9K%!75JC
M,%//;S^UF*O:B&*NB^>?4+U5,TUB+^7`ZZ_2I22BZJZ\V"I<OJ%B*Q9B/9*4
M1>G/L*)3EES:4W)UVYNK48%U]O-"\ST[=1G6P2!]&=8UCE2N6)]`F8_3:=E0
M<AX+#XH@F#K1@B`35#!UH@5!)JA@AC6M7%QGF=6)%E0,I2_$G$YW+V41WJ:(
MLWHBPF+7*"(4T:G>TAV=:H9E6!.4D;#3Z'(R<>A$\YICC<K=Y5%`#X`]$J]$
MQ7]Q9Z0`$HPME:$<*RS'V"(GRE%D.>[Q<S[8EN=HNN=KYI(+7XPQ2E5HJ>Z9
MG=<@5,-R#7W)@[\TTV^.4#-RE$2NLU&#/5Z'$WUD<^^VW"D6^F)MX*JHL)M-
M_9%0EZ22^]BCO)%Z1#O*&ZE/7=UWL+'.:6?)@SG5G()7"U#.Z*,7J<J[G:9K
M<G&.<.9WFO5HP)=*U;%19[-+58LJS9J3=R18!RUY@'`54)XU)P_A6B]YUIR\
M_9&;TE:ZXD1N*$CT5/=JTU[)H5?I(!4G]!(PUU#!9(+<[C4ZE2"J-&M.WI':
M5RV[[3@*M)GD(5YK)M":D[<_^.JTI8$XP1<*$GW5_0M?,BY\B1)]83HA"T0K
M;:71V011I5ES\HX$:[?L+60HT&:2=Z2[@'`55)XU)V]_\"6U.[CR);X@T55=
MTHH](X2(NS"3D%'<5>:6F-+S"*)*L^;D'9OVZK>4;A_Q*IY`:TX>XK5F`JTY
M>6D.B\D]<0(O%"3ZJD('7J4#5)S`"[,(68!9;:N8D150FC4G[\CM6W)+D<KT
M8U&>S20/X5HO>=:<O/UAE]SN"11VH2#14Q4Z["H=H.*$77N:W)Y4*E1DN.=)
M][&A6Q]/,E12WHUG0$7WCR'D$?((>90X,B"S@B,JGGFK@ZC1<Z]**%LZR"O3
MWR`*^K?@1H67C6S_\;AV$14NKYHK7XXMFC(<-CD]5%\\((/RF3"MGJJTNI*,
MLZ:.H$`&Y31K.CAKZ@L*9-#)`;W:EE1Q`GJ<*QB_5,.PR&57TBE]JL33`J\]
MWIQU\3%QS]8/_"80N3.BSMLSZ8Q$_.)CNY`EZ=4;PB\Z-[6Y[7L78^,G';TY
M(SHU63]*W;`F_$;V>::-1N%G3@7/5BS^&D5_O8[_Z2S_C`CX\[4[MR[N]2<Z
M\DUZ,_ZN.8YF>;%>PI?6*-:1]H'_#_WIO3=M_>]WO_SCEW\0\B=[QK7K^IJE
M+Y_A/MBWOJ,_:2Y\]\&>3FWKWH.;B&Y;'CSACH[?GMU>NC>6+/U0NC\4259^
MA/=^I=-'ZOCN1--F]Y[FT2FUO(__]0UO#D^:V19\="]_&NX9,4:`.$WWC-$/
M5>J<$=\R@D>[3YI#X8(1U0U`A?OV[/K;I[-W/;4[Z'8#NE./.4YH=&G(%<H[
M9]]2YYZ]+TD<$";)G+`'.SLBNS$B_W5_]6-&G1_\Y7%:E;-WK%1K0.?.(<=I
MXU^\!^I';`34<C7/L*U+=O>$#^_]?'G)K39G7UV^:,YHY0T,)=]\1MZZM"7U
MAYP-(WK[I:UTF=(,49XY<46S#EBF2(QU\JFLZ^]GG2Q5AG5_4=>C(ZZI9E2'
M/Q]L]E5,B^4/QL%^CF:)Q;0D[]!<3!@[E)<$8.N%RBL[-@U3*B]6Z6RC\EH;
M]?$4`C6!>I9!/6<UM60IM7J6.X=3>&WI#A^)9C+)6VX14I/E)$UQ2J2S=_W>
M`M?KPXL&[[OG[*T7ER9X#O#FT>8IL)FH?B@H%8@:`HKXWS\^4XLZF@F3X'(T
M-2S#]1QXQC,-G^'"#W?4A2!/?X(_K^@S->T9ISBX(,X-&+@]I0N>?&%C9#,2
M>'$J\Y2=S`/&'<::3!FJQ!BJ5(6AZDZ&RAR,)?!4KC)(.SMYJBAE,[620.WN
M9FH_"Z@>[4D$X[^V@'<^^]*]\9ZH\_"D63<S]@@WYDM\IRQO`/[&,[!]0N_H
M5`.N6Y,/("L'J/4U\X$Z4S?5C$A$(;(:9^X=&_0VSE]:P%7#])F@[ZGN.X9G
M4#":NNF/Z.B38T\9!WR/,^!F_%%SV!#=R(J^GV]^P`:Y]<[>W2K_5K\N92,4
ME^L&@8Z`$.@#!#K_5H97B($B,``&1D`0#``$W:^R@B`H"`2*@"`8`@C4?\M?
ME0'"H!`8J*J`ND`!A^U6_G<?85`8#/I=`6$@<]>P\U7N(PQR@L$*QY5`_\K(
M[V*\<0$GG<HAT/DJO".6]5K)M07<,NQ1`3E>I<,U6_;K/1$-Q?(HE]R^TF4!
M00$\,JQGZGH7U_S_L1N7]\P,A[_H"D9=P&JSTCM[!X_IG\O2N=+]\W7*D55(
M*>;#MGZ(%"$94)QTOMD<*'2T8TE;#>;I"@-3K*?"?!S*@UX13%ZAHS@&?N:3
M:XL=B"7'%WQ45O@XW,_'X2#8$E,T-8)Q<8<3JDK[N2B5Q\"3S-'J*R)O\`30
MJ7**[27]WD#N]4^TI7L'7RJ+=B%*286H8IB3/VX_V<Z8&J`_3P"5NI]C@TY'
M[:M%3,0U@L3CY2[TI=@H68@^*Y&-Z5V352!V4VBW'C@GDEQKUV0O`[>B+\7&
MS48Q<,5OYT:>15&?-,/Y2S-]FMYO5ONIMY\-"W'YTA-9ECMX(/=3V:I!:BGT
M"\'X@117312[3%VJ':=2*?Y[:CGDZP;F,`$Z!^R"E?-V<RO.YAW@[LCIP2T(
MCPOS*7UP*_)`MI(2V6I;50ITH5.16RDA[,*]*I)2%U,"F7B7J^#OI/<NATWU
M+D]A_%;`IS_T)RKCMQY$/&+Z]P[BQM8W9S(TX9?/.^E#PBTGDO+CEH"[OSOI
M8S=FX`MEEX`[I3MI3_3M.8Z<`[N$W%3<31L9;3T!F2._!-Q_VTT5X@3\*G@Z
M"KE1M7M`?%(POH3<T=E-%4IP?O6[*?AULNL%GE7@8ZW[8"G.LV_QF+HI%GRR
M2[D?0()H;!/>F^NF67T*2S>@($5V-+MIEL$&\B"++%)]!"F@"]Q-44TE*CN$
MDA3;.T^Q[3"J*82B%#MP2+'SL2OWE6X?12EX3--+L?VR)RL22E+T:*N78F=H
MB>KUI#72[>_;<.+CT`"NEV*_J-P)`[BBR1"1?<('<KT4^UDSJ<%73X$*&-#U
MTB19@H`.!5J%P*Z7(M<2KR>+$A4^P.NE2+ID4:>SIA(5,,[KI<B^1'$>BK0:
M\5Z*+$P8[Z%$JQ'WI4G&E*MV$_'FX_YW/QZ\9^IR,G'H1//HM>4YAN4:.M\@
M%8M&T\>#_95M!*M%4&5Y/8@NB:BJ,%CXB+&_NPQSMX,B/TWD`L:4_=W5HWLH
M\M-$+F#4V=]=W[J+FOTTF0L9E_9W%^!&@9\D<`'#UO[NXN`H\!,$+F10V^^A
MP',3N(@Q;[]?18'?.K9.Z<AEC."]SU9.?!Y1;:0_V,D(14UZ-'M'L(91=M&3
M;8ZHXP8<^69[],IP==-V?6?9K^Z(H0_/WD7=`J-^?;I)->?BT?:>DJT-5SL;
MKO9!_'IY]_GZVP6!O^'?S^#FX#>R<F\K^*)%[JECC$FB:6%FPS"LX!^\7I7;
M0]:ID3=.O/YV]9$-[#SX=OGRQZA_X!C8N+7;XX>;+S=W%^31U/2_^;V#-N\Y
MR&Y:-"!\7#STL&<MNS4N1Q07?_#[0)'[;T@`A>7KUD<1;\]8*F>/94(9))T1
MS30FUMNS__BN9XSG9\>AX@KT)JAXT%<$]"LE4[C[R274`B4,L)]Y7&4356H1
M-BU;_$JF'C5K3@S7]>&RC6^-&HW^MD+;;ZW?7#:;?HMZABY&%\A!&<JM7J^7
M8"D)4I7$'H/J8-T@X4T`MA8!5H`NL:C.-!-Y,;PG/CX:JBAV`[^2V('N:I&Q
M[9!9J-G8S]H,/OT$+>A1<TY^S9(44*B+=JT1)1OF8-4ZE1ZL[E?MQ*HI/\$N
M#"2Q[,*6N3<($9'B$K(.D,4LR(C0>%O>4'F\(9LTS&Z+$U<EFR?`L`VC\,@7
MVW7)#)0(E_86(Y2'UBR,4+++%`A$WF%4,=F9D>RX!@:%SQ0P>.6@]1_G!(@P
M>(1@19?"ETP!OX2GT8D6'$<G5K!Z%E/@H49?>L!M<L6\>;BIP)>"!6$!1V0"
MZ7@,MF3U#D)!O3UK)O/LV^32-*-?E]]'CWZA<#E$.L9Y%)H0S5NWHPI<,PH-
MJN82U]>YX0J(M6SBTIGF!)6E%S$0-UVCC2QJDX>G.+FAM>,O>0D7W/CMC,99
MV%EYW9IZ3S!63@$-PS`R!N>?WQ4;"+>;5AP<"69%[TGC3@1O4UL#J=/J#B0^
M8##_JM+J2G*+`$=95U7@HCEO\1\/>+@2/+S34KJ#5K_3"Q^N*IV6+"G)A]?(
M+&^UKIEMDUXO>+UW;7RE?LD@Q?;C#H@-I);!!N1MXQ6Q1.,JH])L-P9$`Z!+
M+-'(M@I\U2PM>/JMJ5F9!/T#52SG+ICXX4"^7U\]_),]@,WV]S=W5Q_OSL&D
M?KF\O8=WZK9I:C.7KAO6N.+8HP\(5RAOS]@[8J-PEG^.HM&$`WA_\_!P\_6"
M_%^JT^%HL!C8EX^?'F+?WEY>75U_^[RX'/P$N/3RP_]\OKOYU[>K\]`U\``P
M,#P'9+J\)W@4OR-D@?)J^>O=]>=_1C^'[WZXN5T?4'C=VHCXQ7#W&7D.HUO/
MGBT8H;S:EX'9YOT<[ORL9#@R"V_7#$U63R[NP3OL9&"E$)P'@Q-4KFU-CH1J
M;OA4-OA%R9$*+OYAKS#YPZO*`L#2]L;RKBYAAOAH^;V.V9FEF[GN#5<@CBTP
M3YLW*0^QY"O$<"QZ]1V'A;P6T73=G_HFZUP-+N+8T`T>R&::TNSWDQFIJ6&:
M+#3UGAS;GSQMB/#:Y/LR*ZM3[D>R8;$O_NMKC@?7!@'<__,AI`MODY)YY@2I
M%EM(8X&UKKE/9&S:+T&4:D,D&L:G+EP,H30CF;UAQ!_VZ,/7U'6#8#G^:(@#
M+2^(+^E/%A.ZQ+.YOVI8/F5_LRM&+8C3'UD(X1F:2;2I[;.P>D,*VIC.3#X=
M>8(!KHE>37B#=#J9MU;R#C.8JA:,<^;8(U_W0'Z+5NDL)V$['OBCNFE8A@ZO
M]AP8@!L,V`G[J_,/(W"[[6?JS*.;]L2U62$^6E!1ANT^6V7`R;MM\@;=GT+P
ML'DP]JV1FP#["\PI`#E#K1V"FJ>%`'S_8<DI^';*KAO#LVP'8.#:4Y[,>7DR
M&`X<@#J=VP`'VP]"3<<V.>A=&MT4PH_R%X\A6+%?`(H7B):3EN1VN%05BAW'
M$ON_5?\L^C9;_RR5>[8RH,@]6QW1;O?L-.]LJ_V\GT\?;3.YKGK$&L'A7G21
M4NH4)J6.(%(:#"6Y<F(:2H7):2CM%53>UI2[38X]<9A?!=9OZ0BQG#[?"W:`
M!./A#FK)TN<?:DG4DJ@E,]*2X;HP"Q`A/)S1A+;D*E2;HJY$78FZ$G5ETW5E
MW*.<.721<F/*<_$AGIU#;Q,U*&I0U*"H03=H4/9YPU(&5ZZ:PY1FL&#R\A3N
M,HRORL`-E*WW&)9GKRQSQ/4OO(ROM:#^1?V+^A?U;Y/UKVZ[H%TUU[5U@^\#
MX-J5K0JQQ6GP7%>6D`,O-UARUMG6V!'<A8H4%2DJ4E2D35:DS!?5'@W3\.;!
M?@MP0C6VTX=M08(';75'34.GELNV]6C+_?;!01QX#G79/@##?2(6?=GAT\+G
MS0]"U8RJ&54SJF94S9%JUO0G`U0GVXD*VM6VJ$M\:T0=5*"H0$N7$BK02HBI
M>0HT2!08UK-M/O,4*TL#N%3W^99UOA'>&ML.VUU*9IK'G%+=U(QIX,G:[%@H
MR\M2TZ3!AF:X?48=4,D..X/OOF'7H:I%58NJ%E4MJMHP`6!,F3[ENZ\F[*"6
M[<R#^E,P_'U'=4HZFU?-LQE%'\/C!2'Y22^(07@M,6);+`_O3\-*++RTRE2;
M,T/YS(^4/5+RPDYB)H^CL4L69W\>><XIEKX/#@NY-H0Y#K&9"283AVKL#%UT
M'`U>9+&3;V&FRISS:C2ZP:RXVR:W-C/F[/R::_N.'M14&QN69NG+:C@T.J=F
MZ`!5,SA4]V3,W!:9^8\06!%>1,UX9H2ZFDD7B[TA&8ECJ%'1'8>,Z*,7<R#"
M$<3/PBT>YBX*>K)Z-:X/1#"6L'<`M=/8"_GQ)A,X%E2O(#?C,64E[=9`YOJS
M34IXJ[2CRH#W7]?Q&C[K".A<1NO5`21`4HEU;KY@\P&H!79],KS_G5!',T>!
MQF?_@.!V4#*(<TJ;\).+_%$,6<:(!H?)8A&R;EM\@8<=$?7.X<?SJ>;\33WR
M^^7#US\6$@W9QBOL^#-V8Z8G1^5N@HN+DZ-,UAN+^Q%.DL$@&LR6$662-]@Q
M2<T+D&`$!]\8+]KD<KGE@$]`]K?A`KA-(&O]/*EE`UVVR8[.SJ,A!)D#=B6P
MIJ"SDWCP^5"-RW2D2^G?0?I'9WM-@KI6JZJ)!AHA@+M+7IXH/ZL;J%.7GY0<
M:\^VP\_FC8*3OB:HY',&-*)K,\,#1>FPQSA!^BBIK$<V#7#TI+$Z7_`-`[#A
ML977C>J5XQ8PR8`;'-^%^6\PW.D0/#%E#V/DNG%%Z;.;^;E0F`?:LV:8?,B<
M(&8MX'WL$#97C$$1K^A:G1VYYA<#;0:H"F`/_*Z99IM<)W0V<33#A0$'-N:1
ML=@T^:"70]DR4^&9H49?:FV=E0IR/(.]FFNVU5)C,$-?P(PQN\)#27BP%TU@
M^M-P>23JQFI,+H@*:Z"M$6`$PHBH#<WGDOLQ=K48XQF.X'&^%=VA:PYX9+;O
M)<Z+\\/97+UH;,G&-[VD,F&/X0!@Y\3!"S7&AJYQRVN"P^=QMR!V-CV0^O),
M>"L:(5N>C\`9'>V&E[E!0;?%_2^V#TH+QLW<#+:*;[+7.U-@R.Y9+FC=LE3%
MHS:6FK[FU6>#`K:WP`I[Q(MJ@Y+BO[AI*D[]"&SMTM1>6J,/=J*(.>4E%6XU
MQYL_L"!'XR?]W??S^"_K9<<'.SI)G/?.WLF\SU:BA4@:HC@G_OP_Y^>?;-MC
M!5?)?5AZ`%YT?AXQ"F;NWQ=CN`1F!/T"'\A/_A7X2B#Q)\^;7;Q^_?+RTO[Y
MZ)AMVYF\5B1)?<U^?LTN/`NO]^8SN!Z8R&LTG+WC#W^]]G3X_L_7[%'&!?M?
M/HK_#U!+`P04````"`!@:6Y#X;DVHH,(``#Y;P``%``<`'-Y;BTR,#$S,#DS
M,%]C86PN>&UL550)``,S$H52,Q*%4G5X"P`!!"4.```$.0$``.U=;7/B.!+^
M?E7['WSL9P=(]F62FMDMAB135&5#:I*YNZJKK2EA-T$U1N(DD<!N[7^_EH$$
M&]F6P029VD]A0"WWTT]WJ]66/>]_G8TC[PF$I)Q]:+1/6@T/6,!#RAX_-+X\
M7/OO&MZOOWSWC_?_]'WO$S`01$'H#>;>)5'D09#@FUS)>RA^\L[3'\[\6_[D
MG[;:9]Y_6S]=_/CSQ6GK=^_/N]_^\J[N'SS?>WY^/@EQ!A7/<!+PL>?[^CH1
M9=\&1(*'BC'YH3%2:G+1;.KQLX&(3KAX;)ZV6F?-U<#&8N3%3-+$Z.>SU=AV
M\S^_W=P'(Q@3GS*I"`M>I?0T)KGV^?EY,_X5ATIZ(6/Y&QX0%9NJ4"\O<X3^
ME[\:YNNO_/:I?]8^F<FP@3;PO/>"1_`9AEZLP(6:3^!#0]+Q)-**Q]^-!`SQ
MNSF+K=PZ/VMI\>_O(8(`&?I((@WS?@2@>FS(Q3C6N^'IF;]\[B4`X"QJ!(H&
M`\HC_DB#F)"F'MHLG+")&N^HL^+!MQ&/0G2CJ_]-J9IOH:9ACMTUNZ0RX$Q1
M-H6P/]&^CY!E?]@)@3/215$:D.B&##C^Q,6\P\);KO!:`=`G,HC@$A2AD2R/
MI[HK[VZ%+EZ91S0D*3?8`E;.5!7X4;ZK;LV%[;QOA:"]+PCMJKWE'A,\C($I
M]-Q7+][-;;+FW)_F72)'UQ%_KE#QM2D=R%('2$]KN'%@,(WB&6X090(_S!2P
M$,*5!?3%WSZ'QFLR:AKQ(*%=I*L!+I+T+)6+E_PAD8-XW9]*_Y&025/SUH1(
MR=4W,9-^J[U<_K]??OVUAT78&&ZXE->"C\U(;D'UAP]DUE%*T,%4:94?^&>8
M<(%#'Z]00"^#"^4B,H`H5OGK'JZQ(O-MC80J3[@DT2?!IQ-$$TUUW6H$LOS`
M'E]!YUAFUXG7S+'FW1V1M`P1P4H'_+CAVLFB<3FB*:?C1<[V*6:3E?P0"=P;
MN4N=>;4VFDJ$RR?Z=Q(U/"ZP=,,="&Y`GH$^CA1^+N]7&[D1O_CZ&N'7`!JT
M@?F,<0X068V3K]C+P+D7,@X7Y%>S"3`)%4?XRZQ'YQ656,7L0Z=K/N0?S(D6
MG8L(5_A..,9U7RJM_!,4.TJA9$V=(84\[0F%L-\N?9=`]YK9[D$\T0!DETME
M6NFKFOBXV*_**L6IX)#+R2:03X0RG1?[;(6^/S0.7%5,^2M+)1=PP+/>HH:L
MQ%;6_H;&;*;VFWO?AF;WO`ZPK^Q("<:$F!YPF.A<7+T[%0*8J4S/&.=`K"0-
MFW;TE+X.E]NZ,Y5C^,7/SM@[Y2EILR^T==C:=P(FA(;+Y1BKK3ZF$6$;!5;2
M=>'*"HS#A<6=X+@PJ?D=9GB%ZNN[4!/=[C4W'.S$G"$OF[4\]1VF2W=Z)2I\
MPPF3KRU?5/N6LZ`P].S$G:?/#H:9QK-][/6P;I14R63XYS)B)^8L$W;JFQGX
MX>\"=R.N;R@9T(@J&ONUZ5A`9DP7BQXF5:WI9:>]$^YN2T0Z)25P.%RZ=8*`
M3YF2=V2N4Z;%GB5#P"VN,G<P&=H[S%"IX"\(=P>8*15%II$.5V-=/AYS%BO]
M+Q)-\QKRFT,=H,F>F$WU'8Z@3AC2A5YWN#7KL2Z94$6B-0QY^<Y"N%;4V0!R
M.,8^Z],L#,(K(AAECQ(S^G2L+0[A)0QI0/,6+QOA6I%I`\AZWW.(JMOR5.(!
M2O!2/:R"EM7V6\ED/PDWMQ+0FT:XBE["$T0\[E)D["<M91UP^&Q;KV\P+?$X
MO!+%.%\;%/*3X-+6NS+%:L&?'12'UYVD\Y7M:M>3K`P,1["@M`^QHNR[M^X"
ME#B>MP&S%'0@/FQHLKZ!L(3E\)J4*!DG`@*Z#)1)!+'M6=@9ZV,0?\3?9R+-
M[QE5=(F:ND=U!K`_GGCH'GK&$RX'R+NW>@6P."^?&G>8<$R>5NHNC@OAUF[]
M(:%,!#;"#H20D9!TS-A@<3BM%JO_$;`J@<6X!S(#>353@B`&RHB8]]""\<TS
ME$3C1O')9P4"9%ZFW>M5'?`<^^@H[TX[6,9A/TP?ELU+'X:QM>!\YTC:V*5N
M&J*8XK^?"]C3?C7+@]TX[5]56]O4S"HFL$"N3O050'&X-X3)A2<?3RHF+D?&
M`=*V7V=S<#G,8(\]X7*@_6VALU6IE27B`'^%'KE9'F6A<3AIQIW,;8*O2+".
M#!9A<CKZZOJ:@!KMH'>"7)M'D\RO)SE`TTE?_`X$Y2'2((!(N(3%W[Q303E"
M!RIM0,5*"?Y$D9^/\R\24+F7HJX38(5==*BSS"0.!%<Q=1M%3PF`#J^GNS=*
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MCJXU.;G(,KC8L8]DY.*U8K\G$62\+2Z#&4O9VO-DB3.#M1U;2WN]H[*X`;_C
M'17C)`Z07MD=%2-`AUN]N'['-R,?>"?`%"-@F\<GRDSB`-GE'7SC:9H2@%T^
MEYEAB6O*"`MV#'7C)`ZP7UFH&P&^Z2V#`"",CT[TI)SJAPG[P[6W)%QS$?_M
MQ]I<S4`$U'R\>K?I'."TO!^GNLY;0G?X)NPZJ'\3(8@^J9KM`G9BM:;:#N*.
M!XG>O_S'=+&I_@]02P,$%`````@`8&EN0]Z$<'(E)```LU@"`!0`'`!S>6XM
M,C`Q,S`Y,S!?9&5F+GAM;%54"0`#,Q*%4C,2A5)U>`L``00E#@``!#D!``#M
M75MOX\AR?@^0_^#,>?;8DBS;&NSF0./+P,B,;7B\NSD(`H*F6C)S*%+#B\?:
M(/\]U=2-%/M*=HLEG?.RZ[&[F_55%=EUZ^I?_OH^#8[>2)SX4?CKA\['TP]'
M)/2BD1].?OWPV_/M\>6'H[_^^[_^RR__=GQ\](6$)'93,CIZF1]=NZG['+O>
MWY/5_".8_O'RB/[0.[Z/WHZ[IYW>T7^=GG_J7WSJGO[WT?\^?ON_HYOOST?'
M1S]__OPX@A72?(6/7C0].CZFSPG\\.\O;D*.@+`P^?7#:YK./IV<T/'O+W'P
M,8HG)]W3T][):N"'Q<A/[XE?&OVSMQK;.?G/;U^_>Z]DZA[[89*ZH;>919=A
MS>L,!H.3_*\P-/$_)?G\KY'GICFKI'0=<4?0?QVOAAW37QUWNL>]SL?W9+2F
M"\:,TO5CB@OT3Q9__`#L.CKZ)8X"\D3&1SFMG]+YC/SZ(?&GLX!BS'_W&I,Q
M_&X>Y@(Y'?1.Z9/^<NTG7A2F?IB1T<.,"A:`)0_CX8A$H7L%4WW/#;ZZ+Q'\
M*8KGPW!T'Z7P+(_X;^Y+0*Y)ZOI!\N&(DO#;TUV)*?"X])6DOO?B1T$T\;U<
MR"=TZ(FY)Y\`#YIQX0J>'`7^B*KU9S>@NO']E9"T!BS!4LWI-,6S9_*>9F[0
MGM#6!#3GR:WKQ[^[048>QK=^"/SVW>`.7O`XFY(P39HBUER^.9[O)"#>EO+<
MA>,HGN;,KOV^J:Z[*P0=6Q`ZN\/0M86A:P1#&GGY]C*ZBJ8S$B8-%4B\G&5Z
MZZB+9#W+%-?^Y*BM:HCZQRSV7N%9?[AQ[&X^:#6IYJYFE]JZRL%?SJ)-\>C&
M9$E7'>U07=<NQYLIMVQ10[2_1L$(O)*;'YF?SHT0+ES1`-792T)^9"#&FS?X
M3V.2Q<N9U?'OX,>1W"9Z&&],PV;ZS5O3'N57;O)Z&T0_#1)>6-*`!Q!YN>$)
MAO4-V.'IO&`[U##GA:LUI_:;&[J3!1\>X4O55)\ERS6G]YZD7Z,D>23Q]U?X
MFC:E5[+<FEXW]E8D+W\L/F7M]OMA>C+RIR?+,2=N$'R08N0$(%;Q`QIYZ.?8
M\]6:D@0_@[T"VG,\(F,W"U*#!#+6-DAN-'7]T`ZURZ4;$YNO<SPETQ<2FZ2T
MO&Y3,E^!HMC+7LCQF@4&B66NWI3D,$J'1M^EU8)KPD!C_="GG]6OL%SI0?`U
M(.&(C%:/HA3M/HB6AQ&!T"#R2M0%--89Q4P^Y#P8N\E+SH@L.9ZX[NR$?E!/
M2)`FJ]_DG]CCT\XRN/F7Y:^=]1X)+"%W\&.R>DK@OI`@?[;#'^STSS8,;HGR
M9\I"%:KS@4[_M$3Q1BF&<9EV4,S5JDL=U=H-QG$T56+?\IF1E.HL`0JB&:65
M[EQ1#%;PKQ_`3UIH_B>JA*#(-T$^#]X>,J$_;/X>1.#._OHAC3/2EM3N0GAM
MR!I<T7>"UV(X&OD+>/2=`G*SF"2?Y_"/692XP9<XRF8)+!%D-"W"?N^&[[Y(
MAW=#@-/O6-0RP===H'4;16)KW`XYP];D;EM*J07BWIV2ZY*APM"RFBLZ_:Y%
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MZO0'^Z4;IC!SHD*G^Z09"T^`IFD,*\=F8>?<9MS/QDYN`"]'-SKFMHHJ+1L2
M'L8<KXQOD!E8U3FW&7HS;5*;`,N1<IOAM"K)7X!M.:)PI=<<;.!6/(R?W7?Q
ME\#``YQSJ\$VL:*8DCWWTV&*01SE:BV<MN'/+3"3$S!8`ABF:>R_9"D-?#]'
M3V06Q?GNF5=92',$!I[AG+<8:[&K8F9YQ-&R91@-.'=23M[:3NGR#Q#L88[V
MO#4OH6Z.]MQFU$4W1TO9IY2C/><&6/8K1[N&]=TCH1O[D22ERASOG-N,P#3)
M@)YS73$^$&0)RQ5]OX7)C'C^V"<C:=:(.\<YMQI544XZ\KG/D980$+(LH&F)
MX<KDF12=A=2:&1$.DP0,`(5L0GF@<X$S\,#?UACT&TN?F1$%K>86"(#^V;E`
M$`9@<)+-\C7%R))ICS&9N?YH&6\<AJ,',)GC!:RK+(X7I@M/#@JSG8L6G7!M
M,:D"0I9F4Y77%I"S/9),E71C63)3;U($)FLZIV<F\J,>/S)_1K_([&H!E6G.
M!8+B`8UW1X($68:+EF@G0.?7R`V33:TV4'L?A9[T75*9[EP@J"Y0%J`R(G,9
M*7;6@<RBQ$^3\N=7*!25:<X%@I(!J3"4D9A+_9C<@Z2;CW.!(,6ON>OD-&-+
MPGSUW1<_`,[E[VSUW*R"'Z.ZA'.!(/6NY>%H(<.6`1EZ7I31TY?NG'Y_%<PZ
MY@3G$H%?JB4(SCO(1R?.*K3Z3JJ]=LXE@EI=`S+:AL013&OQA%J?1P$G+A&X
M3@;$)D'(D6*;P8HQ@;=_`3;O%R4.3FR/=BX1.%02IG,#$TPP'!&U%HFXBJ;3
M*%22S_90YQ*!LU1+.$PD',FT%I_8'+=Y=/W177CESOS4#0JTBRP,Z63G$H%W
M54MZBM@X\FPM?/%$SY2'9'3CQJ$?3A(PD[)I%M""AFO@O>>+MC;Y9.<2@9]6
M2YZ*V#@9W];*:JM8M4P3YQ*%CU9#7APL'/FT%M^0F5L-_&QG<!B>FA).CER[
M;56"F6ZVNH?U8YW3%K]Z]0K(!C;]9MT"LIQ_O(];A>Q#J""[`D_$3V]=C[[N
M<TGY6'6P,[#I/S>I':,"XACY;!3("L?*5$HKD%C#G8%5)UFY7(S#<!7I%(`@
M*Q,S(Q]<Q6$F!(6V*(RZ@?`U\:EW")\5;E\&X7AG@""TP7U%^$$--A!DM6)/
M)/?M'MTXG3_';IB`D4I-N,_SXE\D>Y3Z(LX`:]TS?^_21(>L1JU(H_2+61WL
M#'"4/VL*02[)`CQD]6C-)89KA[,G.MF^9ZKI`\^;_1IXM5H-K><Y`P1Q)\Y;
M49:#.AR,A6JE>BQ965II,+BG""JE]=QF'@ILO1"^1N'DF<33:_*2/L+&#?C<
M"?E,W-@/)[_#?RGU=^#/QR1)GX`#HBBA[EK`$@2UU7J"K0G2<I^#QSAZ\^E6
M<!O%OX5>%-#;8WRJ>*"'PW"T)FBMD;P>.#56<GH8PK]J8FP$45Q!M_O(K]ZE
M4WL9UVTMVUPWKMLYM1E\T@_L5JP($=V'$-DU<S:X<VHSX-'$2<X%)1%I%0JR
M**_9PZ:=4ZNE&PW/!^?\YPA,#`E9Z->XT'#YR&:EAS<>[":O8.30_]&D]IL;
M4%MAF%ZY<3S/;5A)U9O*?.```J]:;T/4`"8,(._>#E2\LW,?#<`V*ZYK&H`=
MFSZMM@'8D5L+!;K_:0"NO_L=FP4:C0S`3J7%N`*4PS8`.U:/,S0U`#O<O)8$
MTF$;@)VSO3``:TIO5Q<PE#L^)$\D(8"=6C+7Y(T$T6S*/W&L-!?`($C^J^UM
MFJ"0%0+D9Z4+4<<O<90H-,4030.<*(XUZ!@F<CS(\OMEC=/M.K-!AN+`@HZD
M!$"0)?2UN@(Q>N9T.DC]6<EKQ$`AS--C=5X[>^F]=O<O?=%%Y;UVE=,7W0/Q
M7KE-B#[/G^'9$E]683:P"JUGV^5ZMLK`D/FY7+HIU5+G26$VH,;A^RI+2%/`
MVU"1^<0[$3`N/WDWDD:;0%G3*RVEWQH)J!!T;U!^T=C28V*R>W?A532=92G8
MLN'H83SV/2*7@,HT(!U!7*.F.-0!&O.5)?=*J@F%.QZ(11"H:"`-"3)D_C`7
M:!YLJ;-CY1,!*U(_F>])J"!"UJJUU!%B%A//7_K*LX#DO`Y'PRF]PN3/_/=<
MA`(YFWJ$`Q^,?=,(L]B1%>/;://;Z2$MT*_QUJ_QB$OUL0;*NGL9*.NUMA'6
M#I3U;+K=VH&R'O\F"P;=AQ`H6^.Z"EQZ3UC>K46UU&-[#K#%IFO6*"C6$S0>
M$L)!%@HK$BGO&U`9#)BLNFOZ11YLKK-%Q<.#+)IE0$:X8E4&A:48D&K!,*!T
MOKCP1:81`>#,WE=]GNU?U>>932]'VQPX4Z[Z/..?:]LK<^#)#2>R[-AZ#,"V
MZ;`TVN[/N$=/M\A'MKWGU$E#XH51@,+JZ5_UOA9EO@J87R0<V<Y=B_VX]NHZ
M<D";)?H&/)QF4ZE$2N,`$8)V^A559TN"03FR>LIO[KN:#(KC``F"WOBJ,JA2
M;C??\_W5C<GG;5MS&,>4WD4.>#/DT9W37PU_NO%H?59]F"39-"<ON7FG_;D2
M\AC['GD(6>:6]6<"TQ!D`=5LN!TQ`UFJRC#B61Y$O?;?_!&X7)*6)M:?#1Q'
MD/;4="%VPQ1D.3<KJ'^/`EB&MC-L0Q'+3P>N(RU`W[$JLMB"+(EG%/>3G_S]
M-B:J;9ZL/QLXCK2(8$>*R&<*MO9A.:9*Z+$*^T7G_:/MM3HR!;3R4*?31UJL
M(-$\B]RPW+FL]HOS4*;X-HK'Q$^SF-"WY2Y\)+$?C4Q[%$H/!;XA+8<P[%)H
M<`-;ZS1ASF0_#QOU]Z^&HH^JAJ*O7$/1/[0:BF:M,OIH:R?Z\MJ)*A1DB17#
M71?ZR*HHJOSG"$P,"5DZQKC0<*5JS$H/;1*GJ67TD*5)ZH8C/YS<9Y(DA/%G
M`6>1QG,$&ZT=)B#+2S5%^04&IHG`Q['S(.`ETKB,/85B<0!9]Y'<E;D#'QX^
MJ1GM0KZ@-8>5Y']<^VF+;(]08[07<SKG2&,F(GN^'LI#R8PMT6T<=GK=);CQ
M_O+RR!U\6J3/!HXCC:+8^]HH,N50,F/EERR_)\.VE51Y%G`40<G-;M6,PX1#
MR7%5;<$_B#]Y3<EH^$9B=T)*90^[,<E%%`#W$50<M6:HRUF#,NLE`I]H696V
MM-,<%2`&!)TK#&NH:?:82Y0AT=(5QM8558L0$`;2@CZ+NEJ#0^*,'$)U;6H[
MMV0$-*(+1(6T/+!%)TC.,(YNMY<-,&>PMZ3%BA0`^__A0H1:K.%H9KL9CCK5
M0U([_HE06<'OKZ(PC5V/WD%'RXJZ,BW=+35.YV+_PI=ML8FCO>TF4AHP@O_J
M\AAAI2ZQ/C5.;T\=LS;8Q-'>]A(WYF(H=X#7#Q/?D]W>9>V9\(%`>I?O3H)8
M+&9P]*W==)&9%Z\,=T<?Q:V'`I/W,VQJD1L<E:N1&K)2K%T.J>7_N@;VK2O1
M+95KRQX+O-N;771W_.#HTM[F@X3Q7"5=;(D2$,?A131ML(A3N-M>QT;1(8,]
MOI:]=]E>O*+N48,+FW$IW:,&.0-YI4E5N@_AJ`'MLWKO3J47F!2&.9U+FZ&9
M1@<+J%C8`JPB0':>8$6@_'**TD#`8K4>2_VBD0J#Q8(HDH_LE$`#4>`Z#U!?
M)KNZ)C/?B^GCNZ>G'>$5!8R10"B"X`9+H1G.`8]\NY=T%!][H<S?BS6!"(KP
M]/E;(M]RXZ7-8SNGJOQ=C00"$81*M/E;)A]9\?43R2\(>'3C=/X,#DGB>KGG
M\GE>_(NL(Z7R(L`#M*<L^<:0+CYDE<U%(J5[='4P8,)QV%)7#')A%@$BJQLV
M(#1<QI5-Z<G,KSI%MLS]ZV8Z"Z(YR6MZKOV8>#`M$>YC@AE`.8*R*-[[4-W3
MI%`L-UDI/O\*-`<$3L-KRNROS`&J$9PMK2<`#AAT]9#92T)^9+#+WKR1Q05D
MLNX,[!D`SV;LRY+E(`2#KKZO2JS\M#]OCM,96*U(4F_1(!*!LM2*H-!5OYF6
M&R[#P;0`I<9":X5@=Z$73<DFTDZ?1/DM_F`*9@%<M#<$\#^:4D#82J`X!$M?
M0N$\@(KC8@&I.+2D6`2'K;3(FAQQ?5!M"53Z8355P/.%A"1V`WJ!Y6@*/$Q2
M>K;BC=`6?F&2F\=/)"'`FE?JJI`W$D3YK8C+`4*/P<SBP`\$L6"%=[#J99AD
M`+;J&\W[=08VX\VV@I5E\L75)/MPPTO/:LBXU@4[`V[A0X5P#O];.T];B_^X
M]J\Z@I#M3=W6(B3UKG?IH0@=;BL[6Q0,RCE"V-NCC2VWR!O@+/P5%8C980)'
MK_:V]>)VC7.4"$.GYI\&;,59M6M1M[ALX&B7L>(3HW3O]CA"H89Y@&!G4E,8
MZVS@*$QK@:IAD"].1FS42P=.\(516P#`(\BKZ7TT=)!QQ-I:W&J5%_Q.XC??
M(VP$]U'X1A)Z_(!J;_(<I6Y0_/M5E*3W4?HWDCX1+YJ$_I_`BT(328%6[.3Y
MP'J<31D$2K5#QG!T\K+54R./6>R]`MX_W#C_3.[Q;=[=TQ9;X]8[+=(]M9E`
MT#TMDC.08[`QZ#Z$TR+#,/5'?I#1Z.EWXF4Q,)\D-^]>D,%K=0M<H^]YEN:O
M^</XQHWIL?\$3(G%EV+.7D`2O[3X5!"-S:AVDXAHKC2<K=TV0Y`=C6&3JW1"
M0S85\%HMP58.QEJ7J8XJ;?,'V?D<R_J`*SB,6#'07A"R-,^D(>C2.$"$(.JH
M]D*R9<:`<RA7;-S\R/QT?A<F8/[07R8/8*C'SZ]NN'0:UDZ'O7"U+@T@`9R1
M(Y'ENEOF8+NSPQIZ^W?#:)(`_,<9TFI%.5F\,7:PS7!L?(OT2H]AX^%QV0.!
M73@#60Q5V@4GD)V6L_?6+%L"DU&KW[4*%4ZW@[-W:"N?-@Y[D)T.W('=T4IK
M*8/D@=P0=#O`HM:Z?-N[RTH,V3(XM5ZWCUBW@Z#X&(OJUV*>Y:.L]FRJ.@K<
M,D7`<01]/3`8Q(JL0G?(U[8U1F_1P/EEUB$0A(<@8HKELZS/.?%Y:5PE#IV]
MK''HM5>`7;?&H8.I(V;.0+4:A\Z!=,0\P!J'+M9^G;G2M%#CT,77_M-J3KN+
MHT6H=9G6365W\?4@M:P/_T`U#LT4X]!J'+H(8HAJ+Z12C4/79`?5-HYD=[MH
M"Q#YF_,6^<BR^/HG@KM='$6`6WP5,+](.+8.K'78CVL_JB,'V49AJE=(Z?9*
M<<MLUE`@%4',IJ+#U:`DGWACJ4L%_O8T&-Q;$XG@A*DVATO4V^XZ6GKRF0:/
MS]94(BBMT^9QB7K;S46+3P8C6)W)Z\%`)X(:,5TN;Y%O+K>@PN:N#IN[:SH1
MU$_IL[E$OKG>GW(V]WH:VKP>['1[",J"=-F\1;ZY5IT*;+[H:[!Y-1CHM!IM
MLL3F,OGF&FDJ['^#@<8&N!H,="+PY+5WP#+YYOI>,MF\2F&52.!PF3D6J$2:
MR*_F920@L+6FK)V'O8^6"==J0G87/8LT'@^,1^!J:6;U=L87K'?B\H%LO5TT
M2,;5LUV3`#Q%X'2J?ZEVSQMLG3OM%:(47KBM0I0G0L4(O[^*PC1V/7K3Z3.)
MQ645F.@$42+P^W?T2;7'0&P]5&O?ORYET7`RB<D$Q%6^E[W`.9GJMT26TSO?
MFP\Z'GZ)F]/NOJ*.7FH3!?Z(]N'Z[`9N2'LF$9(FC\"&Y;3]O&RZ>[9WETUW
MSVP&)K1+Z\Y4+YO.Z3Z$TKHUKN\>"=W8CV0W)['&`SML!CX:9<S/N&4+`BC(
M"M%6!/X6)C/B^6.?C.27[_#F`$*K!W?4+TWB\Y\C,#$D9-5BQH6&*Q]O5GIH
M2[H>82T2Q\MNB&`B/,0Y\E%N[*RJW00B55L`>(`T+L7?$G60(:L'*Y.>TYD,
ML_0UBFGC2V5I;D\$K$@=!%4ILA$A*R9CD7R7))FVY!:3`"/2`(:>U(IHD-6?
ML<A5\_<E,P$M@G*(YK*K0$+6L.0JFDZCL.X>J#`;4",HN-`3I#(L9(T]"G1K
M;'V"64ZWCZ",H[;PV'"P=:>H$"S=\C@S`!Z":I"&TBI",5>U9TE2:EN=:!H`
M15!:TE!F%3SB.D!<AZV?8>5L3^/"Y^U%KNK&A?LVW6'MN/`Y/ZK!H/N@XL*+
M/!!-'D4A30.IQH=9\X`]-OWC1G'B/O=J.05(R.+%6X1*PX[,\8#,JENL'R?F
M\Y\M.`$L9+%B8P)#&B,V)CFT<>*:1W_["*(7@M>$+1T&!F3Q7<'MXP+9B.XL
M[_9MAB<L[5Q20,@"N\*KQ/4%M]+D<ZO!">5]3"H-+2$6P2&+]EH3(Z[=S98\
M=W5J^0L)2>P&PW`T'$V!A4D:N[3]P_(:P@3^\$02`IQYA1^OR1L)HEF^FR\&
M"$_(F%D<V($@5*7P!I9%;9H!=D]7TU`:K8)[&*]"'L_1*@CR,"Y$<3BB5IX/
M8)"VC*WZ]S6`63Z@S3Q()$B^2.<`U4A/4K'%H0`&6R0859VY*&J#B4X0)=):
M&$$8$!\#[33P38CW<1*]`5=IJ_?%F[#X>?L=6/P6-D_Z/PIM\_[._'BQ@P*+
M&5JI.!-@(JVVJ>J)%B3+Y_9KZ^K.#ML)CHV=(RW586]9MCA@N>5`8[)_7]PU
M'8ZH,>O!C\\1_97*:>"=/A^XB2``MT-]TF.,Y98+X%?%.=5NL'1Z>!Y&92#0
MA[1<B.-*<!!8[K9@\OMCZRXSP:.<[@72NB+[G_LR#\RUBE#Q+>GS:[B7E6E`
M.X+P36T/DX/'7)<$0VV)@WQQ,F*K'__3JK<`@$=:@L1WRW20B9L1M%2,]!H%
M0$:R\!(/H!+IHKTK%^M6(EV@JD2B#.2$(!AT'U0E4K,3JA=H*X\NY)5'52C(
M*HX,'W:\0%9Y5.4_1V!B2,BJCHP+#5=^UJSTT%8>Y7;"HAS^.HO!@U_X#8N2
MZ_R/6S?!":\$UEX,>(/4$Q=ME?50(JMR>HPCCY!10B_CT!6T=*[3O43J>_/E
MJ@A*6/74@J&?O23D1T93_V^T_F[_K?Q!>UVKZEKYES8K$[2M_`'W?AP6W0=A
MY9=?@F=XGLS.9\\`EMBL:FADZ5_RVW2)P&"S]:NTRLU&WAQ`:#79KV[KBR2@
M++0B*&S6OFFQ(;/V#<L/K[U?IEIZXH`Y'A!BJ)T0OT!*4BOBL6*?KRI>1L1?
M"`E^V)8-_,KY2B9N<!.F?CKG[%R,44"WS5"'X=V*"\#*.0)5QB^(X7[+MH<`
MQ59S_M(=A\O%*K.K=%LI];?(:1R;1`.6[ZH:_\H-8>"MG_XYH77CM$:#IJK<
M<"ZLLY=-`P@MAF?8.EQ-O*JA$);!M]M(=OWM3![&#_#-S=.+R7XZ[^VU7Z_K
MO`]LVC+ZSCOWZ`^+[H-PWLVDZ`9H3:$!/V?`AX+-;3>;[1FT:T0I\%\[R3/@
MVE>'DJ(;(+''[$@/K<N^M`C"R?KPWTN2G]@02)$[Q^F=(DW,\#<^"1AD>37)
MT4V!T"0S`2V">DB),-@25$*&K)V`\'RM0(K">8`401ED+1DJX$+62:`"4^>#
M"8@0'#>N)2D.%F1-81?GXK]&29YPIZ<0_3`#HC<.\&<RCF*R&/?LOI/DYAVP
M`]T^[.+S?-NXCT+JX@!+@;[)'3@[,4E$&Z/%IP*7D9Z(YF^MUMF!K'DMD!JM
MWHX%IN4[HF!32><"8J1'C_D*H`@*6SO;S5'8!=%*;SY["@!$D,Q2E`/O+19!
MP];6(#^CSL4KVJ.%$P$L@M.]C>2H`M#.P7P+7]0Z7U*`B.!$;2,92K"9.YV_
M*RNLD3$%H)'6]S:QB1:HS!VCMR'*:S_Q%J23T8;R>Y(^C,&,&Z9I[+]D*0U0
M/T=/9!;%N<.09]N4)=[@&4ZOLW=Q*,/@S9V/-_0E)^D&H>CK71P'4!`$I31M
MWBH`<R?I#;7T=6/:FR=9G1W^[":^1R,O?I#1%@QR;T5Q!8"/(""E)S\M:.;.
MON]JPP586XAD-^347A-8A"#(I27/NGNVD`/8#N7K[#1-U:76ZL`V!+$NXXK3
M@!?B!@#H=I#Z.P?`11#E,B!Z)9R<,HS6`E];7?P6_98>QCF`0A\F=6G76Q"8
M@R!HIF<V-$&*^1KZ8O7@E9N\W@;1S[TL'NQU]^ZFH5['9GA#MW@P9R!;^5ET
M_[-X<%4SU.O:#$8T*1[,!241:17*01</]KI6(PX-BP=S_G,$)H9TT,6#@'`?
MB@?K2@]M\2#X+M0F>(RC-Q^,C<_SW^"3?1>N2T2&7NJ_`?^5J@KU%P/>(`@P
MZ&V5=5$BJT.L&<[M(O#KZTI`*=S;Y3KKK45[AZ/_R1;Y^X3F"L#N\OR`E.A^
MCLR]QC8>!WQ%$!4PJSCV^(2L4)+=WU*TSS,G`#8$00%[4N/8!0)>("NYO":S
M&$P7F72+PP`'@JJ:7<NTR@&[ERCE9%.[]3:*?P-(04"`7O#_AIX798`:,!/_
MC1.;T%S!Z=D]PHY+I+688_DR)BX]]U%*AN%H5;^W(8MEP-5<"1`B*,E!(7X9
MD[!53GX!SE+./(37?C*+DEQH#^-ADI!49.(+YP'7_H'T08,EYBHMF1\!VI4[
M/T)S-YVY?IR[IVQ/33#:Z?40E%'M\F46,L+RW4<;I?GN!N1AS$P7<P2H-!=0
M(*BFVJ4X-=B"L-XR)F#W7Y/%_POXK]R9G[J!@B^NO@@P`4&EEED/6Q<]MI+)
M*OU*!KO.=`".((*J*RA5<?/P8JO'K%+^&!/8?T;79$SBF(Q6)P3"47Z(0VJ2
MU5L0F(,@/&M+&=0Y8/E"HRIIUR2W$1.I?'6F`Q8$,=-FTM3'B[#6DO-1>G3G
MM3_@R[D`&4%(U/;7NP066R$DD^P8S,NOOOOB![FMHBOBK>D`'$&0U**4F7BQ
ME4:JFZ9&4MS`!`1A5..I4BWTXK)(-"JP.!]MJ-I!L!@P!4$HS4BU@Q0E1_2M
MU9@M+\1,GJ.A]R/S8P*(0&W3^6/@ABF]LW85.!*(7'T1IW>&(/!65WAL5=!%
MSU&!UBK6U+EAY*T')B`(UIE5`5WT'!7`5NYVZX=NZ!G:``2+`5,0Q.B,;`!2
ME!S1F[K>NW@;$[UL"X@A#^.K:#J-POQVIMLH+MS2M+JD29`HK;4<8$40?JLK
M(V8NM`$?.#)O+2Q71+.\?EFD""K3`"B"$)L9@:OCY0BVM8HT=?Q&OM_`!`21
M.+-"UT7/48'6XG(Y\?G-BMLA"8'(^9,`)()(G-[6+$/#$5EKH39*KT0X0#B"
M4)F^&!9T<X[HM'=A83:;+4[GN<'JZ.==.([B:9XW5[!Q%5<`^'L7V=""QI%L
M:Y&L54W:H^N+3F\7ASF]/H*0A!;7>2'H;5`<Z;06;"JT0Y4*J#02X""(&1B1
M$0,71TR]MD[)7T=>1E'2T%7>>*L`LOX!>=7[KE9/+SSTJ^!@O&R*T[MHN,\T
M()QW+%XTW.F=[_QPO!H3RRHMQW!0!^6O`C=)'L:YDZ]Z6'Y[CM.[M!GG4CHP
M+Q<;QRP0@T)V=+Y(I/3X=74P8+(:OM(_+,_F.L?PYN!!=E+>@(R0GHUO+BS+
M!^/U[IY\(I/\ZI$PO7>GO.V,-12VC19S_74W-3Z25J^Z79!U!6!B-[@#X^[]
M/PBKYRQW+&!H^5;*^M)@0FGU`MRK+(Z!J%L_\=S@;\2-;\+1-;S_'(GPAL/+
MWJ+W65<H8C0(KLN]]0,27P%%DR@6OR2ED4!_BWYFLU>$`<3*.6I503S'+NT+
M]WT^?8D"C@A*8P!>BZ'FNLQG0+!R>8OF-K')3.8'[9-"IS[QGB&8".A:#$(W
MW$"DN.S<U:(;/'B&924!`SH$2-[##U45@9VCPJI,'P(Q(TK0;>#R7HO2&""Z
MQ4*5NFQG0+!S'8JNLB^2=&+#B3D60+187M)4_1E0[-QOHBN/A3VW(.\6?B>+
MMU;&`Y@6"P*:RH4#Q\X!VGJRH;:VNF36HP%(B]4Y9N2R!49\IG7W29-O;NA.
M%OV$:=WO-4E=/TB>8<T,Z-O#ML)GIZU%!FNW%1Y@:BN<,U`23"_0?0C9DB<2
MT-;:CVZ<SL$Q"A/7HWB2S_/B7R3I$_5%@,5H&Q#S&ZKKXD.66BD2*0W;5P<#
M)AQ]B'7%(!=F$2"R7(L!H>'*M=B4GH7D"[-6_\H-8>"MG_XYH=>\CX;AZ"KZ
M5C*BMLKQ!3.`<`1G*'BO0YG]2E"0]05^H@9=2$:KZT^&'ABG68[V&CCM^:)R
M0?EDP(R@?E[/BE%%A:QM<!X$I(<X@,PL!L(7'M_O;I"1>_(S_XO85E:8#\@1
ME,;K6J7*P(0IGMT[7_<D[V:VNI+H`)RO]OISU76^SJS>:*GM?%$&*CE?9X*+
M+/?*^3);JG9F]8++)JY5+C"):-EPD'E230N@SNS>0FF@2.V,?XT<#P\RQ\F`
MC'`Y3@:%A?;V%G9O^2$]P;D(T7Z>;X8LVS<,?[KQ:'%ZMY@;7EQW)_J"FGX6
M<!:IY2C84NTP`9D+6!LE;0!"3U$D8![D&8*\N]OSJQLN\=]'>:<(,K*G;KHT
M@`1P'ORTH8;UF"/T:YE.T"\GE.X7>'S.U_\'4$L#!!0````(`&!I;D/W"L9Y
M2#D``%I%`P`4`!P`<WEN+3(P,3,P.3,P7VQA8BYX;6Q55`D``S,2A5(S$H52
M=7@+``$$)0X```0Y`0``[7U[;R0WDN?_!]QWX'D.@S90ZK?M:<_,+M12JR%<
MNR6T9,\MC,4@E<DJY3HKLYS,4JM\N.]^##(?K'SPD95)LC0'S+A+57Q$!'\1
M#)+!X-_^_7&=H`><DSA+__[-J^<OOT$X#;,H3E=__^;GVXN3OWR#_OW?_OM_
M^]O_.#E!'W&*\Z#`$;K;H?.@"&[S(/R-5/41K?[\+P@^O#GYG#V<O'[YZ@WZ
M]>7W/W[WPX^O7_XG^C_7/_U?].'F%IV@KU^_/H]H"P5KX7F8K=')"?23Q.EO
M=P'!B!*6DK]_<U\4FQ]?O(#RCW=Y\CS+5R]>OWSYYD55\!M>\L='$N^5_OJF
M*OOJQ?_^Z=-->(_7P4F<DB)(PZ86---7[]6[=^]>L%]I41+_2%C]3UD8%$Q4
M2KK08`GXZZ0J=@)?G;QZ??+FU?-'$GU#98#0W_(LP5_P$C$"?BQV&_SW;TB\
MWB1`./ON/L?+?BJ2/'\!]5^D>`6#!3V\@QY>?0\]_*G\^E-PAY-O$)3\^<OE
M($/O]MHJ*[V@5-JB\QKG<19]2,<1W*YMG_*;(LB+`V@7Z]ND_C8K@F04W6)-
MFQ1_QN/DW-2S*E]J-/$X^0HUIZ:XZ%)K+-2.-!/X^Q.E88\Z_%C@-,)111_4
MEMA5UCBSQ\Q$0K-9N-=@`L8YRWOY96TM`W+'&MR2DU40;%[`!/4")P6IOF%3
MULG+5Z4U_E/Y]3^O\E60QG\PVW^6I21+XHC]<9I&USDF."W8GU?+BSBE\TL<
M)%1O"[RF/Y#3.P+37%$1QL3!R/WGQ.U7$J]DOB<>VDRVS4-L)&\^DOMT!W=3
MTTWG8MHZN!PX/?GYYIM_$]M=H+V649!&2&P;94M4MXZ:YM&O50?_^3?.2$LZ
MI_D^?H(\K%BE'Q7B*4N\"#/J36R*DSU)+?-L/<L`E^1FLXR"B!Y[JG6SW5`C
M!:0$R?L@`>?LYA[CXCPF89*1+:7_EIJ*]Y2$WR0:9-:,=44QY+*M#V)U5-9'
MK`$DM(!^A380:V0`\P<S2GW]NZR>?KSGUZ:.CT%R6Y7'P]B>QC:T7"W/LO4&
MIX29ER\X`??D+",%N;D/<@SKF^@ZV.G.@H<V;%VK#Y9$&_=-@S"KB4VBLDW$
M&ET@UNP):Q=5#7LUXTV#DK9^3`D1#S7FO4BUSK1W<,O^ZLR@+"1*<Z6C-.];
M2N/-I#FK:$;9$Z_FUXFT:+1)T5$A'9M"=BDS%"_?O7G)S`3]XI\W!6WKF@+K
MGO;RCR#/`_F<J5''FFKKT-_Q\*`\JBJ@JH874YCV>%10,AR,:4$BFR9T*KF'
MB70E,(03YU;[V-B)LG"[KK8"IN+G]AXCVF9,)YBHF6N668X(XW13<?JU;.RY
MAVH].$68JH_%71.@ZCY+(IR3#[]OXV+W.2NPQAI+5='^SHB*DUX5*BO\^4]O
MWOT5\6H(ZGDQ?Y@-4F<+P&"$7`.N\9VT]NCTV_`$AOW\R1"Y!T;!_78_7TW-
M:5?WC-AUKX@2\.KII!*Y-G?1[PC^?4NGX@\/FKMMPU4<[(X/4M_=&:Z*(E[6
M+XNO&(;N=J_.&-C=J,JH.Y=N<72U@6`?ZBN2TS2B/VPR$B0?\VR[T=W+-6K)
MR4:4&:]]NRM5"ZAI@IU05HT@WHI7*!TYRGT;)Z.'>/P:.+S'T3;!5\O];B[3
M,-E"W%H_6?3G;(WK8T]*Y6D4Q?!3D(B'*\%=(O5E[)-@=WUN5[H=ZUYV#QNY
M;0VJ24!#>L>I:$(`F"(VA+2.#H$6Y-PK\TGHV9,1NM9>AUNITP+;),C%;1,J
M_ZB2_XK1LD!?[^/P'JV#'8H971@5]QBM@CA%SV@U\BW*<9BMTO@/.BST2_@U
MYD-"]H:D]X<PV+##@.(^**H."/]+Z&*!@G6V!5^+4IACZJEL,9_E-CDN@D?Z
M3[:,"Y3E",K3(ILL+S@]D0B;K):BZVT@!Y/(WJ:2LQG$XI*DYO&*8B\_V^8Y
MT$P(+M33[)A&["];3#B4376L.BKK(]Z`-S/4M-QF!W)K=35GC.#.^FXD?.UI
MZ74.1KG87=/A`H,"NQL;,"XZVJE3V;I6:G'4QF=5:8%8-3:YU16]4T6'+-K4
M/WULMO7.%)CC5Z-U8(`8.G`*IT0K-D>_WW5B!TZ_!CF=U*O5<G6F]`LFU&<"
M8A\W.&3W*."KJVT!5Y;`*6"_X3R,"3,=6DM5?^BSNX[UA^_N7`@=(QZ%M!>2
M(Y"'WN^06*XD$3$:44DD4^'Z")G3R=6ZI!3=9NQK)!!;%JC)]<:X'<6PE1%2
M@\-VM^N+I#(=ML*G8=-:2WL\;CT+[9R%=A&0,V%*QD<K%$<UV!]5L=RF'-6`
MC6HFC&H5Y8`>FE'%PJC"URAKC2INF'&]+/9H&+MK9G^(<[V@[A<%.Z2LF`V+
M^"$N=B,6VN,;=[@`/T`BLH6Y&#`L-KQ`/)"K;'N!JM:]F4WMB"A;HJ%I\7`1
MN5GJ'ZI;PUL`TRC6!`=GI1G4MA%&M1T=5ZEXDFEY6=<_)9Z(Q<PEBV9',:8\
M]I^BE&X8"LIF7+M59IK7?U!@H';3F8@#-Q]&-^?6B!RP1NRQ*EXLXL88F@G$
MD'DFAE'&:*ZE9V6E/%X/'F@/I);,]]56=<K*R)%&->\7=!"ZW**T&[5;G?=S
M1?/!W^Z5;C?L=EBT]I#0.G47K^4/G<"_WQF=ZY\^QD2",%L$6$>N-<GV1&X*
M84[H<["&FR.TK`>J81=N;95S@36K\<WZA`(JSK-U$'<\A?U8VG$MNHAW'LF[
M7'O(0ATEN"A5C#?I@9(="(2>4.C#43!ZV78:8:J29[18'++,>UD.-7<_X?4=
MSGO`JU/)ZA),R4$;@KP"JFJ@I@KZE5=R?']<;TQ$!]ED0!RXP9_B%%_2CS)'
MI:^P.W=8I%CB$D,QQ,IY8)>&Q3WH&P_(>K0U:9!W@3'YC(>R3_24LVHS^NAL
M#[-@%J`0HJ7<;;`8$KRDA18HG8UBG;T0'9(A!0"/#X?M'CCM3@F&D/"'.&IB
MTC<LF2W+#)`T/(:07`4"SR$P,H+4T?3W.TQ+\3CWNS+U&V&IWR**>,<[(H/*
M(5IRA6983%O*?8YT]8&/BE8JTN$Z]M.+2NCOI`RMRJ*JL/+.G:TSV'%LL,1#
M=5P05/O1_?RD1%0G-ZD>G.SI!$]BG[#%[)KZ6D!-$3_@DCZ)9BAK6M</-2]M
M>)4URDM:8IT*96Y5Y3".@KTZ[K5%$VMMG3$"VF@_;V_-*E^R-A/:#<X?XA`3
M9IP&',,I&K;J24XB"<46HVJ+1%S!5DWS*<"=PSJ+7.![<!0%+Y"451PZNK.P
MRAY"*'W<O$RW6&1]G-.?TPCG_&65(&4IM8H=BK8Y(`8\87ZG$O[BGK1C/W@Z
MXR$ZSE-;#D<;RW+*VQZ1[N:R::MN-YB-92"WG^H]Y@7JK`!FLB>%\+Z))6%P
M2Y+5#(;UVJ!<;P_83F=;ZN-40+JM?@C^_38$_,SM4T9D>ZN'-GP4YF!/$E-:
MA#)+Q3-H^MMCLPM2J<#7"+1Q*-7"<5J&KDY,81R&%.*0152WNZ87EM^A[PQ<
MGMCYX%9M+Y\.E(%>8JU*B1GB>8*@WHPTKK?]YI$)SYK`FW"X$3@AZ%N>_W2(
M=YPO[V,0IXSHM#)1`^1_QL75\C9XE,_ZDW3@1W:],9+1LPT+])'E*V+S.[I*
MFT16@X9B`:>!\#/MQ_V[#[/(BLF$&DY:F<5B#T=->.$D3*A*6KD*#]0CVQ&H
M0.H%E=M`5%%)XVE1Y/'=MF!!U-F7:MOH`]M14@:93M*'HSC2:>33UJ&]E0."
M]B5!;K5!62"Q'\C#<!U`ZA^72P\;4N(IZ<R7([9,K3VD+"5(<6]M)[<H_7'$
MDYL3!X%OPJN9UQEAX<]:[RSH5'<7'"?G:CA<[DI\;+6JZ55V8Y.!&PRJTQXU
M!X"\"7$:Y'&FN#4R4-X=Y%IT=R\-\I^]N8@A%?@@<H:E;3-3"*?AYY1L<!@O
M8QPI+S)(ZCC(ZS%,_Q!L%D@H[=%-`^58=!-&:`V$/33Q=)4:<UZ[H'7<="CM
M7!LHDXUZ$ABH2:][$/=#H(U<V?C;@^M90.XE(.4_6X=F254G&H9^[1:#]@GC
M`2QTPLR+`XA#08'N\"I.4SC?RY9E7,RL-'](HP,IQFFDHM6F7HNZTM;FKJ+8
MS$J,-T$<E6?YIVG$3C^X?2F3*$M47*NV@[S$.CQUL_:R6E5("XOYX$=!O.:B
M2J0]U\X2SG7R$1_"6A7"PGC+&&]AF1P\\&3^,\!C-Q6Q(1AM.W9J?7*M.2H@
M6=($G3U6%:D\D&L_][U[>&L!V0O(#B;V[K^GJ%?-GQ3U_3?LI)G;%^XN-1[(
M#H]?;/B8[ZJCENH:<L$TV;WJZBB$=G9\AU<5X3U-2-'[*0M2\@6'.'Z`XP!*
MT><L#953E%YUZXJNR54;6ZS:`K%:3$O*S6BZT&D:88I/_U,WY-8(C&3U4Y:N
M3JB3N48I/"&;UQ7=JY8))-LJ9H['\2&(>`,G%&3?M91JC5XUNT&$:BXZD4!E
ME<Z:R+E.3,$07PC)%D`'<Z%U,<J<C;,@SW=@JQZ"9,OBCJKGXXJ<:L,2L[O^
M18:*^SB';/IY$=/5'Z0&()@V"S>?-MN<]EN]10>I]\4T^G=@*(IMGD)D`172
M9I/$[!=(]TZ:_/Q+:EA0EF*TPT'.4POLLO(M/.$RQ2X$:QHO44*-$0@=KI(F
M)&M>Q`M6JQRO`FJ@PHHYSM."CA!PV)^L8`$_I;6LRM$$2T<YI7S3(LFNR@[9
MY$IH-41E2'E>T\)Y'"0@'6K`2!S5;^D)>*^ZZ)48K?P'EQ@T0(<^:HOH&?T-
M*$BS?+U_X:0EHV]=WS_3-'I[,:9&%L_V,ERY_G:V\#8\E["YT!Y<8?NULI8O
MJ5WA[E,<W,74GL3,4^D^<:]QXJ??A'7L&G#7\4F;JFPN$"LC7MN;(\29V/SS
MG]Z\^VO)JWLM,D5J6\_&P=3B#!"&S$&Z#G:P2M#8D1VH8'^&&**\,V.4!5%9
M<N[=6MT3>&/Z-[RD>Z60@Z8SU6@@QLG4HS>[N)U`Y,9S@21[@7:\(3FMW"42
MRK@';P\`)$;;7<CE")_(*R_(R"'H\W/ZKS%XX_Z,YD]T<#S(JV;NT_CGQ5S3
MMMC>#B/M%]C\D0=I=$N[",KHH;DG4J'<M6+%%H@57*!+0K9XKI`C[<,W,PX(
MY^!_OGS^\N4KV'SCVW1_1:]>+EZ^9/_GCUW21<&VN,]RV#-:P"X61C'CEV]/
M-J]WN-<>"?)ZPC'DL+,8J)BMU^7[;RIEZ1:U'\#8I;:;V@N*>*@C^K1+M$.J
M'F_?+GYX\]WB+^^^%Y6$?OO]=V\7;U^]%?5E@6AMV)J-'W"R6U0EW]+_OW[S
MLE7_S?>O%S^\_<MP???:-X3C3D"A%,065]OU(Q;701Q=IF?!)J8.LD">;.6M
M4=G^*ER'HVX*_:H2@EKH,D5EO042-=GQ`OU`UB#V[B1.4<CKN=<6??1UEO"&
MT+.G45]P$<0ICCX$.41CD],PW*ZW+.'A.5[&82Q;+^E4MJY16ARU85=50E4M
M]$RHA\J*<Z6?TE2H49R);$2\E'M-TD==6Y-,(>=RQ\%HI\&+'0:#E;>'61*T
M^.$[:OX>F`S#2+V-X,&><.\AS0''D!X>/XX[=O1DCUF7H\[&\Y&?,XX]7W2V
MPY!CZC)>!"$0MU/D"^@K;'^7H8_BSEJ=%4)5*6\2!@R+N[,45LC:%42460+Z
MBSN&R6!N@`Y0O,D*(!.['"QN<P'`8A,>:H8UZ`;G@R\,*LH[V;WLH[MO&Y"7
M0ZR@XC5!FQN8.N1?4Z#%A,#3`A"![L%;B%K`Z=LI5*#&YN8&6QC2E4FQNX4`
MYB!D8;?O=^(OBLG5I!$'FQT&''8W/?BV`"OCS51L/FC=/8)Q(^8&F,J)NZ^P
M4Z`-3MHM0'DS90^+6P8=*P_]?DK"46_]"O6\>.Y7Y$/_Q=\%HO4\F.J,1DCG
MY=^!X;%\*7/O]IK$PO05=G/ALDUQ&TJ#MRD]N$&IHOVSE[<D>S'2>R=2`A"+
M6XU9NKK%^?H<WQ77U-&$.W`K_!X'\-S6+_2_0-]E6F`ZVL47:LME>X_F;=G?
MC!S!;^]%76@$02L+U+2#RH90U1*JFMHK!>TZOBLQE1B*6<1@=:=SK`9TMCX/
M@[\]G;\(XIR%G9SSZY;;7.LY9'DUZYJLX*(ST]'B/!`+"16\2M>K,RYMT.D/
MBMVT@Z=I!/_`IO]#D%!5(*=%=1M:&>*G5]])XD(=OOHSWJ418A^$J@O(@U??
M$6?5W:/0:/3Z,N49#MWH)>!^.C'J3A%J:D/H_AP_X"1C>5P&EH&:=:TN!77Y
M4>3%(ZBJR3`GU'67`6(L:W2VS/%CEJ)-R6,NLA8U=16//Q[,HTY^B+%,WFS7
M5=Z$*CL$XS5.41`]L/0'D!!"R;KC/`1&ZBBN^4?HHKVYC*5':%9JY&.>$8T\
M@?)JUF<N!1?]#ZP)Y1>(U?#DINHH;IJ-`@_N_.F@JCVUZD/*57):TW2TOB2@
MU4XYZPG^3:GWYV%D*5[DZ6(=(]THZ[(729:U$@];S9^L$UJG1;4G"2?U,Q_[
MD^BXV2:XQ8_%>]K3;S?;S29A#[9H;`)IUG?RR*8.7WUO:/)Z""HB5A,U5;W:
M(#(:O+YW'PU'SH-DQN]WM[1O14B)5FU_4AOO\628X1AJ>A-:8C!JVHEWAX;,
M`RP"8<KH$JW:_F!QCZ=16/0F*L5@W+31.#1H]M!8DZ(,,.V4M(ZR+JUM1-4E
M/(DF55/\4Y!NEW1FW+(#3:Q)OTW<#R"DC7$I/$9OPI]EZ\VVH,YM&ETMEW&(
MU7C5JV9UZUV#BY[P:%:%IUQFE9`NNFUMR>H.CK@;:S8RHW'SJ0[MT@.,I+Q5
MI,CH[@1(U&6]0X92_"(D-&7O@8?&]D3'.&=E17_\LHH30Y>,57.].VF-)2^\
MRSW,:3N6/8"SFF2UN>2_R7$8LW--^CG!['WG-#I=P\OC?[#O!YF0:-IT7;A(
MY#J5=&3)(\2V%ZANG<%?;)^JQ;Z"+/8U9&IM?\>EE+(D_\I''F<4UB=,"`KV
MTFTT';@W"%,K44^:VADTR,$C[6=)0,C5DMT%UWVHO5O'W6/M/?1W%@-0!((X
M6"%O]N>40S#X=+M<_A9#"04ZU#>R>PK;#Q+LHUB%%V_VT(;EW8GT4PC;XN4_
M*EG5"8%0QOY5/X&^S@T_^,T;>]&19.<Z7[\8+8^U<B=TKY2;\1[<%"A'W!N-
M[Y%H[ZB[7?'_%*?Q>KM6CGRKG/6Q;]/9V4WFOWNP"R25;!L!$K%:Q$#PJ(>!
M_7+V,="BLWNB\.@;!OHDV\'`L%A'[P+?0/K@]P'!$6P[XY2PI<QIGH/%X:?!
M39%K_I;=*;QL5U][.25DN]ZP=`0?'B%1!L'7>1SBJ[3OAHF%/JWN1L\MOTZH
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M,A4^4MOX)2:_7=`5BF;^(PM]'[==')"G1:L(%"`@H<Y(-*=1I#U8-HF:$F9B
M6((8XDH,N1?)F*RI[ZPF4:V[E@WBG9JQ.Q-;#VFN7JDLX4R=NC&!<TG0A4<(
M?3NW>+8$6G.=Q$NVFYAM_(@?FU\Q>VV<!:VT?QQTM4_3198O<5QL<PR6]S*]
MQGF<15.?!VEV>AP'0KH2G/Q$")4]-^:IZ9OY9O`:(^_^"`^$QHJU%L:RKN$R
MM95U_F_O,4JW<-(,)KM\99:=`97VFZ#B/BC05^I?L?PF3%A%ANXP"B%E5I+`
M+BB_M`?'0SG>0*PL_6O#^D0!00'DU-HF!9L5PI`E9@C9'!$@R&L:I_R$"3\`
M6N&=V7@98Y:8B]IX=E]^&R0H@$,LX)A`V_"<GG@LQ0+\.,UH0WD\UN,H(Q,[
MR7G4"/MZ!/L,)5=7S2/&G[>*@)89^CJ>?02)O&;PG:\J9_E*?&2:]SB3_>7V
MZ*8(\F*VK0(#(=82>(]7<<I,V?L@`9,Z*_\?4N55$ZO<?V#E9F8=WH]-V4/&
M'[=Q!!UYH4%W<@VZJS3H;AH-.HK])979GFP_2<]F'\]$]Y$6+(AD#3971T<W
MQ74D->?\QCMKUE;LT0]TM1167W,M..;=%=<5YKXD\,#B\IAL4[^F36V89&IF
M^7'P2T*V.#IGBSQ.#J.<L!_KU0,/8)-:GA&-N7E<W)3C.2U(U0^9;X/&["KR
M)!+JL#?7KI.>%9QNT*=QZII!C^6#;O>:ZUACT/L$_`&6X'C<,F&:A\OBCYLX
M9RW8\-0T^CXZYTU'GG-:8Z%_GAZBH<`;^^Q`Q&WY/`4_3UMUIW;]#/7V>(QA
M:<W94WQS;\;V]'5TQJY/7A9<S?)QRCDW8^<.8S408!_WQV^\!E5M:F.ET+/C
M,4["3N`_<+RZIW/8*85IL,)[E[/LG!_)*3@Z0Z8O6VMG314=J"2D=3'V21U"
M&<I<(9JG?60UM:QT#KB.:6(Q-),SGM?HVTB/)B%BM.T[UT0T)17^34:3RGC,
MA$3&GPZYF9:F<L=GE;S2U![/"=/T5L#8SLYE`H[(UM:;[*[-K2$AQV=Q324]
MJ]'M.5!S97>G.:*?6_IJ'U=^AG=4IG>449C<^AY@$3PRP(?N<SO:ASF0+O_,
M\\SCX/R\[;C-M^7145KS?Z4C/!=;&!.:E^.Q]<(Q@2.KKDW!T=EO?=E:.SP\
M[FV,V>2MZTD_N3-(%W9VE,(?0<((Y4[X%[SFER//FMN3<'W\M<JZVJ;F>%),
M'"1S=V>:-55((&O.O!0F%MCY.&B*ZU.\A#-/?H`G"MP3"^W&ADR6]&(J`W(\
MEGMX8AIB=98<0(=0<W26>YS,+83X#_C+3]5R3S,.1I;;/Y_:C>V8VF(?;#B.
M9_="F)PN*4=Q2N*0)6JR$PW8[O/H=BAD\K/F'=<]\Z1M3RK"3RG5T]4J9]='
MVF)XVM%\A\CE"4?N]1NQ&6/U9!;L*!WW?88L^>>=3H_9#>]*T-KNM)V9P+Y'
MK1:IS-P]43=Y0%-G](:E:NHL:>=^0!_[ZYP"H<XYVF/"['1[5(D[-:0X7^K.
M=K@P_P(!`4(VXN--WSE"N%P"$4A@"1)X8/F8Z_3#!*UD0<$'"\5&4L\14KG8
M$P7/C?DLRU%6W.,<`;OP/?Y]&Q>[;RL1B6D\^Y-W!NFNK%3N;84BG"'K9M7#
M/?U(_X?7FR3;X3H]Y]<4Y^0^WO"RSS[<7%U_>^2).G7-ZI2I.LULJCW_^IJ.
MZN=@K7HD?+^8=1^V165;=^!G!+][\UQXGUC;[LNP3.T/__Z#]A(`]+UG;Q4"
M-:42$'CS@GB_>(>`T"?;\;XGF&]HF=+]:O!AZ,&2=CV\7EH[3AF;D-@P0SG%
M(]%6G"<MNAFQ`O'N'[=6X&-OWE.!8Q*`_J`-T!^<`_0'38#^X!E`A^EFQ'H-
MT!_T`-H+CBD`^NJE+D";DJX`*M`J!>BKEWX!5$(W(]9G@+;Q,0#0?G",!NB'
M<JD&,>GG<8Y#6HU(@2JM816P<MH[;WY4I1$MCNKRG@!!8QQ$0&@/PB3`.*.+
MSVU2P.I3&QH]=9R!HX]^.3R$&AX"9'`\AB"B&`R+1W';.X)_W^*T^`"OOMS2
M_A2[!H,U[!^"#=+>F2/KDH@515#6FWT%Q1AT3DAT!L`I@I0;#Y(Z/J!H<#MB
M`$?>;$THQT(#2V,W+*9!TV4:9FM\4P0%VX#]!#W!GJS<)DEK64>4G(<VIGAI
M5!='57EO[)/&F+1QI3T@SI&EM%6*>KZ@:]!F2?#EC=W2&AM-C$VZX?H1IS@/
M$NJQG4;K.(U)`7>$'S`\TI82YLI]P013=N_!\<</.,DV0$U90.J=3]6X53=^
M,HET3I!YPRR[P'[3J&J;_5:USOX0VJ]*>;(\F!8YXCIB#M@<3PAX^\PU(]+%
MRAR]'5W8=[_,[#ZWQ'KU(,+/DABGN9M4BC'6$N,QQ4!+M'C>!YQZ5-B32$"[
M`8!/(^[/4;C?TXOQ4PIR-H,VNRSMAP;^_XA`#R,"+08".H__.TU8XSCJYZM<
M!TC<9MT&K'O"VIQU+EQ4%=&@FUM6=NNC3L9@C[V6,FC3>S3#9]LA'`-.>[I7
MG?+=X/PA#G$_C9^S]`$3N*@-1H3<9D60B+^?9:3XG!7_@8LO.,Q6:?P'Y59X
MCD^BNI;ZMZ[YMN0Z=`R-RHX'[<<"U;USMX>Z.XR`?24$$FC)`E$B4$/%H@R%
M*0EQ:X0\DW77E)G*>F<N:YOVT*K-:)M3!P;#HB>4%G$4)UO8'[W!(76CBQB3
M#X]ALHUP=$%'`KC8\L7!U?)#D,,%?$+]."Z'77\#BN/(67NU[W/-*L..'R,4
M1DUI5/6'H$,D]`B/N%=]PJJ2&XT%+.V'VO+E8-4".CO.DRUHNM9QK0LPZJJ>
M:)OTDLP`S!>^79S1'2@]S!YRN68:X/TC@`V"8O",=Z"<=4BUZ>QD\>*_>W!P
M*I5L&Q82L1[!<>8'MEMWF9(B9]N3Y`KVYV[O@[1TF6J7:[XG>LUI.)ZCSQ'R
MG>%`E%.!!#(0HP,!(<VV>$W+S,_]VDB*-8'@^0^PKUWJ.'E*V;%F$M"329,U
MUC).=G!\F%E\"G//_GF&DZFG3<(3FGDZTG4W\;2/MH_R@9[#!=YG3X_G%<N)
MU=R>'97IN(.HG!9UG;??)@_,47=X)+$Y&I*;(3RG8\_ZGI2<VJ*]XW),6?:^
M02?1NCA[/4+Y<Y">1]8<)`3"4/.U%`7"E22ZD31'&^2B:ZVFB7,Q,U5/P0>N
MG]]SZ@;W4/&$/.$^&;MSAFMJ7,\>?@B^;TIY"F]2CM=\>YZQ0NV?@GVM-U%:
MCU9H9<3UB[PG9)&-1L6+#?/.&S0VD_'ZM:$^9LR43V'^*VZ\SR+(?\$->FW3
M[F#OWM"N/X4I=W^_S<]YUYC&)S3YFH^//R<'CB?B""_C-`;:/F[C"`SLD8Z@
M<AKYESN7\'`2.<A(>7BR,68J<$[1$SD;&6WF+1R>N+7ITE-C_P9%O0!XTN<Q
M!XDL*$4FO!T3$-AZA(,:=@N:ORU3WXTN+P4%#,QP9YF(%YS+>]5;ZA%\6[Y`
M4Q8"?:A.@^`:^A,_!#*>.YV3\]367.5.[I8JM)\++C,"G]!JRW!DG)]+`:&.
M5UF.X[@.'#'E!/VO=+IE9)"L'WR-L$;C$ZN7*&`@D+^JTU_4;AKU?FH[5ZGW
MH(U\>%AG).7/7[WUX&:2"BA[B=Z5*)D(JV\,P/K&`[2^T1[T-][A59_VYV]>
M>PG8-[J([87*1)!]:P#9MQY`]JWVL*NLU/S;(6,I?_Z]ZM4@-X!]JPO87J!,
M`]C7K^6O1`T5=@=9D6+%R-.BOME9$^J?*\EW@ML.9`:!.X"7J9#[V@2YKWU`
M[FOML:?8]0^Z^N0_5Y+O"+JOM:';"YAIH/OFC8'1%0J[@ZY(L6+LWZ`WWEE=
M$_*?*\EW`MT.9@:A.P"8B:#[PW<&T&T*.X2N0+$2NC]\YQUT#<A_KB3?#73;
MF!F&;C]@)EJ;O7MGL#AK"CM<G0D4JQ8Y[][YAEP3ZI\KR7>S1&M#9GB-UH^7
MT<BMKJ3L=3(`W(&R5G$[1.]`+B;2.IMP!UE=PJW0JQ/A8$SPAJE8&6M071EU
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MO`)!M\<:7'N`B9XDFO9@^WP$CK\R'DR8N%OQ8%\PY'ZFWY]E:9$'8;$-DEN<
MKV=Y#G0>.H]G*3'3.+F+J=U;>W0"0VN:D4`T8E0?Y0K%TO!IRO%3O'3\RI;O
M@N3XOI/K@?S)Q4$]*.;4@Z-8HLXYZ=B+E#YXQAF]Z"TS6-R`"WH=@#MXCXLX
M#)+3.\+Z&UBI:M2SNKS4X:.MF64=Q"JAO5KHUZK>7"=,.FN6B9ERZ[MK(TUT
MN`UA9L]+OJ9M8;I\XB]C4=*N\IL"\L"QVPS5$SL2]U6W`>M^I39G;>35%?F3
M;`L`'[K*$:_-[S(UCSJY=1HF8))P)C=!=<GU69RB*$N2("=P%94OG[]U/[>:
M0;4]Z8W!J2LU9*20TVUQG^7P:IVV^G4K.E:['DZ4ZL;KH*:23RIFQ%"I6N56
M5Z!@R)TN#>%-KD-RL+G5G4M"ML9Z4U7R0F=J#G3UA5?P3U<T&-G7DUC"B&L=
MV<>5CG[T@<JM;@B+-$,%V:OIA9;L\Z*K*LI3;9?ZHLO2OM)D/AW4:Z).1WT&
M(6=/A\ZR]3I+QZZ/M&I;UR4]GMK@X[6.8%ET$'M'LR`R`&9;U8Q1Z43=#-9!
MTEHNU4MCP;"O5IXM?T:QXN_"1P-=$EWQ9<G3(4FYWAFLX5XW!A<(?7JQ\&*=
M8\S#GD(LO%GB*'"DU`2WBYL..7HK&WDU]_H@7P#T*X4W*YIQW'B\EM$!F5)/
M/%C%,`\/#NKX(2Z<_&8IG.&>/L;2\"1Y/?OA0@H^.E=J>,Q!4P[]"B4]>%!>
M:T0Z9_?ZPV$/6RU:SC,XZY=@:J"\=2P-T:W"$/J5%_4`1%+1M\&C(??1`1B7
M9>SNU;**!+W-KNF`W0>$?B=8Q(%`#(/Z5@,R3/AJXZ:JBZZ:]\K0;8:J^O"]
M.)^[NU$Y"9?"JVRH$+C,K'"I$XAR")LU:]QY!PXW%8>AX,8X#BTWUD,Q3&6D
M$DY[8UJRJ:I1Q_T-:LD.X\!-:M?;IL?$RNCKUA)>ZDU=%*RS+9W?]R]>^WCO
M>FB#UU!#3'U$@L/GJ^SA1<P>K.(>(O_<]@WYM_^\9/_`@#54;>*<C1XDSNU1
M<NV:UE1=GY?.W%A7$6_65958AFPW*N^`)1OZ8HBZ2FM&0<[^!5UKUW"/_K*M
MW2NU]B_-:DSH]F1WV*60YB%G:]*;]9ZMZ6W:M'[26KR]VKJS6MP'!5H'.W0'
MBPUJIG+V0HWD"NZQWG"U<X]UPMNJ\YCX7]CUY],THC,0#NG'VPR^TDD]8[G_
MXYH0#.0ZXSS!J6"7URLZ8%\(OA:/<HY_#CE4W%--+7T"+[H"GSGECY5YYP"1
MGTKFDP7[OIFLFNVPE`J2)WM8;I-D5V5N`%EC0=;P=?D(6E\B!\@/L3>Y-?D;
MA,?2CGU6,S7KDTYVXVSZ^!.!-,P974$"':9D:$>OKZ#=/?X^2KOKWKH0*DNY
MW,G6(?GV/B8()]Q4YG@#R5:XRC:L8%Z;_IP$I::"SJVS*%[&(;>X?N4A',;5
MWE:V`E1>K-ZK-P@MK-^;KH[+8>N7EJ4U?/WH[!&[8`8"G&,A'\\L0MMK>8D,
M1;8+G*_!;GIB,^<T6G,MR/LMUE1GC=##B./&GFHN3QS[N-!)8.?MN:/G#(TX
M?33B2-P"Y#F@Z[-)OTXA!]5'<A"IT!V;MR*S$..(7%`.63A#ZVUH^<5A95T'
M-R/5_'0O$O(Z""KQP)PJ`]/LC\)KWXX\@*VE,5MV;TAJ(K![1]((?A;CB[=W
M!/^^A<C4!_J?P5<[%.7MQQ,/T-UQD.MRB!7TX.D++=%W`HC5<A\;%!+AF..%
M?FC#A'[UST]X11?C:1$7NX&@\]Y2UB#13V,;"*P$XD6<QY)+Q%H-O%*F<PTW
M[V\P&+Q;Q.I`MZCKK.7*\74>Z#TD27%XA\4X>K5T1OVV++^(BS]6.`\2V#6&
M%5V0[J3O,:FK65TM:7#1N9'$JJ"F#CO(*&MY\%S3)"S].5AO_DJ9\F`2,P&;
MN+8P0YH]/^@R#;,UKJ_I2-)/*FM8]X6&:>\Y#*$E45U4F6?2IC^D&(*V1Z0E
M?WL`^H()I@S?4T"?XP><9!MVW6OP!$VSGG4PJ?AH0ZHJS^RM4&/FPS;-M>A!
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M^:$J#B;I0>HE-P]YV<7<4Z*F@ACQP'^"&$Q:TKT^J-#3G8ETH&-Q$0B&9E`W
M92M"147[RT,5)_TV5CJ'N-6+D1S%)1-8RH35]:,6R#J+20.$>>!WC?&W?/*S
M3/TKE\LH$R;*#99>AVJ!4NS!GJ*Q:GBG%>H%UD';)E[N?ARRB7%:%'E\MRU8
MI"*DM`KRP=UM7W8FI!L,O6RZURQ]7)IO&3B;@7#1$">;=?;+V9]I6G1V9A=<
MH'V%\4\K='B`GUP^(:M#8S)(H]5YK@^YG;EM&+864W(&.;RV2:I0Z_<!B4,X
MO8N3+5P"5>^Q:;=@/VVG-F^=J*ZR9G-/8(%8;7[HS.M[L^\VGL^N9:H91B=M
MCN,'[,&^G"%@.ZE-QZ#5)_>2$MZB6?6RS`%M>NB,#O,_UD==,-!WU=N#]VFF
M%(?`>];XY[Z^67.P(IB[N5I:X,H4G,<DY#3CJ"&9VN^KY6WP>*A1&-FZ8_,P
M5B8:AD)L>L]4P(QYM833^*,Q&U.):4\F1V="#E(@N3&90'N\<?C'._K^.?AC
M'7NOO7G)VEQPWGW524WT&7KMKG3I'SA>W<.J@0YML"HS`UXM&8E"MB1]%1O;
MH'7-&\UYYT9[V1`J6RH3J\$<RY_$V4^[YIFN3B^&H!1#DT"M^]@1BK8Y_`.Y
MEC8L]47O8IT9`5[;`\T_3%?:!F$*17'PIM+5\BP@]Q=)]I5H[*S)J[E[4:F?
MB\Y%Z/K.#[Q>0BL@5L.K&T`Z`S/XLI)R5*R>E``MUWGV$$<X>K_[F>#H,JVC
MU$]#:A#B(L8ZL!O3F(LS%W..^QPGALRJ&4C]]0Q:0I?IM\)=A:8U;S9])Q&`
MH)870O3T'L<>[/F.AW?/F<M!V+:GTJ?1?VUY_!RYS;Y@D%2<X+TSH]ML.J6?
MISOK9F$FJ742X#;=P/%MW1'J'JC0GX_5Q#@09I&AO!9F6I[GPK?P.00Y;D%T
MU+%MXK4"WHD7EFI.K6W;LOE5UJ*'W)L/4.8;#U2P[Q4/4=Z?.;.;>M2MCNN3
M#TFDRH2>H9)\JTZ\%#L=]UT#./9P?P[)EL-8A?;]8M8QWJ*R<S`@_.P6S0<3
M:A.W?6/?1NOPP(_.V,-F`T+;N\CRG^E,D2283@-W"3X-0WC4CM"I!,</$)K6
M@TCC%JSF\3'CK2<G(*^-EEF.]NJCJ@'4M.`NM\^4;&[WV`PJ-O.YV=3)D'H8
MGZ?U&XT]N>N_YM1C/(FRKRQK?<,MJ1+;ER\\BB]3L&<G&`TX>@YN?K*-X$[V
MW;9`,4%I1MW5>!WSTHL^63K.S3I"]<542J/U?GI;]3DK\&D:59?*FH[[XH1'
MM^2'[9+R:F+#H"%V0E!?+A3:\M":'<#XOE5+*\;CBO%\=L8/LF]&G+NV<U+I
M^FKQU`9$R_+I6@][*XJ/09S"TO\J/8_))B,QX.]J>4H(+F27*!3UK*\Y5'RT
MM0#*5WMN\+QL4PF`3P=P@_-BAZYII0)]^'T;L\Q4D%`%X,TB0N.$P?AC0)KR
M\,5MS,YBJ^^F-ACON$!2O`*E52UQ3.7"`D/@S?F`&D*P$17K[A=`6E!MKX@,
M<&HU5C/'`<'GF/\K[+&=!9NX"!*]_([:C;B(O-3GL/=)+%H)/:NJ?PM/Y@BY
MP'@3WNQ\'\3MV3T\8D):F]0,G\R<)'%P%R>^G*V90[<G&'(4;EVJI]9>AUEU
M#U12:UD\H(P6-CC,)KJ1[)WJ[F"X53+UBGL\^EPJUG6.-T$<G>,ESG,<5:F/
MTHCE)5!ZH6,;]$#Y-#G75,>RM2HW)ILX>&H'WI)ONCF2^XK-<N7*)\B,\1EN
M<[@47<Z</NJP"=;56FT.],->7-WK_!PS5YHH%=6LNOW76?6X&E3"JBZH8%7;
M$]T[D,4];KB&R33+RO[7`>S<PM;5:I4SF?'H$.9VB['15*&RG'G?990T]<C7
M68IW!*WB!YQ2`2""J9V)B]V";7G1MO(@6:`L1^L@7\$EBI*@Y^@T(1FDG"HW
MPX0NP=%G`NVX^[!5QG[Z&E-,17@9ISQZ!<@K@L<LS=8['Y[)-3`&G<=SC2V!
M#X[_=;`;[?77=3WP.KK\F/K[94W?%MQJQFH.-C(._'#S6W#3]_%[L>9C8+E$
MDTP:\3B0O`>"(P+('2?YF8#7DCT#[OR,%1]2QK%P=:Z5/.7J1-<]I(WYHJ5R
MC@VUM6[,QUCL2030ON[1Q[$'6]+CX:VIRMK8MOC4,'_CG-QFI^'OVSC'U6DC
M.["DWG1]9"E199-&[#\^;,)A9Y^HK`S7*<KJ]7GL@A_J+OA;,O+C35L;9(<Q
M2XFZ!X\]6Z*->!#MT=FM.5X[+Q2/!*N/T^PDTZO7T^HTTZF'SJ\AKY7SJ\^=
MGS/GX3.F9UIY$:=!&D[D_$H;\T5+Y1P;:FO=V!$YOV8":#N_?1S[Z_QJP%M3
ME;6Q?4C4=HAQQ')C71*RI=WAJ^59MEYG*;M&=I'E[-^K#1P.?'C$>1CW/\MX
M6'.VX[?'<MT3R\R:*E=I96,LCP9K#K%V$&VP_,2;1'6;3H.Y)Y<"R[L>5U*@
M3G'(I4`8[Q#NS3]E7`IX9BEH1G9/)08XZ6(WG^-T2:T7EP:+W(XB%OP8)/1W
M'C_'GFV#Q.(@AS+`&_,7Z@?%%+D/T3[(6K3BM"<P%197_0*]_PCR/("W<H>M
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M&HJE#S+;#=KKPJ`;GS>$`=OO@=P&CY@H$=LJZ>B=#I'6@3<W6!$OL*LB>!^^
M!93T`;N]F.A_KF(`$!:?X,Y701K_P8S_69:2+(DC/A.DT34=W&I/]6I9KF""
MI$ZV3,[K*?,6/Q;O*9F_251@^J[L/_,]O;0ZSV@+72S07B<LWD3L!DX?ZHY0
MTQ-JND*_0F>(]>;83_-->-D4PK-I6>;2U<[;Y[,JJL5$CBP919!\S+/MAO"<
M.7&ZZG\:R,R6'=ZT_821ATNCY_4IUB3B;2Y0W>KP8UU>FJ9CE(W5M)@3:5(G
ME>:D:F3/LEP$<?Y+D&QQ0Q/1,1N*>M9M@HJ/-JBA/&(5!*P2S\"J-3AM)!J,
MC..KDCE5BD]-NAKYFE.CNA\7)KM<Z=^9A+I(J.Q\V3J&O8J/1,6'\\N3`P#4
MNC\I19_KU/:G<'*^8F[L^UU3I`R*/_T:Y!&/42$?X8B=SE?\)*/U\!7[\9SZ
MP[5-D9T=V*;$DV3\<\I:-\L_$HB`(VFQ7$D(8I0LRF`^ZJ)Q:E@V&$;/`G5>
MRV-%$!"%FOG2QQ<%;(Y!YS&]%9-2!%):@I0>AJ7D_N&"V2V#WHL(ELR"93M\
MIV;SKLTFW$,J=I<I*7(6]TE88HO;^R`M!7!:Y2&YA.C+E,0A8U1XAU!EE)V1
MY<9"NQN%?G-])S?7=Y6YONLSUYPP)%!6)@LJ*&V-,:_)0S5]W%HOQ!=./3#=
M_@S.H,@\,=V.C4FO'??"DHR^.7)>AM;#[4\6MJX7'*-?U>J-$$UN.KMY935T
M"O>9>?2^22R,K<!]D\$2@_3-1\K422`X?+[*'EY$..;^`?W0=@OH5S4E`@&W
M`UFAY,6MP4I!]2"4]O##2CL$CX[H*\#HRWTND'",?L&K&*"9%I^#]1!`^HM:
M!<<`M6U@E&:E*8>@H%M(R`0MPD$MY7FA<$:AF`?)91KAQ_^%=U(L=,HZ`$.7
MW@$TE`41*XEH41_P,"#M+B"DHIX+$6<\2>U%3,(@^0\<Y!_2"%:[`Z`8+FX5
M%Q*J.V%/919>7A9!8>J31&S+R2T\5*(7$:(G]WG-QD6<X/R,=KK*<KG1:)5T
M8#+:M`X8#%8,5>5\L!:]0N[:"HF$YP+!;1[`0NEFM[[+.L(O>6B5L3KP;?HZ
MUY#Y[X@7<#O6O;(41UDBR)E]@^:J,5MK$_DFH&Y%%UZ#G),A%T+(3[#@NV9$
MO;]EV:/0&*,>]T)[@.9>K=[29A4K5%[$R:JTI&YP)0J_^['T%.78M]SL"G&N
MD3VEW470Y442#)F)5AFK8]NFK_L"8?D[@@)N1[=7EN+P2@0YM^;R$S+Y$F&@
MK!-=;M,[J-3EE5<_%@92:?<IND34<R."KT@X`1?TN[X0*T5Y)\CHHWL0'>7:
ML00)*^X'0@:EWX<2A>CM(`76KOHX$4H[1(E(LPHC;'_!.X1TI#Z,CP&16SS!
M^!2G^++`:Q5$^JNX/LD0J=<[S8`:B%7Q[TBC,Q:*8XV!@1A]GEJGT+U<;X(X
MAT_P=NK`$>I@::NGIL,T=]:<54G4%$50UEWZ.WWB!9(IBA/V2J_R==Z#6=#)
M73>*AZ1\9KAF0'R(B3^_Y#C/G$(7Q!-J+448K93-"\8W08*OEKTW4`945+.N
M5875Y:?WQ>[J>>J;\GGJ_OM*[A3Z(.:$9[<CD:^LOF?D4,T/XBQIO2H^P)YW
M1L!(]T23,$+QQD=!U=>"?@K2@,=N05)\5024LIK=Z"<U%SWW&*L[B4T=]KJ#
M/T%/FF.S%_!D-#"C8;/?N-X=8\UZ5H&CPT<;.6VXV+WYJV-NQW!U6Z;OI5PT
M&:/`W#:-_?E/;][]E3"F'9M6;?B)JF&(O=&Z<1:DM.!%7/RQ@A<^H],T.LM^
MPNL[G`]HA;2&57V0T][-4P.E45.<A9&>9>A77L6Q_=08"!$?VJ-@\1X)'`%"
M<FD<G3/OAF\)LHCHS_@K^T5V4U:SOOV;&9I\=:Y0L`S'O"+B->O[:N4%!UJ=
M%_#@FJG1\'5"[,W'SAXP/P1Y2DDBE"9V0JV137*XBG7X2:CO[/N410%F/,;`
M"_=0=QS:H-(;!'<XTDDV(:GC'$DR#ZL/2EXEF%`.A@I-K9&@/'">/M'*]&_Z
M%_T`5X(8D_\/4$L#!!0````(`&!I;D/NT=C>SRD``(?9`@`4`!P`<WEN+3(P
M,3,P.3,P7W!R92YX;6Q55`D``S,2A5(S$H52=7@+``$$)0X```0Y`0``[5U;
M<^.X<GY/5?Z#,^?9,Y9D>ZRMW9R2;U.NS%HJV[LGIU(I%BU!,K,4J>7%8V\J
M_ST-ZD:1N)*@T.+,RX[7)D!\_37`1G>C\?/?W^;^T2N)8B\,?OG0^7CRX8@$
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MR0>0P='1SU'HDP<R/<H&\%/ROB"_?(B]^<*G`\]^]Q*1*?SN/<BD?-+OG=#F
M?[L.Q^F<!,D@F-P$B9>\WP73,)IG@_YP1+O][>%N9_301?)"$F_\[(5^.//&
M&1N?Z*.?Q+U]@K'6&^TC\<D8].G2]2DICR^$)+4&+.W0P)B3<)PQ-[D*YPL2
MQ%6'RNG'T`A':31^@=[_X4:1&R1QQ0&6NS$TOI?0G\"R<?-G"FI5<7"%/NJ/
M[)XD7\,X'I'H\<6-B/ZP2AT8D%;Z'),_4YB%-Z_PGPJB*G90?TS77CP.84$(
M4C(9+N@W`50W'DX'$Q(&[A4T]<:N_]5]#N%/8?0.Z\=]F,"[QL1[=9]]\D3_
M4T$GC;VX\;6K*D+%;IM:QRH/6]A;0VM:K<'R.JL_UBM0R=#W)FZ!Q@HC%715
M?YR_NH$[(_3['H^@ZVN2N)X?/Y&W)'5]_;%*ND.PZJR&9&'9V;P9CQ0J\VQ\
M`/5E<NMZT>^NGY+A]-8+8)9XKG\'EGZ46:]Q7<2:W3?^;:FLQZK][@M!IRD(
MG?UAZ#:%H=O<5[ZZ`HF[:WB\5=1%TE_#(ZZ\Y*CUVJ"M,H+MRVIX5<:OVF]#
MEF$]!>?VUNQHJZHWO[MFQUM/N66=-N%G,#)P88_&?1!UARSIKOYX+]W8`^MO
M%)$8)G9%9QBS$^.^D]KTB[LSNQH_@AB6NZGA=&MFUUN)>7TV-_(K-WZY]<-O
M!@>>Z[+^N(?1S`V\OS)!T(V*FZ01R0L'?FE$PRN_R/@^O_;.'L4NUL*^=0\[
M5>-[T]R8%SFU^@I#W!D\K&$DF)#)>OBT;S-AHBR@!:_WP_'.&WT:2@LCB;S@
M%XZH^\%S3$.(R;H;WWTF?M:YH]K4Z9U?;,6D.M*5:++(7DS&'V?AZZ<)\3[1
MT=,?,AC')YU57.]O\*O-:(K^7,;@18_#@/L[`\XS.XAV!^]&XW7W\&.)UMW(
MY.J)3XO,2#\>OWC^1B.F43BO(MC58$)57&D,(PP7]+?THQI&8&S]\@&,64`Y
M)5%$)E^78N*BR"!DLJQ'Z]2-G[->T_AXYKJ+);?$3^+U;XHDKW[M;#Y75[X;
MPQ*3V8V#-R]F,"UMX_0NNC;IEE.V2[$B(#;/W8/B.8_L.IR[7B`@N/PP"*)G
MDUE%IMCT\N"P>>U9X+7&L@S?1W(',F%-6%D3I_?YY)#FJQH>-JVGB&E=?I<>
MR,RCGZ,@N7?GO"\MZU&`?8&0Q@(M92KY6-@4GJ&G\`HD$%&K=D+>_H.\"SDL
M/`O`K9I*]4AD@F&S>(Z8Q:LTHC*ZA?V7Z_^3N-%-,+F&+PZ'2-[C\'G!N*Y*
MN13C8=/Y&3&=2]V\]7P270&,&6R5A5-RYTD`W3E$$KE0V/Q=(.;O*7)I>N_C
M^_PY]#G,[3P#,CD_1,X8(-AL]1&SM?H2A/-Y&&2V=N;&CX=I0A.9*3[Q]U#0
M$$3R^1!Y547&\22<(&9[+8XGZ%:R]:"/`,Z#7$W+&#A<V7#[J'(U``03BN+6
M=WF3<.<90(K1D2-EBP&"0Y<-[XWNU!J1R`LG8A.4^2P@M^JMJ3O9&&`X-!Z"
MLV9I3B\QW<+O9)Z:TO,@@;-#II,#B$,I9D?-+B*Z0U(G=/,TH#\]?#H+<#AD
MUG'9@&0^%2.!S4<(9>>RM(*$9GSW^8#\-M5@&9W/1^!S<=5M%H(@[&BT?Z?3
MMQ;#2A<+/QN-Z^=IHV%T/XQ3@$`S7RYA"'^(PEH:W3A=JPX>\\QQ`F.Z(C$4
M$GTET7,8DZ_6%P/VR4<+:\!6XL-I?BP/Q*=91U=AG,39YC(;[<A]5YW\]3IV
MNEU;LUYYX)?Y@:LL!#5[=KHH0J4&B&4O"B;$T\9UHG0`N7X^$;-?22*1L(W3
M/=.?K^I#$\TN>2.G:]5YJR:\W3FA"*J-ZKY[I-W")[$\"IH$J?#)$S=TNC5S
M[$PCVJZW2E:L:A].UVJ\68,,CFVJ!;1E,[!8O<'"]+MQH\`+9ILQ*$P\7A/G
M].2SK3E7')/*'..V`2!6,W'4!,V>3Q)0YI-=+7V["C5&;'RX=H>@LDOC-7%Z
M'9O"-%7DQ-*&NCQT&"#\81'&KO\E"M.%Z@Y:HR>G=VK*!!^_D$GJPS9L]TUW
MP=A/:7"9/3+X<S@G&S\0#'0PF7C+B9UW[&3\R`SZ/0[!Z5F-@M2AF[%IV+?@
M6F8`J14?^N&LY[A\>];LK:WB#X'<:)5R.(ACDLB7'/U.G!X*@\P<:YS-D)Y`
M&EL,]J]/HRB$U3%YI\<]LS->L!5<9!D["GHD;^ST4.R2F]8?14$8.@F%YB,B
M*@7W(\BSW35V3%FLF[!`?A0#ZC)=GMJ^?"]%#@;?W`@LH+65M7:P_DYB&#E5
MU;=%9@D\A?17N=3*[&\D&GOQ9J<A-6>QC,\YM9I_9U!O&*8O*B&WZ%.X-0+8
M(LZ6N[40QXGWZB7O%4RNJIT[IVV(BY9UVK"$VOB-Y50PQ1@@/346(-VHP^H=
MRE-.H[5SBCQD>LH.F6J@0[%`JS%<T_BHV)US:O5LC#$=T(';LD627SS92EQ]
MM7',;29'89QY&96BZ_+FSGF%5=8P.EX]&_:#SKG5A59;N+R8>0E3JXK8/(Y)
MX$9>J%K`)O^\<VYU&150).&R!*(-]6K6H'X+8MC9>5./3*1E:[AMG',43F`^
M8[P-A0@/GNHU!B;N5T$5&_[#CMWJ8M6G["X"/`5KJC.Y##4HF`>[#SIV"Q!)
MB&&SR$!@J%X-!B<2K5DJH(_^V;%[E%O``YNPS9@-%:3!0-,H(@O7R_R>04Q@
MOY3%_98B647_A'$O:6O'[@EP;9)5(1FJ8I.0R+(&J')=$('5HZ?:K)8';ZB*
M31(F66(:PL#U/1%/77XSQ^XY\0IS5H+%4!$<#`LVS7NDH:NOH1O$VP1(0'H?
M!F/I+%9I[M@M?J1-OS(F4^5Q&O`!7Y,%=;_$NQ\<(:4JS1R[]8Z4J53&8JIJ
M#H:IO`0H_>0Z=JMR5OS6.OSZF_I%<^Q_9;]Z[K/G>XF7K33E,T,*.U;5+AR[
M!3PK[66UL)FJP8-B#H_'84IOB7#?Z3='P8QF-G#L%OJL1"-G]O/QF2K4@X'W
MG*34IKR#H_"Y`8:+H$R5[+&_R%=:U@4RO$"Q239`N00C1P,.U2&V''&&.;MG
M1NP`*S[M7*#8/$LHXSJ_F'`X!&M[NS`0G*NB*F.W^*AS@6)C7(E:)A8.K]I>
M,`R\;@^PC5QO<A=<N0L//B@YW"*K3-K8N4"QDZ[$O2(ZCC8<I)OL@=Y4&)#)
M^C0ZF*7I/,TR<Z_)U!M[HD^ZO+%S@6)/7DD;%-%QLC_V["QKRK#3,NB<"R0[
M\@IL<]!PV-7VH]DWVF7F;0V/C--ORZY<"2E')VI[Z^SDPA:N\"Q<75O_R,#V
M_,?V3?1%LOL9)<V<7M]BW:AJ.:V]OOW;&97$RELBRVC:D,ZZ.HDT<J/D_2ER
M@QCD0`\-7;[G_R+)<57OQ#D]0;%<LNCD64)ZV-J0$)M')LV$+3\,@D"1M*5+
MG5P!\OCLYL0R/S=7;@`/WGK)7S,2N3X]K'H5_DKFSR3B?&D$+0`EBJPLGOS+
MP6$IF#8DO]9-8SX]01%C4%^`>1CPW-N(UP-Q>H(BNL"CL++O(<.%Y\K'FDZ'
MNSA.`5L:`=KES269]_6>?,O^(I[@"NU!7$C"#3IJH`'-_&V1!UKB<+6!_;YJ
M')[:NPRDXE[X#,4>J(J<E3;'9^8NY["Z.!<*(.8/2_.*(5Z^:Y58E.RK]S,`
MYPS%;HVA1&QMVZ-4VK"9UT).KT67[O@K]NB<H=A/[E%]V/I;1WP(G0X\XT3H
M=Q`W<LY0[%'K$%7V3BA`_N&?@'F#:\<J^QAQ$-AU3C#GZ5;C;@F)V0>_F,\Y
M9UAWCV?,<M=L`"TZC[M:=(+9Z@"J4BEG7AOG#$F^F@*[:F`,>0,P,/V%!-23
MG=DE<_AP4)2)]TI6N`5\2UHZ9R@RU<1$LLE706;HX&X39_CR-H78I-BN8X\D
M>O7&),[J1?)S!FIV[)RAR%?3T0F#P%MT_%=#(D5AJ^[Z]'IUSE#DQE59;>JB
M-G6<V'X.715)+/?:]/8PPXJU[=@Y1^%,U;)?#"`V=<:YCEYQ4]Y**+:#S^Z@
M8?E,Y!EQ-7IUSG&Y.&5;&!-P39VK1O)%*\/]XGI!)HU@/9\X<H$MX'#ZY+[I
MQIRT7^"<6_5PFM(<[J)E2D1M.MR]E>TM$,'Q#:[`#Y(D\I[3)*LQ'#Z011AE
M]@(T$.:@&WN'<V[5L=JL@IJ5DJF#Z#@2W4UE%E1*C3_T!(-^U[HS73/!H(\E
M?J(M9Z4$@SY_?AY4K.0*1NDEM^Z8'KN1)=F7'W;Z&&,E?6Y&%P=!&X+LN]"D
M$736XTX?19B%0Y(*HSD<;2@838\^TWLAZ(EH6+VX\6SA\TX?17B%2Q2'5RX4
M0R%J#);[OH\^]5&$7)17:TUD[4C'KW?NJ8\B@*))G)S]'#J[.?=:^4=?_7&E
M%*1-.\?NB54)$^H)1KN`S.?*'UZ.40?E(53^4LR#8"C,;97+K##O3D%>`9?E
MAT$06%W['?Z94AX.0T%HJX1^#8/9$XGFU^0Y&8$12<F8D4OBTC,\O\-_*>*[
M("%`5/(`4A/PK=T7B!%%DK&>.E2$B;A4]2@*7[T8!G8;1K\%X]#W"1@A5-5!
M\P?!9`-F,P=X>2T5>G)Z.&JRJ"E!+9"FPL#6C[[=NEZ4'>W+739W%\1)E&;5
M6>R[GS<#S)T+4/`UBYJ!-IQ:-Z$T/<L='$=)Y6)5<B1W^*='#\N3;.96PLX)
M"F<5BR0)G648;?`JF[V8L'."RP%5YHQ#LAA1&US-]3>T*#Q/%29N`4,;3D#1
M*^!HZ1GXAQ;.>W5]:L$,DBLWBMXS@UY245BE/8@+A7>*1R0GKJ`.S;P_V8YA
M^TBH+;][U?9=,`VC>?8RBQ4;AM',#;R_LF%L+P6GZA-,1CEYY"SR#=M*1XY,
M].]T.AWKJ[*NC=Q!X8,P*'\U8[K#]TD<U`)NR)CNH$C"89&D94QWN,DVW[4Q
MW<&5>U/F3-N8[G!S<;XS8[J#PL518>(6,-@UICE^X?S-N?$#2!:D0FW":_)*
M_#"[D9/K"59H"\AQ^3`*G+!\O\JP6G3U=W9[8\Z=_24*8X4+AD7-0$:X'!Q"
MZM41M:ARP:ZNZ]X=OI4*+F^'$L\"*"TJ6*!U,SSCUO1.!ZU70S*%&3@:NCX<
MLQ^C8^MDR#(&1..#E_"F/Q[3Q<+/&%0\#R)M[W2ZA^>(Z*)P1&C(5\W1T&V)
MHX%[)_WE^Q.\6^)V4&@-HD+IA.AR]S+*H-K@DN""I5"ES@F%UB`J%&X*958U
ME:*(M`WNBPTXZ8&3PI,@`A2."V6VV&0S4:$X=L*^<R.<+]($[+]@,IQ.O3&1
M\Z?2#&"C\&-4)%,=(NI*B6I<<I\'A"@\$C5(E&!KQQT,-?W%75SN"*F-Q</0
MAJ,A7%7/_&I5K*FL(0@(K6.BRTVW4,&$HE2B&>YW+HJ!X8^]E6L"MIJKN/=@
M3@M]+&/B7.D(M,34*QSXY!R>/IE%7_>P2W^I>0&9T0%9]FMSD(J/,XF:@8S0
M'FRJL.)L$#55$!&S5[3;8J]HKV?=;M/UBO90^$0TY*OF%>UQ'2"'Y17=X+KR
M75H0++L(3#4%J]@&Q(+"*<(B2T(K&TH;_)YY9/):.:6'01`H?",2IMCT\N"T
MP759>R?=0^$NJ3!7"QC,9UY9,F^HECZ[,9E09QX)8MLYZ]N/YG":']*J2$96
MSOWQ!5C.!CURWU63U>MU#*P?W"6$G5,4.U`3@E>SCTY;<BWA@QO,9+'AS3,`
M&]<V,D<&F[;"T-M@[V20I.&\W%,`'47F1H$+`6'Y<;?!E/G5"[QY.I>2MO,<
MP$>1;E%BA$T<8^QM.'_YJ_NF1EW^.8"/PBN@2EUY[&THP%=[`W&*<K//_]CQ
M,""LLY<989?%O<`@BJC&+G-YMH^L[+3!-S>:;&IU#.(XG6>8XILW6EXT)J/(
M&Y-AP#);&W\G2!J7&Z&@`^5@_![$T:)<=,/26F2._FOOU9O`AEI2N*SQ=P-;
MN'PE0N7=LUA:%--N1&*_A["WSBI!VU#CW;<#8[C29^PI,DLP+;J6T*C,'KSX
MC]N(J!:2;/S=P!;:!*$]J3%?+,9B_B3"H,,EAWA98,\Z\YZ6_NS(E+>1ESJ=
M,Q1.X`I:VZ`\C-VM6$-=S6[!AKM8;\-H2KPDC0B=HW?!B$1>.#&]!U-Z*4@<
MEW^ZN4V8ACR:N[L181S1\IE19('$L\/+ISI#X3DU(7BU0.)9VQ*MZM6Y.D/I
M<^7?OBR`T89@H^$Z5V>X?*1ESC@DBQ&U(419.UARALN#J#YQ"QC:$+2L:U4.
MTR1.W(#>(W^?2@*?QM\%-*#UX9UQK[AJ2`R&XK"+;#L`B*+$OL>CAI2^P(-)
M+-AC-O,BX`*M/ZXYE63)P%`H&8'OC6XB[^(XA4]Y2F_&6:+,!!)G?]SLL)>1
M3:&V:7?F=,[1^LH$&E419]TX,*+#>74GU=910^^NOGE;>*N;K/>PJ$G?#6RA
M]9\UM\XIBJ5N'+A%2FS9/CQ'D<YJW3X\YV;':D=TE_;A37#8:KGZZF27(#:M
MEJ5W`1\HTG7WJY8<,>"X3!"'5N9F[C^(-WN!Q7\`N-P9V4F:V\\2*AH!4(?"
M]VYM894+QU0P]V#VX['6'K$I_38W"J`15X#!C(Z;%E!S(>,#U/&U?*RKN=9`
M@$A<P9;]:'H%&7&473M^@\"IU?1.V)(!4VM<0#*NT!0.IX9<9)QYH1T*._QY
M<4@F_/<=.Y,+AZ/5%4-J+7*96-)LQ1$`>=]A"$Y+.!S-/LB[?2IG94N7A`="
M$W?@]U=AD"7KI:Y/T[6[,AW?[VB<SN=##!#:$A1']P_WJ&D-(?(7#9X0&SDO
M4GTT3N]@G30V!,71_>_KA&IY`;D#67E![(UE5Z0W]DY8FK[O2"5+'!QMK1BR
M/``7^H%I['<8Q)2(@Y/'KQW,1+1C-/.9VA76GHR(PDN!HD,-6C8H#X[*:L<I
M&[CBR&Q6:O9_UR#ZS6G<A@Z>REX+<C\@FW5_$N%H8CLCB76BL$J:;&DD0&4;
M8XE-"(FC[]K!Q(,X;$WO&H"]Z(\CU[F3OY\OK"U/58]<?T;A63<A>-ZQA3+>
M-ARYIO?BW+MSZ=6^N<><S@4NMW*.$C9YY=&WX5SU&I7\7MZ=!T$`*`YHE$D1
MDY<?O=W3TNP]"?W(T;%"]QWA[9R,)P$5"B\?2]8,JY\'`.^EN/DA?U9FY_,&
M'`J/ECX[.P`,G0-NEIW.B2H[ZR<!'`KOC38[NP`,G8K%L,==65LC-TK>GV"/
M$X-M13=#E^_YO\@NC%#N!.2'RVTBM4=TL;7A'MP\,JG%4GX8!('"?:!+G5P!
M\O@,U0DV:=?<S!=^^$ZR%-!K+R)C:!8+UVA!"T")(H^6)__R>BT%8^CT9%.4
M78%NIGY"O5#*I)7:`%(4*:'5:./`,76^T&Z5GO0Y)G^F(+N;5_KE@??):J:Q
M6X!,4'APU#^B0B"F#MEA(U=>.(W7QNGT<7AM1+0I,YW'9.J@F56N[X)Q."?;
MX`1]$R5&/)D%K4`V*-P\ZA-:"L;4(2N,1$LGMK`=R`>%_TA*H1;S>6RF#A*9
MM+.^D(!$K@\FQF`R]P*/1A$2[Y70@LI!G-D>#T`#B/"%6H_DE?AA=O?\Z@&A
M06:F<Q`>"M>5`L-E(\ZD"$P=V;&[A]:[:+./PB^FX1;9';JILRCV*=.Z:;.'
MPYM5($/`6'[<ILY06.6LVGV-/22NC2(E;.888S=U!N"@:Q#W<`03-+;!'`RF
M<N1_%"&N7EVMCV(EYVD(1Y^:$8.I!/@)F8(E2+OYDGH3-Z#GB@]3-XNYKV$L
M7*K,OPV(01%2V:]^<@7QW>2[[S?-/9?;VD=A(*FI6^.":%-2^\#/.B<3ML16
MVW'!ZJ;6`0@.11A*;\'2P=9<YO?^E6(=@GLDT:LW)FST]V'P2F*:$D_G3?P4
M)JZ?_SO-V+T/DW^2Y(&,PUG@_05RS!4)%^C47MX/M.$*FRFIY!Y%P]%H`SF!
M=LXRT&!RZ(/E"8*Y='UJ@#Z^$)+$HXRGK)GN:0;F-S_?^4[?@O,'2NV<[NF)
M]=VYYO&"[JG56):&7"6;]!R<-IP>,'-A6_<41?"*19*$SC*,-APL,'MA6_<4
M101*P!F'9#&B'Q>V4>EA=):J3-P"AC9<V#9:#W698NY&PRB#.\DVG;`'S<P\
M`<%J'8#`L'HU,RK9Q.M@0W%.H@F=6-ZQ-$B3ES"BUKJR+A0;@IRP>@Z5=8"-
MJ46G,%APE_=N:?*^;`3RP>J^T^0\C\?0R0JL?.>",9JDYUJ"I+"ZW329+X$R
M=-X"`_U7X7P>!E6__0JM06)875T"-5`&9N@<!S)5T/CD"UHYW3,<N>-5J6<#
M:M,-4R6PTD\]IP6(!E?>>#6N\V!,'09!R;/:)U[4#(2$R_]6C?$2HN8N(+)8
M1FF41N,7-R;_<*,LNKRJHF0@X,#L7A)L$+9QX!76/5NZ@883JU-!4:9J0883
M_APX*,?6($B\B>>G-/7_D8S3R$L\$M^\C?T4IM(M"(^&)=,E2</IC1O1.M?Q
MVKR[?&=W(`E5-/A6H`:72SRG,)P<AJ:%T8:P"1NC4H4F65,0$@I/>^-ZH*-^
M1?&T(2*S6N^E1P]VG@/X*%SR:C2Q*68`:D-0IG:$[027HUWZI>!A,!14.<S3
M"#=_IE[R?A>`#9=F%2>'8.1'3R]NL,J5VN1:-7=*07<,0!M:?_])J>:')?$8
M"A<=_#T44NGMID);T>_=(0!_:(,:-M2;)1U#P;$Z=W<:/@Y1`%VZZ-?XB0C9
M"T'0:(,J937<ARSJAN3Z2Z4+R(P&>EJZG*YNYB43JRMJ:11.MX,V3F1C4>4(
MJ&ZH\;M0<90F<0=M:`R%2=SA!]L.^::K9H5GY0X7@\,#VM&&#ZW."D7)F8I.
M?V^;2)SS1O?"GVX'5R@(U39447RF`OTF:DOL><-:91)8'A%PAB*6A6'+JR@L
M4X4OZWABL'\<5GNM%)0)YY=!9X!`.XJ('I;/@K[L3-4+;?.4:=,6!%>8])"V
M(-S@K'YQ5-:>'5^N9`=GLF3GX"Y][':LQBX49:J6+-EIR7V.+4R6[.***>04
MQD*R9+<EEU<VFBS91>&F;UP/JB9+=JW?H&DU6;*+PEVM1I-2LF37W-6;]FNE
M*Y>W[W9Q>4ZEWX7"T-N0$:E?W;[;1>'\*W`A("P_;D/I?A4I8]_UMG(ICB)O
M3,3W#K,>!5PH'$TE49>]L/SAHRCBH,!.3X.>W@8@"L^&-C\[XT=19D&!H%,-
M@DXW`%&D26L3M#-^0\4/C&=Z[@P9;%YU?C8/`T`4B;ZZ!!4`X*A5H$)25X>D
M[@8CBC18?9)V`.`H-"`GJ=?3F$F;AYUN#X4G1I>D`H#FR@(8)NGSF09)ZX<!
M(PKGAS9)NP!,1;P;-QGZ?0V;8?TP8$3A@]`V&G8!F(JQ8JBK4ON@9N_`O!$\
M#)8O2F1.N75@9T<9.3..^2Q`0^%VX`F]/.\$,$S=BXABVE6-@=^'JV!W.1B^
MCSN_-%X/I*%PL:CIWOXE8^K*2#S'#/DB*,QJND9S=73?0P`V4+B:U-?(_4O'
MU!69;<XJRTWS0OK1`Z&!+?C]51AD"1JIZS^12&QJ81HG*`$*9]^>EO+F1&CJ
M<E(D\^A9+MQG;>$.9K,H.^%Y!Q+T@M@;9QE[:O4>;0[+Z9T?T(<$C\1,79%Z
M"/4JGZ#GU,@]60UD8IZ=6O="Z&9BGEG=8BC*5.*(R$%I0R;F!M=R@:"K2AC0
M]4'UCBQ6.Q`/KK4U1YJ$7CZ<-N0S%M!)DQB9SX,X<-F7?,[89`M0?<<)AV<H
M`M`";MAD,E"T(<OP+@`+A6R-0_HFRH1X51:T`M&@"%ZKK\E2,&W(3>2`E*[,
MPG9.]QQ%#%S*H!;Q>6P(<QR_D(!$KC\()H/)W`L\:E/2M.G5U=DQ_.$!6``)
MOL"/U^25^.$B^WPM'Q!&:,UT#K)#$797(+CL1S4I`D.YF#@L]ZJQX',4T?T*
M-GH!@Z&\39-K`;W7A5;F&$[7>\RG<+WK'$YSEX)PIKMR>Y``KHA^@9OR--:$
MAN+"*_5PO^`2,VD;`(PV_,_F4@$.CHS0']$HBZ&4<[2)!66M1BQ"'&F[^9D4
MD_''6?CZR<OJ."SGT?+GX@Q:_A;L/OH/%<MVY5AXT=+X`WH8.JW8$D2$R^,H
MU#(M4(@S@2O/DKUEF`@R)<YQ.3&E']NF9(`XB;DVY-^S^C*P':1[P#'\^!32
M7ZDDW^WU_<`$"N_K'K513S0XDKC9>[U@'&6(77_E:>!MZDH/`C9</EGY[HV#
M`6,^MLD%LZFK%P2O<KJ?43AQ[7RA=J6`(YE<Q0U`QU[!$U!J!KA1N&HK.P,X
MB$SE46/P!PS\K',R82L^_VN@UP$(#I>G5FD'K8/-5,(RJIRRE]`'&/'2(5`G
MH<Q4N*`XIOLP(8(4-+6&0.#AY:%]1N*1D@M6$@G)X6E5,MKCF`0N?/Y5D]#R
MSX,X<+F"<B1)Z"S#:$/2V1K5;T$,.SUOZI&)-+V!VP;$@LMO4^:,0[(841L2
MSVI'I#_C<H*H3]P"AC8DH&5?)QJL!3U-(R^8+?=CF3479W\L7!<@O-U-NS,0
M)%K7R&=!O=YJ.`UELMD_:#2*PC$ADYC6#=55$FE;IWN!UB/"UPE%6(8RVK!L
M@>Y)\C6,-V5B[>]_BH5K%78^O";.:>$"R0/8\YSBN!10+%*EW<ZIX/Z^`_O"
MKG!=^6X<#Z?9XJ"ZXRFV`;'@<A+ER)+0RH;2AIU/'IETRU-^&`2!*[F/S12;
M7AZ<'QL=*C9<B7[J<[6`H14;G<KWII42NIJKY,-[%]"`Q)?)5A"..C4CAC:<
M!_J^KJH^17LC5A/:6TT\YH\ZV=D1@C@\,`A&N1?8V`<.HYD;>']E[[\"F8>^
M-UD2&$SR8QM.;[W`#<:>ZV_40U2QP6C_3F]]@-Y2`#-]CLF?*71^\PK_L;][
M+PQ(A0A>$Z=[T;5N..I&+"]P;`2$(E6+55[PJW<>UH=Z5Q9/\#[9WIW=`D2"
M<3>0$<6A5`2D#?MV!D!YQ)+7!L2"PT07L:9,=!Y3*[;RNQ"E13.8SX,X<-BQ
M8KZ42,XCPK.]7Q\UFA!OR2W\4*04?N5\)3/7OPD2L+,YJS'C*0"+*Z>`NP)S
M!X]GZZO*U!(!=UDM/@(PK28'<"5?)J@\;(35*J[<`!Z\]9*_9K2J`CV(07>S
M;O`NK$,A:P9XK8;MV?+?Y4@=!XHKNW"XK+M]7*%WN9'*P6"^6H2=+?K6MT`F
M6P?"<#I<D.4)TMC&/KU0V45AF\YI`62=69\KNKOT/@HK4"A1M4UZGW_N^+"L
M>S,)Q7V4YF&?GVO*A]&*[;G9A.(^KJS3,F<<DL6(6K$YKVVTX,HA59^X!0QX
M-N(U`B]+PR28;0JV*013>&V<W@DN>[1`&)M>"1Q#FW@,VPU)L3X!Y9*6("D4
MB8P2*MG\*V%K+!%X_UH@K,<HT`%A.Y`2BDS'2AJ@@*Q%3H>2B'26>I`&BJ!G
M)9XY:`PY'Y(P<7VKS"[WF#3#GQYKH`7+O"`%N%OOPR69AA%9/O?DOI'XY@VD
M!H@]L%K?LT_E?0A_#1*`!..;W04)`8;EOH)&W@K\X(K"*AD4C0O$U)7KUA46
M0(;K.;F4QFIF*EBATK8@*QPA7BWE4835I@J>VXI[2\!*:PZ["0@'A;=/D47>
M^B$"AZ_B9`U3A*9:<F4ELDN$#4%0*'R#M;1`!2*.*I0-?PNJ?`-`/"C\A[4T
M0(+.5(E(^V:`W&"J97Z"N'!Y'`U9D4M<IHHP8E.#:R\>+T&3R1;S/4F&4S"9
M!TD2><]I0GVW3^$#6811MK'+L@R4M:7&.YQ>YP!]G8;AFRHPB>+[0Y*M=$3?
MG/QS(`84CD_-/489@JE:CO97D>)A=GK"94P]>YZ?TMJV^A4&.#V`X%"X//6X
MUP+7IKJ0\N\IB*0@#5ZMT-I]@GA1N%&UM*&JG2*407-5)FVKF/CK6E?9*O4.
M(D?A3S6N=C6D8>H^>0P**)%K]6\>B`J%+]6`XB@A;>X^=0LWS^Y>:+,\Q3R<
M9N!S9_;5=:5:AR!8%*Y9/7.I#E:.$AGPU.)*;KYRXY=;/_QF);=Y,Y#<.)3J
M)_.;`7L7MB9KU2SG7@>7BXLK5O8T8Z'YD>J\SC?M=7&YFG(D2>@LP_B1ZEQ,
M#.YU<;F0RIQQ2!8C^I'J3*6'RT.D/G$+&-J0Z@R[0?I-&D7AJP<FT.7[;S&9
MW`6;I+#!./%>O<13RH'6[PP$B<+EPZ.8ZRJNA+-%6=,5`P-=%)Z6JOPI!0ZZ
M7/>)?MS`>I'LP>1_TF7634RC7>,P&'L^V4'\%)I;0)IX'3""PDMC5NF:DU2+
MDKK9Y>]$U@JS`<@%A9.F.<XY=H]`&H;2PS%HR36!,8\]F6[D'P,9H,BEV[=&
ME&5@*.NZ@=L.,\@QC.LVC'X#<?@^`:Q@Z@_&XS`%B8&\B/?*\2AI]N#T[-9\
MV;="5!(/CO1L/67)[CD+)NMLXRTDEM%;L2>0#@H_)0KED8FI39G>7UPOH%(=
M!M=>O`AC;UEM=1#')!%MJH3M0.+?E39I"*5V9GA_J3L!F=%PC\D%B!9<S@Y8
MWLT7KA=EK@CVSEKPM-/KH?")[W,A$8K"5#9X`U^<K;H^NCX93IG)&ASZE=J"
M!%"XT/>I#!J",94ACN$[DEUU#_NT:[+\-R>[*W?A):ZO5MU*L1,0(`H/OEF/
MBB[^-J5YE[$K;9)TFH/04'CZ=6E6518>XMHYY$9LCJ;49!01^.I.KE=(UN>X
M@DEV4$]JR%;K$`2+(HS0E"JIRZ!V*GIS!FT9UC7)K/)8JATZS4$.*+S[]71!
M'W'M#''4R\IZ,1VY[Y4_/:NV("X4SONFOSL[<-N4OLV$'(%!_]5SGST_L^]T
M%:30'(2&PIW?H(XP$;<IH5M],V`D@04$B,+A;SR500N_J61N^P<D.<B754<,
MY4$).@-QHG#:&LF#DN+DJ,U!5NA8W9H7/X6#\9^I%Q&0!DR7Y'WDNT$"IMO&
M02E0&/5.G-XI"A=O5>K9BJ2+GZ-`ZGY=1-:ONB2-K#@@0!1N8;,*I(N?HT`'
M6!^$@WQU8Z.9#Y>@,Q`G"E^PD0^7%"=';?;L\^5E,(P)F60'?^_B.`4@9#B]
M"N?S,,AN-K\-H^S?Y06N-V\D&GOL.J=UN@,YH7#S5F68F:E00Q(<C3G(&LEY
M2?S#I9<()R(U4FD&0D+ARC6C+NJ(.6IQD%FVZK(S\N4!`:+P^)I5&5W\'`4Z
MP/K,&6P2>>&DZ+@2J`N_$8@'A;]7SR"1X>'0?8#5C2E2";$`&84[5I_"Y<@Y
MASRUW:J+3"%@%%%R`)2A<(=6HHQ_!9&V(W-)V4U@UZ7PF"X6?B8&UU]7'+@+
MIF$T7_*A<B.]4@\@O`-T6VJ!XVC&0?HJUTG5(]<3E;+)/^;TSE#X&[4XX\7%
MBK`XW.XY/=1DF;7LW@0IO3M/@BA0.`2-,,Q`QB'90**GG8)#PVCF!MY?2Z$$
MDWLW22.2OTP5?DDK+\7#Z2@W"!MEB/)#W=9)6HX[/[;A=+7/<?UM"265.]=,
M]`]:TK,U:6L!H,G-?A@#^T^@4)<PS#^:DA7C52`V%)X;@SK`7E2:$9RA.DY8
M%J5?W<"=+2'3D)W>8L/T9V\EM^V;=BU8%E2:.;W"S<?51[C[`K79J-0.QFAU
M_ZLNQ[*W7!&<^3)F=O2>76)U.!U,"""[@@Z]<>9P"2.J5>_T@QTF))=5;^&S
MS!YT5JB1'IQS_2]1F"Y4/L":/<'2U[?UJ=T=$5B*?DIK5+(1Z'U:ZW;M],Y1
M[+$JL<G^:)H12<L^DK>N%_WN^BG)F0IW`0@SS3Z<-I:"S9"V'*C,>U$SH*YK
M:Y*SQJ4R@X7M`!"*D+9<Z.RYJ`!N;Y_CGS_1(3Z[,<G$^?]02P,$%`````@`
M8&EN0X*!(WLV#```X(D``!``'`!S>6XM,C`Q,S`Y,S`N>'-D550)``,S$H52
M,Q*%4G5X"P`!!"4.```$.0$``.U=7V_;.!)_7V"_`\\'''H/CF.[_Y)K=I$V
M21&@38(FW5W@<%C0$FT3*Y,N227Q'NZ[WY"2+-F2*,I6L^JN7A);G!G.\$>.
MAB-J_.;'QT6`[HF0E+.3WO#@L(<(\[A/V>RD]_GNHO^ZAW[\X?OOWORMWT?O
M"2,"*^*CR0J=887O!/9^DPD_`O:#UTA_&/>O^'U_=#@<HW\?OCQ^\>IX=/@?
M]-^;C_]#Y[=WJ(\>'AX.?)"@C(0#CR]0OZ_[D=Z<+#!26,R(NL(+(I?8(R>]
MN5++X\%`\\D54W.BJ#>A/.`SZAG^@>[M\&BL+0C(@C!UP<7BC$QQ&*B3WI<0
M!W1*B=]#8#*3QR"EGE3#ML'R,#[@8@8DA\/!+Q\_W!K5$_D!9;]M4#].1)#0
MCP>Z>8(E2<AUJZ_6#%GB%X.H<4T:6.3^\@$$9X52"S%E4F'FI4KDE(Y-'!X=
M'0U,:T(:ROX,X^6:>(KEQ)#&#6;@^H?#_GB8L'@\9$JL-FV4Q#N8\?M!W%C$
M%@H!<[*,+V[5C*--1I_08AYH*.B'/'KS8GK=4L!`V3V1JI@E:BM@8AAF5C&/
M:=(LPTT62;UB!F@H(`<`U&I)9"$TIJ5`+:F6HJ03:"GHQ2=+03SM#$KGU]$`
M"T_P@(`&GNJ3QV6`&59<K"[@^WI`.&/AHEB(K\1`:SP`HCY0$4&]-5\U4\P`
M;@6A-Y@Q#OX&_)3YKJ\LEY1->?P5+NCY?:P5O@-VI#]\_G3IXB2,D6?<"[7;
M.67^.5-4K2Y!N%B8+GN(PCA9*=9J)(KX9$H9-0H/#X?@,Q/V[$<0A2)9*"/L
MS6!;PO??;8L/)?&OV0_F,T`I09KAU?XCYH])[+QI)W4Y/1QX85#::<PVV$`E
M(W)/N-YQ)GE`?3V%W^)`N\';.2%*1EB5-]N!&@$ZMS"2)$8J*P?%@E`DJ4-I
M#Y1N,+C]B`T'%9!MTMKQ&[OCAYYM"/YGAV<]/-?#+*^GUTL=68).!<NOA,Z.
MXW,;CJE$Q*<HE=DAN#N"[["<7P3\H0+`E,R.WPMW_+1(9&1V^%7C=RUFF-'?
M3?<0/5QA%0J275AP\2V6%+"ZR0Q/A.JNS':L7^J(ADHOX!+$P9=L-PA#B!-U
MM+E838/I3%_/=M=-@^II\!%"\5FTAF[@IA;!NWW1#MNK;=A2]G_\?7ST+XFT
MD`X,AZT#C"*'*)Z%T-]Z@E]/3WW"&7X'PG6`\0%/N##[)[WTN"*?B$?H/9X$
M)-Y?["W&#OCK;<"S'697)JS'J$^4=(K27J,%#?VBM.-NDE1/D@M,Q4\X",'?
M7E`&<2C%P2632IB=8'S;K2*R`WRT#;`6AXP\C>E:(LJ([*"KANZ6!,3;VI7D
ML@-51%;HAH?;T"7B-C<M79:@)G**>R9/Z[_CBR5A,@M8<9L=IV$.)RVE_U:+
M05DY'3J.Z-R$PIO#\/V,A<!K1UC<9,=F5(@-2J2@1$P'C2,T<Q[X1,CS+R%5
MJPPNF]?MH(P+08DEF#@317(Z5*I1N2+J`Y?RAHC;.19QV+A]T8['\VT\@!UI
M?@3Q'S(2.B0<UD<XD>1+"&:?W\.?>'%L7;0C\2*W,M;LR/!W.#S!UNM._Y$-
M;<!B87;<<^F2QK9AZ%FD0)?*WC^HS\X+-U([ZKEL2W6`W\&Y=Z2_@:*-P@Y>
M+G-2%O5WD.T;_N<0*R&P`Y;+A)1L!3J\=L\YGQ&%:2#OR*,*DV>X=A(K9J-<
M"J0P'XV>Q4)1++6#[BG"I'C0&XJ3$FGV"9'+M308*,4:=)/G"2?/AJ=H6JA]
M*N520\U/I<X?-?<PI&C"U&.Q3X=<4LKA04D']%?896W<5AQI[=#F\ELN^ZSN
M;M`THL,ZD`XK,,UGRMPQ1<,.U<90'=5!=52!:BX/5@?548?JSDF13:=K);$C
MF,]IE:9%.@_;$&I#!]BJ_&F-=%;G11M#;B.:=:*THUB<X[*BV$6N>V8G\ZZS
MC,**W3A_W*<L/]DYSF8@&U9C5N$VQ\5G?RR@=5YS;]CR3K."T`ZAZQ&ASF4V
M<VBH%$4;E1U"YP-%'88-'#$J`M!.8D?/X?A1A]LNN)6^\U/[?9YQ+MW2O:73
MS"FQ0F]H);$#E<^@;)T@^TLO)?U'[[`^D2DRM2^.=5F!DYZDBZ5^Y2:Z-A=D
M"M=6K)^4"OD5;#YX7`0)A>[`4H3#`+T]3'&_B8BXD(*]-`<(X>`$%25RD.C>
M0X/F[`(\ZMJU"6$KK0KPI*Y5P$*"UAH$D[^N05OKI5FSHK66K;8!W[+5.,PE
ML(H+A5AAR9^RLC51M:`/W#.B+"SZ6S_AZ^M+_>&H/QX>/$H_'?PZ2J0VUE,B
MX=M!B>*B0([=)PRZWQ>N/5JK^I1T;#HM9!R00,GD2C\55<M^2X4=FT(%;/'G
M?14IJESDHDF6+_FRMRY%U9"<E,DRKK_U4S$[J9,KG.2BRIK)?-IW1/)%E5QT
M2+FBC_U4P$Y:;%=J<M$AX=$?]NY_NXB3DP()D_FT@PKY@E#F9L/(3%=Q</-<
M@1`;7-I]'6FW.7RYMQJ.SC.C@FJD>WM9+%>5LE+.4R$[:&@MCN8R4Q(>_6&'
M!6LOW^4T(-M<^^)47'FLGB:<7>VLC+UFV^YW7B.K'**X<J)1J"1=>CJ1NF@C
M3-0H'#4U!H_A&F6S2T46>BO50SBF.NDI$>I@U5!!?$BY?V?X_%#$209&@T"?
MA$MH)6Q"%56A;GTO>+A,.J$@/MKT0KS[:X5V=6S2F]NW`30D1D5%Z8Y5<KW(
ML"D.Y!-:EM&QS#28%7X8D.LI[.F77.+`]"$OF1>$NJ)G\9%):.8+LBZI<\K\
M4]\W6S8<I,F!Z-A\VP;J22TN&W:=<WR[_23V5*,6'3Y_NTI);O#*=/F`!2AD
MM('N$XQ_@G"4^+H\X./2G&2YX_K2=:CTQD4;9-J(\*A<OR[6-DS:,QR5ZR3N
MZ-13])ZJ52N'TU595V._K<FTL_8EPU%V.OPC64R(V#+:YPM,V9/>U*KT*S$K
M);P@1%Z1K;OS@D/HBL6J(?`BVDETR.ZDYPD"WM/9Q`)=2ZS:<.IVGYX*O27B
MGGI$ON-2UX)XNF'PR:3&*#1A6_FPY85$]SS]H,S<+`ONBJT)[/;6OVQ<"(PX
M5?H.<ZWF1)Q*292\XBQ*=S2Q9J(,HVIZKE0J7M/;?0B\MCN\C(HEQMT(LL34
MQ`9,$OF)2`);XCD,TAFY)P%?+MJ,J:/V);;KT"I4,!-@1DRGX!+TB07#TA9<
MJS6LO)6USB:+:DWO#=8O*\%:#Q=19!Q'.^1&P'!>,[(>$!B-97R6XAN)]=W,
M^TH;KF0W<<'%E%!=6/03[`0OV8T9FJU1]8#Y&QE41_.^TJB^-UNVI!OS[0SZ
M72/=XHCTZYMN34:!TOHG1-KBY0J5<C#@51L->.5NP/"PA0:D2I48<+Y8!GP%
M&RD=.5`!*Y\+V19#K,HY&*2+?H>!CKY::5*!>B5&1;^<%)A,XP)"7:VFHO<D
M"?^@H3@"C`G:8GU3=CS)/>BO=^MQN./LW)_>>-[-,;O>C-;D=MP4IPVT$/FM
M!$[5MCWY</Y,Z&RNL]_WL.!FI#R>^@:C_R:,+[M[9#<1K0FIBK5R,F'<3AO&
MM8QXWDXCGM<Q8C1J37Q8II>;&:.6FC&J8\9XW$XT,GHYF?'J13O-2/5R6N!'
M1ZTT(Z-7B1G)H^8-MC_^UEJB5M-1R!6/;\'1"V^98D5;"F@3KL(LPCN'>:7I
M]*\==>QD;,F(9PN7;/P(7&L>HCEH6&+;I92A9ET_<Y=W/#F,=#V%08<-E,E0
M_.%3H8:F=99_6AV]E6X@5:]I=_`G7/3UE_;>756?6OJS#*J[I66NAGG"?,=!
MG"!J[X&-(EV?8`$6IU<2&[^1#;_5+C?7K'G:[9T+-"Q[>@]<7%Q0]?M,9U-]
MDTI>+#%KS3&T:@U+#V7P>RI!^`47GYG'`UV1C8("IYYYQ4EF?[.NK4N]EA%U
M!T*7?X7AO&2*@,-7J:@6'U;;R1B;SP<'<4:B_Y>L^'A3BY/V[B:43PZ/$%]>
M"+Y(@]A,P`KC;/['&Y8D/]KJ&;*C166']>)?N-?1A?E]^TP5Q]9LLMR4+,N@
M)&>(+L&Q4J$_Z>.-[<6X5.&RAYYPUS('-MDMCM_1R!_;;*^YCNI;#N%&[Y&D
MOT*@'^FW9^Y6*EABV29Y*J9EKPXXJ%DG/&MU9)8-RMX,HK<#C6W_!U!+`0(>
M`Q0````(`&!I;D/^LJ#CKX(``*OA"@`0`!@```````$```"D@0````!S>6XM
M,C`Q,S`Y,S`N>&UL550%``,S$H52=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8&EN0^&Y-J*#"```^6\``!0`&````````0```*2!^8(``'-Y;BTR,#$S
M,#DS,%]C86PN>&UL550%``,S$H52=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8&EN0]Z$<'(E)```LU@"`!0`&````````0```*2!RHL``'-Y;BTR,#$S
M,#DS,%]D968N>&UL550%``,S$H52=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8&EN0_<*QGE(.0``6D4#`!0`&````````0```*2!/;```'-Y;BTR,#$S
M,#DS,%]L86(N>&UL550%``,S$H52=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8&EN0^[1V-[/*0``A]D"`!0`&````````0```*2!T^D``'-Y;BTR,#$S
M,#DS,%]P<F4N>&UL550%``,S$H52=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8&EN0X*!(WLV#```X(D``!``&````````0```*2!\!,!`'-Y;BTR,#$S
M,#DS,"YX<V155`4``S,2A5)U>`L``00E#@``!#D!``!02P4&``````8`!@`4
)`@``<"`!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBF">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details Textual) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="nump">$ 5.1<span></span></td>
        <td class="nump">$ 10.0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">$ 1,890<span></span></td>
        <td class="nump">$ 1,073<span></span></td>
        <td class="nump">$ 4,270<span></span></td>
        <td class="nump">$ 3,717<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract', window );"><strong>Other Income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(104)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">389<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Adeona Clinical Laboratory [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LaboratoryFeesNet', window );">Laboratory fees, net</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">115<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">104<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">287<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts', window );">Cost of laboratory services</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">116<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating costs and expenses</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">104<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">403<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(104)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(288)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract', window );"><strong>Other Income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on sale of Adeona Clinical Laboratory</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">677<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="num">$ (104)<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 389<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DiscontinuedOperationIncomeLossOfDiscontinuedOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to laboratory services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LaboratoryFeesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for laboratory costs incurred on or before the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_LaboratoryFeesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating expenses attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating income or loss attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 12, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Synthetic Biologics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">SYN<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44,654,414<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 08, 2012

</div>
          <div>Promissory Note [Member]

</div>
          <div>Adeona Clinical Laboratory, Llc [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financing Receivable, Net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 700,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.70%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProvisionForUncollectibleNoteAndInterestReceivables', window );">Provision for Uncollectible Note and Interest Receivables</a></td>
        <td class="nump">$ 763,000<span></span></td>
        <td class="nump">$ 763,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProvisionForUncollectibleNoteAndInterestReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, note and interest receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProvisionForUncollectibleNoteAndInterestReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtPercentageBearingVariableInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
